1,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy. "
4,"Rilonacept","DB06372","decreases effects of toxoids by pharmacodynamic antagonism. "
4,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
5,"Abatacept","DB01281","Avoid combination because of increased adverse effects of Abatacept."
5,"Anakinra","DB00026","Avoid combination due to increased adverse effects of anakinra and increased risk of infections."
5,"Belimumab","DB08879","Avoid combination because of enhanced adverse effects of belimumab."
5,"Belimumab","DB08879","Avoid combination due to enhanced toxic effects of belimumab."
5,"Canakinumab","DB06168","Combination should be avoided because Etanercept increase the toxic effects of canakinumab including neutropenia. "
5,"Certolizumab pegol","DB08904","Avoid combination as certolizumab pegol toxic effects would be enhanced."
5,"Cyclophosphamide","DB00531","Avoid combination due to enhanced adverse effects of cyclophosphasmide and increased risk of solid cancer development. "
5,"Denosumab","DB06643","Monitor therapy as there may be an enhanced immunosuppressive effect."
5,"Infliximab","DB00065","Avoid combination because etanercept may increase immunosuppressive effects of infliximab."
5,"Leflunomide","DB01097","Consider modifying therapy due to enhanced adverse effects of leflunomide including hematologic toxicity."
5,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab and increased risk of infections."
5,"Pimecrolimus","DB00337","Avoid combination due to enhanced immunosuppressive effects."
5,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5,"Roflumilast","DB01656","Due to enhanced immunosuppressive effects, therapy modification should be considered."
5,"Sipuleucel-T","DB06688","Monitor therapy because of reduced therapeutic effect of sipuleucel-T."
5,"Tacrolimus","DB00864","Avoid combination due to enhanced immunosuppressive effects"
5,"Tocilizumab","DB06273","Avoid combination due to enhanced immunosuppressive effects."
5,"Tofacitinib","DB08895","Etanercept increases the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
5,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
6,"Deferasirox","DB01609","Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity."
6,"Gemcitabine","DB00441","Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity. "
6,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
6,"Rivaroxaban","DB06228","Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. "
6,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant therapy. "
8,"Aminophylline","DB01223","Interferon increases the effect and toxicity of theophylline"
8,"Dyphylline","DB00651","Interferon increases the effect and toxicity of theophylline"
8,"Etravirine","DB06414","Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy."
8,"Oxtriphylline","DB01303","Interferon increases the effect and toxicity of theophylline"
8,"Telbivudine","DB01265","Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy."
8,"Theophylline","DB00277","Interferon increases the effect and toxicity of theophylline"
9,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
9,"Nitroglycerin","DB00727","IV nitroglycerin may decrease the effect of alteplase."
9,"Ticlopidine","DB00208","Increased bleeding risk. Monitor for signs of bleeding."
11,"Aminophylline","DB01223","Interferon increases the effect and toxicity of theophylline"
11,"Dyphylline","DB00651","Interferon increases the effect and toxicity of theophylline"
11,"Oxtriphylline","DB01303","Interferon increases the effect and toxicity of theophylline"
11,"Theophylline","DB00277","Interferon increases the effect and toxicity of theophylline"
13,"Aprotinin","DB06692","Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase."
13,"Drotrecogin alfa","DB00055","Increased risk of bleeding. "
13,"Ginkgo biloba","DB01381","Increased risk of bleeding. "
13,"Ginseng","DB01404","Increased risk of bleeding. "
15,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
15,"Ticlopidine","DB00208","Increased bleeding risk. Monitor for signs of bleeding."
17,"Lithium","DB01356","Monitor therapy because calcitonin may reduce the serum concentration of lithium. "
21,"Clidinium","DB00771","Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely."
21,"Tiotropium","DB01409","The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
21,"Tolterodine","DB01036","The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
21,"Trihexyphenidyl","DB00376","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
21,"Trimethobenzamide","DB00662","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
21,"Trospium","DB00209","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
22,"Aminophylline","DB01223","Interferon increases the effect and toxicity of theophylline"
22,"Dyphylline","DB00651","Interferon increases the effect and toxicity of theophylline"
22,"Oxtriphylline","DB01303","Interferon increases the effect and toxicity of theophylline"
22,"Theophylline","DB00277","Interferon increases the effect and toxicity of theophylline"
23,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
26,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of abatacept"
26,"Canakinumab","DB06168","results in increased immunosuppressive effects; increases the risk of infection. "
26,"Certolizumab pegol","DB08904","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
26,"Etanercept","DB00005","Avoid combination due to increased adverse effects of anakinra and increased risk of infections."
26,"golimumab","DB06674","Avoid combination with anakinra due to the increased chance of serious infection.\
"
26,"Infliximab","DB00065","Combination may enhance the toxic effect of Anakinra and should be avoided otherwise there may be an increased risk of infection"
26,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
26,"Thalidomide","DB01041","Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided. "
26,"Tofacitinib","DB08895","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
"
26,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
30,"Liraglutide","DB06655","Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.\
"
31,"Aprotinin","DB06692","Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase. "
31,"Drotrecogin alfa","DB00055","Increased risk of bleeding. "
31,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
31,"Ginseng","DB01404","Increased risk of bleeding. "
31,"Ticlopidine","DB00208","Increased bleeding risk. Monitor for signs of bleeding."
34,"Aminophylline","DB01223","Interferon increases the effect and toxicity of theophylline"
34,"Dyphylline","DB00651","Interferon increases the effect and toxicity of theophylline"
34,"Oxtriphylline","DB01303","Interferon increases the effect and toxicity of theophylline"
34,"Theophylline","DB00277","Interferon increases the effect and toxicity of theophylline"
35,"Dihydrocodeine","DB01551","Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy. "
37,"Dihydrocodeine","DB01551","May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation. "
38,"Bendamustine","DB06769","Increases toxicity of bendamustine. Should not be administered within a 24 hour time period of antineoplastic agent administration. "
38,"Pralatrexate","DB06813","Increases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate. "
39,"Indomethacin","DB00328","Monitor therapy due to diminished therapeutic effect of glucagon."
39,"Warfarin","DB00682","Monitor therapy due to enhanced anticoagulant effects."
40,"Clobetasol propionate","DB01013","Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
40,"Clocortolone","DB00838","Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
40,"Clozapine","DB00363","Avoid combination due to enhanced adverse effects of clozapine, especially the risk of agranulocytosis."
40,"Corticotropin","DB01285","Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
40,"Duloxetine","DB00476","Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine. "
42,"Belimumab","DB08879","Avoid combination due to enhanced toxic effects of monoclonal antibodies."
42,"Denosumab","DB06643","Monitor therapy due to increased risk of infections consequent to increased adverse effects of immunosuppressants."
42,"Leflunomide","DB01097","Consider modifying therapy due to increased adverse effects of leflunomide including hematological toxicity."
42,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections. "
42,"Pimecrolimus","DB00337","Avoid combination due to enhanced adverse effects of immunosuppressants."
42,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive effects."
42,"Sipuleucel-T","DB06688","Monitor therapy due to diminished therapeutic effect of sipuleucel-t."
42,"Tacrolimus","DB00864","Avoid combination due to enhanced adverse toxic effects."
42,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
42,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
45,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
45,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
45,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
45,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
45,"Dextropropoxyphene","DB00647","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Disopyramide","DB00280","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Enalapril","DB00584","Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Epinephrine","DB00668","Concomitant therapy with sympathomimetic agents may reduce the blood-glucose-lowering effect of insulin lispro. "
45,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
45,"Fenofibrate","DB01039","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Fluoxetine","DB00472","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Hydrochlorothiazide","DB00999","Concomitant therapy with diuretics may reduce the blood-glucose-lowering effect of insulin lispro. "
45,"Losartan","DB00678","Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Octreotide","DB00104","Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Pentoxifylline","DB00806","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Pramlintide","DB01278","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
45,"Prednisone","DB00635","Concomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro. "
45,"Ramipril","DB00178","Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
46,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
46,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
46,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
46,"Bevantolol","DB01295","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
46,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
46,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
46,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
46,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
46,"Labetalol","DB00598","The beta-blocker, labetolol, may decrease symptoms of hypoglycemia."
46,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
46,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
46,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
46,"Penbutolol","DB01359","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
46,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
46,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
46,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
46,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars. "
46,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
46,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
47,"Eptifibatide","DB00063","Monitor therapy due to increased adverse effects of collagenase including risk of injection site bruising or bleeding."
50,"Canakinumab","DB06168","Increases immunosuppressive effects and risk of infection. "
50,"Infliximab","DB00065","Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided. "
50,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
50,"Tofacitinib","DB08895","Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
50,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
51,"Acarbose","DB00284","Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars."
51,"Chlorpropamide","DB00672","Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars."
51,"Exenatide","DB01276","Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars."
51,"Gliclazide","DB01120","Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars."
51,"Glimepiride","DB00222","Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars."
51,"Glipizide","DB01067","Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars."
51,"Glyburide","DB01016","Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars."
51,"Insulin Aspart","DB01306","Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars."
51,"Insulin Detemir","DB01307","Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars."
51,"Insulin Glargine","DB00047","Somatropin may antagonize the hypoglycemic effect of insulin glargine. Monitor for changes in fasting and postprandial blood sugars. "
51,"Insulin Glulisine","DB01309","Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars."
51,"Liraglutide","DB06655","Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars."
51,"Metformin","DB00331","Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars."
51,"Miglitol","DB00491","Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars."
51,"Nateglinide","DB00731","Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars."
51,"Pioglitazone","DB01132","Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars."
51,"Rosiglitazone","DB00412","Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars."
51,"Saxagliptin","DB06335","Somatropin may antagonize the hypoglycemic effect of saxagliptin. Monitor for changes in fasting and postprandial blood sugars."
51,"Sitagliptin","DB01261","Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars."
51,"Tolazamide","DB00839","Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required."
51,"Tolbutamide","DB01124","Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required."
53,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
53,"Tirofiban","DB00775","Additive effects. Concomitant use is contraindicated."
53,"Trastuzumab","DB00072","Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab."
53,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy. "
54,"Clopidogrel","DB00758","Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents."
54,"Dalteparin","DB06779","Low molecular weight heparin (LMWH) such as dalteparin may enhance the adverse/toxic effect of drotrecogin alfa. Bleeding may occur. "
54,"Enoxaparin","DB01225","Combination should be used with caution after weighing advantages and disadvantages. Low molecular weight heparins such as enoxaparin may increase the adverse effects of drotrecogin. Monitor for bleeding if used concomitantly. "
54,"Fondaparinux sodium","DB00569","Drotrecogin alfa may increase the adverse effects of fondaparinux, resulting in excessive bleeding. Concomitant use should be avoided."
54,"Heparin","DB01109","The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. "
54,"Ketoprofen","DB01009","The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. "
54,"Nadroparin","DB08813","The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. "
54,"Tenecteplase","DB00031","Increased risk of bleeding. "
54,"Tinzaparin","DB06822","Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs."
54,"Tolmetin","DB00500","Increased risk of bleeding. Monitor for increased bleeding during concomitant therapy. "
54,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy. "
54,"Urokinase","DB00013","Increased risk of bleeding. "
54,"Vilazodone","DB06684","Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents. "
54,"Warfarin","DB00682","Increased risk of bleeding."
55,"Belimumab","DB08879","Avoid combination due to enhanced adverse effects of belimumab."
55,"Clozapine","DB00363","Avoid combination due to adverse effects of clozapine including the risk of agranulocytosis."
55,"Denosumab","DB06643","Monitor therapy due to enhanced adverse effects of immunosuppressants including the risk of infections. "
55,"Leflunomide","DB01097","Consider modifying therapy due to adverse effects of leflunomide including the risk of hematologic toxicity."
55,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections."
55,"Pimecrolimus","DB00337","Avoid combination due to toxic effects of immunosuppressants."
55,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive effect."
55,"Sipuleucel-T","DB06688","Monitor therapy due to reduced therapeutic effect of sipuleucel-t."
55,"Tacrolimus","DB00864","Avoid combination of adverse effects of immunosuppressants."
55,"Tofacitinib","DB08895","Avoid combination due to enhancement of immunosuppressants."
55,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
58,"Denosumab","DB06643","Monitor therapy due to increased immunosuppressive effect and risk of infections."
58,"Leflunomide","DB01097","Immunosuppressants can increase toxic effects of leflunomide such as hematologic toxicity."
58,"Natalizumab","DB00108","Avoid combination because of increased immunosuppressants and risk of infections."
58,"Pimecrolimus","DB00337","Avoid combination because pimecrolimus enhances the adverse effects of immunosuppressants."
58,"Roflumilast","DB01656","Consider therapy modification because pegaspargase enhances the immunosuppressive effect of roflumilast."
58,"Sipuleucel-T","DB06688","Monitor therapy because pegaspargase may diminish therapeutic effect of sipuleucel-T."
58,"Tacrolimus","DB00864","Tacrolimus enhances adverse effects of pegaspargase therefore the combination should be avoided."
58,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
58,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
60,"Pentostatin","DB00552","Avoid combination due to decreased effect of both drugs"
62,"Apixaban","DB06605","Monitor therapy due to potential risk of bleeding. "
62,"Collagenase","DB00048","Monitor therapy due to increased adverse effects of collagenase including risk of injection site bruising or bleeding."
62,"Dabigatran etexilate","DB06695","Monitor therapy due to increased bleeding."
62,"Dasatinib","DB01254","Monitor therapy due to enhanced anticoagulant effect."
62,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
62,"Glucosamine","DB01296","Monitor therapy due to enhanced antiplatelet effect."
62,"Ibritumomab","DB00078","Monitor therapy due to enhanced adverse effects, ie bleeding of ibritumomab."
62,"Obinutuzumab","DB08935","Monitor therapy due to increased risk of bleeding events."
62,"Pentosan Polysulfate","DB00686","Pentosan can potentiate adverse effects of antiplatelet agents and thus increase bleeding risk. Combination must be used with caution."
62,"Pentoxifylline","DB00806","Monitor therapy due to enhanced antiplatelet effect."
62,"Rivaroxaban","DB06228","Consider modifying therapy due to enhanced anticoagulant effect."
62,"Tipranavir","DB00932","Monitor therapy due to increased antiplatelet effect."
62,"Tirofiban","DB00775","Additive effects. Concomitant use is contraindicated."
62,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy. "
64,"Abatacept","DB01281","The combination shoould be avoided as there have been reports of increased risk of serious infections. "
64,"Adalimumab","DB00051","Both bind to TNF alfa and thus combination results in enhanced immunosuppressive effect. It is recommended that simultaneous use of both agents be avoided. "
64,"Anakinra","DB00026","Combination may enhance the toxic effect of Anakinra and should be avoided otherwise there may be an increased risk of infection"
64,"Canakinumab","DB06168","Avoid combination due to increased risk of infection as anti-TNF agents enhance adverse effects of Canakinumab."
64,"Certolizumab pegol","DB08904","Avoid combination because anti-TNF agents increase adverse effects of certolizumab pegol"
64,"Denosumab","DB06643","Therapy should be monitored when combination is initiated as there may be an increase in serious infections. "
64,"Etanercept","DB00005","Avoid combination because etanercept may increase immunosuppressive effects of infliximab."
64,"golimumab","DB06674","Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.\
\
"
64,"Leflunomide","DB01097","Therapy modification should be considered in order to reduce the risk of hematologic toxicities."
64,"Natalizumab","DB00108","Increase adverse effects of natalizumab. Avoid combination"
64,"Pimecrolimus","DB00337","Pimecrolimus enhances the adverse effects of immune suppressants thus the combination should be avoided."
64,"Rilonacept","DB06372","Anti-TNF alfa agents enhance adverse effects of rilonacept thus combination should be avoided."
64,"Roflumilast","DB01656","Roflumilast enhances the adverse effects of immune suppressants thus a therapy modification should be considered."
64,"Sipuleucel-T","DB06688","Monitoring is required because immunosuppressants can decrease the therapeutic effect of Sipuleucel-T."
64,"Tacrolimus","DB00864","Avoid combination because of risk of enhance adverse effects of immunosuppressants"
64,"Tocilizumab","DB06273","Avoid combination because enhanced immunosuppression by anti-TNF agents."
64,"Tofacitinib","DB08895","Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects.\
"
64,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
67,"Zidovudine","DB00495","The interferon increases the effect and toxicity of zidovudine"
69,"Dopamine","DB00988","Consider modifying therapy due to enhanced adverse effects of dopamine."
69,"Phenylephrine","DB00388","Avoid combination because hyaluronidase can potentiate the vasoconstrictive effect of phenylephrine."
71,"Abatacept","DB01281","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Abciximab","DB00054","Abciximab may increase the risk of a hypersensitivy reaction to Trastuzumab."
71,"Adalimumab","DB00051","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Alemtuzumab","DB00087","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Altretamine","DB00488","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Amsacrine","DB00276","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Anakinra","DB00026","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Antithymocyte globulin","DB00098","Monitor therapy due to enhanced neutropenic effect"
71,"Asparaginase","DB00023","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Azacitidine","DB00928","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Azathioprine","DB00993","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Basiliximab","DB00074","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Belatacept","DB06681","Monitor therapy due to enhanced neutropenic effect of immunosuppressants. "
71,"Betamethasone","DB00443","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Bleomycin","DB00290","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Busulfan","DB01008","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Capecitabine","DB01101","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Carboplatin","DB00958","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Carmustine","DB00262","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Chlorambucil","DB00291","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cisplatin","DB00515","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cladribine","DB00242","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Clofarabine","DB00631","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Corticotropin","DB01285","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cortisone acetate","DB01380","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cyclophosphamide","DB00531","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cyclosporine","DB00091","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Cytarabine","DB00987","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Dacarbazine","DB00851","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Daclizumab","DB00111","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Dactinomycin","DB00970","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Daunorubicin","DB00694","Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Denileukin diftitox","DB00004","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Dexamethasone","DB01234","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Docetaxel","DB01248","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Doxorubicin","DB00997","Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Efalizumab","DB00095","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Epirubicin","DB00445","Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Erlotinib","DB00530","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Estramustine","DB01196","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Etanercept","DB00005","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Etoposide","DB00773","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Floxuridine","DB00322","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Fludarabine","DB01073","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Fludrocortisone","DB00687","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Fluorouracil","DB00544","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Gefitinib","DB00317","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Gemcitabine","DB00441","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Gemtuzumab ozogamicin","DB00056","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
71,"Glatiramer Acetate","DB05259","Monitor therapy due to enhanced neutropenic effects of immunosuppressants."
71,"Hydrocortisone","DB00741","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Hydroxyurea","DB01005","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Ibritumomab","DB00078","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Ibritumomab","DB00078","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
71,"Idarubicin","DB01177","Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Ifosfamide","DB01181","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Imatinib","DB00619","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Infliximab","DB00065","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Irinotecan","DB00762","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Lenalidomide","DB00480","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Lomustine","DB01206","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Mechlorethamine","DB00888","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Melphalan","DB01042","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Mercaptopurine","DB01033","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Methotrexate","DB00563","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Methylprednisolone","DB00959","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Mitomycin","DB00305","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Mitoxantrone","DB01204","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Muromonab","DB00075","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Mycophenolate mofetil","DB00688","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Mycophenolic acid","DB01024","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Natalizumab","DB00108","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Nelarabine","DB01280","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Nilotinib","DB04868","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Obinutuzumab","DB08935","Monitor therapy due to enhanced neutropenic effect of immunosuppressants\
"
71,"Omalizumab","DB00043","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
71,"Oxaliplatin","DB00526","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Paclitaxel","DB01229","Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.  "
71,"Pegaspargase","DB00059","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Pentostatin","DB00552","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Prednisolone","DB00860","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Prednisone","DB00635","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Procarbazine","DB01168","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Rilonacept","DB06372","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Rituximab","DB00073","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Sirolimus","DB00877","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Sorafenib","DB00398","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Streptozocin","DB00428","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Sunitinib","DB01268","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Tacrolimus","DB00864","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Temozolomide","DB00853","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Temsirolimus","DB06287","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Teniposide","DB00444","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Thalidomide","DB01041","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Thiotepa","DB04572","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Tioguanine","DB00352","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Tofacitinib","DB08895","Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy. "
71,"Topotecan","DB01030","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Tositumomab","DB00081","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Tretinoin","DB00755","Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy."
71,"Triamcinolone","DB00620","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Valrubicin","DB00385","Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
71,"Vinblastine","DB00570","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Vincristine","DB00541","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
71,"Vinorelbine","DB00361","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
72,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of abatacept."
72,"Aliskiren","DB09026","Consider therapy modification due to enhanced hypotensive effect of rituximab."
72,"Azilsartan medoxomil","DB08822","Azilsartan medoxomil used in combination with rituximab may lead to hypotension."
72,"Betaxolol","DB00195","Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion. "
72,"Certolizumab pegol","DB08904","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
72,"Chlorothiazide","DB00880","Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion."
72,"Telmisartan","DB00966","Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration. "
72,"Terazosin","DB01162","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab."
72,"Tofacitinib","DB08895","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
\
"
72,"Tolazamide","DB00839","Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab."
72,"Torasemide","DB00214","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab."
72,"Trandolapril","DB00519","Trandolapril may incresae the hypotensive effect of Rituximab. "
72,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
72,"Trichlormethiazide","DB01021","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab."
72,"Valsartan","DB00177","Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab."
72,"Verapamil","DB00661","Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion. "
73,"Canakinumab","DB06168","results in increased immunosuppressive effects; increases the risk of infection. "
73,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
73,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
74,"Cyclosporine","DB00091","Muromonab increases the levels of cyclosporine"
74,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
74,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
75,"Cinitapride","DB08810","Cinitapride can alter the absorption of digoxin as it simulates gastric emptying."
76,"Belimumab","DB08879","Avoid combination due to enhanced adverse effects of belimumab."
76,"Clozapine","DB00363","Avoid combination due to enhanced adverse effects of clozapine, including agranulocytosis."
76,"Denosumab","DB06643","Monitor therapy for enhanced immunosuppressive effects and increased risk of infections."
76,"Eptifibatide","DB00063","Monitor therapy due to enhanced adverse effects, ie bleeding of ibritumomab."
76,"Leflunomide","DB01097","May need to modify therapy to avoid adverse effects of leflunomide such as hematologic toxicity."
76,"Natalizumab","DB00108","Avoid combination due to increased adverse effects of natalizumab and increased risk of infections."
76,"Pimecrolimus","DB00337","Avoid combination due to increased immunosuppressive effects."
76,"Roflumilast","DB01656","Consider modifying therapy due to enhanced immunosuppressive effect."
76,"Sipuleucel-T","DB06688","Monitor therapy due to diminished therapeutic effect of sipuleucel-t."
76,"Tacrolimus","DB00864","Avoid combination due to enhanced adverse effects of immunosuppressants. "
76,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
76,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
76,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect of immunosuppressants."
78,"Natalizumab","DB00108","The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
78,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
79,"Dihydrocodeine","DB01551","Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy. "
79,"Exenatide","DB01276","Monitor therapy due to enhanced hypoglycemic effect."
79,"Insulin Aspart","DB01306","Monitor therapy due to enhanced hypoglycemic effect."
81,"Iron","DB01592","If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose."
82,"Ticlopidine","DB00208","Increased bleeding risk. Monitor for signs of bleeding."
83,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
85,"Buserelin","DB06719","Avoid combination because luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide."
87,"Acetazolamide","DB00819","Acetazolamide may increase the effect and toxicity of cyclosporine."
87,"Aliskiren","DB09026","Avoid combination because cyclosporine increases aliskiren serum concentration."
87,"Allopurinol","DB00437","Allopurinol increases the effect and toxicity of cyclosporine"
87,"Amiodarone","DB01118","Amiodarone may increase the therapeutic and adverse effects of cyclosporine."
87,"Amobarbital","DB01351","The barbiturate, amobarbital, increases the effect of cyclosporine."
87,"Amphotericin B","DB00681","Monitor for nephrotoxicity"
87,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may increase the effect of cyclosporine."
87,"Aprobarbital","DB01352","The barbiturate, aprobarbital, increases the effect of cyclosporine."
87,"Atazanavir","DB01072","Atazanavir may increase the therapeutic and adverse effects of cyclosporine."
87,"Atorvastatin","DB01076","Possible myopathy and rhabdomyolysis"
87,"Azithromycin","DB00207","The macrolide, azithromycin, may increase the effect of cyclosporine."
87,"Bezafibrate","DB01393","Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary."
87,"Bosentan","DB00559","Cyclosporine may increase the effect and toxicity of bosentan."
87,"Bupropion","DB01156","Bupropion may decrease the therapeutic effect of cyclosporine."
87,"Butabarbital","DB00237","The barbiturate, butabarbital, increases the effect of cyclosporine."
87,"Butalbital","DB00241","The barbiturate, butalbital, increases the effect of cyclosporine."
87,"Butethal","DB01353","The barbiturate, butethal, increases the effect of cyclosporine."
87,"Carbamazepine","DB00564","Carbamazepine may decrease the therapeutic effect of cyclosporine."
87,"Carvedilol","DB01136","Carvedilol may increase the therapeutic and adverse effects of cyclosporine."
87,"Caspofungin","DB00520","Cyclosporine increases the effect and toxicity of caspofungin"
87,"Cerivastatin","DB00439","Possible myopathy and rhabdomyolysis"
87,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of cyclosporine."
87,"Chloroquine","DB00608","Chloroquine may increase the therapeutic and adverse effects of cyclosporine."
87,"Cilastatin","DB01597","Imipenem increases the effect and toxicity of cyclosporine"
87,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect and toxicity of cyclosporine."
87,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of cyclosporine."
87,"Clindamycin","DB01190","Clindamycin may decrease the therapeutic effect of cyclosporine."
87,"Colchicine","DB01394","Increased toxicity of both drugs"
87,"Danazol","DB01406","The androgen, danazol, may increase the effect and toxicity of cyclosporine."
87,"Diclofenac","DB00586","Monitor for nephrotoxicity"
87,"Digoxin","DB00390","Cyclosporine may increase the effect of digoxin."
87,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine."
87,"Diltiazem","DB00343","Diltiazem may increase the effect and toxicity of cyclosporine."
87,"Dronedarone","DB04855","Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
87,"Efavirenz","DB00625","Efavirenz decreases the levels of cyclosporine"
87,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of cyclosporine."
87,"Ethinyl Estradiol","DB00977","The contraceptive increases the effect and toxicity of cyclosporine"
87,"Ethotoin","DB00754","The hydantoin decreases the effect of cyclosporine"
87,"Etodolac","DB00749","Monitor for nephrotoxicity"
87,"Etoposide","DB00773","Cyclosporine may increase the therapeutic and adverse effects of etoposide."
87,"Ezetimibe","DB00973","Cyclosporine may increase the therapeutic and adverse effects of ezetimibe."
87,"Fenoprofen","DB00573","Monitor for nephrotoxicity"
87,"Fidaxomicin","DB08874","Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite. "
87,"Fluconazole","DB00196","Fluconazole may increase the therapeutic and adverse effects of the cyclosporine."
87,"Fluoxetine","DB00472","The antidepressant increases the effect and toxicity of cyclosporine"
87,"Flurbiprofen","DB00712","Monitor for nephrotoxicity"
87,"Fluvastatin","DB01095","Possible myopathy and rhabdomyolysis"
87,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine."
87,"Foscarnet","DB00529","Monitor for nephrotoxicity"
87,"Fosphenytoin","DB01320","The hydantoin decreases the effect of cyclosporine"
87,"Glimepiride","DB00222","The sulfonylurea, glimepiride, may increase the effect of cyclosporine."
87,"Glipizide","DB01067","The sulfonylurea, glipizide, may increase the effect of cyclosporine."
87,"Glyburide","DB01016","The sulfonylurea, glibenclamide, may increase the effect of cyclosporine."
87,"Griseofulvin","DB00400","Griseofulvin decreases the effect of cyclosporine"
87,"Heptabarbital","DB01354","The barbiturate, heptabarbital, increases the effect of cyclosporine."
87,"Hexobarbital","DB01355","The barbiturate, hexobarbital, increases the effect of cyclosporine."
87,"Ibuprofen","DB01050","Monitor for nephrotoxicity"
87,"Imatinib","DB00619","Imatinib increases the effect and toxicity of cyclosporine"
87,"Imipenem","DB01598","Imipenem increases the effect and toxicity of cyclosporine"
87,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of cyclosporine."
87,"Indomethacin","DB00328","Monitor for nephrotoxicity"
87,"Itraconazole","DB01167","Itraconazole may increase the effect of cyclosporine."
87,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of cyclosporine."
87,"Ketoconazole","DB01026","Ketoconazole may increase the effect of cyclosporine."
87,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine."
87,"Lovastatin","DB00227","Possible myopathy and rhabdomyolysis"
87,"Meclofenamic acid","DB00939","Monitor for nephrotoxicity"
87,"Mefenamic acid","DB00784","Monitor for nephrotoxicity"
87,"Melphalan","DB01042","Melphalan increases toxicity of cyclosporine"
87,"Mephenytoin","DB00532","The hydantoin decreases the effect of cyclosporine"
87,"Mestranol","DB01357","The contraceptive increases the effect and toxicity of cyclosporine"
87,"Methohexital","DB00474","The barbiturate, methohexital, increases the effect of cyclosporine."
87,"Methotrexate","DB00563","Cyclosporine may increase the effect and toxicity of methotrexate."
87,"Methylphenidate","DB00422","Methylphenidate increases the effect and toxicity of cyclosporine"
87,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, increases the effect of cyclosporine."
87,"Metoclopramide","DB01233","Metoclopramide increases serum levels of cyclosporine"
87,"Modafinil","DB00745","Modafinil decreases the effect of cyclosporine"
87,"Muromonab","DB00075","Muromonab increases the levels of cyclosporine"
87,"Nabumetone","DB00461","Monitor for nephrotoxicity"
87,"Nafcillin","DB00607","Nafcillin alters serum levels of cyclosporine"
87,"Naproxen","DB00788","Monitor for nephrotoxicity"
87,"Nefazodone","DB01149","The antidepressant increases the effect and toxicity of cyclosporine"
87,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of cyclosporine."
87,"Nicardipine","DB00622","Nicardipine increases the effect and toxicity of cyclosporine"
87,"Nifedipine","DB01115","Increased risk of gingivitis"
87,"Norfloxacin","DB01059","Norfloxacin may increase the effect and toxicity of cyclosporine."
87,"Octreotide","DB00104","Octreotide decreases the effect of cyclosporine"
87,"Omeprazole","DB00338","Omeprazole increases the effect and toxicity of cyclosporine"
87,"Orlistat","DB01083","Orlistat decreases the effect of cyclosporine"
87,"Oxaprozin","DB00991","Monitor for nephrotoxicity"
87,"Oxcarbazepine","DB00776","Oxcarbazepine decreases the effect of cyclosporine"
87,"Pentobarbital","DB00312","The barbiturate, pentobarbital, increases the effect of cyclosporine."
87,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism."
87,"Phenytoin","DB00252","The hydantoin decreases the effect of cyclosporine"
87,"Piroxicam","DB00554","Monitor for nephrotoxicity"
87,"Pitavastatin","DB08860","Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."
87,"Posaconazole","DB01263","Increased level of cyclosporine"
87,"Pravastatin","DB00175","Possible myopathy and rhabdomyolysis"
87,"Primidone","DB00794","The barbiturate, primidone, increases the effect of cyclosporine."
87,"Probucol","DB01599","Probucol decreases the effect of cyclosporine"
87,"Propafenone","DB01182","Propafenone increases the effect and toxicity of cyclosporine"
87,"Pyrazinamide","DB00339","Pyrazinamide decreases the effect of cyclosporine"
87,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, increases the effect of cyclosporine."
87,"Quinupristin","DB01369","Synercid increases the effect of cyclosporine"
87,"Repaglinide","DB00912","Cyclosporine may increase the therapeutic and adverse effects of repaglinide."
87,"Rifabutin","DB00615","The rifamycin decreases the effect of cyclosporine"
87,"Rifampicin","DB01045","The rifamycin decreases the effect of cyclosporine"
87,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
87,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of cyclosporine."
87,"Rosuvastatin","DB01098","Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed."
87,"Roxithromycin","DB00778","The macrolide, roxithromycin, may increase the effect of cyclosporine."
87,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of cyclosporine."
87,"Secobarbital","DB00418","The barbiturate, secobarbital, increases the effect of cyclosporine."
87,"Sevelamer","DB00658","Sevelamer decreases the effect of cyclosporine"
87,"Sibutramine","DB01105","Sibutramine increases the effect and toxicity of cyclosporine"
87,"Simvastatin","DB00641","Possible myopathy and rhabdomyolysis"
87,"Sirolimus","DB00877","Increases the effect and toxicity of sirolimus"
87,"St. John's Wort","DB01323","St. John's Wort decreases the effect of cyclosporine"
87,"Sulfadiazine","DB00359","The sulfonamide decreases the effect of cyclosporine"
87,"Sulfamethazine","DB01582","The sulfonamide decreases the effect of cyclosporine"
87,"Sulfamethoxazole","DB01015","The sulfonamide decreases the effect of cyclosporine"
87,"Sulfasalazine","DB00795","The sulfonamide decreases the effect of cyclosporine"
87,"Sulfinpyrazone","DB01138","Sulfinpyrazone decreases the effect of cyclosporine"
87,"Sulindac","DB00605","The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy."
87,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided."
87,"Talbutal","DB00306","The sulfonamide decreases the effect of cyclosporine"
87,"Tamsulosin","DB00706","Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed."
87,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. "
87,"Telithromycin","DB00976","Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed."
87,"Tenoxicam","DB00469","Monitor for nephrotoxicity"
87,"Terbinafine","DB00857","Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine."
87,"Testolactone","DB00894","The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. "
87,"Testosterone","DB00624","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. "
87,"Testosterone Propionate","DB01420","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."
87,"Thiopental","DB00599","Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed."
87,"Tiaprofenic acid","DB01600","Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy."
87,"Ticlopidine","DB00208","Ticlopidine decreases the effect of cyclosporine"
87,"Tipranavir","DB00932","Tipranavir may affect the efficacy/toxicity of Cyclosporine. "
87,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
87,"Tofacitinib","DB08895","Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy. "
87,"Tolmetin","DB00500","Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy."
87,"Tolterodine","DB01036","Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
87,"Topotecan","DB01030","The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
87,"Tramadol","DB00193","Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
87,"Trandolapril","DB00519","The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine. "
87,"transdermal testosterone gel","DB05275","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."
87,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
87,"Trazodone","DB00656","The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed."
87,"Troglitazone","DB00197","Troglitazone decreases the effect of the immunosuppressant"
87,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect of cyclosporine."
87,"Ursodeoxycholic acid","DB01586","Ursodiol increases the levels of cyclosporine"
87,"Verapamil","DB00661","Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed."
87,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy."
88,"Canakinumab","DB06168","Increases immunosuppressive effects and risk of infection. "
88,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
91,"Ergonovine","DB01253","The antiretroviral agent may increase the ergot derivative"
91,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
91,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
94,"Canakinumab","DB06168","results in increased immunosuppressive effects; increases the risk of infection. "
94,"Denosumab","DB06643","Monitor therapy because of the enhanced immunosuppressive effect and increased risk of infections."
94,"Leflunomide","DB01097","Therapy modification may be required because the combination enhances toxic effects of leflunomide. "
94,"Natalizumab","DB00108","Avoid combination due to enhanced toxic effects of natalizumab."
94,"Pimecrolimus","DB00337","Avoid combination due to enhanced immunosuppressive effects and increased risk of infections."
94,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
94,"Roflumilast","DB01656","Therapy may need to be modified due to enhanced immunosuppressive effects."
94,"Sipuleucel-T","DB06688","Monitor therapy due to potential decreased therapeutic effect of sipuleucel-T."
94,"Tacrolimus","DB00864","Avoid combination due to increased immunosuppressive effects"
94,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effects."
94,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect"
95,"Bleomycin","DB00290","Monitor therapy due to enhanced adverse effects of bleomycin especially pulmonary toxicity."
95,"Cyclophosphamide","DB00531","Monitor therapy due to adverse effects of cyclophosphamide, especially pulmonary toxicity."
95,"Topotecan","DB01030","Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia. "
99,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
99,"Cyclosporine","DB00091","Octreotide decreases the effect of cyclosporine"
99,"Dihydrocodeine","DB01551","Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.  "
99,"Insulin Lispro","DB00046","Concomitant therapy with somatostatin analogs may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
99,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
99,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
99,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
99,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
99,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
99,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
99,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
99,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
99,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
99,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
100,"Aminophylline","DB01223","Interferon increases the effect and toxicity of theophylline"
100,"Dyphylline","DB00651","Interferon increases the effect and toxicity of theophylline"
100,"Oxtriphylline","DB01303","Interferon increases the effect and toxicity of theophylline"
100,"Theophylline","DB00277","Interferon increases the effect and toxicity of theophylline"
101,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
101,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
101,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
101,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
101,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). "
101,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
101,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. "
101,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
102,"Carboprost Tromethamine","DB00429","Avoid combination due to enhanced oxytocic effects. "
102,"Dinoprostone","DB00917","Therapy modification should be considered because of enhanced oxytocic effects"
102,"Epinephrine","DB00668","Possible marked increase of arterial pressure"
102,"Mifepristone","DB00834","Consider therapy modification because of potential enhanced effect of Q-Tc prolongation"
102,"Misoprostol","DB00929","Avoid combination. Manufacturer advises not to administer concomitantly due to enhanced adverse effects of oxytocin, especially when given within 4 hours of oxytocin initiation. "
102,"Phenylephrine","DB00388","Possible marked increase of arterial pressure"
103,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of natalizumab and the risk of infections."
103,"ado-trastuzumab emtansine","DB05773","Avoid combination due to the increased risk of infection."
103,"Antithymocyte globulin","DB00098","Avoid combination due to enhanced toxic effects of natalizumab."
103,"Belatacept","DB06681","Avoid infection due to enhanced adverse effects of natalizumab and the risk of infections. "
103,"Belimumab","DB08879","Avoid combination due to enhance adverse effects of natalizumab such as the risk of concurrent infections. "
103,"Bleomycin","DB00290","Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
103,"Brentuximab vedotin","DB08870","Avoid combination due to the increased risk of concurrent infection."
103,"Canakinumab","DB06168","Avoid combination due to the increased risk of infection.\
\
"
103,"Carboplatin","DB00958","Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
103,"Carmustine","DB00262","Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
103,"Certolizumab pegol","DB08904","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
103,"Chlorambucil","DB00291","Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
103,"Cisplatin","DB00515","Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab."
103,"Cladribine","DB00242","Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. "
103,"Clofarabine","DB00631","Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. "
103,"Etanercept","DB00005","Avoid combination due to enhanced adverse effects of natalizumab and increased risk of infections."
103,"Gemtuzumab ozogamicin","DB00056","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections."
103,"Glatiramer Acetate","DB05259","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections."
103,"golimumab","DB06674","Avoid combination due to the increased chance of infection.\
\
"
103,"Homoharringtonine","DB04865","Avoid combination due to the increased risk of infection.\
"
103,"Ibritumomab","DB00078","Avoid combination due to increased adverse effects of natalizumab and increased risk of infections."
103,"Infliximab","DB00065","Increase adverse effects of natalizumab. Avoid combination"
103,"Obinutuzumab","DB08935","Avoid combination due to enhanced adverse effects of natalizumab. "
103,"Omalizumab","DB00043","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections. "
103,"Paclitaxel","DB01229","Avoid combination due to the increased risk of infection.\
"
103,"Pegaspargase","DB00059","Avoid combination because of increased immunosuppressants and risk of infections."
103,"Tacrolimus","DB00864","Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."
103,"Temozolomide","DB00853","The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided. "
103,"Temsirolimus","DB06287","Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided."
103,"Teniposide","DB00444","The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
103,"Teriflunomide","DB08880","Avoid combination due to the increased risk of infection.\
\
"
103,"Thalidomide","DB01041","Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."
103,"Thiotepa","DB04572","The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
103,"Tioguanine","DB00352","The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
103,"Tofacitinib","DB08895","Avoid combination due to the increased risk of infection.\
\
"
103,"Topotecan","DB01030","The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
103,"Tositumomab","DB00081","The immunosuppressant, Tositumomab, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
103,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
103,"Tretinoin","DB00755","Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided."
103,"Valrubicin","DB00385","Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided. "
103,"Vinblastine","DB00570","Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided. "
103,"Vincristine","DB00541","Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.\
"
103,"Vinorelbine","DB00361","Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided."
106,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
106,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
107,"Belimumab","DB08879","Avoid combination due to enhanced adverse effects of bevacizumab"
107,"Clozapine","DB00363","Avoid combination due to increased adverse effects of clozapine, especially the risk of agranulocytosis. "
107,"Irinotecan","DB00762","Monitor therapy due to increased adverse effects of irinotecan."
107,"Sorafenib","DB00398","Monitor therapy due to increased adverse effects of sorafenib, especially hand-foot skin reaction."
107,"Sunitinib","DB01268","Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated."
113,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
113,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
113,"Ketoprofen","DB01009","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
113,"Sulindac","DB00605","S-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided. "
113,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
113,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
113,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
113,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
113,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
113,"Warfarin","DB00682","Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided."
113,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
120,"Deferoxamine","DB00746","Vitamin C may increase the adverse effects of deferoxamine. Transient deterioration of left ventricular function has been observed during concomitant therapy. Use caution during concomitant therapy. "
120,"Indinavir","DB00224","Vitamin C decreases indinavir levels"
130,"Cholecalciferol","DB00169","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
130,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
130,"Telithromycin","DB00976","Telithromycin may reduce clearance of Calcitriol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Calcitriol if Telithromycin is initiated, discontinued or dose changed."
130,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of calcitriol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed."
144,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
144,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
144,"Vilazodone","DB06684","Due to risks of enhanced serotonin activity and/or adverse reactions (e.g., serotonin syndrome), concomitant use of selective serotonin reuptake inhibitors (SSRIs) and tryptophan is not recommended. Avoid combination."
144,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
147,"Cholecalciferol","DB00169","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
147,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
152,"Amobarbital","DB01351","Folic acid decreases the effect of anticonvulsant, amobarbital."
152,"Aprobarbital","DB01352","Folic acid decreases the effect of anticonvulsant, aprobarbital."
152,"Butabarbital","DB00237","Folic acid decreases the effect of anticonvulsant, butabarbital."
152,"Butalbital","DB00241","Folic acid decreases the effect of anticonvulsant, butalbital."
152,"Butethal","DB01353","Folic acid decreases the effect of anticonvulsant, butethal."
152,"Dihydroquinidine barbiturate","DB01341","Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate."
152,"Ethotoin","DB00754","Folic acid decreases the levels of hydantoin"
152,"Fosphenytoin","DB01320","Folic acid decreases the levels of hydantoin"
152,"Heptabarbital","DB01354","Folic acid decreases the effect of anticonvulsant, heptabarbital."
152,"Hexobarbital","DB01355","Folic acid decreases the effect of anticonvulsant, hexobarbital."
152,"Mephenytoin","DB00532","Folic acid decreases the levels of hydantoin"
152,"Methohexital","DB00474","Folic acid decreases the effect of anticonvulsant, methohexital."
152,"Methylphenobarbital","DB00849","Folic acid decreases the effect of anticonvulsant, methylphenobarbital."
152,"Pentobarbital","DB00312","Folic acid decreases the effect of anticonvulsant, pentobarbital."
152,"Phenobarbital","DB01174","Folic acid decreases the effect of anticonvulsant, phenobarbital."
152,"Phenytoin","DB00252","Folic acid may decrease the levels of phenytoin."
152,"Primidone","DB00794","Folic acid decreases the effect of anticonvulsant, primidone."
152,"Quinidine barbiturate","DB01346","Folic acid decreases the effect of anticonvulsant, quinidine barbiturate."
152,"Secobarbital","DB00418","Folic acid decreases the effect of anticonvulsant, secobarbital."
152,"Talbutal","DB00306","Folic acid decreases the effect of anticonvulsant, talbutal."
156,"Acitretin","DB00459","Acitretin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking acitretin. "
156,"Bexarotene","DB00307","Bexarotene increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking bexarotene."
156,"Isotretinoin","DB00982","Isotretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking isotretinoin."
156,"Orlistat","DB01083","Orlistat may impair the absorption of vitamin A, a fat soluble vitamin. Oral vitamin A should be administered 2 hours prior to or post orlistat administration. "
156,"Tretinoin","DB00755","Tretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking systemic tretinoin."
157,"Amprenavir","DB00701","Increased serum levels of vitamin E"
157,"Orlistat","DB01083","Orlistat may impair the absorption of vitamin E, a fat soluble vitamin. Oral vitamin E should be administered 2 hours prior to or post orlistat administration.\
"
162,"Alfacalcidol","DB01436","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Aluminum hydroxide","DB06723","Vitamin D analogs such as cholecalciferol may increase the serum concentration of aluminum hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
162,"Calcipotriol","DB02300","Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). hough not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Calcitriol","DB00136","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Cholestyramine","DB01432","Bile acid sequestrants such as cholestyramine may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
162,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
162,"Colestipol","DB00375","Bile acid sequestrants such as colestipol may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
162,"Doxercalciferol","DB06410","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Ergocalciferol","DB00153","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Orlistat","DB01083","Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat. "
162,"Paricalcitol","DB00910","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
162,"Sucralfate","DB00364","Vitamin D analogs such as cholecalciferol may increase the serum concentration of sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
168,"Bezafibrate","DB01393","Increased risk of myopathy/rhabdomyolysis"
168,"Boceprevir","DB08873","Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored. "
168,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
168,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction. "
168,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
168,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
168,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
168,"Repaglinide","DB00912","Substrates of organic anion transporters may increase levels of repaglinide. Monitor concomitant therapy closely. "
168,"Tipranavir","DB00932","Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy."
169,"Acenocoumarol","DB01418","Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
169,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
169,"Aminophylline","DB01223","Fluvoxamine may increase the effect and toxicity of aminophylline."
169,"Amitriptyline","DB00321","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed."
169,"Amoxapine","DB00543","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed."
169,"Amphetamine","DB00182","Risk of serotoninergic syndrome"
169,"Anisindione","DB01125","Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration."
169,"Asenapine","DB06216","Fluvoxamine is a CYP1A2 inhibitor that increases exposure of asenapine by 30%. "
169,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
169,"Bendamustine","DB06769","Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. "
169,"Benzphetamine","DB00865","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
169,"Carbamazepine","DB00564","Fluvoxamine increases the effect of carbamazepine"
169,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
169,"Cilostazol","DB01166","Fluvoxamine increases the effect of cilostazol"
169,"Clomipramine","DB01242","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed."
169,"Clozapine","DB00363","The antidepressant increases the effect of clozapine"
169,"Desipramine","DB01151","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed."
169,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
169,"Dexfenfluramine","DB01191","Risk of serotoninergic syndrome"
169,"Dextroamphetamine","DB01576","Risk of serotoninergic syndrome"
169,"Dicoumarol","DB00266","Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
169,"Diethylpropion","DB00937","Risk of serotoninergic syndrome"
169,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
169,"Doxepin","DB01142","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed."
169,"Duloxetine","DB00476","Fluvoxamine increases the effect and toxicity of duloxetine"
169,"Dyphylline","DB00651","Increases the effect and toxicity of theophylline"
169,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
169,"Eltrombopag","DB06210","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
169,"Eltrombopag","DB06210","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
169,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
169,"Ethotoin","DB00754","Increases the effect of hydantoin"
169,"Fenfluramine","DB00574","Risk of serotoninergic syndrome"
169,"Fosphenytoin","DB01320","Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin."
169,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
169,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
169,"Imipramine","DB00458","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed."
169,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
169,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
169,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
169,"Lithium","DB01356","The SSRI, fluvoxamine, increases serum levels of lithium."
169,"Mazindol","DB00579","Risk of serotoninergic syndrome"
169,"Mephenytoin","DB00532","Increases the effect of hydantoin"
169,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
169,"Methadone","DB00333","Fluvoxamine increases the effect and toxicity of methadone"
169,"Methamphetamine","DB01577","Risk of serotoninergic syndrome"
169,"Mexiletine","DB00379","Fluvoxamine may increase the therapeutic and adverse effects of mexiletine."
169,"Mirtazapine","DB00370","Fluvoxamine may increase the therapeutic and adverse effects of mirtazapine."
169,"Moclobemide","DB01171","Increased incidence of adverse effects with this association"
169,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
169,"Nortriptyline","DB00540","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed."
169,"Olanzapine","DB00334","Fluvoxamine increases the effect and toxicity of olanzapine"
169,"Oxtriphylline","DB01303","Fluvoxamine may increase the therapeutic and adverse effects of oxtriphylline."
169,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
169,"Phendimetrazine","DB01579","Risk of serotoninergic syndrome"
169,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
169,"Phentermine","DB00191","Risk of serotoninergic syndrome"
169,"Phenylpropanolamine","DB00397","Risk of serotoninergic syndrome"
169,"Phenytoin","DB00252","Fluvoxamine may increase the therapeutic effect of phenytoin."
169,"Protriptyline","DB00344","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed."
169,"Ramelteon","DB00980","Fluvoxamine may increase the serum level and toxicity of ramelteon."
169,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
169,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
169,"Roflumilast","DB01656","Increases roflumilast levels. "
169,"Ropinirole","DB00268","Increases the effect and toxicity of ropinirole"
169,"Ropivacaine","DB00296","Increases the effect and toxicity of ropivacaine"
169,"Selegiline","DB01037","Possible severe adverse reaction with this combination"
169,"Sibutramine","DB01105","Risk of serotoninergic syndrome"
169,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine."
169,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
169,"Tacrine","DB00382","Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine."
169,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed."
169,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
169,"Theophylline","DB00277","Fluvoxamine may increase the therapeutic and adverse effects of theophylline."
169,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed."
169,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
169,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed. "
169,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
169,"Tizanidine","DB00697","Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated."
169,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
169,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizures."
169,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
169,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
169,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy. "
169,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, fluvoxamine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Additive modulation of serotonin activity may also increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome and changes in therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed."
169,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
169,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
169,"Warfarin","DB00682","Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration."
169,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
170,"Amifostine","DB01143","Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Valsartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."
170,"Amiloride","DB00594","Increased risk of hyperkalemia"
170,"Eltrombopag","DB06210","Eltrombopag may increase the therapeutic and/or toxic effects of Valsartan. Increased Valsartan serum concentrations may be caused by inhibition of hepatic uptake and decreased metabolism. Consider dose modification, alternate therapy or monitor for changes in the therapeutic and toxic effects of Valsartan if Eltrombopag is initiated, discontinued or dose changed.  "
170,"Lithium","DB01356","Valsartan may increase serum lithium concentrations. Monitor serum lithium levels during concomitant therapy to avoid lithium toxicity."
170,"Potassium","DB01345","Increased risk of hyperkalemia"
170,"Rituximab","DB00073","Additive hypotensive effects may occur. Increased risk of hypotension. Consider withholding Valsartan for 12 hours prior to administration of Rituximab."
170,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
170,"Trandolapril","DB00519","The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril. "
170,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
170,"Triamterene","DB00384","Increased risk of hyperkalemia"
171,"Amiloride","DB00594","Increased risk of hyperkalemia"
171,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
171,"Drospirenone","DB01395","Increased risk of hyperkalemia"
171,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
171,"Insulin Lispro","DB00046","Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
171,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
171,"Potassium","DB01345","Increased risk of hyperkalemia"
171,"Spironolactone","DB00421","Increased risk of hyperkalemia"
171,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
171,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
171,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
171,"Triamterene","DB00384","Increased risk of hyperkalemia"
173,"Telithromycin","DB00976","Telithromycin may reduce clearance of Flunisolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flunisolide if Telithromycin is initiated, discontinued or dose changed."
173,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flunisolide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flunisolide if voriconazole is initiated, discontinued or dose changed."
174,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Baclofen, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
175,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
175,"Dihydrocodeine","DB01551","Amphetamines may enhance analgesic effects of dihydrocodeine. Monitor for enhanced analgesia. Dose reductions of dihydrocodeine may be appropriate. "
175,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
175,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
175,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
175,"Guanethidine","DB01170","Amphetamine may decrease the effect of guanethidine."
175,"Isocarboxazid","DB01247","Possible hypertensive crisis"
175,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
175,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
175,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
175,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
175,"Phenelzine","DB00780","Possible hypertensive crisis"
175,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase pyschotic symptoms"
175,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms"
175,"Propericiazine","DB01608","Decreased anorexic effect, may increase pyschotic symptoms"
175,"Rasagiline","DB01367","Possible hypertensive crisis"
175,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
175,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
178,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
178,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Cevimeline, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
179,"Clozapine","DB00363","Increased risk of toxicity"
179,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, lorazepam."
179,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Lorazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
179,"Valproic Acid","DB00313","Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity. "
180,"Acetohexamide","DB00414","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Chlorpropamide","DB00672","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
180,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
180,"Disopyramide","DB00280","The beta-blocker, esmolol, may increase the adverse effects of disopyramide."
180,"Epinephrine","DB00668","Hypertension, then bradycardia"
180,"Ergonovine","DB01253","Ischemia with risk of gangrene"
180,"Ergotamine","DB00696","Ischemia with risk of gangrene"
180,"Fenoterol","DB01288","Antagonism"
180,"Formoterol","DB00983","Antagonism"
180,"Gliclazide","DB01120","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Glipizide","DB01067","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Glisoxepide","DB01289","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Glyburide","DB01016","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Glycodiazine","DB01382","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
180,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
180,"Insulin Aspart","DB01306","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Insulin Detemir","DB01307","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Insulin Glargine","DB00047","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Insulin Glulisine","DB01309","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Insulin Lispro","DB00046","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Isoprenaline","DB01064","Antagonism"
180,"Lidocaine","DB00281","The beta-blocker, esmolol, may increase the effect and toxicity of lidocaine."
180,"Methysergide","DB00247","Ischemia with risk of gangrene"
180,"Orciprenaline","DB00816","Antagonism"
180,"Pipobroman","DB00236","Antagonism"
180,"Pirbuterol","DB01291","Antagonism"
180,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
180,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
180,"Procaterol","DB01366","Antagonism"
180,"Repaglinide","DB00912","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Salbutamol","DB01001","Antagonism"
180,"Salmeterol","DB00938","Antagonism"
180,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
180,"Terbutaline","DB00871","Antagonism"
180,"Tolazamide","DB00839","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Tolbutamide","DB01124","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
180,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
180,"Verapamil","DB00661","Increased effect of both drugs"
181,"Clopidogrel","DB00758","Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel. "
181,"Etravirine","DB06414","Bortezombib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
181,"Telithromycin","DB00976","Telithromycin may reduce clearance of Bortezomib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bortezomib if Telithromycin is initiated, discontinued or dose changed."
181,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Bortezomib. Consider alternate therapy or monitor for adverse/toxic effects of Bortezomib if Ticlopidine is initiated, discontinued or dose changed."
181,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bortezomib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bortezomib if voriconazole is initiated, discontinued or dose changed."
182,"Acenocoumarol","DB01418","Ethchlorvynol may decrease the anticoagulant effect of acenocoumarol."
182,"Anisindione","DB01125","Ethchlorvynol may decrease the anticoagulant effect of anisindione."
182,"Dicoumarol","DB00266","Ethchlorvynol may decrease the anticoagulant effect of dicumarol."
182,"Warfarin","DB00682","Ethchlorvynol may decrease the anticoagulant effect of warfarin."
184,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
184,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
184,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
184,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
184,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
184,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
184,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
184,"Guanethidine","DB01170","Phentermine may decrease the effect of guanethidine."
184,"Isocarboxazid","DB01247","Possible hypertensive crisis"
184,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
184,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
184,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
184,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
184,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
184,"Phenelzine","DB00780","Possible hypertensive crisis"
184,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
184,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
184,"Promethazine","DB01069","Decreased anorexic effect, may increase psychotic symptoms."
184,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
184,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
184,"Rasagiline","DB01367","Possible hypertensive crisis"
184,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
184,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
184,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
184,"Trandolapril","DB00519","Phentermine may reduce the efficacy of Trandolapril. "
184,"Tranylcypromine","DB00752","The MAO inhibitor, tranylcypromine, may increase the vasopressor effect of the amphetamine, phentermine. Concomitant therapy should be avoided."
184,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
184,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
184,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Phentermine."
184,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
186,"Almotriptan","DB00918","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
186,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
186,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Amiodarone","DB01118","Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Amitriptyline","DB00321","Tramadol increases the risk of serotonin syndrome and seizures. "
186,"Amoxapine","DB00543","Tramadol increases the risk of serotonin syndrome and seizures. "
186,"Amprenavir","DB00701","Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Aprepitant","DB00673","Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Atazanavir","DB01072","Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Benzphetamine","DB00865","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Bosentan","DB00559","Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Cabergoline","DB00248","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Carbamazepine","DB00564","Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance."
186,"Chloroquine","DB00608","Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Chlorpromazine","DB00477","Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Cimetidine","DB00501","Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Cinacalcet","DB01012","Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Citalopram","DB00215","The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
186,"Clarithromycin","DB01211","Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Clomipramine","DB01242","Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Clotrimazole","DB00257","Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Clozapine","DB00363","Clozapine may decrease the effect of Tramadol by decreasing active metabolite production. \
"
186,"Cocaine","DB00907","Cocaine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Conivaptan","DB00872","Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Cyclobenzaprine","DB00924","Increases risk of seizure. "
186,"Cyclosporine","DB00091","Cyclosporine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Darifenacin","DB00496","Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Darunavir","DB01264","Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Delavirdine","DB00705","Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Desipramine","DB01151","Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Dexamethasone","DB01234","Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Dextroamphetamine","DB01576","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Diltiazem","DB00343","Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Diphenhydramine","DB01075","Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Doxepin","DB01142","Tramadol increases the risk of serotonin syndrome and seizures. "
186,"Duloxetine","DB00476","Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome."
186,"Efavirenz","DB00625","Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Erythromycin","DB00199","Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Escitalopram","DB01175","Tramadol may increase the risk of serotonin syndrome and seizures."
186,"Etravirine","DB06414","Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance."
186,"Fluconazole","DB00196","Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Fluoxetine","DB00472","The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production."
186,"Fluvoxamine","DB00176","Tramadol may increase the risk of serotonin syndrome and seizures."
186,"Fosamprenavir","DB01319","Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Fosphenytoin","DB01320","Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Furazolidone","DB00614","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone. "
186,"Haloperidol","DB00502","Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Imatinib","DB00619","Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.  "
186,"Imipramine","DB00458","Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Indinavir","DB00224","Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Isocarboxazid","DB01247","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid."
186,"Isoniazid","DB00951","Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Itraconazole","DB01167","Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Ketoconazole","DB01026","Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Lapatinib","DB01259","Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Lidocaine","DB00281","Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production."
186,"Linezolid","DB00601","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid. "
186,"Lisdexamfetamine","DB01255","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Lopinavir","DB01601","Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Maprotiline","DB00934","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Methadone","DB00333","Methadone may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Methamphetamine","DB01577","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Methotrimeprazine","DB01403","Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required. "
186,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Metronidazole","DB00916","Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Miconazole","DB01110","Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Mirtazapine","DB00370","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Moclobemide","DB01171","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide."
186,"Nafcillin","DB00607","Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Nefazodone","DB01149","Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome."
186,"Nelfinavir","DB00220","Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Nevirapine","DB00238","Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Nicardipine","DB00622","Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Nilotinib","DB04868","Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Norfloxacin","DB01059","Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Nortriptyline","DB00540","Tramadol increases the risk of serotonin syndrome and seizures. "
186,"Oxcarbazepine","DB00776","Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Paroxetine","DB00715","Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production."
186,"Pentobarbital","DB00312","Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Pergolide","DB01186","Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome."
186,"Pethidine","DB00454","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Phendimetrazine","DB01579","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Phenelzine","DB00780","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine."
186,"Phenobarbital","DB01174","Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Phentermine","DB00191","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Phenytoin","DB00252","Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Pioglitazone","DB01132","Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Posaconazole","DB01263","Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Primidone","DB00794","Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Procarbazine","DB01168","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine."
186,"Promethazine","DB01069","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Protriptyline","DB00344","Tramadol increases the risk of serotonin syndrome and seizures. "
186,"Pyrimethamine","DB00205","Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Quinidine","DB00908","Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Quinine","DB00468","Quinine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Ranolazine","DB00243","Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Rasagiline","DB01367","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline."
186,"Rifabutin","DB00615","Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Rifampicin","DB01045","Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Rifapentine","DB01201","Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
186,"Ritonavir","DB00503","Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Rizatriptan","DB00953","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Saquinavir","DB01232","Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
186,"Selegiline","DB01037","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline."
186,"Sertraline","DB01104","Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production."
186,"Sibutramine","DB01105","Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided. "
186,"Sitaxentan","DB06268","Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"St. John's Wort","DB01323","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Sumatriptan","DB00669","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Telithromycin","DB00976","Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.\
"
186,"Terbinafine","DB00857","Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Tetracycline","DB00759","Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Thioridazine","DB00679","Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Ticlopidine","DB00208","Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production. "
186,"Tranylcypromine","DB00752","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production."
186,"Trazodone","DB00656","The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Trimipramine","DB00726","Tramadol may increase the risk of serotonin syndrome and seizures."
186,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
186,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
186,"Verapamil","DB00661","Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
186,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed."
186,"Zolmitriptan","DB00315","The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
188,"Acetohexamide","DB00414","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Chlorpropamide","DB00672","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
188,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
188,"Disopyramide","DB00280","The beta-blocker, betaxolol, may increase the toxicity of disopyramide."
188,"Epinephrine","DB00668","Beta-Blockers such as betaxolol may enhance the vasopressor effect of epinephrine. Monitor for increases in pressor effects of alpha-/beta-agonists if used in patients receiving beta-blocker therapy (including ophthalmic products). Beta1-selective (i.e., ''cardioselective'') agents may confer a more limited risk if used in low enough doses to allow them to retain their selectivity. The amount of epinephrine used in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (e.g., more than 0.06mg epinephrine) may cause clinically-relevant problems. Patients with allergies that require carrying and periodically using subcutaneous epinephrine (e.g., bee sting kits) should probably avoid the use of beta blockers. "
188,"Ergotamine","DB00696","Ischemia with risk of gangrene"
188,"Fenoterol","DB01288","Beta-Blockers (Beta-1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like fenoterol.  Therapy should be monitored."
188,"Formoterol","DB00983","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like formoterol. Therapy should be monitored."
188,"Gliclazide","DB01120","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Glyburide","DB01016","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Ibuprofen","DB01050","Nonsteroidal Anti-Inflammatory Agents such as ibuprofen may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
188,"Indomethacin","DB00328","Nonsteroidal Anti-Inflammatory Agents such as indomethacin may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
188,"Insulin Glargine","DB00047","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Methacholine","DB06709","Beta-Blockers like betaxolol may worsen brochoconstriction and decrease the effectiveness of agents used to treat the resulting bronchoconstriction. Use of betaxolol and methacholine concomitantly is contraindicated."
188,"Methysergide","DB00247","Ischemia with risk of gangrene"
188,"Orciprenaline","DB00816","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like orciprenaline. Therapy should be monitored."
188,"Pipobroman","DB00236","Antagonism"
188,"Piroxicam","DB00554","Nonsteroidal Anti-Inflammatory Agents such as piroxicam may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
188,"Prazosin","DB00457","Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension."
188,"Repaglinide","DB00912","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
188,"Rituximab","DB00073","Antihypertensives like betaxolol may enhance the hypotensive effect of rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion. "
188,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
188,"Terbutaline","DB00871","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like terbutaline. Therapy should be monitored."
188,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed"
188,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
189,"Acenocoumarol","DB01418","Fluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism."
189,"Alfentanil","DB00802","Increases the effect and toxicity of alfentanil"
189,"Alprazolam","DB00404","Fluconazole may increase the effect of the benzodiazepine, alprazolam."
189,"Amitriptyline","DB00321","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
189,"Anisindione","DB01125","Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism."
189,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
189,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
189,"Bromazepam","DB01558","Fluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed. "
189,"Carbamazepine","DB00564","Fluconazole may increase the therapeutic and adverse effects of carbamazepine."
189,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
189,"Celecoxib","DB00482","Fluconazole may increase the effect of celecoxib."
189,"Chlordiazepoxide","DB00475","Fluconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
189,"Cilostazol","DB01166","Fluconazole may decrease the effect of cilostazol."
189,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
189,"Clonazepam","DB01068","Fluconazole may increase the effect of the benzodiazepine, clonazepam."
189,"Clorazepate","DB00628","Fluconazole may increase the effect of the benzodiazepine, clorazepate."
189,"Conivaptan","DB00872","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
189,"Cyclophosphamide","DB00531","Fluconazole reduces metabolism and clearance of cyclophosphamide."
189,"Cyclosporine","DB00091","Fluconazole may increase the therapeutic and adverse effects of the cyclosporine."
189,"Diazepam","DB00829","Fluconazole may increase the effect of the benzodiazepine, diazepam."
189,"Dicoumarol","DB00266","Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism."
189,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
189,"Eplerenone","DB00700","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
189,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
189,"Estazolam","DB01215","Fluconazole may increase the effect of the benzodiazepine, estazolam."
189,"Ethotoin","DB00754","Increases the effect of hydantoin"
189,"Everolimus","DB01590","Fluconazole may increase everolimus levels/toxicity."
189,"Fentanyl","DB00813","Fluconazole may increase levels/toxicity of fentanyl."
189,"Fesoterodine","DB06702","Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine. "
189,"Flurazepam","DB00690","Fluconazole may increase the effect of the benzodiazepine, flurazepam."
189,"Fluvastatin","DB01095","Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed."
189,"Fosphenytoin","DB01320","Fluconazole may increase the effect of hydantoin."
189,"Halazepam","DB00801","Fluconazole may increase the effect of the benzodiazepine, halazepam."
189,"Haloperidol","DB00502","Fluconazole may increase the effect and toxicity of haloperidol."
189,"Imipramine","DB00458","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
189,"Ivacaftor","DB08820","Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. "
189,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
189,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
189,"Mephenytoin","DB00532","Increases the effect of hydantoin"
189,"Midazolam","DB00683","Fluconazole may increase the effect of the benzodiazepine, midazolam."
189,"Nortriptyline","DB00540","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
189,"Ospemifene","DB04938","Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events. "
189,"Phenytoin","DB00252","Fluconazole may increase the therapeutic and adverse effects of phenytoin."
189,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
189,"Quazepam","DB01589","Fluconazole may increase the effect of the benzodiazepine, quazepam."
189,"Ramelteon","DB00980","Fluconazole may increase the serum levels and toxcity of ramelteon."
189,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
189,"Rifabutin","DB00615","Fluconazole may increase levels/toxicity of rifabutin."
189,"Rifampicin","DB01045","Rifampin may decrease the effect of fluconazole."
189,"Silodosin","DB06207","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
189,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
189,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus."
189,"Tamoxifen","DB00675","Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.\
"
189,"Tamsulosin","DB00706","Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed."
189,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
189,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
189,"Tipranavir","DB00932","Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required."
189,"Tofacitinib","DB08895","Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily. "
189,"Tolbutamide","DB01124","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed. "
189,"Tolterodine","DB01036","Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity."
189,"Tolvaptan","DB06212","Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
189,"Torasemide","DB00214","Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed. "
189,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
189,"Tramadol","DB00193","Fluconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
189,"Trazodone","DB00656","The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed."
189,"Triazolam","DB00897","Fluconazole may increase the effect of the benzodiazepine, triazolam."
189,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed."
189,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution."
189,"Valdecoxib","DB00580","Fluconazole may increase the effect and toxicity of valdecoxib."
189,"Verapamil","DB00661","Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed."
189,"Vinblastine","DB00570","Increases the effect and toxicity of anticancer agent"
189,"Vincristine","DB00541","Increases the effect and toxicity of anticancer agent"
189,"Voriconazole","DB00582","Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.	"
189,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
189,"Warfarin","DB00682","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed."
189,"Zafirlukast","DB00549","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed."
189,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
189,"Zolpidem","DB00425","Fluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed."
189,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
190,"Cholestyramine","DB01432","Decreases the effect of troglitazone"
190,"Cyclosporine","DB00091","Troglitazone decreases the effect of the immunosuppressant"
190,"Ethinyl Estradiol","DB00977","Possible loss of contracepitve effect"
190,"Norethindrone","DB00717","Possible loss of contraceptive effect"
192,"Acenocoumarol","DB01418","The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol."
192,"Alfentanil","DB00802","The macrolide, erythromycin, may increase the effect and toxicity of alfentanil."
192,"Alprazolam","DB00404","The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam."
192,"Aminophylline","DB01223","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline."
192,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
192,"Anisindione","DB01125","The macrolide, erythromycin, may increase the anticoagulant effect of anisindione."
192,"Aprepitant","DB00673","Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant."
192,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
192,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
192,"Atorvastatin","DB01076","The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin."
192,"Avanafil","DB06237","Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.\
"
192,"Bendamustine","DB06769","Decreases metabolism, thus decreasing the effects of bendamustine. "
192,"Bretylium","DB01158","Increased risk of cardiotoxicity and arryhthmias"
192,"Bromazepam","DB01558","Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required. "
192,"Bromocriptine","DB01200","Erythromycin increases serum levels of bromocriptine"
192,"Buspirone","DB00490","The macrolide, erythromycin, may increase the effect and toxicity of buspirone."
192,"Cabergoline","DB00248","Erythromycin increases serum levels and toxicity of cabergoline"
192,"Carbamazepine","DB00564","The macrolide, erythromycin, may increase the effect of carbamazepine."
192,"Cerivastatin","DB00439","The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin."
192,"Cilostazol","DB01166","Erythromycin increases the effect of cilostazol"
192,"Cinacalcet","DB01012","The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet."
192,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
192,"Citalopram","DB00215","Possible serotoninergic syndrome with this combination"
192,"Clozapine","DB00363","Erythromycin increases the effect of clozapine"
192,"Colchicine","DB01394","Severe colchicine toxicity can occur"
192,"Cyclosporine","DB00091","The macrolide, erythromycin, may increase the effect of cyclosporine."
192,"Diazepam","DB00829","The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam."
192,"Dicoumarol","DB00266","The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol.."
192,"Digoxin","DB00390","The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients."
192,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
192,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
192,"Docetaxel","DB01248","Erythromycin may increase the serum levels and toxicity of docetaxel."
192,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
192,"Dyphylline","DB00651","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline."
192,"Eletriptan","DB00216","The macrolide, erythromycin, may increase the effect and toxicity of eletriptan."
192,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
192,"Eplerenone","DB00700","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
192,"Ergonovine","DB01253","Possible ergotism and severe ischemia with this combination"
192,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
192,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
192,"Everolimus","DB01590","The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus."
192,"Felodipine","DB01023","Erythromycin increases the effect of felodipine"
192,"Fluoxetine","DB00472","Possible serotoninergic syndrome with this combination"
192,"Gefitinib","DB00317","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
192,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
192,"Imatinib","DB00619","The macrolide, erythromycin, may increase the serum concentration of imatinib."
192,"Indacaterol","DB05039","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
192,"Itraconazole","DB01167","The macrolide, erythromycin, may increase the effect and toxicity of itraconazole."
192,"Ivacaftor","DB08820","Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. "
192,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
192,"Lincomycin","DB01627","Possible antagonism of action with this combination."
192,"Lovastatin","DB00227","The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin."
192,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
192,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
192,"Methylergometrine","DB00353","Possible ergotism and severe ischemia with this combination"
192,"Methylprednisolone","DB00959","The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone."
192,"Methysergide","DB00247","Possible ergotism and severe ischemia with this combination"
192,"Midazolam","DB00683","The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam."
192,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
192,"Oxtriphylline","DB01303","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
192,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
192,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
192,"Pitavastatin","DB08860","Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy. "
192,"Quetiapine","DB01224","The macrolide, erythromycin, may increase the effect and toxicity of quetiapine."
192,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
192,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
192,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
192,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
192,"Repaglinide","DB00912","The macrolide, erythromycin, may increase the effect of repaglinide."
192,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin."
192,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin."
192,"Ritonavir","DB00503","Increased toxicity of both agents"
192,"Roflumilast","DB01656","Increases roflumilast levels. "
192,"Saxagliptin","DB06335","Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
192,"Sertraline","DB01104","Possible serotoninergic syndrome with this combination"
192,"Sibutramine","DB01105","Erythromycin increases the effect and toxicity of sibutramine"
192,"Sildenafil","DB00203","The macrolide, erythromycin, may increase the effect and toxicity of sildenafil."
192,"Silodosin","DB06207","Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects"
192,"Simvastatin","DB00641","The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin."
192,"Sirolimus","DB00877","The macrolide, erythromycin, may increase the serum concentration of sirolimus."
192,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
192,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
192,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus."
192,"Tamsulosin","DB00706","Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed."
192,"Telithromycin","DB00976","Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed."
192,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
192,"Theophylline","DB00277","The macrolide, erythromycin, may increase the effect and toxicity of theophylline."
192,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
192,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
192,"Tolvaptan","DB06212","Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
192,"Topotecan","DB01030","The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
192,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
192,"Tramadol","DB00193","Erythromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
192,"Trazodone","DB00656","The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed."
192,"Triazolam","DB00897","The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam."
192,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
192,"Valproic Acid","DB00313","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed. "
192,"Vardenafil","DB00862","Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed."
192,"Verapamil","DB00661","Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed."
192,"Vinblastine","DB00570","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed."
192,"Vincristine","DB00541","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed."
192,"Vinorelbine","DB00361","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed."
192,"Vismodegib","DB08828","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
192,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. "
192,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
192,"Warfarin","DB00682","The macrolide, erythromycin, may increase the anticoagulant effect of warfarin."
192,"Zafirlukast","DB00549","Erythromycin may decrease the serum concentration and effect of zafirlukast."
192,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
192,"Zopiclone","DB01198","The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed. "
192,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
194,"Adenosine","DB00640","Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible."
194,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect and toxicity of caffeine."
194,"Clozapine","DB00363","Caffeine increases the effect and toxicity of clozapine"
194,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 substrates such as caffeine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
194,"Grepafloxacin","DB00365","Grepafloxacin may increase the effect and toxicity of caffeine."
194,"Lithium","DB01356","Caffeine decreases serum levels of lithium"
194,"Norfloxacin","DB01059","Norfloxacin may increase the effect and toxicity of caffeine."
194,"Regadenoson","DB06213","Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear. "
194,"Tamsulosin","DB00706","Caffeine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Caffeine is initiated, discontinued, or dose changed."
194,"Terbinafine","DB00857","Terbinafine may increase the plasma concentration of Caffeine."
194,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed."
194,"Tolterodine","DB01036","Caffeine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
194,"Vemurafenib","DB08881","Vemurafenib increases the AUC of caffeine (CYP1A2 substrate) 2.6-fold. "
195,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
195,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
195,"Cyclophosphamide","DB00531","Cyclophosphamide may increase the effect of succinylcholine."
195,"Dihydrocodeine","DB01551","May enhance the bradycardic effect of opioid analgesics. It is recommended to monitor therapy. "
195,"Echothiophate","DB01057","Echothiophate iodide may increase the effect of succinylcholine."
195,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
195,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
195,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
195,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
195,"Quinidine","DB00908","The quinine derivative increases the effect of the muscle relaxant"
195,"Quinine","DB00468","The quinine derivative increases the effect of the muscle relaxant"
195,"Tacrine","DB00382","Tacrine may increase the effects of Succinylcholine. Monitor Succinylcholine therapy for increased effects."
195,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
196,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may increase the effect and toxicity of sildenafil."
196,"Asenapine","DB06216","Increased incidence of adverse effects (hypotension) due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
196,"Atazanavir","DB01072","Increases the effect and toxicity of sildenafil"
196,"Cimetidine","DB00501","Increases the effect and toxicity of sildenafil"
196,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the serum level of sildenafil."
196,"Clarithromycin","DB01211","Increases the effect and toxicity of sildenafil"
196,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Sildenafil. When sildenanfil is used for treatment of pulmonary arterial hypertension, concurrent use with strong CYP3A4 inhibitors is not recommended. When sildenafil is used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking a strong CYP3A4 inhibitor. Due to the particularly strong effects of ritonavir, sildenafil (for erectile dysfunction) doses greater than 25 mg per 48 hours are not recommended. Of note, the interaction between CYP3A4 inhibitors and sildenafil is predicted to be greater with orally administered than with injected sildenafil. "
196,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of sildenafil."
196,"Etravirine","DB06414","Sildenafil (and other phosphodiesterase 5 inhibitors), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor the efficacy of sildenafil therapy."
196,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of sildenafil."
196,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect and toxicity of sildenafil."
196,"Isosorbide Dinitrate","DB00883","Possible significant hypotension with this combination"
196,"Isosorbide Mononitrate","DB01020","Possible significant hypotension with this combination"
196,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of sildenafil."
196,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of sildenafil."
196,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect and toxicity of sildenafil."
196,"Nitroglycerin","DB00727","Possible significant hypotension with this combination"
196,"Pentaerythritol Tetranitrate","DB06154","Possible significant hypotension with this combination"
196,"Telithromycin","DB00976","Telithromycin may reduce clearance of Sildenafil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sildenafil if Telithromycin is initiated, discontinued or dose changed."
196,"Terazosin","DB01162","Increased risk of hypotension. "
196,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the concentration of Sildenafil. Alternate therapy should be considered."
196,"Vigabatrin","DB01080","Increased anticonvulsant effects of vigabatrin due to pharmacodynamic synergism. Monitor for adverse effects during concomitant therapy. "
196,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sildenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sildenafil if voriconazole is initiated, discontinued or dose changed."
197,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
197,"Bendroflumethiazide","DB00436","Increased risk of cardiotoxicity and arrhythmias"
197,"Chlorothiazide","DB00880","Thiazide diuretics such as chlorothiazide may enhance the QTc-prolonging effect of dofetilide. Thiazide diuretics may increase the serum concentration of dofetilide. The concomitant use of hydrochlorothiazide and dofetilide is contraindicated by the manufacturer of dofetilide. Monitor for increased risk of QTc-prolongation and associated ventricular arrythmias during concomitant use of dofetilide and thiazide diuretics."
197,"Chlorthalidone","DB00310","Increased risk of cardiotoxicity and arrythmias"
197,"Cimetidine","DB00501","Increases effect/toxicity of dofetilide"
197,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
197,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
197,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
197,"Hydrochlorothiazide","DB00999","Increased risk of cardiotoxicity and arrhythmias"
197,"Indapamide","DB00808","Increased risk of cardiotoxicity and arrhythmias"
197,"Itraconazole","DB01167","This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide"
197,"Ketoconazole","DB01026","This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide"
197,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
197,"Metolazone","DB00524","Increased risk of cardiotoxicity and arrhythmias"
197,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
197,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
197,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
197,"Telithromycin","DB00976","Increased risk of cardiotoxicity and arrhythmias"
197,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
197,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
197,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
197,"Trichlormethiazide","DB01021","Trichlormethiazide may increase Dofetilide serum concentrations and increase the QTc-prolonging effect of Dofetilide. Increased risk of ventricular arrhythmias. "
197,"Trimethoprim","DB00440","Trimethoprim may significantly reduced the clearance of Dofetilide. Trimethoprim is a cation transport inhibitor and may interfere with renal excretion of Dofetilide. Concomitant use is contraindicated."
197,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
197,"Verapamil","DB00661","Verapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated. "
197,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of dofetilide by decreasing its metabolism. Concomitant therapy is contraindicated. "
197,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
197,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
197,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
198,"Artemether","DB06697","Pyrimethamine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
198,"Lumefantrine","DB06708","Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
198,"Tamoxifen","DB00675","Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
198,"Tamsulosin","DB00706","Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed."
198,"Tramadol","DB00193","Pyrimethamine may decrease the effect of Tramadol by decreasing active metabolite production. "
199,"Dobutamine","DB00841","Increased arterial pressure"
199,"Dopamine","DB00988","Increased arterial pressure"
199,"Ephedra","DB01363","Increased arterial pressure"
199,"Ephedrine","DB01364","Increased arterial pressure"
199,"Epinephrine","DB00668","Increased arterial pressure"
199,"Fenoterol","DB01288","Increased arterial pressure"
199,"Iobenguane","DB06704","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores"
199,"Isoprenaline","DB01064","Increased arterial pressure"
199,"Mephentermine","DB01365","Increased arterial pressure"
199,"Metaraminol","DB00610","Increased arterial pressure"
199,"Methoxamine","DB00723","Increased arterial pressure"
199,"Norepinephrine","DB00368","Increased arterial pressure"
199,"Orciprenaline","DB00816","Increased arterial pressure"
199,"Phenylephrine","DB00388","Increased arterial pressure"
199,"Phenylpropanolamine","DB00397","Increased arterial pressure"
199,"Pirbuterol","DB01291","Increased arterial pressure"
199,"Procaterol","DB01366","Increased arterial pressure"
199,"Pseudoephedrine","DB00852","Increased arterial pressure"
199,"Salbutamol","DB01001","Increased arterial pressure"
199,"Terbutaline","DB00871","Increased arterial pressure"
199,"Tetrabenazine","DB04844","Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated."
199,"Topotecan","DB01030","The p-glycoprotein inhibitor, Reserpine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
199,"Tranylcypromine","DB00752","Addition of Reserpine to Tranylcypromine therapy may induce paradoxical Reserpine effects, including peripheral hypertension and central exciation. Close monitoring for adverse effects is required. Addition of Tranylcypromine to Reserpine therapy may be less of a concern. "
199,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
199,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Reserpine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
200,"Acenocoumarol","DB01418","Azithromycin may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
200,"Anisindione","DB01125","Azithromycin may increase the anticoagulant effect of anisindione by increasing its serum concentration."
200,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
200,"Cyclosporine","DB00091","The macrolide, azithromycin, may increase the effect of cyclosporine."
200,"Dicoumarol","DB00266","Azithromycin may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
200,"Disopyramide","DB00280","The macrolide, azithromycin, may increase the effect of disopyramide."
200,"Lovastatin","DB00227","The macrolide antibiotic, azithromycin, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if azithromycin is initiated, discontinued or dose changed."
200,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
200,"Vismodegib","DB08828","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
200,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
200,"Warfarin","DB00682","Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration."
200,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
200,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
201,"Acetylsalicylic acid","DB00945","Increased effect of ticlopidine"
201,"Alteplase","DB00009","Increased bleeding risk. Monitor for signs of bleeding."
201,"ambrisentan","DB06403","Ticlopidine may decrease the metabolism and clearance of Ambrisentan. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Ticlopidine is initiated, discontinued or dose changed. "
201,"Aminophylline","DB01223","Ticlopidine increases the effect and toxicity of theophylline"
201,"Bortezomib","DB00188","Ticlopidine may decrease the metabolism and clearance of Bortezomib. Consider alternate therapy or monitor for adverse/toxic effects of Bortezomib if Ticlopidine is initiated, discontinued or dose changed."
201,"Carbamazepine","DB00564","Ticlopidine increases the effect of carbamazepine"
201,"Carisoprodol","DB00395","Ticlopidine may decrease the metabolism and clearance of Carisoprodol. Consider alternate therapy or monitor for adverse/toxic effects of Carisoprodol if Ticlopidine is initiated, discontinued or dose changed."
201,"Cilostazol","DB01166","Ticlopidine may decrease the metabolism and clearance of Cilostazol. Consider alternate therapy or monitor for adverse/toxic effects of Cilostazol if Ticlopidine is initiated, discontinued or dose changed."
201,"Cimetidine","DB00501","Cimetidine may increase Ticlopidine levels. Avoid concomitant therapy. "
201,"Citalopram","DB00215","Ticlopidine may decrease the metabolism and clearance of Citalopram. Consider alternate therapy or monitor for adverse/toxic effects of Citalopram if Ticlopidine is initiated, discontinued or dose changed."
201,"Clobazam","DB00349","Ticlopidine may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for adverse/toxic effects of Clobazam if Ticlopidine is initiated, discontinued or dose changed."
201,"Clomipramine","DB01242","Ticlopidine may decrease the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for adverse/toxic effects of Clomipramine if Ticlopidine is initiated, discontinued or dose changed."
201,"Cyclosporine","DB00091","Ticlopidine decreases the effect of cyclosporine"
201,"Diazepam","DB00829","Ticlopidine may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for adverse/toxic effects of Diazepam if Ticlopidine is initiated, discontinued or dose changed."
201,"Digoxin","DB00390","Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed."
201,"Dyphylline","DB00651","Ticlopidine increases the effect and toxicity of theophylline"
201,"Escitalopram","DB01175","Ticlopidine may decrease the metabolism and clearance of Escitalopram. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Escitalopram is initiated, discontinued or dose changed."
201,"Ethotoin","DB00754","Ticlopidine increases the effect of hydantoin"
201,"Fosphenytoin","DB01320","Ticlopidine may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for adverse/toxic effects of Fosphenytoin if Ticlopidine is initiated, discontinued or dose changed."
201,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
201,"Heparin","DB01109","Increased bleeding risk. Monitor aPTT."
201,"Ifosfamide","DB01181","Ticlopidine may decrease the metabolism and clearance of Ifosfamide. Consider alternate therapy or monitor for adverse/toxic effects of Ifosfamide if Ticlopidine is initiated, discontinued or dose changed."
201,"Imipramine","DB00458","Ticlopidine may decrease the metabolism and clearance of Imipramine. Consider alternate therapy or monitor for adverse/toxic effects of Imipramine if Ticlopidine is initiated, discontinued or dose changed."
201,"Mephenytoin","DB00532","Ticlopidine increases the effect of hydantoin"
201,"Methsuximide","DB05246","Ticlopidine may decrease the metabolism and clearance of Methsuximide. Consider alternate therapy or monitor for adverse/toxic effects of Methsuximide if Ticlopidine is initiated, discontinued or dose changed."
201,"Moclobemide","DB01171","Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed."
201,"Nilutamide","DB00665","Ticlopidine may decrease the metabolism and clearance of Nilutamide. Consider alternate therapy or monitor for adverse/toxic effects of Nilutamide if Ticlopidine is initiated, discontinued or dose changed."
201,"Oxtriphylline","DB01303","Ticlopidine increases the effect and toxicity of theophylline"
201,"Pentamidine","DB00738","Ticlopidine may decrease the metabolism and clearance of Pentamidine. Consider alternate therapy or monitor for adverse/toxic effects of Pentamidine if Ticlopidine is initiated, discontinued or dose changed."
201,"Phenobarbital","DB01174","Ticlopidine may decrease the metabolism and clearance of Phenobarbital. Consider alternate therapy or monitor for adverse/toxic effects of Phenobarbital if Ticlopidine is initiated, discontinued or dose changed."
201,"Phenytoin","DB00252","Ticlopidine may decrease the metabolism and clearance of phenytoin. Consider alternate therapy or monitor for adverse/toxic effects of phenytoin if ticlopidine is initiated, discontinued or dose changed."
201,"Pimozide","DB01100","Avoid combination with pimozide and other major CYP3A4 substrates due to the potential increase of pimozide concentration.\
\
"
201,"Reteplase","DB00015","Increased bleeding risk. Monitor for signs of bleeding."
201,"Sodium bicarbonate","DB01390","Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart. "
201,"Streptokinase","DB00086","Increased bleeding risk. Monitor for signs of bleeding."
201,"Tamoxifen","DB00675","Ticlopidine may decrease the therapeutic effect of tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
201,"Tamsulosin","DB00706","Ticlopidine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ticlopidine is initiated, discontinued, or dose changed."
201,"Tenecteplase","DB00031","Increased bleeding risk. Monitor for signs of bleeding."
201,"Theophylline","DB00277","Ticlopidine increases the effect and toxicity of theophylline"
201,"Thioridazine","DB00679","Ticlopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated."
201,"Tizanidine","DB00697","Ticlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
201,"Tramadol","DB00193","Ticlopidine may decrease the effect of Tramadol by decreasing active metabolite production. "
201,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy. "
201,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, ticlopidine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of trimipramine if ticlopidine is initiated, discontinued or dose changed."
201,"Warfarin","DB00682","Increased bleeding risk. Monitor INR."
202,"Acetophenazine","DB01063","Trospium and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Alimemazine","DB01246","Trospium and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Amitriptyline","DB00321","Trospium and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Amoxapine","DB00543","Trospium and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Atropine","DB00572","Trospium and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Azelastine","DB00972","Trospium and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Benzatropine","DB00245","Trospium and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Biperiden","DB00810","Trospium and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Bromodiphenhydramine","DB01237","Trospium and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Brompheniramine","DB00835","Trospium and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Carbinoxamine","DB00748","Trospium and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Chlorphenamine","DB01114","Trospium and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Chlorpromazine","DB00477","Trospium and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Clemastine","DB00283","Trospium and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Clidinium","DB00771","Trospium and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Clomipramine","DB01242","Trospium and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Clozapine","DB00363","Trospium and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Cyclizine","DB01176","Trospium and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Cyclobenzaprine","DB00924","Trospium and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Cyclopentolate","DB00979","Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Cyproheptadine","DB00434","Trospium and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Darifenacin","DB00496","Trospium and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Desipramine","DB01151","Trospium and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Desloratadine","DB00967","Trospium and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Dexbrompheniramine","DB00405","Trospium and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Dicyclomine","DB00804","Trospium and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Dimenhydrinate","DB00985","Trospium and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Diphenhydramine","DB01075","Trospium and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Donepezil","DB00843","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
202,"Doxepin","DB01142","Trospium and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Doxylamine","DB00366","Trospium and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Dronabinol","DB00470","Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended."
202,"Droperidol","DB00450","Trospium and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Fexofenadine","DB00950","Trospium and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Flavoxate","DB01148","Trospium and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Flupentixol","DB00875","Trospium and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Fluphenazine","DB00623","Trospium and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Galantamine","DB00674","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
202,"Glycopyrrolate","DB00986","Trospium and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Haloperidol","DB00502","Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Homatropine Methylbromide","DB00725","Trospium and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Hydroxyzine","DB00557","Trospium and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Hyoscyamine","DB00424","Trospium and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Imipramine","DB00458","Trospium and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Ipratropium bromide","DB00332","Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Isocarboxazid","DB01247","Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Ketotifen","DB00920","Trospium and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Loratadine","DB00455","Trospium and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Loxapine","DB00408","Trospium and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Maprotiline","DB00934","Trospium and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Meclizine","DB00737","Trospium and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Mepenzolate","DB04843","Trospium and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Mesoridazine","DB00933","Trospium and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Methantheline","DB00940","Trospium and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Methylscopolamine bromide","DB00462","Trospium and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Moclobemide","DB01171","Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Molindone","DB01618","Trospium and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Nabilone","DB00486","Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended."
202,"Nortriptyline","DB00540","Trospium and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Olanzapine","DB00334","Trospium and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Orphenadrine","DB01173","Trospium and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Oxybutynin","DB01062","Trospium and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Perphenazine","DB00850","Trospium and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Phenelzine","DB00780","Trospium and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Phenindamine","DB01619","Trospium and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Pimozide","DB01100","Trospium and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Pizotifen","DB06153","Trospium and Pizotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Potassium Chloride","DB00761","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trospium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
202,"Pramlintide","DB01278","The anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
202,"Prochlorperazine","DB00433","Trospium and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Procyclidine","DB00387","Trospium and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Promethazine","DB01069","Trospium and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Propantheline","DB00782","Trospium and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Protriptyline","DB00344","Trospium and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Quetiapine","DB01224","Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Risperidone","DB00734","Trospium and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Rivastigmine","DB00989","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
202,"Scopolamine","DB00747","Trospium and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Secretin","DB00021","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trospium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
202,"Solifenacin","DB01591","Trospium and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trospium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
202,"Thioridazine","DB00679","Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Thiothixene","DB01623","Trospium and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Tiotropium","DB01409","Trospium and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Tolterodine","DB01036","Trospium and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Tranylcypromine","DB00752","Trospium and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Trifluoperazine","DB00831","Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Trihexyphenidyl","DB00376","Trospium and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Trimethobenzamide","DB00662","Trospium and Trimethobenzamide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Trimipramine","DB00726","Trospium and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Triprolidine","DB00427","Trospium and Triprolidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
202,"Zuclopenthixol","DB01624","Trospium and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
204,"Betamethasone","DB00443","Increased arterial pressure"
204,"Cortisone acetate","DB01380","Increased arterial pressure"
204,"Dexamethasone","DB01234","Increased arterial pressure"
204,"Dobutamine","DB00841","Increased arterial pressure"
204,"Dopamine","DB00988","Increased arterial pressure"
204,"Ephedra","DB01363","Increased arterial pressure"
204,"Ephedrine","DB01364","Increased arterial pressure"
204,"Epinephrine","DB00668","Increased arterial pressure"
204,"Fenoterol","DB01288","Increased arterial pressure"
204,"Fludrocortisone","DB00687","Increased arterial pressure"
204,"Hydrocortisone","DB00741","Increased arterial pressure"
204,"Isocarboxazid","DB01247","Possible hypertensive crisis with this combination"
204,"Isoprenaline","DB01064","Increased arterial pressure"
204,"Mephentermine","DB01365","Increased arterial pressure"
204,"Metaraminol","DB00610","Increased arterial pressure"
204,"Methoxamine","DB00723","Increased arterial pressure"
204,"Methylprednisolone","DB00959","Increased arterial pressure"
204,"Norepinephrine","DB00368","Increased arterial pressure"
204,"Orciprenaline","DB00816","Increased arterial pressure"
204,"Paramethasone","DB01384","Increased arterial pressure"
204,"Phenelzine","DB00780","Possible hypertensive crisis with this combination"
204,"Phenylephrine","DB00388","Increased arterial pressure"
204,"Phenylpropanolamine","DB00397","Increased arterial pressure"
204,"Pirbuterol","DB01291","Increased arterial pressure"
204,"Prednisolone","DB00860","Increased arterial pressure"
204,"Prednisone","DB00635","Increased arterial pressure"
204,"Procaterol","DB01366","Increased arterial pressure"
204,"Pseudoephedrine","DB00852","Increased arterial pressure"
204,"Rasagiline","DB01367","Risk of hypertensive crisis."
204,"Salbutamol","DB01001","Increased arterial pressure"
204,"Terbutaline","DB00871","Increased arterial pressure"
204,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Midodrine. Concomitant therapy should be avoided."
204,"Triamcinolone","DB00620","Increased arterial pressure"
204,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Midodrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
206,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
206,"Cefditoren","DB01066","Proton pump inhibitors such as pantoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
206,"Clopidogrel","DB00758","Pantoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent pantoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with pantoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."
206,"Dabigatran etexilate","DB06695","Proton pump inhibitors may decrease the bioavailability of dabigatran by 28% and increase inter-patient pharmacokinetic variability, especially in females. However, dose adjustment is not required. "
206,"Dabrafenib","DB08912","Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability. "
206,"Dasatinib","DB01254","Pantoprazole may decrease the serum level of dasatinib."
206,"Enoxacin","DB00467","Pantoprazole may decrease the absorption of enoxacin."
206,"Indinavir","DB00224","Omeprazole decreases the absorption of indinavir"
206,"Itraconazole","DB01167","The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole."
206,"Ketoconazole","DB01026","The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole."
206,"Rilpivirine","DB08864","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
206,"Topotecan","DB01030","The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed. "
207,"Amifostine","DB01143","Torasemide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Torasemide should be withheld for  24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
207,"Amikacin","DB00479","Increased ototoxicity"
207,"Capecitabine","DB01101","Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed. "
207,"Cholestyramine","DB01432","Cholestyramine may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
207,"Colesevelam","DB00930","Colesevelam may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
207,"Colestipol","DB00375","Colestipol may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
207,"Delavirdine","DB00705","Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Delavirdine is initiated, discontinued or dose changed. "
207,"Floxuridine","DB00322","Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Floxuridine is initiated, discontinued or dose changed. "
207,"Fluconazole","DB00196","Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluconazole is initiated, discontinued or dose changed. "
207,"Fluorouracil","DB00544","Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluorouracil is initiated, discontinued or dose changed. "
207,"Flurbiprofen","DB00712","Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Flurbiprofen is initiated, discontinued or dose changed. "
207,"Gemfibrozil","DB01241","Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed. "
207,"Gentamicin","DB00798","Increased ototoxicity"
207,"Ibuprofen","DB01050","The NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, torasemide."
207,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide."
207,"Ketoconazole","DB01026","Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed. "
207,"Mefenamic acid","DB00784","Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed. "
207,"Miconazole","DB01110","Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Miconazole is initiated, discontinued or dose changed. "
207,"Netilmicin","DB00955","Increased ototoxicity"
207,"Nicardipine","DB00622","Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed. "
207,"Piroxicam","DB00554","Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Piroxicam is initiated, discontinued or dose changed. "
207,"Rituximab","DB00073","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Torasemide for 12 hours prior to administration of Rituximab."
207,"Sitaxentan","DB06268","Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sitaxsentan is initiated, discontinued or dose changed. "
207,"Sulfadiazine","DB00359","Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed. "
207,"Sulfisoxazole","DB00263","Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed. "
207,"Tobramycin","DB00684","Increased ototoxicity"
207,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Tolbutamide is initiated, discontinued or dose changed."
207,"Trandolapril","DB00519","The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril. "
207,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
208,"Acenocoumarol","DB01418","The SSRI, citalopram, increases the effect of anticoagulant, acenocoumarol."
208,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
208,"Anisindione","DB01125","The SSRI, citalopram, increases the effect of anticoagulant, anisindione."
208,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
208,"Carvedilol","DB01136","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, carvedilol."
208,"Clarithromycin","DB01211","Possible serotoninergic syndrome with this combination"
208,"Clozapine","DB00363","The antidepressant increases the effect of clozapine"
208,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
208,"Dicoumarol","DB00266","The SSRI, citalopram, increases the effect of anticoagulant, dicumarol."
208,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
208,"Erythromycin","DB00199","Possible serotoninergic syndrome with this combination"
208,"Etravirine","DB06414","Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. \
\
It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes). "
208,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
208,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
208,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
208,"Josamycin","DB01321","Possible serotoninergic sydrome with this combination"
208,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
208,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
208,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
208,"Metoprolol","DB00264","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol."
208,"Moclobemide","DB01171","Possible serotoninergic syndrome"
208,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
208,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
208,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
208,"Pimozide","DB01100","The SSRI, citalopram, may increase the effect and toxicity of pimozide."
208,"Propranolol","DB00571","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol."
208,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
208,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
208,"Selegiline","DB01037","Possible severe adverse reaction with this combination"
208,"Sibutramine","DB01105","Risk of serotoninergic syndrome "
208,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, citalopram."
208,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
208,"Telithromycin","DB00976","Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed."
208,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
208,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Citalopram. Consider alternate therapy or monitor for adverse/toxic effects of Citalopram if Ticlopidine is initiated, discontinued or dose changed."
208,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
208,"Tramadol","DB00193","The use of two serotonin modulators, such as citalopram and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
208,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
208,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
208,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy. "
208,"Trimipramine","DB00726","The SSRI, Citalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Citalopram is initiated, discontinued or dose changed. "
208,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Citalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
208,"Troleandomycin","DB01361","Possible serotoninergic syndrome with this combination"
208,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
208,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed."
208,"Warfarin","DB00682","The SSRI, citalopram, increases the effect of anticoagulant, warfarin."
208,"Ziprasidone","DB00246","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
208,"Zolmitriptan","DB00315","The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
208,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
209,"Citalopram","DB00215","Increased risk of CNS adverse effects"
209,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect and toxicity of eletriptan."
209,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
209,"Dihydroergotamine","DB00320","Possible severe and prolonged vasoconstriction"
209,"Ergonovine","DB01253","Possible severe and prolonged vasoconstriction"
209,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction"
209,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of eletriptan."
209,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
209,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
209,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
209,"Itraconazole","DB01167","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
209,"Ketoconazole","DB01026","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
209,"Methylergometrine","DB00353","Possible severe and prolonged vasoconstriction"
209,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
209,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
209,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect and toxicity of eletriptan."
209,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
209,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan."
209,"Sertraline","DB01104","Increased risk of CNS adverse effects"
209,"Telithromycin","DB00976","Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed."
209,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
209,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
209,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
209,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
209,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan."
209,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
209,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed."
209,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
211,"Acenocoumarol","DB01418","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of acenocoumarol."
211,"Aluminium","DB01370","Formation of non-absorbable complexes"
211,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
211,"Anisindione","DB01125","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione."
211,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
211,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
211,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
211,"Calcium","DB01373","Formation of non-absorbable complexes"
211,"Dicoumarol","DB00266","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of dicumarol."
211,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
211,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
211,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
211,"Iron","DB01592","Formation of non-absorbable complexes"
211,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
211,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
211,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
211,"Magnesium","DB01378","Formation of non-absorbable complexes"
211,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
211,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
211,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
211,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
211,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
211,"Sucralfate","DB00364","Formation of non-absorbable complexes"
211,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
211,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
211,"Tizanidine","DB00697","Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
211,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
211,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
211,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
211,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
211,"Warfarin","DB00682","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin."
211,"Zinc","DB01593","Formation of non-absorbable complexes"
211,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
211,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
213,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Nelfinavir. The antiviral response should be closely monitored."
213,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
213,"Acenocoumarol","DB01418","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of acenocoumarol."
213,"Alprazolam","DB00404","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, alprazolam."
213,"Amiodarone","DB01118","Nelfinavir may increase the effect and toxicity of amiodarone."
213,"Anisindione","DB01125","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of anisindione."
213,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
213,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
213,"Atorvastatin","DB01076","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nelfinavir is initiated, discontinued or dose changed."
213,"Bromazepam","DB01558","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nelfinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
213,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
213,"Chlordiazepoxide","DB00475","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
213,"Ciclesonide","DB01410","Increased effects/toxicity of ciclesonide"
213,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
213,"Clonazepam","DB01068","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clonazepam."
213,"Clorazepate","DB00628","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clorazepate."
213,"Cyclosporine","DB00091","The protease inhibitor, nelfinavir, may increase the effect of cyclosporine."
213,"Dantrolene","DB01219","Nelfinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nelfinavir is initiated, discontinued or dose changed. "
213,"Darifenacin","DB00496","Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of darifenacin/solifenacin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of darifenacin if nelfinavir is initiated, discontinued or dose changed."
213,"Diazepam","DB00829","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, diazepam."
213,"Dicoumarol","DB00266","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of dicumarol."
213,"Dihydroergotamine","DB00320","Nelfinavir increases the effect and toxicity of ergot derivative"
213,"Dihydroquinidine barbiturate","DB01341","Nelfinavir increases the effect and toxicity of quindine"
213,"Eletriptan","DB00216","The protease inhibitor, nelfinavir, may increase the effect and toxicity of eletriptan."
213,"Eplerenone","DB00700","The protease inhibitor, nelfinavir, may increase the effect and toxicity of eplerenone."
213,"Ergotamine","DB00696","Nelfinavir increases the effect and toxicity of ergot derivative"
213,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
213,"Estazolam","DB01215","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, estazolam."
213,"Ethinyl Estradiol","DB00977","Ritonavir could decrease the contraceptive efficacy"
213,"Felodipine","DB01023","Nelfinavir increases the effect and toxicity of felodipine"
213,"Fentanyl","DB00813","The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl."
213,"Flurazepam","DB00690","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, flurazepam."
213,"Fusidic Acid","DB02703","The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid."
213,"Halazepam","DB00801","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, halazepam."
213,"Lovastatin","DB00227","Nelfinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
213,"Mestranol","DB01357","Ritonavir could decrease the contraceptive efficacy"
213,"Methadone","DB00333","Nelfinavir decreases the effect of methadone"
213,"Midazolam","DB00683","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam."
213,"Nevirapine","DB00238","Nevirapine may decrease the effect of nelfinavir."
213,"Pimozide","DB01100","Nelfinavir increases the effect and toxicity of pimozide"
213,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
213,"Prazepam","DB01588","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, prazepam."
213,"Quazepam","DB01589","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, quazepam."
213,"Quinidine","DB00908","Nelfinavir increases the effect and toxicity of quinidine"
213,"Quinidine barbiturate","DB01346","Nelfinavir increases the effect and toxicity of quinidine"
213,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
213,"Rifampicin","DB01045","Rifampin decreases the effect of nelfinavir"
213,"Saxagliptin","DB06335","Nelfinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
213,"Sildenafil","DB00203","The protease inhibitor, nelfinavir, may increase the effect and toxicity of sildenafil."
213,"Simvastatin","DB00641","Nelfinavir may increase the effect and toxicity of simvastatin. Concomitant therapy should be avoided."
213,"Solifenacin","DB01591","This potent CYP3A4 inhibitor slows darifenacin / solifenacin metabolism"
213,"St. John's Wort","DB01323","St. John's Wort decreases the effect of indinavir"
213,"Sunitinib","DB01268","Possible increase in sunitinib levels"
213,"Tacrolimus","DB00864","The protease inhibitor, Nelfinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nelfinavir therapy is initiated, discontinued or altered."
213,"Tadalafil","DB00820","Nelfinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
213,"Tamoxifen","DB00675","Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
213,"Tamsulosin","DB00706","Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nelfinavir is initiated, discontinued, or dose changed."
213,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
213,"Telithromycin","DB00976","Nelfinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
213,"Temsirolimus","DB06287","Nelfinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
213,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nelfinavir is initiated, discontinued or dose changed."
213,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
213,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nelfinavir is initiated, discontinued or dose changed."
213,"Tolterodine","DB01036","Nelfinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
213,"Topotecan","DB01030","The p-glycoprotein inhibitor, Nelfinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
213,"Tramadol","DB00193","Nelfinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
213,"Trazodone","DB00656","The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed. "
213,"Triazolam","DB00897","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, triazolam."
213,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nelfinavir is initiated, discontinued or dose changed. "
213,"Vardenafil","DB00862","Nelfinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
213,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
213,"Venlafaxine","DB00285","Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nelfinavir is initiated, discontinued, or dose changed."
213,"Verapamil","DB00661","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed."
213,"Vinblastine","DB00570","Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nelfinavir is initiated, discontinued or dose changed."
213,"Vincristine","DB00541","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nelfinavir is initiated, discontinued or dose changed."
213,"Vinorelbine","DB00361","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nelfinavir is initiated, discontinued or dose changed."
213,"Voriconazole","DB00582","Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased nelfinavir adverse effects during concomitant therapy."
213,"Warfarin","DB00682","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin."
213,"Zolpidem","DB00425","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nelfinavir is initiated, discontinued or dose changed. "
213,"Zonisamide","DB00909","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nelfinavir is initiated, discontinued or dose changed."
213,"Zopiclone","DB01198","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nelfinavir is initiated, discontinued or dose changed."
214,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, isoetharine."
215,"Cyclosporine","DB00091","The sulfonylurea, glimepiride, may increase the effect of cyclosporine."
215,"Gemfibrozil","DB01241","Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone"
215,"Glucosamine","DB01296","Possible hyperglycemia"
215,"Ketoconazole","DB01026","Ketoconazole increases the effect of rosiglitazone"
215,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, glimepiride."
215,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of glimepiride. Monitor for changes in fasting and postprandial blood sugars."
215,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
217,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Indinavir. The antiviral response should be closely monitored."
217,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
217,"Acenocoumarol","DB01418","The protease inhibitor, indinavir, may increase the anticoagulant effect of acenocoumarol."
217,"Alprazolam","DB00404","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, alprazolam."
217,"Aluminium","DB01370","The antacid decreases the absorption of indinavir"
217,"Amiodarone","DB01118","Indinavir increases the effect and toxicity of amiodarone"
217,"Anisindione","DB01125","The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione."
217,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
217,"Atazanavir","DB01072","Increased risk of hyperbilirubinemia with this association"
217,"Atorvastatin","DB01076","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
217,"Bromazepam","DB01558","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if indinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
217,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
217,"Calcium","DB01373","Calcium may decrease the absorption of indinavir."
217,"Carbamazepine","DB00564","Indinavir increases the effect and toxicity of carbamazepine"
217,"Chlordiazepoxide","DB00475","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
217,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
217,"Clarithromycin","DB01211","Indinavir may decrease the effectiveness of clarithromycin by decreasing the formatin of the active metabolite, 14-hydroxy-clarithromycin. Clarithromycin may increase the serum concentration of indinavir. Indinavir may increase the serum concentration of clarithromycin. Consider alternate therapy or monitor the efficacy and adverse effects of both agents more closely during concomitant therapy."
217,"Clonazepam","DB01068","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clonazepam."
217,"Clorazepate","DB00628","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clorazepate."
217,"Cyclosporine","DB00091","The protease inhibitor, indinavir, may increase the effect of cyclosporine."
217,"Dantrolene","DB01219","Indinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if indinavir is initiated, discontinued or dose changed. "
217,"Delavirdine","DB00705","Delavirdine may increase the effect of indinavir."
217,"Diazepam","DB00829","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, diazepam."
217,"Dicoumarol","DB00266","The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol."
217,"Dihydroergotamine","DB00320","Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated."
217,"Efavirenz","DB00625","Efavirenz decreases the effect of indinavir"
217,"Ergotamine","DB00696","Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated."
217,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
217,"Esomeprazole","DB00736","Omeprazole decreases the absorption of indinavir"
217,"Estazolam","DB01215","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, estazolam."
217,"Fentanyl","DB00813","The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl."
217,"Flurazepam","DB00690","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam."
217,"Fusidic Acid","DB02703","Indinavir may increase the effect and toxicity of fusidic acid."
217,"Halazepam","DB00801","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, halazepam."
217,"Ketoconazole","DB01026","Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed."
217,"Lansoprazole","DB00448","Omeprazole decreases the absorption of indinavir"
217,"Lovastatin","DB00227","Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. "
217,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
217,"Magnesium","DB01378","Magnesium may decrease the absorption of indinavir."
217,"Magnesium oxide","DB01377","The antacid decreases the absorption of indinavir"
217,"Midazolam","DB00683","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam."
217,"Omeprazole","DB00338","Omeprazole decreases the absorption of indinavir"
217,"Pantoprazole","DB00213","Omeprazole decreases the absorption of indinavir"
217,"Pimozide","DB01100","The protease inhibitor, indinavir, may increase the effect and toxicity of pimozide."
217,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
217,"Prazepam","DB01588","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, prazepam."
217,"Quazepam","DB01589","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, quazepam."
217,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
217,"Rabeprazole","DB01129","Omeprazole decreases the absorption of indinavir"
217,"Ranolazine","DB00243","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Concomitant therapy is contraindicated."
217,"Rifabutin","DB00615","Rifabutin decreases the effect of indinavir"
217,"Rifampicin","DB01045","Rifampin decreases the effect of indinavir"
217,"Risperidone","DB00734","Increased risk of extrapyramidal symptoms"
217,"Saquinavir","DB01232","Possible antagonism of action"
217,"Saxagliptin","DB06335","Indinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
217,"Sildenafil","DB00203","The protease inhibitor, indinavir, may increase the effect and toxicity of sildenafil."
217,"Silodosin","DB06207","Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. "
217,"St. John's Wort","DB01323","St. John's Wort decreases the effect of indinavir"
217,"Sunitinib","DB01268","Possible increase in sunitinib levels"
217,"Tacrolimus","DB00864","The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered."
217,"Tadalafil","DB00820","Indinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
217,"Tamoxifen","DB00675","Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
217,"Tamsulosin","DB00706","Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed."
217,"Telithromycin","DB00976","Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
217,"Temsirolimus","DB06287","Indinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
217,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Indinavir is initiated, discontinued or dose changed."
217,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
217,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Indinavir is initiated, discontinued or dose changed."
217,"Tolterodine","DB01036","Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.\
"
217,"Tramadol","DB00193","Indinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
217,"Trazodone","DB00656","The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed."
217,"Triazolam","DB00897","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, triazolam."
217,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Indinavir is initiated, discontinued or dose changed. "
217,"Vardenafil","DB00862","Indinavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
217,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
217,"Venlafaxine","DB00285","Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed."
217,"Verapamil","DB00661","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed. "
217,"Vinblastine","DB00570","Indinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Indinavir is initiated, discontinued or dose changed."
217,"Vincristine","DB00541","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Indinavir is initiated, discontinued or dose changed."
217,"Vinorelbine","DB00361","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Indinavir is initiated, discontinued or dose changed."
217,"Vitamin C","DB00126","Vitamin C decreases indinavir levels"
217,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
217,"Warfarin","DB00682","The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin."
217,"Zolpidem","DB00425","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if indinavir is initiated, discontinued or dose changed. "
217,"Zonisamide","DB00909","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed."
217,"Zopiclone","DB01198","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if indinavir is initiated, discontinued or dose changed."
220,"Acenocoumarol","DB01418","Lovastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if lovastatin is initiated, discontinued or dose changed."
220,"Amprenavir","DB00701","Amprenavir may increase the serum concentration of the lovastatin. Concomitant therapy is contraindicated."
220,"Anisindione","DB01125","Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed."
220,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
220,"Azithromycin","DB00207","The macrolide antibiotic, azithromycin, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if azithromycin is initiated, discontinued or dose changed."
220,"Bezafibrate","DB01393","Increased risk of myopathy/rhabdomyolysis"
220,"Bosentan","DB00559","Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed."
220,"Carbamazepine","DB00564","Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed."
220,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the toxicity of the statin, lovastatin."
220,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
220,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
220,"Danazol","DB01406","Risk of severe myopathy/rhabdomyolysis with this combination"
220,"Darunavir","DB01264","Darunavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. \
"
220,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if delavirdine is initiated, discontinued or dose changed."
220,"Dicoumarol","DB00266","Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed."
220,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of lovastatin. Lovastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
220,"Efavirenz","DB00625","Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed."
220,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin."
220,"Etravirine","DB06414","Lovastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of lovastatin therapy. "
220,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
220,"Fluconazole","DB00196","Increased risk of myopathy/rhabdomyolysis"
220,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
220,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
220,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if imatinib is initiated, discontinued or dose changed."
220,"Indinavir","DB00224","Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. "
220,"Itraconazole","DB01167","Increased risk of myopathy/rhabdomyolysis"
220,"Josamycin","DB01321","The macrolide, josamycin, may increase the toxicity of the statin, lovastatin."
220,"Ketoconazole","DB01026","Increased risk of myopathy/rhabdomyolysis"
220,"Lomitapide","DB08827","Lovastatin plasma concentrations may increase by lomitapide."
220,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if nefazodone is initiated, discontinued or dose changed."
220,"Nelfinavir","DB00220","Nelfinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
220,"Nevirapine","DB00238","The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed."
220,"Niacin","DB00627","Risk of severe myopathy/rhabdomyolysis with this combination"
220,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
220,"Rifabutin","DB00615","Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed."
220,"Rifampicin","DB01045","Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed."
220,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
220,"Saquinavir","DB01232","Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. "
220,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
220,"Telithromycin","DB00976","Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided."
220,"Ticagrelor","DB08816","Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects. "
220,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated."
220,"Verapamil","DB00661","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed."
220,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed."
220,"Warfarin","DB00682","Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed ."
221,"Labetalol","DB00598","Monitor arterial pressure closely"
221,"Rotigotine","DB05271","Risk of sedation may increase with concomitant therapy. Monitor therapy closely. "
223,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Pregabalin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
224,"Aminophylline","DB01223","Aminophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Aminophylline is initiated, discontinued or dose changed. "
224,"Clozapine","DB00363","The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated. "
224,"Dyphylline","DB00651","Dyphylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Dyphylline is initiated, discontinued or dose changed. "
224,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, temazepam."
224,"Theophylline","DB00277","Theophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Theophylline is initiated, discontinued or dose changed. "
224,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Temazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
225,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
225,"Lithium","DB01356","The thiazide diuretic, methyclothiazide, may increase serum levels of lithium."
225,"Trandolapril","DB00519","The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
225,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
226,"Azathioprine","DB00993","Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine."
226,"Mercaptopurine","DB01033","Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine."
226,"Sulindac","DB00605","Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. "
226,"Tiaprofenic acid","DB01600","Increased risk of gastrointestinal bleeding. "
226,"Tioguanine","DB00352","Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine."
226,"Tolmetin","DB00500","Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. "
226,"Trandolapril","DB00519","The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed. "
226,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy. "
226,"Warfarin","DB00682","The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin. "
229,"Acebutolol","DB01193","Antagonism"
229,"Atenolol","DB00335","Antagonism"
229,"Betaxolol","DB00195","Antagonism"
229,"Bevantolol","DB01295","Antagonism"
229,"Bisoprolol","DB00612","Antagonism"
229,"Carteolol","DB00521","Antagonism"
229,"Carvedilol","DB01136","Antagonism"
229,"Esmolol","DB00187","Antagonism"
229,"Labetalol","DB00598","Antagonism"
229,"Metoprolol","DB00264","Antagonism"
229,"Nadolol","DB01203","Antagonism"
229,"Oxprenolol","DB01580","Antagonism"
229,"Penbutolol","DB01359","Antagonism"
229,"Pindolol","DB00960","Antagonism"
229,"Practolol","DB01297","Antagonism"
229,"Propranolol","DB00571","Antagonism"
229,"Sotalol","DB00489","Antagonism"
229,"Timolol","DB00373","Antagonism"
230,"Acenocoumarol","DB01418","Barbiturates like butabarbital may increase the metabolism of Vitamin K Antagonists like acenocoumarol. onitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. "
230,"Aminophylline","DB01223","The barbiturate, butabarbital, decreases the effect of aminophylline."
230,"Amitriptyline","DB00321","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Amoxapine","DB00543","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Bendamustine","DB06769","Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites. "
230,"Betamethasone","DB00443","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone."
230,"Clomifene","DB00882","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene."
230,"Clomipramine","DB01242","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Conjugated Estrogens","DB00286","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, conjugated estrogens."
230,"Cyclosporine","DB00091","The barbiturate, butabarbital, increases the effect of cyclosporine."
230,"Desipramine","DB01151","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Dexamethasone","DB01234","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone."
230,"Diethylstilbestrol","DB00255","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol."
230,"Disopyramide","DB00280","arbiturates may increase the metabolism of Disopyramide. Monitor for decreased therapeutic effects of disopyramide if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
230,"Doxepin","DB01142","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Doxycycline","DB00254","The anticonvulsant, butabarbital, decreases the effect of doxycycline."
230,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of CNS Depressants like butabarbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. "
230,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
230,"Estradiol","DB00783","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol."
230,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
230,"Felodipine","DB01023","The barbiturate, butabarbital, decreases the effect of felodipine."
230,"Fludrocortisone","DB00687","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone."
230,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, butabarbital."
230,"Gefitinib","DB00317","The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
230,"Griseofulvin","DB00400","The barbiturate, butabarbital, decreases the effect of griseofulvin."
230,"Hydrocortisone","DB00741","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone."
230,"Hydroxyzine","DB00557","Hydroxyzine may enhance the CNS depressant effect of barbiturates like butabarbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.  "
230,"Imipramine","DB00458","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Lamotrigine","DB00555","Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
230,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
230,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone."
230,"Megestrol acetate","DB00351","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol."
230,"Methadone","DB00333","The barbiturate, butabarbital, decreases the effect of methadone."
230,"Metronidazole","DB00916","The barbiturate, butabarbital, decreases the effect of metronidazole."
230,"Nifedipine","DB01115","The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine."
230,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
230,"Nortriptyline","DB00540","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Oxtriphylline","DB01303","The barbiturate, butabarbital, decreases the effect of oxtriphylline."
230,"Prednisolone","DB00860","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone."
230,"Prednisone","DB00635","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone."
230,"Protriptyline","DB00344","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
230,"Quinidine","DB00908","The anticonvulsant, butabarbital, decreases the effect of quinidine."
230,"Teniposide","DB00444","Barbiturates like butabarbital may decrease the serum concentration of Teniposide. arbiturates may decrease the serum concentration of Teniposide. "
230,"Theophylline","DB00277","The barbiturate, butabarbital, decreases the effect of theophylline."
230,"Triamcinolone","DB00620","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone."
230,"Trimipramine","DB00726","The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
230,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
230,"Verapamil","DB00661","Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed. "
230,"Voriconazole","DB00582","Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
230,"Warfarin","DB00682","Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed. "
231,"Acenocoumarol","DB01418","Nevirapine may decrease the anticoagulant effect of acenocoumarol."
231,"Anisindione","DB01125","Nevirapine may decrease the anticoagulant effect of anisindione."
231,"Atazanavir","DB01072","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed."
231,"Atorvastatin","DB01076","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed."
231,"Dicoumarol","DB00266","Nevirapine may decrease the anticoagulant effect of dicumarol."
231,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
231,"Etravirine","DB06414","Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy."
231,"Ketoconazole","DB01026","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed."
231,"Lovastatin","DB00227","The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed."
231,"Methadone","DB00333","The antiretroviral agent decreases the effect of methadone"
231,"Nelfinavir","DB00220","Nevirapine may decrease the effect of nelfinavir."
231,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
231,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
231,"Saquinavir","DB01232","Decreases the effect of saquinavir"
231,"Simvastatin","DB00641","The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed."
231,"St. John's Wort","DB01323","St. John's Wort decreases nevirapine effect"
231,"Telithromycin","DB00976","Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
231,"Temsirolimus","DB06287","Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
231,"Tipranavir","DB00932","Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed. "
231,"Tramadol","DB00193","Nevirapine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
231,"Trazodone","DB00656","The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed."
231,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
231,"Warfarin","DB00682","Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4."
234,"Acenocoumarol","DB01418","Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. "
234,"Aminophylline","DB01223","The barbiturate, butalbital, decreases the effect of aminophylline."
234,"Amitriptyline","DB00321","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Amoxapine","DB00543","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Betamethasone","DB00443","The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone."
234,"Chloramphenicol","DB00446","Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased. "
234,"Clomifene","DB00882","The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene."
234,"Clomipramine","DB01242","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Conjugated Estrogens","DB00286","The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens."
234,"Cyclosporine","DB00091","The barbiturate, butalbital, increases the effect of cyclosporine."
234,"Desipramine","DB01151","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Dexamethasone","DB01234","The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone."
234,"Diethylstilbestrol","DB00255","The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol."
234,"Doxepin","DB01142","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Doxycycline","DB00254","The anticonvulsant, butalbital, decreases the effect of doxycycline."
234,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.\
"
234,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
234,"Estradiol","DB00783","The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol."
234,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
234,"Felodipine","DB01023","The barbiturate, butalbital, decreases the effect of felodipine."
234,"Fludrocortisone","DB00687","The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone."
234,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, butalbital."
234,"Gefitinib","DB00317","The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib."
234,"Griseofulvin","DB00400","The barbiturate, butalbital, decreases the effect of griseofulvin."
234,"Hydrocortisone","DB00741","The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone."
234,"Hydroxyzine","DB00557","Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination. "
234,"Imipramine","DB00458","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Lamotrigine","DB00555","Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
234,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
234,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone."
234,"Megestrol acetate","DB00351","The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol."
234,"Methadone","DB00333","The barbiturate, butalbital, decreases the effect of methadone."
234,"Metronidazole","DB00916","The barbiturate, butalbital, decreases the effect of metronidazole."
234,"Nifedipine","DB01115","The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine."
234,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
234,"Nortriptyline","DB00540","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Oxtriphylline","DB01303","The barbiturate, butalbital, decreases the effect of oxtriphylline."
234,"Prednisolone","DB00860","The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone."
234,"Prednisone","DB00635","The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone."
234,"Protriptyline","DB00344","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
234,"Quinidine","DB00908","The anticonvulsant, butalbital, decreases the effect of quinidine."
234,"Teniposide","DB00444","Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely. "
234,"Theophylline","DB00277","The barbiturate, butalbital, decreases the effect of theophylline."
234,"Triamcinolone","DB00620","The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone."
234,"Trimipramine","DB00726","The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
234,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
234,"Verapamil","DB00661","Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.  "
234,"Voriconazole","DB00582","Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
234,"Warfarin","DB00682","Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed. "
235,"Leflunomide","DB01097","Immunosuppressants such as cladribine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
235,"Natalizumab","DB00108","Immunosuppressants such as cladribine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. "
235,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cladribine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
235,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
235,"Tacrolimus","DB00864","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
235,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
236,"Amiodarone","DB01118","Possible additive effect on QT prolongation"
236,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentratin of ranolazine by inhibiting its metabolism. Concomitant therapy is contraindicated."
236,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
236,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."
236,"Bicalutamide","DB01128","CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification."
236,"Bretylium","DB01158","Possible additive effect on QT prolongation"
236,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."
236,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use."
236,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors (such as the azole antifungals).1 Monitor for increased effects/toxicity of ranolazine during concomitant use. "
236,"Digoxin","DB00390","Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed."
236,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of ranolazine. Consider alternate therapy or limit ranolazine dose to 500 mg twice daily and monitor for changes in the therapeutic and adverse effects if diltiazem is initiated, discontinued or dose changed."
236,"Dirithromycin","DB00954","Increased levels of ranolazine - risk of toxicity"
236,"Disopyramide","DB00280","Possible additive effect on QT prolongation"
236,"Dofetilide","DB00204","Possible additive effect on QT prolongation"
236,"Erythromycin","DB00199","Increased levels of ranolazine - risk of toxicity"
236,"Fluconazole","DB00196","Increased levels of ranolazine - risk of toxicity"
236,"Fosamprenavir","DB01319","Increased levels of ranolazine - risk of toxicity"
236,"Ibutilide","DB00308","Possible additive effect on QT prolongation"
236,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Concomitant therapy is contraindicated."
236,"Itraconazole","DB01167","Increased levels of ranolazine - risk of toxicity"
236,"Ketoconazole","DB01026","Increased levels of ranolazine - risk of toxicity"
236,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
236,"Moricizine","DB00680","Possible additive effect on QT prolongation"
236,"Nelfinavir","DB00220","Increased levels of ranolazine - risk of toxicity"
236,"Procainamide","DB01035","Possible additive effect on QT prolongation"
236,"Quinidine","DB00908","Possible additive effect on QT prolongation"
236,"Ritonavir","DB00503","Increased levels of ranolazine - risk of toxicity"
236,"Saquinavir","DB01232","Increased levels of ranolazine - risk of toxicity"
236,"Simvastatin","DB00641","Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed."
236,"Sotalol","DB00489","Possible additive effect on QT prolongation"
236,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
236,"Tamoxifen","DB00675","Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
236,"Tamsulosin","DB00706","Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed."
236,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided."
236,"Thioridazine","DB00679","Possible additive effect on QT prolongation"
236,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
236,"Tipranavir","DB00932","Increased levels of ranolazine - risk of toxicity"
236,"Tolterodine","DB01036","Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
236,"Topotecan","DB01030","The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
236,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
236,"Tramadol","DB00193","Ranolazine may decrease the effect of Tramadol by decreasing active metabolite production. "
236,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
236,"Verapamil","DB00661","Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated."
236,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated."
236,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
236,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
236,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
237,"Azathioprine","DB00993","Mesalazine may increase the toxicity of thiopurine, azathioprine."
237,"Mercaptopurine","DB01033","Mesalazine may increase the toxicity of thiopurine, mercaptopurine."
237,"Tioguanine","DB00352","Mesalazine may increase the toxicity of thiopurine, thioguanine."
238,"Donepezil","DB00843","Possible antagonism of action"
238,"Galantamine","DB00674","Possible antagonism of action"
238,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
238,"Rivastigmine","DB00989","Possible antagonism of action"
238,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Benztropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
238,"Trimethobenzamide","DB00662","Trimethobenzamide and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
238,"Triprolidine","DB00427","Triprolidine and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
238,"Trospium","DB00209","Trospium and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
239,"Abarelix","DB00106","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. "
239,"Amantadine","DB00915","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Amiodarone","DB01118","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Amitriptyline","DB00321","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. "
239,"Amoxapine","DB00543","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Apomorphine","DB00714","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Arsenic trioxide","DB01169","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
239,"Asenapine","DB06216","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Azithromycin","DB00207","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Bromocriptine","DB01200","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Carbamazepine","DB00564","Increases the effect and toxicity of ziprasidone"
239,"Chlorpromazine","DB00477","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Cisapride","DB00604","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Citalopram","DB00215","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
239,"Clarithromycin","DB01211","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Clomipramine","DB01242","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Dasatinib","DB01254","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Desipramine","DB01151","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Disopyramide","DB00280","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Dofetilide","DB00204","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Dolasetron","DB00757","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Domperidone","DB01184","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Donepezil","DB00843","Possible antagonism of action"
239,"Doxepin","DB01142","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Dronedarone","DB04855","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
239,"Droperidol","DB00450","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Erythromycin","DB00199","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Escitalopram","DB01175","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
239,"Flecainide","DB01195","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Fluconazole","DB00196","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Fluoxetine","DB00472","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Flupentixol","DB00875","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Foscarnet","DB00529","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Galantamine","DB00674","Possible antagonism of action"
239,"Gatifloxacin","DB01044","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Halofantrine","DB01218","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Haloperidol","DB00502","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Ibutilide","DB00308","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Iloperidone","DB04946","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
239,"Imipramine","DB00458","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Indapamide","DB00808","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Isradipine","DB00270","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Ketoconazole","DB01026","Ketoconazole increases the effect and toxicity of ziprasidone"
239,"L-DOPA","DB01235","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Lapatinib","DB01259","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Levofloxacin","DB01137","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Loxapine","DB00408","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
239,"Maprotiline","DB00934","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Mefloquine","DB00358","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Mesoridazine","DB00933","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Methadone","DB00333","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Methotrimeprazine","DB01403","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
239,"Moxifloxacin","DB00218","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Nilotinib","DB04868","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
239,"Norfloxacin","DB01059","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Nortriptyline","DB00540","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Octreotide","DB00104","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Pazopanib","DB06589","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Pentamidine","DB00738","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Perflutren","DB00556","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Pergolide","DB01186","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Pimozide","DB01100","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Pramipexole","DB00413","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Probucol","DB01599","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Procainamide","DB01035","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Propafenone","DB01182","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Protriptyline","DB00344","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Quetiapine","DB01224","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Quinidine","DB00908","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Quinine","DB00468","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
239,"Ranolazine","DB00243","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Risperidone","DB00734","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Romidepsin","DB06176","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided."
239,"Ropinirole","DB00268","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder. "
239,"Rotigotine","DB05271","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder."
239,"Sotalol","DB00489","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Sparfloxacin","DB01208","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Sunitinib","DB01268","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Tacrine","DB00382","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms."
239,"Tacrolimus","DB00864","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Telavancin","DB06402","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
239,"Telithromycin","DB00976","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Tetrabenazine","DB04844","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Thioridazine","DB00679","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Thiothixene","DB01623","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Toremifene","DB00539","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Trimipramine","DB00726","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
239,"Voriconazole","DB00582","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Vorinostat","DB02546","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
239,"Zuclopenthixol","DB01624","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
240,"Acebutolol","DB01193","Ischemia with risk of gangrene"
240,"Almotriptan","DB00918","Possible severe and prolonged vasoconstriction"
240,"Amyl Nitrite","DB01612","Possible antagonism of action"
240,"Atenolol","DB00335","Ischemia with risk of gangrene"
240,"Betaxolol","DB00195","Ischemia with risk of gangrene"
240,"Bevantolol","DB01295","Ischemia with risk of gangrene"
240,"Bisoprolol","DB00612","Ischemia with risk of gangrene"
240,"Carteolol","DB00521","Ischemia with risk of gangrene"
240,"Carvedilol","DB01136","Ischemia with risk of gangrene"
240,"Clarithromycin","DB01211","Risk of ergotism and severe ischemia with this association"
240,"Delavirdine","DB00705","The antiretroviral agent may increase the ergot derivative toxicity"
240,"Efavirenz","DB00625","The antiretroviral agent may increase the ergot derivative toxicity"
240,"Eletriptan","DB00216","Possible severe and prolonged vasoconstriction"
240,"Erythrityl Tetranitrate","DB01613","Possible antagonism of action"
240,"Erythromycin","DB00199","Possible ergotism and severe ischemia with this combination"
240,"Esmolol","DB00187","Ischemia with risk of gangrene"
240,"Frovatriptan","DB00998","Possible severe and prolonged vasoconstriction"
240,"Isosorbide Dinitrate","DB00883","Possible antagonism of action"
240,"Isosorbide Mononitrate","DB01020","Possible antagonism of action"
240,"Josamycin","DB01321","Possible ergotism and severe ischemia with this combination"
240,"Labetalol","DB00598","Ischemia with risk of gangrene"
240,"Metoprolol","DB00264","Ischemia with risk of gangrene"
240,"Nadolol","DB01203","Ischemia with risk of gangrene"
240,"Naratriptan","DB00952","Possible severe and prolonged vasoconstriction."
240,"Nitroglycerin","DB00727","Possible antagonism of action"
240,"Oxprenolol","DB01580","Ischemia with risk of gangrene"
240,"Penbutolol","DB01359","Ischemia with risk of gangrene"
240,"Pentaerythritol Tetranitrate","DB06154","Possible antagonism of action"
240,"Pindolol","DB00960","Ischemia with risk of gangrene"
240,"Posaconazole","DB01263","Contraindicated co-administration"
240,"Practolol","DB01297","Ischemia with risk of gangrene"
240,"Propranolol","DB00571","Ischemia with risk of gangrene"
240,"Rizatriptan","DB00953","Possible severe and prolonged vasoconstriction"
240,"Sibutramine","DB01105","Possible serotoninergic syndrome"
240,"Sotalol","DB00489","Ischemia with risk of gangrene"
240,"Sumatriptan","DB00669","Possible severe and prolonged vasoconstriction"
240,"Telithromycin","DB00976","Risk of ergotism and severe ischemia with this association"
240,"Timolol","DB00373","Ischemia with risk of gangrene"
240,"Troleandomycin","DB01361","Possible ergotism and severe ischemia with this combination"
240,"Zolmitriptan","DB00315","Possible severe and prolonged vasoconstriction"
241,"Erythromycin","DB00199","Erythromycin increases serum levels and toxicity of cabergoline"
241,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
241,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
241,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
241,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
241,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
241,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated."
241,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \
Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
243,"Aluminium","DB01370","Formation of non-absorbable complexes"
243,"Calcium","DB01373","Formation of non-absorbable complexes"
243,"Lumefantrine","DB06708","Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions. "
243,"Magnesium","DB01378","Formation of non-absorbable complexes"
243,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
243,"Rifabutin","DB00615","Decreased levels of dapsone"
243,"Rifampicin","DB01045","Decreased levels of dapsone"
243,"Telithromycin","DB00976","Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed."
243,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
243,"Trimethoprim","DB00440","Increased toxicity of both products"
243,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed."
245,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
245,"Acenocoumarol","DB01418","Increased hydantoin levels and risk of bleeding"
245,"ado-trastuzumab emtansine","DB05773","Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1."
245,"Alprazolam","DB00404","Phenytoin may increase the metabolism of alprazolam via CYP3A4."
245,"Aminophylline","DB01223","Decreased effect of both products"
245,"Amiodarone","DB01118","Amiodarone may increase the therapeutic and adverse effects of phenytoin."
245,"Anisindione","DB01125","Increased hydantoin levels and risk of bleeding"
245,"Aprepitant","DB00673","The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant."
245,"Asenapine","DB06216","Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine. "
245,"Atracurium","DB00732","Phenytoin decreases the effect of the muscle relaxant"
245,"Axitinib","DB06626","Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib.\
\
\
"
245,"Betamethasone","DB00443","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone."
245,"Bleomycin","DB00290","The antineoplasic agent decreases the effect of hydantoin"
245,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
245,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
245,"Canagliflozin","DB08907","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
245,"Capecitabine","DB01101","Capecitabine increases the effect of hydantoin"
245,"Carboplatin","DB00958","The antineoplasic agent decreases the effect of hydantoin"
245,"Carmustine","DB00262","The antineoplasic agent decreases the effect of hydantoin"
245,"Chloramphenicol","DB00446","Increases phenytoin, modifies chloramphenicol"
245,"Chlordiazepoxide","DB00475","Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
245,"Chlorotrianisene","DB00269","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene."
245,"Chlorphenamine","DB01114","The antihistamine increases the effect of hydantoin"
245,"Cimetidine","DB00501","Cimetidine may increase the therapeutic effect of phenytoin."
245,"Ciprofloxacin","DB00537","Ciprofloxacin may decrease the therapeutic effect of phenytoin."
245,"Cisplatin","DB00515","The antineoplasic agent decreases the effect of hydantoin"
245,"Clarithromycin","DB01211","Clarithromycin may increase the therapeutic and adverse effects of phenytoin."
245,"Clomifene","DB00882","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene."
245,"Clorazepate","DB00628","Phenytoin may increase the metabolism of clorazepate via CYP3A4."
245,"Clozapine","DB00363","Phenytoin may decrease the effect of clozapine."
245,"Colesevelam","DB00930","Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam. "
245,"Conjugated Estrogens","DB00286","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens."
245,"Cortisone acetate","DB01380","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate."
245,"Cyclosporine","DB00091","The hydantoin decreases the effect of cyclosporine"
245,"Dabrafenib","DB08912","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
245,"Dasatinib","DB01254","Phenytoin may decrease the serum level and efficacy of dasatinib."
245,"Delavirdine","DB00705","The anticonvulsant, phenytoin, decreases the effect of delavirdine."
245,"Dexamethasone","DB01234","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone."
245,"Diazepam","DB00829","Phenytoin may increase the metabolism of diazepam via CYP3A4."
245,"Diazoxide","DB01119","Diazoxide decreases the efficacy of phenytoin. "
245,"Dicoumarol","DB00266","Increased hydantoin levels and risk of bleeding"
245,"Diethylstilbestrol","DB00255","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol."
245,"Disopyramide","DB00280","The hydantoin decreases the effect of disopyramide"
245,"Disulfiram","DB00822","Disulfiram may increase the therapeutic and adverse effects of phenytoin."
245,"Dopamine","DB00988","Risk of severe hypotension"
245,"Doxacurium chloride","DB01135","Phenytoin decreases the effect of the muscle relaxant"
245,"Doxycycline","DB00254","The anticonvulsant, phenytoin, may decrease the effect of doxycycline."
245,"Dyphylline","DB00651","Decreased effect of both products"
245,"Estradiol","DB00783","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol."
245,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
245,"Estriol","DB04573","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol."
245,"Estrone","DB00655","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone."
245,"Estropipate","DB04574","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate."
245,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
245,"Etravirine","DB06414","Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
245,"Ezogabine","DB04953","Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown. "
245,"Felbamate","DB00949","Increased phenytoin levels and decreased felbamate levels"
245,"Felodipine","DB01023","The hydantoin decreases the effect of felodipine"
245,"Fluconazole","DB00196","Fluconazole may increase the therapeutic and adverse effects of phenytoin."
245,"Fludrocortisone","DB00687","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
245,"Fluorouracil","DB00544","Fluorouracil increases the effect of hydantoin"
245,"Fluoxetine","DB00472","Fluoxetine increases the effect of phenytoin"
245,"Flurazepam","DB00690","Phenytoin may increase the metabolism of flurazepam via CYP3A4."
245,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic effect of phenytoin."
245,"Folic Acid","DB00158","Folic acid may decrease the levels of phenytoin."
245,"Furosemide","DB00695","The hydantoin decreases the effect of furosemide"
245,"Gabapentin","DB00996","Gabapentin may increase the therapeutic and adverse effects of phenytoin."
245,"Gefitinib","DB00317","The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
245,"Hydrocortisone","DB00741","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
245,"Imatinib","DB00619","The hydantoin decreases the levels of imatinib"
245,"Irinotecan","DB00762","The hydantoin decreases the effect of irinotecan"
245,"Isoniazid","DB00951","Isoniazid increases the effect of phenytoin in 20% of patients"
245,"Itraconazole","DB01167","Phenytoin decreases the effect of itraconazole"
245,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
245,"L-DOPA","DB01235","The hydantoin decreases the effect of levodopa"
245,"Lamotrigine","DB00555","Phenytoin may reduce levels of lamotrigine"
245,"Levonorgestrel","DB00367","Phenytoin decreases the contraceptive effect"
245,"Lopinavir","DB01601","Levels of both drugs are affected"
245,"Mebendazole","DB00643","The hydantoin decreases the efficiency of mebendazole"
245,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone."
245,"Megestrol acetate","DB00351","The enzyme inducer, phenytoin, may decrease the effect of megestrol."
245,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
245,"Methadone","DB00333","The hydantoin decreases the effect of methadone"
245,"Methotrexate","DB00563","The antineoplasic agent decreases the effect of hydantoin"
245,"Methoxsalen","DB00553","The hydantoin decreases the effect of psoralene"
245,"Methylprednisolone","DB00959","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone."
245,"Metocurine","DB01336","Phenytoin decreases the effect of the muscle relaxant"
245,"Metyrapone","DB01011","The combination renders the test invalid"
245,"Mexiletine","DB00379","The hydantoin decreases the effect of mexiletine"
245,"Midazolam","DB00683","Phenytoin may increase the metabolism of midazolam via CYP3A4."
245,"Mirtazapine","DB00370","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
245,"Mivacurium","DB01226","Phenytoin decreases the effect of the muscle relaxant"
245,"Nisoldipine","DB00401","Phenytoin decreases the efficiency of nisoldipine"
245,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
245,"Omeprazole","DB00338","Omeprazole increases the effect of hydantoin"
245,"Oxcarbazepine","DB00776","Oxcarbazepine increases the effect of hydantoin"
245,"Oxtriphylline","DB01303","Decreased effect of both products"
245,"Oxyphenbutazone","DB03585","The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin."
245,"Pancuronium","DB01337","Phenytoin decreases the effect of the muscle relaxant"
245,"Paramethasone","DB01384","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone."
245,"Perampanel","DB08883","Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary.\
 "
245,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin."
245,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
245,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
245,"Posaconazole","DB01263","Modifications of drug levels for both agents"
245,"Praziquantel","DB01058","Markedly lower praziquantel levels"
245,"Prednisolone","DB00860","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone."
245,"Prednisone","DB00635","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone."
245,"Quetiapine","DB01224","Phenytoin decreases the effect of quetiapine"
245,"Quinestrol","DB04575","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol."
245,"Quinidine","DB00908","The anticonvulsant, phenytoin, decreases the effect of quinidine."
245,"Regorafenib","DB08896","Strong CYP3A4 inducers may decrease levels of regorafenib. "
245,"Rifampicin","DB01045","Rifampin may decrease the therapeutic and adverse effects of phenytoin."
245,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
245,"Rufinamide","DB06201","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
245,"Sertraline","DB01104","Sertraline increases the effect of hydantoin"
245,"Sirolimus","DB00877","The hydantoin decreases sirolimus levels"
245,"Sucralfate","DB00364","Sucralfate decreases the effect of hydantoin"
245,"Sulfadiazine","DB00359","The sulfonamide increases the effect of hydantoin"
245,"Sulfamethizole","DB00576","The sulfonamide increases the effect of hydantoin"
245,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
245,"Tacrolimus","DB00864","Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered."
245,"Telithromycin","DB00976","Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy."
245,"Temsirolimus","DB06287","Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
245,"Theophylline","DB00277","Decreased effect of both products"
245,"Thiotepa","DB04572","Possible increase in thiotepa levels"
245,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of phenytoin. Consider alternate therapy or monitor for adverse/toxic effects of phenytoin if ticlopidine is initiated, discontinued or dose changed."
245,"Tipranavir","DB00932","Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."
245,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
245,"Tofacitinib","DB08895","Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels.\
\
"
245,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
245,"Tolvaptan","DB06212","Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
245,"Topiramate","DB00273","Increased phenytoin/decreased topiramate"
245,"Tramadol","DB00193","Phenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
245,"Trazodone","DB00656","The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed."
245,"Tretinoin","DB00755","The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed. "
245,"Triamcinolone","DB00620","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone."
245,"Triazolam","DB00897","Phenytoin may increase the metabolism of triazolam via CYP3A4."
245,"Trimethoprim","DB00440","Trimethoprim increases the effect of hydantoin"
245,"Trioxsalen","DB04571","The hydantoin decreases the effect of psoralene"
245,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
245,"Tubocurarine","DB01199","Phenytoin decreases the effect of the muscle relaxant"
245,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
245,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
245,"Vecuronium","DB01339","Phenytoin decreases the effect of the muscle relaxant"
245,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
245,"Verapamil","DB00661","Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed. "
245,"Vigabatrin","DB01080","Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment. "
245,"Vinblastine","DB00570","The antineoplasic agent decreases the effect of hydantoin"
245,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity."
245,"Warfarin","DB00682","Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy."
247,"Acenocoumarol","DB01418","The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol."
247,"Acitretin","DB00459","Increased risk of intracranial hypertension"
247,"Aluminium","DB01370","Formation of non-absorbable complexes"
247,"Amobarbital","DB01351","The anticonvulsant, amobarbital, decreases the effect of doxycycline."
247,"Amoxicillin","DB01060","Possible antagonism of action"
247,"Ampicillin","DB00415","Possible antagonism of action"
247,"Anisindione","DB01125","The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione."
247,"Aprobarbital","DB01352","The anticonvulsant, aprobarbital, decreases the effect of doxycycline."
247,"Attapulgite","DB01574","Formation of non-absorbable complexes"
247,"Azlocillin","DB01061","Possible antagonism of action"
247,"Aztreonam","DB00355","Possible antagonism of action"
247,"Bacampicillin","DB01602","Possible antagonism of action"
247,"Benzylpenicillin","DB01053","Possible antagonism of action"
247,"Bexarotene","DB00307","Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
247,"Butabarbital","DB00237","The anticonvulsant, butabarbital, decreases the effect of doxycycline."
247,"Butalbital","DB00241","The anticonvulsant, butalbital, decreases the effect of doxycycline."
247,"Butethal","DB01353","The anticonvulsant, butethal, decreases the effect of doxycycline."
247,"Calcium","DB01373","Formation of non-absorbable complexes"
247,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
247,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
247,"Carbamazepine","DB00564","The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline."
247,"Carbenicillin","DB00578","Possible antagonism of action"
247,"Clavulanate","DB00766","Possible antagonism of action"
247,"Cloxacillin","DB01147","Possible antagonism of action"
247,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
247,"Cyclacillin","DB01000","Possible antagonism of action"
247,"Dicloxacillin","DB00485","Possible antagonism of action"
247,"Dicoumarol","DB00266","The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol."
247,"Dihydroquinidine barbiturate","DB01341","The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline."
247,"Ethinyl Estradiol","DB00977","Doxycycline may decrease the contraceptive effect of ethinyl estradiol."
247,"Ethotoin","DB00754","The anticonvulsant, ethotoin, decreases the effect of doxycycline."
247,"Etretinate","DB00926","Increased risk of intracranial hypertension"
247,"Flucloxacillin","DB00301","Possible antagonism of action"
247,"Fosphenytoin","DB01320","The anticonvulsant, fosphenytoin, decreases the effect of doxycycline."
247,"Heptabarbital","DB01354","The anticonvulsant, heptabarbital, decreases the effect of doxycycline."
247,"Hetacillin","DB00739","Possible antagonism of action"
247,"Hexobarbital","DB01355","The anticonvulsant, hexobarbital, decreases the effect of doxycycline."
247,"Iron","DB01592","Formation of non-absorbable complexes"
247,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
247,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
247,"Magnesium","DB01378","Formation of non-absorbable complexes"
247,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
247,"Mephenytoin","DB00532","The anticonvulsant, mephenytoin, decreases the effect of doxycycline."
247,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
247,"Methohexital","DB00474","The anticonvulsant, methohexital, decreases the effect of doxycycline."
247,"Methotrexate","DB00563","The tetracycline, doxycycline, may increase methotrexate toxicity."
247,"Methylphenobarbital","DB00849","The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline."
247,"Meticillin","DB01603","Possible antagonism of action"
247,"Mezlocillin","DB00948","Possible antagonism of action"
247,"Nafcillin","DB00607","Possible antagonism of action"
247,"Oxacillin","DB00713","Possible antagonism of action"
247,"Penicillin V","DB00417","Possible antagonism of action"
247,"Pentobarbital","DB00312","The anticonvulsant, pentobarbital, decreases the effect of doxycycline."
247,"Phenobarbital","DB01174","The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline."
247,"Phenytoin","DB00252","The anticonvulsant, phenytoin, may decrease the effect of doxycycline."
247,"Piperacillin","DB00319","Possible antagonism of action"
247,"Pivampicillin","DB01604","Possible antagonism of action"
247,"Pivmecillinam","DB01605","Possible antagonism of action"
247,"Primidone","DB00794","The anticonvulsant, primidone, decreases the effect of doxycycline."
247,"Quinidine barbiturate","DB01346","The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline."
247,"Rifabutin","DB00615","The rifamycin decreases the effect of doxycycline"
247,"Rifampicin","DB01045","The rifamycin decreases the effect of doxycycline"
247,"Secobarbital","DB00418","The anticonvulsant , secobarbital, decreases the effect of doxycycline."
247,"Talbutal","DB00306","The anticonvulsant, talbutal, decreases the effect of doxycycline."
247,"Tamsulosin","DB00706","Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed."
247,"Tazobactam","DB01606","Possible antagonism of action"
247,"Thiopental","DB00599","Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered. "
247,"Ticarcillin","DB01607","Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline."
247,"Tolterodine","DB01036","Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
247,"Tretinoin","DB00755","Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
247,"Warfarin","DB00682","The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin."
247,"Zinc","DB01593","Formation of non-absorbable complexes"
248,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol."
248,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol."
248,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Prednisolone","DB00860","The estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone."
248,"Prednisone","DB00635","The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone."
248,"Primidone","DB00794","The enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol."
248,"Raloxifene","DB00481","Association not recommended"
248,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, diethylstilbestrol."
248,"Tipranavir","DB00932","Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy. "
248,"Ursodeoxycholic acid","DB01586","Estrogens decreases the effect of ursodiol"
250,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
250,"Budesonide","DB01222","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. "
250,"Colchicine","DB01394","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function. "
250,"Everolimus","DB01590","CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction. "
250,"Fentanyl","DB00813","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. "
250,"Halofantrine","DB01218","CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).\
"
250,"Lurasidone","DB08815","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor. "
250,"Ranolazine","DB00243","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of ranolazine. Limit the ranolazine dose to a maximum of 500mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.). Monitor for increased effects/toxicity of ranolazine during concomitant use."
250,"Tacrolimus","DB00864","The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered. "
250,"Tamsulosin","DB00706","Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed."
250,"Tolterodine","DB01036","Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
250,"Tolvaptan","DB06212","CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. "
250,"Tramadol","DB00193","Clotrimazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
250,"Trazodone","DB00656","The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed."
251,"Alendronate","DB00630","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate. "
251,"Calcium carbonate","DB06724","Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
251,"Calcium Chloride","DB01164","Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
251,"Ceftriaxone","DB01212","Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. "
251,"Ciprofloxacin","DB00537","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Clodronate","DB00720","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
251,"Demeclocycline","DB00618","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
251,"Doxycycline","DB00254","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
251,"Eltrombopag","DB06210","Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. "
251,"Estramustine","DB01196","Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk. "
251,"Etidronic acid","DB01077","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate. "
251,"Gemifloxacin","DB01155","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Ibandronate","DB00710","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate. "
251,"Levofloxacin","DB01137","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Levothyroxine","DB00451","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
251,"Liothyronine","DB00279","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
251,"Liotrix","DB01583","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
251,"Lomefloxacin","DB00978","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Minocycline","DB01017","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
251,"Nalidixic Acid","DB00779","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Norfloxacin","DB01059","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Ofloxacin","DB01165","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Risedronate","DB00884","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate. "
251,"Sparfloxacin","DB01208","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
251,"Tetracycline","DB00759","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
251,"Tiludronate","DB01133","The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
251,"Trientine hydrochloride","DB06824","Calcium salts such as calcium acetate may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of Calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk. "
251,"Trovafloxacin","DB00685","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction. "
254,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
254,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy. "
255,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
255,"Cimetidine","DB00501","Increases myelosuppression caused by carmustine"
255,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
255,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
255,"Leflunomide","DB01097","Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
255,"Natalizumab","DB00108","Immunosuppressants such as carmustine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
255,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
255,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
255,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
255,"Tacrolimus","DB00864","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.\
"
255,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
256,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
256,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
256,"Tamoxifen","DB00675","Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed."
256,"Tolbutamide","DB01124","Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. "
256,"Torasemide","DB00214","Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfisoxazole is initiated, discontinued or dose changed. "
256,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed."
256,"Voriconazole","DB00582","Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.	"
256,"Warfarin","DB00682","Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed."
256,"Zafirlukast","DB00549","Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed."
257,"Acetohexamide","DB00414","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Chlorpropamide","DB00672","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism."
257,"Citalopram","DB00215","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, metoprolol."
257,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
257,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
257,"Diltiazem","DB00343","Increased risk of bradycardia"
257,"Disopyramide","DB00280","The beta-blocker, metoprolol, may increase adverse effects of disopyramide."
257,"Dronedarone","DB04855","Metoprolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase metoprolol exposure 1.6-fold. Lower dose of metoprolol. "
257,"Epinephrine","DB00668","Hypertension, then bradycardia"
257,"Ergonovine","DB01253","Ischemia with risk of gangrene"
257,"Ergotamine","DB00696","Ischemia with risk of gangrene"
257,"Escitalopram","DB01175","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol."
257,"Fenoterol","DB01288","Antagonism"
257,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol."
257,"Formoterol","DB00983","Antagonism"
257,"Gliclazide","DB01120","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Glipizide","DB01067","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Glisoxepide","DB01289","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Glyburide","DB01016","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Glycodiazine","DB01382","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Hydralazine","DB01275","Increased effect of both drugs"
257,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
257,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
257,"Insulin Glargine","DB00047","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Isoprenaline","DB01064","Antagonism"
257,"Lidocaine","DB00281","The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine"
257,"Methysergide","DB00247","Ischemia with risk of gangrene"
257,"Mirabegron","DB08893","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
257,"Orciprenaline","DB00816","Antagonism"
257,"Paroxetine","DB00715","The SSRI increases the effect of the beta-blocker"
257,"Phenobarbital","DB01174","The barbiturate decreases the effect of the metabolized beta-blocker"
257,"Pipobroman","DB00236","Antagonism"
257,"Pirbuterol","DB01291","Antagonism"
257,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
257,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
257,"Primidone","DB00794","The barbiturate decreases the effect of metabolized beta-blocker"
257,"Procaterol","DB01366","Antagonism"
257,"Propafenone","DB01182","Propafenone may increase the effect of beta-blocker, metoprolol."
257,"Repaglinide","DB00912","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism."
257,"Salbutamol","DB01001","Antagonism"
257,"Salmeterol","DB00938","Antagonism"
257,"Sertraline","DB01104","The SSRI increases the effect of the beta-blocker"
257,"Telithromycin","DB00976","Telithromycin may possibly increase metoprolol effect"
257,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
257,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Metoprolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Metoprolol if Terbinafine is initiated, discontinued or dose changed."
257,"Terbutaline","DB00871","Antagonism"
257,"Tolazamide","DB00839","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Tolbutamide","DB01124","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
257,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
257,"Verapamil","DB00661","Increased effect of both drugs"
259,"Acetaminophen","DB00316","\
	  may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed."
259,"Acetohexamide","DB00414","Dicumarol may increase the effect of sulfonylurea, acetohexamide."
259,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases effect of the anticoagulant, dicumarol."
259,"Allopurinol","DB00437","Allopurinol may increase the anticoagulant effect of dicumarol."
259,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the anticoagulant effect of dicumarol."
259,"Amiodarone","DB01118","Amiodarone may increase the anticoagulant effect of dicumarol."
259,"Amprenavir","DB00701","Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
259,"Aprepitant","DB00673","Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."
259,"Atazanavir","DB01072","The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol."
259,"Azathioprine","DB00993","Azathioprine may decrease the anticoagulant effect of dicumarol."
259,"Azithromycin","DB00207","Azithromycin may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
259,"Betamethasone","DB00443","The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol."
259,"Bosentan","DB00559","Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism."
259,"Capecitabine","DB01101","Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
259,"Carbamazepine","DB00564","Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."
259,"Cefotetan","DB01330","The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol."
259,"Cefoxitin","DB01331","The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol."
259,"Ceftriaxone","DB01212","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol."
259,"Celecoxib","DB00482","Celecoxib may increase the anticoagulant effect of dicumarol."
259,"Chlorpropamide","DB00672","Dicumarol may increase the effect of sulfonylurea, chlorpropamide."
259,"Cholestyramine","DB01432","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."
259,"Cimetidine","DB00501","Cimetidine may increase the anticoagulant effect of dicumarol."
259,"Ciprofloxacin","DB00537","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol."
259,"Cisapride","DB00604","Cisapride may increase the anticoagulant effect of dicumarol."
259,"Citalopram","DB00215","The SSRI, citalopram, increases the effect of anticoagulant, dicumarol."
259,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol."
259,"Clofibrate","DB00636","The fibrate increases the anticoagulant effect"
259,"Colestipol","DB00375","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."
259,"Cyclophosphamide","DB00531","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol."
259,"Danazol","DB01406","The androgen, danazol, may increase the anticoagulant effect of dicumarol."
259,"Demeclocycline","DB00618","The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol."
259,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol."
259,"Dextropropoxyphene","DB00647","Propoxyphene may increase the anticoagulant effect of dicumarol."
259,"Dextrothyroxine","DB00509","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol."
259,"Diclofenac","DB00586","The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol."
259,"Dicloxacillin","DB00485","Dicloxacillin may decrease the anticoagulant effect of dicumarol."
259,"Diflunisal","DB00861","The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol."
259,"Disulfiram","DB00822","Disulfiram may increase the anticoagulant effect of dicumarol."
259,"Doxycycline","DB00254","The tetracycline, doxycycline, may increase the anticoagulant effect of dicumarol."
259,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the anticoagulant effect of dicumarol.."
259,"Ethchlorvynol","DB00189","Ethchlorvynol may decrease the anticoagulant effect of dicumarol."
259,"Ethinyl Estradiol","DB00977","Increased thrombotic risk due to estrogen"
259,"Etodolac","DB00749","The NSAID, etodolac, may increase the anticoagulant effect of dicumarol."
259,"Etoricoxib","DB01628","Etoricoxib may increase the anticoagulant effect of dicumarol."
259,"Fenofibrate","DB01039","Fenofibrate may increase the anticoagulant effect of dicumarol."
259,"Fenoprofen","DB00573","The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol."
259,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of dicumarol by decreasing its metabolism."
259,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol."
259,"Fluorouracil","DB00544","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol."
259,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol."
259,"Fluoxymesterone","DB01185","The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol."
259,"Flurbiprofen","DB00712","The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol."
259,"Fluvastatin","DB01095","Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed."
259,"Fluvoxamine","DB00176","Fluvoxamine may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
259,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol."
259,"Fosphenytoin","DB01320","Increased hydantoin levels and risk of bleeding"
259,"Gefitinib","DB00317","Gefitinib may increase the anticoagulant effect of dicumarol."
259,"Gemcitabine","DB00441","Gemcitabine may increase the anticoagulant effect of dicumarol."
259,"Gemfibrozil","DB01241","Gemfibrozil may increase the anticoagulant effect of dicumarol."
259,"Gliclazide","DB01120","Dicumarol may increase the effect of sulfonylurea, gliclazide."
259,"Glutethimide","DB01437","Glutethimide may decrease the anticoagulant effect of dicumarol."
259,"Glyburide","DB01016","Dicumarol may increase the effect of sulfonylurea, glibenclamide."
259,"Griseofulvin","DB00400","Griseofulvin may decrease the anticoagulant effect of dicumarol."
259,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol."
259,"Ibuprofen","DB01050","The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol."
259,"Imatinib","DB00619","Imatinib may increase the anticoagulant effect of dicumarol."
259,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the anticoagulant effect of dicumarol."
259,"Indomethacin","DB00328","The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol."
259,"Isoniazid","DB00951","Isoniazid may increase the anticoagulant effect of dicumarol."
259,"Itraconazole","DB01167","Itraconazole may increase the anticoagulant effect of dicumarol."
259,"Ketoconazole","DB01026","Ketoconazole may increase the anticoagulant effect of dicumarol."
259,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol."
259,"Ketorolac","DB00465","The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol."
259,"Leflunomide","DB01097","Leflunomide may increase the anticoagulant effect of dicumarol."
259,"Levamisole","DB00848","Levamisole may increase the anticoagulant effect of dicumarol."
259,"Levofloxacin","DB01137","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol."
259,"Levothyroxine","DB00451","The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol."
259,"Lovastatin","DB00227","Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed."
259,"Lumiracoxib","DB01283","Lumiracoxib may increase the anticoagulant effect of dicumarol."
259,"Medroxyprogesterone Acetate","DB00603","Medroxyprogesterone may increase the anticoagulant effect of dicumarol."
259,"Mefenamic acid","DB00784","The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol."
259,"Mefloquine","DB00358","Mefloquine may increase the anticoagulant effect of dicumarol."
259,"Meloxicam","DB00814","Meloxicam may increase the anticoagulant effect of dicumarol."
259,"Mercaptopurine","DB01033","Mercaptopurine may decrease the anticoagulant effect of dicumarol."
259,"Methimazole","DB00763","The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol."
259,"Metronidazole","DB00916","Metronidazole may increase the anticoagulant effect of dicumarol."
259,"Miconazole","DB01110","Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism."
259,"Minocycline","DB01017","The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol."
259,"Mitotane","DB00648","Mitotane may decrease the anticoagulant effect of dicumarol."
259,"Moxifloxacin","DB00218","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of dicumarol."
259,"Nabumetone","DB00461","The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol."
259,"Nalidixic Acid","DB00779","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol."
259,"Naproxen","DB00788","The NSAID, naproxen, may increase the anticoagulant effect of dicumarol."
259,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of dicumarol."
259,"Nevirapine","DB00238","Nevirapine may decrease the anticoagulant effect of dicumarol."
259,"Norfloxacin","DB01059","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol."
259,"Ofloxacin","DB01165","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol."
259,"Orlistat","DB01083","Orlistat may increase the anticoagulant effect of dicumarol."
259,"Oxaprozin","DB00991","The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol."
259,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol."
259,"Paroxetine","DB00715","The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.\
"
259,"Pentoxifylline","DB00806","Pentoxifylline may increase the anticoagulant effect of dicumarol."
259,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol."
259,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol."
259,"Phenytoin","DB00252","Increased hydantoin levels and risk of bleeding"
259,"Piroxicam","DB00554","The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol."
259,"Prednisolone","DB00860","The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol."
259,"Prednisone","DB00635","The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol."
259,"Primidone","DB00794","The barbiturate, primidone, decreases the anticoagulant effect, dicumarol."
259,"Propafenone","DB01182","Propafenone may increase the anticoagulant effect of dicumarol."
259,"Propylthiouracil","DB00550","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol."
259,"Quinidine","DB00908","Quinidine may increase the anticoagulant effect of dicumarol."
259,"Quinine","DB00468","Quinine may increase the anticoagulant effect of dicumarol."
259,"Ranitidine","DB00863","Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)"
259,"Rifabutin","DB00615","Rifabutin may decrease the anticoagulant effect of dicumarol."
259,"Rifampicin","DB01045","Rifampin may decrease the anticoagulant effect of dicumarol."
259,"Telithromycin","DB00976","Telithromycin may increase the anticoagulant effect of dicumarol."
259,"Tenoxicam","DB00469","The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol."
259,"Testosterone","DB00624","The androgen may increase the anticoagulant effect of dicumarol."
259,"Tetracycline","DB00759","Tetracycline may increase the anticoagulant effect of dicumarol."
259,"Tigecycline","DB00560","Tigecycline may increase the anticoagulant effect of dicumarol."
259,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol."
261,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect and toxicity of ropinirole."
261,"Dihydrocodeine","DB01551","Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy"
261,"Fluvoxamine","DB00176","Increases the effect and toxicity of ropinirole"
261,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
261,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Ropinirole. Consider alternate therapy or monitor for decreased effects of both agents. "
261,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder. "
261,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
262,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene."
262,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene."
262,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene."
262,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, chlorotrianisene."
262,"Prednisolone","DB00860","The estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone."
262,"Prednisone","DB00635","The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone."
262,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene."
262,"Raloxifene","DB00481","Association not recommended"
263,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
263,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
263,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
263,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
263,"Telithromycin","DB00976","Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed."
263,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed."
263,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
263,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. "
263,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
263,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
263,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
263,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed."
263,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
263,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
263,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
266,"Acetazolamide","DB00819","Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy. "
266,"Brinzolamide","DB01194","As both brinzolamide and topiramate are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
266,"Carbamazepine","DB00564","Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy."
266,"Chlorothiazide","DB00880","Thiazide diuretics such as chlorothiazide may enhance the hypokalemic effect of topiramate. Thiazide diuretics may increase the serum concentration of topiramate. Monitor for increased topiramate concentrations/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary. "
266,"Ethinyl Estradiol","DB00977","Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy."
266,"Fosphenytoin","DB01320","Increased phenytoin/decreased topiramate"
266,"Lithium","DB01356","Topiramate could modify lithium levels"
266,"Maraviroc","DB04835","Topiramate, a CYP3A4 inducer, may decrease the serum concentration of Maraviroc by increasing Maraviroc metabolism and clearance. A dose adjustment of Maraviroc may be required. Monitor for changes in Maraviroc therapeutic and adverse effects if Topiramate is initiated, discontinued or dose changed. "
266,"Mestranol","DB01357","Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy."
266,"Phenytoin","DB00252","Increased phenytoin/decreased topiramate"
266,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
266,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Topiramate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
266,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
267,"Probenecid","DB01032","Probenecid may increase the serum level of cefmatzole."
268,"Drospirenone","DB01395","Increased risk of hyperkalemia"
268,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
268,"Trandolapril","DB00519","The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril. "
268,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
269,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
270,"Aciclovir","DB00787","Acyclovir may increase the effect and toxicity of theophylline."
270,"Adenosine","DB00640","Theophylline may decrease the effect of adenosine."
270,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of theophylline."
270,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of theophylline."
270,"Atracurium","DB00732","Theophylline decreases the effect of the muscle relaxant"
270,"Bromazepam","DB01558","Theophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if theophylline is initiated, discontinued or dose changed. "
270,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of theophylline."
270,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of theophylline."
270,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of theophylline."
270,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
270,"Carteolol","DB00521","Antagonism of action and increased effect of theophylline"
270,"Cimetidine","DB00501","Cimetidine may increase the effect of theophylline."
270,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect of theophylline."
270,"Clarithromycin","DB01211","Clarithromycin may increase the therapeutic and adverse effects of theophylline."
270,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline."
270,"Disulfiram","DB00822","Disulfiram may increase the effect and toxicity of theophylline."
270,"Doxacurium chloride","DB01135","Theophylline decreases the effect of the muscle relaxant"
270,"Enoxacin","DB00467","Enoxacin may increase the effect of theophylline."
270,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of theophylline."
270,"Ethinyl Estradiol","DB00977","The contraceptive increases the effect and toxicity of theophylline"
270,"Ethotoin","DB00754","Decreased effect of both products"
270,"Febuxostat","DB04854","Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes."
270,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic and adverse effects of theophylline."
270,"Fosphenytoin","DB01320","Decreased effect of both products"
270,"Grepafloxacin","DB00365","Grepafloxacin may increase the effect of theophylline."
270,"Halothane","DB01159","Increased risk of cardiac arrhythmia"
270,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of theophylline."
270,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of theophylline."
270,"Interferon Alfa-2a, Recombinant","DB00034","Interferon increases the effect and toxicity of theophylline"
270,"Interferon Alfa-2b, Recombinant","DB00105","Interferon increases the effect and toxicity of theophylline"
270,"Interferon alfa-n1","DB00011","Interferon increases the effect and toxicity of theophylline"
270,"Isoniazid","DB00951","Isoniazid may increase the therapeutic and adverse effects of theophylline."
270,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect and toxicity of theophylline."
270,"Lithium","DB01356","Theophylline decreases serum levels of lithium"
270,"Mephenytoin","DB00532","Decreased effect of both products"
270,"Mestranol","DB01357","The contraceptive increases the effect and toxicity of theophylline"
270,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of theophylline."
270,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of theophylline."
270,"Metocurine","DB01336","Theophylline decreases the effect of the muscle relaxant"
270,"Mexiletine","DB00379","Mexiletine increases the effect and toxicity of theophylline"
270,"Mivacurium","DB01226","Theophylline decreases the effect of the muscle relaxant"
270,"Nadolol","DB01203","Antagonism of action and increased effect of theophylline"
270,"Norfloxacin","DB01059","Norfloxacin may increase the effect of theophylline."
270,"Pancuronium","DB01337","Theophylline decreases the effect of the muscle relaxant"
270,"Pefloxacin","DB00487","Pefloxacin may increase the effect of theophylline."
270,"Peginterferon alfa-2a","DB00008","Interferon increases the effect and toxicity of theophylline"
270,"Peginterferon alfa-2b","DB00022","Interferon increases the effect and toxicity of theophylline"
270,"Penbutolol","DB01359","Antagonism of action and increased effect of theophylline"
270,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of theophylline."
270,"Pentoxifylline","DB00806","Pentoxifylline increases the effect and toxicity of theophylline"
270,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of theophylline."
270,"Phenytoin","DB00252","Decreased effect of both products"
270,"Pindolol","DB00960","Antagonism of action and increased effect of theophylline"
270,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of theophylline."
270,"Propafenone","DB01182","Propafenone increases the effect of theophylline"
270,"Propranolol","DB00571","Antagonism of action and increased effect of theophylline"
270,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of theophylline."
270,"Regadenoson","DB06213","Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson. "
270,"Rifampicin","DB01045","Rifampin decreases the effect of theophylline"
270,"Ritonavir","DB00503","Ritonavir decreases the effect of theophylline"
270,"Rofecoxib","DB00533","Rofecoxib increases the effect and toxicity of theophylline"
270,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of theophylline."
270,"Sotalol","DB00489","Antagonism of action and increased effect of theophylline"
270,"St. John's Wort","DB01323","St. John's Wort decreases the effect of theophylline"
270,"Tacrine","DB00382","Tacrine may reduce the elimination rate of Theophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed."
270,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of theophylline."
270,"Telithromycin","DB00976","Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed."
270,"Temazepam","DB00231","Theophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Theophylline is initiated, discontinued or dose changed. "
270,"Terbinafine","DB00857","Terbinafine increases the effect and toxicity of theophylline"
270,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed."
270,"Ticlopidine","DB00208","Ticlopidine increases the effect and toxicity of theophylline"
270,"Timolol","DB00373","Antagonism of action and increased effect of theophylline"
270,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline. "
270,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect and toxicity of theophylline."
270,"Tubocurarine","DB01199","Theophylline decreases the effect of the muscle relaxant"
270,"Vecuronium","DB01339","Theophylline decreases the effect of the muscle relaxant"
270,"Verapamil","DB00661","Verapamil increases the effect of theophylline"
270,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed."
270,"Zafirlukast","DB00549","Zafirlukast serum concentrations may be decreased by Theophylline."
270,"Zileuton","DB00744","Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered."
271,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
271,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy. "
272,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
272,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
272,"Cholestyramine","DB01432","The resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine."
272,"Colestipol","DB00375","The resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine."
272,"Digoxin","DB00390","The thyroid hormone, liothyronine, decreases the effect of digoxin."
272,"Warfarin","DB00682","Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed."
273,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
273,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
273,"Atenolol","DB00335","The beta-blocker, atenolol, may increase the toxicity of disopyramide."
273,"Azithromycin","DB00207","The macrolide, azithromycin, may increase the effect of disopyramide."
273,"Betaxolol","DB00195","The beta-blocker, betaxolol, may increase the toxicity of disopyramide."
273,"Bevantolol","DB01295","The beta-blocker, bevantolol, may increase the toxicity of disopyramide."
273,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may increase the toxicity of disopyramide."
273,"Butabarbital","DB00237","arbiturates may increase the metabolism of Disopyramide. Monitor for decreased therapeutic effects of disopyramide if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
273,"Carteolol","DB00521","The beta-blocker, carteolol, may increase the toxicity of disopyramide."
273,"Carvedilol","DB01136","The beta-blocker, carvedilol, may increase the toxicity of disopyramide."
273,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
273,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
273,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
273,"Donepezil","DB00843","Possible antagonism of action"
273,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
273,"Esmolol","DB00187","The beta-blocker, esmolol, may increase the adverse effects of disopyramide."
273,"Ethotoin","DB00754","The hydantoin decreases the effect of disopyramide"
273,"Etravirine","DB06414","Disopyramide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for disopyramide therapy. "
273,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
273,"Fosphenytoin","DB01320","The hydantoin decreases the effect of disopyramide"
273,"Galantamine","DB00674","Possible antagonism of action"
273,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
273,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
273,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
273,"Labetalol","DB00598","The beta-blocker, labetolol, may increase the toxicity of disopyramide."
273,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
273,"Mephenytoin","DB00532","The hydantoin decreases the effect of disopyramide"
273,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
273,"Metoprolol","DB00264","The beta-blocker, metoprolol, may increase adverse effects of disopyramide."
273,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
273,"Nadolol","DB01203","The beta-blocker, nadolol, may increase the toxicity of disopyramide."
273,"Omeprazole","DB00338","The beta-blocker increases toxicity of disopyramide"
273,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may increase the toxicity of disopyramide."
273,"Penbutolol","DB01359","The beta-blocker, penbutolol,  may increase the toxicity of disopyramide."
273,"Phenobarbital","DB01174","Phenobarbital decreases levels of disopyramide"
273,"Phenytoin","DB00252","The hydantoin decreases the effect of disopyramide"
273,"Pindolol","DB00960","The beta-blocker, pindolol, may increase the toxicity of disopyramide."
273,"Practolol","DB01297","The beta-blocker, practolol, may increase the toxicity of disopyramide."
273,"Propranolol","DB00571","The beta-blocker, propranolol, may increase the toxicity of disopyramide."
273,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
273,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
273,"Rifampicin","DB01045","Rifampin decreases the effect of disopyramide"
273,"Rivastigmine","DB00989","Possible antagonism of action"
273,"Sotalol","DB00489","The beta-blocker, sotalol, may increase the toxicity of disopyramide."
273,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
273,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
273,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
273,"Telithromycin","DB00976","Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided."
273,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
273,"Thiopental","DB00599","Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed."
273,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
273,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
273,"Timolol","DB00373","The beta-blocker, timolol, may increase the toxicity of disopyramide."
273,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
273,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
273,"Voriconazole","DB00582","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed."
273,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
273,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
273,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
274,"Acebutolol","DB01193","The beta-blocker, acebutolol, may increase the effect and toxicity of lidocaine. "
274,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias"
274,"Atenolol","DB00335","The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine."
274,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine."
274,"Carvedilol","DB01136","The beta-blocker, carvedilol, may increase the effect and toxicity of lidocaine."
274,"Cimetidine","DB00501","Increases the effect and toxicity of lidocaine"
274,"Darunavir","DB01264","Possible increase in lidocaine levels"
274,"Esmolol","DB00187","The beta-blocker, esmolol, may increase the effect and toxicity of lidocaine."
274,"Etravirine","DB06414","Lidocaine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor lidocaine therapy."
274,"Labetalol","DB00598","The beta-blocker, labetalol, may increase the effect and toxicity of lidocaine."
274,"Metoprolol","DB00264","The beta-blocker, metoprolol, may increase the effect and toxicity of lidocaine"
274,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
274,"Oxprenolol","DB01580","The beta-blocker increases the effect and toxicity of lidocaine"
274,"Penbutolol","DB01359","Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine."
274,"Pindolol","DB00960","The beta-blocker increases the effect and toxicity of lidocaine"
274,"Propranolol","DB00571","The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine."
274,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
274,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed."
274,"Tamoxifen","DB00675","Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
274,"Tamsulosin","DB00706","Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed."
274,"Telithromycin","DB00976","Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed."
274,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Lidocaine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lidocaine if Terbinafine is initiated, discontinued or dose changed."
274,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Lidocaine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Lidocaine is initiated, discontinued or dose changed. "
274,"Timolol","DB00373","The beta-blocker, timolol, may increase the effect and toxicity of lidocaine."
274,"Tizanidine","DB00697","Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
274,"Tolterodine","DB01036","Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
274,"Tramadol","DB00193","Lidocaine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lidocaine may decrease the effect of Tramadol by decreasing active metabolite production."
274,"Trazodone","DB00656","The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed."
274,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed."
276,"Donepezil","DB00843","Possible antagonism of action"
276,"Galantamine","DB00674","Possible antagonism of action"
276,"Rivastigmine","DB00989","Possible antagonism of action"
276,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clemastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
276,"Trimethobenzamide","DB00662","Trimethobenzamide and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
276,"Triprolidine","DB00427","Concomitant therapy with triprolidine and clemastine, two anticholinergics and CNS depressants, may result in additive  adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy. "
276,"Trospium","DB00209","Trospium and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
277,"Digoxin","DB00390","Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed."
277,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of acarbose. Monitor for changes in fasting and postprandial blood sugars."
278,"Almotriptan","DB00918","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Amitriptyline","DB00321","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Amoxapine","DB00543","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Amprenavir","DB00701","Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed."
278,"Atazanavir","DB01072","Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed."
278,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Buspirone","DB00490","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Cabergoline","DB00248","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Chlorpromazine","DB00477","Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed."
278,"Cinacalcet","DB01012","Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed."
278,"Citalopram","DB00215","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Clarithromycin","DB01211","Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed."
278,"Clomipramine","DB01242","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Cocaine","DB00907","Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed."
278,"Conivaptan","DB00872","Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed."
278,"Darunavir","DB01264","Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed."
278,"Delavirdine","DB00705","Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed."
278,"Desipramine","DB01151","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Dexfenfluramine","DB01191","Risk of serotoninergic syndrome"
278,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Diethylpropion","DB00937","Risk of serotoninergic syndrome"
278,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Dipivefrin","DB00449","Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
278,"Doxepin","DB01142","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Duloxetine","DB00476","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Ephedrine","DB01364","Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
278,"Epinephrine","DB00668","Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
278,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Escitalopram","DB01175","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Fenfluramine","DB00574","Risk of serotoninergic syndrome"
278,"Fluoxetine","DB00472","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Fluvoxamine","DB00176","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Fosamprenavir","DB01319","Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed."
278,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Furazolidone","DB00614","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
278,"Imatinib","DB00619","Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed."
278,"Imipramine","DB00458","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Indinavir","DB00224","Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Indinavir is initiated, discontinued, or dose changed."
278,"Isocarboxazid","DB01247","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
278,"Isoniazid","DB00951","Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed."
278,"Itraconazole","DB01167","Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed."
278,"Ketoconazole","DB01026","Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed."
278,"Linezolid","DB00601","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
278,"Lithium","DB01356","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Lopinavir","DB01601","Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed."
278,"Maprotiline","DB00934","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Mazindol","DB00579","Risk of serotoninergic syndrome"
278,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Metoclopramide","DB01233","Possible serotoninergic syndrome with this combination"
278,"Miconazole","DB01110","Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed."
278,"Milnacipran","DB04896","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Mirtazapine","DB00370","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Moclobemide","DB01171","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
278,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Nefazodone","DB01149","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Nelfinavir","DB00220","Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nelfinavir is initiated, discontinued, or dose changed."
278,"Nicardipine","DB00622","Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed."
278,"Norepinephrine","DB00368","Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. "
278,"Nortriptyline","DB00540","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Paroxetine","DB00715","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Pergolide","DB01186","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Pethidine","DB00454","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Phenelzine","DB00780","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
278,"Phentermine","DB00191","Risk of serotoninergic syndrome"
278,"Phenylpropanolamine","DB00397","Risk of serotoninergic syndrome"
278,"Posaconazole","DB01263","Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed."
278,"Procarbazine","DB01168","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
278,"Promethazine","DB01069","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Propafenone","DB01182","Propafenone increases the effect and toxicity of venlafaxine"
278,"Protriptyline","DB00344","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Pseudoephedrine","DB00852","Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. "
278,"Quinidine","DB00908","Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed."
278,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
278,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
278,"Ritonavir","DB00503","Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed."
278,"Rizatriptan","DB00953","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Saquinavir","DB01232","Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed."
278,"Selegiline","DB01037","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
278,"Sertraline","DB01104","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Sibutramine","DB01105","Increased risk of serotonin syndrome. Concurrent therapy should be avoided. "
278,"St. John's Wort","DB01323","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Sumatriptan","DB00669","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Telithromycin","DB00976","Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed."
278,"Terbinafine","DB00857","Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed."
278,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
278,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
278,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
278,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed."
278,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
279,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, conjugated estrogens."
279,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens."
279,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens."
279,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens."
279,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, conjugated estrogens."
279,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, conjugated estrogens."
279,"Prednisolone","DB00860","The estrogenic agent may increase the effect of the corticosteroid, prednisolone."
279,"Prednisone","DB00635","The estrogenic agent may increase the effect of corticosteroid, prednisone."
279,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens."
279,"Raloxifene","DB00481","Association not recommended"
279,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, conjugated estrogens."
279,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, conjugated estrogens."
279,"Tipranavir","DB00932","Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy. "
279,"Ursodeoxycholic acid","DB01586","Estrogens decreases the effect of ursodiol"
282,"Amiodarone","DB01118","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Chloroquine","DB00608","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Cocaine","DB00907","CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor."
282,"Dextropropoxyphene","DB00647","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Diphenhydramine","DB01075","Diphenhydramine, a moderate CYP2D6 inhibitor, may increase the therapeutic and adverse effects of atomoxetine by decreasing its metabolism."
282,"Fluoxetine","DB00472","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Fluphenazine","DB00623","Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy."
282,"Haloperidol","DB00502","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
282,"Lomustine","DB01206","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Mibefradil","DB01388","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Paroxetine","DB00715","The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine."
282,"Perphenazine","DB00850","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
282,"Quinacrine","DB01103","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Quinidine","DB00908","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Quinidine barbiturate","DB01346","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Quinine","DB00468","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
282,"Ritonavir","DB00503","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Terbinafine","DB00857","Terbinafine, a CYP2D6 inhibitor, may reduce the metabolism and clearance of Atomoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Atomoxetine if Terbinafine is initiated, discontinued or dose changed."
282,"Thioridazine","DB00679","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Atomoxetine. These agents should not be administered within 14 days of each other."
282,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Atomoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. \
"
282,"Vinorelbine","DB00361","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
282,"Yohimbine","DB01392","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
283,"Brentuximab vedotin","DB08870","Pulmonary toxicity of bleomycin may be increased. Avoid combination."
283,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
283,"Filgrastim","DB00099","Monitor therapy due to enhanced adverse effects of bleomycin especially pulmonary toxicity."
283,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
283,"Leflunomide","DB01097","Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. "
283,"Natalizumab","DB00108","Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
283,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
283,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated"
283,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning."
283,"Tacrolimus","DB00864","Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
283,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
284,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
284,"Leflunomide","DB01097","Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
284,"Natalizumab","DB00108","Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
284,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as chlorambucil. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
284,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as chlorambucil. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
284,"Tacrolimus","DB00864","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
284,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
287,"Artemether","DB06697","Artemether may decrease the effectiveness of etonogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
287,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
287,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
287,"Thiopental","DB00599","Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
287,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy. "
287,"Warfarin","DB00682","Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed."
288,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
288,"Eltrombopag","DB06210","Eltrombopag increases Morphine levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance. "
288,"Rifampicin","DB01045","Rifampin decreases the effect of morphine/codeine"
288,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Morphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
288,"Trovafloxacin","DB00685","Morphine may reduce serum levels of Trovafloxacin decreasing the efficacy of the antibiotic. IV doses of morphine should be administered at least 2 hours after a dose of Trovafloxacin given in a fasting state or 4 hours after if given in a fed state."
289,"Fluvoxamine","DB00176","Increases the effect and toxicity of ropivacaine"
290,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 Substrates such as bupivacaine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
291,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Dapiprazole, may result in additive antihypertensive effects. Combination therapy is not recommended."
292,"Aluminium","DB01370","The multivalent agent decreases the effect of penicillamine"
292,"Attapulgite","DB01574","The multivalent agent decreases the effect of penicillamine"
292,"Digoxin","DB00390","The multivalent agent decreases the effect of penicillamine"
292,"Iron","DB01592","The multivalent agent decreases the effect of penicillamine"
292,"Kaolin","DB01575","The multivalent agent decreases the effect of penicillamine"
293,"Atazanavir","DB01072","Concomitant therapy may result in decreased serum levels of Atazanavir and increased levels of Tenofovir. Concomitant therapy should only be used with the inclusion of Ritonavir."
293,"Didanosine","DB00900","Tenofovir may decrease the therapeutic effects and increase the adverse effects of Didanosine. Monitor for changes in virologic response and Didanosine toxicity during concomitant therapy."
293,"Valganciclovir","DB01610","The excretion rates of Valganciclovir and/or Tenofovir may decrease as both drugs are eliminated by active tubular secretion. Monitor for increased serum concentrations and toxicity of both agents."
294,"Demeclocycline","DB00618","Possible antagonism of action"
294,"Doxycycline","DB00254","Possible antagonism of action"
294,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
294,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
294,"Methacycline","DB00931","Possible antagonism of action"
294,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
294,"Minocycline","DB01017","Possible antagonism of action"
294,"Oxytetracycline","DB00595","Possible antagonism of action"
294,"Rolitetracycline","DB01301","Possible antagonism of action"
294,"Tetracycline","DB00759","Possible antagonism of action"
297,"Artemether","DB06697","Artemether may decrease the effectiveness of desogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
297,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of desogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
297,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
297,"Lamotrigine","DB00555","The oral contraceptive decreases the effect of lamotrigine"
297,"Thiopental","DB00599","Thiopental may decrease the effect of Desogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
297,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Desogestrel. An alternate form of contraception should be used during concomitant therapy. "
297,"Warfarin","DB00682","Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed. "
298,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
298,"Vinblastine","DB00570","Potentially severe lung toxicity"
298,"Vincristine","DB00541","Potentially severe lung toxicity"
298,"Vindesine","DB00309","Potentially severe lung toxicity"
299,"Aminophylline","DB01223","The barbiturate, talbutal, decreases the effect of aminophylline."
299,"Betamethasone","DB00443","The barbiturate, talbutal, may decrease the effect of the corticosteroid, betamethasone."
299,"Clomifene","DB00882","The enzyme inducer, talbutal, decreases the effect of the hormone agent, clomifene."
299,"Conjugated Estrogens","DB00286","The enzyme inducer, talbutal, decreases the effect of the hormone agent, conjugated estrogens."
299,"Cyclosporine","DB00091","The sulfonamide decreases the effect of cyclosporine"
299,"Dexamethasone","DB01234","The barbiturate, talbutal, may decrease the effect of the corticosteroid, dexamethasone."
299,"Diethylstilbestrol","DB00255","The enzyme inducer, talbutal, decreases the effect of the hormone agent, diethylstilbestrol."
299,"Doxycycline","DB00254","The anticonvulsant, talbutal, decreases the effect of doxycycline."
299,"Estradiol","DB00783","The enzyme inducer, talbutal, decreases the effect of the hormone agent, estradiol."
299,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
299,"Felodipine","DB01023","The barbiturate, talbutal, decreases the effect of felodipine."
299,"Fludrocortisone","DB00687","The barbiturate, talbutal, may decrease the effect of the corticosteroid, fludrocortisone."
299,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, talbutal."
299,"Gefitinib","DB00317","The CYP3A4 inducer, talbutal, may decrease the serum concentration and therapeutic effects of gefitinib."
299,"Griseofulvin","DB00400","The barbiturate, talbutal, decreases the effect of griseofulvin."
299,"Hydrocortisone","DB00741","The barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone."
299,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
299,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, talbutal, decreases the effect of the hormone agent, medroxyprogesterone."
299,"Megestrol acetate","DB00351","The enzyme inducer, talbutal, decreases the effect of the hormone agent, megestrol."
299,"Methadone","DB00333","The barbiturate, talbutal, decreases the effect of methadone."
299,"Metronidazole","DB00916","The barbiturate, talbutal, decreases the effect of metronidazole."
299,"Nifedipine","DB01115","The barbiturate, talbutal, decreases the effect of the calcium channel blocker, nifedipine."
299,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
299,"Oxtriphylline","DB01303","The barbiturate, talbutal, decreases the effect of oxtriphylline."
299,"Prednisolone","DB00860","The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisolone."
299,"Prednisone","DB00635","The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone."
299,"Quinidine","DB00908","The anticonvulsant, talbutal, decreases the effect of quinidine."
299,"Theophylline","DB00277","The barbiturate, talbutal, decreases the effect of theophylline."
299,"Triamcinolone","DB00620","The barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone."
300,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification."
300,"Demeclocycline","DB00618","Tetracycline derivatives like demeclocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache)."
300,"Desogestrel","DB00304","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of desogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Doxycycline","DB00254","Tetracycline derivatives like doxycycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
300,"Drospirenone","DB01395","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Ethynodiol","DB00823","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of ethynodiol diacetate it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Etonogestrel","DB00294","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of etonogestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Gemfibrozil","DB01241","Gemfibrozil may increase the serum concentration of bexarotene. This combination should be avoided."
300,"Levonorgestrel","DB00367","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of levonorgestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Medroxyprogesterone Acetate","DB00603","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of medroxyprogesterone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Minocycline","DB01017","Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
300,"Norelgestromin","DB06713","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norelgestromin, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Norethindrone","DB00717","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Norgestimate","DB00957","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norgestimate, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
300,"Tetracycline","DB00759","Tetracycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
300,"Tigecycline","DB00560","Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri (intracranial hypertension) is of particular concern. Avoid this combination."
300,"Vitamin A","DB00162","Bexarotene increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking bexarotene."
301,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
301,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
301,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
301,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
301,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
301,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
301,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
301,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
301,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
301,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
301,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
301,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
301,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
301,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
302,"Mitomycin","DB00305","Potentially severe lung toxicity"
302,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
303,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
303,"Diazoxide","DB01119","Significant hyperglycemic effect"
303,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
303,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
303,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrythmias"
303,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
303,"Lithium","DB01356","The thiazide diuretic, chlorthalidone, may increase serum levels of lithium."
303,"Tenoxicam","DB00469","Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed. "
303,"Trandolapril","DB00519","The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
303,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
305,"Aminophylline","DB01223","The barbiturate, pentobarbital, decreases the effect of aminophylline."
305,"Bendamustine","DB06769","Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine. "
305,"Betamethasone","DB00443","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone."
305,"Clomifene","DB00882","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene."
305,"Conjugated Estrogens","DB00286","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, conjugated estrogens."
305,"Cyclosporine","DB00091","The barbiturate, pentobarbital, increases the effect of cyclosporine."
305,"Dexamethasone","DB01234","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone."
305,"Diethylstilbestrol","DB00255","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
305,"Doxycycline","DB00254","The anticonvulsant, pentobarbital, decreases the effect of doxycycline."
305,"Estradiol","DB00783","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, estradiol."
305,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
305,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
305,"Felodipine","DB01023","The barbiturate, pentobarbital, decreases the effect of felodipine."
305,"Fludrocortisone","DB00687","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
305,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, pentobarbital."
305,"Gefitinib","DB00317","The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
305,"Griseofulvin","DB00400","The barbiturate, pentobarbital, decreases the effect of griseofulvin."
305,"Hydrocortisone","DB00741","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
305,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
305,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
305,"Megestrol acetate","DB00351","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, megestrol."
305,"Methadone","DB00333","The barbiturate, pentobarbital, decreases the effect of methadone."
305,"Metronidazole","DB00916","The barbiturate, pentobarbital, decreases the effect of metronidazole."
305,"Nifedipine","DB01115","The barbiturate, pentobarbital, decreases the effect of the calcium channel blocker, nifedipine."
305,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
305,"Oxtriphylline","DB01303","The barbiturate, pentobarbital, decreases the effect of oxtriphylline."
305,"Prednisolone","DB00860","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone."
305,"Prednisone","DB00635","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone."
305,"Quinidine","DB00908","The anticonvulsant, pentobarbital, decreases the effect of quinidine."
305,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
305,"Telithromycin","DB00976","Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
305,"Temsirolimus","DB06287","Pentobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
305,"Theophylline","DB00277","The barbiturate, pentobarbital, decreases the effect of theophylline."
305,"Tramadol","DB00193","Pentobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
305,"Trazodone","DB00656","The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed."
305,"Triamcinolone","DB00620","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone."
305,"Trimipramine","DB00726","The barbiturate, Pentobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Pentobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
305,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Pentobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
305,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
305,"Verapamil","DB00661","Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed."
305,"Warfarin","DB00682","Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed. "
306,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of valproic acid."
306,"Asenapine","DB06216","Valproate completely inhibits the glucuronidation of asenapine but does not effect its exposure. Dose adjustment is not necessary with concomitant therapy. "
306,"Carbamazepine","DB00564","Decreases the effect of valproic acid"
306,"Clarithromycin","DB01211","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed. "
306,"Eltrombopag","DB06210","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
306,"Erythromycin","DB00199","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed. "
306,"Felbamate","DB00949","Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed. "
306,"Glycerol Phenylbutyrate","DB08909","Valproic acid may induce hyperammonemia. Monitor ammonia levels closely when use of valproic acid is necessary in UCD patients."
306,"Lacosamide","DB06218","Valproic acid toxicity may occur at any time during the treatment course and should be considered in patients with acute changes in mentation, especially if there has been a recent change in antiepileptic therapy.\
"
306,"Lamotrigine","DB00555","Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. "
306,"Lorazepam","DB00186","Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity. "
306,"Nimodipine","DB00393","Valproic acid increases the effect of nimodipine"
306,"Rifampicin","DB01045","Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed. "
306,"Rufinamide","DB06201","Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations. "
306,"Silodosin","DB06207","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
306,"Telithromycin","DB00976","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed. "
306,"Tipranavir","DB00932","Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy."
306,"Vigabatrin","DB01080","Vigabatrin reduces serum concentrations of valproic acid by 8%. "
308,"Almotriptan","DB00918","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Amitriptyline","DB00321","Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Amoxapine","DB00543","Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Bromocriptine","DB01200","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \
Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Buspirone","DB00490","Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Cabergoline","DB00248","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \
Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Citalopram","DB00215","The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Clomipramine","DB01242","Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"D-Tryptophan","DB03225","Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Desipramine","DB01151","Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
308,"Dextromethorphan","DB00514","Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Dihydroergotamine","DB00320","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Doxepin","DB01142","Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Duloxetine","DB00476","Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Eletriptan","DB00216","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Ergoloid mesylate","DB01049","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
308,"Ergonovine","DB01253","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
308,"Ergotamine","DB00696","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Escitalopram","DB01175","Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Fluoxetine","DB00472","Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Fluvoxamine","DB00176","Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Frovatriptan","DB00998","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Furazolidone","DB00614","The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated. "
308,"Imipramine","DB00458","Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Isocarboxazid","DB01247","The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated."
308,"L-Tryptophan","DB00150","Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Linezolid","DB00601","The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated. "
308,"Lithium","DB01356","Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Maprotiline","DB00934","Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Methylergometrine","DB00353","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
308,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
308,"Milnacipran","DB04896","Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Mirtazapine","DB00370","Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Moclobemide","DB01171","The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated. "
308,"Naratriptan","DB00952","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Nefazodone","DB01149","Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Nortriptyline","DB00540","Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Paroxetine","DB00715","Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Pergolide","DB01186","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
308,"Pethidine","DB00454","Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Phenelzine","DB00780","The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated."
308,"Procarbazine","DB01168","The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated. "
308,"Promethazine","DB01069","Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Protriptyline","DB00344","Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Rasagiline","DB01367","The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated. "
308,"Rizatriptan","DB00953","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"S-Adenosylmethionine","DB00118","Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Selegiline","DB01037","The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated. "
308,"Sertraline","DB01104","Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Sibutramine","DB01105","Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated. "
308,"St. John's Wort","DB01323","Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Sumatriptan","DB00669","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
308,"Tapentadol","DB06204","Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
308,"Tramadol","DB00193","The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Tranylcypromine","DB00752","The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated."
308,"Trazodone","DB00656","Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Trimipramine","DB00726","Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
308,"Venlafaxine","DB00285","Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
309,"Acenocoumarol","DB01418","Acetaminophen may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if acetaminophen is initiated, discontinued or dose changed. "
309,"Anisindione","DB01125","Acetaminophen increases the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if acetaminophen is initiated, discontinued or dose changed. "
309,"Dicoumarol","DB00266","Acetaminophen may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if acetaminophen is initiated, discontinued or dose changed."
309,"Eltrombopag","DB06210","Eltrombopag increases acetaminophen levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance. "
309,"Imatinib","DB00619","Increased hepatic toxicity of both agents"
309,"Isoniazid","DB00951","Risk of hepatotoxicity"
309,"Liraglutide","DB06655","These agents may have decreased C max and a delayed T max during coadministration."
309,"Warfarin","DB00682","Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed. "
310,"Acenocoumarol","DB01418","Gefitinib may increase the anticoagulant effect of acenocoumarol."
310,"Amobarbital","DB01351","The CYP3A4 inducer, amobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Anisindione","DB01125","Gefitinib may increase the anticoagulant effect of anisindione."
310,"Aprobarbital","DB01352","The CYP3A4 inducer, aprobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Butabarbital","DB00237","The CYP3A4 inducer, butabarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Butalbital","DB00241","The CYP3A4 inducer, butalbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Butethal","DB01353","The CYP3A4 inducer, butethal, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Carbamazepine","DB00564","The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Clarithromycin","DB01211","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
310,"Dicoumarol","DB00266","Gefitinib may increase the anticoagulant effect of dicumarol."
310,"Dihydroquinidine barbiturate","DB01341","The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Erythromycin","DB00199","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
310,"Ethotoin","DB00754","The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Etravirine","DB06414","Gefitinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase gefitinib dosage, if clinically appropriate, and to monitor for gefitinib therapy for efficacy and toxicity. "
310,"Fosphenytoin","DB01320","The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Heptabarbital","DB01354","The CYP3A4 inducer, heptabarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Hexobarbital","DB01355","The CYP3A4 inducer, hexobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed."
310,"Ketoconazole","DB01026","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
310,"Mephenytoin","DB00532","The CYP3A4 inducer, mephenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Methohexital","DB00474","The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Methylphenobarbital","DB00849","The CYP3A4 inducer, methylphenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Pentobarbital","DB00312","The CYP3A4 inducer, pentobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Phenobarbital","DB01174","The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Phenytoin","DB00252","The CYP3A4 inducer, phenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Primidone","DB00794","The CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Quinidine barbiturate","DB01346","The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Rifampicin","DB01045","Rifampin reduces levels and efficacy of gefitinib"
310,"Ritonavir","DB00503","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
310,"Secobarbital","DB00418","The CYP3A4 inducer, secobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"St. John's Wort","DB01323","The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Talbutal","DB00306","The CYP3A4 inducer, talbutal, may decrease the serum concentration and therapeutic effects of gefitinib."
310,"Telithromycin","DB00976","Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed."
310,"Topotecan","DB01030","The BCRP/ABCG2 inhibitor, Gefitnib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Gefitinib is initiated, discontinued or dose changed. "
310,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
310,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed."
310,"Warfarin","DB00682","Gefitinib may increase the anticoagulant effect of warfarin."
311,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
311,"Cimetidine","DB00501","Cimetidine may decrease the therapeutic effect of codeine by decreasing its metabolism to its active metabolite, morphine. Monitor for changes in the therapeutic effect of codeine if cimetidine is initiated, discontinued or dose changed."
311,"Dihydroquinidine barbiturate","DB01341","Quinidine decreases the analgesic effect of codeine"
311,"Quinidine","DB00908","Quinidine decreases the analgesic effect of codeine"
311,"Quinidine barbiturate","DB01346","Quinidine decreases the analgesic effect of codeine"
311,"Terbinafine","DB00857","Terbinafine may decrease the efficacy of Codeine by inhibiting active metabolite production. Consider an alternate analgesic or monitor for effectiveness of Codeine. "
311,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Codeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
312,"Atracurium","DB00732","The agent increases the effect of the muscle relaxant"
312,"Demeclocycline","DB00618","Possible antagonism of action"
312,"Doxacurium chloride","DB01135","The agent increases the effect of the muscle relaxant"
312,"Doxycycline","DB00254","Possible antagonism of action"
312,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
312,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
312,"Methacycline","DB00931","Possible antagonism of action"
312,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
312,"Metocurine","DB01336","The agent increases the effect of the muscle relaxant"
312,"Minocycline","DB01017","Possible antagonism of action"
312,"Mivacurium","DB01226","The agent increases the effect of the muscle relaxant"
312,"Oxytetracycline","DB00595","Possible antagonism of action"
312,"Pancuronium","DB01337","The agent increases the effect of the muscle relaxant"
312,"Pipecuronium","DB01338","The agent increases the effect of the muscle relaxant"
312,"Rocuronium","DB00728","The agent increases the effect of the muscle relaxant"
312,"Rolitetracycline","DB01301","Possible antagonism of action"
312,"Succinylcholine","DB00202","The agent increases the effect of the muscle relaxant"
312,"Tetracycline","DB00759","Possible antagonism of action"
312,"Tubocurarine","DB01199","The agent increases the effect of the muscle relaxant"
312,"Vecuronium","DB01339","The agent increases the effect of the muscle relaxant"
313,"Acebutolol","DB01193","Ischemia with risk of gangrene"
313,"Almotriptan","DB00918","Possible severe and prolonged vasoconstriction"
313,"Amprenavir","DB00701","Amprenavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated."
313,"Amyl Nitrite","DB01612","Possible antagonism of action"
313,"Atazanavir","DB01072","Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine."
313,"Atenolol","DB00335","Ischemia with risk of gangrene"
313,"Betaxolol","DB00195","Ischemia with risk of gangrene"
313,"Bevantolol","DB01295","Ischemia with risk of gangrene"
313,"Bisoprolol","DB00612","Ischemia with risk of gangrene"
313,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
313,"Carteolol","DB00521","Ischemia with risk of gangrene"
313,"Carvedilol","DB01136","Ischemia with risk of gangrene"
313,"Clarithromycin","DB01211","Risk of ergotism and severe ischemia with this association"
313,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed."
313,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
313,"Efavirenz","DB00625","Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated."
313,"Eletriptan","DB00216","Possible severe and prolonged vasoconstriction"
313,"Erythrityl Tetranitrate","DB01613","Possible antagonism of action"
313,"Erythromycin","DB00199","Possible ergotism and severe ischemia with this combination"
313,"Esmolol","DB00187","Ischemia with risk of gangrene"
313,"Fluconazole","DB00196","Possible ergotism and severe ischemia with this combination"
313,"Fluoxetine","DB00472","Possible ergotism and severe ischemia with this combination"
313,"Fluvoxamine","DB00176","Possible ergotism and severe ischemia with this combination"
313,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of ergot derivative"
313,"Frovatriptan","DB00998","Possible severe and prolonged vasoconstriction"
313,"Indinavir","DB00224","Indinavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated."
313,"Isosorbide Dinitrate","DB00883","Possible antagonism of action"
313,"Isosorbide Mononitrate","DB01020","Possible antagonism of action"
313,"Itraconazole","DB01167","Possible ergotism and severe ischemia with this combination"
313,"Josamycin","DB01321","Possible ergotism and severe ischemia with this combination"
313,"Ketoconazole","DB01026","Possible ergotism and severe ischemia with this combination"
313,"Labetalol","DB00598","Ischemia with risk of gangrene"
313,"Metoprolol","DB00264","Ischemia with risk of gangrene"
313,"Nadolol","DB01203","Ischemia with risk of gangrene."
313,"Naratriptan","DB00952","Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated."
313,"Nefazodone","DB01149","Possible ergotism and severe ischemia with this combination"
313,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of ergot derivative"
313,"Nitroglycerin","DB00727","Possible antagonism of action"
313,"Oxprenolol","DB01580","Ischemia with risk of gangrene"
313,"Penbutolol","DB01359","Ischemia with risk of gangrene"
313,"Pentaerythritol Tetranitrate","DB06154","Possible antagonism of action"
313,"Pindolol","DB00960","Ischemia with risk of gangrene"
313,"Posaconazole","DB01263","Contraindicated co-administration"
313,"Practolol","DB01297","Ischemia with risk of gangrene"
313,"Propranolol","DB00571","Ischemia with risk of gangrene"
313,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine."
313,"Rizatriptan","DB00953","Possible severe and prolonged vasoconstriction"
313,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine."
313,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
313,"Sotalol","DB00489","Ischemia with risk of gangrene"
313,"Sumatriptan","DB00669","Possible severe and prolonged vasoconstriction"
313,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
313,"Telithromycin","DB00976","Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated."
313,"Timolol","DB00373","Ischemia with risk of gangrene"
313,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated."
313,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
313,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
313,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
313,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
313,"Troleandomycin","DB01361","Possible ergotism and severe ischemia with this combination"
313,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
313,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated."
313,"Zileuton","DB00744","Possible ergotism and severe ischemia with this combination"
313,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
314,"Altretamine","DB00488","Risk of severe hypotension"
314,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
314,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if atazanavir if initiated, discontinued or dose changed."
314,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
314,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as amitriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
314,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed."
314,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if cimetidine is initiated, discontinued or dose changed."
314,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
314,"Clonidine","DB00575","The tricyclic antidepressant, amitriptyline, decreases the effect of clonidine."
314,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
314,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline."
314,"Dobutamine","DB00841","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine."
314,"Donepezil","DB00843","Possible antagonism of action"
314,"Dopamine","DB00988","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dopamine."
314,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
314,"Ephedra","DB01363","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedra."
314,"Ephedrine","DB01364","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedrine."
314,"Epinephrine","DB00668","The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of epinephrine."
314,"Fenoterol","DB01288","The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of fenoterol."
314,"Fluconazole","DB00196","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
314,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed."
314,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluvoxamine is initiated, discontinued or dose changed."
314,"Galantamine","DB00674","Possible antagonism of action"
314,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
314,"Guanethidine","DB01170","The tricyclic antidepressant, amitriptyline, decreases the effect of guanethidine."
314,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
314,"Iobenguane","DB06704","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function"
314,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
314,"Isoprenaline","DB01064","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of isoproterenol."
314,"Ketoconazole","DB01026","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed."
314,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
314,"Mephentermine","DB01365","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of mephentermine."
314,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
314,"Metaraminol","DB00610","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol."
314,"Methoxamine","DB00723","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine."
314,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
314,"Norepinephrine","DB00368","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of norepinephrine."
314,"Orciprenaline","DB00816","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of orciprenaline."
314,"Phenelzine","DB00780","Possibility of severe adverse effects"
314,"Phenylephrine","DB00388","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine."
314,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine."
314,"Pirbuterol","DB01291","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pirbuterol."
314,"Procaterol","DB01366","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of procaterol."
314,"Pseudoephedrine","DB00852","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pseudoephedrine."
314,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
314,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline."
314,"Rasagiline","DB01367","Possibility of severe adverse effects"
314,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifabutin is initiated, discontinued or dose changed."
314,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed."
314,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ritonavir if initiated, discontinued or dose changed."
314,"Rivastigmine","DB00989","Possible antagonism of action"
314,"Salbutamol","DB01001","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of salbutamol."
314,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
314,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
314,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amitriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
314,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
314,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Amitryptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Terbinafine is initiated, discontinued or dose changed. "
314,"Terbutaline","DB00871","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of terbutaline."
314,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
314,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
314,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
314,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
314,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. "
314,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
314,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
314,"Trimethobenzamide","DB00662","Trimethobenzamide and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
314,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
314,"Triprolidine","DB00427","Triprolidine and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
314,"Trospium","DB00209","Trospium and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
314,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
314,"Vilazodone","DB06684","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved."
314,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
314,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
314,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. "
314,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
314,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
315,"Tamoxifen","DB00675","Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed."
315,"Tolbutamide","DB01124","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed. "
315,"Torasemide","DB00214","Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Floxuridine is initiated, discontinued or dose changed. "
315,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
315,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Floxuridine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Floxuridine is initiated, discontinued or dose changed."
315,"Voriconazole","DB00582","Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if floxuridine is initiated, discontinued or dose changed.	"
315,"Warfarin","DB00682","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed."
315,"Zafirlukast","DB00549","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if floxuridine is initiated, discontinued or dose changed."
316,"Furazolidone","DB00614","Tolcapone and Furazolidone decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Isocarboxazid","DB01247","Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
316,"Linezolid","DB00601","Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Moclobemide","DB01171","Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Phenelzine","DB00780","Tolcapone and Phenelzine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
316,"Procarbazine","DB01168","Tolcapone and Procarbazine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Rasagiline","DB01367","Tolcapone and Rasagiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Selegiline","DB01037","Tolcapone and Selegiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
316,"Tranylcypromine","DB00752","Tolcapone and Tranylcypromine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
316,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Tolcapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
318,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
319,"Trovafloxacin","DB00685","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.  "
320,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
320,"Eltrombopag","DB06210","Increases levels of Hydromorphone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
320,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Hydromorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
321,"Acebutolol","DB01193","Risk of inhibition of renal prostaglandins"
321,"Acenocoumarol","DB01418","The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol."
321,"Alendronate","DB00630","Increased risk of gastric toxicity"
321,"Anisindione","DB01125","The NSAID, indomethacin, may increase the anticoagulant effect of anisindione."
321,"Atenolol","DB00335","Risk of inhibition of renal prostaglandins"
321,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
321,"Betaxolol","DB00195","Nonsteroidal Anti-Inflammatory Agents such as indomethacin may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
321,"Bevantolol","DB01295","Risk of inhibition of renal prostaglandins"
321,"Bisoprolol","DB00612","Risk of inhibition of renal prostaglandins"
321,"Bumetanide","DB00887","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
321,"Carteolol","DB00521","Risk of inhibition of renal prostaglandins"
321,"Carvedilol","DB01136","Risk of inhibition of renal prostaglandins"
321,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
321,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
321,"Dicoumarol","DB00266","The NSAID, indomethacin, may increase the anticoagulant effect of dicumarol."
321,"Diflunisal","DB00861","Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure)."
321,"Eltrombopag","DB06210","Increases levels of Indomethacin via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
321,"Esmolol","DB00187","Risk of inhibition of renal prostaglandins"
321,"Ethacrynic acid","DB00903","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid."
321,"Furosemide","DB00695","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide."
321,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
321,"Glucagon recombinant","DB00040","Monitor therapy due to diminished therapeutic effect of glucagon."
321,"Labetalol","DB00598","Risk of inhibition of renal prostaglandins"
321,"Lithium","DB01356","The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
321,"Losartan","DB00678","Indomethacin decreases the effect of losartan"
321,"Methotrexate","DB00563","The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
321,"Metoprolol","DB00264","Risk of inhibition of renal prostaglandins"
321,"Nadolol","DB01203","Risk of inhibition of renal prostaglandins"
321,"Oxprenolol","DB01580","Risk of inhibition of renal prostaglandins"
321,"Penbutolol","DB01359","Risk of inhibition of renal prostaglandins"
321,"Pindolol","DB00960","Risk of inhibition of renal prostaglandins"
321,"Practolol","DB01297","Risk of inhibition of renal prostaglandins"
321,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
321,"Probenecid","DB01032","Probenecid increases the effect/toxicity of indomethacin"
321,"Propranolol","DB00571","Risk of inhibition of renal prostaglandins"
321,"Sotalol","DB00489","Risk of inhibition of renal prostaglandins"
321,"Tamoxifen","DB00675","Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed."
321,"Telmisartan","DB00966","Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
321,"Timolol","DB00373","Risk of inhibition of renal prostaglandins"
321,"Tolbutamide","DB01124","Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed. "
321,"Torasemide","DB00214","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, torasemide."
321,"Trandolapril","DB00519","The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. "
321,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy. "
321,"Triamterene","DB00384","Risk of acute renal impairment with this combination"
321,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed."
321,"Voriconazole","DB00582","Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed.	"
321,"Warfarin","DB00682","Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed."
323,"Cimetidine","DB00501","Cimetidine may increase the therapeutic and adverse effects of metformin by increasing its serum concentration. Consider alternate therapy."
323,"Glucosamine","DB01296","Possible hyperglycemia"
323,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of metformin. Monitor for changes in fasting and postprandial blood sugars."
324,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
324,"Trimethobenzamide","DB00662","Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
324,"Triprolidine","DB00427","Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
324,"Trospium","DB00209","Trospium and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
325,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
325,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of methadone."
325,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may decrease the effect of methadone."
325,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of methadone."
325,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
325,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of methadone."
325,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of methadone."
325,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of methadone."
325,"Carbamazepine","DB00564","Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed."
325,"Cimetidine","DB00501","Cimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed."
325,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone."
325,"Efavirenz","DB00625","Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed."
325,"Eltrombopag","DB06210","Increases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
325,"Ethotoin","DB00754","The hydantoin decreases the effect of methadone"
325,"Etravirine","DB06414","Methadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal."
325,"Fluvoxamine","DB00176","Fluvoxamine increases the effect and toxicity of methadone"
325,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may decrease the effect of methadone."
325,"Fosphenytoin","DB01320","The hydantoin decreases the effect of methadone"
325,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of methadone."
325,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of methadone."
325,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
325,"Mephenytoin","DB00532","The hydantoin decreases the effect of methadone"
325,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of methadone."
325,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of methadone."
325,"Nelfinavir","DB00220","Nelfinavir decreases the effect of methadone"
325,"Nevirapine","DB00238","The antiretroviral agent decreases the effect of methadone"
325,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of methadone."
325,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of methadone."
325,"Phenytoin","DB00252","The hydantoin decreases the effect of methadone"
325,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of methadone."
325,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of methadone."
325,"Rifabutin","DB00615","The rifamycin decreases the effect of methadone"
325,"Rifampicin","DB01045","The rifamycin decreases the effect of methadone"
325,"Rifapentine","DB01201","The rifamycin decreases the effect of methadone"
325,"Rilpivirine","DB08864","Dose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone. "
325,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may decrease the effect of methadone."
325,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of methadone."
325,"St. John's Wort","DB01323","St. John's Wort decreases levels/effect of methadone"
325,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
325,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of methadone."
325,"Tamoxifen","DB00675","Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
325,"Tamsulosin","DB00706","Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed."
325,"Telaprevir","DB05521","Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients. "
325,"Telithromycin","DB00976","Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed."
325,"Thiopental","DB00599","Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. "
325,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
325,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal. "
325,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
325,"Tramadol","DB00193","Methadone may decrease the effect of Tramadol by decreasing active metabolite production. "
325,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
325,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
325,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed."
325,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
325,"Zidovudine","DB00495","Methadone increases the effect and toxicity of zidovudine"
325,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
325,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
326,"Donepezil","DB00843","Possible antagonism of action"
326,"Fluvoxamine","DB00176","Fluvoxamine increases the effect and toxicity of olanzapine"
326,"Galantamine","DB00674","Possible antagonism of action"
326,"Ritonavir","DB00503","Ritonavir decreases the effect of olanzapine"
326,"Rivastigmine","DB00989","Possible antagonism of action"
326,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Olanzapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
326,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
326,"Trimethobenzamide","DB00662","Trimethobenzamide and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
326,"Triprolidine","DB00427","Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
326,"Trospium","DB00209","Trospium and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
327,"Acetohexamide","DB00414","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Ampicillin","DB00415","Ampicillin decreases bioavailability of atenolol"
327,"Chlorpropamide","DB00672","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
327,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
327,"Diltiazem","DB00343","Increased risk of bradycardia"
327,"Disopyramide","DB00280","The beta-blocker, atenolol, may increase the toxicity of disopyramide."
327,"Epinephrine","DB00668","Hypertension, then bradycardia"
327,"Ergonovine","DB01253","Ischmeia with risk of gangrene"
327,"Ergotamine","DB00696","Ischemia with risk of gangrene"
327,"Fenoterol","DB01288","Antagonism"
327,"Formoterol","DB00983","Antagonism"
327,"Gliclazide","DB01120","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Glipizide","DB01067","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Glisoxepide","DB01289","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Glyburide","DB01016","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Glycodiazine","DB01382","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
327,"Indacaterol","DB05039","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
327,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
327,"Insulin Aspart","DB01306","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Insulin Detemir","DB01307","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Insulin Glargine","DB00047","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Insulin Glulisine","DB01309","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Insulin Lispro","DB00046","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Isoprenaline","DB01064","Antagonism"
327,"Lidocaine","DB00281","The beta-blocker, atenolol, may increase the effect and toxicity of lidocaine."
327,"Methysergide","DB00247","Ischemia with risk of gangrene"
327,"Orciprenaline","DB00816","Antagonism"
327,"Pipobroman","DB00236","Antagonism"
327,"Pirbuterol","DB01291","Antagonism"
327,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
327,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
327,"Procaterol","DB01366","Antagonism"
327,"Repaglinide","DB00912","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Salbutamol","DB01001","Antagonism"
327,"Salmeterol","DB00938","Antagonism"
327,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
327,"Terbutaline","DB00871","Antagonism"
327,"Tolazamide","DB00839","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Tolbutamide","DB01124","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
327,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
327,"Verapamil","DB00661","Increased effect of both drugs"
329,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of immunosuppressive agents."
329,"ado-trastuzumab emtansine","DB05773","Avoid combination due to the increase in immunosuppressant side effects.\
\
"
329,"Antithymocyte globulin","DB00098","Avoid combination due to enhanced immunosuppressive effects and increased risk of infections."
329,"Belatacept","DB06681","Avoid combination due to enhanced effects of immunosuppressants."
329,"Belimumab","DB08879","Avoid combination due to enhanced toxic effects of immunosuppressants."
329,"Bleomycin","DB00290","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants like bleomycin. This combination is contraindicated"
329,"Brentuximab vedotin","DB08870","Avoid combination due to the potential enhancement of toxic effects of immunosuppressants"
329,"Canakinumab","DB06168","Avoid combination due the potential increase in immunosuppressant adverse effects.\
"
329,"Carboplatin","DB00958","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
329,"Carmustine","DB00262","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
329,"Chlorambucil","DB00291","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as chlorambucil. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
329,"Cisplatin","DB00515","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cisplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
329,"Cladribine","DB00242","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cladribine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
329,"Clofarabine","DB00631","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants."
329,"Etanercept","DB00005","Avoid combination due to enhanced immunosuppressive effects."
329,"Gemtuzumab ozogamicin","DB00056","Avoid combination due to toxic effects of immunosuppressants."
329,"Glatiramer Acetate","DB05259","Avoid combination due to enhanced immunosuppressive effects."
329,"golimumab","DB06674","Avoid combination due to enhancement of side effects from immunosuppressants.\
"
329,"Homoharringtonine","DB04865","Avoid combination as there is potential to increase immunosuppressant adverse effects. \
"
329,"Ibritumomab","DB00078","Avoid combination due to increased immunosuppressive effects."
329,"Infliximab","DB00065","Pimecrolimus enhances the adverse effects of immune suppressants thus the combination should be avoided."
329,"Obinutuzumab","DB08935","Avoid combination due to enhanced immunosuppressive effects.\
"
329,"Omalizumab","DB00043","Avoid combination due to enhanced adverse effects of immunosuppressants."
329,"Paclitaxel","DB01229","Avoid combination due to the enhancement of adverse effects of immunosuppressants. "
329,"Pegaspargase","DB00059","Avoid combination because pimecrolimus enhances the adverse effects of immunosuppressants."
329,"Teriflunomide","DB08880","Avoid combination due to the increased toxic effects of immunosuppressants. "
329,"Tofacitinib","DB08895","Avoid combination due to the potential increase in immunosuppressant associated adverse effects.\
\
"
330,"Alprazolam","DB00404","Omeprazole may increase the effect of the benzodiazepine, alprazolam."
330,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
330,"Avanafil","DB06237","Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole. "
330,"Bendamustine","DB06769","Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. "
330,"Cefditoren","DB01066","Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
330,"Chlordiazepoxide","DB00475","Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide."
330,"Cilostazol","DB01166","Omeprazole increases the effect of cilostazol"
330,"Clonazepam","DB01068","Omeprazole may increase the effect of the benzodiazepine, clonazepam."
330,"Clopidogrel","DB00758","Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness. "
330,"Clorazepate","DB00628","Omeprazole may increase the effect of the benzodiazepine, clorazepate."
330,"Cyclosporine","DB00091","Omeprazole increases the effect and toxicity of cyclosporine"
330,"Dasatinib","DB01254","Omeprazole may decrease the serum level of dasatinib."
330,"Diazepam","DB00829","Omeprazole may increase the effect of the benzodiazepine, diazepam."
330,"Disopyramide","DB00280","The beta-blocker increases toxicity of disopyramide"
330,"Enoxacin","DB00467","Omeprazole may decrease the absorption of enoxacin."
330,"Estazolam","DB01215","Omeprazole may increase the effect of the benzodiazepine, estazolam."
330,"Ethotoin","DB00754","Omeprazole increases the effect of hydantoin"
330,"Flurazepam","DB00690","Omeprazole may increase the effect of the benzodiazepine, flurazepam."
330,"Fosphenytoin","DB01320","Omeprazole increases the effect of hydantoin"
330,"Halazepam","DB00801","Omeprazole may increase the effect of the benzodiazepine, halazepam."
330,"Indinavir","DB00224","Omeprazole decreases the absorption of indinavir"
330,"Itraconazole","DB01167","The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole."
330,"Ketazolam","DB01587","Omeprazole may increase the effect of the benzodiazepine, ketazolam."
330,"Ketoconazole","DB01026","The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole."
330,"Mephenytoin","DB00532","Omeprazole increases the effect of hydantoin"
330,"Methotrexate","DB00563","Omeprazole increases the levels of methotrexate"
330,"Midazolam","DB00683","Omeprazole may increase the effect of the benzodiazepine, midazolam."
330,"Ospemifene","DB04938","Moderate CYP2C19 inhibitors may increase levels of ospemifene. Monitor concomitant therapy closely. "
330,"Phenytoin","DB00252","Omeprazole increases the effect of hydantoin"
330,"Prazepam","DB01588","Omeprazole may increase the effect of the benzodiazepine, prazepam."
330,"Quazepam","DB01589","Omeprazole may increase the effect of the benzodiazepine, quazepam."
330,"Rilpivirine","DB08864","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
330,"Roflumilast","DB01656","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
330,"St. John's Wort","DB01323","St. John's Wort decreases the levels/effects of omeprazole "
330,"Tacrolimus","DB00864","Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered."
330,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response. "
330,"Tocilizumab","DB06273","Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab.. "
330,"Triazolam","DB00897","Omeprazole may increase the effect of the benzodiazepine, triazolam."
330,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed. "
330,"Vismodegib","DB08828","Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole."
330,"Voriconazole","DB00582","Voriconazole increases the effect and toxicity of omeprazole"
331,"Cyclosporine","DB00091","Pyrazinamide decreases the effect of cyclosporine"
334,"Acetophenazine","DB01063","Increased risk of cardiotoxicity and arrhythmias"
334,"Alimemazine","DB01246","Increased risk of cardiotoxicity and arrhythmias"
334,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
334,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
334,"Amoxapine","DB00543","Increased risk of cardiotoxicity and arrhythmias"
334,"Amprenavir","DB00701","Increased risk of cardiotoxicity and arrhythmias"
334,"Aprepitant","DB00673","Increased risk of cardiotoxicity and arrhythmias"
334,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
334,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
334,"Cimetidine","DB00501","Increased risk of cardiotoxicity and arrhythmias"
334,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
334,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
334,"Clomipramine","DB01242","Increased risk of cardiotoxicity and arrhythmias"
334,"Delavirdine","DB00705","Increased risk of cardiotoxicity and arrhythmias"
334,"Desipramine","DB01151","Increased risk of cardiotoxicity and arrhythmias"
334,"Diltiazem","DB00343","Increased risk of cardiotoxicity and arrhythmias"
334,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
334,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
334,"Efavirenz","DB00625","Increased risk of cardiotoxicity and arrhythmias"
334,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
334,"Flecainide","DB01195","Increased risk of cardiotoxicity and arrhythmias"
334,"Fluconazole","DB00196","Increased risk of cardiotoxicity and arrhythmias"
334,"Fluoxetine","DB00472","Increased risk of cardiotoxicity and arrhythmias"
334,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
334,"Fluvoxamine","DB00176","Increased risk of cardiotoxicity and arrhythmias"
334,"Fosamprenavir","DB01319","Increased risk of cardiotoxicity and arrhythmias"
334,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
334,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
334,"Indinavir","DB00224","Increased risk of cardiotoxicity and arrhythmias"
334,"Itraconazole","DB01167","Increased risk of cardiotoxicity and arrhythmias"
334,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
334,"Ketoconazole","DB01026","Increased risk of cardiotoxicity and arrhythmias"
334,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
334,"Methdilazine","DB00902","Increased risk of cardiotoxicity and arrhythmias"
334,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
334,"Mexiletine","DB00379","Increased risk of cardiotoxicity and arrhythmias"
334,"Mibefradil","DB01388","Increased risk of cardiotoxicity and arrhythmias"
334,"Nefazodone","DB01149","Increased risk of cardiotoxicity and arrhythmias"
334,"Nelfinavir","DB00220","Increased risk of cardiotoxicity and arrhythmias"
334,"Nicardipine","DB00622","Increased risk of cardiotoxicity and arrhythmias"
334,"Nortriptyline","DB00540","Increased risk of cardiotoxicity and arrhythmias"
334,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
334,"Posaconazole","DB01263","Contraindicated co-administration"
334,"Procainamide","DB01035","Increased risk of cardiotoxicity and arrhythmias"
334,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
334,"Promazine","DB00420","Increased risk of cardiotoxicity and arrhythmias"
334,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
334,"Propafenone","DB01182","Increased risk of cardiotoxicity and arrhythmias."
334,"Propericiazine","DB01608","Increased risk of cardiotoxicity and arrhythmias"
334,"Propiomazine","DB00777","Increased risk of cardiotoxicity and arrhythmias"
334,"Protriptyline","DB00344","Increased risk of cardiotoxicity and arrhythmias"
334,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
334,"Quinine","DB00468","Increased risk of cardiotoxicity and arrhythmias"
334,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
334,"Ritonavir","DB00503","Increased risk of cardiotoxicity and arrhythmias"
334,"Saquinavir","DB01232","Increased risk of cardiotoxicity and arrhythmias"
334,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
334,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
334,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
334,"Telithromycin","DB00976","Increased risk of cardiotoxicity and arrhythmias"
334,"Thiethylperazine","DB00372","Increased risk of cardiotoxicity and arrhythmias"
334,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
334,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated."
334,"Tocainide","DB01056","Increased risk of cardiotoxicity and arrhythmias"
334,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
334,"Triflupromazine","DB00508","Increased risk of cardiotoxicity and arrhythmias"
334,"Trimipramine","DB00726","Increased risk of cardiotoxicity and arrhythmias"
334,"Troleandomycin","DB01361","Increased risk of cardiotoxicity and arrhythmias"
334,"Verapamil","DB00661","Increased risk of cardiotoxicity and arrhythmias"
334,"Voriconazole","DB00582","Increased risk of cardiotoxicity and arrhythmias"
335,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
335,"Amlodipine","DB00381","Diltiazem may increase the serum concentration of amlodipine. Concomitant therapy will result in additive hypotensive effects. Monitor for changes in the hypotensive effect of amlodipine if diltiazem is initiated, discontinued or dose changed."
335,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
335,"Atazanavir","DB01072","Atazanavir may increase the therapeutic and adverse effects of diltiazem resulting in increased risk of AV block. Consider alternate therapy, a 50% dose reduction of diltiazem and monitor for changes in the therapeutic and adverse effects of diltiazem if atazanavir is initiated, discontinued or dose changed."
335,"Atenolol","DB00335","Increased risk of bradycardia"
335,"Atorvastatin","DB01076","Diltiazem may increase the serum concentration of atorvastatin. Atorvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
335,"Bromazepam","DB01558","Diltiazem may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if diltiazem is initiated, discontinued or dose changed."
335,"Buspirone","DB00490","The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone."
335,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of diltiazem by increasing its metabolism. Diltiazem may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if dosages are changed."
335,"Cerivastatin","DB00439","Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
335,"Cilostazol","DB01166","Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cilostazol if diltiazem is initiated, discontinued or dose changed."
335,"Cisapride","DB00604","Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cisapride by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cisapride if diltiazem is initiated, discontinued or dose changed."
335,"Cyclosporine","DB00091","Diltiazem may increase the effect and toxicity of cyclosporine."
335,"Dihydroquinidine barbiturate","DB01341","Increases the effect and toxicity of quinidine"
335,"Dronedarone","DB04855","Diltiazem is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker. "
335,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
335,"Lovastatin","DB00227","Diltiazem may increase the serum concentration of lovastatin. Lovastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
335,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
335,"Metoprolol","DB00264","Increased risk of bradycardia"
335,"Midazolam","DB00683","The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, midazolam."
335,"Moricizine","DB00680","Increased effect/toxicity of moricizine"
335,"Pindolol","DB00960","Increased risk of bradycardia"
335,"Propranolol","DB00571","Increased risk of bradycardia"
335,"Quinidine","DB00908","Diltiazem may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if diltiazem is initiated, discontinued or dose changed."
335,"Quinidine barbiturate","DB01346","Increases the effect and toxicity of quinidine"
335,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
335,"Ranolazine","DB00243","Diltiazem may increase the serum concentration of ranolazine. Consider alternate therapy or limit ranolazine dose to 500 mg twice daily and monitor for changes in the therapeutic and adverse effects if diltiazem is initiated, discontinued or dose changed."
335,"Rifampicin","DB01045","Rifampin decreases levels of diltiazem"
335,"Ritonavir","DB00503","Ritonavir increases diltiazem levels"
335,"Saxagliptin","DB06335","Diltiazem is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 109%. Exposure of the active metabolite decreased by 34%. However, these changes in pharmacokinetics are not clinical significant. "
335,"Silodosin","DB06207","Moderate inhibitors of CYP3A4 may increase levels of silodosin. Monitor concomitant therapy closely. "
335,"Simvastatin","DB00641","Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
335,"Sirolimus","DB00877","Increases the effect and toxicity of sirolimus"
335,"Tacrolimus","DB00864","Diltiazem may increase the serum concentration of tacrolimus by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tacrolimus if diltiazem therapy is initiated, discontinued or dose changed."
335,"Tamsulosin","DB00706","Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed."
335,"Telithromycin","DB00976","Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed."
335,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
335,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed."
335,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
335,"Timolol","DB00373","Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. "
335,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem. "
335,"Tolterodine","DB01036","Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
335,"Tolvaptan","DB06212","Diltiazem is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
335,"Tramadol","DB00193","Diltiazem may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
335,"Trazodone","DB00656","The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed."
335,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
335,"Triazolam","DB00897","The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam."
335,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed."
336,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
336,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if atazanavir if initiated, discontinued or dose changed."
336,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
336,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as protriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
336,"Cimetidine","DB00501","Cimetidine may increase the effect of tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed."
336,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
336,"Clonidine","DB00575","The tricyclic antidepressant, protriptyline, decreases the effect of clonidine."
336,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
336,"Donepezil","DB00843","Possible antagonism of action"
336,"Epinephrine","DB00668","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of epinephrine."
336,"Fenoterol","DB01288","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of fenoterol."
336,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluoxetine is initiated, discontinued or dose changed."
336,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluvoxamine is initiated, discontinued or dose changed."
336,"Galantamine","DB00674","Possible antagonism of action"
336,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
336,"Guanethidine","DB01170","The tricyclic antidepressant, protriptyline, decreases the effect of guanethidine."
336,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
336,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
336,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
336,"Orciprenaline","DB00816","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of orciprenaline."
336,"Phenelzine","DB00780","Possibility of severe adverse effects"
336,"Phenylephrine","DB00388","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine."
336,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine."
336,"Pseudoephedrine","DB00852","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of pseudoephedrine."
336,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
336,"Rasagiline","DB01367","Possibility of severe adverse effects"
336,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifabutin is initiated, discontinued or dose changed."
336,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed."
336,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Protriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
336,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
336,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Protriptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Protriptyline if Terbinafine is initiated, discontinued or dose changed."
336,"Terbutaline","DB00871","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of terbutaline."
336,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
336,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
336,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
336,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. "
336,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
336,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
336,"Trimethobenzamide","DB00662","Trimethobenzamide and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
336,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
336,"Triprolidine","DB00427","Triprolidine and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
336,"Trospium","DB00209","Trospium and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
336,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
336,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
336,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
336,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
336,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
336,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
338,"Aliskiren","DB09026","Monitor therapy due to enhanced hypotensive effect of aliskiren."
338,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
338,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication according to alfuzosin prescribing information. "
338,"Itraconazole","DB01167","The antifungal increases the effect of alfuzosin"
338,"Ketoconazole","DB01026","The antifungal increases the effect of alfuzosin"
338,"Ritonavir","DB00503","Ritonavir increases the effect/toxicity of alfuzosin"
338,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Alfusozin. Monitor for hypotension during concomitant therapy.  "
338,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may result in additive antihypertensive effects. Combination therapy is not recommended. "
338,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
338,"Telithromycin","DB00976","Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy."
338,"Terazosin","DB01162","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided."
338,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Alfuzosin, may occur. Monitor for hypotension during concomitant therapy."
338,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by the manufacturer. "
339,"Disulfiram","DB00822","Disulfiram, a strong CYP2E1 inhibitor, may decrease the metabolism and clearance of Trimethadione, a CYP2E1 substrate. Consider alternate therapy or monitor for changes in Trimethadione therapeutic and adverse effects if Disulfiram is initiated, discontinued or dose changed. "
339,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Trimethadione, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
341,"Axitinib","DB06626","Clobazam decreases levels by affecting CYP3A4 metabolism. Consider alternate therapy. "
341,"Clozapine","DB00363","Increased risk of toxicity"
341,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, clobazam."
341,"Ketoconazole","DB01026","Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary. "
341,"Midazolam","DB00683","Clobazam decrease the Cmax and AUC of midazolam by approximately 25% of both and increases the Cmax and AUC of its metabolite. Dose adjustment is not necessary. "
341,"Rotigotine","DB05271","Concomitant therapy may potentiate adverse CNS effects such as increased sedation or respiratory depression. Monitor therapy closely. "
341,"Telithromycin","DB00976","Telithromycin may reduce clearance of Clobazam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clobazam if Telithromycin is initiated, discontinued or dose changed."
341,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for adverse/toxic effects of Clobazam if Ticlopidine is initiated, discontinued or dose changed."
341,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for Clobazam toxic effects if Tipranavir is initiated or dose increased. "
341,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Clobazam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
341,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of clobazam by decreasing its metabolism. Monitor for clobazam toxicity if voriconazole is initiated or dose increased."
342,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
343,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, megestrol."
343,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, megestrol."
343,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, megestrol."
343,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, megestrol."
343,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, megestrol."
343,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, megestrol."
343,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, megestrol."
343,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, may decrease the effect of the hormone, megestrol."
343,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, megestrol."
343,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, megestrol."
343,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, megestrol."
343,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol."
343,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, megestrol."
343,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, megestrol."
343,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, may decrease the effect of the hormone, megestrol."
343,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of megestrol."
343,"Primidone","DB00794","The enzyme inducer, primidone, may decrease the effect of the hormone, megestrol."
343,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, megestrol."
343,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, megestrol."
344,"Aminosalicylic Acid","DB00233","Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine."
344,"Busulfan","DB01008","Busulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy. "
344,"Mercaptopurine","DB01033","Complete cross resistance may occur. "
344,"Mesalazine","DB00244","Mesalazine may increase the toxicity of thiopurine, thioguanine."
344,"Natalizumab","DB00108","The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
344,"Olsalazine","DB01250","Olsalazine may increase the toxicity of thiopurine, thioguanine."
344,"Sulfasalazine","DB00795","Sulfasalazine may increase the toxicity of thiopurine, thioguanine."
344,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
345,"Almotriptan","DB00918","Possible severe and prolonged vasoconstriction"
345,"Atazanavir","DB01072","Increases the effect and toxicity of ergot derivative"
345,"Delavirdine","DB00705","The antiretroviral agent may increase the ergot derivative toxicity"
345,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
345,"Efavirenz","DB00625","The antiretroviral agent may increase the ergot derivative toxicity"
345,"Eletriptan","DB00216","Possible severe and prolonged vasoconstriction"
345,"Epinephrine","DB00668","Possible marked increase of arterial pressure"
345,"Erythromycin","DB00199","Possible ergotism and severe ischemia with this combination"
345,"Frovatriptan","DB00998","Possible severe and prolonged vasoconstriction"
345,"Isosorbide Dinitrate","DB00883","Possible antagonism of action"
345,"Isosorbide Mononitrate","DB01020","Possible antagonism of action"
345,"Naratriptan","DB00952","Possible severe and prolonged vasocontriction"
345,"Nitroglycerin","DB00727","Possible antagonism of action"
345,"Pentaerythritol Tetranitrate","DB06154","Possible antagonism of action"
345,"Phenylephrine","DB00388","Possible marked increase of arterial pressure"
345,"Telithromycin","DB00976","Telithromycin may reduce clearance of Methylergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methylergonovine if Telithromycin is initiated, discontinued or dose changed."
345,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Methylergonovine. Concomitant therapy is contraindicated."
345,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
345,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
345,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
345,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
345,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
345,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methylergonovine  by decreasing its metabolism. Concomitant therapy is contraindicated. "
345,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
347,"Demeclocycline","DB00618","Possible antagonism of action"
347,"Doxycycline","DB00254","Possible antagonism of action"
347,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
347,"Minocycline","DB01017","Possible antagonism of action"
347,"Tetracycline","DB00759","Possible antagonism of action"
348,"Disulfiram","DB00822","Disulfiram may increase the serum level of chlorzoxazone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorzoxazone if diltiazem is initiated, discontinued or dose changed."
348,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Chlorzoxazone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
349,"Acenocoumarol","DB01418","Aminoglutethimide may decrease the anticoagulant effect of acenocoumarol."
349,"Anisindione","DB01125","Aminoglutethimide may decrease the anticoagulant effect of anisindione."
349,"Dexamethasone","DB01234","Aminoglutethimide may decrease the effect of dexamethasone."
349,"Dicoumarol","DB00266","Aminoglutethimide may decrease the anticoagulant effect of dicumarol."
349,"Tamoxifen","DB00675","Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed."
349,"Telithromycin","DB00976","Aminoglutethimide may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
349,"Temsirolimus","DB06287","Aminoglutethimide may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."
349,"Tramadol","DB00193","Aminoglutethimide may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
349,"Trazodone","DB00656","The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed."
349,"Warfarin","DB00682","Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed."
350,"Acenocoumarol","DB01418","Mefloquine may increase the anticoagulant effect of acenocoumarol."
350,"Anisindione","DB01125","Mefloquine may increase the anticoagulant effect of anisindione."
350,"Artemether","DB06697","Mefloquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
350,"Dicoumarol","DB00266","Mefloquine may increase the anticoagulant effect of dicumarol."
350,"Halofantrine","DB01218","Increased risk of cardiac toxicity"
350,"Lumefantrine","DB06708","Mefloquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
350,"Rifampicin","DB01045","Rifampin lowers mefloquine levels"
350,"Ritonavir","DB00503","Mefloquine decreases the effect of ritonavir"
350,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
350,"Telithromycin","DB00976","Telithromycin may reduce clearance of Mefloquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mefloquine if Telithromycin is initiated, discontinued or dose changed."
350,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
350,"Tiagabine","DB00906","Mefloquine increases the risk of seizure and is contraindicated in persons with a history of convulsions. Possible reduction in the therapeutic effect of Tiagabine when used for other indications may also occur. "
350,"Topotecan","DB01030","The p-glycoprotein inhibitor, Mefloquine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
350,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
350,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
350,"Vigabatrin","DB01080","Mefloquine may decrease the serum concentration of Vigabatrin. This may increase the risk of seizure in patients receiving Vigabatrin to prevent seizures. Consider alternate therapy or monitor for changes in Vigabatrin serum concentration, therapeutic or adverse effects if Mefloquin is initiated, discontinued or dose changed. "
350,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mefloquine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of mefloquine if voriconazole is initiated, discontinued or dose changed."
350,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
350,"Warfarin","DB00682","Mefloquine may increase the anticoagulant effect of warfarin."
350,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
350,"Zonisamide","DB00909","Mefloquine may decrease the serum concentration and therapeutic effect of zonisamide. Concomitant therapy is contraindicated in patients with history of convulsions. "
350,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
351,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
351,"Cyclosporine","DB00091","The sulfonamide decreases the effect of cyclosporine"
351,"Fosphenytoin","DB01320","The sulfonamide increases the effect of hydantoin"
351,"Methenamine mandelate","DB06146","Possible crystallization of urates with this combination"
351,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
351,"Phenytoin","DB00252","The sulfonamide increases the effect of hydantoin"
351,"Tamoxifen","DB00675","Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed."
351,"Tolbutamide","DB01124","Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. "
351,"Torasemide","DB00214","Sulfadiazine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sulfadiazine is initiated, discontinued or dose changed. "
351,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed."
351,"Warfarin","DB00682","Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed."
351,"Zafirlukast","DB00549","Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed."
353,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Amprenavir is initiated, discontinued or dose changed."
353,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, vinorelbine."
353,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Atazanavir is initiated, discontinued or dose changed."
353,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
353,"Clarithromycin","DB01211","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Clarithromycin is initiated, discontinued or dose changed.\
"
353,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Conivaptan is initiated, discontinued or dose changed."
353,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Darunavir is initiated, discontinued or dose changed."
353,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Delavirdine is initiated, discontinued or dose changed."
353,"Dirithromycin","DB00954","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Dirithromycin is initiated, discontinued or dose changed."
353,"Erythromycin","DB00199","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Erythromycin is initiated, discontinued or dose changed."
353,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed."
353,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Imatinib is initiated, discontinued or dose changed."
353,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Indinavir is initiated, discontinued or dose changed."
353,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed."
353,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.\
"
353,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed."
353,"Leflunomide","DB01097","Vinorelbine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinorelbine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.\
"
353,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Lopinavir is initiated, discontinued or dose changed."
353,"Miconazole","DB01110","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Miconazole is initiated, discontinued or dose changed."
353,"Natalizumab","DB00108","Concomitant Vinorelbine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided."
353,"Nefazodone","DB01149","Nafazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nefazodone is initiated, discontinued or dose changed."
353,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nelfinavir is initiated, discontinued or dose changed."
353,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed."
353,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Posaconazole is initiated, discontinued or dose changed."
353,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Quinidine is initiated, discontinued or dose changed."
353,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
353,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ritonavir is initiated, discontinued or dose changed."
353,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Saquinavir is initiated, discontinued or dose changed."
353,"Spiramycin","DB06145","Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Spiramycine is initiated, discontinued or dose changed."
353,"Telithromycin","DB00976","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Telithromycin is initiated, discontinued or dose changed."
353,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
353,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Voriconazole is initiated, discontinued or dose changed."
355,"ado-trastuzumab emtansine","DB05773","Avoid combination due to the increased potential for agranulocytosis. "
355,"Aflibercept","DB08885","Avoid combination with systemic aflibercept due to enhanced adverse effects of clozapine, including the risk of agranulocytosis"
355,"Aldesleukin","DB00041","Avoid combination due to enhanced adverse effects of clozapine, especially the risk of agranulocytosis."
355,"Alprazolam","DB00404","Increased risk of toxicity"
355,"Bevacizumab","DB00112","Avoid combination due to increased adverse effects of clozapine, especially the risk of agranulocytosis. "
355,"Bromazepam","DB01558","Bromazepam may increase the adverse effects of clozapine. Consider alternate therapy or a reduction in the bromazepam dose. Monitor for respiratory depression and hypotension if concomitant therapy is initiated."
355,"Caffeine","DB00201","Caffeine increases the effect and toxicity of clozapine"
355,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed."
355,"Chlordiazepoxide","DB00475","Increased risk of toxicity"
355,"Cimetidine","DB00501","Cimetidine may increase the serum concentratin of clozapine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if cimetidine is initiated, discontinued or dose changed."
355,"Cinolazepam","DB01594","Increased risk of toxicity"
355,"Ciprofloxacin","DB00537","Ciprofloxacin may increase clozapine serum levels"
355,"Citalopram","DB00215","The antidepressant increases the effect of clozapine"
355,"Clobazam","DB00349","Increased risk of toxicity"
355,"Clonazepam","DB01068","Increased risk of toxicity"
355,"Clorazepate","DB00628","Increased risk of toxicity"
355,"Diazepam","DB00829","Increased risk of toxicity"
355,"Dihydrocodeine","DB01551","CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy. "
355,"Donepezil","DB00843","Possible antagonism of action"
355,"Erythromycin","DB00199","Erythromycin increases the effect of clozapine"
355,"Estazolam","DB01215","Increased risk of toxicity"
355,"Ethotoin","DB00754","Hydantoin decreases the effect of clozapine"
355,"Flunitrazepam","DB01544","Increased risk of toxicity"
355,"Fluoxetine","DB00472","The antidepressant increases the effect of clozapine"
355,"Flurazepam","DB00690","Increased risk of toxicity"
355,"Fluvoxamine","DB00176","The antidepressant increases the effect of clozapine"
355,"Fosphenytoin","DB01320","Hydantoin decreases the effect of clozapine"
355,"Galantamine","DB00674","Possible antagonism of action"
355,"Gemtuzumab ozogamicin","DB00056","Avoid combination due to adverse effects of clozapine including the risk of agranulocytosis."
355,"Halazepam","DB00801","Increased risk of toxicity"
355,"Haloperidol","DB00502","Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy."
355,"Ibritumomab","DB00078","Avoid combination due to enhanced adverse effects of clozapine, including agranulocytosis."
355,"Josamycin","DB01321","Erythromycin increases the effect of clozapine"
355,"Ketazolam","DB01587","Increased risk of toxicity"
355,"Lamotrigine","DB00555","Lamotrigine increases the effect and toxicity of clozapine"
355,"Lorazepam","DB00186","Increased risk of toxicity"
355,"Mephenytoin","DB00532","Hydantoin decreases the effect of clozapine"
355,"Midazolam","DB00683","Increased risk of toxicity"
355,"Modafinil","DB00745","Modafinil increases the effect and toxicity of clozapine"
355,"Nitrazepam","DB01595","Increased risk of toxicity"
355,"Norfloxacin","DB01059","Ciprofloxacin may increase clozapine serum levels"
355,"Obinutuzumab","DB08935","Risk of agranulocytosis may be increased due to enhanced adverse effects of clozapine by myelosuppressive agents. It is recommanded that combination may be avoided."
355,"Oxazepam","DB00842","Increased risk of toxicity"
355,"Paclitaxel","DB01229","Avoid combination due to the potential enhancement of agranulocytosis by clozapine. "
355,"Phenytoin","DB00252","Phenytoin may decrease the effect of clozapine."
355,"Prazepam","DB01588","Increased risk of toxicity"
355,"Quazepam","DB01589","Increased risk of toxicity"
355,"Rifabutin","DB00615","Rifabutin decreases the effect of clozapine"
355,"Rifampicin","DB01045","Rifampin decreases the effect of clozapine"
355,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of clozapine"
355,"Rivastigmine","DB00989","Possible antagonism of action"
355,"Sertraline","DB01104","The antidepressant increases the effect of clozapine"
355,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Clozapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
355,"Tamoxifen","DB00675","Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
355,"Tamsulosin","DB00706","Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed."
355,"Temazepam","DB00231","The benzodiazepine, Temazepam, may increase the adverse effects of Clozapine. Monitor for respiratory depression and hypotension if concomitant therapy is initiated. "
355,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
355,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed."
355,"Tofacitinib","DB08895","Avoid combination due to the increased risk of clozapine induced agranulocytosis. \
"
355,"Tramadol","DB00193","Clozapine may decrease the effect of Tramadol by decreasing active metabolite production. \
"
355,"Triazolam","DB00897","Increased risk of toxicity"
355,"Trimethobenzamide","DB00662","Trimethobenzamide and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
355,"Triprolidine","DB00427","Triprolidine and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
355,"Trospium","DB00209","Trospium and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
355,"Vilazodone","DB06684","Selective Serotonin Reuptake Inhibitors may decrease the metabolism of clozapine. If concurrent use of these agents is employed, monitor for increased toxic effects of clozapine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if a SSRI is discontinued/dose decreased."
356,"Calcipotriol","DB02300","Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
356,"Cholecalciferol","DB00169","Vitamin D analogs such as cholecalciferol may increase the serum concentration of sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
356,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
356,"Clodronate","DB00720","Formation of non-absorbable complexes"
356,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
356,"Fosphenytoin","DB01320","Sucralfate decreases the effect of hydantoin"
356,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
356,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
356,"Grepafloxacin","DB00365","Formation of non-absorbable complexes "
356,"Ibandronate","DB00710","Formation of non absorbable complexes"
356,"Itraconazole","DB01167","Sucralfate may decrease the absorption of itraconazole."
356,"Ketoconazole","DB01026","Sucralfate may decrease the absorption of ketoconazole."
356,"Lansoprazole","DB00448","Sucralfate decreases the effect of lansoprazole"
356,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
356,"Levothyroxine","DB00451","Sucralfate decreases the effect of levothyroxine"
356,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
356,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
356,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
356,"Phenytoin","DB00252","Sucralfate decreases the effect of hydantoin"
356,"Trovafloxacin","DB00685","Sucralfate may decrease the absorption of orally administered Trovafloxacin. The Sucralfate formulation contains aluminum ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sucralfate dose to minimize the interaction. "
356,"Warfarin","DB00682","Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed. "
357,"Aluminium","DB01370","Formation of non-absorbable complexes "
357,"Aminophylline","DB01223","Grepafloxacin may increase the effect of aminophylline."
357,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
357,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
357,"Amoxapine","DB00543","Increased risk of cardiotoxicity and arrhythmias"
357,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
357,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
357,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
357,"Caffeine","DB00201","Grepafloxacin may increase the effect and toxicity of caffeine."
357,"Calcium","DB01373","Calcium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours."
357,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
357,"Clomipramine","DB01242","Increased risk of cardiotoxicity and arrhythmias"
357,"Desipramine","DB01151","Increased risk of cardiotoxicity and arrhythmias"
357,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
357,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
357,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
357,"Dyphylline","DB00651","Grepafloxacin may increase the effect of dyphylline."
357,"Eltrombopag","DB06210","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
357,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
357,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
357,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
357,"Iron","DB01592","Formation of non-absorbable complexes "
357,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
357,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
357,"Magnesium","DB01378","Magnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours."
357,"Magnesium oxide","DB01377","Formation of non-absorbable complexes "
357,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
357,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
357,"Nortriptyline","DB00540","Increased risk of cardiotoxicity and arrhythmias"
357,"Oxtriphylline","DB01303","Grepafloxacin may increase the effect of oxtriphylline."
357,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
357,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
357,"Promazine","DB00420","Increased risk of cardiotoxicity and arrhythmias"
357,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
357,"Propiomazine","DB00777","Increased risk of cardiotoxicity and arrhythmias"
357,"Protriptyline","DB00344","Increased risk of cardiotoxicity and arrhythmias"
357,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
357,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
357,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
357,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
357,"Sucralfate","DB00364","Formation of non-absorbable complexes "
357,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
357,"Theophylline","DB00277","Grepafloxacin may increase the effect of theophylline."
357,"Thiethylperazine","DB00372","Increased risk of cardiotoxicity and arrhythmias"
357,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
357,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
357,"Triflupromazine","DB00508","Increased risk of cardiotoxicity and arrhythmias"
357,"Trimipramine","DB00726","Increased risk of cardiotoxicity and arrhythmias"
357,"Zinc","DB01593","Formation of non-absorbable complexes "
358,"Donepezil","DB00843","Possible antagonism of action"
358,"Galantamine","DB00674","Possible antagonism of action"
358,"Pramlintide","DB01278","May cause additive slowing of GI motility."
358,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxylamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
358,"Trimethobenzamide","DB00662","Trimethobenzamide and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
358,"Triprolidine","DB00427","Triprolidine and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
358,"Trospium","DB00209","Trospium and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
359,"Amobarbital","DB01351","Phenobarbital decreases the effect of levonorgestrel"
359,"Aprobarbital","DB01352","Phenobarbital decreases the effect of levonorgestrel"
359,"Artemether","DB06697","Artemether may decrease the effectiveness of levonorgestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
359,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of levonorgestrel, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
359,"Butabarbital","DB00237","Phenobarbital decreases the effect of levonorgestrel"
359,"Butalbital","DB00241","Phenobarbital decreases the effect of levonorgestrel"
359,"Butethal","DB01353","Phenobarbital decreases the effect of levonorgestrel"
359,"Carbamazepine","DB00564","Carbamazepine may decrease the contraceptive effect of levonorgestrel."
359,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
359,"Dihydroquinidine barbiturate","DB01341","Phenobarbital decreases the effect of levonorgestrel"
359,"Ethotoin","DB00754","Phenytoin decreases the contraceptive effect"
359,"Fosphenytoin","DB01320","Phenytoin decreases the contraceptive effect"
359,"Heptabarbital","DB01354","Phenobarbital decreases the effect of levonorgestrel"
359,"Hexobarbital","DB01355","Phenobarbital decreases the effect of levonorgestrel"
359,"Mephenytoin","DB00532","Phenytoin decreases the contraceptive effect"
359,"Methohexital","DB00474","Phenobarbital decreases the effect of levonorgestrel"
359,"Methylphenobarbital","DB00849","Phenobarbital decreases the effect of levonorgestrel"
359,"Pentobarbital","DB00312","Phenobarbital decreases the effect of levonorgestrel"
359,"Phenobarbital","DB01174","Phenobarbital decreases the effect of levonorgestrel"
359,"Phenytoin","DB00252","Phenytoin decreases the contraceptive effect"
359,"Primidone","DB00794","Phenobarbital decreases the effect of levonorgestrel"
359,"Quinidine barbiturate","DB01346","Phenobarbital decreases the effect of levonorgestrel"
359,"Secobarbital","DB00418","Phenobarbital decreases the effect of levonorgestrel"
359,"Talbutal","DB00306","Phenobarbital decreases the effect of levonorgestrel"
359,"Thiopental","DB00599","Thiopental may decrease the effect of Levonorgestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
359,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Levonorgestrel. An alternate form of contraception should be used during concomitant therapy. "
359,"Warfarin","DB00682","Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed."
360,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of norepinephrine."
360,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of norepinephrine."
360,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of norepinephrine."
360,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of norepinephrine."
360,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
360,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of norepinephrine."
360,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, norepinephrine."
360,"Guanethidine","DB01170","Norepinephrine may decrease the effect of guanethidine."
360,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of norepinephrine."
360,"Isocarboxazid","DB01247","Increased arterial pressure"
360,"Linezolid","DB00601","Possible increase of arterial pressure"
360,"Methyldopa","DB00968","Increased arterial pressure"
360,"Midodrine","DB00211","Increased arterial pressure"
360,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of norepinephrine."
360,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of norepinephrine."
360,"Phenelzine","DB00780","Increased arterial pressure"
360,"Rasagiline","DB01367","Increased arterial pressure"
360,"Reserpine","DB00206","Increased arterial pressure"
360,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Norepinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
360,"Venlafaxine","DB00285","Venlafaxine may increase the tachycardic and vasopressor effects of Norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. "
362,"Clonidine","DB00575","Possible hypertensive crisis"
362,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
362,"Donepezil","DB00843","Possible antagonism of action"
362,"Ethotoin","DB00754","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
362,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic and adverse effects of mirtazapine."
362,"Fosphenytoin","DB01320","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
362,"Galantamine","DB00674","Possible antagonism of action"
362,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
362,"Mephenytoin","DB00532","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
362,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
362,"Phenytoin","DB00252","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
362,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
362,"Rivastigmine","DB00989","Possible antagonism of action"
362,"Telithromycin","DB00976","Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed."
362,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Mirtazapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mirtazapine if Terbinafine is initiated, discontinued or dose changed."
362,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
362,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Mirtazapine. These agents should not be administered within 14 days of each other."
362,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
362,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
362,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
362,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
362,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed."
362,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
364,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
364,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
364,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
364,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
364,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
364,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
364,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
364,"Guanethidine","DB01170","Thiethylperazine may decrease the effect of guanethidine."
364,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
364,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
364,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
364,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
364,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
365,"Acetohexamide","DB00414","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
365,"Celecoxib","DB00482","The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol."
365,"Chlorpropamide","DB00672","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of timolol by decreasing its metabolism."
365,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
365,"Diclofenac","DB00586","The NSAID, Diclofenac, may antagonize the antihypertensive effect of Timolol."
365,"Diflunisal","DB00861","The NSAID, Diflunisal, may antagonize the antihypertensive effect of Timolol."
365,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
365,"Diltiazem","DB00343","Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. "
365,"Disopyramide","DB00280","The beta-blocker, timolol, may increase the toxicity of disopyramide."
365,"Dyphylline","DB00651","Antagonism of action and increased effect of theophylline"
365,"Epinephrine","DB00668","Hypertension, then bradycardia"
365,"Ergonovine","DB01253","Ischemia with risk of gangrene"
365,"Ergotamine","DB00696","Ischemia with risk of gangrene"
365,"Etodolac","DB00749","The NSAID, Etodolac, may antagonize the antihypertensive effect of Timolol."
365,"Fenoprofen","DB00573","The NSAID, Fenoprofen, may antagonize the antihypertensive effect of Timolol."
365,"Fenoterol","DB01288","Antagonism"
365,"Flurbiprofen","DB00712","The NSAID, Flurbiprofen, may antagonize the antihypertensive effect of Timolol."
365,"Formoterol","DB00983","Antagonism"
365,"Gliclazide","DB01120","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Glipizide","DB01067","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Glisoxepide","DB01289","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Glyburide","DB01016","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Glycodiazine","DB01382","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
365,"Insulin Glargine","DB00047","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"insulin inhaled","DB05334","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Isoprenaline","DB01064","Antagonism"
365,"Ketoprofen","DB01009","The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol."
365,"Ketorolac","DB00465","The NSAID, Ketorolac, may antagonize the antihypertensive effect of Timolol."
365,"Lidocaine","DB00281","The beta-blocker, timolol, may increase the effect and toxicity of lidocaine."
365,"Lumiracoxib","DB01283","The NSAID, Lumiracoxib, may antagonize the antihypertensive effect of Timolol."
365,"Meclofenamic acid","DB00939","The NSAID, Meclofenamate, may antagonize the antihypertensive effect of Timolol."
365,"Meloxicam","DB00814","The NSAID, Meloxicam, may antagonize the antihypertensive effect of Timolol."
365,"Methyldopa","DB00968","Possible hypertensive crisis"
365,"Methysergide","DB00247","Ischemia with risk of gangrene"
365,"Nabumetone","DB00461","The NSAID, Nabumetone, may antagonize the antihypertensive effect of Timolol."
365,"Naproxen","DB00788","The NSAID, Naproxen, may antagonize the antihypertensive effect of Timolol."
365,"Orciprenaline","DB00816","Antagonism"
365,"Oxaprozin","DB00991","The NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol."
365,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
365,"Pipobroman","DB00236","Antagonism"
365,"Pirbuterol","DB01291","Antagonism"
365,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
365,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
365,"Procaterol","DB01366","Antagonism"
365,"Repaglinide","DB00912","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Salbutamol","DB01001","Antagonism"
365,"Salmeterol","DB00938","Antagonism"
365,"Sulindac","DB00605","The NSAID, Sulindac, may antagonize the antihypertensive effect of Timolol."
365,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
365,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Timolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Timolol is initiated, discontinued or dose changed."
365,"Terbutaline","DB00871","Antagonism"
365,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
365,"Tiaprofenic acid","DB01600","The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol."
365,"Tolazamide","DB00839","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Tolbutamide","DB01124","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
365,"Tolmetin","DB00500","The NSAID, Tolmetin, may antagonize the antihypertensive effect of Timolol."
365,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
365,"Verapamil","DB00661","Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. "
366,"Abciximab","DB00054","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Abciximab. Monitor for increased bleeding during concomitant thearpy. "
366,"Acebutolol","DB01193","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Acenocoumarol","DB01418","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy. "
366,"Acetazolamide","DB00819","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Acetylsalicylic acid","DB00945","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy. "
366,"Amiloride","DB00594","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Aminosalicylic Acid","DB00233","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Aminosalicylic acid. Monitor for increased bleeding during concomitant thearpy. "
366,"Amlodipine","DB00381","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Amyl Nitrite","DB01612","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Anagrelide","DB00261","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Anagrelide. Monitor for increased bleeding during concomitant thearpy. "
366,"Apraclonidine","DB00964","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Argatroban","DB00278","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Argatroban. Monitor for increased bleeding during concomitant thearpy. "
366,"Atenolol","DB00335","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Benazepril","DB00542","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Bendroflumethiazide","DB00436","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Betaxolol","DB00195","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Bisoprolol","DB00612","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Bivalirudin","DB00006","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Bivalirudin. Monitor for increased bleeding during concomitant therapy. "
366,"Brimonidine","DB00484","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Bumetanide","DB00887","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Candesartan","DB00796","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Captopril","DB01197","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Carteolol","DB00521","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Carvedilol","DB01136","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Celecoxib","DB00482","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy. "
366,"Celiprolol","DB04846","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Chlorothiazide","DB00880","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Chlorthalidone","DB00310","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Cilazapril","DB01340","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Cilostazol","DB01166","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy. "
366,"Citalopram","DB00215","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Citalopram. Monitor for increased bleeding during concomitant thearpy. "
366,"Clevidipine","DB04920","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Clonidine","DB00575","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Clopidogrel","DB00758","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy. "
366,"Cyclandelate","DB04838","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Dexmedetomidine","DB00633","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Diclofenac","DB00586","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy. "
366,"Diclofenamide","DB01144","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Diflunisal","DB00861","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy. "
366,"Diltiazem","DB00343","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Dipyridamole","DB00975","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."
366,"Doxazosin","DB00590","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Drospirenone","DB01395","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Drotrecogin alfa","DB00055","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Drotrecogin alfa. Monitor for increased bleeding during concomitant thearpy. "
366,"Enalapril","DB00584","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Enoxaparin","DB01225","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy. "
366,"Eplerenone","DB00700","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Eprosartan","DB00876","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Eptifibatide","DB00063","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Eptifibatide. Monitor for increased bleeding during concomitant thearpy. "
366,"Escitalopram","DB01175","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy. "
366,"Esmolol","DB00187","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Ethacrynic acid","DB00903","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Etodolac","DB00749","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy. "
366,"Felodipine","DB01023","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Fenoprofen","DB00573","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy. "
366,"Fluoxetine","DB00472","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy. "
366,"Flurbiprofen","DB00712","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy. "
366,"Fluvoxamine","DB00176","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluvoxamine. Monitor for increased bleeding during concomitant thearpy. "
366,"Fosinopril","DB00492","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Furosemide","DB00695","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Guanabenz","DB00629","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Guanfacine","DB01018","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Heparin","DB01109","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy. "
366,"Hydralazine","DB01275","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Hydrochlorothiazide","DB00999","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Hydroflumethiazide","DB00774","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Ibuprofen","DB01050","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy. "
366,"Indapamide","DB00808","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Indomethacin","DB00328","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Indomethacin. Monitor for increased bleeding during concomitant thearpy. "
366,"Irbesartan","DB01029","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Isosorbide Dinitrate","DB00883","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Isosorbide Mononitrate","DB01020","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Isradipine","DB00270","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Ketoprofen","DB01009","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy. "
366,"Ketorolac","DB00465","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy. "
366,"Labetalol","DB00598","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Lepirudin","DB00001","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Lepirudin. Monitor for increased bleeding during concomitant thearpy. "
366,"Levobunolol","DB01210","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Lisinopril","DB00722","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Losartan","DB00678","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Lumiracoxib","DB01283","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy. "
366,"Mannitol","DB00742","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Meclofenamic acid","DB00939","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy. "
366,"Mefenamic acid","DB00784","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy. "
366,"Meloxicam","DB00814","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy. "
366,"Methazolamide","DB00703","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Methyclothiazide","DB00232","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Metipranolol","DB01214","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Metolazone","DB00524","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Metoprolol","DB00264","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Minoxidil","DB00350","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Moexipril","DB00691","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nabumetone","DB00461","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy. "
366,"Nadolol","DB01203","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Naproxen","DB00788","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy. "
366,"Nebivolol","DB04861","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nesiritide","DB04899","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nicardipine","DB00622","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nifedipine","DB01115","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nimodipine","DB00393","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nisoldipine","DB00401","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nitrendipine","DB01054","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nitroglycerin","DB00727","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Nitroprusside","DB00325","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Olmesartan","DB00275","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Oxaprozin","DB00991","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy. "
366,"Oxprenolol","DB01580","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Papaverine","DB01113","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Paroxetine","DB00715","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy. "
366,"Penbutolol","DB01359","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Perindopril","DB00790","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Phenoxybenzamine","DB00925","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Phentolamine","DB00692","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Pindolol","DB00960","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Piroxicam","DB00554","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy. "
366,"Polythiazide","DB01324","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Prazosin","DB00457","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Quinapril","DB00881","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Ramipril","DB00178","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Reserpine","DB00206","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Rivaroxaban","DB06228","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy. "
366,"Salsalate","DB01399","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy. "
366,"Sertraline","DB01104","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy. "
366,"Sotalol","DB00489","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Spironolactone","DB00421","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Sulindac","DB00605","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy. "
366,"Telmisartan","DB00966","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Terazosin","DB01162","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Tiaprofenic acid","DB01600","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy. "
366,"Ticlopidine","DB00208","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Ticlopidine. Monitor for increased bleeding during concomitant thearpy. "
366,"Timolol","DB00373","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Tirofiban","DB00775","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy. "
366,"Tizanidine","DB00697","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Tolazoline","DB00797","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Tolmetin","DB00500","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy. "
366,"Torasemide","DB00214","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Trandolapril","DB00519","The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril."
366,"Triamterene","DB00384","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Trichlormethiazide","DB01021","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Urea","DB03904","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Valsartan","DB00177","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Verapamil","DB00661","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
366,"Warfarin","DB00682","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy. "
367,"Acenocoumarol","DB01418","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption."
367,"Anisindione","DB01125","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of anisindione by decreasing its absorption."
367,"Chlorothiazide","DB00880","Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. "
367,"Cholecalciferol","DB00169","Bile acid sequestrants such as colestipol may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
367,"Dicoumarol","DB00266","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."
367,"Digoxin","DB00390","The resin decreases the effect of digoxin"
367,"Fluvastatin","DB01095","Increased/decreased effect according to spacing"
367,"Hydrocortisone","DB00741","Cholestyramine decreases the effect of hydrocortisone"
367,"Levothyroxine","DB00451","The resin, colestipol, decreases the absorption of the thyroid hormone, levothyroxine."
367,"Liothyronine","DB00279","The resin, colestipol, decreases the absorption of the thyroid hormone, liothyronine."
367,"Liotrix","DB01583","The resin, colestipol, decreases the absorption of the thyroid hormone, liotrix."
367,"Lomitapide","DB08827","Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours. "
367,"Raloxifene","DB00481","The resin decreases the effect of raloxifene"
367,"Sulindac","DB00605","The bile acid sequestrant, colestipol, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if colestipol is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions."
367,"Thyroglobulin","DB01584","The resin, colestipol, decreases the absorption of the thyroid hormone, thyroglobulin."
367,"Tiaprofenic acid","DB01600","The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect."
367,"Tolmetin","DB00500","Colestipol may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
367,"Torasemide","DB00214","Colestipol may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
367,"Trichlormethiazide","DB01021","The bile acid sequestrant, Colestipol, may inhibit the absorption of Trichlormethiazide."
367,"Ursodeoxycholic acid","DB01586","The resin decreases the effect of ursodiol"
367,"Warfarin","DB00682","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption."
368,"Donepezil","DB00843","Possible antagonism of action"
368,"Galantamine","DB00674","Possible antagonism of action"
368,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
368,"Potassium Chloride","DB00761","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trihexyphenidyl, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations. "
368,"Pramlintide","DB01278","The anticholinergic effects of Trihexyphenidyl may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
368,"Rivastigmine","DB00989","Possible antagonism of action"
368,"Secretin","DB00021","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trihexyphenidyl. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
368,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trihexyphenidyl, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
368,"Trimethobenzamide","DB00662","Trimethobenzamide and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
368,"Triprolidine","DB00427","Triprolidine and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
368,"Trospium","DB00209","Trospium and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
371,"Aminophylline","DB01223","Mexiletine increases the effect and toxicity of theophylline"
371,"Bendamustine","DB06769","Affects hepatic CYP1A2 metabolism, thus increasing bendamustine levels. Concentration of active metabolites may be decreased due to decreased conversion. "
371,"Dyphylline","DB00651","Mexiletine increases the effect and toxicity of theophylline"
371,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
371,"Ethotoin","DB00754","The hydantoin decreases the effect of mexiletine"
371,"Etravirine","DB06414","Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness."
371,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic and adverse effects of mexiletine."
371,"Fosphenytoin","DB01320","The hydantoin decreases the effect of mexiletine"
371,"Mephenytoin","DB00532","The hydantoin decreases the effect of mexiletine"
371,"Oxtriphylline","DB01303","Mexiletine increases the effect and toxicity of theophylline"
371,"Phenytoin","DB00252","The hydantoin decreases the effect of mexiletine"
371,"Propafenone","DB01182","Propafenone may increase the effect and toxicity of mexilitine."
371,"Ramelteon","DB00980","Mexiletine increases levels/toxicity of ramelteon"
371,"Rifampicin","DB01045","Rifampin decreases the effect of mexiletine"
371,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed."
371,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed."
371,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
371,"Theophylline","DB00277","Mexiletine increases the effect and toxicity of theophylline"
371,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed. "
371,"Tizanidine","DB00697","Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
371,"Vilazodone","DB06684","Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased. "
373,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of amlodipine. Concomitant therapy will result in additive hypotensive effects. Monitor for changes in the hypotensive effect of amlodipine if diltiazem is initiated, discontinued or dose changed."
373,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
373,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Amlopidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Amlopidine is initiated, discontinued or if the dose is changed."
373,"Telaprevir","DB05521","Telaprevir inhibits the metabolism of amlodipine and concomitant therapy is contraindicated. "
373,"Telithromycin","DB00976","Telithromycin may reduce clearance of Amlopidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amlopidine if Telithromycin is initiated, discontinued or dose changed."
373,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Amlodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Amlodipine if Thiopental is initiated, discontinued or dose changed."
373,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Amlopidine. Monitor for changes in Amlopidine therapeutic and toxic effects if Tipranavir is initiated, discontinued or dose changed. "
373,"Tizanidine","DB00697","Amlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
373,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
373,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of amlodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amlodipine if voriconazole is initiated, discontinued or dose changed. "
374,"Acetophenazine","DB01063","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Acetophenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Acetylcholine","DB03128","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Acetylcholine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity. "
374,"Alimemazine","DB01246","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimeprazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Ambenonium","DB01122","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Ambenonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity. "
374,"Aminophylline","DB01223","Tacrine may reduce the elimination rate of Aminophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed."
374,"Amitriptyline","DB00321","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amitriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Amlodipine","DB00381","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Amlopidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Amlopidine is initiated, discontinued or if the dose is changed."
374,"Amoxapine","DB00543","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amoxapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Aripiprazole","DB01238","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Aripiprazole. Monitor for extrapyramidal symptoms. "
374,"Atropine","DB00572","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Atropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Azelastine","DB00972","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Azelastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Bendamustine","DB06769","CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. "
374,"Benzatropine","DB00245","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Benztropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Betamethasone","DB00443","Tacrine and Betamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects. "
374,"Bethanechol","DB01019","The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Bethanecol, a cholinergic agonist. Monitor for increased cholinergic effects."
374,"Biperiden","DB00810","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Biperidin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Bromodiphenhydramine","DB01237","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Bromodiphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Brompheniramine","DB00835","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Brompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Carbachol","DB00411","The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Carbachol, a cholinergic agonist. Monitor for increased cholinergic effects."
374,"Carbinoxamine","DB00748","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Carbinoxamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Cevimeline","DB00185","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Cevimeline, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
374,"Chlorphenamine","DB01114","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Chlorpheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Chlorpromazine","DB00477","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Chlorpromazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Cimetidine","DB00501","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Cimetidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Cimetidine is initiated, discontinued or if the dose is changed."
374,"Ciprofloxacin","DB00537","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed."
374,"Clemastine","DB00283","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clemastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Clidinium","DB00771","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Clomipramine","DB01242","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clomipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Clozapine","DB00363","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Clozapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Corticotropin","DB01285","Tacrine and Corticotropin may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Cortisone acetate","DB01380","Tacrine and Cortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Cyclizine","DB01176","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Cyclobenzaprine","DB00924","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclobenzaprine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Cyclopentolate","DB00979","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Cyproheptadine","DB00434","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyproheptadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Darifenacin","DB00496","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Darifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Demecarium","DB00944","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Demcarium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
374,"Desipramine","DB01151","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Desloratadine","DB00967","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desloratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Dexamethasone","DB01234","Tacrine and Dexamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Dexbrompheniramine","DB00405","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dexbrompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Diclofenac","DB00586","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Diclofenac, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Diclofenac is initiated, discontinued or if the dose is changed."
374,"Dicyclomine","DB00804","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dicyclomine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Dimenhydrinate","DB00985","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Diphenhydramine","DB01075","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Diphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Doxepin","DB01142","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxepin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Doxylamine","DB00366","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxylamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Droperidol","DB00450","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Droperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Edrophonium","DB01010","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Edrophonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
374,"Fexofenadine","DB00950","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Fexofenadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Flavoxate","DB01148","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Flavoxate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Fludrocortisone","DB00687","Tacrine and Fludrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Fluoxetine","DB00472","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Fluoxetine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Fluoxetine is initiated, discontinued or if the dose is changed."
374,"Flupentixol","DB00875","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Flupenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Fluphenazine","DB00623","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Fluphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Fluvoxamine","DB00176","Fluvoxamine, a strong CYP1A2 inhibitor, may decrease the metabolism and clearance of tacrine, a CYP1A2 substrate. Concomitant therapy should be avoided as it could lead to severe toxic effects such as hepatotoxicity. If concomitant therapy is used, monitor for altered efficacy and toxic effects, such as gastrointestinal and hepatic effects, of tacrine."
374,"Gemfibrozil","DB01241","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Gemfibrozil, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Gemfibrozil is initiated, discontinued or if the dose is changed."
374,"Ginkgo biloba","DB01381","Ginkgo biloba may cause additive/toxic cholinergic effects when administered with Tacrine. Monitor for cholinergic toxicity. "
374,"Glycopyrrolate","DB00986","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Glycopyrrolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Guanidine","DB00536","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Guanidine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
374,"Haloperidol","DB00502","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Homatropine Methylbromide","DB00725","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Homatropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Hydrocortisone","DB00741","Tacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Hydroxyzine","DB00557","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hydroxyzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Hyoscyamine","DB00424","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hyoscyamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Imipramine","DB00458","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Imipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Ipratropium bromide","DB00332","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ipratropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Isocarboxazid","DB01247","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Ketoconazole","DB01026","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed."
374,"Ketotifen","DB00920","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ketotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Lidocaine","DB00281","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Lidocaine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Lidocaine is initiated, discontinued or if the dose is changed."
374,"Loratadine","DB00455","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Loratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Loxapine","DB00408","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Loxapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Maprotiline","DB00934","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Maprotiline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Meclizine","DB00737","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Meclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Mepenzolate","DB04843","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Mepenzolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Mesoridazine","DB00933","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Mesoridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Methantheline","DB00940","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Methoxsalen","DB00553","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Methoxsalen. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Methoxsalen is initiated, discontinued or if the dose is changed."
374,"Methylprednisolone","DB00959","Tacrine and Methylprednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Methylscopolamine bromide","DB00462","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methylscopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Mexiletine","DB00379","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Mexiletine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Mexiletine is initiated, discontinued or if the dose is changed."
374,"Miconazole","DB01110","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Miconazole, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Miconazole is initiated, discontinued or if the dose is changed."
374,"Moclobemide","DB01171","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Molindone","DB01618","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Molindone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Nifedipine","DB01115","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Nifedipine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Nifedipine is initiated, discontinued or if the dose is changed."
374,"Norfloxacin","DB01059","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Norfloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Norfloxacin is initiated, discontinued or if the dose is changed."
374,"Nortriptyline","DB00540","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Nortriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Ofloxacin","DB01165","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed."
374,"Olanzapine","DB00334","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Olanzapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Orphenadrine","DB01173","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Orphenadrine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Oxtriphylline","DB01303","Tacrine increases the effect and toxicity of theophylline"
374,"Oxybutynin","DB01062","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Oxybutynin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Paliperidone","DB01267","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Paliperidone. Monitor for extrapyramidal symptoms."
374,"Perphenazine","DB00850","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Perphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Phenelzine","DB00780","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenelzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Phenindamine","DB01619","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenindamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Pilocarpine","DB01085","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Pilocarpine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
374,"Pimozide","DB01100","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Pimozide, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Pizotifen","DB06153","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Pizotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Prednisolone","DB00860","Tacrine and Prednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Prednisone","DB00635","Tacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Primaquine","DB01087","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Primaquine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Primaquine is initiated, discontinued or if the dose is changed."
374,"Prochlorperazine","DB00433","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Prochlorperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Procyclidine","DB00387","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Procyclidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Promethazine","DB01069","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Promethazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Propantheline","DB00782","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Propantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Propofol","DB00818","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Propofol, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Propofol is initiated, discontinued or if the dose is changed."
374,"Protriptyline","DB00344","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Protriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Quetiapine","DB01224","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Ramelteon","DB00980","Tacrine increases levels/toxicity of ramelteon"
374,"Risperidone","DB00734","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Risperidone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Scopolamine","DB00747","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Scopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Solifenacin","DB01591","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Solifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Succinylcholine","DB00202","Tacrine may increase the effects of Succinylcholine. Monitor Succinylcholine therapy for increased effects."
374,"Theophylline","DB00277","Tacrine may reduce the elimination rate of Theophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed."
374,"Thiabendazole","DB00730","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed."
374,"Thioridazine","DB00679","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Thiothixene","DB01623","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thiothixene, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Tiotropium","DB01409","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tiotropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Tolterodine","DB01036","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tolterodine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Tranylcypromine","DB00752","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. "
374,"Triamcinolone","DB00620","Tacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
374,"Trifluoperazine","DB00831","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
374,"Trihexyphenidyl","DB00376","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trihexyphenidyl, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Trimethobenzamide","DB00662","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimethobenzamide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Trimipramine","DB00726","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Triprolidine","DB00427","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Triprolidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Trospium","DB00209","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trospium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
374,"Ziprasidone","DB00246","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms."
374,"Zuclopenthixol","DB01624","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Zuclopenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
375,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
376,"Benazepril","DB00542","Increased risk of hyperkalemia"
376,"Candesartan","DB00796","Increased risk of hyperkalemia"
376,"Captopril","DB01197","Increased risk of hyperkalemia"
376,"Cilazapril","DB01340","Increased risk of hyperkalemia"
376,"Drospirenone","DB01395","Increased risk of hyperkalemia"
376,"Enalapril","DB00584","Increased risk of hyperkalemia"
376,"Eplerenone","DB00700","This association presents an increased risk of hyperkalemia"
376,"Eprosartan","DB00876","Increased risk of hyperkalemia"
376,"Forasartan","DB01342","Increased risk of hyperkalemia"
376,"Fosinopril","DB00492","Increased risk of hyperkalemia"
376,"Indomethacin","DB00328","Risk of acute renal impairment with this combination"
376,"Irbesartan","DB01029","Increased risk of hyperkalemia"
376,"Lisinopril","DB00722","Increased risk of hyperkalemia"
376,"Losartan","DB00678","Increased risk of hyperkalemia"
376,"Moexipril","DB00691","Increased risk of hyperkalemia"
376,"Perindopril","DB00790","Increased risk of hyperkalemia"
376,"Polystyrene sulfonate","DB01344","Antagonism of action"
376,"Potassium","DB01345","Increased risk of hyperkalemia"
376,"Quinapril","DB00881","Increased risk of hyperkalemia"
376,"Ramipril","DB00178","Increased risk of hyperkalemia"
376,"Saprisartan","DB01347","Increased risk of hyperkalemia"
376,"Spirapril","DB01348","Increased risk of hyperkalemia"
376,"Tasosartan","DB01349","Increased risk of hyperkalemia"
376,"Telmisartan","DB00966","Telmisartan may increase the hyperkalemic effect of Triamterene. Monitor for increased serum potassium concentrations during concomitant therapy."
376,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels."
376,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
376,"Valsartan","DB00177","Increased risk of hyperkalemia"
377,"Docetaxel","DB01248","The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects. "
377,"Natalizumab","DB00108","Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided. "
377,"Paclitaxel","DB01229","The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects."
377,"Trastuzumab","DB00072","Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
378,"Epinephrine","DB00668","Increased arterial pressure"
378,"Fenoterol","DB01288","Increased arterial pressure"
378,"Orciprenaline","DB00816","Increased arterial pressure"
378,"Phenylephrine","DB00388","Increased arterial pressure"
378,"Phenylpropanolamine","DB00397","Increased arterial pressure"
378,"Pseudoephedrine","DB00852","Increased arterial pressure"
378,"Terbutaline","DB00871","Increased arterial pressure"
379,"Donepezil","DB00843","Possible antagonism of action"
379,"Galantamine","DB00674","Possible antagonism of action"
379,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
379,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Procyclidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
379,"Trimethobenzamide","DB00662","Trimethobenzamide and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
379,"Triprolidine","DB00427","Triprolidine and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
379,"Trospium","DB00209","Trospium and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
380,"Alseroxylon","DB00386","Increased arterial pressure"
380,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylephrine."
380,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine."
380,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine."
380,"Deserpidine","DB01089","Increased arterial pressure"
380,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine."
380,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine."
380,"Ergonovine","DB01253","Possible marked increase of arterial pressure"
380,"Guanethidine","DB01170","Phenylephrine may decrease the effect of guanethidine."
380,"Hyaluronidase","DB00070","Avoid combination because hyaluronidase can potentiate the vasoconstrictive effect of phenylephrine."
380,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine."
380,"Iobenguane","DB06704","Sympathomimetic that increase chances of producing a false negative imaging result "
380,"Isocarboxazid","DB01247","Increased arterial pressure"
380,"Linezolid","DB00601","Possible increase of arterial pressure"
380,"Methyldopa","DB00968","Increased arterial pressure"
380,"Methylergometrine","DB00353","Possible marked increase of arterial pressure"
380,"Midodrine","DB00211","Increased arterial pressure"
380,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of phenylephrine."
380,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine."
380,"Oxytocin","DB00107","Possible marked increase of arterial pressure"
380,"Pargyline","DB01626","Increased arterial pressure"
380,"Phenelzine","DB00780","Increased arterial pressure"
380,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylephrine."
380,"Rasagiline","DB01367","Increased arterial pressure"
380,"Reserpine","DB00206","Increased arterial pressure"
380,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided."
380,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
382,"Acarbose","DB00284","Acarbose may decrease the serum levels of digoin. It is thought that acarbose reduces digoin absorption. Monitor for changes in digoxin serum levels and therapeutic and adverse effects if acarbose is initiated, discontinued or dose changed."
382,"Alprazolam","DB00404","The benzodiazepine, alprazolam, may increase the effect of digoxin."
382,"Amiodarone","DB01118","Amiodarone may increase the effect of digoxin."
382,"Bendroflumethiazide","DB00436","Possible electrolyte variations and arrhythmias"
382,"Benzthiazide","DB00562","Possible electrolyte variations and arrhythmias"
382,"Bleomycin","DB00290","The antineoplasic agent decreases the effect of digoxin"
382,"Bosutinib","DB06616","Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates. "
382,"Bumetanide","DB00887","Possible electrolyte variations and arrhythmias"
382,"Canagliflozin","DB08907","When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely. "
382,"Carmustine","DB00262","The antineoplasic agent decreases the effect of digoxin"
382,"Carvedilol","DB01136","Carvedilol may increase the serum levels and effect of digoxin."
382,"Chlorothiazide","DB00880","Possible electrolyte variations and arrhythmias"
382,"Chlorthalidone","DB00310","Possible electrolyte variations and arrhythmias"
382,"Cholestyramine","DB01432","The resin decreases the effect of digoxin"
382,"Cinitapride","DB08810","Cinitapride can alter the absorption of digoxin as it simulates gastric emptying."
382,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients."
382,"Colestipol","DB00375","The resin decreases the effect of digoxin"
382,"Cyclophosphamide","DB00531","The antineoplasic agent decreases the effect of digoxin"
382,"Cyclosporine","DB00091","Cyclosporine may increase the effect of digoxin."
382,"Cyclothiazide","DB00606","Possible electrolyte variations and arrhythmias"
382,"Cytarabine","DB00987","The antineoplasic agent decreases the effect of digoxin"
382,"Dextrothyroxine","DB00509","The thyroid hormone, dextrothyroxine, decreases the effect of digoxin."
382,"Diazepam","DB00829","The benzodiazepine, diazepam, may increase the effect of digoxin."
382,"Dihydroquinidine barbiturate","DB01341","Quinine/quinidine increases the effect of digoxin"
382,"Doxorubicin","DB00997","The antineoplasic agent decreases the effect of digoxin"
382,"Dronedarone","DB04855","Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold. "
382,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of digoxin in 10% of patients."
382,"Ethacrynic acid","DB00903","Possible electrolyte variations and arrhythmias"
382,"Etravirine","DB06414","Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required."
382,"Furosemide","DB00695","Possible electrolyte variations and arrhythmias"
382,"Gatifloxacin","DB01044","Gatifloxacin increases the effect of digoxin"
382,"Ginseng","DB01404","Changes in digoxin serum levels"
382,"Hydrochlorothiazide","DB00999","Possible electrolyte variations and arrhythmias"
382,"Hydroflumethiazide","DB00774","Possible electrolyte variations and arrhythmias"
382,"Hydroxychloroquine","DB01611","Hydroxychloroquine increases the effect of digoxin"
382,"Indapamide","DB00808","Possible electrolyte variations and arrhythmias"
382,"Itraconazole","DB01167","Itraconazole increases the effect of digoxin"
382,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of digoxin in 10% of patients."
382,"Levothyroxine","DB00451","The thyroid hormone, levothyroxine, decreases the effect of digoxin."
382,"Liothyronine","DB00279","The thyroid hormone, liothyronine, decreases the effect of digoxin."
382,"Liotrix","DB01583","The thyroid hormone, liotrix, decreases the effect of digoxin."
382,"Liraglutide","DB06655","These agents may have decreased C max and a delayed T max during coadministration."
382,"Methimazole","DB00763","The antithyroid agent increases the effect of digoxin"
382,"Methotrexate","DB00563","The antineoplasic agent decreases the effect of digoxin"
382,"Methyclothiazide","DB00232","Possible electrolyte variations and arrhythmias"
382,"Metolazone","DB00524","Possible electrolyte variations and arrhythmias"
382,"Milnacipran","DB04896","Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided. "
382,"Mirabegron","DB08893","Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely. "
382,"Penbutolol","DB01359","Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia."
382,"Penciclovir","DB00299","The multivalent agent decreases the effect of penicillamine"
382,"Penicillamine","DB00859","Penicillamine decreases the effect of digoxin"
382,"Polythiazide","DB01324","Possible electrolyte variations and arrhythmias"
382,"Prazosin","DB00457","Prazosin increases the effect of digoxin"
382,"Procarbazine","DB01168","The antineoplasic agent decreases the effect of digoxin"
382,"Propafenone","DB01182","Propafenone increases the effect of digoxin"
382,"Propylthiouracil","DB00550","The antithyroid agent may increase the effect of digoxin."
382,"Quinethazone","DB01325","Possible electrolyte variations and arrhythmias"
382,"Quinidine","DB00908","Quinine/quinidine increases the effect of digoxin"
382,"Quinidine barbiturate","DB01346","Quinine/quinidine increases the effect of digoxin"
382,"Quinine","DB00468","Quinine/quinidine increases the effect of digoxin"
382,"Rabeprazole","DB01129","Rabeprazole increases the effect of digoxin"
382,"Ranolazine","DB00243","Ranolazine may increase the serum level of digoxin. Monitor for changes in the serum level and therapeutic and adverse effects of digoxin if ranolazine is initiated, discontinued or dose changed."
382,"Ritonavir","DB00503","Ritonavir increases levels/effect of digoxin"
382,"Spironolactone","DB00421","Increased digoxin levels and decreased effect in presence of spironolactone"
382,"St. John's Wort","DB01323","St. John's Wort decreases the effect of digoxin"
382,"Sulfasalazine","DB00795","Sulfasalazine may decrease the effect of digoxin."
382,"Telaprevir","DB05521","Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored. \
"
382,"Telithromycin","DB00976","Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed."
382,"Telmisartan","DB00966","Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed."
382,"Thyroglobulin","DB01584","The thyroid hormone, thyroglobulin, decreases the effect of digoxin."
382,"Ticlopidine","DB00208","Ticlopidine may decrease Digoxin levels. Monitor for Digoxin levels with Ticlopidine is initiated, discontinued or dose changed."
382,"Tolbutamide","DB01124","Tolbutamide increases the effect of digoxin"
382,"Tolvaptan","DB06212","Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. "
382,"Trichlormethiazide","DB01021","Possible electrolyte variations and arrhythmias"
382,"Trimetrexate","DB01157","The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered."
382,"Verapamil","DB00661","Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed."
382,"Vincristine","DB00541","The antineoplasic agent decreases the effect of digoxin"
382,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased."
384,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
384,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
384,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
384,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
384,"Donepezil","DB00843","Possible antagonism of action"
384,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
384,"Galantamine","DB00674","Possible antagonism of action"
384,"Guanethidine","DB01170","Ethopropazine may decrease the effect of guanethidine."
384,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
384,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
384,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
384,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
385,"Cimetidine","DB00501","Cimetidine increases the effect of the calcium channel blocker, nimodipine."
385,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
385,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nimodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nimodipine if Telithromycin is initiated, discontinued or dose changed."
385,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nimodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nimodipine if Thiopental is initiated, discontinued or dose changed."
385,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nimodipine. Monitor for changes in Nimodipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."
385,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
385,"Valproic Acid","DB00313","Valproic acid increases the effect of nimodipine"
385,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nimodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nimodipine if voriconazole is initiated, discontinued or dose changed."
387,"Delavirdine","DB00705","Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use. "
387,"Fluconazole","DB00196","Strong CYP2C19 inhibitors such as fluconazole may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Fluvoxamine","DB00176","Strong CYP2C19 inhibitors such as fluvoxamine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Gemfibrozil","DB01241","Strong CYP2C19 inhibitors such as gemfibrozil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Isoniazid","DB00951","Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Methotrimeprazine","DB01403","Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy. "
387,"Modafinil","DB00745","Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Sitaxentan","DB06268","Strong CYP2C19 inhibitors such as sitaxentan may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
387,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Carisoprodol. Consider alternate therapy or monitor for adverse/toxic effects of Carisoprodol if Ticlopidine is initiated, discontinued or dose changed."
387,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Carisoprodol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
388,"Topotecan","DB01030","The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
389,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
389,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
389,"Alseroxylon","DB00386","Increased arterial pressure"
389,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of phenylpropanolamine."
389,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine."
389,"Bromocriptine","DB01200","The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine."
389,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
389,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine."
389,"Deserpidine","DB01089","Increased arterial pressure"
389,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine."
389,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine."
389,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
389,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
389,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
389,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
389,"Guanethidine","DB01170","Phenylpropanolamine may decrease the effect of guanethidine."
389,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine."
389,"Iobenguane","DB06704","Sympathomimetic that increase chances of producing a false negative imaging result "
389,"Isocarboxazid","DB01247","Increased arterial pressure"
389,"Linezolid","DB00601","Possible increase of arterial pressure"
389,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
389,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
389,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
389,"Methyldopa","DB00968","Increased arterial pressure"
389,"Midodrine","DB00211","Increased arterial pressure"
389,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of phenylpropanolamine."
389,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine."
389,"Pargyline","DB01626","Increased arterial pressure"
389,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
389,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
389,"Phenelzine","DB00780","Increased arterial pressure"
389,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
389,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
389,"Promethazine","DB01069","Decreased anorexic effect, may increase psychotic symptoms."
389,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
389,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
389,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of phenylpropanolamine."
389,"Rasagiline","DB01367","Increased arterial pressure"
389,"Reserpine","DB00206","Increased arterial pressure"
389,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
389,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
389,"Tranylcypromine","DB00752","Increased arterial pressure"
389,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
389,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
389,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine."
389,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
390,"Bevacizumab","DB00112","Monitor therapy due to increased adverse effects of sorafenib, especially hand-foot skin reaction."
390,"Carboplatin","DB00958","Sorafenib may enhance the adverse/toxic effect of carboplatin. Concurrent use of sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution."
390,"Etravirine","DB06414","Sorafebib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
390,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
390,"Tretinoin","DB00755","The strong CYP2C8 inhibitor, Sorafenib, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Sorafenib is initiated, discontinued to dose changed. "
392,"Acenocoumarol","DB01418","Griseofulvin may decrease the anticoagulant effect of acenocoumarol."
392,"Acetylsalicylic acid","DB00945","Griseofulvin may decrease the efficacy of acetylsalicylic acid. "
392,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of griseofulvin."
392,"Anisindione","DB01125","Griseofulvin may decrease the anticoagulant effect of anisindione."
392,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of griseofulvin."
392,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of griseofulvin."
392,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of griseofulvin."
392,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of griseofulvin."
392,"Chlorotrianisene","DB00269","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent,  chlorotrianisene."
392,"Clomifene","DB00882","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene."
392,"Conjugated Estrogens","DB00286","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, conjugated estrogens."
392,"Cyclosporine","DB00091","Griseofulvin decreases the effect of cyclosporine"
392,"Dicoumarol","DB00266","Griseofulvin may decrease the anticoagulant effect of dicumarol."
392,"Diethylstilbestrol","DB00255","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, diethylstilbestrol."
392,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin."
392,"Estradiol","DB00783","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estradiol."
392,"Estriol","DB04573","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estriol."
392,"Estrone","DB00655","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone."
392,"Estropipate","DB04574","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estropipate."
392,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
392,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of griseofulvin."
392,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of griseofulvin."
392,"Liraglutide","DB06655","Cmax may be increased.\
"
392,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, griseofulvin, may decrease the effect of the hormone, medroxyprogesterone."
392,"Megestrol acetate","DB00351","The enzyme inducer, griseofulvin, may decrease the effect of the hormone, megestrol."
392,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
392,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of griseofulvin."
392,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of griseofulvin."
392,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
392,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of griseofulvin."
392,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of griseofulvin."
392,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of griseofulvin."
392,"Quinestrol","DB04575","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, quinestrol."
392,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin."
392,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of griseofulvin."
392,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of griseofulvin."
392,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
392,"Warfarin","DB00682","Griseofulvin may decrease the anticoagulant effect of warfarin."
393,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. Avoid concurrent use of nisoldipine with strong inhibitors of CYP3A4, as the combination may lead to substantial increases in nisoldipine concentrations. "
393,"Etravirine","DB06414","Nisoldipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
393,"Fosphenytoin","DB01320","Phenytoin decreases the efficiency of nisoldipine"
393,"Phenytoin","DB00252","Phenytoin decreases the efficiency of nisoldipine"
393,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
393,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nisoldipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nisoldipine if Telithromycin is initiated, discontinued or dose changed."
393,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nisoldipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nisoldipine if Thiopental is initiated, discontinued or dose changed."
393,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may alter the concentration of Nisoldipine. Monitor for efficacy and adverse/toxic effects of Nisoldipine."
393,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
393,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nisoldipine by decreasing its metabolism. Concomitant therapy should be avoided. "
394,"Telithromycin","DB00976","Telithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed."
394,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Eszopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
394,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed."
396,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Aprepitant","DB00673","Aprepitant may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Carbamazepine","DB00564","Carbamazepine may decrease the effect of the benzodiazepine, alprazolam."
396,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, alprazolam."
396,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, alprazolam."
396,"Clozapine","DB00363","Increased risk of toxicity"
396,"Delavirdine","DB00705","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Digoxin","DB00390","The benzodiazepine, alprazolam, may increase the effect of digoxin."
396,"Efavirenz","DB00625","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of the benzodiazepine, alprazolam."
396,"Ethotoin","DB00754","Ethotoin may increase the metabolism of alprazolam via CYP3A4."
396,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, alprazolam."
396,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of alprazolam via CYP3A4."
396,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, alprazolam."
396,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, alprazolam."
396,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam."
396,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, alprazolam."
396,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, alprazolam."
396,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of alprazolam via CYP3A4."
396,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, alprazolam."
396,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, alprazolam."
396,"Phenytoin","DB00252","Phenytoin may increase the metabolism of alprazolam via CYP3A4."
396,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, alprazolam."
396,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, alprazolam."
396,"St. John's Wort","DB01323","St. John's Wort may decrease the effect of the benzodiazepine, alprazolam."
396,"Telaprevir","DB05521","Telaprevir inhibits systemic metabolism of alprazolam and dose adjustment may be necessary. "
396,"Telithromycin","DB00976","Telithromycin may increase the effect and toxicity of the benzodiazepine, alprazolam."
396,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Alprazolam. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. "
396,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Alprazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
396,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of alprazolam by decreasing its metabolism. Monitor for alprazolam toxicity if voriconazole is initiated or dose increased."
397,"Donepezil","DB00843","Possible antagonism of action"
397,"Galantamine","DB00674","Possible antagonism of action"
397,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dexbrompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
397,"Trimethobenzamide","DB00662","Trimethobenzamide and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
397,"Triprolidine","DB00427","Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
397,"Trospium","DB00209","Trospium and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
400,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
400,"Donepezil","DB00843","Possible antagonism of action"
400,"Galantamine","DB00674","Possible antagonism of action"
400,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
400,"Rivastigmine","DB00989","Possible antagonism of action"
400,"Rotigotine","DB05271","Pharmacodynamic antagonism may decrease the effects of rotigotine. Consider alternate therapy. "
400,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Loxapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
400,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
400,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
400,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
400,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
400,"Trimethobenzamide","DB00662","Trimethobenzamide and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
400,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
400,"Triprolidine","DB00427","Triprolidine and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
400,"Trospium","DB00209","Trospium and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
400,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
400,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
400,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
400,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
403,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Carbachol, a cholinergic agonist. Monitor for increased cholinergic effects."
404,"Avanafil","DB06237","Co-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone. "
404,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents. "
404,"Gemfibrozil","DB01241","Increases the effect and toxicity of rosiglitazone/pioglitazone"
404,"Ketoconazole","DB01026","Ketoconazole increases the effect of rosiglitazone"
404,"Rifampicin","DB01045","Rifampin reduces levels and efficacy of rosiglitazone"
404,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of rosiglitazone. Monitor for changes in fasting and postprandial blood sugars."
404,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed."
405,"Cimetidine","DB00501","Cimetidine may increase the effect and toxicity of pramipexole."
405,"Dihydrocodeine","DB01551","Dihydrocodeine may enhance the sedative effect of pramipexole. It is recommended to monitor therapy"
405,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, pramipexole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
405,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pramipexole. Consider alternate therapy or monitor for decreased effects of both agents. "
405,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Pramipexole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
405,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder. "
405,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
406,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
406,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide."
406,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
406,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
406,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
406,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
406,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
406,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, acetohexamide."
406,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, acetohexamide."
406,"Dicoumarol","DB00266","Dicumarol may increase the effect of sulfonylurea, acetohexamide."
406,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
406,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
406,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
406,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
406,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
406,"Phenylbutazone","DB00812","Phenylbutazone may increase the effect of acetohexamide."
406,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
406,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
406,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
406,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, acetohexamide."
406,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
406,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
407,"Atenolol","DB00335","Ampicillin decreases bioavailability of atenolol"
407,"Demeclocycline","DB00618","Possible antagonism of action"
407,"Doxycycline","DB00254","Possible antagonism of action"
407,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
407,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
407,"Methacycline","DB00931","Possible antagonism of action"
407,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
407,"Minocycline","DB01017","Possible antagonism of action"
407,"Oxytetracycline","DB00595","Possible antagonism of action"
407,"Rolitetracycline","DB01301","Possible antagonism of action"
407,"Tetracycline","DB00759","Possible antagonism of action"
409,"Demeclocycline","DB00618","Possible antagonism of action"
409,"Doxycycline","DB00254","Possible antagonism of action"
409,"Fusidic Acid","DB02703","Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid."
409,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
409,"Methacycline","DB00931","Possible antagonism of action"
409,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
409,"Minocycline","DB01017","Possible antagonism of action"
409,"Oxytetracycline","DB00595","Possible antagonism of action"
409,"Rolitetracycline","DB01301","Possible antagonism of action"
409,"Tetracycline","DB00759","Possible antagonism of action"
410,"Aminophylline","DB01223","The barbiturate, secobarbital, decreases the effect of aminophylline."
410,"Bendamustine","DB06769","CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. "
410,"Betamethasone","DB00443","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, betamethasone."
410,"Clomifene","DB00882","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, clomifene."
410,"Conjugated Estrogens","DB00286","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, conjugated estrogens."
410,"Cyclosporine","DB00091","The barbiturate, secobarbital, increases the effect of cyclosporine."
410,"Dexamethasone","DB01234","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, dexamethasone."
410,"Diethylstilbestrol","DB00255","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
410,"Doxycycline","DB00254","The anticonvulsant , secobarbital, decreases the effect of doxycycline."
410,"Estradiol","DB00783","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, estradiol."
410,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
410,"Felodipine","DB01023","The barbiturate, secobarbital, decreases the effect of felodipine."
410,"Fludrocortisone","DB00687","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
410,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, secobarbital."
410,"Gefitinib","DB00317","The CYP3A4 inducer, secobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
410,"Griseofulvin","DB00400","The barbiturate, secobarbital, decreases the effect of griseofulvin."
410,"Hydrocortisone","DB00741","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
410,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
410,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
410,"Megestrol acetate","DB00351","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, megestrol."
410,"Methadone","DB00333","The barbiturate, secobarbital, decreases the effect of methadone."
410,"Metronidazole","DB00916","The barbiturate, secobarbital, decreases the effect of metronidazole."
410,"Nifedipine","DB01115","The barbiturate, secobarbital, decreases the effect of the calcium channel blocker, nifedipine."
410,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
410,"Oxtriphylline","DB01303","The barbiturate, secobarbital, decreases the effect of oxtriphylline."
410,"Prednisolone","DB00860","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisolone."
410,"Prednisone","DB00635","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone."
410,"Quinidine","DB00908","The anticonvulsant, secobarbital, decreases the effect of quinidine."
410,"Theophylline","DB00277","The barbiturate, secobarbital, decreases the effect of theophylline."
410,"Tretinoin","DB00755","The strong CYP2C8 inducer, Secobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Secobarbital is initiated, discontinued or dose changed. "
410,"Triamcinolone","DB00620","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone."
410,"Trimipramine","DB00726","The barbiturate, Secobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Secobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
410,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Secobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
410,"Verapamil","DB00661","Secobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Secobarbital is initiated, discontinued or dose changed."
410,"Warfarin","DB00682","Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed. "
412,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
412,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
412,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
412,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
412,"Donepezil","DB00843","Possible antagonism of action"
412,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
412,"Galantamine","DB00674","Possible antagonism of action"
412,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
412,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
412,"Guanethidine","DB01170","Promazine may decrease the effect of guanethidine."
412,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
412,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
412,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
412,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
412,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
413,"Benazepril","DB00542","Increased risk of hyperkalemia"
413,"Candesartan","DB00796","Increased risk of hyperkalemia"
413,"Captopril","DB01197","Increased risk of hyperkalemia"
413,"Cholestyramine","DB01432","Increased risk of acidosis and hyperkalemia"
413,"Cilazapril","DB01340","Increased risk of hyperkalemia"
413,"Digoxin","DB00390","Increased digoxin levels and decreased effect in presence of spironolactone"
413,"Enalapril","DB00584","Increased risk of hyperkalemia"
413,"Eplerenone","DB00700","This association presents an increased risk of hyperkalemia"
413,"Eprosartan","DB00876","Increased risk of hyperkalemia"
413,"Fosinopril","DB00492","Increased risk of hyperkalemia"
413,"Irbesartan","DB01029","Increased risk of hyperkalemia"
413,"Lisinopril","DB00722","Increased risk of hyperkalemia"
413,"Losartan","DB00678","Increased risk of hyperkalemia"
413,"Mitotane","DB00648","Spironolactone antagonizes the effect of mitotane"
413,"Perindopril","DB00790","Increased risk of hyperkalemia"
413,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
413,"Potassium","DB01345","Increased risk of hyperkalemia"
413,"Quinapril","DB00881","Increased risk of hyperkalemia"
413,"Ramipril","DB00178","Increased risk of hyperkalemia"
413,"Telmisartan","DB00966","Telmisartan may increase the hyperkalemic effect of Spironolactone. Monitor for increased serum potassium concentrations during concomitant therapy. "
413,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
413,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels. "
413,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
414,"Aliskiren","DB09026","Monitor therapy due to reduced antihypertensive effect of aliskiren."
414,"Carbamazepine","DB00564","Carbamazepine may decrease the effect of methylphendiate."
414,"Cyclosporine","DB00091","Methylphenidate increases the effect and toxicity of cyclosporine"
414,"Guanethidine","DB01170","Methylphenidate may decrease the effect of guanethidine."
414,"Isocarboxazid","DB01247","Possible hypertensive crisis with this combination"
414,"Phenelzine","DB00780","Possible hypertensive crisis with this combination"
414,"Rasagiline","DB01367","Possible hypertensive crisis with this combination."
414,"Trandolapril","DB00519","Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed."
414,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated."
415,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Methocarbamol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
416,"Donepezil","DB00843","Possible antagonism of action"
416,"Galantamine","DB00674","Possible antagonism of action"
416,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
416,"Rivastigmine","DB00989","Possible antagonism of action"
416,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hyoscyamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
416,"Trimethobenzamide","DB00662","Trimethobenzamide and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
416,"Triprolidine","DB00427","Triprolidine and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
416,"Trospium","DB00209","Trospium and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
417,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if amprenavir is initiated, discontinued or dose changed. "
417,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed. "
417,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if clarithromycin is initiated, discontinued or dose changed. "
417,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if conivaptan is initiated, discontinued or dose changed. "
417,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if darunavir is initiated, discontinued or dose changed. "
417,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if delavirdine is initiated, discontinued or dose changed. "
417,"Dihydrocodeine","DB01551","Enhanced CNS depressant effects contraindicates concurrent use for certain brand name formulations of zolpidem. "
417,"Fluconazole","DB00196","Fluconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fluconazole is initiated, discontinued or dose changed."
417,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fosamprenavir is initiated, discontinued or dose changed. "
417,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if indinavir is initiated, discontinued or dose changed. "
417,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed. "
417,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed. "
417,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed. "
417,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if lopinavir is initiated, discontinued or dose changed. "
417,"Methotrimeprazine","DB01403","Additive CNS depressant effects. Reduce zolpidem dose by half upon initiation of methotrimeprazine. Zolpidem dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression. "
417,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nefazodone is initiated, discontinued or dose changed. "
417,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nelfinavir is initiated, discontinued or dose changed. "
417,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed. "
417,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if posaconazole is initiated, discontinued or dose changed. "
417,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if quinidine is initiated, discontinued or dose changed. "
417,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ritonavir is initiated, discontinued or dose changed. "
417,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if saquinavir is initiated, discontinued or dose changed. "
417,"Telithromycin","DB00976","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if telithromycin is initiated, discontinued or dose changed."
417,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Zolpidem, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
417,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed."
419,"Acetazolamide","DB00819","The CNS depressants, Triprolidine and Acetazolamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Acetophenazine","DB01063","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Acetophenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Alfentanil","DB00802","The CNS depressants, Triprolidine and Alfentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. \
"
419,"Alimemazine","DB01246","Triprolidine and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Alprazolam","DB00404","The CNS depressants, Triprolidine and Alprazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Amitriptyline","DB00321","Triprolidine and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Amobarbital","DB01351","The CNS depressants, Triprolidine and Amobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Amoxapine","DB00543","Triprolidine and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Aripiprazole","DB01238","The CNS depressants, Triprolidine and Aripiprazole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Atomoxetine","DB00289","The CNS depressants, Triprolidine and Atomoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. \
"
419,"Atropine","DB00572","Triprolidine and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Azelastine","DB00972","Concomitant therapy with triprolidine and azelastine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."
419,"Baclofen","DB00181","The CNS depressants, Triprolidine and Baclofen, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Benzatropine","DB00245","Triprolidine and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Benzphetamine","DB00865","Triprolidine may reduce the sedative effect of the antihistamine, Benzphetamine."
419,"Biperiden","DB00810","Triprolidine and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Bromazepam","DB01558","The CNS depressants, Triprolidine and Bromazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Bromodiphenhydramine","DB01237","Triprolidine and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Brompheniramine","DB00835","Triprolidine and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Buprenorphine","DB00921","The CNS depressants, Triprolidine and Buprenorphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Bupropion","DB01156","The CNS depressants, Triprolidine and Bupropion, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Butabarbital","DB00237","The CNS depressants, Triprolidine and Butabarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Butalbital","DB00241","The CNS depressants, Triprolidine and Butalbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Butorphanol","DB00611","The CNS depressants, Triprolidine and Butorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Carbamazepine","DB00564","The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Carbinoxamine","DB00748","Triprolidine and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Carisoprodol","DB00395","The CNS depressants, Triprolidine and Carisoprodol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Chloral hydrate","DB01563","The CNS depressants, Triprolidine and Chloral hydrate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Chlordiazepoxide","DB00475","The CNS depressants, Triprolidine and Chlordiazepoxide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Chlorphenamine","DB01114","Triprolidine and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Chlorphenesin","DB00856","The CNS depressants, Triprolidine and Chlorphenesin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Chlorpromazine","DB00477","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Chlorpromazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Chlorzoxazone","DB00356","The CNS depressants, Triprolidine and Chlorzoxazone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Citalopram","DB00215","The CNS depressants, Triprolidine and Citalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Clemastine","DB00283","Concomitant therapy with triprolidine and clemastine, two anticholinergics and CNS depressants, may result in additive  adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy. "
419,"Clidinium","DB00771","Triprolidine and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Clobazam","DB00349","The CNS depressants, Triprolidine and Clobazam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Clomipramine","DB01242","Triprolidine and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Clonazepam","DB01068","The CNS depressants, Triprolidine and Clonazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Clorazepate","DB00628","The CNS depressants, Triprolidine and Clorazepate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Clozapine","DB00363","Triprolidine and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Codeine","DB00318","The CNS depressants, Triprolidine and Codeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Cyclizine","DB01176","Triprolidine and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Cyclobenzaprine","DB00924","Triprolidine and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Cyclopentolate","DB00979","Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Cyproheptadine","DB00434","Triprolidine and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Dantrolene","DB01219","The CNS depressants, Triprolidine and Dantrolene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Darifenacin","DB00496","Triprolidine and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Desipramine","DB01151","Triprolidine and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Desloratadine","DB00967","Triprolidine and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Dexbrompheniramine","DB00405","Triprolidine and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Dextroamphetamine","DB01576","Triprolidine may reduce the sedative effect of the antihistamine, Dextroamphetamine."
419,"Dextropropoxyphene","DB00647","The CNS depressants, Triprolidine and Propoxyphene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Dezocine","DB01209","The CNS depressants, Triprolidine and Dezocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Diazepam","DB00829","The CNS depressants, Triprolidine and Diazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Dicyclomine","DB00804","Triprolidine and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Dihydrocodeine","DB01551","The CNS depressants, Triprolidine and Dihydrocodeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Dimenhydrinate","DB00985","Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Diphenhydramine","DB01075","Triprolidine and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Donepezil","DB00843","Possible antagonism of action"
419,"Doxepin","DB01142","Triprolidine and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Doxylamine","DB00366","Triprolidine and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Droperidol","DB00450","Triprolidine and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Duloxetine","DB00476","The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Entacapone","DB00494","The CNS depressants, Triprolidine and Entacapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Escitalopram","DB01175","The CNS depressants, Triprolidine and Escitalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Estazolam","DB01215","The CNS depressants, Triprolidine and Estazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Eszopiclone","DB00402","The CNS depressants, Triprolidine and Eszopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Ethanol","DB00898","Triprolidine may enhance the CNS depressant effects of Ethanol."
419,"Ethosuximide","DB00593","The CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Ethotoin","DB00754","The CNS depressants, Triprolidine and Ethotoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Felbamate","DB00949","The CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Fentanyl","DB00813","The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Fexofenadine","DB00950","Triprolidine and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Flavoxate","DB01148","Triprolidine and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Flunarizine","DB04841","The CNS depressants, Triprolidine and Flunarizine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Fluoxetine","DB00472","The CNS depressants, Triprolidine and Fluoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Flupentixol","DB00875","Triprolidine and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Fluphenazine","DB00623","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Fluphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Flurazepam","DB00690","The CNS depressants, Triprolidine and Flurazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Fluvoxamine","DB00176","The CNS depressants, Triprolidine and Fluvoxamine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Fosphenytoin","DB01320","The CNS depressants, Triprolidine and Fosphenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Gabapentin","DB00996","The CNS depressants, Triprolidine and Gabapentin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Galantamine","DB00674","Possible antagonism of action"
419,"Glutethimide","DB01437","The CNS depressants, Triprolidine and Glutethimide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Glycopyrrolate","DB00986","Triprolidine and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Haloperidol","DB00502","Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Homatropine Methylbromide","DB00725","Triprolidine and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Hydrocodone","DB00956","The CNS depressants, Triprolidine and Hydrocodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Hydromorphone","DB00327","The CNS depressants, Triprolidine and Hydromorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Hydroxyzine","DB00557","Triprolidine and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Hyoscyamine","DB00424","Triprolidine and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Imipramine","DB00458","Triprolidine and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Ipratropium bromide","DB00332","Triprolidine and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Isocarboxazid","DB01247","Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Ketotifen","DB00920","Triprolidine and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Lamotrigine","DB00555","The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Levetiracetam","DB01202","The CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Levorphanol","DB00854","The CNS depressants, Triprolidine and Levorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Lisdexamfetamine","DB01255","Triprolidine may reduce the sedative effect of the antihistamine, Lisdexamfetamine."
419,"Loratadine","DB00455","Triprolidine and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Lorazepam","DB00186","The CNS depressants, Triprolidine and Lorazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Loxapine","DB00408","Triprolidine and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Magnesium Sulfate","DB00653","The CNS depressants, Triprolidine and Magnesium sulfate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Maprotiline","DB00934","Triprolidine and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Meclizine","DB00737","Triprolidine and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Mepenzolate","DB04843","Triprolidine and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Mesoridazine","DB00933","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Mesoridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Metaxalone","DB00660","The CNS depressants, Triprolidine and Metaxalone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Methadone","DB00333","The CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Methamphetamine","DB01577","Triprolidine may reduce the sedative effect of the antihistamine, Methamphetamine."
419,"Methantheline","DB00940","Triprolidine and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Methocarbamol","DB00423","The CNS depressants, Triprolidine and Methocarbamol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Methohexital","DB00474","The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Methsuximide","DB05246","The CNS depressants, Triprolidine and Methsuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Methylscopolamine bromide","DB00462","Triprolidine and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Midazolam","DB00683","The CNS depressants, Triprolidine and Midazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Mirtazapine","DB00370","The CNS depressants, Triprolidine and Mirtazapine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Moclobemide","DB01171","Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Molindone","DB01618","Triprolidine and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Morphine","DB00295","The CNS depressants, Triprolidine and Morphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Nabilone","DB00486","The CNS depressants, Triprolidine and Nabilone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Nalbuphine","DB00844","The CNS depressants, Triprolidine and Nalbuphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Nefazodone","DB01149","The CNS depressants, Triprolidine and Nefazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Nortriptyline","DB00540","Triprolidine and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Olanzapine","DB00334","Triprolidine and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Orphenadrine","DB01173","Triprolidine and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Oxazepam","DB00842","The CNS depressants, Triprolidine and Oxazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Oxybutynin","DB01062","Triprolidine and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Oxycodone","DB00497","The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Oxymorphone","DB01192","The CNS depressants, Triprolidine and Oxymorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Paliperidone","DB01267","The CNS depressants, Triprolidine and Paliperidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Paroxetine","DB00715","The CNS depressants, Triprolidine and Paroxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Pentazocine","DB00652","The CNS depressants, Triprolidine and Pentazocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Pentobarbital","DB00312","The CNS depressants, Triprolidine and Pentobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Perphenazine","DB00850","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Pethidine","DB00454","The CNS depressants, Triprolidine and Meperidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Phendimetrazine","DB01579","Triprolidine may reduce the sedative effect of the antihistamine, Phendimetrazine."
419,"Phenelzine","DB00780","Triprolidine and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Phenindamine","DB01619","Triprolidine and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Phenobarbital","DB01174","The CNS depressants, Triprolidine and Phenobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Phentermine","DB00191","Triprolidine may reduce the sedative effect of the antihistamine, Phentermine."
419,"Phenytoin","DB00252","The CNS depressants, Triprolidine and Phenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Pimozide","DB01100","Triprolidine and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Pipotiazine","DB01621","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Pipotiazine. Monitor for symptoms of ventricular arrhythmias."
419,"Pizotifen","DB06153","Concomitant therapy with triprolidine and pizotifen, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."
419,"Pramipexole","DB00413","The CNS depressants, Triprolidine and Pramipexole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Pramlintide","DB01278","The anticholinergic effects of Triprolidine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
419,"Prazepam","DB01588","The CNS depressants, Triprolidine and Prazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Pregabalin","DB00230","The CNS depressants, Triprolidine and Pregabalin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Primidone","DB00794","The CNS depressants, Triprolidine and Primidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Prochlorperazine","DB00433","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Prochlorperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Procyclidine","DB00387","Triprolidine and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Promethazine","DB01069","Triprolidine and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Propantheline","DB00782","Triprolidine and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Protriptyline","DB00344","Triprolidine and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Quazepam","DB01589","The CNS depressants, Triprolidine and Quazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Quetiapine","DB01224","Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Ramelteon","DB00980","The CNS depressants, Triprolidine and Ramelteon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Remifentanil","DB00899","The CNS depressants, Triprolidine and Remifentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Reserpine","DB00206","The CNS depressants, Triprolidine and Reserpine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Risperidone","DB00734","Triprolidine and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Rotigotine","DB05271","The CNS depressants, Triprolidine and Rotigotine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Scopolamine","DB00747","Triprolidine and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Secobarbital","DB00418","The CNS depressants, Triprolidine and Secobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Sertraline","DB01104","The CNS depressants, Triprolidine and Sertraline, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Solifenacin","DB01591","Triprolidine and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Sufentanil","DB00708","The CNS depressants, Triprolidine and Sufentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Triprolidine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
419,"Temazepam","DB00231","The CNS depressants, Triprolidine and Temazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tetrabenazine","DB04844","The CNS depressants, Triprolidine and Tetrabenazine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Thalidomide","DB01041","The CNS depressants, Triprolidine and Thalidomide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Thiopental","DB00599","The CNS depressants, Triprolidine and Thiopental, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Thioridazine","DB00679","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Thiothixene","DB01623","Triprolidine and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Tiagabine","DB00906","The CNS depressants, Triprolidine and Tiagabine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tiotropium","DB01409","Triprolidine and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Tizanidine","DB00697","The CNS depressants, Triprolidine and Tizanidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tolcapone","DB00323","The CNS depressants, Triprolidine and Tolcapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tolterodine","DB01036","Triprolidine and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Topiramate","DB00273","The CNS depressants, Triprolidine and Topiramate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tramadol","DB00193","The CNS depressants, Triprolidine and Tramadol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Tranylcypromine","DB00752","Concomitant therapy with triprolidine and tranylcypromine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."
419,"Trazodone","DB00656","The CNS depressants, Triprolidine and Trazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Triazolam","DB00897","The CNS depressants, Triprolidine and Triazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Trifluoperazine","DB00831","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Trihexyphenidyl","DB00376","Triprolidine and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Trimethadione","DB00347","The CNS depressants, Triprolidine and Trimethadione, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Trimethobenzamide","DB00662","Concomitant therapy with Triprolidine and Trimethobenzamide, two anticholinergics, may result in additive anticholinergic effects. Monitor for enhanced anticholinergic effects."
419,"Trimipramine","DB00726","Triprolidine and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
419,"Trospium","DB00209","Trospium and Triprolidine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
419,"Venlafaxine","DB00285","The CNS depressants, Triprolidine and Venlafaxine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Vigabatrin","DB01080","The CNS depressants, Triprolidine and Vigabatrin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Zaleplon","DB00962","The CNS depressants, Triprolidine and Zaleplon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Ziconotide","DB06283","The CNS depressants, Triprolidine and Ziconotide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Ziprasidone","DB00246","The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Zolpidem","DB00425","The CNS depressants, Triprolidine and Zolpidem, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Zonisamide","DB00909","The CNS depressants, Triprolidine and Zonisamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Zopiclone","DB01198","The CNS depressants, Triprolidine and Zopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
419,"Zuclopenthixol","DB01624","Triprolidine and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
420,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
420,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
421,"Oxytocin","DB00107","Avoid combination due to enhanced oxytocic effects. "
425,"Amphetamine","DB00182","Decreased anorexic effect, may increase pyschotic symptoms"
425,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
425,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
425,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
425,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms."
425,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase pyschotic symptoms"
425,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms."
425,"Donepezil","DB00843","Possible antagonism of action"
425,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms."
425,"Galantamine","DB00674","Possible antagonism of action"
425,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
425,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
425,"Guanethidine","DB01170","Prochlorperazine may decrease the effect of guanethidine."
425,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
425,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms."
425,"Methamphetamine","DB01577","Decreased anorexic effect, may increase pyschotic symptoms"
425,"Metrizamide","DB01578","Increased risk of convulsions"
425,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase pyschotic symptoms"
425,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase pyschotic symptoms"
425,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms."
425,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms."
425,"Rivastigmine","DB00989","Possible antagonism of action"
425,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
425,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Prochlorperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
425,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
425,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
425,"Trimethobenzamide","DB00662","Trimethobenzamide and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
425,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Prochlorperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
425,"Trospium","DB00209","Trospium and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
426,"Donepezil","DB00843","Possible antagonism of action"
426,"Fluoxetine","DB00472","Possible antagonism of action"
426,"Galantamine","DB00674","Possible antagonism of action"
426,"Metyrapone","DB01011","This combination renders test invalid"
426,"Rivastigmine","DB00989","Possible antagonism of action"
426,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyproheptadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
426,"Triprolidine","DB00427","Triprolidine and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
426,"Trospium","DB00209","Trospium and Cyproheptadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
428,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
428,"Diazoxide","DB01119","Significant hyperglycemic effect"
428,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
428,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
428,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
428,"Lithium","DB01356","The thiazide diuretic, bendroflumethiazide, may increase serum levels of lithium."
428,"Trandolapril","DB00519","The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
428,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
429,"Acenocoumarol","DB01418","Allopurinol may increase the anticoagulant effect of acenocoumarol."
429,"Anisindione","DB01125","Allopurinol may increase the anticoagulant effect of anisindione."
429,"Azathioprine","DB00993","Allopurinol may increase the effect of thiopurine, azathioprine."
429,"Cyclosporine","DB00091","Allopurinol increases the effect and toxicity of cyclosporine"
429,"Dicoumarol","DB00266","Allopurinol may increase the anticoagulant effect of dicumarol."
429,"Mercaptopurine","DB01033","Allopurinol may increase the effect of thiopurine, mercaptopurine."
429,"Trandolapril","DB00519","The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol. "
429,"Warfarin","DB00682","Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed."
430,"Amikacin","DB00479","Increased risk of nephrotoxicity"
430,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
430,"Kanamycin","DB01172","Increased risk of nephrotoxicity"
430,"Neomycin","DB00994","Increased risk of nephrotoxicity"
430,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
430,"Streptomycin","DB01082","Increased risk of nephrotoxicity"
430,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
431,"Bezafibrate","DB01393","Increased risk of myopathy/rhabdomyolysis"
431,"Bosentan","DB00559","Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed."
431,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin."
431,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
431,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
431,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of cerivastatin. Cerivastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
431,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the toxicity of the statin, cerivastatin."
431,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
431,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
431,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed."
431,"Itraconazole","DB01167","Increased risk of myopathy/rhabdomyolysis"
431,"Josamycin","DB01321","The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin."
431,"Ketoconazole","DB01026","Increased risk of myopathy/rhabdomyolysis"
431,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed."
431,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
431,"Rifabutin","DB00615","Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed."
431,"Rifampicin","DB01045","Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed."
432,"Capecitabine","DB01101","The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed."
432,"Dapsone","DB00250","Increased toxicity of both products"
432,"Delavirdine","DB00705","The strong CYP2C9 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Delavirdine is initiated, discontinued or dose changed."
432,"Dofetilide","DB00204","Trimethoprim may significantly reduced the clearance of Dofetilide. Trimethoprim is a cation transport inhibitor and may interfere with renal excretion of Dofetilide. Concomitant use is contraindicated."
432,"Floxuridine","DB00322","The strong CYP2C9 inhibitor, Floxuridine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Floxuridine is initiated, discontinued or dose changed."
432,"Fluconazole","DB00196","The strong CYP2C9 inhibitor, Fluconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluconazole is initiated, discontinued or dose changed."
432,"Fluorouracil","DB00544","The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed."
432,"Flurbiprofen","DB00712","The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed."
432,"Fosphenytoin","DB01320","Trimethoprim increases the effect of hydantoin"
432,"Gemfibrozil","DB01241","The strong CYP2C9 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed."
432,"Ibuprofen","DB01050","The strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed."
432,"Indomethacin","DB00328","The strong CYP2C9 inhibitor, Indomethacine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Indomethacine is initiated, discontinued or dose changed."
432,"Ketoconazole","DB01026","The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed."
432,"Leucovorin","DB00650","The efficacy of Trimethoprim may be reduced by Leucovorin (folinic acid). The antibiotic, Trimethoprim, acts by blocking bacterial folic acid metabolism. Leucovorin may reduce the efficacy of Trimethoprim by providing an alternate source of folic acid. The therapeutic effect of Trimethoprim should be closely monitored."
432,"Mefenamic acid","DB00784","The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed."
432,"Methotrexate","DB00563","Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity."
432,"Miconazole","DB01110","The strong CYP2C9 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Miconazole is initiated, discontinued or dose changed."
432,"Nicardipine","DB00622","The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed."
432,"Phenytoin","DB00252","Trimethoprim increases the effect of hydantoin"
432,"Piroxicam","DB00554","The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed."
432,"Procainamide","DB01035","Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide."
432,"Rifampicin","DB01045","Rifampin decreases the effect of trimethoprim"
432,"Sitaxentan","DB06268","The strong CYP2C9 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sitaxsentan is initiated, discontinued or dose changed."
432,"Sulfadiazine","DB00359","The strong CYP2C9 inhibitor, Sulfadiazine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfadiazine is initiated, discontinued or dose changed."
432,"Sulfisoxazole","DB00263","The strong CYP2C9 inhibitor, Sulfisoxazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sulfisoxazole is initiated, discontinued or dose changed."
432,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
432,"Tolbutamide","DB01124","The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed."
432,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels. "
432,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed."
433,"Acenocoumarol","DB01418","Gemcitabine may increase the anticoagulant effect of acenocoumarol."
433,"Anisindione","DB01125","Gemcitabine may increase the anticoagulant effect of anisindione."
433,"Bivalirudin","DB00006","Gemcitabine may enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased. Use extreme caution if using gemcitabine and bleomycin in combination. Monitor for the development of pulmonary toxicity. "
433,"Dicoumarol","DB00266","Gemcitabine may increase the anticoagulant effect of dicumarol."
433,"Paclitaxel","DB01229","Paclitaxel increases the effect/toxicity of gemcitabine"
433,"Temsirolimus","DB06287","Co-administration of Temsirolimus and Gemcitabine may result in serious adverse drug reactions. "
433,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
433,"Warfarin","DB00682","Gemcitabine may increase the anticoagulant effect of warfarin."
435,"Acenocoumarol","DB01418","The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol."
435,"Acetylsalicylic acid","DB00945","The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
435,"Ambenonium","DB01122","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium."
435,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Anisindione","DB01125","The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione."
435,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Bismuth Subsalicylate","DB01294","The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate."
435,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone."
435,"Dicoumarol","DB00266","The corticosteroid, betamethasone, alters the anticoagulant effect of dicumarol."
435,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."
435,"Edrophonium","DB01010","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium."
435,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone."
435,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone."
435,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
435,"Magnesium salicylate","DB01397","The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate. "
435,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone."
435,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone."
435,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Midodrine","DB00211","Increased arterial pressure"
435,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, betamethasone."
435,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone."
435,"Pyridostigmine","DB00545","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
435,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."
435,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone."
435,"Salicylate-sodium","DB01398","The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium."
435,"Salsalate","DB01399","The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate."
435,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, betamethasone."
435,"Tacrine","DB00382","Tacrine and Betamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects. "
435,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, betamethasone."
435,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
435,"Trisalicylate-choline","DB01401","The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline."
435,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
435,"Warfarin","DB00682","The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin."
436,"Amprenavir","DB00701","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Amprenavir is initiated, discontinued or dose changed."
436,"Atazanavir","DB01072","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed."
436,"Butabarbital","DB00237","Barbiturates like butabarbital may decrease the serum concentration of Teniposide. arbiturates may decrease the serum concentration of Teniposide. "
436,"Butalbital","DB00241","Barbiturates such as butalbital may decrease the serum concentration of teniposide. Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations. If the combination cannot be avoided, monitor teniposide response closely. "
436,"Clarithromycin","DB01211","The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Clarithromycin is initiated, discontinued or dose changed."
436,"Conivaptan","DB00872","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Conivaptan is initiated, discontinued or dose changed."
436,"Darunavir","DB01264","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Darunavir is initiated, discontinued or dose changed."
436,"Delavirdine","DB00705","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Delavirdine is initiated, discontinued or dose changed."
436,"Fosamprenavir","DB01319","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Fosamprenavir is initiated, discontinued or dose changed."
436,"Imatinib","DB00619","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Imatinib is initiated, discontinued or dose changed."
436,"Indinavir","DB00224","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Indinavir is initiated, discontinued or dose changed."
436,"Isoniazid","DB00951","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed."
436,"Itraconazole","DB01167","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed."
436,"Ketoconazole","DB01026","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed."
436,"Lopinavir","DB01601","The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Lopinavir is initiated, discontinued or dose changed."
436,"Miconazole","DB01110","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Miconazole is initiated, discontinued or dose changed."
436,"Natalizumab","DB00108","The immunosuppressant, Teniposide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
436,"Nefazodone","DB01149","The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nefazodone is initiated, discontinued or dose changed."
436,"Nelfinavir","DB00220","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nelfinavir is initiated, discontinued or dose changed."
436,"Nicardipine","DB00622","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed."
436,"Posaconazole","DB01263","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Posaconazole is initiated, discontinued or dose changed."
436,"Quinidine","DB00908","The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed."
436,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
436,"Ritonavir","DB00503","The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed."
436,"Saquinavir","DB01232","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed."
436,"Telithromycin","DB00976","The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed."
436,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
436,"Voriconazole","DB00582","The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed."
437,"Cimetidine","DB00501","Cimetidine can increase epirubicin levels"
437,"Trastuzumab","DB00072","Trastuzumab may increase the cardiotoxicity of Epirubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
438,"Acetohexamide","DB00414","Chloramphenicol may increase the effect of sulfonylurea, acetohexamide."
438,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased. "
438,"Chlorpropamide","DB00672","Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide."
438,"Cyclosporine","DB00091","Chloramphenicol may increase the effect of cyclosporine."
438,"Ethotoin","DB00754","Increases phenytoin, modifies chloramphenicol"
438,"Fosphenytoin","DB01320","Increases phenytoin, modifies chloramphenicol"
438,"Gliclazide","DB01120","Chloramphenicol may increase the effect of sulfonylurea, gliclazide."
438,"Glipizide","DB01067","Chloramphenicol may increase the effect of sulfonylurea, glipizide."
438,"Glisoxepide","DB01289","Chloramphenicol may increase the effect of sulfonylurea, glisoxepide."
438,"Glyburide","DB01016","Chloramphenicol may increase the effect of sulfonylurea, glibenclamide."
438,"Glycodiazine","DB01382","Chloramphenicol may increase the effect of sulfonylurea, glycodiazine."
438,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
438,"Mephenytoin","DB00532","Increases phenytoin, modifies chloramphenicol"
438,"Phenytoin","DB00252","Increases phenytoin, modifies chloramphenicol"
438,"Rifampicin","DB01045","Rifampin decreases the effect of chloramphenicol"
438,"Silodosin","DB06207","Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. "
438,"Tacrolimus","DB00864","Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered."
438,"Thiopental","DB00599","Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted. "
438,"Tolazamide","DB00839","Chloramphenicol may increase the effect of sulfonylurea, tolazamide."
438,"Tolbutamide","DB01124","Chloramphenicol may increase the effect of sulfonylurea, tolbutamide."
439,"Probenecid","DB01032","Probenecid may increase the serum level of loracarbef."
440,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
440,"Bosutinib","DB06616","Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours. "
440,"Cefditoren","DB01066","Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
440,"Clopidogrel","DB00758","Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. "
440,"Enoxacin","DB00467","Lansoprazole may decrease the absorption of enoxacin."
440,"Indinavir","DB00224","Omeprazole decreases the absorption of indinavir"
440,"Itraconazole","DB01167","The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole."
440,"Ketoconazole","DB01026","The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole."
440,"Prasugrel","DB06209","Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation. "
440,"Rilpivirine","DB08864","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
440,"Sucralfate","DB00364","Sucralfate decreases the effect of lansoprazole"
441,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
441,"Venlafaxine","DB00285","Venlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
442,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
442,"Brimonidine","DB00484","Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification."
442,"Buprenorphine","DB00921","Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. "
442,"Butabarbital","DB00237","Droperidol may enhance the CNS depressant effect of CNS Depressants like butabarbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. "
442,"Butalbital","DB00241","Droperidol may enhance the CNS depressant effect of CNS depressants such as butalbital. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.\
"
442,"Butorphanol","DB00611","Droperidol may enhance the CNS depressant effect of butorphanol. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.\
"
442,"Carisoprodol","DB00395","Droperidol may enhance the CNS depressant effect of carisoprodol. Consider dose reductions of droperidol or of other CNS agents with concomitant use. "
442,"Dihydrocodeine","DB01551","Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable.  "
442,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
442,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
442,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Droperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
442,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
442,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
442,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
442,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
442,"Trimethobenzamide","DB00662","Trimethobenzamide and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
442,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
442,"Triprolidine","DB00427","Triprolidine and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
442,"Trospium","DB00209","Trospium and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
442,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
442,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
442,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
442,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
443,"Acenocoumarol","DB01418","The thyroid hormone, levothyroxine, increase the anticoagulant effect of acenocoumarol."
443,"Anisindione","DB01125","The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione."
443,"Calcium","DB01373","Calcium decreases absorption of levothyroxine"
443,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
443,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
443,"Cholestyramine","DB01432","The resin, cholestyramine, decreases the absorption of the thyroid hormone, levothyroxine."
443,"Colestipol","DB00375","The resin, colestipol, decreases the absorption of the thyroid hormone, levothyroxine."
443,"Dicoumarol","DB00266","The thyroid hormone, levothyroxine, increase the anticoagulant effect of dicumarol."
443,"Digoxin","DB00390","The thyroid hormone, levothyroxine, decreases the effect of digoxin."
443,"Iron","DB01592","Iron decreases absorption of levothyroxine"
443,"Iron Dextran","DB00893","Iron decreases the absorption of levothyroxine"
443,"Raloxifene","DB00481","Raloxifene decreases absorption of levothyroxine"
443,"Sucralfate","DB00364","Sucralfate decreases the effect of levothyroxine"
443,"Warfarin","DB00682","Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed."
446,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
446,"Chlorpromazine","DB00477","Increased sedation and hypotension"
446,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
446,"Donepezil","DB00843","Possible antagonism of action"
446,"Eltrombopag","DB06210","Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
446,"Galantamine","DB00674","Possible antagonism of action"
446,"Isocarboxazid","DB01247","Potentially fatal adverse effects"
446,"Isoniazid","DB00951","Possible episodes of hypotension"
446,"Moclobemide","DB01171","Increased CNS toxicity (can cause death)"
446,"Phenelzine","DB00780","Potentially fatal adverse effects"
446,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Concomitant use should be avoided."
446,"Ritonavir","DB00503","Ritonavir increases the levels of analgesic"
446,"Rivastigmine","DB00989","Possible antagonism of action"
446,"Selegiline","DB01037","Potentially fatal adverse effects"
446,"Sibutramine","DB01105","Possible serotoninergic syndrome"
446,"Tipranavir","DB00932","Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use. "
446,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
446,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant use should be avoided."
446,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
446,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
446,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Meperidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
446,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
446,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
447,"Nefazodone","DB01149","Increased risk of cardiotoxicity"
447,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Loratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
447,"Trimethobenzamide","DB00662","Trimethobenzamide and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
447,"Triprolidine","DB00427","Triprolidine and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
447,"Trospium","DB00209","Trospium and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
448,"Amikacin","DB00479","Increased risk of nephrotoxicity"
449,"Acebutolol","DB01193","Risk of hypotension at the beginning of therapy"
449,"Atenolol","DB00335","Risk of hypotension at the beginning of therapy"
449,"Betaxolol","DB00195","Beta-Blockers such as betaxolol may enhance the orthostatic hypotensive effect of Alpha1-Blockers such as prazosin. The risk associated with ophthalmic products is probably less than systemic products. Exercise caution if an alpha1-blocker is added to existing beta-blocker therapy. Monitor for hypotension during first few days of concomitant therapy. A priori reduction in alpha1-blocker (especially systemic) dose may be warranted. Administering the first dose of systemic agents at bedtime may help minimize risk of severe hypotension. The risk associated with the use of ophthalmic products in either interacting group is probably less than that associated with systemic agents. If the alpha1-blocker is being used to treat BPH, consider using tamsulosin since its alpha1-A selectivity is least likely to cause hypotension."
449,"Bevantolol","DB01295","Risk of hypotension at the beginning of therapy"
449,"Bisoprolol","DB00612","Risk of hypotension at the beginning of therapy"
449,"Carteolol","DB00521","Risk of hypotension at the beginning of therapy"
449,"Carvedilol","DB01136","Risk of hypotension at the beginning of therapy"
449,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
449,"Digoxin","DB00390","Prazosin increases the effect of digoxin"
449,"Esmolol","DB00187","Risk of hypotension at the beginning of therapy"
449,"Labetalol","DB00598","Risk of hypotension at the beginning of therapy"
449,"Metoprolol","DB00264","Risk of hypotension at the beginning of therapy"
449,"Nadolol","DB01203","Risk of hypotension at the beginning of therapy"
449,"Oxprenolol","DB01580","Risk of hypotension at the beginning of therapy"
449,"Penbutolol","DB01359","Risk of hypotension at the beginning of therapy"
449,"Pindolol","DB00960","Risk of hypotension at the beginning of therapy"
449,"Practolol","DB01297","Risk of hypotension at the beginning of therapy"
449,"Propranolol","DB00571","Risk of hypotension at the beginning of therapy"
449,"Sotalol","DB00489","Risk of hypotension at the beginning of therapy"
449,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy."
449,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
449,"Timolol","DB00373","Risk of hypotension at the beginning of therapy"
449,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
449,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy. "
449,"Verapamil","DB00661","Risk of hypotension at the beginning of therapy"
450,"Altretamine","DB00488","Risk of severe hypotension"
450,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
450,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed."
450,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
450,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as imipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
450,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed."
450,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if cimetidine is initiated, discontinued or dose changed."
450,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
450,"Clonidine","DB00575","The tricyclic antidepressant, imipramine, decreases the effect of clonidine."
450,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
450,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine."
450,"Dobutamine","DB00841","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine."
450,"Donepezil","DB00843","Possible antagonism of action"
450,"Dopamine","DB00988","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dopamine."
450,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
450,"Ephedra","DB01363","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedra."
450,"Ephedrine","DB01364","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedrine."
450,"Epinephrine","DB00668","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of epinephrine."
450,"Fenoterol","DB01288","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of fenoterol."
450,"Fluconazole","DB00196","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of imipramine if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
450,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed."
450,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluvoxamine is initiated, discontinued or dose changed."
450,"Galantamine","DB00674","Possible antagonism of action"
450,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
450,"Guanethidine","DB01170","The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine."
450,"Iobenguane","DB06704","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function"
450,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
450,"Isoprenaline","DB01064","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of isoproterenol."
450,"Ketoconazole","DB01026","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed."
450,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
450,"Mephentermine","DB01365","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of mephentermine."
450,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
450,"Metaraminol","DB00610","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol."
450,"Methoxamine","DB00723","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine."
450,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
450,"Norepinephrine","DB00368","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of norepinephrine."
450,"Orciprenaline","DB00816","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline."
450,"Phenelzine","DB00780","Possibility of severe adverse effects"
450,"Phenylephrine","DB00388","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylephrine."
450,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of phenylpropanolamine."
450,"Pirbuterol","DB01291","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pirbuterol."
450,"Procaterol","DB01366","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of procaterol."
450,"Pseudoephedrine","DB00852","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pseudoephedrine."
450,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
450,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine."
450,"Rasagiline","DB01367","Possibility of severe adverse effects"
450,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed."
450,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed."
450,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed."
450,"Rivastigmine","DB00989","Possible antagonism of action"
450,"Salbutamol","DB01001","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of salbutamol."
450,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
450,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
450,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Imipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
450,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
450,"Tamoxifen","DB00675","Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
450,"Tamsulosin","DB00706","Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed."
450,"Terbinafine","DB00857","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if terbinafine is initiated, discontinued or dose changed."
450,"Terbutaline","DB00871","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of terbutaline."
450,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
450,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
450,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
450,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Imipramine. Consider alternate therapy or monitor for adverse/toxic effects of Imipramine if Ticlopidine is initiated, discontinued or dose changed."
450,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
450,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. Imipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
450,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
450,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
450,"Trimethobenzamide","DB00662","Trimethobenzamide and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
450,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
450,"Triprolidine","DB00427","Triprolidine and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
450,"Trospium","DB00209","Trospium and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
450,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
450,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
450,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
450,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
450,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
450,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
451,"Demeclocycline","DB00618","Increased risk of intracranial hypertension"
451,"Doxycycline","DB00254","Increased risk of intracranial hypertension"
451,"Methacycline","DB00931","Increased risk of intracranial hypertension"
451,"Methotrexate","DB00563","Acitretin/etretinate increases the effect and toxicity of methotrexate"
451,"Minocycline","DB01017","Increased risk of intracranial hypertension."
451,"Norethindrone","DB00717","Acitretine may cause a loss of contraceptive effect"
451,"Oxytetracycline","DB00595","Increased risk of intracranial hypertension"
451,"Rolitetracycline","DB01301","Increased risk of intracranial hypertension"
451,"Tetracycline","DB00759","Increased risk of intracranial hypertension"
451,"Vitamin A","DB00162","Acitretin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking acitretin. "
453,"Acenocoumarol","DB01418","The NSAID, nabumetone, may increase the anticoagulant effect of acenocoumarol."
453,"Alendronate","DB00630","Increased risk of gastric toxicity"
453,"Anisindione","DB01125","The NSAID, nabumetone, may increase the anticoagulant effect anisindione."
453,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
453,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
453,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
453,"Dicoumarol","DB00266","The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol."
453,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
453,"Methotrexate","DB00563","The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
453,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
453,"Telmisartan","DB00966","Concomitant use of Telmisartan and Nabumetone may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
453,"Timolol","DB00373","The NSAID, Nabumetone, may antagonize the antihypertensive effect of Timolol."
453,"Trandolapril","DB00519","The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed. "
453,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy. "
453,"Warfarin","DB00682","The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
454,"Cinitapride","DB08810","Anticholinergic agents like methylscopolamine may reduce the action of cinitapride. "
454,"Donepezil","DB00843","Possible antagonism of action"
454,"Galantamine","DB00674","Possible antagonism of action"
454,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methylscopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
454,"Trimethobenzamide","DB00662","Trimethobenzamide and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
454,"Triprolidine","DB00427","Triprolidine and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
454,"Trospium","DB00209","Trospium and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
457,"Acenocoumarol","DB01418","The NSAID, ketorolac, may increase the anticoagulant effect of acenocoumarol."
457,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid may increase the adverse GI effects ketorolac."
457,"Alendronate","DB00630","Increased risk of gasrtic toxicity"
457,"Anisindione","DB01125","The NSAID, ketorolac, may increase the anticoagulant effect of anisindione."
457,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
457,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
457,"Dicoumarol","DB00266","The NSAID, ketorolac, may increase the anticoagulant effect of dicumarol."
457,"Difluprednate","DB06781","NSAIDs may slow healing. "
457,"Eltrombopag","DB06210","Increases levels of Ketorolac via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
457,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
457,"Ketoprofen","DB01009","Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).  "
457,"Lithium","DB01356","The NSAID, ketorolac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
457,"Methotrexate","DB00563","The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
457,"Probenecid","DB01032","Probenecid increases toxicity of ketorolac"
457,"Sulindac","DB00605","May cause additive or synergistic NSAID toxicities (e.g. GI bleeding, renal dysfunction, etc.). Concomitant therapy is contraindicated. "
457,"Telmisartan","DB00966","Concomitant use of Telmisartan and Ketorolac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
457,"Tiaprofenic acid","DB01600","Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity."
457,"Timolol","DB00373","The NSAID, Ketorolac, may antagonize the antihypertensive effect of Timolol."
457,"Tolmetin","DB00500","Risk of adverse NSAID toxic effects (e.g. GI bleeding, renal dysfunction). Concomitant therapy is contraindicated."
457,"Trandolapril","DB00519","The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.  "
457,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketorolac. Monitor for increased bleeding during concomitant thearpy. "
457,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of vilazodone and ketorolac"
457,"Warfarin","DB00682","The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
459,"Aminophylline","DB01223","Enoxacin may increase the effect of aminophylline."
459,"Calcium","DB01373","Formation of non-absorbable complexes"
459,"Cimetidine","DB00501","Cimetidine may decrease the absorption of enoxacin."
459,"Eltrombopag","DB06210","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
459,"Esomeprazole","DB00736","Esomeprazole may decrease the absorption of enoxacin."
459,"Famotidine","DB00927","Famotidine may decrease the absorption of enoxacin."
459,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
459,"Lansoprazole","DB00448","Lansoprazole may decrease the absorption of enoxacin."
459,"Magnesium","DB01378","Formation of non-absorbable complexes"
459,"Nizatidine","DB00585","Nizatidine may decrease the absorption of enoxacin."
459,"Omeprazole","DB00338","Omeprazole may decrease the absorption of enoxacin."
459,"Oxtriphylline","DB01303","Enoxacin may increase the effect of oxtriphylline."
459,"Pantoprazole","DB00213","Pantoprazole may decrease the absorption of enoxacin."
459,"Rabeprazole","DB01129","Rabeprazole may decrease the absorption of enoxacin."
459,"Ramelteon","DB00980","Enoxacin increases levels/toxicity of ramelteon"
459,"Theophylline","DB00277","Enoxacin may increase the effect of theophylline."
460,"Acenocoumarol","DB01418","Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of acenocoumarol by decreasing its metabolism via CYP2C9."
460,"Anisindione","DB01125","Quinine may increase the anticoagulant effect of anisindione."
460,"Artemether","DB06697","Quinine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
460,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
460,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
460,"Atracurium","DB00732","The quinine derivative increases the effect of the muscle relaxant"
460,"Dicoumarol","DB00266","Quinine may increase the anticoagulant effect of dicumarol."
460,"Digitoxin","DB01396","Quinine/quinidine increases the effect of digoxin"
460,"Digoxin","DB00390","Quinine/quinidine increases the effect of digoxin"
460,"Lumefantrine","DB06708","Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
460,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
460,"Metocurine","DB01336","The quinine derivative increases the effect of the muscle relaxant"
460,"Pancuronium","DB01337","The quinine derivative increases the effect of the muscle relaxant"
460,"Succinylcholine","DB00202","The quinine derivative increases the effect of the muscle relaxant"
460,"Tamoxifen","DB00675","Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
460,"Tamsulosin","DB00706","Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed."
460,"Telithromycin","DB00976","Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed."
460,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
460,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
460,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
460,"Toremifene","DB00539","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
460,"Tramadol","DB00193","Quinine may decrease the effect of Tramadol by decreasing active metabolite production. "
460,"Trandolapril","DB00519","May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed. "
460,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed."
460,"Vecuronium","DB01339","Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided."
460,"Voriconazole","DB00582","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
460,"Vorinostat","DB02546","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
460,"Warfarin","DB00682","Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9."
460,"Ziprasidone","DB00246","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
460,"Zuclopenthixol","DB01624","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided."
461,"Acenocoumarol","DB01418","The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol."
461,"Alendronate","DB00630","Increased risk of gastric toxicity"
461,"Anisindione","DB01125","The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione."
461,"Chlorthalidone","DB00310","Tenoxicam may antagonize the blood pressure lowering effect of Chlorthalidone. Monitor for changes in the therapeutic effect of Chlorthalidone if Tenoxicam is initiated, discontinued or dose changed. "
461,"Cholestyramine","DB01432","Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed. "
461,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
461,"Dicoumarol","DB00266","The NSAID, tenoxicam, may increase the anticoagulant effect of dicumarol."
461,"Hydrochlorothiazide","DB00999","Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed. "
461,"Lithium","DB01356","Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed."
461,"Methotrexate","DB00563","Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed."
461,"Metolazone","DB00524","Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed. "
461,"Warfarin","DB00682","The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin."
462,"Trimethobenzamide","DB00662","Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended."
462,"Trospium","DB00209","Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended."
463,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
464,"Acenocoumarol","DB01418","The SSRI, fluoxetine, increases the effect of anticoagulant, acenocoumarol."
464,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
464,"Amitriptyline","DB00321","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amitriptyline if fluoxetine is initiated, discontinued or dose changed."
464,"Amoxapine","DB00543","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed."
464,"Amphetamine","DB00182","Risk of serotoninergic syndrome"
464,"Anisindione","DB01125","The SSRI, fluoxetine, increases the effect of anticoagulant, anisindione."
464,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
464,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
464,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
464,"Benzphetamine","DB00865","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
464,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of fluoxetine by increasing its metabolism. Fluoxetine may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses are changed."
464,"Carvedilol","DB01136","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, carvedilol."
464,"Cilostazol","DB01166","Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed."
464,"Clarithromycin","DB01211","Possible serotoninergic syndrome with this combination"
464,"Clomipramine","DB01242","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluoxetine is initiated, discontinued or dose changed."
464,"Clozapine","DB00363","The antidepressant increases the effect of clozapine"
464,"Cyclosporine","DB00091","The antidepressant increases the effect and toxicity of cyclosporine"
464,"Cyproheptadine","DB00434","Possible antagonism of action"
464,"Desipramine","DB01151","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluoxetine is initiated, discontinued or dose changed."
464,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
464,"Dexfenfluramine","DB01191","Risk of serotoninergic syndrome"
464,"Dextroamphetamine","DB01576","Risk of serotoninergic syndrome"
464,"Dextromethorphan","DB00514","Combination associated with possible serotoninergic syndrome"
464,"Dicoumarol","DB00266","The SSRI, fluoxetine, increases the effect of anticoagulant, dicumarol."
464,"Diethylpropion","DB00937","Risk of serotoninergic syndrome"
464,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
464,"Doxepin","DB01142","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed."
464,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
464,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
464,"Erythromycin","DB00199","Possible serotoninergic syndrome with this combination"
464,"Ethotoin","DB00754","Fluoxetine increases the effect of phenytoin"
464,"Fenfluramine","DB00574","Risk of serotoninergic syndrome"
464,"Fosphenytoin","DB01320","Fluoxetine increases the effect of phenytoin"
464,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
464,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
464,"Iloperidone","DB04946","Fluoxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% "
464,"Imipramine","DB00458","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of imipramine if fluoxetine is initiated, discontinued or dose changed."
464,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
464,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
464,"Josamycin","DB01321","Possible serotoninergic syndrome with this combination"
464,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
464,"Linezolid","DB00601","Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided."
464,"Lithium","DB01356","The SSRI, fluoxetine, increases serum levels of lithium."
464,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
464,"Mazindol","DB00579","Risk of serotoninergic syndrome"
464,"Mephenytoin","DB00532","Fluoxetine increases the effect of phenytoin"
464,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
464,"Methamphetamine","DB01577","Risk of serotoninergic syndrome"
464,"Metoprolol","DB00264","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, metoprolol."
464,"Moclobemide","DB01171","Risk of serotoninergic syndrome"
464,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
464,"Nortriptyline","DB00540","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluoxetine is initiated, discontinued or dose changed."
464,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
464,"Phendimetrazine","DB01579","Risk of serotoninergic syndrome"
464,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
464,"Phentermine","DB00191","Risk of serotoninergic syndrome"
464,"Phenylpropanolamine","DB00397","Risk of serotoninergic syndrome"
464,"Phenytoin","DB00252","Fluoxetine increases the effect of phenytoin"
464,"Propafenone","DB01182","Additive QTc-prolongation may occur increasing the risk of serious life-threatening arrhythmias. Fluoxetine may also increase the serum concentration of propafenone. Use caution during concomitant therapy and monitor for QTc-prolongation."
464,"Propranolol","DB00571","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, propranolol."
464,"Protriptyline","DB00344","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of protriptyline if fluoxetine is initiated, discontinued or dose changed."
464,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
464,"Risperidone","DB00734","The SSRI, fluoxetine, increases the effect and toxicity of risperidone."
464,"Ritonavir","DB00503","Increased risk of serotonin syndrome"
464,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
464,"Selegiline","DB01037","Possible severe adverse reaction with this combination"
464,"Sibutramine","DB01105","Risk of serotoninergic syndrome"
464,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine."
464,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
464,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Fluoxetine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Fluoxetine is initiated, discontinued or if the dose is changed."
464,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
464,"Tamoxifen","DB00675","Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
464,"Tamsulosin","DB00706","Fluoxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluoxetine is initiated, discontinued, or dose changed."
464,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluoxetine if Terbinafine is initiated, discontinued or dose changed."
464,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
464,"Tetrabenazine","DB04844","Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. "
464,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
464,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
464,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
464,"Tipranavir","DB00932","Tipranavir increases the concentration of Fluoxetine. The Fluoxetine dose may require an adjustment."
464,"Tizanidine","DB00697","Fluoxetine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
464,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
464,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
464,"Tolterodine","DB01036","Fluoxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
464,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
464,"Tramadol","DB00193","The use of two serotonin modulators, such as fluoxetine and tramadol, may increase the risk of serotonin syndrome. Fluoxetine may decrease the effect of tramadol by decreasing active metabolite production."
464,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
464,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
464,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Fluoxetine. Monitor for increased bleeding during concomitant thearpy. "
464,"Trimipramine","DB00726","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used cautiously."
464,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Fluoxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
464,"Troleandomycin","DB01361","Possible serotoninergic syndrome with this combination"
464,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
464,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
464,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
464,"Warfarin","DB00682","The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin."
464,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
464,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
464,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed. "
466,"Aminophylline","DB01223","The barbiturate, methohexital, decreases the effect of aminophylline."
466,"Betamethasone","DB00443","The barbiturate, methohexital, may decrease the effect of the corticosteroid, betamethasone."
466,"Clomifene","DB00882","The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene."
466,"Conjugated Estrogens","DB00286","The enzyme inducer, methohexital, decreases the effect of the hormone agent, conjugated estrogens."
466,"Cyclosporine","DB00091","The barbiturate, methohexital, increases the effect of cyclosporine."
466,"Dexamethasone","DB01234","The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone."
466,"Diethylstilbestrol","DB00255","The enzyme inducer, methohexital, decreases the effect of the hormone agent, diethylstilbestrol."
466,"Doxycycline","DB00254","The anticonvulsant, methohexital, decreases the effect of doxycycline."
466,"Estradiol","DB00783","The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol."
466,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
466,"Felodipine","DB01023","The barbiturate, methohexital, decreases the effect of felodipine."
466,"Fludrocortisone","DB00687","The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone."
466,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, methohexital."
466,"Gefitinib","DB00317","The CYP3A4 inducer, methohexital, may decrease the serum concentration and therapeutic effects of gefitinib."
466,"Griseofulvin","DB00400","The barbiturate, methohexital, decreases the effect of griseofulvin."
466,"Hydrocortisone","DB00741","The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone."
466,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
466,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone."
466,"Megestrol acetate","DB00351","The enzyme inducer, methohexital, decreases the effect of the hormone agent, megestrol."
466,"Methadone","DB00333","The barbiturate, methohexital, decreases the effect of methadone."
466,"Metronidazole","DB00916","The barbiturate, methohexital, decreases the effect of metronidazole."
466,"Nifedipine","DB01115","The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine."
466,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
466,"Oxtriphylline","DB01303","The barbiturate, methohexital, decreases the effect of oxtriphylline."
466,"Prednisolone","DB00860","The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone."
466,"Prednisone","DB00635","The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone."
466,"Quinidine","DB00908","The anticonvulsant, methohexital, decreases the effect of quinidine."
466,"Theophylline","DB00277","The barbiturate, methohexital, decreases the effect of theophylline."
466,"Triamcinolone","DB00620","The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone."
466,"Trimipramine","DB00726","The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
466,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Methohexital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
466,"Verapamil","DB00661","Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed."
466,"Warfarin","DB00682","Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed. "
467,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Clozapine","DB00363","Increased risk of toxicity"
467,"Ethotoin","DB00754","Ethotoin may increase the metabolism of chlordiazepoxide via CYP3A4."
467,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
467,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
467,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Phenytoin","DB00252","Phenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
467,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
467,"Telithromycin","DB00976","Telithromycin may reduce clearance of Chlordiazepoxide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlordiazepoxide if Telithromycin is initiated, discontinued or dose changed."
467,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Chlordiazepoxide. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. "
467,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Chlordiazepoxide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
467,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of chlordiazepoxide by decreasing its metabolism. Monitor for chlordiazepoxide toxicity if voriconazole is initiated or dose increased."
468,"Aldesleukin","DB00041","Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine. "
468,"Aliskiren","DB09026","Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine."
468,"Amitriptyline","DB00321","Possible increase in the levels of this agent when used with duloxetine"
468,"Ciprofloxacin","DB00537","Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued."
468,"Desipramine","DB01151","Possible increase in the levels of this agent when used with duloxetine"
468,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
468,"Flecainide","DB01195","Possible increase in the levels of this agent when used with duloxetine"
468,"Fluvoxamine","DB00176","Fluvoxamine increases the effect and toxicity of duloxetine"
468,"Imipramine","DB00458","Possible increase in the levels of this agent when used with duloxetine"
468,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
468,"Nortriptyline","DB00540","Possible increase in the levels of this agent when used with duloxetine"
468,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
468,"Propafenone","DB01182","Possible increase in the levels of this agent when used with duloxetine"
468,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
468,"Tamoxifen","DB00675","Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
468,"Tamsulosin","DB00706","Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed."
468,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Duloxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Duloxetine if Terbinafine is initiated, discontinued or dose changed."
468,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed."
468,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
468,"Tramadol","DB00193","Duloxetine may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome."
468,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
468,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
468,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
468,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Duloxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
468,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
468,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
469,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
469,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
469,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
469,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
469,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
469,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms."
469,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increases psychotic symptoms"
469,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
469,"Dihydrocodeine","DB01551","Phenothiazines may enhance hypotensive effects of opioid analgesics. It is recommended to monitor patients for hypotension.  "
469,"Donepezil","DB00843","Possible antagonism of action"
469,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
469,"Galantamine","DB00674","Possible antagonism of action"
469,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
469,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
469,"Guanethidine","DB01170","Chlorpromazine may decrease the effect of guanethidine."
469,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
469,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
469,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
469,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
469,"Methamphetamine","DB01577","Decreased anorexic effect, may increases psychotic symptoms"
469,"Metrizamide","DB01578","Increased risk of convulsions"
469,"Pethidine","DB00454","Increased sedation and hypotension"
469,"Phendimetrazine","DB01579","Decreased anorexic effect, may increases psychotic symptoms"
469,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
469,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
469,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
469,"Pindolol","DB00960","Increased effect of both drugs"
469,"Propranolol","DB00571","Increased effect of both drugs"
469,"Rivastigmine","DB00989","Possible antagonism of action"
469,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
469,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Chlorpromazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
469,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
469,"Tamoxifen","DB00675","Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
469,"Tamsulosin","DB00706","Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chlorpromazine is initiated, discontinued, or dose changed."
469,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Chlorpromazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chlorpromazine if Terbinafine is initiated, discontinued or dose changed."
469,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
469,"Tetrabenazine","DB04844","May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
469,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
469,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
469,"Tolterodine","DB01036","Chlorpromazine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
469,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
469,"Tramadol","DB00193","Chlorpromazine may decrease the effect of Tramadol by decreasing active metabolite production. "
469,"Trimethobenzamide","DB00662","Trimethobenzamide and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
469,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Chlorpromazine, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Caution should be used during concomitant therapy. "
469,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Chlorpromazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
469,"Trospium","DB00209","Trospium and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
469,"Venlafaxine","DB00285","Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Chlorpromazine is initiated, discontinued, or dose changed."
469,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
469,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
469,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed. "
471,"Atracurium","DB00732","The agent increases the effect of muscle relaxant"
471,"Bumetanide","DB00887","Increased ototoxicity"
471,"Cefalotin","DB00456","Increased risk of nephrotoxicity"
471,"Cefamandole","DB01326","Increased risk of nephrotoxicity"
471,"Cefapirin","DB01139","Increased risk of nephrotoxicity"
471,"Cefazolin","DB01327","Increased risk of nephrotoxicity"
471,"Cefonicid","DB01328","Increased risk of nephrotoxicity"
471,"Cefoperazone","DB01329","Increased risk of nephrotoxicity"
471,"Ceforanide","DB00923","Increased risk of nephrotoxicity"
471,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
471,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
471,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
471,"Cefradine","DB01333","Increased risk of nephrotoxicity"
471,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
471,"Ceftizoxime","DB01332","Increased risk of nephrotoxicity"
471,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
471,"Cefuroxime","DB01112","Increased risk of nephrotoxicity"
471,"Cisplatin","DB00515","Increased risk of nephrotoxicity"
471,"Colistimethate","DB01111","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
471,"Doxacurium chloride","DB01135","The agent increases the effect of muscle relaxant"
471,"Ethacrynic acid","DB00903","Increased ototoxicity"
471,"Furosemide","DB00695","Increased ototoxicity"
471,"Metocurine","DB01336","The agent increases the effect of muscle relaxant"
471,"Mivacurium","DB01226","The agent increases the effect of muscle relaxant"
471,"Pancuronium","DB01337","The agent increases the effect of muscle relaxant"
471,"Pipecuronium","DB01338","The agent increases the effect of muscle relaxant"
471,"Rocuronium","DB00728","The agent increases the effect of muscle relaxant"
471,"Succinylcholine","DB00202","The agent increases the effect of muscle relaxant"
471,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy. "
471,"Thalidomide","DB01041","Thalidomide increases the renal toxicity of the aminoglycoside"
471,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line. "
471,"Torasemide","DB00214","Increased ototoxicity"
471,"Tubocurarine","DB01199","The agent increases the effect of muscle relaxant"
471,"Vecuronium","DB01339","The agent increases the effect of muscle relaxant"
472,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
473,"Chlorotrianisene","DB00269","Association not recommended"
473,"Cholestyramine","DB01432","The resin decreases the effect of raloxifene"
473,"Clomifene","DB00882","Association not recommended"
473,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the absorption of Raloxifene. It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.1 The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
473,"Colestipol","DB00375","The resin decreases the effect of raloxifene"
473,"Conjugated Estrogens","DB00286","Association not recommended"
473,"Diethylstilbestrol","DB00255","Association not recommended"
473,"Estradiol","DB00783","Association not recommended"
473,"Estriol","DB04573","Association not recommended"
473,"Estropipate","DB04574","Association not recommended"
473,"Ethinyl Estradiol","DB00977","Association not recommended"
473,"Levothyroxine","DB00451","Raloxifene decreases absorption of levothyroxine"
473,"Mestranol","DB01357","Association not recommended"
474,"Acenocoumarol","DB01418","Celecoxib may increase the anticoagulant effect of acenocoumarol."
474,"Anisindione","DB01125","Celecoxib may increase the anticoagulant effect of anisindione."
474,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
474,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
474,"Dicoumarol","DB00266","Celecoxib may increase the anticoagulant effect of dicumarol."
474,"Eltrombopag","DB06210","Eltrombopag increases levels of Celecoxib via metabolism decrease."
474,"Fluconazole","DB00196","Fluconazole may increase the effect of celecoxib."
474,"Lithium","DB01356","The COX-2 inhibitor increases serum levels of lithium"
474,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
474,"Rifampicin","DB01045","Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed."
474,"Telmisartan","DB00966","Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
474,"Timolol","DB00373","The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol."
474,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
474,"Trandolapril","DB00519","The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed. "
474,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy. "
474,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed."
474,"Vilazodone","DB06684","Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). To minimize the risk of bleeding associated with this combination, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor for the time that combined selective serotonin reuptake inhibitor (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is necessary. "
474,"Warfarin","DB00682","Celecoxib may increase the anticoagulant effect of warfarin."
476,"Aliskiren","DB09026","Monitor therapy because of enhanced hypotensive effect."
476,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of brimonidine. Consider therapy modification."
476,"Isocarboxazid","DB01247","MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Linezolid","DB00601","MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Methotrimeprazine","DB01403","Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification. "
476,"Moclobemide","DB01171","MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Phenelzine","DB00780","MAO Inhibitors like phenelzine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Procarbazine","DB01168","MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Rasagiline","DB01367","MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Selegiline","DB01037","MAO Inhibitors like selegiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
476,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Brimonidine. Concomitant therapy is contraindicated."
476,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
477,"Acenocoumarol","DB01418","Dicloxacillin may decrease the anticoagulant effect of acenocoumarol."
477,"Anisindione","DB01125","Dicloxacillin may decrease the anticoagulant effect of anisindione."
477,"Demeclocycline","DB00618","Possible antagonism of action"
477,"Dicoumarol","DB00266","Dicloxacillin may decrease the anticoagulant effect of dicumarol."
477,"Doxycycline","DB00254","Possible antagonism of action"
477,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
477,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
477,"Methacycline","DB00931","Possible antagonism of action"
477,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
477,"Minocycline","DB01017","Possible antagonism of action"
477,"Oxytetracycline","DB00595","Possible antagonism of action"
477,"Rolitetracycline","DB01301","Possible antagonism of action"
477,"Tetracycline","DB00759","Possible antagonism of action"
477,"Warfarin","DB00682","Dicloxacillin may decrease the anticoagulant effect of warfarin."
478,"Trimethobenzamide","DB00662","Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended."
478,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Nabilone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
478,"Trospium","DB00209","Anticholinergics, such as Trospium, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended."
479,"Aminophylline","DB01223","Pefloxacin may increase the effect of aminophylline."
479,"Calcium","DB01373","Formation of non-absorbable complexes"
479,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
479,"Magnesium","DB01378","Formation of non-absorbable complexes"
479,"Oxtriphylline","DB01303","Pefloxacin may increase the effect of oxtriphylline."
479,"Theophylline","DB00277","Pefloxacin may increase the effect of theophylline."
480,"Amitriptyline","DB00321","Risk of severe hypotension"
480,"Amoxapine","DB00543","Risk of severe hypotension"
480,"Clomipramine","DB01242","Risk of severe hypotension"
480,"Desipramine","DB01151","Risk of severe hypotension"
480,"Doxepin","DB01142","Risk of severe hypotension"
480,"Imipramine","DB00458","Risk of severe hypotension"
480,"Isocarboxazid","DB01247","Risk of severe hypotension"
480,"Nortriptyline","DB00540","Risk of hypotension"
480,"Phenelzine","DB00780","Risk of severe hypotension"
480,"Rasagiline","DB01367","Risk of severe hypotension"
480,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
481,"Acetohexamide","DB00414","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
481,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
481,"Chlorpropamide","DB00672","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
481,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
481,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
481,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
481,"Disopyramide","DB00280","The beta-blocker, sotalol, may increase the toxicity of disopyramide."
481,"Epinephrine","DB00668","Hypertension, then bradycardia"
481,"Ergotamine","DB00696","Ischemia with risk of gangrene"
481,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
481,"Fenoterol","DB01288","Antagonism"
481,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
481,"Formoterol","DB00983","Antagonism"
481,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
481,"Gliclazide","DB01120","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Glyburide","DB01016","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
481,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
481,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
481,"Insulin Glargine","DB00047","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
481,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
481,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
481,"Methyldopa","DB00968","Possible hypertensive crisis"
481,"Methysergide","DB00247","Ischemia with risk of gangrene"
481,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
481,"Orciprenaline","DB00816","Antagonism"
481,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
481,"Pipobroman","DB00236","Antagonism"
481,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
481,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
481,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
481,"Repaglinide","DB00912","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
481,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
481,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
481,"Telithromycin","DB00976","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
481,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
481,"Terbutaline","DB00871","Antagonism"
481,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
481,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
481,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
481,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
481,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
481,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
481,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
481,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
481,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
481,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
481,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
482,"Clarithromycin","DB01211","Clarithromycin may increase the effect and toxicity of buspirone."
482,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
482,"Diltiazem","DB00343","The calcium channel blocker, diltiazem, increases the effect and toxicity of buspirone."
482,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of buspirone."
482,"Isocarboxazid","DB01247","Possible blood pressure elevation"
482,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect and toxicity of buspirone."
482,"Nefazodone","DB01149","Nefazodone increases the effect of buspirone"
482,"Phenelzine","DB00780","Possible blood pressure elevation"
482,"Rasagiline","DB01367","Possible blood pressure elevation"
482,"Rifabutin","DB00615","Rifabutin decreases the effect of buspirone"
482,"Rifampicin","DB01045","Rifampin decreases the effect of buspirone"
482,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of buspirone"
482,"Telithromycin","DB00976","Telithromycin may reduce clearance of Buspirone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buspirone if Telithromycin is initiated, discontinued or dose changed."
482,"Tranylcypromine","DB00752","Buspirone may increase the adverse effects of Tranylcypromine. Elevation of blood pressure may occur. Concomitant therapy also may increase the risk of serotonin syndrome. Concomitant therapy should be avoided."
482,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
482,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
482,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
482,"Verapamil","DB00661","Verapamil may increase the serum concentration of Buspirone. The likely occurs via Verapamil-mediated CYP3A4 inhibition resulting in decreased Buspirone metabolism. Monitor for changes in the therapeutic/adverse effects of Buspirone if Verpamil is initiated, discontinued or dose changed."
482,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of buspirone likely by decreasing its metabolism via CYP3A4. Monitor for changes in the therapeutic and adverse effects of buspirone if voriconazole is initiated, discontinued or dose changed. "
482,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
483,"Glucosamine","DB01296","Possible hyperglycemia"
483,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of miglitol. Monitor for changes in fasting and postprandial blood sugars."
484,"Amiloride","DB00594","Increased risk of hyperkalemia"
484,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
484,"Drospirenone","DB01395","Increased risk of hyperkalemia"
484,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
484,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
484,"Potassium","DB01345","Increased risk of hyperkalemia"
484,"Spironolactone","DB00421","Increased risk of hyperkalemia"
484,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
484,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
484,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
484,"Triamterene","DB00384","Increased risk of hyperkalemia"
485,"Amikacin","DB00479","Increased risk of nephrotoxicity"
485,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
485,"Kanamycin","DB01172","Increased risk of nephrotoxicity"
485,"Neomycin","DB00994","Increased risk of nephrotoxicity"
485,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
485,"Probenecid","DB01032","Probenecid may increase the serum level of cefotaxime."
485,"Streptomycin","DB01082","Increased risk of nephrotoxicity"
485,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
486,"Apomorphine","DB00714","Entacapone increases the effect and toxicity of the sympathomimetic, apomorphine."
486,"Bitolterol","DB00901","Entacapone may increase the effect and toxicity of bitolterol. "
486,"Dobutamine","DB00841","Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine."
486,"Dopamine","DB00988","Entacapone increases the effect and toxicity of the sympathomimetic, dopamine."
486,"Epinephrine","DB00668","Entacapone may increase the effect and toxicity of the sympathomimetic, epinephrine."
486,"Isocarboxazid","DB01247","Possible hypertensive crisis with this combination"
486,"Isoetarine","DB00221","Entacapone increases the effect and toxicity of the sympathomimetic, isoetharine."
486,"Isoprenaline","DB01064","Entacapone increases the effect and toxicity of the sympathomimetic, isoproterenol."
486,"Methyldopa","DB00968","Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa."
486,"Norepinephrine","DB00368","Entacapone increases the effect and toxicity of the sympathomimetic, norepinephrine."
486,"Phenelzine","DB00780","Possible hypertensive crisis with this combination"
486,"Tranylcypromine","DB00752","Additive inhibition of endogenous catecholamine metabolism may increase the therapeutic/adverse effects of both agents. Concomitant therapy should be avoided."
486,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Entacapone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
487,"Atovaquone","DB01117","Atovaquone increases the effect and toxicity of zidovudine"
487,"Clarithromycin","DB01211","Clarithromycin may decrease the serum concentration of zidovudine. Increased myelosuppression in mice has been observed. Consider staggering doses during concomitant therapy and closely monitor response to zidovudine therapy."
487,"Doxorubicin","DB00997","Additive myelosuppression may occur. Doxorubicin may decrease the efficacy of zidovudine. Concomitant therapy should be avoided. "
487,"Ganciclovir","DB01004","Increased risk of hematologic toxicity. Concomitant therapy should be avoided."
487,"Interferon beta-1b","DB00068","The interferon increases the effect and toxicity of zidovudine"
487,"Methadone","DB00333","Methadone increases the effect and toxicity of zidovudine"
487,"Probenecid","DB01032","Rash, malaise, myalgia"
487,"Ribavirin","DB00811","Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia. "
487,"Rifabutin","DB00615","The rifamycin decreases levels of zidovudine"
487,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed."
487,"Rifapentine","DB01201","Rifapentin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifapentin is initiated, discontinued or dose changed. "
487,"Stavudine","DB00649","Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided. "
487,"Tipranavir","DB00932","Tipranavir decreases the concentration of Zidovudine. "
487,"Valganciclovir","DB01610","The adverse/toxic effects of Zidovudine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided."
488,"Clarithromycin","DB01211","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
488,"Donepezil","DB00843","Possible antagonism of action"
488,"Galantamine","DB00674","Possible antagonism of action"
488,"Itraconazole","DB01167","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
488,"Ketoconazole","DB01026","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
488,"Nefazodone","DB01149","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
488,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of darifenacin/solifenacin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of darifenacin if nelfinavir is initiated, discontinued or dose changed."
488,"Ritonavir","DB00503","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
488,"Rivastigmine","DB00989","Possible antagonism of action"
488,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Darifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
488,"Tamoxifen","DB00675","Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
488,"Tamsulosin","DB00706","Darifenacin, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darifenacin is initiated, discontinued, or dose changed."
488,"Telithromycin","DB00976","Telithromycin may reduce clearance of Darifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Darifenacin if Telithromycin is initiated, discontinued or dose changed."
488,"Tramadol","DB00193","Darifenacin may decrease the effect of Tramadol by decreasing active metabolite production. "
488,"Triprolidine","DB00427","Triprolidine and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
488,"Trospium","DB00209","Trospium and Darifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
488,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of darifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of darifenacin  if voriconazole is initiated, discontinued or dose changed."
489,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
489,"Cimetidine","DB00501","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of oxycodone. Monitor for changes in the therapeutic and adverse effects of oxycodone if cimetidine is initiated, discontinued or dose changed."
489,"Citalopram","DB00215","Increased risk of serotonin syndrome"
489,"Escitalopram","DB01175","Increased risk of serotonin syndrome"
489,"Fluoxetine","DB00472","Increased risk of serotonin syndrome"
489,"Fluvoxamine","DB00176","Increased risk of serotonin syndrome"
489,"Paroxetine","DB00715","Increased risk of serotonin syndrome"
489,"Sertraline","DB01104","Increased risk of serotonin syndrome"
489,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Oxycodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
491,"Telithromycin","DB00976","Telithromycin may reduce clearance of Flutamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flutamide if Telithromycin is initiated, discontinued or dose changed."
491,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed."
491,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flutamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flutamide if voriconazole is initiated, discontinued or dose changed."
492,"Acenocoumarol","DB01418","Increased risk of bleeding. Monitor for signs and symptoms of bleeding."
492,"Acetylsalicylic acid","DB00945","Additive adverse effects increase the risk of gastrointestinal bleeding. Possible decrease in the cardioprotective effect of acetylsalicylic acid. Monitor for increased bleeding risk during concomitant therapy. "
492,"Aminosalicylic Acid","DB00233","Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. "
492,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
492,"Cholestyramine","DB01432","Cholestyramine may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
492,"Citalopram","DB00215","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Colesevelam","DB00930","Colesevelam may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
492,"Colestipol","DB00375","Colestipol may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colestipol is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
492,"Cyclosporine","DB00091","Tolmetin may increase the serum concentration of cyclosporine and/or increase the nephrotoxicity of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine serum concentration and nephrotoxicity during concomitant therapy."
492,"Drotrecogin alfa","DB00055","Increased risk of bleeding. Monitor for increased bleeding during concomitant therapy. "
492,"Escitalopram","DB01175","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Fluoxetine","DB00472","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Fluvoxamine","DB00176","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Ginkgo biloba","DB01381","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
492,"Ginseng","DB01404","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
492,"Ketorolac","DB00465","Risk of adverse NSAID toxic effects (e.g. GI bleeding, renal dysfunction). Concomitant therapy is contraindicated."
492,"Lithium","DB01356","Tolmetin may increase the risk of Lithium toxicity by decreasing the renal elminiation of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tolmetin is initiated, discontinued or dose changed. "
492,"Methotrexate","DB00563","Tolmetin may decrease the renal excretion of Methotrexate. Alternate therapy should be considered. Otherwise, monitor for hemotologic and renal toxicities."
492,"Paroxetine","DB00715","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Pemetrexed","DB00642","Tolmetin may decrease the renal excretion of Pemetrexed in patients with decreased creatinine clearance. Tolmetin may be withheld in these patients from 2 days before to 2 days after Pemetrexed administration. "
492,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
492,"Salsalate","DB01399","Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. "
492,"Sertraline","DB01104","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
492,"Telmisartan","DB00966","Concomitant use of Telmisartan and Tolmetin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
492,"Timolol","DB00373","The NSAID, Tolmetin, may antagonize the antihypertensive effect of Timolol."
492,"Trandolapril","DB00519","The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed. "
492,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tolmetin. Monitor for increased bleeding during concomitant thearpy. "
492,"Warfarin","DB00682","The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
493,"Acenocoumarol","DB01418","Cimetidine may increase the anticoagulant effect of acenocoumarol."
493,"Alfentanil","DB00802","Increases the effect of the narcotic"
493,"Alprazolam","DB00404","Cimetidine may increase the effect of the benzodiazepine, alprazolam."
493,"Aminophylline","DB01223","Cimetidine may increase the serum concentration of aminophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aminophylline if cimetidine is initiated, discontinued or dose changed."
493,"Amitriptyline","DB00321","Cimetidine may increase the effect of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if cimetidine is initiated, discontinued or dose changed."
493,"Amoxapine","DB00543","Cimetidine may increase the effect of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if cimetidine is initiated, discontinued or dose changed."
493,"Anisindione","DB01125","Cimetidine may increase the anticoagulant effect of anisindione."
493,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
493,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
493,"Bendamustine","DB06769","CA1A2 hepatic enzyme metabolism is affected by increased amounts of bendamustine by cimetidine. In addition, decreased conversion of bendamustine to active metabolites occurs. Amounts of active metabolites may be decreased. Decreased conversion of bendamustine to active metabolites also occurs. "
493,"Bromazepam","DB01558","Co-administration with cimetidine will cause a reduction in bromazepam clearance and increases half-life. "
493,"Carbamazepine","DB00564","Cimetidine may increase the serum concentration of carbamazepine during the first few days of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of carbamazepine if cimetidine is initiated, discontinued or dose changed."
493,"Carmustine","DB00262","Increases myelosuppression caused by carmustine"
493,"Cefditoren","DB01066","H2-Antagonists such as cimetidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
493,"Chlordiazepoxide","DB00475","Cimetidine may increase the effect of the benzodiazepine, chlordiazepoxide."
493,"Clomipramine","DB01242","Cimetidine may increase the effect of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if cimetidine is initiated, discontinued or dose changed."
493,"Clonazepam","DB01068","Cimetidine may increase the effect of the benzodiazepine, clonazepam."
493,"Clorazepate","DB00628","Cimetidine may increase the effect of the benzodiazepine, clorazepate."
493,"Clozapine","DB00363","Cimetidine may increase the serum concentratin of clozapine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if cimetidine is initiated, discontinued or dose changed."
493,"Codeine","DB00318","Cimetidine may decrease the therapeutic effect of codeine by decreasing its metabolism to its active metabolite, morphine. Monitor for changes in the therapeutic effect of codeine if cimetidine is initiated, discontinued or dose changed."
493,"Desipramine","DB01151","Cimetidine may increase the effect of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if cimetidine is initiated, discontinued or dose changed."
493,"Dextropropoxyphene","DB00647","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of propoxyphene. Monitor for changes in the therapeutic and adverse effects of propoxyphene if cimetidine is intitiated, discontinued or dose changed."
493,"Diazepam","DB00829","Cimetidine may increase the effect of the benzodiazepine, diazepam."
493,"Dicoumarol","DB00266","Cimetidine may increase the anticoagulant effect of dicumarol."
493,"Dihydroquinidine barbiturate","DB01341","Increases the effect of quinidine"
493,"Dofetilide","DB00204","Increases effect/toxicity of dofetilide"
493,"Donepezil","DB00843","Possible antagonism of action"
493,"Doxepin","DB01142","Cimetidine may increase the effect of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if cimetidine is initiated, discontinued or dose changed."
493,"Dyphylline","DB00651","Increases the effect of theophylline"
493,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
493,"Enoxacin","DB00467","Cimetidine may decrease the absorption of enoxacin."
493,"Epirubicin","DB00445","Cimetidine can increase epirubicin levels"
493,"Estazolam","DB01215","Cimetidine may increase the effect of the benzodiazepine, estazolam."
493,"Ethotoin","DB00754","Increases the effect of hydantoin"
493,"Fentanyl","DB00813","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed."
493,"Flecainide","DB01195","Cimetidine, a moderate CYP2D6 inhibitor, may decrease the metabolism of flecainide."
493,"Flurazepam","DB00690","Cimetidine may increase the effect of the benzodiazepine, flurazepam."
493,"Fosphenytoin","DB01320","Cimetidine may increase the serum concentration of fosphenytoin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fosphenytoin if cimetidine is initiated, discontinued or dose changed."
493,"Galantamine","DB00674","Possible antagonism of action"
493,"Halazepam","DB00801","Cimetidine may increase the effect of the benzodiazepine, halazepam."
493,"Heroin","DB01452","Cimetidine increases the effect of the narcotic"
493,"Imipramine","DB00458","Cimetidine may increase the effect of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if cimetidine is initiated, discontinued or dose changed."
493,"Itraconazole","DB01167","The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole."
493,"Ketazolam","DB01587","Cimetidine may increase the effect of the benzodiazepine, ketazolam."
493,"Ketoconazole","DB01026","The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole."
493,"Labetalol","DB00598","Cimetidine may increase the serum concentration of labetolol by decreasing its metabolism."
493,"Lidocaine","DB00281","Increases the effect and toxicity of lidocaine"
493,"Mephenytoin","DB00532","Increases the effect of hydantoin"
493,"Metformin","DB00331","Cimetidine may increase the therapeutic and adverse effects of metformin by increasing its serum concentration. Consider alternate therapy."
493,"Methadone","DB00333","Cimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed."
493,"Metoprolol","DB00264","Cimetidine may increase the serum concentration of metoprolol by decreasing its metabolism."
493,"Midazolam","DB00683","Cimetidine may increase the effect of the benzodiazepine, midazolam."
493,"Moclobemide","DB01171","Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed."
493,"Nalbuphine","DB00844","Increases the effect of the narcotic"
493,"Nifedipine","DB01115","Cimetidine may increase the effect of the calcium channel blocker, nifedipine."
493,"Nimodipine","DB00393","Cimetidine increases the effect of the calcium channel blocker, nimodipine."
493,"Nitrendipine","DB01054","Cimetidine increases the effect of the calcium channel blocker, nitrendipine. "
493,"Nortriptyline","DB00540","Cimetidine may increase the effect of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if cimetidine is initiated, discontinued or dose changed."
493,"Oxtriphylline","DB01303","Cimetidine may increase the serum concentration of oxtriphylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of oxtriphylline if cimetidine is initiated, discontinued or dose changed."
493,"Oxycodone","DB00497","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of oxycodone. Monitor for changes in the therapeutic and adverse effects of oxycodone if cimetidine is initiated, discontinued or dose changed."
493,"Oxymorphone","DB01192","Increases the effect of the narcotic"
493,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
493,"Phenytoin","DB00252","Cimetidine may increase the therapeutic effect of phenytoin."
493,"Posaconazole","DB01263","Significant decrease of posaconazole levels"
493,"Pramipexole","DB00413","Cimetidine may increase the effect and toxicity of pramipexole."
493,"Prazepam","DB01588","Cimetidine may increase the effect of the benzodiazepine, prazepam."
493,"Procainamide","DB01035","The histamine H2-receptor antagonist, cimetidine, may increase the effect of procainamide."
493,"Propranolol","DB00571","Cimetidine may increase the serum concentration of propranolol by decreasing its metabolism."
493,"Protriptyline","DB00344","Cimetidine may increase the effect of tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed."
493,"Quazepam","DB01589","Cimetidine may increase the effect of the benzodiazepine, quazepam."
493,"Quinidine","DB00908","Cimetidine may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if cimetidine is initiated, discontinued or dose changed."
493,"Quinidine barbiturate","DB01346","Increases the effect of quinidine"
493,"Rivastigmine","DB00989","Possible antagonism of action"
493,"Roflumilast","DB01656","Increases roflumilast levels. "
493,"Sildenafil","DB00203","Increases the effect and toxicity of sildenafil"
493,"Sufentanil","DB00708","Increases the effect of the narcotic"
493,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Cimetidine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Cimetidine is initiated, discontinued or if the dose is changed."
493,"Tacrolimus","DB00864","Cimetidine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Cimetidine therapy is initiated, discontinued or altered."
493,"Tamoxifen","DB00675","Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
493,"Tamsulosin","DB00706","Cimetidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cimetidine is initiated, discontinued, or dose changed."
493,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
493,"Theophylline","DB00277","Cimetidine may increase the effect of theophylline."
493,"Ticlopidine","DB00208","Cimetidine may increase Ticlopidine levels. Avoid concomitant therapy. "
493,"Timolol","DB00373","Cimetidine may increase the serum concentration of timolol by decreasing its metabolism."
493,"Tizanidine","DB00697","Cimetidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
493,"Tolazoline","DB00797","Anticipated loss of efficacy of tolazoline"
493,"Tolterodine","DB01036","Cimetidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
493,"Tramadol","DB00193","Cimetidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Cimetidine may decrease the effect of Tramadol by decreasing active metabolite production. "
493,"Trazodone","DB00656","The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed."
493,"Triazolam","DB00897","Cimetidine may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of triazolam if cimetidine is initiated, discontinued or dose changed."
493,"Trimipramine","DB00726","Cimetidine may increase the effect of tricyclic antidepressant, trimipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed."
493,"Vilazodone","DB06684","Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. Consider using an alternative H2-antagonist to avoid the risk of selective serotonin reuptake inhibitor (SSRI) toxicity. Monitor for increased therapeutic or toxic effects of SSRI if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased. "
493,"Warfarin","DB00682","Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed."
493,"Zaleplon","DB00962","Cimetidine may increase the serum concentration of zaleplon by decreasing its metabolism. Reduce the initial dose of zaleplon to 5 mg in patients receiving cimetidine."
494,"Anisotropine Methylbromide","DB00517","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
494,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
494,"Atropine","DB00572","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Benzatropine","DB00245","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Biperiden","DB00810","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed."
494,"Clidinium","DB00771","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Clozapine","DB00363","Clozapine, a moderate CYP2D6 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive CNS despresant and anticholinergic effects may also occur. Monitor for changes in the therapeutic and adverse effects of haloperidol if clozapine is initiated, discontinued or dose changed. Also monitor for increased CNS depressant and anticholinergic effects during concomitant therapy."
494,"Dicyclomine","DB00804","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Ethopropazine","DB00392","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Fluconazole","DB00196","Fluconazole may increase the effect and toxicity of haloperidol."
494,"Glycerol Phenylbutyrate","DB08909","Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients."
494,"Glycopyrrolate","DB00986","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Guanethidine","DB01170","Haloperidol may decrease the effect of guanethidine."
494,"Homatropine Methylbromide","DB00725","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Hyoscyamine","DB00424","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
494,"Isopropamide","DB01625","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of haloperidol."
494,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of haloperidol."
494,"Lithium","DB01356","Possible extrapyramidal effects and neurotoxicity with this combination"
494,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
494,"Mepenzolate","DB04843","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
494,"Methantheline","DB00940","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Methyldopa","DB00968","Methyldopa increases haloperidol effect or risk of psychosis"
494,"Orphenadrine","DB01173","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Oxyphencyclimine","DB00383","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Procyclidine","DB00387","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Propantheline","DB00782","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Propranolol","DB00571","Increased effect of both drugs"
494,"Rifabutin","DB00615","The rifamycin decreases the effect of haloperidol"
494,"Rifampicin","DB01045","The rifamycin decreases the effect of haloperidol"
494,"Scopolamine","DB00747","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Haloperidol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
494,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
494,"Tamoxifen","DB00675","Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
494,"Tamsulosin","DB00706","Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed."
494,"Telithromycin","DB00976","Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed."
494,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed."
494,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
494,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
494,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
494,"Tolterodine","DB01036","Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
494,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
494,"Tramadol","DB00193","Haloperidol may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Haloperidol may decrease the effect of Tramadol by decreasing active metabolite production. "
494,"Trazodone","DB00656","The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed."
494,"Tridihexethyl","DB00505","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Trihexyphenidyl","DB00376","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
494,"Trimethobenzamide","DB00662","Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
494,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
494,"Triprolidine","DB00427","Triprolidine and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
494,"Trospium","DB00209","Trospium and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
494,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed."
494,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
494,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
494,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
495,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Ritonavir. The antiviral response should be closely monitored."
495,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
495,"Alfuzosin","DB00346","Ritonavir increases the effect/toxicity of alfuzosin"
495,"Alprazolam","DB00404","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, alprazolam."
495,"Aminophylline","DB01223","Ritonavir decreases the effect of theophylline"
495,"Amiodarone","DB01118","Ritonavir increases the effect and toxicity of amiodarone"
495,"Amitriptyline","DB00321","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ritonavir if initiated, discontinued or dose changed."
495,"Amoxapine","DB00543","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed."
495,"Apixaban","DB06605","Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration."
495,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
495,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
495,"Atazanavir","DB01072","Association with dose adjustment"
495,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
495,"Atorvastatin","DB01076","Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed."
495,"Avanafil","DB06237","Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil. "
495,"Bepridil","DB01244","Ritonavir increases the effect and toxicity of bepridil"
495,"Bromazepam","DB01558","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if ritonavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
495,"Bupropion","DB01156","Ritonavir increases the effect and toxicity of bupropion"
495,"Buspirone","DB00490","Ritonavir increases the effect and toxicity of buspirone"
495,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
495,"Canagliflozin","DB08907","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
495,"Carbamazepine","DB00564","Ritonavir increases the effect of carbamazepine"
495,"Chlordiazepoxide","DB00475","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
495,"Ciclesonide","DB01410","Increased effects/toxicity of ciclesonide"
495,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
495,"Clomipramine","DB01242","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if ritonavir if initiated, discontinued or dose changed."
495,"Clonazepam","DB01068","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clonazepam."
495,"Clorazepate","DB00628","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clorazepate."
495,"Clozapine","DB00363","Ritonavir increases the effect and toxicity of clozapine"
495,"Cyclosporine","DB00091","The protease inhibitor, ritonavir, may increase the effect of cyclosporine."
495,"Dantrolene","DB01219","Ritonavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ritonavir is initiated, discontinued or dose changed. "
495,"Darifenacin","DB00496","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
495,"Delavirdine","DB00705","Increases the effect of ritonavir"
495,"Desipramine","DB01151","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if ritonavir if initiated, discontinued or dose changed."
495,"Dextropropoxyphene","DB00647","Ritonavir increases the levels of analgesic"
495,"Diazepam","DB00829","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, diazepam."
495,"Digoxin","DB00390","Ritonavir increases levels/effect of digoxin"
495,"Dihydroergotamine","DB00320","The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine."
495,"Diltiazem","DB00343","Ritonavir increases diltiazem levels"
495,"Doxepin","DB01142","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed."
495,"Dronedarone","DB04855","Ritonavir is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
495,"Eletriptan","DB00216","The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan."
495,"Eplerenone","DB00700","This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone."
495,"Ergotamine","DB00696","The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine."
495,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
495,"Erythromycin","DB00199","Increased toxicity of both agents"
495,"Estazolam","DB01215","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, estazolam."
495,"Ethinyl Estradiol","DB00977","Ritonavir could decrease the contraceptive efficacy"
495,"Fentanyl","DB00813","Ritonavir increases the effect and toxicity of fentanyl/alfentanyl"
495,"Flecainide","DB01195","Ritonavir increases the toxicity of the anti-arrhythmic"
495,"Fluoxetine","DB00472","Increased risk of serotonin syndrome"
495,"Flurazepam","DB00690","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam."
495,"Fluticasone furoate","DB08906","Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy. "
495,"Fusidic Acid","DB02703","The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid."
495,"Gefitinib","DB00317","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
495,"Imipramine","DB00458","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed."
495,"Indacaterol","DB05039","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
495,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of ritonavir."
495,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of ritonavir."
495,"Linagliptin","DB08882","CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely. "
495,"Lovastatin","DB00227","Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
495,"Mefloquine","DB00358","Mefloquine decreases the effect of ritonavir"
495,"Methadone","DB00333","The protease inhibitor, ritonavir, may decrease the effect of methadone."
495,"Midazolam","DB00683","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam."
495,"Nortriptyline","DB00540","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ritonavir if initiated, discontinued or dose changed."
495,"Olanzapine","DB00334","Ritonavir decreases the effect of olanzapine"
495,"Oxtriphylline","DB01303","Ritonavir decreases the effect of theophylline"
495,"Pazopanib","DB06589","Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. "
495,"Pethidine","DB00454","Ritonavir increases the levels of analgesic"
495,"Pimozide","DB01100","The protease inhibitor, ritonavir, may increase the effect and toxicity of pimozide."
495,"Piroxicam","DB00554","Ritonavir increases the toxicity of piroxicam"
495,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
495,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
495,"Prasugrel","DB06209","Ritonavir is a inhibitor of CYP3A4, thus blocking the bioactivation of prasugrel. As a result, a reduction in prasugrel efficiency may be observed in patients.  "
495,"Propafenone","DB01182","Ritonavir increases the effect and toxicity of propafenone"
495,"Quinidine","DB00908","Ritonavir increases the effect and toxicity of quinidine"
495,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
495,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
495,"Rifabutin","DB00615","Rifabutin decreases the effect of ritonavir"
495,"Rifampicin","DB01045","Rifampin decreases the effect of ritonavir"
495,"Rivaroxaban","DB06228","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 like ritonavir and P-glycoproteins are contraindicated."
495,"Roflumilast","DB01656","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
495,"Saxagliptin","DB06335","Ritonavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
495,"Silodosin","DB06207","Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. "
495,"Tacrolimus","DB00864","The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered."
495,"Tadalafil","DB00820","Ritonavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
495,"Tamoxifen","DB00675","Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
495,"Tamsulosin","DB00706","Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed."
495,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
495,"Telithromycin","DB00976","Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
495,"Temsirolimus","DB06287","Ritonavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
495,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed."
495,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
495,"Theophylline","DB00277","Ritonavir decreases the effect of theophylline"
495,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ritonavir is initiated, discontinued or dose changed."
495,"Tolterodine","DB01036","Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
495,"Tolvaptan","DB06212","Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
495,"Topotecan","DB01030","The p-glycoprotein inhibitor, Ritonavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
495,"Tramadol","DB00193","Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production. "
495,"Trazodone","DB00656","The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed. "
495,"Tretinoin","DB00755","The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed. "
495,"Triazolam","DB00897","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, triazolam."
495,"Trimipramine","DB00726","The strong CYP3A4/CYP2D6 inhibitor, Ritonavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ritonavir is initiated, discontinued or dose changed. "
495,"Vardenafil","DB00862","Ritonavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
495,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
495,"Venlafaxine","DB00285","Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed."
495,"Verapamil","DB00661","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed."
495,"Vinblastine","DB00570","Ritonavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ritonavir is initiated, discontinued or dose changed."
495,"Vincristine","DB00541","Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed."
495,"Vinorelbine","DB00361","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ritonavir is initiated, discontinued or dose changed."
495,"Voriconazole","DB00582","Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur. "
495,"Zolpidem","DB00425","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ritonavir is initiated, discontinued or dose changed. "
495,"Zonisamide","DB00909","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed."
495,"Zopiclone","DB01198","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ritonavir is initiated, discontinued or dose changed."
495,"Zuclopenthixol","DB01624","Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed. "
497,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
499,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
499,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
499,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
499,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
499,"Donepezil","DB00843","Possible antagonism of action"
499,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
499,"Galantamine","DB00674","Possible antagonism of action"
499,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
499,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
499,"Guanethidine","DB01170","Triflupromazine may decrease the effect of guanethidine."
499,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
499,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
499,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
499,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
499,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
500,"Acenocoumarol","DB01418","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of acenocoumarol."
500,"Anisindione","DB01125","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of anisindione."
500,"Dicoumarol","DB00266","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of dicumarol."
500,"Digoxin","DB00390","The thyroid hormone, dextrothyroxine, decreases the effect of digoxin."
500,"Warfarin","DB00682","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin."
502,"Colistimethate","DB01111","Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy."
502,"Gallium nitrate","DB05260","Additive nephrotoxic effects may occur. Avoid concomitant therapy. "
502,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
504,"Abiraterone","DB05812","Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. "
504,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
504,"Dihydroquinidine barbiturate","DB01341","Quinidine increases the toxicity of dextromethorphan"
504,"Fluoxetine","DB00472","Combination associated with possible serotoninergic syndrome"
504,"Isocarboxazid","DB01247","Possible severe adverse reaction"
504,"Moclobemide","DB01171","Increased CNS toxicity"
504,"Paroxetine","DB00715","Combination associated with possible serotoninergic syndrome"
504,"Phenelzine","DB00780","Possible severe adverse reaction"
504,"Quinidine","DB00908","Quinidine increases the toxicity of dextromethorphan"
504,"Quinidine barbiturate","DB01346","Quinidine increases the toxicity of dextromethorphan"
504,"Rasagiline","DB01367","Possible severe adverse reaction"
504,"Selegiline","DB01037","Combination associated with possible serotoninergic syndrome"
504,"Sibutramine","DB01105","Combination associated with possible serotoninergic syndrome"
504,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Dextromethorphan. Consider alternate therapy or monitor for therapeutic/adverse effects of Dextromethorphan if Terbinafine is initiated, discontinued or dose changed."
504,"Tocilizumab","DB06273","Dextromethorphan is a CYP2D6 and CYP3A4 substrate. Exposure of dextromethorphan decreases following administration of tocilizumab."
504,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
504,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant use should be avoided."
504,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
504,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
504,"Vemurafenib","DB08881","Vemurafenib increases the AUC (CYP2D6 substrate) by 47% . "
504,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
504,"Vilazodone","DB06684","Consideration should be given to avoiding the concomitant use of dextromethorphan and selective serotonin reuptake inhibitors (SSRI). Monitor for toxic effects of dextromethorphan (eg, CNS, Cardiovascular) if an SSRI is initiated or the dose is increased. SSRIs, other than fluoxetine and paroxetine, may be safer alternatives due to lesser CYP2D6 inhibition; however, the mechanism for the interaction is not fully understood, and caution is still advised. "
504,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
505,"Amikacin","DB00479","Increased risk of nephrotoxicity"
505,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
505,"Bumetanide","DB00887","Increased ototoxicity"
505,"Cabazitaxel","DB06772","Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent. "
505,"Docetaxel","DB01248","Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent. "
505,"Ethacrynic acid","DB00903","Increased ototoxicity"
505,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
505,"Furosemide","DB00695","Increased ototoxicity"
505,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
505,"Leflunomide","DB01097","Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
505,"Methotrexate","DB00563","Cisplatin increases methotrexate toxicity"
505,"Natalizumab","DB00108","Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab."
505,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
505,"Paclitaxel","DB01229","Cisplatin increases the effect and toxicity of paclitaxel"
505,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
505,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as cisplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
505,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cisplatin. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."
505,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Cisplatin. Use caution during concomitant therapy. "
505,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
505,"Topotecan","DB01030","Administration of Topotecan after Cisplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
505,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
507,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
509,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed. "
509,"Allopurinol","DB00437","The ACE inhibitor, Trandolapril, may increase the risk of hypersensitivity reactions to Allopurinol. "
509,"Amifostine","DB01143","Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
509,"Amiloride","DB00594","Increased risk of hyperkalemia. Monitor serum potassium levels."
509,"Aminosalicylic Acid","DB00233","The salicylate, Aminosalicylic acid, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Aminosalicylic acid is initiated, discontinued or dose changed. "
509,"Azathioprine","DB00993","Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased. "
509,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
509,"Bendroflumethiazide","DB00436","The thiazide diuretic, Bendroflumethiazide, may increase the hypotensive effect of Trandolapril. Bendroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Benzphetamine","DB00865","Benzphetamine may reduce the efficacy of Trandolapril. "
509,"Bumetanide","DB00887","The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril. "
509,"Candesartan","DB00796","The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril. "
509,"Celecoxib","DB00482","The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed. "
509,"Chlorothiazide","DB00880","The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Chlorthalidone","DB00310","The thiazide diuretic, Chlorthalidone, may increase the hypotensive effect of Trandolapril. Chlorthalidone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Cyclosporine","DB00091","The ACE inhibitor, Trandolapril, may increase the nephrotoxicity of Cyclosporine. "
509,"Dextroamphetamine","DB01576","Dextroamphetamine may reduce the efficacy of Trandolapril. "
509,"Diazoxide","DB01119","Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure."
509,"Diclofenac","DB00586","The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed. "
509,"Diflunisal","DB00861","The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.  "
509,"Drospirenone","DB01395","Increased risk of hyperkalemia. Monitor serum potassium levels. "
509,"Ephedra","DB01363","Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy."
509,"Eplerenone","DB00700","Increased risk of hyperkalemia. Monitor serum potassium levels. "
509,"Epoprostenol","DB01240","The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril. "
509,"Eprosartan","DB00876","The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril. "
509,"Ethacrynic acid","DB00903","The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril.  "
509,"Etodolac","DB00749","The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.  "
509,"Fenoprofen","DB00573","The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed. "
509,"Flurbiprofen","DB00712","The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed.  "
509,"Furosemide","DB00695","The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril. "
509,"Ginseng","DB01404","Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy."
509,"Hydrochlorothiazide","DB00999","The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Hydroflumethiazide","DB00774","The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Ibuprofen","DB01050","The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed. "
509,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
509,"Iloprost","DB01088","The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril."
509,"Indapamide","DB00808","The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Indomethacin","DB00328","The NSAID, Indomethacin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Indomethacin is initiated, discontinued or dose changed. "
509,"Irbesartan","DB01029","The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril. "
509,"Ketoprofen","DB01009","The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.  "
509,"Ketorolac","DB00465","The NSAID, Ketorolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketorolac is initiated, discontinued or dose changed.  "
509,"Lisdexamfetamine","DB01255","Lisdexamfetamine may reduce the efficacy of Trandolapril. "
509,"Lithium","DB01356","Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed."
509,"Losartan","DB00678","The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril. "
509,"Lumiracoxib","DB01283","The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed. "
509,"Meclofenamic acid","DB00939","The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed. "
509,"Mefenamic acid","DB00784","The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.  "
509,"Meloxicam","DB00814","The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed. "
509,"Methamphetamine","DB01577","Methamphetamine may reduce the efficacy of Trandolapril. "
509,"Methyclothiazide","DB00232","The thiazide diuretic, Methyclothiazide, may increase the hypotensive effect of Trandolapril. Methyclothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Methylphenidate","DB00422","Methylphenidate may antagonize the antihypertensive effect of Trandolapril. Monitor for changes in blood pressure if Methylphenidate is initiated, discontinued or dose changed."
509,"Metolazone","DB00524","The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Nabumetone","DB00461","The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed. "
509,"Naproxen","DB00788","The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.  "
509,"Olmesartan","DB00275","The angiotensin II receptor blocker, Olmesartan, may increase the adverse effects of Trandolapril. "
509,"Oxaprozin","DB00991","The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed. "
509,"Phendimetrazine","DB01579","Phendimetrazine may reduce the efficacy of Trandolapril. "
509,"Phentermine","DB00191","Phentermine may reduce the efficacy of Trandolapril. "
509,"Piroxicam","DB00554","The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed. "
509,"Polythiazide","DB01324","The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Potassium","DB01345","Increased risk of hyperkalemia"
509,"Potassium Chloride","DB00761","The potassium salt may increase the hyperkalemic effect of Trandolapril."
509,"Quinine","DB00468","May cause additive hypotensive effects. Monitor for changes in blood pressure if Quinine is initiated, discontinued or dose changed. "
509,"Rituximab","DB00073","Trandolapril may incresae the hypotensive effect of Rituximab. "
509,"Salsalate","DB01399","The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed. "
509,"Sirolimus","DB00877","Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema."
509,"Sodium bicarbonate","DB01390","Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced."
509,"Spironolactone","DB00421","Increased risk of hyperkalemia. Monitor serum potassium levels. "
509,"Sulindac","DB00605","The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed. "
509,"Telmisartan","DB00966","The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril. "
509,"Temsirolimus","DB06287","Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema."
509,"Tiaprofenic acid","DB01600","The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.  "
509,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
509,"Tolmetin","DB00500","The NSAID, Tolmetin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tolmetin is initiated, discontinued or dose changed. "
509,"Torasemide","DB00214","The loop diuretic, Torasemide, may increase the hypotensive effect of Trandolapril. Torasemide may also increase the nephrotoxicity of Trandolapril. "
509,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the hypotensive effect of Trandolapril."
509,"Triamterene","DB00384","Increased risk of hyperkalemia. Monitor serum potassium levels."
509,"Trichlormethiazide","DB01021","The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
509,"Trimethoprim","DB00440","Increased risk of hyperkalemia. Monitor serum potassium levels. "
509,"Valsartan","DB00177","The angiotensin II receptor blocker, Valsartan, may increase the adverse effects of Trandolapril. "
510,"Cyclosporine","DB00091","Cyclosporine increases the effect and toxicity of caspofungin"
510,"Rifampicin","DB01045","Decreased levels/effects of caspofungin"
510,"Tacrolimus","DB00864","Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered."
511,"Acetohexamide","DB00414","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
511,"Chlorpropamide","DB00672","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
511,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
511,"Disopyramide","DB00280","The beta-blocker, carteolol, may increase the toxicity of disopyramide."
511,"Epinephrine","DB00668","Hypertension, then bradycardia"
511,"Ergotamine","DB00696","Ischemia with risk of gangrene"
511,"Fenoterol","DB01288","Antagonism"
511,"Formoterol","DB00983","Antagonism"
511,"Gliclazide","DB01120","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Glyburide","DB01016","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
511,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
511,"Insulin Glargine","DB00047","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Methyldopa","DB00968","Possible hypertensive crisis"
511,"Methysergide","DB00247","Ischemia with risk of gangrene"
511,"Orciprenaline","DB00816","Antagonism"
511,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
511,"Pipobroman","DB00236","Antagonism"
511,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
511,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
511,"Repaglinide","DB00912","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
511,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
511,"Terbutaline","DB00871","Antagonism"
511,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
511,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
514,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
514,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
514,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
514,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
514,"Lithium","DB01356","The thiazide diuretic, metolazone, may increase serum levels of lithium."
514,"Tenoxicam","DB00469","Tenoxicam may antagonize the blood pressure lowering effect of Metolazone. Monitor for changes in the therapeutic effect of Metolazone if Tenoxicam is initiated, discontinued or dose changed. "
514,"Trandolapril","DB00519","The thiazide diuretic, Metolazone, may increase the hypotensive effect of Trandolapril. Metolazone may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
514,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
516,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
516,"Topotecan","DB01030","Administration of Topotecan after Oxaliplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
516,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
518,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
519,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
519,"Ciprofloxacin","DB00537","Increased risk of convulsions"
519,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
519,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
519,"Norfloxacin","DB01059","Increased risk of convulsions"
519,"Ofloxacin","DB01165","Increased risk of convulsions"
519,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
519,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
519,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
519,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
519,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
519,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
519,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
519,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
519,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
520,"Atazanavir","DB01072","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Clarithromycin","DB01211","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Erythromycin","DB00199","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Indinavir","DB00224","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Itraconazole","DB01167","Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed."
520,"Ketoconazole","DB01026","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Nefazodone","DB01149","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Nelfinavir","DB00220","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Rifabutin","DB00615","Decreased levels/effect of erlotinib"
520,"Rifampicin","DB01045","Decreased levels/effect of erlotinib"
520,"Rifapentine","DB01201","Decreased levels/effect of erlotinib"
520,"Ritonavir","DB00503","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Saquinavir","DB01232","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"St. John's Wort","DB01323","Decreased levels/effect of erlotinib"
520,"Telithromycin","DB00976","Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed."
520,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
520,"Troleandomycin","DB01361","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
520,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed."
521,"Acenocoumarol","DB01418","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of acenocoumarol."
521,"Anisindione","DB01125","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione."
521,"Belimumab","DB08879","Avoid combination due to enhanced toxic effects of cyclophosphamide."
521,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
521,"Dicoumarol","DB00266","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of dicumarol."
521,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
521,"Etanercept","DB00005","Avoid combination due to enhanced adverse effects of cyclophosphasmide and increased risk of solid cancer development. "
521,"Filgrastim","DB00099","Monitor therapy due to adverse effects of cyclophosphamide, especially pulmonary toxicity."
521,"Fluconazole","DB00196","Fluconazole reduces metabolism and clearance of cyclophosphamide."
521,"Pentostatin","DB00552","Increased toxicity of cyclophosphamide"
521,"Succinylcholine","DB00202","Cyclophosphamide may increase the effect of succinylcholine."
521,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed. "
521,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
521,"Warfarin","DB00682","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin."
522,"Alprazolam","DB00404","Mephenytoin may increase the metabolism of alprazolam via CYP3A4."
522,"Aminophylline","DB01223","Decreased effect of both products"
522,"Amiodarone","DB01118","Increases the effect of hydantoin"
522,"Aprepitant","DB00673","The CYP3A4 inducer, mephenytoin, may decrease the effect of aprepitant."
522,"Betamethasone","DB00443","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, betamethasone."
522,"Capecitabine","DB01101","Capecitabine increases the effect of hydantoin"
522,"Chloramphenicol","DB00446","Increases phenytoin, modifies chloramphenicol"
522,"Chlordiazepoxide","DB00475","Mephenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
522,"Chlorphenamine","DB01114","The antihistamine increases the effect of hydantoin"
522,"Cimetidine","DB00501","Increases the effect of hydantoin"
522,"Ciprofloxacin","DB00537","Decreases the hydantoin effect"
522,"Clomifene","DB00882","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, clomifene."
522,"Clorazepate","DB00628","Mephenytoin may increase the metabolism of clorazepate via CYP3A4."
522,"Clozapine","DB00363","Hydantoin decreases the effect of clozapine"
522,"Conjugated Estrogens","DB00286","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, conjugated estrogens."
522,"Cyclosporine","DB00091","The hydantoin decreases the effect of cyclosporine"
522,"Dexamethasone","DB01234","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, dexamethasone."
522,"Diazepam","DB00829","Mephenytoin may increase the metabolism of diazepam via CYP3A4."
522,"Diethylstilbestrol","DB00255","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, diethylstilbestrol."
522,"Disopyramide","DB00280","The hydantoin decreases the effect of disopyramide"
522,"Disulfiram","DB00822","Increases the effect of phenytoin"
522,"Doxycycline","DB00254","The anticonvulsant, mephenytoin, decreases the effect of doxycycline."
522,"Estradiol","DB00783","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, estradiol."
522,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
522,"Felbamate","DB00949","Increased phenytoin levels and decreased felbamate levels"
522,"Felodipine","DB01023","The hydantoin decreases the effect of felodipine"
522,"Fluconazole","DB00196","Increases the effect of hydantoin"
522,"Fludrocortisone","DB00687","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
522,"Fluorouracil","DB00544","Fluorouracil increases the effect of hydantoin"
522,"Fluoxetine","DB00472","Fluoxetine increases the effect of phenytoin"
522,"Flurazepam","DB00690","Mephenytoin may increase the metabolism of flurazepam via CYP3A4."
522,"Fluvoxamine","DB00176","Increases the effect of hydantoin"
522,"Folic Acid","DB00158","Folic acid decreases the levels of hydantoin"
522,"Furosemide","DB00695","The hydantoin decreases the effect of furosemide"
522,"Gabapentin","DB00996","Increases the effect of hydantoin"
522,"Gefitinib","DB00317","The CYP3A4 inducer, mephenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
522,"Hydrocortisone","DB00741","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
522,"Imatinib","DB00619","The hydantoin decreases the levels of imatinib"
522,"Isoniazid","DB00951","Isoniazid increases the effect of phenytoin in 20% of patients"
522,"Itraconazole","DB01167","Phenytoin decreases the effect of itraconazole"
522,"Lamotrigine","DB00555","Phenytoin may reduce levels of lamotrigine"
522,"Levonorgestrel","DB00367","Phenytoin decreases the contraceptive effect"
522,"Mebendazole","DB00643","The hydantoin decreases the efficiency of mebendazole"
522,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, medroxyprogesterone."
522,"Megestrol acetate","DB00351","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, megestrol."
522,"Methadone","DB00333","The hydantoin decreases the effect of methadone"
522,"Methotrexate","DB00563","The antineoplasic agent decreases the effect of hydantoin"
522,"Methoxsalen","DB00553","The hydantoin decreases the effect of psoralene"
522,"Mexiletine","DB00379","The hydantoin decreases the effect of mexiletine"
522,"Midazolam","DB00683","Mephenytoin may increase the metabolism of midazolam via CYP3A4."
522,"Mirtazapine","DB00370","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
522,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
522,"Omeprazole","DB00338","Omeprazole increases the effect of hydantoin"
522,"Oxcarbazepine","DB00776","Oxcarbazepine increases the effect of hydantoin"
522,"Oxtriphylline","DB01303","Decreased effect of both products"
522,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the hydantoin effect of mephenytoin."
522,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the hydantoin effect of mephenytoin."
522,"Prednisolone","DB00860","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisolone."
522,"Prednisone","DB00635","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone."
522,"Quetiapine","DB01224","Phenytoin decreases the effect of quetiapine"
522,"Rifampicin","DB01045","Rifampin decreases the effect of the hydantoin"
522,"Theophylline","DB00277","Decreased effect of both products"
522,"Ticlopidine","DB00208","Ticlopidine increases the effect of hydantoin"
522,"Triamcinolone","DB00620","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone."
522,"Triazolam","DB00897","Mephenytoin may increase the metabolism of triazolam via CYP3A4."
523,"Aminophylline","DB01223","Rofecoxib increases the effect and toxicity of theophylline"
523,"Lithium","DB01356","The COX-2 inhibitor increases serum levels of lithium"
523,"Methotrexate","DB00563","Rofecoxib increases the levels of methotrexate"
523,"Oxtriphylline","DB01303","Rofecoxib increases the effect and toxicity of theophylline"
523,"Theophylline","DB00277","Rofecoxib increases the effect and toxicity of theophylline"
526,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Guanidine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
527,"Acenocoumarol","DB01418","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol."
527,"Aluminium","DB01370","Formation of non-absorbable complexes"
527,"Aminophylline","DB01223","Ciprofloxacin may increase the effect of aminophylline."
527,"Anisindione","DB01125","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione."
527,"Bendamustine","DB06769","Decreases metabolism, thus INCREASING levels of bendamustine. Decreased conversion of bendamustine to active metabolites. Concurrent administration of Ciproflaxacin or other CYP1A2 inhibitors may also increase the levels of bendamustine into active metabolites. "
527,"Caffeine","DB00201","Ciprofloxacin may increase the effect and toxicity of caffeine."
527,"Calcium","DB01373","Formation of non-absorbable complexes"
527,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ciprofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
527,"Clozapine","DB00363","Ciprofloxacin may increase clozapine serum levels"
527,"Cyclosporine","DB00091","Ciprofloxacin may increase the effect and toxicity of cyclosporine."
527,"Dicoumarol","DB00266","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of dicumarol."
527,"Dihydroxyaluminium","DB01375","Formation of non-absorbable complexes"
527,"Duloxetine","DB00476","Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of duloxetine. Monitor for changes in the therapeutic and adverse effects of duloxetine if ciprofloxacin is initiated or discontinued."
527,"Dyphylline","DB00651","Ciprofloxacin may increase the effect of dyphylline."
527,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag."
527,"Ethotoin","DB00754","Decreases the hydantoin effect"
527,"Foscarnet","DB00529","Increased risk of convulsions"
527,"Iron","DB01592","Formation of non-absorbable complexes"
527,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
527,"Lomitapide","DB08827","The effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.  "
527,"Magnesium","DB01378","Formation of non-absorbable complexes"
527,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
527,"Mephenytoin","DB00532","Decreases the hydantoin effect"
527,"Methotrexate","DB00563","Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated."
527,"Oxtriphylline","DB01303","Ciprofloxacin may increase the effect of oxtriphylline."
527,"Phenytoin","DB00252","Ciprofloxacin may decrease the therapeutic effect of phenytoin."
527,"Procainamide","DB01035","Ciprofloxacin may increase the effect of procainamide."
527,"Ramelteon","DB00980","Ciprofloxacin increases levels/toxicity of ramelteon"
527,"Rasagiline","DB01367","Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued."
527,"Ropinirole","DB00268","Ciprofloxacin may increase the effect and toxicity of ropinirole."
527,"Sevelamer","DB00658","Sevelamer decreases ciprofloxacin bioavailability"
527,"Sildenafil","DB00203","Ciprofloxacin may increase the serum level of sildenafil."
527,"Sucralfate","DB00364","Formation of non-absorbable complexes"
527,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ciprofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ciprofloxacin is initiated, discontinued or if the dose is changed."
527,"Theophylline","DB00277","Ciprofloxacin may increase the effect of theophylline."
527,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed. "
527,"Tizanidine","DB00697","Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated."
527,"Warfarin","DB00682","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin."
527,"Zinc","DB01593","Formation of non-absorbable complexes"
529,"Abarelix","DB00106","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Amiodarone","DB01118","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Amitriptyline","DB00321","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Amoxapine","DB00543","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Apomorphine","DB00714","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
529,"Asenapine","DB06216","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
529,"Chlorpromazine","DB00477","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Cisapride","DB00604","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Clarithromycin","DB01211","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Clomipramine","DB01242","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. Concurrent use of toremifene with strong CYP3A4 inhibitors should be avoided. "
529,"Dasatinib","DB01254","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Desipramine","DB01151","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Disopyramide","DB00280","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Dofetilide","DB00204","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Dolasetron","DB00757","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Domperidone","DB01184","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Doxepin","DB01142","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Droperidol","DB00450","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Erythromycin","DB00199","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Etravirine","DB06414","Toremifene, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
529,"Flecainide","DB01195","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Fluconazole","DB00196","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Fluoxetine","DB00472","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Flupentixol","DB00875","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Foscarnet","DB00529","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Gatifloxacin","DB01044","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Halofantrine","DB01218","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Haloperidol","DB00502","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Ibutilide","DB00308","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Imipramine","DB00458","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Indapamide","DB00808","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Isradipine","DB00270","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Lapatinib","DB01259","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Levofloxacin","DB01137","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Loxapine","DB00408","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
529,"Maprotiline","DB00934","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Mefloquine","DB00358","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Mesoridazine","DB00933","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Methadone","DB00333","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Moxifloxacin","DB00218","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Nilotinib","DB04868","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
529,"Norfloxacin","DB01059","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Nortriptyline","DB00540","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Octreotide","DB00104","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Pazopanib","DB06589","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
529,"Pentamidine","DB00738","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Perflutren","DB00556","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Pimozide","DB01100","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Probucol","DB01599","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Procainamide","DB01035","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Propafenone","DB01182","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Protriptyline","DB00344","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Quetiapine","DB01224","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Quinidine","DB00908","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Quinine","DB00468","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
529,"Ranolazine","DB00243","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Rifabutin","DB00615","The rifamycin decreases the effect of anti-estrogen"
529,"Rifampicin","DB01045","The rifamycin decreases the effect of anti-estrogen"
529,"Risperidone","DB00734","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Sotalol","DB00489","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Sparfloxacin","DB01208","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Sunitinib","DB01268","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Tacrolimus","DB00864","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Telithromycin","DB00976","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Tetrabenazine","DB04844","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
529,"Thioridazine","DB00679","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
529,"Thiothixene","DB01623","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Voriconazole","DB00582","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Vorinostat","DB02546","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
529,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
529,"Zuclopenthixol","DB01624","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
530,"Altretamine","DB00488","Risk of hypotension"
530,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
530,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if atazanavir if initiated, discontinued or dose changed."
530,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
530,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as nortriptyline. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
530,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed."
530,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if cimetidine is initiated, discontinued or dose changed."
530,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
530,"Clonidine","DB00575","The tricyclic antidepressant, nortriptyline, decreases the effect of clonidine."
530,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
530,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline."
530,"Dobutamine","DB00841","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine."
530,"Donepezil","DB00843","Possible antagonism of action"
530,"Dopamine","DB00988","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dopamine."
530,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
530,"Ephedra","DB01363","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedra."
530,"Ephedrine","DB01364","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedrine."
530,"Epinephrine","DB00668","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of epinephrine."
530,"Fenoterol","DB01288","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of fenoterol."
530,"Fluconazole","DB00196","Fluconazole may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive QTc-prolonging effects may also occur. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluconazole is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
530,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluoxetine is initiated, discontinued or dose changed."
530,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of nortriptyline if fluvoxamine is initiated, discontinued or dose changed."
530,"Galantamine","DB00674","Possible antagonism of action"
530,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
530,"Guanethidine","DB01170","The tricyclic antidepressant, nortriptyline, decreases the effect of guanethidine."
530,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
530,"Isoprenaline","DB01064","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of isoproterenol."
530,"Ketoconazole","DB01026","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed."
530,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
530,"Mephentermine","DB01365","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of mephentermine."
530,"Metaraminol","DB00610","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol."
530,"Methoxamine","DB00723","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine."
530,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
530,"Norepinephrine","DB00368","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of norepinephrine."
530,"Orciprenaline","DB00816","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of orciprenaline."
530,"Phenelzine","DB00780","Possibility of severe adverse effects"
530,"Phenylephrine","DB00388","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylephrine."
530,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of phenylpropanolamine."
530,"Pirbuterol","DB01291","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pirbuterol."
530,"Procaterol","DB01366","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of procaterol."
530,"Pseudoephedrine","DB00852","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pseudoephedrine."
530,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
530,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline."
530,"Rasagiline","DB01367","Possibility of severe adverse effects"
530,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifabutin is initiated, discontinued or dose changed."
530,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed."
530,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ritonavir if initiated, discontinued or dose changed."
530,"Rivastigmine","DB00989","Possible antagonism of action"
530,"Salbutamol","DB01001","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of salbutamol."
530,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
530,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
530,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Nortriptyline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
530,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
530,"Terbinafine","DB00857","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if terbinafine is initiated, discontinued or dose changed."
530,"Terbutaline","DB00871","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of terbutaline."
530,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
530,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
530,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
530,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. "
530,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
530,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
530,"Trimethobenzamide","DB00662","Trimethobenzamide and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
530,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
530,"Triprolidine","DB00427","Triprolidine and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
530,"Trospium","DB00209","Trospium and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
530,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
530,"Vilazodone","DB06684","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved. "
530,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
530,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
530,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
530,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
530,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
531,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed.\
"
531,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, vincristine."
531,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Atazanavir is initiated, discontinued or dose changed."
531,"Clarithromycin","DB01211","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Clarithromycin is initiated, discontinued or dose changed."
531,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Conivaptan is initiated, discontinued or dose changed."
531,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Darunavir is initiated, discontinued or dose changed."
531,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Delavirdine is initiated, discontinued or dose changed."
531,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
531,"Dirithromycin","DB00954","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Dirithromycin is initiated, discontinued or dose changed.\
"
531,"Erythromycin","DB00199","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Erythromycin is initiated, discontinued or dose changed."
531,"Etravirine","DB06414","Vincristine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
531,"Fluconazole","DB00196","Increases the effect and toxicity of anticancer agent"
531,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Fosamprenavir is initiated, discontinued or dose changed."
531,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Imatinib is initiated, discontinued or dose changed."
531,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Indinavir is initiated, discontinued or dose changed."
531,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed."
531,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed."
531,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed."
531,"Leflunomide","DB01097","Vincristine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vincristine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.\
"
531,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Lopinavir is initiated, discontinued or dose changed."
531,"Miconazole","DB01110","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Miconazole is initiated, discontinued or dose changed."
531,"Mitomycin","DB00305","Potentially severe lung toxicity"
531,"Natalizumab","DB00108","Concomitant Vincristine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided.\
"
531,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nefazodone is initiated, discontinued or dose changed."
531,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nelfinavir is initiated, discontinued or dose changed."
531,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed."
531,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Posaconazole is initiated, discontinued or dose changed."
531,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Quinidine is initiated, discontinued or dose changed."
531,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
531,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed."
531,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Saquinavir is initiated, discontinued or dose changed."
531,"Spiramycin","DB06145","Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Spiramycin is initiated, discontinued or dose changed."
531,"Telithromycin","DB00976","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Telithromycin is initiated, discontinued or dose changed."
531,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
531,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Voriconazole is initiated, discontinued or dose changed."
532,"Amiloride","DB00594","Increased risk of hyperkalemia"
532,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
532,"Drospirenone","DB01395","Increased risk of hyperkalemia"
532,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
532,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
532,"Potassium","DB01345","Increased risk of hyperkalemia"
532,"Spironolactone","DB00421","Increased risk of hyperkalemia"
532,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
532,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
532,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
532,"Triamterene","DB00384","Increased risk of hyperkalemia"
533,"Altretamine","DB00488","Risk of severe hypotension"
533,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
533,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed."
533,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like amoxipine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
533,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants amoxapine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
533,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if cimetidine is initiated, discontinued or dose changed."
533,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
533,"Clonidine","DB00575","The tricyclic antidepressant, amoxapine, decreases the effect of clonidine."
533,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
533,"Dobutamine","DB00841","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine."
533,"Donepezil","DB00843","Possible antagonism of action"
533,"Dopamine","DB00988","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dopamine."
533,"Ephedra","DB01363","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedra."
533,"Ephedrine","DB01364","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedrine."
533,"Epinephrine","DB00668","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of epinephrine."
533,"Fenoterol","DB01288","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol."
533,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluoxetine is initiated, discontinued or dose changed."
533,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of amoxapine if fluvoxamine is initiated, discontinued or dose changed."
533,"Galantamine","DB00674","Possible antagonism of action"
533,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
533,"Guanethidine","DB01170","The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine."
533,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
533,"Isoprenaline","DB01064","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of isoproterenol."
533,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
533,"Mephentermine","DB01365","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine."
533,"Metaraminol","DB00610","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol."
533,"Methoxamine","DB00723","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine."
533,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
533,"Norepinephrine","DB00368","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of norepinephrine."
533,"Orciprenaline","DB00816","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline."
533,"Phenelzine","DB00780","Possibility of severe adverse effects"
533,"Phenylephrine","DB00388","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylephrine."
533,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of phenylpropanolamine."
533,"Pirbuterol","DB01291","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pirbuterol."
533,"Procaterol","DB01366","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of procaterol."
533,"Pseudoephedrine","DB00852","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pseudoephedrine."
533,"Rasagiline","DB01367","Possibility of severe adverse effects"
533,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed."
533,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed."
533,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed."
533,"Rivastigmine","DB00989","Possible antagonism of action"
533,"Salbutamol","DB01001","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of salbutamol."
533,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
533,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
533,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Amoxapine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
533,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
533,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Amoxapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Amoxapine if Terbinafine is initiated, discontinued or dose changed."
533,"Terbutaline","DB00871","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of terbutaline."
533,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
533,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
533,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
533,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. "
533,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
533,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
533,"Trimethobenzamide","DB00662","Trimethobenzamide and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
533,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
533,"Triprolidine","DB00427","Triprolidine and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
533,"Trospium","DB00209","Trospium and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
533,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
533,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
533,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
533,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
533,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
533,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
534,"Acenocoumarol","DB01418","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of acenocoumarol."
534,"Anisindione","DB01125","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione."
534,"Dicoumarol","DB00266","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of dicumarol."
534,"Ethotoin","DB00754","Fluorouracil increases the effect of hydantoin"
534,"Fosphenytoin","DB01320","Fluorouracil increases the effect of hydantoin"
534,"Mephenytoin","DB00532","Fluorouracil increases the effect of hydantoin"
534,"Metronidazole","DB00916","Risk of 5-FU toxicity when associated with metronidazole"
534,"Phenytoin","DB00252","Fluorouracil increases the effect of hydantoin"
534,"Tamoxifen","DB00675","Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed."
534,"Temsirolimus","DB06287","Co-administration of Temsirolimus and Fluorouracil may result in serious adverse drug reactions. "
534,"Tolbutamide","DB01124","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed. "
534,"Torasemide","DB00214","Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Fluorouracil is initiated, discontinued or dose changed. "
534,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
534,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Fluorouracil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Fluorouracil is initiated, discontinued or dose changed."
534,"Voriconazole","DB00582","Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed.	"
534,"Warfarin","DB00682","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed."
534,"Zafirlukast","DB00549","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed."
535,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Corticotropin","DB01285","The corticosteroid, corticotropin, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Cortisone acetate","DB01380","The corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Methylprednisolone","DB00959","The corticosteroid, methylprednisolone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Paramethasone","DB01384","The corticosteroid, paramethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine."
535,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine."
539,"Acenocoumarol","DB01418","Zafirlukast may inhibit the metabolism of the vitamin K antagonist Acenocoumarol and increase INR and risk of bleeding."
539,"Aminophylline","DB01223","Zafirlukast serum concentrations may be decreased by the theophylline derivative Aminophylline."
539,"Capecitabine","DB01101","Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed."
539,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
539,"Delavirdine","DB00705","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if delavirdine is initiated, discontinued or dose changed."
539,"Erythromycin","DB00199","Erythromycin may decrease the serum concentration and effect of zafirlukast."
539,"Floxuridine","DB00322","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if floxuridine is initiated, discontinued or dose changed."
539,"Fluconazole","DB00196","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluconazole is initiated, discontinued or dose changed."
539,"Fluorouracil","DB00544","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if fluorouracil is initiated, discontinued or dose changed."
539,"Gemfibrozil","DB01241","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if gemfibrozil is initiated, discontinued or dose changed."
539,"Ketoconazole","DB01026","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed."
539,"Nicardipine","DB00622","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed."
539,"Roflumilast","DB01656","Increases roflumilast levels. "
539,"Sitaxentan","DB06268","Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sitaxentan is initiated, discontinued or dose changed."
539,"Sulfadiazine","DB00359","Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfadiazine is initiated, discontinued or dose changed."
539,"Sulfisoxazole","DB00263","Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sulfisoxazole is initiated, discontinued or dose changed."
539,"Theophylline","DB00277","Zafirlukast serum concentrations may be decreased by Theophylline."
539,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed."
540,"Acenocoumarol","DB01418","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of acenocoumarol."
540,"Anisindione","DB01125","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of anisindione."
540,"Dicoumarol","DB00266","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of dicumarol."
540,"Digoxin","DB00390","The antithyroid agent may increase the effect of digoxin."
540,"Warfarin","DB00682","Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed."
542,"Cyclophosphamide","DB00531","Increased toxicity of cyclophosphamide"
542,"Fludarabine","DB01073","Unacceptable pulmonary toxicity"
542,"Pegademase bovine","DB00061","Avoid combination due to decreased effect of both drugs"
542,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
543,"Ethotoin","DB00754","The hydantoin decreases the effect of psoralene"
543,"Fosphenytoin","DB01320","The hydantoin decreases the effect of psoralene"
543,"Mephenytoin","DB00532","The hydantoin decreases the effect of psoralene"
543,"Phenytoin","DB00252","The hydantoin decreases the effect of psoralene"
543,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Methoxsalen. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Methoxsalen is initiated, discontinued or if the dose is changed."
543,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Methoxsalen, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Methoxsalen is initiated, discontinued or dose changed. "
543,"Tizanidine","DB00697","Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
544,"Acebutolol","DB01193","Risk of inhibition of renal prostaglandins"
544,"Acenocoumarol","DB01418","The NSAID, piroxicam, may increase the anticoagulant effect of acenocoumarol."
544,"Alendronate","DB00630","Increased risk of gastric toxicity"
544,"Anisindione","DB01125","The NSAID, piroxicam, may increase the anticoagulant effect of anisindione."
544,"Atenolol","DB00335","Risk of inhibition of renal prostaglandins"
544,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
544,"Betaxolol","DB00195","Nonsteroidal Anti-Inflammatory Agents such as piroxicam may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
544,"Bevantolol","DB01295","Risk of inhibition of renal prostaglandins"
544,"Bisoprolol","DB00612","Risk of inhibition of renal prostaglandins"
544,"Carteolol","DB00521","Risk of inhibition of renal prostaglandins"
544,"Carvedilol","DB01136","Risk of inhibition of renal prostaglandins"
544,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
544,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
544,"Dicoumarol","DB00266","The NSAID, piroxicam, may increase the anticoagulant effect of dicumarol."
544,"Esmolol","DB00187","Risk of inhibition of renal prostaglandins"
544,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
544,"Labetalol","DB00598","Risk of inhibition of renal prostaglandins"
544,"Lithium","DB01356","The NSAID, piroxicam, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
544,"Methotrexate","DB00563","The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
544,"Metoprolol","DB00264","Risk of inhibition of renal prostaglandins"
544,"Nadolol","DB01203","Risk of inhibition of renal prostaglandins"
544,"Oxprenolol","DB01580","Risk of inhibition of renal prostaglandins"
544,"Penbutolol","DB01359","Risk of inhibition of renal prostaglandins"
544,"Pindolol","DB00960","Risk of inhibition of renal prostaglandins"
544,"Practolol","DB01297","Risk of inhibition of renal prostaglandins"
544,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
544,"Propranolol","DB00571","Risk of inhibition of renal prostaglandins"
544,"Ritonavir","DB00503","Ritonavir increases the toxicity of piroxicam"
544,"Sotalol","DB00489","Risk of inhibition of renal prostaglandins"
544,"Tamoxifen","DB00675","Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed."
544,"Telmisartan","DB00966","Concomitant use of Telmisartan and Piroxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
544,"Timolol","DB00373","Risk of inhibition of renal prostaglandins"
544,"Tolbutamide","DB01124","Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed. "
544,"Torasemide","DB00214","Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Piroxicam is initiated, discontinued or dose changed. "
544,"Trandolapril","DB00519","The NSAID, Piroxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Piroxicam is initiated, discontinued or dose changed. "
544,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Piroxicam. Monitor for increased bleeding during concomitant thearpy. "
544,"Triflusal","DB08814","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
544,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Piroxicam, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Piroxicam is initiated, discontinued or dose changed."
544,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of NSAIDs and vilazodone"
544,"Voriconazole","DB00582","Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed.	"
544,"Warfarin","DB00682","Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed."
545,"Butabarbital","DB00237","Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
545,"Butalbital","DB00241","Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. "
545,"Carbamazepine","DB00564","Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed."
545,"Clozapine","DB00363","Lamotrigine increases the effect and toxicity of clozapine"
545,"Desogestrel","DB00304","The oral contraceptive decreases the effect of lamotrigine"
545,"Ethinyl Estradiol","DB00977","The oral contraceptive decreases the effect of lamotrigine"
545,"Ethotoin","DB00754","Phenytoin may reduce levels of lamotrigine"
545,"Ezogabine","DB04953","In healthy adults, the AUCs of lamotrigine and ezogabine were both increased. The clinical significance of this is still unknown. Multiple doses of ezogabine also increase the clearance and decrease the terminal half-life of lamotrigine. "
545,"Fosphenytoin","DB01320","Phenytoin may reduce levels of lamotrigine"
545,"Mephenytoin","DB00532","Phenytoin may reduce levels of lamotrigine"
545,"Mestranol","DB01357","The oral contraceptive decreases the effect of lamotrigine"
545,"Methsuximide","DB05246","Methsuximide decreases the effect of lamotrigine"
545,"Norethindrone","DB00717","The oral contraceptive decreases the effect of lamotrigine"
545,"Phenytoin","DB00252","Phenytoin may reduce levels of lamotrigine"
545,"Rifampicin","DB01045","Rifampin decreases levels of lamotrigine"
545,"Thiopental","DB00599","Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated."
545,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
545,"Valproic Acid","DB00313","Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. "
546,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
546,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
546,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
546,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
546,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
546,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
546,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
546,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
546,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
546,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
547,"Butabarbital","DB00237","Hydroxyzine may enhance the CNS depressant effect of barbiturates like butabarbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination.  "
547,"Butalbital","DB00241","Hydroxyzine may enhance the CNS depressant effect of barbiturates such as butalbital. Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine. With concurrent use, monitor patients closely for excessive response to the combination. "
547,"Dihydrocodeine","DB01551","May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. "
547,"Donepezil","DB00843","Possible antagonism of action"
547,"Galantamine","DB00674","Possible antagonism of action"
547,"Rivastigmine","DB00989","Possible antagonism of action"
547,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Hydroxyzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
547,"Trimethobenzamide","DB00662","Trimethobenzamide and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
547,"Triprolidine","DB00427","Triprolidine and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
547,"Trospium","DB00209","Trospium and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
549,"Acenocoumarol","DB01418","Bosentan may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
549,"Anisindione","DB01125","Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism."
549,"Atorvastatin","DB01076","Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed."
549,"Cerivastatin","DB00439","Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed."
549,"Cyclosporine","DB00091","Cyclosporine may increase the effect and toxicity of bosentan."
549,"Dicoumarol","DB00266","Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism."
549,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
549,"Ethinyl Estradiol","DB00977","Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
549,"Glyburide","DB01016","Increased risk of hepatic toxicity"
549,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of bosentan."
549,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of bosentan."
549,"Lovastatin","DB00227","Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed."
549,"Lurasidone","DB08815","Concomitant therapy with a CYP3A4 substrate and inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
549,"Medroxyprogesterone Acetate","DB00603","Bosentan may decrease the contraceptive effect of medroxyprogesterone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
549,"Mestranol","DB01357","Decreases the effect of contraceptive"
549,"Norethindrone","DB00717","Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
549,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
549,"Simvastatin","DB00641","Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed."
549,"Telithromycin","DB00976","Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy."
549,"Temsirolimus","DB06287","Bosentan may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
549,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
549,"Tramadol","DB00193","Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
549,"Trazodone","DB00656","The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed."
549,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
549,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. "
549,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed."
549,"Warfarin","DB00682","Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism."
550,"Acenocoumarol","DB01418","Tigecycline may increase the anticoagulant effect of acenocoumarol."
550,"Anisindione","DB01125","Tigecycline may increase the anticoagulant effect of anisindione."
550,"Bexarotene","DB00307","Tigecycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri (intracranial hypertension) is of particular concern. Avoid this combination."
550,"Dicoumarol","DB00266","Tigecycline may increase the anticoagulant effect of dicumarol."
550,"Tretinoin","DB00755","Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
550,"Warfarin","DB00682","Tigecycline may increase the serum concentration of warfarin."
552,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
552,"Lithium","DB01356","The thiazide diuretic, benzthiazide, may increase serum levels of lithium."
553,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect and toxicity of methotrexate."
553,"Acitretin","DB00459","Acitretin/etretinate increases the effect and toxicity of methotrexate"
553,"Amoxicillin","DB01060","The penicillin increases the effect and toxicity of methotrexate"
553,"Ampicillin","DB00415","The penicillin increases the effect and toxicity of methotrexate"
553,"Bacampicillin","DB01602","The penicillin increases the effect and toxicity of methotrexate"
553,"Benzylpenicillin","DB01053","The penicillin increases the effect and toxicity of methotrexate"
553,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, increases the effect and toxicity of methotrexate."
553,"Carbenicillin","DB00578","The penicillin increases the effect and toxicity of methotrexate"
553,"Cholestyramine","DB01432","Decreased levels of methotrexate"
553,"Ciprofloxacin","DB00537","Ciprofloxacine may decrease the metabolism of methotrexate. Monitor for changes adverse effects of methotrexate if ciprofloxacin is initiated."
553,"Cisplatin","DB00515","Cisplatin increases methotrexate toxicity"
553,"Clavulanate","DB00766","The penicillin increases the effect and toxicity of methotrexate"
553,"Cloxacillin","DB01147","The penicillin increases the effect and toxicity of methotrexate"
553,"Cyclosporine","DB00091","Cyclosporine may increase the effect and toxicity of methotrexate."
553,"Diclofenac","DB00586","The NSAID, diclofenac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Dicloxacillin","DB00485","The penicillin increases the effect and toxicity of methotrexate"
553,"Diflunisal","DB00861","The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. "
553,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
553,"Doxycycline","DB00254","The tetracycline, doxycycline, may increase methotrexate toxicity."
553,"Eltrombopag","DB06210","Increases levels of Methotrexate via metabolism decrease. OATP transporter protein inhibition."
553,"Ethotoin","DB00754","The antineoplasic agent decreases the effect of hydantoin"
553,"Etodolac","DB00749","The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Etretinate","DB00926","Acitretin/etretinate increases the effect and toxicity of methotrexate"
553,"Fenoprofen","DB00573","The NSAID, fenoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Flucloxacillin","DB00301","The penicillin increases the effect and toxicity of methotrexate"
553,"Flurbiprofen","DB00712","The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
553,"Hydroxychloroquine","DB01611","Hydroxychloroquine increases the effect and toxicity of methotrexate"
553,"Ibuprofen","DB01050","The NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Ketoprofen","DB01009","The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Ketorolac","DB00465","The NSAID, ketorolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Magnesium salicylate","DB01397","The salicylate, magnesium salicylate, increases the effect and toxicity of methotrexate."
553,"Meclofenamic acid","DB00939","The NSAID, meclofenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Mefenamic acid","DB00784","The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Mephenytoin","DB00532","The antineoplasic agent decreases the effect of hydantoin"
553,"Methicillin Acyl-Serine","DB02443","The penicillin increases the effect and toxicity of methotrexate"
553,"Mezlocillin","DB00948","The penicillin increases the effect and toxicity of methotrexate"
553,"Nabumetone","DB00461","The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Nafcillin","DB00607","The penicillin increases the effect and toxicity of methotrexate"
553,"Naproxen","DB00788","The NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Omeprazole","DB00338","Omeprazole increases the levels of methotrexate"
553,"Oxaprozin","DB00991","The NSAID, oxaprozin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Penicillin V","DB00417","The penicillin increases the effect and toxicity of methotrexate"
553,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
553,"Piperacillin","DB00319","The penicillin increases the effect and toxicity of methotrexate"
553,"Piroxicam","DB00554","The NSAID, piroxicam, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
553,"Pivampicillin","DB01604","The penicillin increases the effect and toxicity of methotrexate"
553,"Probenecid","DB01032","Probenecid increases the effect and toxicity of methotrexate"
553,"Procarbazine","DB01168","Increased nephrotoxicity with this combination"
553,"Rilonacept","DB06372","Rilonacept and methotrexate both increase immunosuppressive effects; combination may increase risk of myelosuppression. "
553,"Rofecoxib","DB00533","Rofecoxib increases the levels of methotrexate"
553,"Salicylate-sodium","DB01398","The salicylate, salicylate-sodium, increases the effect and toxicity of methotrexate."
553,"Salsalate","DB01399","The salicylate, salsalate, increases the effect and toxicity of methotrexate."
553,"Sulfacytine","DB01298","The sulfamide increases the toxicity of methotrexate"
553,"Sulfadiazine","DB00359","The sulfamide increases the toxicity of methotrexate"
553,"Sulfadimethoxine","DB06150","The sulfamide increases the toxicity of methotrexate"
553,"Sulfadoxine","DB01299","The sulfamide increases the toxicity of methotrexate"
553,"Sulfamerazine","DB01581","The sulfamide increases the toxicity of methotrexate"
553,"Sulfamethazine","DB01582","The sulfamide increases the toxicity of methotrexate"
553,"Sulfamethizole","DB00576","The sulfamide increases the toxicity of methotrexate"
553,"Sulfamethoxazole","DB01015","The sulfamide increases the toxicity of methotrexate"
553,"Sulfapyridine","DB00891","The sulfamide increases the toxicity of methotrexate"
553,"Sulfathiazole","DB06147","The sulfamide increases the toxicity of methotrexate"
553,"Sulfisoxazole","DB00263","The sulfamide increases the toxicity of methotrexate"
553,"Sulindac","DB00605","The NSAID, sulindac, may decrease the clearance methotrexate. Consider alternate therapy, especially in patients receiving high antineoplastic doses of methotrexate. Otherwise, monitor for hematologic and renal toxicities."
553,"Tenoxicam","DB00469","Tenoxicam may increase the serum concentration of Methotrexate by reducing renal tubular secretion of Methotrexate. Monitor for changes in Methotrexate therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed."
553,"Tetracycline","DB00759","Tetracycline may increase methotrexate toxicity."
553,"Tiaprofenic acid","DB01600","Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity."
553,"Ticarcillin","DB01607","The penicillin increases the effect and toxicity of methotrexate"
553,"Tolmetin","DB00500","Tolmetin may decrease the renal excretion of Methotrexate. Alternate therapy should be considered. Otherwise, monitor for hemotologic and renal toxicities."
553,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
553,"Trimethoprim","DB00440","Trimethoprim may increase the adverse/toxic effects of Methotrexate (e.g. bone marrow suppression). Concomitant use should be avoided or closely monitored for Methotrexate toxicity."
553,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, increases the effect and toxicity of methotrexate."
554,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
554,"Acenocoumarol","DB01418","Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration."
554,"Alprazolam","DB00404","Carbamazepine may decrease the effect of the benzodiazepine, alprazolam."
554,"Aminophylline","DB01223","Carbamazepine may decrease the serum concentration of aminophylline. Aminophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
554,"Amitriptyline","DB00321","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if carbamazepine is initiated, discontinued or dose changed."
554,"Anisindione","DB01125","Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration."
554,"Aprepitant","DB00673","The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant."
554,"Aripiprazole","DB01238","Carbamazepine, a strong CYP3A4 inducer, may decrease the serum concentration of aripiprazole by increasing its metabolism."
554,"Asenapine","DB06216","Carbamazepine is a CYP1A2 inducer that decreases asenapine's exposure by 20%. "
554,"Atorvastatin","DB01076","Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed."
554,"Atracurium","DB00732","Decreases the effect of muscle relaxant"
554,"Bendamustine","DB06769","Decreases levels of bendamustine by affecting CYP1A2 hepatic enzyme metabolism. May increase concentrations of active metabolites. "
554,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
554,"Bupropion","DB01156","Carbamazepine, a strong CYP2B6 inducer, may increase the metabolism of bupropion. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bupropion if carbamazepine is initiated, discontinued or dose changed."
554,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
554,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of carbamazepine during the first few days of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of carbamazepine if cimetidine is initiated, discontinued or dose changed."
554,"Clarithromycin","DB01211","Clarithromycin may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic or adverse effects of carbamazepine if clarithromycin is initiated, discontinued or dose changed."
554,"Clozapine","DB00363","Carbamazepine may decrease the serum concentration of clozapine by increasing its metabolism. Concomitant therapy should also be avoided due to increased risk of bone marrow suppression. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of clozapine if carbamazepine is initiated, discontinued or dose changed."
554,"Cyclosporine","DB00091","Carbamazepine may decrease the therapeutic effect of cyclosporine."
554,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
554,"Dabrafenib","DB08912","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
554,"Danazol","DB01406","Danazol may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of carbamazepine if danazol is initiated, discontinued or dose changed."
554,"Delavirdine","DB00705","The anticonvulsant, carbamazepine, decreases the effect of delavirdine."
554,"Desipramine","DB01151","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed."
554,"Dextropropoxyphene","DB00647","Propoxyphene increases the effect of carbamazepine"
554,"Dicoumarol","DB00266","Carbamazepine may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."
554,"Diltiazem","DB00343","Carbamazepine may decrease the serum concentration of diltiazem by increasing its metabolism. Diltiazem may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if dosages are changed."
554,"Doxacurium chloride","DB01135","Decreases the effect of muscle relaxant"
554,"Doxepin","DB01142","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed."
554,"Doxycycline","DB00254","The anticonvulsant, carbamazepine, may decrease the therapeutic effect of doxycycline."
554,"Dyphylline","DB00651","Carbamazepine may decrease the serum concentration of diphylline. Diphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
554,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
554,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of carbamazepine."
554,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
554,"Ethinyl Estradiol","DB00977","Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine."
554,"Etravirine","DB06414","Carbamazepine, when used concomitantly with certain NNRTIs (ie. efavirenz), may experience a decrease in serum concentration. \
\
Etravirine, and other NNRTIs, when used concomitantly with carbamazepine, may experience an increase in serum concentration. \
\
It is recommended to avoid this combination. "
554,"Ezogabine","DB04953","Ezogabine increases the clearance of carbamazepine (30%). The mechanism of this interaction is unknown. "
554,"Felbamate","DB00949","Decreased effect of both products"
554,"Felodipine","DB01023","Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed."
554,"Fluconazole","DB00196","Fluconazole may increase the therapeutic and adverse effects of carbamazepine."
554,"Fluoxetine","DB00472","Carbamazepine may decrease the serum concentration of fluoxetine by increasing its metabolism. Fluoxetine may increase the serum concentration of carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses are changed."
554,"Fluvoxamine","DB00176","Fluvoxamine increases the effect of carbamazepine"
554,"Gefitinib","DB00317","The CYP3A4 inducer, carbamazepine, may decrease the serum concentration and therapeutic effects of gefitinib."
554,"Haloperidol","DB00502","Carbamazepine may decrease the serum concentration of haloperidol by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of haloperidol if carbamazepine is initiated, discontinued or dose changed."
554,"Imatinib","DB00619","Carbamazepine, a strong CYP3A4 inducer, may increase the metabolism of imatinib. Imatinib, a strong CYP3A4 inhibitor, may increase the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed."
554,"Imipramine","DB00458","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if carbamazepine is initiated, discontinued or dose changed."
554,"Indinavir","DB00224","Indinavir increases the effect and toxicity of carbamazepine"
554,"Isoniazid","DB00951","Carbamazepine effect is increased as is isoniazid toxicity"
554,"Isotretinoin","DB00982","Isotretinoine decreases the effect of carbamazepine"
554,"Itraconazole","DB01167","Itraconazole may increase the effect of carbamazepine."
554,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
554,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of carbamazepine."
554,"Ketoconazole","DB01026","Ketoconazole may increase the effect of carbamazepine."
554,"Lamotrigine","DB00555","Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed."
554,"Levetiracetam","DB01202","Concomitant therapy may results in additive adverse CNS effects."
554,"Levonorgestrel","DB00367","Carbamazepine may decrease the contraceptive effect of levonorgestrel."
554,"Linagliptin","DB08882","CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. "
554,"Lovastatin","DB00227","Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed."
554,"Lurasidone","DB08815","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
554,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
554,"Methadone","DB00333","Carbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed."
554,"Methylphenidate","DB00422","Carbamazepine may decrease the effect of methylphendiate."
554,"Metocurine","DB01336","Decreases the effect of muscle relaxant"
554,"Metronidazole","DB00916","Metronidazole increases the effect of carbamazepine"
554,"Midazolam","DB00683","Carbamazepine may decrease the effect of the benzodiazepine, midazolam."
554,"Mivacurium","DB01226","Decrease the effect of muscle relaxant"
554,"Nefazodone","DB01149","Nefazodone increases the effect of carbamazepine"
554,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
554,"Nortriptyline","DB00540","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if carbamazepine is initiated, discontinued or dose changed."
554,"Oxtriphylline","DB01303","Carbamazepine may decrease the serum concentration of oxtriphylline. Oxtriphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
554,"Oxybutynin","DB01062","Oxybutynin may cause carbamazepine toxicity"
554,"Pancuronium","DB01337","Decreases the effect of muscle relaxant"
554,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
554,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
554,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
554,"Praziquantel","DB01058","Markedly lower praziquantel levels"
554,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
554,"Regorafenib","DB08896","Strong CYP3A4 inducers may decrease levels of regorafenib. "
554,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
554,"Risperidone","DB00734","Decreases the effect of risperidone"
554,"Ritonavir","DB00503","Ritonavir increases the effect of carbamazepine"
554,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
554,"Rufinamide","DB06201","Decrease concentration of rufinamide thus monitor therapy "
554,"Sertraline","DB01104","Sertraline increases the effect of carbamazepine"
554,"Simvastatin","DB00641","Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed."
554,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
554,"Tacrolimus","DB00864","Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered."
554,"Telithromycin","DB00976","Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy."
554,"Temsirolimus","DB06287","Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
554,"Theophylline","DB00277","Carbamazepine may decrease the serum concentration of theophylline. Theophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
554,"Ticlopidine","DB00208","Ticlopidine increases the effect of carbamazepine"
554,"Tipranavir","DB00932","Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations. "
554,"Tolvaptan","DB06212","Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
554,"Topiramate","DB00273","Carbamazepine may decrease the effectiveness of Topiramate by increase its clearance. Monitor for changes in the therapeutic and adverse effects of Topiramate if Carbamazepine is initiated, discontinued or dose changed. Adverse effects related to CNS depression have also been observed during concomitant therapy."
554,"Tramadol","DB00193","Carbamazepine may decrease the effect of tramadol by increasing Tramadol metabolism and clearance."
554,"Trazodone","DB00656","The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed."
554,"Tretinoin","DB00755","The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed. "
554,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Carbamazepine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
554,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect of carbamazepine."
554,"Tubocurarine","DB01199","Decreases the effect of muscle relaxant"
554,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
554,"Valproic Acid","DB00313","Decreases the effect of valproic acid"
554,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. "
554,"Vecuronium","DB01339","Decreases the effect of muscle relaxant"
554,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
554,"Verapamil","DB00661","Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed."
554,"Vilazodone","DB06684","Carbamazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors (SSRI). Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Carbamazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes."
554,"Voriconazole","DB00582","Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated."
554,"Warfarin","DB00682","Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed."
554,"Ziprasidone","DB00246","Increases the effect and toxicity of ziprasidone"
555,"Colistimethate","DB01111","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
557,"Probenecid","DB01032","Probenecid may increase the serum level of cephalexin."
559,"Drotrecogin alfa","DB00055","Drotrecogin alfa may increase the adverse effects of fondaparinux, resulting in excessive bleeding. Concomitant use should be avoided."
559,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
560,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Amprenavir is initiated, discontinued or dose changed. "
560,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, vinblastine. "
560,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Atazanavir is initiated, discontinued or dose changed."
560,"Clarithromycin","DB01211","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Clarithromycin is initiated, discontinued or dose changed."
560,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Conivaptan is initiated, discontinued or dose changed."
560,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as vinblastine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
560,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Darunavir is initiated, discontinued or dose changed."
560,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Delavirdine is initiated, discontinued or dose changed."
560,"Dirithromycin","DB00954","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Dirithromycin is initiated, discontinued or dose changed."
560,"Erythromycin","DB00199","Erythromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of vinblastine if erythromycin is initiated, discontinued or dose changed."
560,"Fluconazole","DB00196","Increases the effect and toxicity of anticancer agent"
560,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Fosamprenavir is initiated, discontinued or dose changed."
560,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
560,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Imatinib is initiated, discontinued or dose changed."
560,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Indinavir is initiated, discontinued or dose changed."
560,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed."
560,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed."
560,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed."
560,"Leflunomide","DB01097","Vinblastine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinblastine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy. "
560,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Lopinavir is initiated, discontinued or dose changed."
560,"Miconazole","DB01110","Miconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Miconazole is initiated, discontinued or dose changed."
560,"Mitomycin","DB00305","Potentially severe lung toxicity"
560,"Natalizumab","DB00108","Concomitant Vinblastine and Natalizumab therapy may increase the risk of infection. Concurrent therapy should be avoided. "
560,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nefazodone is initiated, discontinued or dose changed."
560,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nelfinavir is initiated, discontinued or dose changed."
560,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed."
560,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
560,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Posaconazole is initiated, discontinued or dose changed."
560,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Quinidine is initiated, discontinued or dose changed."
560,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
560,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ritonavir is initiated, discontinued or dose changed."
560,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Saquinavir is initiated, discontinued or dose changed."
560,"Spiramycin","DB06145","Spiramycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Spiramycin is initiated, discontinued or dose changed."
560,"Telithromycin","DB00976","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed."
560,"Tolterodine","DB01036","Vinblastine, a CYP3A4 inhibitor, may increase the serum concentration of Tolterodine by decreasing its metabolism. Poor CYP2D6 metabolizers metabolize Tolterodine via CYP3A4. A dose adjustment of Tolterodine may be required. Monitor for changes in the therapeutic/adverse effects of Tolterodine if Vinblastine is initiated, discontinued or dose changed. "
560,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
560,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Voriconazole is initiated, discontinued or dose changed."
561,"Acetohexamide","DB00414","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
561,"Bromazepam","DB01558","Co-administration with propranolol will cause a reduction in bromazepam clearance and increases half-life. "
561,"Chlorpromazine","DB00477","Increased effect of both drugs"
561,"Chlorpropamide","DB00672","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of propranolol by decreasing its metabolism."
561,"Citalopram","DB00215","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, propranolol."
561,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
561,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
561,"Diltiazem","DB00343","Increased risk of bradycardia"
561,"Disopyramide","DB00280","The beta-blocker, propranolol, may increase the toxicity of disopyramide."
561,"Dronedarone","DB04855","Propranolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase propranolol exposure 1.3-fold. Lower dose of metoprolol. "
561,"Dyphylline","DB00651","Antagonism of action and increased effect of theophylline"
561,"Epinephrine","DB00668","Hypertension, then bradycardia"
561,"Ergonovine","DB01253","Ischemia with risk of gangrene"
561,"Ergotamine","DB00696","Ischemia with risk of gangrene"
561,"Escitalopram","DB01175","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, propranolol."
561,"Fenoterol","DB01288","Antagonism"
561,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, propranolol."
561,"Formoterol","DB00983","Antagonism"
561,"Gliclazide","DB01120","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Glipizide","DB01067","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Glisoxepide","DB01289","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Glyburide","DB01016","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Glycodiazine","DB01382","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Haloperidol","DB00502","Increased effect of both drugs"
561,"Hydralazine","DB01275","Increased effect of both drugs"
561,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
561,"Indacaterol","DB05039","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
561,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
561,"Insulin Glargine","DB00047","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Isoprenaline","DB01064","Antagonism"
561,"Lidocaine","DB00281","The beta-blocker, propranolol, may increase the effect and toxicity of lidocaine."
561,"Maprotiline","DB00934","Propranolol increases the serum levels of cisapride"
561,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
561,"Methyldopa","DB00968","Possible hypertensive crisis"
561,"Methysergide","DB00247","Ischemia with risk of gangrene"
561,"Orciprenaline","DB00816","Antagonism"
561,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
561,"Paroxetine","DB00715","The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol."
561,"Phenobarbital","DB01174","The barbiturate decreases the effect of the metabolized beta-blocker"
561,"Pipobroman","DB00236","Antagonism"
561,"Pirbuterol","DB01291","Antagonism"
561,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
561,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
561,"Primidone","DB00794","The barbiturate decreases the effect of metabolized beta-blocker"
561,"Procaterol","DB01366","Antagonism"
561,"Propafenone","DB01182","Propafenone may increase the effect of the beta-blocker, propranolol."
561,"Repaglinide","DB00912","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of propranolol by increasing its metabolism."
561,"Rizatriptan","DB00953","Propranolol increases the effect and toxicity of rizatriptan"
561,"Salbutamol","DB01001","Antagonism"
561,"Salmeterol","DB00938","Antagonism"
561,"Sertraline","DB01104","The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, propranolol."
561,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
561,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Propranolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Propranolol if Terbinafine is initiated, discontinued or dose changed."
561,"Terbutaline","DB00871","Antagonism"
561,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
561,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
561,"Tolazamide","DB00839","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Tolbutamide","DB01124","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
561,"Topotecan","DB01030","The p-glycoprotein inhibitor, Propranolol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
561,"Verapamil","DB00661","Increased effect of both drugs"
562,"Cinitapride","DB08810","Anticholinergic agents like atropine may reduce the action of cinitapride."
562,"Donepezil","DB00843","Possible antagonism of action"
562,"Galantamine","DB00674","Possible antagonism of action"
562,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
562,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Atropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
562,"Trimethobenzamide","DB00662","Trimethobenzamide and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
562,"Triprolidine","DB00427","Triprolidine and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
562,"Trospium","DB00209","Trospium and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
563,"Acenocoumarol","DB01418","The NSAID, fenoprofen, may increase the anticoagulant effect of acenocoumarol."
563,"Alendronate","DB00630","Increased risk of gastric toxicity"
563,"Anisindione","DB01125","The NSAID, fenoprofen, may increase the anticoagulant effect of anisindione."
563,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
563,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
563,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
563,"Dicoumarol","DB00266","The NSAID, fenoprofen, may increase the anticoagulant effect of dicumarol."
563,"Eltrombopag","DB06210","Increases levels of Fenoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
563,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
563,"Methotrexate","DB00563","The NSAID, fenoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
563,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
563,"Telmisartan","DB00966","Concomitant use of Telmisartan and Fenoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
563,"Timolol","DB00373","The NSAID, Fenoprofen, may antagonize the antihypertensive effect of Timolol."
563,"Trandolapril","DB00519","The NSAID, Fenoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Fenoprofen is initiated, discontinued or dose changed. "
563,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Fenoprofen. Monitor for increased bleeding during concomitant thearpy. "
563,"Warfarin","DB00682","The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
564,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
564,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
564,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
564,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
564,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
564,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
564,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
564,"Guanethidine","DB01170","Fenfluramine may decrease the effect of guanethidine."
564,"Insulin Aspart","DB01306","Fenfluramine increases the effect of insulin"
564,"Insulin Detemir","DB01307","Fenfluramine increases the effect of insulin"
564,"Insulin Glulisine","DB01309","Fenfluramine increases the effect of insulin"
564,"Isocarboxazid","DB01247","Possible hypertensive crisis"
564,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
564,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
564,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
564,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
564,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
564,"Phenelzine","DB00780","Possible hypertensive crisis"
564,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
564,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
564,"Promethazine","DB01069","Decreased anorexic effect, may increase psychotic symptoms."
564,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
564,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
564,"Rasagiline","DB01367","Possible hypertensive crisis"
564,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
564,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
564,"Tranylcypromine","DB00752","Possible hypertensive crisis"
564,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
564,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
564,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
565,"Acebutolol","DB01193","Increased hypertension when clonidine stopped"
565,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, decreases the effect of clonidine."
565,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, decreases the effect of clonidine."
565,"Atenolol","DB00335","Increased hypertension when clonidine stopped"
565,"Betaxolol","DB00195","Increased hypertension when clonidine stopped"
565,"Bevantolol","DB01295","Increased hypertension when clonidine stopped"
565,"Bisoprolol","DB00612","Increased hypertension when clonidine stopped"
565,"Carteolol","DB00521","Increased hypertension when clonidine stopped"
565,"Carvedilol","DB01136","Increased hypertension when clonidine stopped"
565,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, may decrease the effect of clonidine."
565,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, decreases the effect of clonidine."
565,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, decreases the effect of clonidine."
565,"Esmolol","DB00187","Increased hypertension when clonidine stopped"
565,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, decreases the effect of clonidine."
565,"Labetalol","DB00598","Increased hypertension when clonidine stopped"
565,"Metoprolol","DB00264","Increased hypertension when clonidine stopped"
565,"Milnacipran","DB04896","Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect."
565,"Mirtazapine","DB00370","Possible hypertensive crisis"
565,"Nadolol","DB01203","Increased hypertension when clonidine stopped"
565,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, decreases the effect of clonidine."
565,"Oxprenolol","DB01580","Increased hypertension when clonidine stopped"
565,"Penbutolol","DB01359","Increased hypertension when clonidine stopped"
565,"Pindolol","DB00960","Increased hypertension when clonidine stopped"
565,"Practolol","DB01297","Increased hypertension when clonidine stopped"
565,"Propranolol","DB00571","Increased hypertension when clonidine stopped"
565,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, decreases the effect of clonidine."
565,"Sotalol","DB00489","Increased hypertension when clonidine stopped"
565,"Timolol","DB00373","Increased hypertension when clonidine stopped"
565,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
565,"Trimipramine","DB00726","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Clonidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Clonidine should be withdrawn very gradually to reduce the risk of hypertensive crisis."
566,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
566,"Fosphenytoin","DB01320","The sulfonamide increases the effect of hydantoin"
566,"Methenamine mandelate","DB06146","Possible crystallization of urates with this combination"
566,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
566,"Phenytoin","DB00252","The sulfonamide increases the effect of hydantoin"
568,"Demeclocycline","DB00618","Possible antagonism of action"
568,"Doxycycline","DB00254","Possible antagonism of action"
568,"Mestranol","DB01357","This anti-infectious agent could decreases the effect of the oral contraceptive"
568,"Methacycline","DB00931","Possible antagonism of action"
568,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
568,"Minocycline","DB01017","Possible antagonism of action"
568,"Oxytetracycline","DB00595","Possible antagonism of action"
568,"Rolitetracycline","DB01301","Possible antagonism of action"
568,"Tetracycline","DB00759","Possible antagonism of action"
569,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
569,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
569,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
569,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
569,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
569,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
569,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
569,"Guanethidine","DB01170","Mazindol may decrease the effect of guanethidine."
569,"Isocarboxazid","DB01247","Possible hypertensive crisis"
569,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
569,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
569,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
569,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
569,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
569,"Phenelzine","DB00780","Possible hypertensive crisis"
569,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
569,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
569,"Promethazine","DB01069","Decreased anorexic effect, may increase psychotic symptoms."
569,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
569,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
569,"Rasagiline","DB01367","Possible hypertensive crisis"
569,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
569,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
569,"Tranylcypromine","DB00752","Possible hypertensive crisis"
569,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
569,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
569,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
570,"Fluconazole","DB00196","Fluconazole may increase the effect and toxicity of valdecoxib."
570,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of valdecoxib."
570,"Lithium","DB01356","The COX-2 inhibitor increases serum levels of lithium"
572,"Abarelix","DB00106","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). "
572,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
572,"Alfentanil","DB00802","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfentanil by decreasing its metabolism. Monitor for increased anesthetic and respiratory depressant effects and consider using lower alfentanil doses or alternate anesthetic. "
572,"Alfuzosin","DB00346","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by the manufacturer. "
572,"Almotriptan","DB00918","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function. "
572,"Alprazolam","DB00404","Voriconazole may increase the serum concentration of alprazolam by decreasing its metabolism. Monitor for alprazolam toxicity if voriconazole is initiated or dose increased."
572,"ambrisentan","DB06403","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ambrisentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed."
572,"Amiodarone","DB01118","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed."
572,"Amitriptyline","DB00321","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Amlodipine","DB00381","Voriconazole may increase the serum concentration of amlodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amlodipine if voriconazole is initiated, discontinued or dose changed. "
572,"Amobarbital","DB01351","Amobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
572,"Amoxapine","DB00543","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Amprenavir","DB00701","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amprenavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by amprenavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
572,"Apixaban","DB06605","Avoid combination. Otherwise, voriconazole will likely increase apixaban serum concentration."
572,"Apomorphine","DB00714","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Aprepitant","DB00673","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed."
572,"Aripiprazole","DB01238","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aripiprazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aripiprazole if voriconazole is initiated, discontinued or dose changed."
572,"armodafinil","DB06413","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of armodafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of armodafinil if voriconazole is initiated, discontinued or dose changed."
572,"Arsenic trioxide","DB01169","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
572,"Asenapine","DB06216","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
572,"Atazanavir","DB01072","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
572,"Atorvastatin","DB01076","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed."
572,"Benzphetamine","DB00865","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of benzphetamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of benzphetamine if voriconazole is initiated, discontinued or dose changed."
572,"Bisoprolol","DB00612","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed."
572,"Bortezomib","DB00188","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bortezomib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bortezomib if voriconazole is initiated, discontinued or dose changed."
572,"Bosentan","DB00559","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed."
572,"Bromazepam","DB01558","Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if voriconazole is initiated, discontinued or dose changed."
572,"Bromocriptine","DB01200","Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Budesonide","DB01222","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed."
572,"Buprenorphine","DB00921","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed."
572,"Buspirone","DB00490","Voriconazole may increase the serum concentration of buspirone likely by decreasing its metabolism via CYP3A4. Monitor for changes in the therapeutic and adverse effects of buspirone if voriconazole is initiated, discontinued or dose changed. "
572,"Busulfan","DB01008","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed."
572,"Butabarbital","DB00237","Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
572,"Butalbital","DB00241","Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
572,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
572,"Cabergoline","DB00248","Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated."
572,"Calcitriol","DB00136","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of calcitriol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed."
572,"Capecitabine","DB01101","Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed. "
572,"Carbamazepine","DB00564","Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated."
572,"Chlordiazepoxide","DB00475","Voriconazole may increase the serum concentration of chlordiazepoxide by decreasing its metabolism. Monitor for chlordiazepoxide toxicity if voriconazole is initiated or dose increased."
572,"Chloroquine","DB00608","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chloroquine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chloroquine if voriconazole is initiated, discontinued or dose changed."
572,"Chlorphenamine","DB01114","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chlorpheniramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorpheniramine if voriconazole is initiated, discontinued or dose changed."
572,"Chlorpropamide","DB00672","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Ciclesonide","DB01410","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ciclesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ciclesonide if voriconazole is initiated, discontinued or dose changed."
572,"Cilostazol","DB01166","Voriconzole may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for increased therapeutic/adverse effects of cilostazol and consider reducing the dose during concomitant therapy. "
572,"Cinacalcet","DB01012","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cinacalcet by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cinacalcet if voriconazole is initiated, discontinued or dose changed."
572,"Cisapride","DB00604","Voriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated."
572,"Citalopram","DB00215","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed."
572,"Clarithromycin","DB01211","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed."
572,"Clobazam","DB00349","Voriconazole may increase the serum concentration of clobazam by decreasing its metabolism. Monitor for clobazam toxicity if voriconazole is initiated or dose increased."
572,"Clomipramine","DB01242","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Clonazepam","DB01068","Voriconazole may increase the serum concentration of clonazepam by decreasing its metabolism. Monitor for clonazepam toxicity if voriconazole is initiated or dose increased."
572,"Clorazepate","DB00628","Voriconazole may increase the serum concentration of clorazepate by decreasing its metabolism. Monitor for clorazepate toxicity if voriconazole is initiated or dose increased."
572,"Cocaine","DB00907","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cocaine if voriconazole is initiated, discontinued or dose changed."
572,"Colchicine","DB01394","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of colchicine by decreasing its metabolism. A dose reduction of colchicine is recommended along with increased monitoring for colchicine toxicity. Concomitant therapy is contraindicated in patients with renal and/or hepatic impairment. "
572,"Conivaptan","DB00872","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of conivaptan by inhibiting its metabolism. Concomitant therapy is contraindicated. "
572,"Cyclosporine","DB00091","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy."
572,"Dantrolene","DB01219","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed."
572,"Dapsone","DB00250","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed."
572,"Darifenacin","DB00496","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of darifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of darifenacin  if voriconazole is initiated, discontinued or dose changed."
572,"Darunavir","DB01264","Darunavir may reduce serum concentrations and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.  "
572,"Dasatinib","DB01254","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed."
572,"Delavirdine","DB00705","Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if delavirdine is initiated, discontinued or dose changed.	"
572,"Desipramine","DB01151","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Dexamethasone","DB01234","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed."
572,"Diazepam","DB00829","Voriconazole may increase the serum concentration of diazepam by decreasing its metabolism. Monitor for diazepam toxicity if voriconazole is initiated or dose increased."
572,"Diclofenac","DB00586","Voriconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of diclofenac by decreasing its metabolism. Renal impairment may increase the risk of diclofenac adverse effects. Monitor for changes in therapeutic and adverse effects of diclofenac if voriconazole is initiated, discontinued or dose changed. "
572,"Didanosine","DB00900","Didanosine may interfere with the absorption of orally administered voriconazole. Enteric coated didanosine does not exert this effect. Didanosine buffered formulations should be administered at least 2 hours from oral voriconazole administration. "
572,"Digitoxin","DB01396","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of digitoxin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of digitoxin if voriconazole is initiated, discontinued or dose changed."
572,"Digoxin","DB00390","Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased."
572,"Dihydroergotamine","DB00320","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated."
572,"Diltiazem","DB00343","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed."
572,"Disopyramide","DB00280","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed."
572,"Docetaxel","DB01248","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed."
572,"Dofetilide","DB00204","Voriconazole may increase the serum concentration of dofetilide by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Dolasetron","DB00757","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Doxepin","DB01142","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed."
572,"Doxorubicin","DB00997","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed."
572,"Dronedarone","DB04855","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated. "
572,"Dronedarone","DB04855","Voriconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
572,"Droperidol","DB00450","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Efavirenz","DB00625","Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy."
572,"Eletriptan","DB00216","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed."
572,"Eplerenone","DB00700","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Ergoloid mesylate","DB01049","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergoloid mesylates by decreasing their metabolism. Concomitant therapy is contraindicated. "
572,"Ergonovine","DB01253","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergonovine by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Ergotamine","DB00696","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated."
572,"Erlotinib","DB00530","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed."
572,"Erythromycin","DB00199","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. "
572,"Escitalopram","DB01175","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of escitalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of escitalopram if voriconazole is initiated, discontinued or dose changed."
572,"Estazolam","DB01215","Voriconazole may increase the serum concentration of estazolam by decreasing its metabolism. Monitor for estazolam toxicity if voriconazole is initiated or dose increased."
572,"Eszopiclone","DB00402","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed."
572,"Ethosuximide","DB00593","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed."
572,"Etoposide","DB00773","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed."
572,"Etravirine","DB06414","Etravirine, when used concomitantly with variconazole, may experience an increase in serum concentration due to decreased metabolism of etravirine. \
\
Voriconazole, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in serum concentration. \
\
Monitor for changes in efficacy and toxicity of both agents if concomitant therapy is initiated, modified or discontinued. "
572,"Everolimus","DB01590","Voriconzole, a strong CYP3A4 inhibitor, may increase the serum concentration of everolimus by decreasing its metabolism. Concurrent therapy should be avoided. "
572,"Felbamate","DB00949","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed."
572,"Felodipine","DB01023","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed."
572,"Fentanyl","DB00813","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed."
572,"Flecainide","DB01195","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Floxuridine","DB00322","Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if floxuridine is initiated, discontinued or dose changed.	"
572,"Fluconazole","DB00196","Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed.	"
572,"Flunisolide","DB00180","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flunisolide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flunisolide if voriconazole is initiated, discontinued or dose changed."
572,"Fluorouracil","DB00544","Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed.	"
572,"Fluoxetine","DB00472","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Flupentixol","DB00875","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Flurazepam","DB00690","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased."
572,"Flurbiprofen","DB00712","Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed.	"
572,"Flutamide","DB00499","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flutamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flutamide if voriconazole is initiated, discontinued or dose changed."
572,"Fluticasone Propionate","DB00588","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed."
572,"Fosamprenavir","DB01319","Voriconazole may increase the serum concentration of fosamprenavir by decreasing its metabolism. Fosamprenavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. "
572,"Foscarnet","DB00529","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Fosphenytoin","DB01320","The hydantoin decreases the effect of voriconazole"
572,"Gatifloxacin","DB01044","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Gefitinib","DB00317","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed."
572,"Gemfibrozil","DB01241","Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed.	"
572,"Halofantrine","DB01218","Voriconazole may increase the serum concentration of halofantrine by decreasing its metabolism by CYP3A4.  Concomitant therapy should be avoided due to the concentration-dependent risk of QTc prolongation related to halofantrine. "
572,"Haloperidol","DB00502","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed."
572,"Ibuprofen","DB01050","Ibuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed.	"
572,"Ibutilide","DB00308","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Ifosfamide","DB01181","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed."
572,"Imatinib","DB00619","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of imatinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of imatinib if voriconazole is initiated, discontinued or dose changed."
572,"Imipramine","DB00458","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Indapamide","DB00808","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Indinavir","DB00224","Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
572,"Indomethacin","DB00328","Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed.	"
572,"Irinotecan","DB00762","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of irinotecan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of irinotecan if voriconazole is initiated, discontinued or dose changed."
572,"Isosorbide Dinitrate","DB00883","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide dinitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide dinitrate if voriconazole is initiated, discontinued or dose changed."
572,"Isosorbide Mononitrate","DB01020","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide mononitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide mononitrate if voriconazole is initiated, discontinued or dose changed."
572,"Isradipine","DB00270","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed."
572,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
572,"Ixabepilone","DB04845","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ixabepilone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ixabepilone if voriconazole is initiated, discontinued or dose changed."
572,"Ketamine","DB01221","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed."
572,"Ketoconazole","DB01026","Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.	"
572,"Lapatinib","DB01259","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lapatinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lapatinib if voriconazole is initiated, discontinued or dose changed."
572,"Levofloxacin","DB01137","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Lidocaine","DB00281","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed."
572,"Lopinavir","DB01601","Lopinavir may reduce serum concentration and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy."
572,"Lovastatin","DB00227","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed."
572,"Loxapine","DB00408","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
572,"Maprotiline","DB00934","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Maraviroc","DB04835","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of maraviroc by decreasing its metabolism. A dose reduction in maraviroc is warranted. Monitor for changes in the therapeutic and adverse effects of maraviroc if voriconazole is initiated, discontinued or dose changed."
572,"Mefenamic acid","DB00784","Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed."
572,"Mefloquine","DB00358","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mefloquine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of mefloquine if voriconazole is initiated, discontinued or dose changed."
572,"Meloxicam","DB00814","Voriconazole may increase the serum concentration of meloxicam by decreasing its metabolism via CYP2C9 and CYP3A4. Monitor for changes in the therapeutic and adverse effects of meloxicam if voriconazole is initiated, discontinued or dose changed. "
572,"Mesoridazine","DB00933","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Methadone","DB00333","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed."
572,"Methotrimeprazine","DB01403","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Methylergometrine","DB00353","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methylergonovine  by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Miconazole","DB01110","Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if miconazole is initiated, discontinued or dose changed.	"
572,"Midazolam","DB00683","Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased."
572,"Mirtazapine","DB00370","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed."
572,"Modafinil","DB00745","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of modafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of modafinil if voriconazole is initiated, discontinued or dose changed."
572,"Moricizine","DB00680","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moricizine if voriconazole is initiated, discontinued or dose changed."
572,"Moxifloxacin","DB00218","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Nateglinide","DB00731","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nateglinide if voriconazole is initiated, discontinued or dose changed."
572,"Nefazodone","DB01149","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nefazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nefazodone if voriconazole is initiated, discontinued or dose changed."
572,"Nelfinavir","DB00220","Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased nelfinavir adverse effects during concomitant therapy."
572,"Nicardipine","DB00622","Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.	"
572,"Nifedipine","DB01115","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nifedipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nifedipine if voriconazole is initiated, discontinued or dose changed."
572,"Nilotinib","DB04868","Voriconazole may increase the serum concentration of nilotinib by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Concomitant therapy should be avoided. "
572,"Nimodipine","DB00393","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nimodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nimodipine if voriconazole is initiated, discontinued or dose changed."
572,"Nisoldipine","DB00401","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nisoldipine by decreasing its metabolism. Concomitant therapy should be avoided. "
572,"Nitrendipine","DB01054","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nitrendipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nitrendipine if voriconazole is initiated, discontinued or dose changed."
572,"Norfloxacin","DB01059","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Nortriptyline","DB00540","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Octreotide","DB00104","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Omeprazole","DB00338","Voriconazole increases the effect and toxicity of omeprazole"
572,"Paclitaxel","DB01229","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed."
572,"Pentamidine","DB00738","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Perflutren","DB00556","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Pergolide","DB01186","Voriconazole may increase the serum concentration of pergolide likely by decreasing its metabolism. Concomitant therapy is contraindicated."
572,"Phencyclidine","DB03575","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of phencyclidine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of phencyclidine if voriconazole is initiated, discontinued or dose changed."
572,"Phenobarbital","DB01174","Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated."
572,"Phenytoin","DB00252","Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity."
572,"Pimozide","DB01100","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pimozide by decreasing its metabolism. Increased risk of QTc prolongation and development arrhythmias. Concomitant use is contraindicated."
572,"Pipotiazine","DB01621","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pipotiazine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of pipotiazine if voriconazole is initiated, discontinued or dose changed."
572,"Piroxicam","DB00554","Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed.	"
572,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
572,"Prazepam","DB01588","Voriconazole may increase the serum concentration of prazepam by decreasing its metabolism. Monitor for prazepam toxicity if voriconazole is initiated or dose increased."
572,"Praziquantel","DB01058","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of praziquantel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of praziquantel if voriconazole is initiated, discontinued or dose changed."
572,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of voriconazole."
572,"Probucol","DB01599","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Procainamide","DB01035","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Propafenone","DB01182","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Protriptyline","DB00344","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Quetiapine","DB01224","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed."
572,"Quinidine","DB00908","Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed."
572,"Quinine","DB00468","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
572,"Ranolazine","DB00243","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated."
572,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
572,"Repaglinide","DB00912","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of repaglinide if voriconazole is initiated, discontinued or dose changed."
572,"Rifabutin","DB00615","Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
572,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
572,"Rifapentine","DB01201","Rifapentine may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifapentin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
572,"Risperidone","DB00734","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Ritonavir","DB00503","Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur. "
572,"Rivaroxaban","DB06228","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of rivaroxaban by decreasing its metabolism. Increased bleed risks may occur. Consider alternate therapy. "
572,"Ruxolitinib","DB08877","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
572,"Salmeterol","DB00938","Voriconazole, a strong CYP3A4 inhibitor may increase the serum concentration of salmeterol by decreasing its metabolism. Consider alternate therapy. "
572,"Saquinavir","DB01232","Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
572,"Saxagliptin","DB06335","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of saxagliptin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of saxagliptin if voriconazole is initiated, discontinued or dose changed."
572,"Sibutramine","DB01105","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sibutramine if voriconazole is initiated, discontinued or dose changed."
572,"Sildenafil","DB00203","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sildenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sildenafil if voriconazole is initiated, discontinued or dose changed."
572,"Silodosin","DB06207","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Simvastatin","DB00641","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed."
572,"Sirolimus","DB00877","Voriconazole may increase the serum concentration of sirolimus likely by inhibition of CYP3A4-mediated metabolism or p-glyprotein transport of sirolimus. Consider alternate therapy or reduce the dose of sirolimus and monitor serum levels during concomitant therapy. "
572,"Sitaxentan","DB06268","Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sitaxsentan is initiated, discontinued or dose changed."
572,"Solifenacin","DB01591","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of solifenacin if voriconazole is initiated, discontinued or dose changed."
572,"Sotalol","DB00489","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Sparfloxacin","DB01208","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Spiramycin","DB06145","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of spiramycin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of spiramycin if voriconazole is initiated, discontinued or dose changed."
572,"St. John's Wort","DB01323","St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated. "
572,"Sufentanil","DB00708","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed."
572,"Sulfisoxazole","DB00263","Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed.	"
572,"Sunitinib","DB01268","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed."
572,"Tacrolimus","DB00864","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed."
572,"Tadalafil","DB00820","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tadalafil by decreasing its metabolism. Concomitant therapy should be avoided if possible due to high risk of tadalafil toxicity."
572,"Tamoxifen","DB00675","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed."
572,"Tamsulosin","DB00706","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed."
572,"Telithromycin","DB00976","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur."
572,"Temsirolimus","DB06287","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of temsirolimus and its active metabolite, sirolimus, by decreasing their metabolism. Concomitant therapy should be avoided."
572,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed."
572,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
572,"Tetrabenazine","DB04844","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
572,"Theophylline","DB00277","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed."
572,"Thioridazine","DB00679","Additive QTc prolongation may occur. Concomitant use is contraindicated. "
572,"Thiothixene","DB01623","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Tiagabine","DB00906","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tiagabine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tiagabine if voriconazole is initiated, discontinued or dose changed."
572,"Tipranavir","DB00932","Voriconazole may increase the serum concentration of tipranavir by decreasing its metabolism. Tipranavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
572,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."
572,"Tolterodine","DB01036","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed."
572,"Tolvaptan","DB06212","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan by decreasing its metabolism. Concomitant therapy is contraindicated. "
572,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
572,"Tramadol","DB00193","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed."
572,"Trazodone","DB00656","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed."
572,"Triazolam","DB00897","Voriconazole may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for triazolam toxicity if voriconazole is initiated or dose increased."
572,"Trimipramine","DB00726","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trimipramine by decreasing its metabolism. Additive QTc prolongation may also occur. Monitor for changes in the therapeutic and adverse effects of trimipramine if voriconazole is initiated, discontinued or dose changed."
572,"Vardenafil","DB00862","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of vardenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of vardenafil if voriconazole is initiated, discontinued or dose changed."
572,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
572,"Venlafaxine","DB00285","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed."
572,"Verapamil","DB00661","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed."
572,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
572,"Vinblastine","DB00570","Voriconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Voriconazole is initiated, discontinued or dose changed."
572,"Vincristine","DB00541","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Voriconazole is initiated, discontinued or dose changed."
572,"Vinorelbine","DB00361","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Voriconazole is initiated, discontinued or dose changed."
572,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
572,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
572,"Zolpidem","DB00425","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed."
572,"Zonisamide","DB00909","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed."
572,"Zopiclone","DB01198","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed."
572,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
574,"Amiloride","DB00594","Increased risk of hyperkalemia"
574,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
574,"Drospirenone","DB01395","Increased risk of hyperkalemia"
574,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
574,"Insulin Lispro","DB00046","Concomitant therapy with ACE inhibitors may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
574,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
574,"Potassium","DB01345","Increased risk of hyperkalemia"
574,"Rifampicin","DB01045","Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed."
574,"Spironolactone","DB00421","Increased risk of hyperkalemia"
574,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
574,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
574,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
574,"Triamterene","DB00384","Increased risk of hyperkalemia"
575,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
575,"Cefditoren","DB01066","H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
575,"Enoxacin","DB00467","Nizatidine may decrease the absorption of enoxacin."
575,"Itraconazole","DB01167","The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole."
575,"Ketoconazole","DB01026","The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole."
576,"Alendronate","DB00630","Increased risk of gastric toxicity"
576,"Anisindione","DB01125","The NSAID, diclofenac, may increase the anticoagulant effect of anisindione."
576,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
576,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
576,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
576,"Dicoumarol","DB00266","The NSAID, diclofenac, may increase the anticoagulant effect of dicumarol."
576,"Difluprednate","DB06781","NSAIDs may slow healing. "
576,"Eltrombopag","DB06210","Eltrombopag increases levels of Diclofenac via metabolism decrease. UDP-glucuronosyltransferase inhibition."
576,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
576,"Lithium","DB01356","The NSAID, diclofenac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
576,"Methotrexate","DB00563","The NSAID, diclofenac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
576,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
576,"Rifampicin","DB01045","Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac."
576,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Diclofenac, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Diclofenac is initiated, discontinued or if the dose is changed."
576,"Telmisartan","DB00966","Concomitant use of Telmisartan and Diclofenac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
576,"Timolol","DB00373","The NSAID, Diclofenac, may antagonize the antihypertensive effect of Timolol."
576,"Tizanidine","DB00697","Diclofenac may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
576,"Trandolapril","DB00519","The NSAID, Diclofenac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diclofenac is initiated, discontinued or dose changed. "
576,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diclofenac. Monitor for increased bleeding during concomitant thearpy. "
576,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of NSAIDs with vilazodone."
576,"Voriconazole","DB00582","Voriconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of diclofenac by decreasing its metabolism. Renal impairment may increase the risk of diclofenac adverse effects. Monitor for changes in therapeutic and adverse effects of diclofenac if voriconazole is initiated, discontinued or dose changed. "
576,"Warfarin","DB00682","The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
578,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended. "
578,"Crizotinib","DB08865","Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy. "
578,"Telithromycin","DB00976","Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed."
578,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible."
578,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fluticasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluticasone if voriconazole is initiated, discontinued or dose changed."
580,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Doxazosin. Monitor for hypotension during concomitant therapy."
580,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
580,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
580,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Doxazosin, may occur. Monitor for hypotension during concomitant therapy."
583,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed."
583,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Ethosuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
583,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed."
584,"Benazepril","DB00542","Increased risk of hyperkalemia"
584,"Candesartan","DB00796","Increased risk of hyperkalemia"
584,"Captopril","DB01197","Increased risk of hyperkalemia"
584,"Cilazapril","DB01340","Increased risk of hyperkalemia"
584,"Dihydroquinidine barbiturate","DB01341","Decreases the antiarrhythmic effect of quinidine"
584,"Enalapril","DB00584","Increased risk of hyperkalemia"
584,"Eplerenone","DB00700","Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy."
584,"Eprosartan","DB00876","Increased risk of hyperkalemia"
584,"Forasartan","DB01342","Increased risk of hyperkalemia"
584,"Fosinopril","DB00492","Increased risk of hyperkalemia"
584,"Irbesartan","DB01029","Increased risk of hyperkalemia"
584,"Lisinopril","DB00722","Increased risk of hyperkalemia"
584,"Losartan","DB00678","Increased risk of hyperkalemia"
584,"Moexipril","DB00691","Increased risk of hyperkalemia"
584,"Perindopril","DB00790","Increased risk of hyperkalemia"
584,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
584,"Potassium","DB01345","Increased risk of hyperkalemia"
584,"Quinapril","DB00881","Increased risk of hyperkalemia"
584,"Quinidine","DB00908","Amiloride may decrease the therapeutic effect of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if amiloride if initiated, discontinued or dose changed."
584,"Quinidine barbiturate","DB01346","Decreases the antiarrhythmic effect of quinidine"
584,"Ramipril","DB00178","Increased risk of hyperkalemia"
584,"Saprisartan","DB01347","Increased risk of hyperkalemia"
584,"Spirapril","DB01348","Increased risk of hyperkalemia"
584,"Tasosartan","DB01349","Increased risk of hyperkalemia"
584,"Telmisartan","DB00966","Telmisartan may increase the hyperkalemic effect of Amiloride. Monitor for increased serum potassium concentrations during concomitant therapy."
584,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels."
584,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
584,"Valsartan","DB00177","Increased risk of hyperkalemia"
585,"Acitretin","DB00459","Increased risk of intracranial hypertension"
585,"Amoxicillin","DB01060","Possible antagonism of action"
585,"Ampicillin","DB00415","Possible antagonism of action"
585,"Benzylpenicillin","DB01053","Possible antagonism of action"
585,"Calcium","DB01373","Formation of non-absorbable complexes"
585,"Carbenicillin","DB00578","Possible antagonism of action"
585,"Clavulanate","DB00766","Possible antagonism of action"
585,"Cloxacillin","DB01147","Possible antagonism of action"
585,"Dicloxacillin","DB00485","Possible antagonism of action"
585,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
585,"Etretinate","DB00926","Increased risk of intracranial hypertension"
585,"Flucloxacillin","DB00301","Possible antagonism of action"
585,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
585,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
585,"Magnesium","DB01378","Formation of non-absorbable complexes"
585,"Penicillin V","DB00417","Possible antagonism of action"
585,"Piperacillin","DB00319","Possible antagonism of action"
585,"Pivampicillin","DB01604","Possible antagonism of action"
585,"Pivmecillinam","DB01605","Possible antagonism of action"
585,"Ticarcillin","DB01607","Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline."
585,"Tretinoin","DB00755","Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
588,"Acetohexamide","DB00414","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Chlorpropamide","DB00672","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of labetolol by decreasing its metabolism."
588,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
588,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
588,"Disopyramide","DB00280","The beta-blocker, labetolol, may increase the toxicity of disopyramide."
588,"Enflurane","DB00228","Monitor arterial pressure closely"
588,"Epinephrine","DB00668","Hypertension, then bradycardia"
588,"Ergonovine","DB01253","Ischemia with risk of gangrene"
588,"Ergotamine","DB00696","Ischemia with risk of gangrene"
588,"Fenoterol","DB01288","Antagonism"
588,"Formoterol","DB00983","Antagonism"
588,"Gliclazide","DB01120","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Glipizide","DB01067","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Glisoxepide","DB01289","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Glyburide","DB01016","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Glycodiazine","DB01382","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Halothane","DB01159","Monitor arterial pressure closely"
588,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
588,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
588,"Insulin Glargine","DB00047","The beta-blocker, labetolol, may decrease symptoms of hypoglycemia."
588,"Iobenguane","DB06704","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores"
588,"Isoflurane","DB00753","Monitor arterial pressure closely"
588,"Isoprenaline","DB01064","Antagonism"
588,"Lidocaine","DB00281","The beta-blocker, labetalol, may increase the effect and toxicity of lidocaine."
588,"Methysergide","DB00247","Ischemia with risk of gangrene"
588,"Orciprenaline","DB00816","Antagonism"
588,"Pipobroman","DB00236","Antagonism"
588,"Pirbuterol","DB01291","Antagonism"
588,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
588,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
588,"Procaterol","DB01366","Antagonism"
588,"Repaglinide","DB00912","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Salbutamol","DB01001","Antagonism"
588,"Salmeterol","DB00938","Antagonism"
588,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
588,"Terbutaline","DB00871","Antagonism"
588,"Tolazamide","DB00839","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Tolbutamide","DB01124","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
588,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
588,"Verapamil","DB00661","Increased effect of both drugs"
589,"Acenocoumarol","DB01418","Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required."
589,"Amlodipine","DB00381","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Amlodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Amlodipine if Thiopental is initiated, discontinued or dose changed."
589,"Chloramphenicol","DB00446","Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted. "
589,"Cyclosporine","DB00091","Thiopental may increase the metabolism and clearance of Cyclosporine. Monitor for changes in the therapeutic/adverse effects of Cyclosporine if Thiopental is initiated, discontinued or dose changed."
589,"Desogestrel","DB00304","Thiopental may decrease the effect of Desogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Diltiazem","DB00343","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Diltiazem, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Diltiazem if Thiopental is initiated, discontinued or dose changed."
589,"Disopyramide","DB00280","Thiopental may increase the metabolism and clearance of Disopyramide. Monitor for changes in therapeutic/adverse effects of Disopyramide if Thiopental is inititaed, discontinued or dose changed."
589,"Doxycycline","DB00254","Thiopental may decrease the serum levels of Doxycycline. A reduction in antimicrobial effects may occur. An alternative antibiotic may be considered. "
589,"Drospirenone","DB01395","Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Ethinyl Estradiol","DB00977","Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Ethynodiol","DB00823","Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Etonogestrel","DB00294","Thiopental may decrease the effect of Etonogestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Felodipine","DB01023","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed."
589,"Isradipine","DB00270","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Isradipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Isradipine if Thiopental is initiated, discontinued or dose changed."
589,"Lamotrigine","DB00555","Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated."
589,"Levonorgestrel","DB00367","Thiopental may decrease the effect of Levonorgestrel. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Medroxyprogesterone Acetate","DB00603","Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Mestranol","DB01357","Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Methadone","DB00333","Thiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur. "
589,"Nicardipine","DB00622","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed."
589,"Nifedipine","DB01115","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed."
589,"Nimodipine","DB00393","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nimodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nimodipine if Thiopental is initiated, discontinued or dose changed."
589,"Nisoldipine","DB00401","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nisoldipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nisoldipine if Thiopental is initiated, discontinued or dose changed."
589,"Nitrendipine","DB01054","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed."
589,"Norethindrone","DB00717","Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Norgestimate","DB00957","Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
589,"Propafenone","DB01182","Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated."
589,"Quinidine","DB00908","Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated."
589,"Trimipramine","DB00726","The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
589,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Thiopental, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
589,"Verapamil","DB00661","Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed."
589,"Warfarin","DB00682","Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed."
591,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid. "
591,"Brimonidine","DB00484","MAO Inhibitors like linezolid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
591,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
591,"Citalopram","DB00215","Combination associated with possible serotoninergic syndrome"
591,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
591,"Dobutamine","DB00841","Possible increase of arterial pressure"
591,"Dopamine","DB00988","Possible increase of arterial pressure"
591,"Ephedra","DB01363","Possible increase of arterial pressure"
591,"Ephedrine","DB01364","Possible increase of arterial pressure"
591,"Epinephrine","DB00668","Possible increase of arterial pressure"
591,"Escitalopram","DB01175","Combination associated with possible serotoninergic syndrome"
591,"Fenoterol","DB01288","Possible increase of arterial pressure"
591,"Fluoxetine","DB00472","Linezolide, a MAO inhibitor, may increase the serotonergic effect of fluoxetine, a SSRI. Increased for of serotonin syndrome. Concomitant therapy should be avoided."
591,"Fluvoxamine","DB00176","Combination associated with possible serotoninergic syndrome"
591,"Isoprenaline","DB01064","Possible increase of arterial pressure"
591,"Mephentermine","DB01365","Possible increase of arterial pressure"
591,"Metaraminol","DB00610","Possible increase of arterial pressure"
591,"Methoxamine","DB00723","Possible increase of arterial pressure"
591,"Nefazodone","DB01149","Combination associated with possible serotoninergic syndrome"
591,"Norepinephrine","DB00368","Possible increase of arterial pressure"
591,"Orciprenaline","DB00816","Possible increase of arterial pressure"
591,"Paroxetine","DB00715","Combination associated with possible serotoninergic syndrome"
591,"Phenylephrine","DB00388","Possible increase of arterial pressure"
591,"Phenylpropanolamine","DB00397","Possible increase of arterial pressure"
591,"Pirbuterol","DB01291","Possible increase of arterial pressure"
591,"Procaterol","DB01366","Possible increase of arterial pressure"
591,"Pseudoephedrine","DB00852","Possible increase of arterial pressure"
591,"Salbutamol","DB01001","Possible increase of arterial pressure"
591,"Sertraline","DB01104","Combination associated with possible serotoninergic syndrome"
591,"Terbutaline","DB00871","Possible increase of arterial pressure"
591,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated."
591,"Tolcapone","DB00323","Tolcapone and Linezolid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
591,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Linezolid. "
591,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other. "
591,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
591,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
591,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
591,"Vilazodone","DB06684","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
591,"Zolmitriptan","DB00315","The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated. "
593,"Acenocoumarol","DB01418","Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol."
593,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Anisindione","DB01125","Medroxyprogesterone may increase the anticoagulant effect of anisindione."
593,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Artemether","DB06697","Artemether may decrease the effectiveness of medroxyprogesterone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
593,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of medroxyprogesterone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
593,"Bosentan","DB00559","Bosentan may decrease the contraceptive effect of medroxyprogesterone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
593,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
593,"Dicoumarol","DB00266","Medroxyprogesterone may increase the anticoagulant effect of dicumarol."
593,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone."
593,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, may decrease the effect of the hormone, medroxyprogesterone."
593,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone."
593,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of medroxyprogesterone."
593,"Primidone","DB00794","The enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone."
593,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, medroxyprogesterone."
593,"Thiopental","DB00599","Thiopental may decrease the effect of Medroxyprogesterone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
593,"Warfarin","DB00682","Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed."
594,"Acenocoumarol","DB01418","Cisapride may increase the anticoagulant effect of acenocoumarol."
594,"Acetophenazine","DB01063","Increased risk of cardiotoxicity and arrhythmias"
594,"Alimemazine","DB01246","Increased risk of cardiotoxicity and arrhythmias"
594,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
594,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
594,"Amoxapine","DB00543","Increased risk of cardiotoxicity and arrhythmias"
594,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of cisapride."
594,"Anisindione","DB01125","Cisapride may increase the anticoagulant effect of anisindione."
594,"Aprepitant","DB00673","Increased risk of cardiotoxicity and arrhythmias"
594,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
594,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
594,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias"
594,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
594,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
594,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
594,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
594,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
594,"Clomipramine","DB01242","Increased risk of cardiotoxicity and arrhythmias"
594,"Crizotinib","DB08865","Concurrent use with drugs that prolong QTc interval is contraindicated. "
594,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the metabolism of cisapride. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cisapride if delavirdine is initiated, discontinued or dose changed."
594,"Desipramine","DB01151","Increased risk of cardiotoxicity and arrhythmias"
594,"Dicoumarol","DB00266","Cisapride may increase the anticoagulant effect of dicumarol."
594,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
594,"Diltiazem","DB00343","Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cisapride by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cisapride if diltiazem is initiated, discontinued or dose changed."
594,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
594,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
594,"Efavirenz","DB00625","Increased risk of cardiotoxicity and arrhythmias"
594,"Encainide","DB01228","Increased risk of cardiotoxicity and arrhythmias"
594,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
594,"Ethopropazine","DB00392","Increased risk of cardiotoxicity and arrhythmias"
594,"Fexofenadine","DB00950","Increased risk of cardiotoxicity and arrhythmias"
594,"Flecainide","DB01195","Increased risk of cardiotoxicity and arrhythmias"
594,"Fluconazole","DB00196","Increased risk of cardiotoxicity and arrhythmias"
594,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
594,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of cisapride"
594,"Ibutilide","DB00308","Increased risk of cardiotoxicity and arrhythmias"
594,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
594,"Indinavir","DB00224","Increased risk of cardiotoxicity and arrhythmias"
594,"Itraconazole","DB01167","Increased risk of cardiotoxicity and arrhythmias"
594,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
594,"Ketoconazole","DB01026","Increased risk of cardiotoxicity and arrhythmias"
594,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
594,"Maprotiline","DB00934","Increased risk of cardiotoxicity and arrhythmias"
594,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
594,"Methdilazine","DB00902","Increased risk of cardiotoxicity and arrhythmias"
594,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
594,"Mibefradil","DB01388","Mibefradil increases levels of cisapride"
594,"Nefazodone","DB01149","Nefazodone increases serum levels of cisapride"
594,"Nelfinavir","DB00220","Increased risk of cardiotoxicity and arrhythmias"
594,"Nifedipine","DB01115","Cisapride may increase the effect and toxicity of nifedipine."
594,"Nortriptyline","DB00540","Increased risk of cardiotoxicity and arrhythmias"
594,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
594,"Posaconazole","DB01263","Contraindicated co-administration"
594,"Procainamide","DB01035","Increased risk of cardiotoxicity and arrhythmias"
594,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
594,"Promazine","DB00420","Increased risk of cardiotoxicity and arrhythmias"
594,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
594,"Propafenone","DB01182","Increased risk of cardiotoxicity and arrhythmias"
594,"Propiomazine","DB00777","Increased risk of cardiotoxicity and arrhythmias"
594,"Protriptyline","DB00344","Increased risk of cardiotoxicity and arrhythmias"
594,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
594,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
594,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
594,"Ritonavir","DB00503","Increased risk of cardiotoxicity and arrhythmias"
594,"Saquinavir","DB01232","Increased risk of cardiotoxicity and arrhythmias"
594,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
594,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood. "
594,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
594,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
594,"Telithromycin","DB00976","Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated."
594,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
594,"Thiethylperazine","DB00372","Increased risk of cardiotoxicity and arrhythmias"
594,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
594,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
594,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated."
594,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
594,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
594,"Triflupromazine","DB00508","Increased risk of cardiotoxicity and arrhythmias"
594,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
594,"Troleandomycin","DB01361","Increased risk of cardiotoxicity and arrhythmias"
594,"Voriconazole","DB00582","Voriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated."
594,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
594,"Warfarin","DB00682","Cisapride may increase the anticoagulant effect of warfarin."
594,"Zafirlukast","DB00549","Increased risk of cardiotoxicity and arrhythmias"
594,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
594,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
595,"Acenocoumarol","DB01418","The NSAID, sulindac, may increase the anticoagulant effect of acenocoumarol. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. "
595,"Acetylsalicylic acid","DB00945","Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. "
595,"Aminosalicylic Acid","DB00233","Risk of additive toxicity (e.g. bleed risk). Aminosalicylic acid may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. "
595,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
595,"Bumetanide","DB00887","The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
595,"Cholestyramine","DB01432","The bile acid sequestrant, cholestyramine, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if cholestyramine is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions."
595,"Colesevelam","DB00930","The bile acid sequestrant, colesevelam, may decrease the absorption of the NSAID, sulindac. Sulindac should be administered at least 1 hour before or 4 hours after colesevelam. Monitor for changes in the therapeutic and adverse effects of sulindac if colesevelam is initiated, discontinued or dose changed. "
595,"Colestipol","DB00375","The bile acid sequestrant, colestipol, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if colestipol is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions."
595,"Cyclosporine","DB00091","The NSAID, sulindac, may increase the nephrotoxic effect of cyclosporine. Sulindac may increase the serum concentration of cyclosporine. Consider alternate therapy or monitor for increased cyclosporine levels and nephrotoxicity during concomitant therapy."
595,"Ethacrynic acid","DB00903","The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacryninc acid."
595,"Furosemide","DB00695","The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide."
595,"Ginkgo biloba","DB01381","Ginkgo biloba may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided."
595,"Ginseng","DB01404","Ginseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided. "
595,"Ketorolac","DB00465","May cause additive or synergistic NSAID toxicities (e.g. GI bleeding, renal dysfunction, etc.). Concomitant therapy is contraindicated. "
595,"Methotrexate","DB00563","The NSAID, sulindac, may decrease the clearance methotrexate. Consider alternate therapy, especially in patients receiving high antineoplastic doses of methotrexate. Otherwise, monitor for hematologic and renal toxicities."
595,"Pemetrexed","DB00642","The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy. "
595,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
595,"S-Adenosylmethionine","DB00118","S-adenosylmethionine may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided. "
595,"Salicylate-sodium","DB01398","Risk of additive toxicity (e.g. bleed risk). Salicylate-sodium may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."
595,"Salsalate","DB01399","Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."
595,"Telmisartan","DB00966","Concomitant use of Telmisartan and Sulindac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
595,"Timolol","DB00373","The NSAID, Sulindac, may antagonize the antihypertensive effect of Timolol."
595,"Trandolapril","DB00519","The NSAID, Sulindac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Sulindac is initiated, discontinued or dose changed. "
595,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Sulindac. Monitor for increased bleeding during concomitant thearpy. "
595,"Warfarin","DB00682","The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
596,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
596,"Lithium","DB01356","The thiazide diuretic, cyclothiazide, may increase serum levels of lithium."
597,"Cyclosporine","DB00091","Nafcillin alters serum levels of cyclosporine"
597,"Demeclocycline","DB00618","Possible antagonism of action"
597,"Doxycycline","DB00254","Possible antagonism of action"
597,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
597,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
597,"Lurasidone","DB08815","Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated. "
597,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
597,"Minocycline","DB01017","Possible antagonism of action"
597,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
597,"Telithromycin","DB00976","Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
597,"Temsirolimus","DB06287","Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
597,"Tetracycline","DB00759","Possible antagonism of action"
597,"Tramadol","DB00193","Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
597,"Trazodone","DB00656","The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed."
597,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
597,"Verapamil","DB00661","Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed. "
597,"Warfarin","DB00682","Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed. "
598,"Aluminium","DB01370","The antiacid decreases the absorption of chloroquine"
598,"Artemether","DB06697","Chloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options. "
598,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
598,"Attapulgite","DB01574","The antiacid decreases the absorption of chloroquine"
598,"Calcium","DB01373","The antiacid decreases the absorption of chloroquine"
598,"Cyclosporine","DB00091","Chloroquine may increase the therapeutic and adverse effects of cyclosporine."
598,"Dihydroxyaluminium","DB01375","The antiacid decreases the absorption of chloroquine"
598,"Kaolin","DB01575","The antiacid decreases the absorption of chloroquine"
598,"Lumefantrine","DB06708","Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
598,"Magnesium","DB01378","The antiacid decreases the absorption of chloroquine"
598,"Magnesium oxide","DB01377","The antiacid decreases the absorption of chloroquine"
598,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
598,"Praziquantel","DB01058","Markedly lower praziquantel levels"
598,"Tamoxifen","DB00675","Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
598,"Tamsulosin","DB00706","Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed."
598,"Telithromycin","DB00976","Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed."
598,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Chloroquine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chloroquine if Terbinafine is initiated, discontinued or dose changed."
598,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
598,"Tramadol","DB00193","Chloroquine may decrease the effect of Tramadol by decreasing active metabolite production. "
598,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chloroquine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chloroquine if voriconazole is initiated, discontinued or dose changed."
600,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of metaraminol."
600,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of metaraminol."
600,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol."
600,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol."
600,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol."
600,"Guanethidine","DB01170","Metaraminol may decrease the effect of guanethidine."
600,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of metaraminol."
600,"Isocarboxazid","DB01247","Increased arterial pressure"
600,"Linezolid","DB00601","Possible increase of arterial pressure"
600,"Methyldopa","DB00968","Increased arterial pressure"
600,"Midodrine","DB00211","Increased arterial pressure"
600,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of metaraminol."
600,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of metaraminol."
600,"Phenelzine","DB00780","Increased arterial pressure"
600,"Rasagiline","DB01367","Increased arterial pressure"
600,"Reserpine","DB00206","Increased arterial pressure"
601,"Alvimopan","DB06274","Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan. "
601,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of butorphanol. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.\
"
601,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Butorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
602,"Acetohexamide","DB00414","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Chlorpropamide","DB00672","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
602,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
602,"Disopyramide","DB00280","The beta-blocker, bisoprolol, may increase the toxicity of disopyramide."
602,"Epinephrine","DB00668","Hypertension, then bradycardia"
602,"Ergonovine","DB01253","Ischemia with risk of gangrene"
602,"Ergotamine","DB00696","Ischemia with risk of gangrene"
602,"Fenoterol","DB01288","Antagonism"
602,"Formoterol","DB00983","Antagonism"
602,"Gliclazide","DB01120","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Glipizide","DB01067","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Glisoxepide","DB01289","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Glyburide","DB01016","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Glycodiazine","DB01382","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
602,"Indacaterol","DB05039","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
602,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
602,"Insulin Aspart","DB01306","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Insulin Detemir","DB01307","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Insulin Glargine","DB00047","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Insulin Glulisine","DB01309","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Insulin Lispro","DB00046","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Isoprenaline","DB01064","Antagonism"
602,"Lidocaine","DB00281","The beta-blocker, bisoprolol, may increase the effect and toxicity of lidocaine."
602,"Methysergide","DB00247","Ischemia with risk of gangrene"
602,"Orciprenaline","DB00816","Antagonism"
602,"Pipobroman","DB00236","Antagonism"
602,"Pirbuterol","DB01291","Antagonism"
602,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
602,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
602,"Procaterol","DB01366","Antagonism"
602,"Repaglinide","DB00912","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism."
602,"Salbutamol","DB01001","Antagonism"
602,"Salmeterol","DB00938","Antagonism"
602,"Telithromycin","DB00976","Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed."
602,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
602,"Terbutaline","DB00871","Antagonism"
602,"Tolazamide","DB00839","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Tolbutamide","DB01124","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
602,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
602,"Verapamil","DB00661","Increased effect of both drugs"
602,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed."
604,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated. "
604,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated."
604,"Tolcapone","DB00323","Tolcapone and Furazolidone decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
604,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Furazolidone. "
604,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
604,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
604,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
604,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
604,"Zolmitriptan","DB00315","The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated. "
605,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
605,"Acenocoumarol","DB01418","Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
605,"Amitriptyline","DB00321","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifabutin is initiated, discontinued or dose changed."
605,"Amoxapine","DB00543","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifabutin is initiated, discontinued or dose changed."
605,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of rifabutin."
605,"Anisindione","DB01125","Rifabutin, may decrease the anticoagulant effect of anisindione."
605,"Atazanavir","DB01072","Atazanavir may increase levels/toxicity of rifabutin."
605,"Atorvastatin","DB01076","Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed."
605,"Atovaquone","DB01117","Rifabutin decreases the effect of atovaquone"
605,"Bromazepam","DB01558","Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed. "
605,"Bupropion","DB01156","Rifampin reduces bupropion levels"
605,"Buspirone","DB00490","Rifabutin decreases the effect of buspirone"
605,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
605,"Cerivastatin","DB00439","Rifabutin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifabutin is initiated, discontinued or dose changed."
605,"Clarithromycin","DB01211","The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin."
605,"Clomipramine","DB01242","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed."
605,"Clozapine","DB00363","Rifabutin decreases the effect of clozapine"
605,"Cyclosporine","DB00091","The rifamycin decreases the effect of cyclosporine"
605,"Dapsone","DB00250","Decreased levels of dapsone"
605,"Delavirdine","DB00705","Rifabutin decreases the effect of delavirdine"
605,"Desipramine","DB01151","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed."
605,"Dicoumarol","DB00266","Rifabutin may decrease the anticoagulant effect of dicumarol."
605,"Doxepin","DB01142","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed."
605,"Doxycycline","DB00254","The rifamycin decreases the effect of doxycycline"
605,"Erlotinib","DB00530","Decreased levels/effect of erlotinib"
605,"Erythromycin","DB00199","The rifamycin, rifabutin, may decrease the effect of the macrolide, erythromycin."
605,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
605,"Ethinyl Estradiol","DB00977","Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."
605,"Etravirine","DB06414","Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used.  "
605,"Fluconazole","DB00196","Fluconazole may increase levels/toxicity of rifabutin."
605,"Fluvastatin","DB01095","Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed."
605,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of rifabutin"
605,"Haloperidol","DB00502","The rifamycin decreases the effect of haloperidol"
605,"Imipramine","DB00458","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifabutin is initiated, discontinued or dose changed."
605,"Indinavir","DB00224","Rifabutin decreases the effect of indinavir"
605,"Itraconazole","DB01167","Rifabutin decreases the effect of itraconazole"
605,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
605,"Josamycin","DB01321","The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin."
605,"Lovastatin","DB00227","Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed."
605,"Mestranol","DB01357","This product may cause a slight decrease of the contraceptive effect"
605,"Methadone","DB00333","The rifamycin decreases the effect of methadone"
605,"Norethindrone","DB00717","Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."
605,"Nortriptyline","DB00540","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifabutin is initiated, discontinued or dose changed."
605,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
605,"Posaconazole","DB01263","Modification of drug levels for both agents"
605,"Propafenone","DB01182","Rifampin decreases the effect of propafenone"
605,"Protriptyline","DB00344","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifabutin is initiated, discontinued or dose changed."
605,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
605,"Ritonavir","DB00503","Rifabutin decreases the effect of ritonavir"
605,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
605,"Saquinavir","DB01232","Rifabutin decreases the effect of saquinavir"
605,"Simvastatin","DB00641","Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed."
605,"Sirolimus","DB00877","The rifamycin decreases the effect of sirolimus"
605,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
605,"Tacrolimus","DB00864","Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered."
605,"Tamoxifen","DB00675","The rifamycin decreases the effect of anti-estrogen"
605,"Telithromycin","DB00976","Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
605,"Temsirolimus","DB06287","Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
605,"Terbinafine","DB00857","Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided."
605,"Tipranavir","DB00932","Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects. "
605,"Tolvaptan","DB06212","Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
605,"Toremifene","DB00539","The rifamycin decreases the effect of anti-estrogen"
605,"Tramadol","DB00193","Rifabutin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
605,"Trazodone","DB00656","The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed."
605,"Trimipramine","DB00726","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed."
605,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
605,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
605,"Verapamil","DB00661","Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed. "
605,"Voriconazole","DB00582","Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
605,"Warfarin","DB00682","Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism."
605,"Zidovudine","DB00495","The rifamycin decreases levels of zidovudine"
608,"Acenocoumarol","DB01418","The tetracycline, demeclocycline, may increase the anticoagulant effect of acenocoumarol."
608,"Acitretin","DB00459","Increased risk of intracranial hypertension"
608,"Aluminium","DB01370","Formation of non-absorbable complexes"
608,"Amoxicillin","DB01060","Possible antagonism of action"
608,"Ampicillin","DB00415","Possible antagonism of action"
608,"Anisindione","DB01125","The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione."
608,"Attapulgite","DB01574","Formation of non-absorbable complexes"
608,"Azlocillin","DB01061","Possible antagonism of action"
608,"Aztreonam","DB00355","Possible antagonism of action"
608,"Bacampicillin","DB01602","Possible antagonism of action"
608,"Benzylpenicillin","DB01053","Possible antagonism of action"
608,"Bexarotene","DB00307","Tetracycline derivatives like demeclocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache)."
608,"Calcium","DB01373","Formation of non-absorbable complexes"
608,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as demeoclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
608,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
608,"Carbenicillin","DB00578","Possible antagonism of action"
608,"Clavulanate","DB00766","Possible antagonism of action"
608,"Cloxacillin","DB01147","Possible antagonism of action"
608,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
608,"Cyclacillin","DB01000","Possible antagonism of action"
608,"Dicloxacillin","DB00485","Possible antagonism of action"
608,"Dicoumarol","DB00266","The tetracycline, demeclocycline, may increase the anticoagulant effect of dicumarol."
608,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
608,"Etretinate","DB00926","Increased risk of intracranial hypertension"
608,"Flucloxacillin","DB00301","Possible antagonism of action"
608,"Hetacillin","DB00739","Possible antagonism of action"
608,"Iron","DB01592","Formation of non-absorbable complexes"
608,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
608,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
608,"Magnesium","DB01378","Formation of non-absorbable complexes"
608,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
608,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
608,"Methoxyflurane","DB01028","The tetracycline, demeclocycline, may increase the renal toxicity of methoxyflurane."
608,"Meticillin","DB01603","Possible antagonism of action"
608,"Mezlocillin","DB00948","Possible antagonism of action"
608,"Nafcillin","DB00607","Possible antagonism of action"
608,"Oxacillin","DB00713","Possible antagonism of action"
608,"Penicillin V","DB00417","Possible antagonism of action"
608,"Piperacillin","DB00319","Possible antagonism of action"
608,"Pivampicillin","DB01604","Possible antagonism of action"
608,"Pivmecillinam","DB01605","Possible antagonism of action"
608,"Tazobactam","DB01606","Possible antagonism of action"
608,"Ticarcillin","DB01607","Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline."
608,"Tretinoin","DB00755","Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided."
608,"Warfarin","DB00682","The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin."
608,"Zinc","DB01593","Formation of non-absorbable complexes"
609,"Acenocoumarol","DB01418","Imatinib may increase the anticoagulant effect of acenocoumarol."
609,"Acetaminophen","DB00316","Increased hepatic toxicity of both agents"
609,"Anisindione","DB01125","Imatinib may increase the anticoagulant effect of anisindione."
609,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, imatinib."
609,"Atorvastatin","DB01076","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed."
609,"Bromazepam","DB01558","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if imatinib is initiated, discontinued or dose changed. Dosage adjustments may be required. "
609,"Carbamazepine","DB00564","Carbamazepine, a strong CYP3A4 inducer, may increase the metabolism of imatinib. Imatinib, a strong CYP3A4 inhibitor, may increase the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed."
609,"Cerivastatin","DB00439","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if imatinib is initiated, discontinued or dose changed."
609,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the serum concentration of imatinib."
609,"Cyclosporine","DB00091","Imatinib increases the effect and toxicity of cyclosporine"
609,"Dantrolene","DB01219","Imatinib may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if imatinib is initiated, discontinued or dose changed. "
609,"Dexamethasone","DB01234","Dexamethasone may decrease levels of imatinib."
609,"Dicoumarol","DB00266","Imatinib may increase the anticoagulant effect of dicumarol."
609,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the serum concentration of imatinib."
609,"Ethotoin","DB00754","The hydantoin decreases the levels of imatinib"
609,"Etravirine","DB06414","Imatinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by a minimum of 50%, and to monitor therapy.  "
609,"Fosphenytoin","DB01320","The hydantoin decreases the levels of imatinib"
609,"Itraconazole","DB01167","Itraconazole may increase the levels of imatinib."
609,"Josamycin","DB01321","The macrolide, josamycin, may increase the serum concentration of imatinib."
609,"Ketoconazole","DB01026","Ketoconazole may increase the levels of imatinib."
609,"Lovastatin","DB00227","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if imatinib is initiated, discontinued or dose changed."
609,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
609,"Mephenytoin","DB00532","The hydantoin decreases the levels of imatinib"
609,"Nifedipine","DB01115","Imatinib increases the effect and toxicity of nifedipine"
609,"Phenobarbital","DB01174","Phenobarbital decreases levels of imatinib"
609,"Phenytoin","DB00252","The hydantoin decreases the levels of imatinib"
609,"Pimozide","DB01100","Imatinib may increase the effect and toxicity of pimozide."
609,"Rifampicin","DB01045","Rifampin decreases levels of imatinib"
609,"Simvastatin","DB00641","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed."
609,"St. John's Wort","DB01323","St. John's Wort decreases levels of imatinib"
609,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed."
609,"Tadalafil","DB00820","Imatinib may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
609,"Tamoxifen","DB00675","Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed."
609,"Tamsulosin","DB00706","Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed."
609,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
609,"Temsirolimus","DB06287","Imatinib may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
609,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Imatinib is initiated, discontinued or dose changed."
609,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Imatinib is initiated, discontinued or dose changed."
609,"Tolterodine","DB01036","Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
609,"Topotecan","DB01030","The BCRP/ABCG2 inhibitor, Imatinib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Imatinib is initiated, discontinued or dose changed. "
609,"Tramadol","DB00193","Imatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Imatinib may decrease the effect of Tramadol by decreasing active metabolite production.  "
609,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
609,"Trazodone","DB00656","The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed. "
609,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Imatinib is initiated, discontinued or dose changed. "
609,"Vardenafil","DB00862","Imatinib, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
609,"Venlafaxine","DB00285","Imatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Imatinib is initiated, discontinued, or dose changed."
609,"Verapamil","DB00661","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed. "
609,"Vinblastine","DB00570","Imatinib, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Imatinib is initiated, discontinued or dose changed."
609,"Vincristine","DB00541","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Imatinib is initiated, discontinued or dose changed."
609,"Vinorelbine","DB00361","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Imatinib is initiated, discontinued or dose changed."
609,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of imatinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of imatinib if voriconazole is initiated, discontinued or dose changed."
609,"Warfarin","DB00682","Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed."
609,"Zonisamide","DB00909","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed."
609,"Zopiclone","DB01198","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if imatinib is initiated, discontinued or dose changed."
610,"Acenocoumarol","DB01418","The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol."
610,"Acetylsalicylic acid","DB00945","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid."
610,"Ambenonium","DB01122","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium."
610,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Anisindione","DB01125","The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione."
610,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Bismuth Subsalicylate","DB01294","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate."
610,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone."
610,"Dicoumarol","DB00266","The corticosteroid, triamcinolone, alters the anticoagulant effect of dicumarol."
610,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."
610,"Edrophonium","DB01010","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium."
610,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone."
610,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone."
610,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Magnesium salicylate","DB01397","The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate."
610,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, triamcinolone."
610,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Midodrine","DB00211","Increased arterial pressure"
610,"Neostigmine","DB01400","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine."
610,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, triamcinolone."
610,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone."
610,"Pyridostigmine","DB00545","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, pyridostigmine."
610,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."
610,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone."
610,"Salicylate-sodium","DB01398","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium."
610,"Salsalate","DB01399","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate."
610,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, triamcinolone."
610,"Tacrine","DB00382","Tacrine and Triamcinolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
610,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, triamcinolone."
610,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
610,"Trisalicylate-choline","DB01401","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline."
610,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
610,"Warfarin","DB00682","The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin."
611,"Warfarin","DB00682","Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed."
612,"Bromazepam","DB01558","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
612,"Cyclosporine","DB00091","Nicardipine increases the effect and toxicity of cyclosporine"
612,"Dantrolene","DB01219","Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed. "
612,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
612,"Tacrolimus","DB00864","The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered."
612,"Tadalafil","DB00820","Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
612,"Tamoxifen","DB00675","Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed."
612,"Tamsulosin","DB00706","Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed."
612,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
612,"Temsirolimus","DB06287","Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
612,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nicardipine is initiated, discontinued or dose changed."
612,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
612,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nicardipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nicardipine if Thiopental is initiated, discontinued or dose changed."
612,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed."
612,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine."
612,"Tolbutamide","DB01124","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed. "
612,"Tolterodine","DB01036","Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.\
"
612,"Topotecan","DB01030","The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
612,"Torasemide","DB00214","Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Nicardipine is initiated, discontinued or dose changed. "
612,"Tramadol","DB00193","Nicardipine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Nicardipine may decrease the effect of Tramadol by decreasing active metabolite production. "
612,"Trazodone","DB00656","The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed. "
612,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
612,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Nicardipine is initiated, discontinued or dose changed."
612,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed. "
612,"Vardenafil","DB00862","Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
612,"Venlafaxine","DB00285","Nicardipine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Nicardipine is initiated, discontinued, or dose changed."
612,"Verapamil","DB00661","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed."
612,"Vinblastine","DB00570","Nicardipine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nicardipine is initiated, discontinued or dose changed."
612,"Vincristine","DB00541","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nicardipine is initiated, discontinued or dose changed."
612,"Vinorelbine","DB00361","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nicardipine is initiated, discontinued or dose changed."
612,"Voriconazole","DB00582","Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed.	"
612,"Warfarin","DB00682","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed."
612,"Zafirlukast","DB00549","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if nicardipine is initiated, discontinued or dose changed."
612,"Zolpidem","DB00425","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nicardipine is initiated, discontinued or dose changed. "
612,"Zonisamide","DB00909","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed."
612,"Zopiclone","DB01198","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed."
613,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
613,"Atomoxetine","DB00289","Risk of additive CNS depressant effects. Monitor for increased CNS depression during concomitant therapy."
613,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
613,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
613,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
613,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
613,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
613,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
613,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
613,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
613,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
613,"Guanethidine","DB01170","Fluphenazine may decrease the effect of guanethidine."
613,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
613,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
613,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
613,"Metrizamide","DB01578","Increased risk of convulsions"
613,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
613,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
613,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
613,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
613,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
613,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Fluphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
613,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed."
613,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
613,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
613,"Trimethobenzamide","DB00662","Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
613,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Fluphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
613,"Trospium","DB00209","Trospium and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
614,"Acenocoumarol","DB01418","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed. "
614,"Anisindione","DB01125","The androgen may increase the anticoagulant effect of anisindione."
614,"Cyclosporine","DB00091","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. "
614,"Dicoumarol","DB00266","The androgen may increase the anticoagulant effect of dicumarol."
614,"Docetaxel","DB01248","Testosterone may increase the serum levels and toxicity of docetaxel."
614,"Warfarin","DB00682","Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed."
615,"Alprazolam","DB00404","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, alprazolam."
615,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
615,"Atazanavir","DB01072","Efavirenz decreases the levels/effects of atazanavir"
615,"Atorvastatin","DB01076","Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed."
615,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
615,"Clarithromycin","DB01211","Efavirenz decreases levels of clarithromycin"
615,"Cyclosporine","DB00091","Efavirenz decreases the levels of cyclosporine"
615,"Dihydroergotamine","DB00320","Efavirenze may increase the adverse/toxic effects of dihydroergotamine. Concomitant therapy is contraindicated."
615,"Eltrombopag","DB06210","Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag. "
615,"Ergotamine","DB00696","The antiretroviral agent may increase the ergot derivative toxicity"
615,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
615,"Etravirine","DB06414","Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination. "
615,"Indinavir","DB00224","Efavirenz decreases the effect of indinavir"
615,"Lovastatin","DB00227","Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed."
615,"Methadone","DB00333","Efavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed."
615,"Methylergometrine","DB00353","The antiretroviral agent may increase the ergot derivative toxicity"
615,"Methysergide","DB00247","The antiretroviral agent may increase the ergot derivative toxicity"
615,"Midazolam","DB00683","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam."
615,"Rilpivirine","DB08864","Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's. "
615,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
615,"Saquinavir","DB01232","Efavirenz decreases the effect of saquinavir"
615,"Simvastatin","DB00641","Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed."
615,"St. John's Wort","DB01323","St. John's Wort decreases the antiretroviral effect"
615,"Tamsulosin","DB00706","Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed."
615,"Telaprevir","DB05521","Inducers of CYP3A enzymes will decrease telaprevir levels. "
615,"Telithromycin","DB00976","Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
615,"Temsirolimus","DB06287","Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
615,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
615,"Tipranavir","DB00932","Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed. "
615,"Tolterodine","DB01036","Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
615,"Tramadol","DB00193","Efavirenz may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
615,"Trazodone","DB00656","The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed."
615,"Triazolam","DB00897","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam."
615,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
615,"Voriconazole","DB00582","Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy."
617,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the absorption of Niacin. It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
617,"Lovastatin","DB00227","Risk of severe myopathy/rhabdomyolysis with this combination"
617,"Pitavastatin","DB08860","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
618,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."
618,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, clorazepate."
618,"Clozapine","DB00363","Increased risk of toxicity"
618,"Ethotoin","DB00754","Ethotoin may increase the metabolism of clorazepate via CYP3A4."
618,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, clorazepate."
618,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."
618,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of clorazepate via CYP3A4."
618,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clorazepate."
618,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, clorazepate."
618,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, clorazepate."
618,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, clorazepate."
618,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of clorazepate via CYP3A4."
618,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clorazepate."
618,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, clorazepate."
618,"Phenytoin","DB00252","Phenytoin may increase the metabolism of clorazepate via CYP3A4."
618,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clorazepate."
618,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate."
618,"Telithromycin","DB00976","Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed."
618,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased. "
618,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Clorazepate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
618,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of clorazepate by decreasing its metabolism. Monitor for clorazepate toxicity if voriconazole is initiated or dose increased."
619,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed."
619,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
619,"Trimipramine","DB00726","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanabenz. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanabenz should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
620,"Calcium","DB01373","Formation of non-absorbable complexes"
620,"Calcium Acetate","DB00258","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as alendronate. Avoid administration of oral calcium supplements within 30 minutes after alendronate. "
620,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. "
620,"Diclofenac","DB00586","Increased risk of gastric toxicity"
620,"Diflunisal","DB00861","Increased risk of gastric toxicity"
620,"Etodolac","DB00749","Increased risk of gastric toxicity"
620,"Fenoprofen","DB00573","Increased risk of gastric toxicity"
620,"Flurbiprofen","DB00712","Increased risk of gastric toxicity"
620,"Ibuprofen","DB01050","Increased risk of gastric toxicity"
620,"Indomethacin","DB00328","Increased risk of gastric toxicity"
620,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
620,"Ketorolac","DB00465","Increased risk of gasrtic toxicity"
620,"Magnesium","DB01378","Formation of non-absorbable complexes"
620,"Mefenamic acid","DB00784","Increased risk of gastric toxicity"
620,"Nabumetone","DB00461","Increased risk of gastric toxicity"
620,"Naproxen","DB00788","Increased risk of gastric toxicity"
620,"Oxaprozin","DB00991","Increased risk of gastric toxicity"
620,"Oxyphenbutazone","DB03585","Increased risk of gastric toxicity"
620,"Piroxicam","DB00554","Increased risk of gastric toxicity"
620,"Tenoxicam","DB00469","Increased risk of gastric toxicity"
621,"Leflunomide","DB01097","Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
621,"Natalizumab","DB00108","Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants, and patients receiving chronic corticosteroids prior to natalizumab should be tapered off of steroids prior to starting natalizumab. "
621,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of pimecrolimus cream in patients receiving immunosuppressants."
621,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
621,"Tacrolimus","DB00864","Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
621,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
623,"Tranylcypromine","DB00752","Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Dexmedetomidine. "
623,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
623,"Trimipramine","DB00726","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Dexmedetomidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Dexmedetomidine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
625,"Acenocoumarol","DB01418","The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol."
625,"Acetylsalicylic acid","DB00945","The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid."
625,"Ambenonium","DB01122","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium."
625,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Anisindione","DB01125","The corticosteroid, prednisone, alters the anticoagulant effect of anisindione."
625,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Bismuth Subsalicylate","DB01294","The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate."
625,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone."
625,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone."
625,"Chlorotrianisene","DB00269","The estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone."
625,"Clomifene","DB00882","The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone."
625,"Conjugated Estrogens","DB00286","The estrogenic agent may increase the effect of corticosteroid, prednisone."
625,"Dicoumarol","DB00266","The corticosteroid, prednisone, alters the anticoagulant effect of dicumarol."
625,"Diethylstilbestrol","DB00255","The estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone."
625,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."
625,"Edrophonium","DB01010","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium."
625,"Estradiol","DB00783","The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone."
625,"Estriol","DB04573","The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone."
625,"Estrone","DB00655","The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone."
625,"Estropipate","DB04574","The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone."
625,"Ethinyl Estradiol","DB00977","The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone."
625,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone."
625,"F","DB06223","decreases the effect of cortisone by metabolism alteration. "
625,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone."
625,"Glycerol Phenylbutyrate","DB08909","Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly."
625,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
625,"Insulin Lispro","DB00046","Concomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro. "
625,"Itraconazole","DB01167","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone."
625,"Ketoconazole","DB01026","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone."
625,"Linagliptin","DB08882","CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. "
625,"Magnesium salicylate","DB01397","The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate. "
625,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone."
625,"Mestranol","DB01357","The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone."
625,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone."
625,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Midodrine","DB00211","Increased arterial pressure"
625,"Neostigmine","DB01400","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine."
625,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone."
625,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone."
625,"Pyridostigmine","DB00545","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine."
625,"Quinestrol","DB04575","The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone."
625,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."
625,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone."
625,"Salicylate-sodium","DB01398","The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium."
625,"Salsalate","DB01399","The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate."
625,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone."
625,"Tacrine","DB00382","Tacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
625,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone."
625,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
625,"Trisalicylate-choline","DB01401","The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline."
625,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
625,"Warfarin","DB00682","The corticosteroid, prednisone, alters the anticoagulant effect of warfarin."
626,"Acenocoumarol","DB01418","The fibrate increases the anticoagulant effect"
626,"Acetohexamide","DB00414","Clofibrate may increase the effect of sulfonylurea, acetohexamide."
626,"Anisindione","DB01125","The fibrate increases the anticoagulant effect"
626,"Chlorpropamide","DB00672","Clofibrate may increase the effect of sulfonylurea, chlorpropamide."
626,"Dicoumarol","DB00266","The fibrate increases the anticoagulant effect"
626,"Gliclazide","DB01120","Clofibrate may increase the effect of sulfonylurea, gliclazide."
626,"Glipizide","DB01067","Clofibrate may increase the effect of sulfonylurea, glipizide."
626,"Glisoxepide","DB01289","Clofibrate may increase the effect of sulfonylurea, glisoxepide."
626,"Glyburide","DB01016","Clofibrate may increase the effect of sulfonylurea, glibenclamide."
626,"Glycodiazine","DB01382","Clofibrate may increase the effect of sulfonylurea, glycodiazine."
626,"Insulin Aspart","DB01306","Increases the effect of insulin"
626,"Insulin Detemir","DB01307","Increases the effect of insulin"
626,"Insulin Glulisine","DB01309","Increases the effect of insulin"
626,"Tolazamide","DB00839","Clofibrate may increase the effect of sulfonylurea, tolazamide."
626,"Tolbutamide","DB01124","Clofibrate may increase the effect of sulfonylurea, tolbutamide."
626,"Ursodeoxycholic acid","DB01586","The fibric acid derivative decreases the effect of ursodiol"
626,"Warfarin","DB00682","The fibrate increases the anticoagulant effect"
627,"Amprenavir","DB00701","Increased risk of cardiotoxicity and arrhythmias"
627,"Aprepitant","DB00673","Increased risk of cardiotoxicity and arrhythmias"
627,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
627,"Cimetidine","DB00501","Increased risk of cardiotoxicity and arrhythmias"
627,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
627,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
627,"Delavirdine","DB00705","Increased risk of cardiotoxicity and arrhythmias"
627,"Efavirenz","DB00625","Increased risk of cardiotoxicity and arrhythmias"
627,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
627,"Fluoxetine","DB00472","Increased risk of cardiotoxicity and arrhythmias"
627,"Fluvoxamine","DB00176","Increased risk of cardiotoxicity and arrhythmias"
627,"Fosamprenavir","DB01319","Increased risk of cardiotoxicity and arrhythmias"
627,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
627,"Indinavir","DB00224","Increased risk of cardiotoxicity and arrhythmias"
627,"Itraconazole","DB01167","Increased risk of cardiotoxicity and arrhythmias"
627,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
627,"Ketoconazole","DB01026","Increased risk of cardiotoxicity and arrhythmias"
627,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
627,"Mibefradil","DB01388","Increased risk of cardiotoxicity and arrhythmias"
627,"Nefazodone","DB01149","Increased risk of cardiotoxicity and arrhythmias"
627,"Nelfinavir","DB00220","Increased risk of cardiotoxicity and arrhythmias"
627,"Posaconazole","DB01263","Contraindicated co-administration"
627,"Quinine","DB00468","Increased risk of cardiotoxicity and arrhythmias"
627,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
627,"Ritonavir","DB00503","Increased risk of cardiotoxicity and arrhythmias"
627,"Saquinavir","DB01232","Increased risk of cardiotoxicity and arrhythmias"
627,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
627,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
627,"Telithromycin","DB00976","Increased risk of cardiotoxicity and arrhythmias"
627,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
627,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated."
627,"Troleandomycin","DB01361","Increased risk of cardiotoxicity and arrhythmias"
627,"Voriconazole","DB00582","Increased risk of cardiotoxicity and arrhythmias"
630,"Aminophylline","DB01223","This xanthine decreases the effect of adenosine"
630,"Caffeine","DB00201","Caffeine may diminish the therapeutic effect of adenosine. Specific management recommendations vary slightly depending on specific adenosine product used (i.e., therapeutic vs. diagnostic use of adenosine). Significantly higher adenosine doses, or alternative agents, may be required. Monitor for decreased therapeutic effects of adenosine if the patient is already receiving caffeine. Discontinue caffeine in advance (5 half-lives, or approximately 24 hours, is specifically recommended) of scheduled diagnostic use of adenosine (e.g., for radionuclide imaging studies) whenever possible."
630,"Dipyridamole","DB00975","Dipyridamole may increase the effect/toxicity of adenosine."
630,"Dyphylline","DB00651","This xanthine decreases the effect of adenosine"
630,"Oxtriphylline","DB01303","This xanthine decreases the effect of adenosine"
630,"Theophylline","DB00277","Theophylline may decrease the effect of adenosine."
631,"Amiodarone","DB01118","Increased risk of rhabdomyolysis"
631,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated."
631,"Atazanavir","DB01072","Increased risk of myopathy/rhabdomyolysis"
631,"Bosentan","DB00559","Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed."
631,"Carbamazepine","DB00564","Carbamazepine, a p-glycoprotein inducer, may decrease the effect of simvastatin by increasing its efflux. Monitor for changes in the therapeutic and adverse effects of simvastatin if carbamazepine is initiated, discontinued or dose changed."
631,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin."
631,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
631,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
631,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed."
631,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of simvastatin. Simvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
631,"Dronedarone","DB04855","Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. "
631,"Efavirenz","DB00625","Efavirenz may decrease the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if efavirenz is initiated, discontinued or dose changed."
631,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the toxicity of the statin, simvastatin."
631,"Etravirine","DB06414","Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy."
631,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
631,"Fluconazole","DB00196","Increased risk of myopathy/rhabdomyolysis"
631,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed."
631,"Fusidic Acid","DB02703","Increased risk of myopathy/rhabdomyolysis"
631,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
631,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if imatinib is initiated, discontinued or dose changed."
631,"Itraconazole","DB01167","Increased risk of myopathy/rhabdomyolysis"
631,"Ketoconazole","DB01026","Increased risk of myopathy/rhabdomyolysis"
631,"Lomitapide","DB08827","Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions. \
"
631,"Nefazodone","DB01149","Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed."
631,"Nelfinavir","DB00220","Nelfinavir may increase the effect and toxicity of simvastatin. Concomitant therapy should be avoided."
631,"Nevirapine","DB00238","The strong CYP3A4 inducer, nevirapine, may decrase the effect of simvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nevirapine is initiated, discontinued or dose changed."
631,"Pazopanib","DB06589","Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects. "
631,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
631,"Ranolazine","DB00243","Ranolazine may increase the serum concentration of simvastatin. Monitor for changes in the therapeutic and adverse effects of simvastatin if ranolazine is initiated, discontinued or dose changed."
631,"Rifabutin","DB00615","Rifabutin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic effect of simvastatin if rifabutin is initiated, discontinued or dose changed."
631,"Rifampicin","DB01045","Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed."
631,"Saxagliptin","DB06335","Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant. "
631,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
631,"Telithromycin","DB00976","Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided."
631,"Ticagrelor","DB08816","Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects. "
631,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated."
631,"Tocilizumab","DB06273","Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab. "
631,"Verapamil","DB00661","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed."
631,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed."
632,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy. "
632,"Sulindac","DB00605","The NSAID, sulindac, may increase the serum concentration of pemetrexed by decreasing its elimination. This interaction more prevalent in patients with mild to moderate renal insufficiency. Consider alternate therapy or monitor for pemetrexed toxicity during concomitant therapy. "
632,"Tiaprofenic acid","DB01600","Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered. "
632,"Tolmetin","DB00500","Tolmetin may decrease the renal excretion of Pemetrexed in patients with decreased creatinine clearance. Tolmetin may be withheld in these patients from 2 days before to 2 days after Pemetrexed administration. "
633,"Ethotoin","DB00754","The hydantoin decreases the efficiency of mebendazole"
633,"Fosphenytoin","DB01320","The hydantoin decreases the efficiency of mebendazole"
633,"Mephenytoin","DB00532","The hydantoin decreases the efficiency of mebendazole"
633,"Phenytoin","DB00252","The hydantoin decreases the efficiency of mebendazole"
637,"Acenocoumarol","DB01418","Propoxyphene may increase the anticoagulant effect of acenocoumarol."
637,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
637,"Anisindione","DB01125","Propoxyphene may increase the anticoagulant effect of anisindione."
637,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
637,"Carbamazepine","DB00564","Propoxyphene increases the effect of carbamazepine"
637,"Cimetidine","DB00501","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of propoxyphene. Monitor for changes in the therapeutic and adverse effects of propoxyphene if cimetidine is intitiated, discontinued or dose changed."
637,"Dicoumarol","DB00266","Propoxyphene may increase the anticoagulant effect of dicumarol."
637,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
637,"Ritonavir","DB00503","Ritonavir increases the levels of analgesic"
637,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant use should be avoided. "
637,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Propoxyphene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
637,"Warfarin","DB00682","Propoxyphene may increase the anticoagulant effect of warfarin."
638,"Acenocoumarol","DB01418","Mitotane may decrease the anticoagulant effect of acenocoumarol."
638,"Anisindione","DB01125","Mitotane may decrease the anticoagulant effect of anisindione."
638,"Dicoumarol","DB00266","Mitotane may decrease the anticoagulant effect of dicumarol."
638,"Spironolactone","DB00421","Spironolactone antagonizes the effect of mitotane"
638,"Warfarin","DB00682","Mitotane may decrease the anticoagulant effect of warfarin."
639,"Zidovudine","DB00495","Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided. "
640,"Glucarpidase","DB08898","Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase."
640,"Trimethoprim","DB00440","The efficacy of Trimethoprim may be reduced by Leucovorin (folinic acid). The antibiotic, Trimethoprim, acts by blocking bacterial folic acid metabolism. Leucovorin may reduce the efficacy of Trimethoprim by providing an alternate source of folic acid. The therapeutic effect of Trimethoprim should be closely monitored."
641,"Aciclovir","DB00787","Acyclovir increases the effect and toxicity of dyphylline."
641,"Adenosine","DB00640","This xanthine decreases the effect of adenosine"
641,"Bromazepam","DB01558","Dyphylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if dyphylline is initiated, discontinued or dose changed. "
641,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of diphylline. Diphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
641,"Cimetidine","DB00501","Increases the effect of theophylline"
641,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect of dyphylline."
641,"Clarithromycin","DB01211","Increases the effect and toxicity of theophylline "
641,"Disulfiram","DB00822","Increases the effect and toxicity of theophylline"
641,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, dyphylline."
641,"Ethinyl Estradiol","DB00977","The contraceptive increases the effect and toxicity of theophylline"
641,"Fluvoxamine","DB00176","Increases the effect and toxicity of theophylline"
641,"Fosphenytoin","DB01320","Decreased effect of both products"
641,"Grepafloxacin","DB00365","Grepafloxacin may increase the effect of dyphylline."
641,"Interferon Alfa-2a, Recombinant","DB00034","Interferon increases the effect and toxicity of theophylline"
641,"Interferon Alfa-2b, Recombinant","DB00105","Interferon increases the effect and toxicity of theophylline"
641,"Interferon alfa-n1","DB00011","Interferon increases the effect and toxicity of theophylline"
641,"Isoniazid","DB00951","Increases the effect and toxicity of theophylline"
641,"Lithium","DB01356","Theophylline decreases serum levels of lithium"
641,"Mexiletine","DB00379","Mexiletine increases the effect and toxicity of theophylline"
641,"Nadolol","DB01203","Antagonism of action and increased effect of theophylline"
641,"Norfloxacin","DB01059","Norfloxacin may increase the effect of dyphylline."
641,"Peginterferon alfa-2a","DB00008","Interferon increases the effect and toxicity of theophylline"
641,"Peginterferon alfa-2b","DB00022","Interferon increases the effect and toxicity of theophylline"
641,"Pentoxifylline","DB00806","Pentoxifylline increases the effect and toxicity of theophylline"
641,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of dyphylline."
641,"Phenytoin","DB00252","Decreased effect of both products"
641,"Pindolol","DB00960","Antagonism of action and increased effect of theophylline"
641,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of dyphylline."
641,"Propafenone","DB01182","Propafenone increases the effect of theophylline"
641,"Propranolol","DB00571","Antagonism of action and increased effect of theophylline"
641,"Rifampicin","DB01045","Rifampin decreases the effect of theophylline"
641,"Temazepam","DB00231","Dyphylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Dyphylline is initiated, discontinued or dose changed. "
641,"Terbinafine","DB00857","Terbinafine increases the effect and toxicity of theophylline"
641,"Ticlopidine","DB00208","Ticlopidine increases the effect and toxicity of theophylline"
641,"Timolol","DB00373","Antagonism of action and increased effect of theophylline"
642,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
642,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Pentazocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
643,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
643,"Dihydrocodeine","DB01551","May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. "
643,"Eltrombopag","DB06210","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
643,"Tiludronate","DB01133","The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
643,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Magnesium sulfate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
643,"Trovafloxacin","DB00685","Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction. "
644,"Bimatoprost","DB00905","The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use. "
645,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone."
645,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone."
645,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone."
645,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone."
645,"Prednisolone","DB00860","The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone."
645,"Prednisone","DB00635","The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone."
645,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone."
645,"Tipranavir","DB00932","Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy. "
646,"Almotriptan","DB00918","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Aminoglutethimide","DB00357","The CYP3A4 inducer, Aminoglutethimide, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aminoglutethimide is initiated, discontinued or dose changed."
646,"Amiodarone","DB01118","The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed."
646,"Amitriptyline","DB00321","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
646,"Amoxapine","DB00543","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Amprenavir","DB00701","The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed. "
646,"Aprepitant","DB00673","The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed."
646,"Atazanavir","DB01072","The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed. "
646,"Bosentan","DB00559","The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed."
646,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Buspirone","DB00490","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Cabergoline","DB00248","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Carbamazepine","DB00564","The CYP3A4 inducer, Carbamazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Carbamazepine is initiated, discontinued or dose changed."
646,"Cimetidine","DB00501","The CYP3A4 inhibitor, Cimetidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cimetidine is initiated, discontinued or dose changed."
646,"Citalopram","DB00215","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Clarithromycin","DB01211","The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed. "
646,"Clomipramine","DB01242","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Clotrimazole","DB00257","The CYP3A4 inhibitor, Clotrimazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Clotrimazole is initiated, discontinued or dose changed."
646,"Conivaptan","DB00872","The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed. "
646,"Cyclosporine","DB00091","The CYP3A4 inhibitor, Cyclosporine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Cyclosporine is initiated, discontinued or dose changed."
646,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
646,"Darunavir","DB01264","The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed. "
646,"Delavirdine","DB00705","The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed. "
646,"Desipramine","DB01151","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Dexamethasone","DB01234","The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed."
646,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Diltiazem","DB00343","The CYP3A4 inhibitor, Diltizem, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Diltiazem is initiated, discontinued or dose changed."
646,"Donepezil","DB00843","Possible antagonism of action"
646,"Doxepin","DB01142","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Duloxetine","DB00476","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
646,"Efavirenz","DB00625","The CYP3A4 inhibitor and inducer, Efavirenz, may alter Trazodone efficacy/toxicity by altering Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Efavirenz is initiated, discontinued or dose changed."
646,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Erythromycin","DB00199","The CYP3A4 inhibitor, Erythromycin , may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Erythromycin is initiated, discontinued or dose changed."
646,"Escitalopram","DB01175","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Etravirine","DB06414","The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed."
646,"Fluconazole","DB00196","The CYP3A4 inhibitor, Fluconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fluconazole is initiated, discontinued or dose changed."
646,"Fluoxetine","DB00472","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Fluvoxamine","DB00176","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Fosamprenavir","DB01319","The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed. "
646,"Fosphenytoin","DB01320","The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed."
646,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Furazolidone","DB00614","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Galantamine","DB00674","Possible antagonism of action"
646,"Ginkgo biloba","DB01381","Increased effect and toxicity of both agents"
646,"Haloperidol","DB00502","The CYP3A4 inhibitor, Haloperidol, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. The CYP2D6 inhibitor, Trazodone, may increase the efficacy of Haloperidol by decreasing Haloperidol metabolism and clearance. Monitor for changes in Trazodone and Haloperidol efficacy/toxicity if either agent is initiated, discontinued or dose changed."
646,"Imatinib","DB00619","The CYP3A4 inhibitor, Imatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Imatinib is initiated, discontinued or dose changed. "
646,"Imipramine","DB00458","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Indinavir","DB00224","The protease inhibitor, Indinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism via CYP3A4. Monitor for changes in Trazodone efficacy/toxicity if Indinavir is initiated, discontinued or dose changed."
646,"Isocarboxazid","DB01247","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Isoniazid","DB00951","The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed. "
646,"Itraconazole","DB01167","The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed."
646,"Ketoconazole","DB01026","The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed."
646,"Lapatinib","DB01259","The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed."
646,"Lidocaine","DB00281","The CYP3A4 inhibitor, Lidocaine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lidocaine is initiated, discontinued or dose changed."
646,"Linezolid","DB00601","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Lithium","DB01356","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Lopinavir","DB01601","The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed. "
646,"Maprotiline","DB00934","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Metronidazole","DB00916","The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed."
646,"Miconazole","DB01110","The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed. "
646,"Mirtazapine","DB00370","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Moclobemide","DB01171","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Nafcillin","DB00607","The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed."
646,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Nefazodone","DB01149","Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed."
646,"Nelfinavir","DB00220","The protease inhibitor, Nelfinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nelfinavir is initiated, discontinued or dose changed. "
646,"Nevirapine","DB00238","The CYP3A4 inducer, Nevirapine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nevirapine is initiated, discontinued or dose changed."
646,"Nicardipine","DB00622","The CYP3A4 inhibitor, Nicardipine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Nicardipine is initiated, discontinued or dose changed. "
646,"Norfloxacin","DB01059","The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."
646,"Nortriptyline","DB00540","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Oxcarbazepine","DB00776","The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed."
646,"Paroxetine","DB00715","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Pentobarbital","DB00312","The CYP3A4 inducer, Pentobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Pentobarbital is initiated, discontinued or dose changed."
646,"Pergolide","DB01186","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Pethidine","DB00454","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Phenelzine","DB00780","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Phenobarbital","DB01174","The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed."
646,"Phenytoin","DB00252","The CYP3A4 inducer, Phenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenytoin is initiated, discontinued or dose changed."
646,"Posaconazole","DB01263","The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed. "
646,"Primidone","DB00794","The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed."
646,"Procarbazine","DB01168","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Promethazine","DB01069","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Protriptyline","DB00344","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Quinidine","DB00908","The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed. "
646,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Rifabutin","DB00615","The CYP3A4 inducer, Rifabutin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifabutin is initiated, discontinued or dose changed."
646,"Rifampicin","DB01045","The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed."
646,"Rifapentine","DB01201","The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed."
646,"Ritonavir","DB00503","The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed. "
646,"Rivastigmine","DB00989","Possible antagonism of action"
646,"Rizatriptan","DB00953","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Saquinavir","DB01232","The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed. "
646,"Selegiline","DB01037","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Sertraline","DB01104","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Sibutramine","DB01105","Increased risk of serotonin syndrome. Avoid concomitant therapy. "
646,"Sitaxentan","DB06268","The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."
646,"St. John's Wort","DB01323","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Sumatriptan","DB00669","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Tamoxifen","DB00675","Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
646,"Tamsulosin","DB00706","Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed."
646,"Telithromycin","DB00976","The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed."
646,"Tetracycline","DB00759","The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed."
646,"Tipranavir","DB00932","The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed."
646,"Tramadol","DB00193","The use of two serotonin modulators, such as trazodone and tramadol, may increase the risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
646,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Trazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
646,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
646,"Verapamil","DB00661","The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed."
646,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed."
646,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
648,"Ciprofloxacin","DB00537","Sevelamer decreases ciprofloxacin bioavailability"
648,"Cyclosporine","DB00091","Sevelamer decreases the effect of cyclosporine"
648,"Trovafloxacin","DB00685","Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction. "
650,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Metaxalone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
651,"Acebutolol","DB01193","Increased effect of both drugs"
651,"Aliskiren","DB09026","Monitor therapy due to increased concentration of aliskiren. "
651,"Amifostine","DB01143","Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended."
651,"Aminophylline","DB01223","Verapamil increases the effect of theophylline"
651,"Amiodarone","DB01118","Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed. "
651,"Amobarbital","DB01351","Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed. "
651,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed. "
651,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed. "
651,"Atenolol","DB00335","Increased effect of both drugs"
651,"Atorvastatin","DB01076","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed."
651,"Bisoprolol","DB00612","Increased effect of both drugs"
651,"Bromazepam","DB01558","Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed."
651,"Buspirone","DB00490","Verapamil may increase the serum concentration of Buspirone. The likely occurs via Verapamil-mediated CYP3A4 inhibition resulting in decreased Buspirone metabolism. Monitor for changes in the therapeutic/adverse effects of Buspirone if Verpamil is initiated, discontinued or dose changed."
651,"Butabarbital","DB00237","Butabarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butabarbital is initiated, discontinued or dose changed. "
651,"Butalbital","DB00241","Butalbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Butalbital is initiated, discontinued or dose changed.  "
651,"Carbamazepine","DB00564","Verapamil may increase the serum concentration of Carbamazepine by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Carbamazepine if Verapamil is initiated, discontinued or dose changed."
651,"Carvedilol","DB01136","Increased effect of both drugs"
651,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed. "
651,"Colchicine","DB01394","Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed."
651,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed. "
651,"Cyclosporine","DB00091","Verapamil may increase the serum concentration of cyclosporine by inhibiting CYP3A4-mediated metabolism of cyclosporine. Monitor for changes in the therapeutic/adverse effects of cyclosporine if verapamil is initiated, discontinued or dose changed."
651,"Dabigatran etexilate","DB06695","Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered."
651,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed. "
651,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed. "
651,"Digitoxin","DB01396","Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed."
651,"Digoxin","DB00390","Verapamil may increase the serum concentration of Digoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digoxin if Verpamail is initiated, discontinued or dose changed."
651,"Dofetilide","DB00204","Verapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated. "
651,"Dronedarone","DB04855","Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker. "
651,"Eplerenone","DB00700","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
651,"Erythromycin","DB00199","Erythromycin, a moderate CYP3A4 inhibitor, may increase the serum concentration of veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of verapamil if erythromycin is initiated, discontinued or dose changed."
651,"Esmolol","DB00187","Increased effect of both drugs"
651,"Everolimus","DB01590","Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided. "
651,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of Verapamil by decreasing Verapamil metabolism. This likely occurs via Fluconazole-mediated CYP3A4 inhibition. Monitor for changes in the therapeutic/adverse effects of Verapamil if Fluconazole is initiated, discontinued, or dose changed."
651,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed. "
651,"Halofantrine","DB01218","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy. "
651,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Imatinib is initiated, discontinued or dose changed. "
651,"Indacaterol","DB05039","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
651,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Indinavir is initiated, discontinued or dose changed. "
651,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed. "
651,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed. "
651,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed."
651,"Labetalol","DB00598","Increased effect of both drugs"
651,"Lithium","DB01356","Signs of lithium toxicity"
651,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed."
651,"Lovastatin","DB00227","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed."
651,"Methohexital","DB00474","Methohexital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methohexital is initiated, discontinued or dose changed."
651,"Methylphenobarbital","DB00849","Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed. "
651,"Metoprolol","DB00264","Increased effect of both drugs"
651,"Miconazole","DB01110","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed."
651,"Midazolam","DB00683","Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam."
651,"Nadolol","DB01203","Increased effect of both drugs"
651,"Nafcillin","DB00607","Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed. "
651,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed."
651,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nelfinavir is initiated, discontinued or dose changed."
651,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nicardipine is initiated, discontinued or dose changed."
651,"Oxprenolol","DB01580","Increased effect of both drugs"
651,"Oxtriphylline","DB01303","Verapamil increases the effect of theophylline"
651,"Pentobarbital","DB00312","Pentobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Pentobarbital is initiated, discontinued or dose changed."
651,"Phenobarbital","DB01174","Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed."
651,"Phenytoin","DB00252","Verapamil may increase the serum concentration of Phenytoin by decreasing its metabolism. Monitor for changes in the therapeutic/adverse effects of Phenytoin if Verapamil is initiated, discontinued or dose changed. "
651,"Pindolol","DB00960","Increased effect of both drugs"
651,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed."
651,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
651,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil."
651,"Propranolol","DB00571","Increased effect of both drugs"
651,"Quinidine","DB00908","Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed."
651,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
651,"Ranolazine","DB00243","Verapamil, a CYP3A4 inhibitor, may increase the serum concentration of Ranolazine. Concomitant therapy is contraindicated."
651,"Rifabutin","DB00615","Rifabutin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifabutin is initiated, discontinued or dose changed. "
651,"Rifampicin","DB01045","Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed."
651,"Rifapentine","DB01201","Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed."
651,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed."
651,"Rituximab","DB00073","Verapamil may increase the hypotensive effects of Rituximab. Consider withholding Verapamil therapy for 12 hours prior to Rituximab infusion. "
651,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed."
651,"Secobarbital","DB00418","Secobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Secobarbital is initiated, discontinued or dose changed."
651,"Silodosin","DB06207","Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects"
651,"Simvastatin","DB00641","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Simvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce Simvastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Simvastatin if Verapamil is initiated, discontinued or dose changed."
651,"Tacrolimus","DB00864","The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered."
651,"Tamsulosin","DB00706","Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed."
651,"Telithromycin","DB00976","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed."
651,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
651,"Theophylline","DB00277","Verapamil increases the effect of theophylline"
651,"Thiopental","DB00599","Thiopental, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Thiopental is initiated, discontinued or dose changed."
651,"Timolol","DB00373","Additive effects of decreased heart rate and contractility may occur. Increased risk of heart block. "
651,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil."
651,"Tolterodine","DB01036","Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
651,"Tolvaptan","DB06212","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated. "
651,"Topotecan","DB01030","The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
651,"Tramadol","DB00193","Verapamil may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
651,"Trazodone","DB00656","The CYP3A4 inhibitor, Verapamil, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Verapamil is initiated, discontinued or dose changed."
651,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
651,"Triazolam","DB00897","Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam."
651,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed."
652,"Acetophenazine","DB01063","Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Alimemazine","DB01246","Trimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Amitriptyline","DB00321","Trimethobenzamide and Amitriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Amoxapine","DB00543","Trimethobenzamide and Amoxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Atropine","DB00572","Trimethobenzamide and Atropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Azelastine","DB00972","Trimethobenzamide and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Benzatropine","DB00245","Trimethobenzamide and Benztropine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Biperiden","DB00810","Trimethobenzamide and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Bromodiphenhydramine","DB01237","Trimethobenzamide and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Brompheniramine","DB00835","Trimethobenzamide and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Carbinoxamine","DB00748","Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Chlorphenamine","DB01114","Trimethobenzamide and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Chlorpromazine","DB00477","Trimethobenzamide and Chlorpromazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Clemastine","DB00283","Trimethobenzamide and Clemastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Clidinium","DB00771","Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Clomipramine","DB01242","Trimethobenzamide and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Clozapine","DB00363","Trimethobenzamide and Clozapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Cyclizine","DB01176","Trimethobenzamide and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Dexbrompheniramine","DB00405","Trimethobenzamide and Dexbrompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Dicyclomine","DB00804","Trimethobenzamide and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Dimenhydrinate","DB00985","Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Diphenhydramine","DB01075","Trimethobenzamide and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Donepezil","DB00843","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
652,"Doxepin","DB01142","Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Doxylamine","DB00366","Trimethobenzamide and Doxylamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Dronabinol","DB00470","Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Marinol. Close monitoring of cardiovascular effects is recommended."
652,"Droperidol","DB00450","Trimethobenzamide and Droperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Fexofenadine","DB00950","Trimethobenzamide and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Flavoxate","DB01148","Trimethobenzamide and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Flupentixol","DB00875","Trimethobenzamide and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Fluphenazine","DB00623","Trimethobenzamide and Fluphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Galantamine","DB00674","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
652,"Glycopyrrolate","DB00986","Trimethobenzamide and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Haloperidol","DB00502","Trimethobenzamide and Haloperidol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Homatropine Methylbromide","DB00725","Trimethobenzamide and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Hydroxyzine","DB00557","Trimethobenzamide and Hydroxyzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Hyoscyamine","DB00424","Trimethobenzamide and Hyoscyamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Imipramine","DB00458","Trimethobenzamide and Imipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Ipratropium bromide","DB00332","Trimethobenzamide and Ipratropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Isocarboxazid","DB01247","Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Ketotifen","DB00920","Trimethobenzamide and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Loratadine","DB00455","Trimethobenzamide and Loratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Loxapine","DB00408","Trimethobenzamide and Loxapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Maprotiline","DB00934","Trimethobenzamide and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Meclizine","DB00737","Trimethobenzamide and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Mepenzolate","DB04843","Trimethobenzamide and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Mesoridazine","DB00933","Trimethobenzamide and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Methantheline","DB00940","Trimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Methylscopolamine bromide","DB00462","Trimethobenzamide and Methylscopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Moclobemide","DB01171","Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Molindone","DB01618","Trimethobenzamide and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Nabilone","DB00486","Anticholinergics, such as Trimethobenzamide, may increase the tachycardic effect of cannabinoids such as Nabilone. Close monitoring of cardiovascular effects is recommended."
652,"Nortriptyline","DB00540","Trimethobenzamide and Nortriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Olanzapine","DB00334","Trimethobenzamide and Olanzapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Orphenadrine","DB01173","Trimethobenzamide and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Oxybutynin","DB01062","Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Perphenazine","DB00850","Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Phenelzine","DB00780","Trimethobenzamide and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Phenindamine","DB01619","Trimethobenzamide and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Pimozide","DB01100","Trimethobenzamide and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Pizotifen","DB06153","Trimethobenzamide and Pizotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Potassium Chloride","DB00761","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
652,"Pramlintide","DB01278","The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
652,"Prochlorperazine","DB00433","Trimethobenzamide and Prochlorperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Procyclidine","DB00387","Trimethobenzamide and Procyclidine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Promethazine","DB01069","Trimethobenzamide and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Propantheline","DB00782","Trimethobenzamide and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Protriptyline","DB00344","Trimethobenzamide and Protriptyline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Quetiapine","DB01224","Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Risperidone","DB00734","Trimethobenzamide and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Rivastigmine","DB00989","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
652,"Scopolamine","DB00747","Trimethobenzamide and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Secretin","DB00021","The stimulatory effect of Secretin may be reduced by anticholinergics such as Trimethobenzamide. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
652,"Solifenacin","DB01591","Trimethobenzamide and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimethobenzamide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
652,"Thioridazine","DB00679","Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Thiothixene","DB01623","Trimethobenzamide and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Tiotropium","DB01409","Trimethobenzamide and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Tolterodine","DB01036","Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Tranylcypromine","DB00752","Trimethobenzamide and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Trifluoperazine","DB00831","Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Trihexyphenidyl","DB00376","Trimethobenzamide and Trihexyphenidyl, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Trimipramine","DB00726","Trimethobenzamide and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Triprolidine","DB00427","Concomitant therapy with Triprolidine and Trimethobenzamide, two anticholinergics, may result in additive anticholinergic effects. Monitor for enhanced anticholinergic effects."
652,"Trospium","DB00209","Trospium and Trimethobenzamide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
652,"Zuclopenthixol","DB01624","Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
655,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Nilutamide. Consider alternate therapy or monitor for adverse/toxic effects of Nilutamide if Ticlopidine is initiated, discontinued or dose changed."
658,"Acebutolol","DB01193","Hypertension, then bradycardia"
658,"Alseroxylon","DB00386","Increased arterial pressure"
658,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of epinephrine."
658,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of epinephrine."
658,"Atenolol","DB00335","Hypertension, then bradycardia"
658,"Betaxolol","DB00195","Beta-Blockers such as betaxolol may enhance the vasopressor effect of epinephrine. Monitor for increases in pressor effects of alpha-/beta-agonists if used in patients receiving beta-blocker therapy (including ophthalmic products). Beta1-selective (i.e., ''cardioselective'') agents may confer a more limited risk if used in low enough doses to allow them to retain their selectivity. The amount of epinephrine used in dental procedures as part of local anesthetic administration is not likely to be of clinical concern. Infiltrating larger volumes of local anesthetics for other surgical procedures (e.g., more than 0.06mg epinephrine) may cause clinically-relevant problems. Patients with allergies that require carrying and periodically using subcutaneous epinephrine (e.g., bee sting kits) should probably avoid the use of beta blockers. "
658,"Bevantolol","DB01295","Hypertension, then bradycardia"
658,"Bisoprolol","DB00612","Hypertension, then bradycardia"
658,"Carteolol","DB00521","Hypertension, then bradycardia"
658,"Carvedilol","DB01136","Hypertension, then bradycardia"
658,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of epinephrine."
658,"Deserpidine","DB01089","Increased arterial pressure"
658,"Desipramine","DB01151","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
658,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
658,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine."
658,"Entacapone","DB00494","Entacapone may increase the effect and toxicity of the sympathomimetic, epinephrine."
658,"Ergonovine","DB01253","Possible marked increase of arterial pressure"
658,"Esmolol","DB00187","Hypertension, then bradycardia"
658,"Guanethidine","DB01170","Epinephrine may decrease the effect of guanethidine."
658,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of epinephrine."
658,"Insulin Lispro","DB00046","Concomitant therapy with sympathomimetic agents may reduce the blood-glucose-lowering effect of insulin lispro. "
658,"Isocarboxazid","DB01247","Increased arterial pressure"
658,"Labetalol","DB00598","Hypertension, then bradycardia"
658,"Linezolid","DB00601","Possible increase of arterial pressure"
658,"Lurasidone","DB08815","Epinephrine increases toxicity (enhance hypotensive effects) of lurasidone by pharmacodynamic synergism. "
658,"Methyldopa","DB00968","Increased arterial pressure"
658,"Methylergometrine","DB00353","Possible marked increase of arterial pressure"
658,"Metoprolol","DB00264","Hypertension, then bradycardia"
658,"Midodrine","DB00211","Increased arterial pressure"
658,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of epinephrine."
658,"Nadolol","DB01203","Hypertension, then bradycardia"
658,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of epinephrine."
658,"Oxprenolol","DB01580","Hypertension, then bradycardia"
658,"Oxytocin","DB00107","Possible marked increase of arterial pressure"
658,"Pargyline","DB01626","Increased arterial pressure"
658,"Penbutolol","DB01359","Hypertension, then bradycardia"
658,"Phenelzine","DB00780","Increased arterial pressure"
658,"Pindolol","DB00960","Hypertension, then bradycardia"
658,"Practolol","DB01297","Hypertension, then bradycardia"
658,"Propranolol","DB00571","Hypertension, then bradycardia"
658,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of epinephrine."
658,"Rasagiline","DB01367","Increased arterial pressure"
658,"Reserpine","DB00206","Increased arterial pressure"
658,"Sotalol","DB00489","Hypertension, then bradycardia"
658,"Timolol","DB00373","Hypertension, then bradycardia"
658,"Tranylcypromine","DB00752","Increased arterial pressure"
658,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
658,"Venlafaxine","DB00285","Venlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
659,"Citalopram","DB00215","Increased risk of CNS adverse effects"
659,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
659,"Dihydroergotamine","DB00320","Possible severe and prolonged vasoconstriction"
659,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction"
659,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
659,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
659,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
659,"Isocarboxazid","DB01247","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."
659,"Lithium","DB01356","Possible serotoninergic syndrome with this combination"
659,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
659,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
659,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
659,"Phenelzine","DB00780","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."
659,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
659,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Sumatriptan. Risk of serotonin syndrome and Sumatriptan toxicity. Concomitant therapy should be avoided. "
659,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
659,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
659,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
659,"Vilazodone","DB06684","Increased risk of serotonin syndrome"
659,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
661,"Probenecid","DB01032","Probenecid may increase the serum level of cefixime."
662,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
662,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide."
662,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
662,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
662,"Bevantolol","DB01295","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
662,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
662,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
662,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
662,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide."
662,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, chlorpropamide."
662,"Diazoxide","DB01119","Antagonism. "
662,"Dicoumarol","DB00266","Dicumarol may increase the effect of sulfonylurea, chlorpropamide."
662,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
662,"Glucosamine","DB01296","Possible hyperglycemia"
662,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
662,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
662,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
662,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
662,"Penbutolol","DB01359","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
662,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
662,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
662,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
662,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
662,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, chlorpropamide."
662,"Salsalate","DB01399","The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide."
662,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of chlorpropamide. Monitor for changes in fasting and postprandial blood sugars."
662,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
662,"Sulfacytine","DB01298","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfadiazine","DB00359","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfadoxine","DB01299","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfamerazine","DB01581","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfamethazine","DB01582","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfamethizole","DB00576","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfamethoxazole","DB01015","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfapyridine","DB00891","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfasalazine","DB00795","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Sulfisoxazole","DB00263","Sulfonamide/sulfonylurea: possible hypoglycemia"
662,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
662,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, chlorpropamide."
662,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
663,"Acenocoumarol","DB01418","Aprepitant may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration."
663,"Alprazolam","DB00404","Aprepitant may increase the effect and toxicity of the benzodiazepine, alprazolam."
663,"Anisindione","DB01125","Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration."
663,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
663,"Carbamazepine","DB00564","The CYP3A4 inducer, carbamazepine, may decrease the effect of aprepitant."
663,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
663,"Clarithromycin","DB01211","The CYP3A4 inhibitor, clarithromycin, may increase the effect and toxicity of aprepitant."
663,"Corticotropin","DB01285","Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen."
663,"Dexamethasone","DB01234","Aprepitant may increase the effect and toxicity of dexamethasone."
663,"Dicoumarol","DB00266","Aprepitant may decrease the anticoagulant effect of dicumarol by decreasing its serum concentration."
663,"Diltiazem","DB00343","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Docetaxel","DB01248","Aprepitant may change levels of the chemotherapy agent, docetaxel."
663,"Erythromycin","DB00199","Erythromycin, a moderate CYP3A4 inhibitor, may increase the effect and toxicity of aprepitant."
663,"Ethinyl Estradiol","DB00977","Aprepitant could decrease the effect of the oral contraceptive"
663,"Ethotoin","DB00754","The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant."
663,"Etoposide","DB00773","Aprepitant may change levels of the chemotherapy agent, etoposide."
663,"Fosphenytoin","DB01320","The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant."
663,"Ifosfamide","DB01181","Aprepitant may change levels of the chemotherapy agent, ifosfamide."
663,"Imatinib","DB00619","Aprepitant may change levels of the chemotherapy agent, imatinib."
663,"Irinotecan","DB00762","Aprepitant may change levels of the chemotherapy agent, irinotecan."
663,"Itraconazole","DB01167","This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant."
663,"Ketoconazole","DB01026","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Mephenytoin","DB00532","The CYP3A4 inducer, mephenytoin, may decrease the effect of aprepitant."
663,"Mestranol","DB01357","Aprepitant could decrease the effect of the oral contraceptive"
663,"Methylprednisolone","DB00959","Increases the effect and toxicity of methylprednisolone"
663,"Midazolam","DB00683","Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam."
663,"Nefazodone","DB01149","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Nelfinavir","DB00220","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Paclitaxel","DB01229","Aprepitant may change levels of the chemotherapy agent, paclitaxel."
663,"Phenytoin","DB00252","The CYP3A4 inducer, phenytoin, may decrease the effect of aprepitant."
663,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
663,"Rifampicin","DB01045","The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant."
663,"Ritonavir","DB00503","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Tamsulosin","DB00706","Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed."
663,"Telithromycin","DB00976","Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed."
663,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
663,"Tolterodine","DB01036","Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
663,"Tramadol","DB00193","Aprepitant may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
663,"Trazodone","DB00656","The CYP3A4 inhibitor, Aprepitant, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Aprepitant is initiated, discontinued or dose changed."
663,"Triazolam","DB00897","Aprepitant may increase the effect and toxicity of the benzodiazepine, triazolam."
663,"Troleandomycin","DB01361","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
663,"Vinblastine","DB00570","Aprepitant may change levels of the chemotherapy agent, vinblastine. "
663,"Vincristine","DB00541","Aprepitant may change levels of the chemotherapy agent, vincristine."
663,"Vinorelbine","DB00361","Aprepitant may change levels of the chemotherapy agent, vinorelbine."
663,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed."
663,"Warfarin","DB00682","Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration."
664,"Acepromazine","DB01614","Possible antagonism of action"
664,"Aceprometazine","DB01615","Possible antagonism of action"
664,"Alimemazine","DB01246","Possible antagonism of action"
664,"Alverine","DB01616","Possible antagonism of action"
664,"Amantadine","DB00915","Possible antagonism of action"
664,"Amitriptyline","DB00321","Possible antagonism of action"
664,"Amoxapine","DB00543","Possible antagonism of action"
664,"Atropine","DB00572","Possible antagonism of action"
664,"Azatadine","DB00719","Possible antagonism of action"
664,"Benzatropine","DB00245","Possible antagonism of action"
664,"Biperiden","DB00810","Possible antagonism of action"
664,"Brompheniramine","DB00835","Possible antagonism of action"
664,"Carbinoxamine","DB00748","Possible antagonism of action"
664,"Chlorphenamine","DB01114","Possible antagonism of action"
664,"Chlorpromazine","DB00477","Possible antagonism of action"
664,"Chlorprothixene","DB01239","Possible antagonism of action"
664,"Cimetidine","DB00501","Possible antagonism of action"
664,"Clemastine","DB00283","Possible antagonism of action"
664,"Clidinium","DB00771","Possible antagonism of action"
664,"Clomipramine","DB01242","Possible antagonism of action"
664,"Clozapine","DB00363","Possible antagonism of action"
664,"Cyclizine","DB01176","Possible antagonism of action"
664,"Cyclobenzaprine","DB00924","Possible antagonism of action"
664,"Cyproheptadine","DB00434","Possible antagonism of action"
664,"Darifenacin","DB00496","Possible antagonism of action"
664,"Desipramine","DB01151","Possible antagonism of action"
664,"Dexbrompheniramine","DB00405","Possible antagonism of action"
664,"Dicyclomine","DB00804","Possible antagonism of action"
664,"Dimenhydrinate","DB00985","Possible antagonism of action"
664,"Diphenhydramine","DB01075","Possible antagonism of action"
664,"Diphenoxylate","DB01081","Possible antagonism of action"
664,"Diphenylpyraline","DB01146","Possible antagonism of action"
664,"Disopyramide","DB00280","Possible antagonism of action"
664,"Doxepin","DB01142","Possible antagonism of action"
664,"Doxylamine","DB00366","Possible antagonism of action"
664,"Ethopropazine","DB00392","Possible antagonism of action"
664,"Flavoxate","DB01148","Possible antagonism of action"
664,"Flupentixol","DB00875","Possible antagonism of action"
664,"Glutethimide","DB01437","Possible antagonism of action"
664,"Glycopyrrolate","DB00986","Possible antagonism of action"
664,"Hydroxyzine","DB00557","Possible antagonism of action"
664,"Hyoscyamine","DB00424","Possible antagonism of action"
664,"Imipramine","DB00458","Possible antagonism of action"
664,"Isocarboxazid","DB01247","Possible antagonism of action"
664,"Isopropamide","DB01625","Possible antagonism of action"
664,"Ketoconazole","DB01026","Ketoconazole increases the effect and toxicity of galantamine"
664,"Loxapine","DB00408","Possible antagonism of action"
664,"Maprotiline","DB00934","Possible antagonism of action"
664,"Meclizine","DB00737","Possible antagonism of action"
664,"Mesoridazine","DB00933","Possible antagonism of action"
664,"Methdilazine","DB00902","Possible antagonism of action"
664,"Methotrimeprazine","DB01403","Possible antagonism of action"
664,"Methylscopolamine bromide","DB00462","Possible antagonism of action"
664,"Mirtazapine","DB00370","Possible antagonism of action"
664,"Moclobemide","DB01171","Possible antagonism of action"
664,"Molindone","DB01618","Possible antagonism of action"
664,"Nortriptyline","DB00540","Possible antagonism of action"
664,"Olanzapine","DB00334","Possible antagonism of action"
664,"Orphenadrine","DB01173","Possible antagonism of action"
664,"Oxybutynin","DB01062","Possible antagonism of action"
664,"Paroxetine","DB00715","Paroxetine increases the effect and toxicity of galantamine"
664,"Perphenazine","DB00850","Possible antagonism of action"
664,"Pethidine","DB00454","Possible antagonism of action"
664,"Phenelzine","DB00780","Possible antagonism of action"
664,"Phenindamine","DB01619","Possible antagonism of action"
664,"Pimozide","DB01100","Possible antagonism of action"
664,"Pipotiazine","DB01621","Possible antagonism of action"
664,"Procainamide","DB01035","Possible antagonism of action"
664,"Prochlorperazine","DB00433","Possible antagonism of action"
664,"Procyclidine","DB00387","Possible antagonism of action"
664,"Promazine","DB00420","Possible antagonism of action"
664,"Promethazine","DB01069","Possible antagonism of action"
664,"Propantheline","DB00782","Possible antagonism of action"
664,"Propericiazine","DB01608","Possible antagonism of action"
664,"Protriptyline","DB00344","Possible antagonism of action"
664,"Quetiapine","DB01224","Possible antagonism of action"
664,"Quinidine","DB00908","Possible antagonism of action"
664,"Quinidine barbiturate","DB01346","Possible antagonism of action"
664,"Risperidone","DB00734","Possible antagonism of action"
664,"Scopolamine","DB00747","Possible antagonism of action"
664,"Sertraline","DB01104","Possible antagonism of action"
664,"Solifenacin","DB01591","Possible antagonism of action"
664,"Thioproperazine","DB01622","Possible antagonism of action"
664,"Thioridazine","DB00679","Possible antagonism of action"
664,"Thiothixene","DB01623","Possible antagonism of action"
664,"Tizanidine","DB00697","Possible antagonism of action"
664,"Tolterodine","DB01036","Possible antagonism of action"
664,"Tranylcypromine","DB00752","Possible antagonism of action"
664,"Trazodone","DB00656","Possible antagonism of action"
664,"Trifluoperazine","DB00831","Possible antagonism of action"
664,"Triflupromazine","DB00508","Possible antagonism of action"
664,"Trihexyphenidyl","DB00376","Possible antagonism of action"
664,"Trimethobenzamide","DB00662","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
664,"Trimipramine","DB00726","Possible antagonism of action"
664,"Tripelennamine","DB00792","Possible antagonism of action"
664,"Triprolidine","DB00427","Possible antagonism of action"
664,"Trospium","DB00209","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Galantamine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
664,"Ziprasidone","DB00246","Possible antagonism of action"
664,"Zuclopenthixol","DB01624","Possible antagonism of action"
665,"Acenocoumarol","DB01418","Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided."
665,"Aminoglutethimide","DB00357","Aminoglutethimide may increase Tamoxifen clearance decreasing its therapeutic effect. Consider alternate therapy or monitor for changes in Tamoxifen effects when Aminoglutethimide is initiated, discontinued or dose changed."
665,"Amiodarone","DB01118","Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Amprenavir","DB00701","Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Atazanavir","DB01072","Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Capecitabine","DB01101","Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed."
665,"Chloroquine","DB00608","Chloroquine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Chlorpromazine","DB00477","Chlorpromazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Cimetidine","DB00501","Cimetidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Cinacalcet","DB01012","Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Clarithromycin","DB01211","Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Clomipramine","DB01242","Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Clozapine","DB00363","Clozapine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Cocaine","DB00907","Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Darifenacin","DB00496","Darifenacin may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Darunavir","DB01264","Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Delavirdine","DB00705","Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Desipramine","DB01151","Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Diphenhydramine","DB01075","Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Duloxetine","DB00476","Duloxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Floxuridine","DB00322","Floxuridine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Floxiridine is initiated, discontinued or dose changed."
665,"Fluconazole","DB00196","Fluconzole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluconazole  is initiated, discontinued or dose changed.\
"
665,"Fluorouracil","DB00544","Fluorouracil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Fluorouracil is initiated, discontinued or dose changed."
665,"Fluoxetine","DB00472","Fluoxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Flurbiprofen","DB00712","Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed."
665,"Fosamprenavir","DB01319","Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Gemfibrozil","DB01241","Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil  is initiated, discontinued or dose changed."
665,"Haloperidol","DB00502","Haloperidol may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Ibuprofen","DB01050","Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed."
665,"Imatinib","DB00619","Imatinib may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Imatinib may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Imatinib is initiated, discontinued or dose changed."
665,"Imipramine","DB00458","Imipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
665,"Indinavir","DB00224","Indinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Indomethacin","DB00328","Indomethacin may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Indomethacin is initiated, discontinued or dose changed."
665,"Isoniazid","DB00951","Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed."
665,"Itraconazole","DB01167","Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Ketoconazole","DB01026","Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed."
665,"Lidocaine","DB00281","Lidocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Lopinavir","DB01601","Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Lumefantrine","DB06708","Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy."
665,"Mefenamic acid","DB00784","Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed."
665,"Methadone","DB00333","Methadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Methimazole","DB00763","Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Miconazole","DB01110","Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Nefazodone","DB01149","Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Nelfinavir","DB00220","Nelfinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Nicardipine","DB00622","Nicardipine may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Nicardipine may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Nicardipine is initiated, discontinued or dose changed."
665,"Nilotinib","DB04868","Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Paroxetine","DB00715","Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Pergolide","DB01186","Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Pioglitazone","DB01132","Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Piroxicam","DB00554","Piroxicam may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Piroxicam is initiated, discontinued or dose changed."
665,"Posaconazole","DB01263","Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Pyrimethamine","DB00205","Pyrimethamine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Quinidine","DB00908","Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Quinine","DB00468","Quinine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
665,"Ranolazine","DB00243","Ranolazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Rifabutin","DB00615","The rifamycin decreases the effect of anti-estrogen"
665,"Rifampicin","DB01045","The rifamycin decreases the effect of anti-estrogen"
665,"Ritonavir","DB00503","Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Rivaroxaban","DB06228","Tamoxifen may increase serum concentrations of Rivaroxaban increasing the risk of bleeding. Concomitant therapy should be avoided."
665,"Saquinavir","DB01232","Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
665,"Sertraline","DB01104","Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Sitaxentan","DB06268","Sitaxsentan may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sitaxsentan is initiated, discontinued or dose changed."
665,"Sulfadiazine","DB00359","Sulfadiazine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfadiazine is initiated, discontinued or dose changed."
665,"Sulfisoxazole","DB00263","Sulfisoxazole may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sulfisoxazole is initiated, discontinued or dose changed."
665,"Telithromycin","DB00976","Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed."
665,"Terbinafine","DB00857","Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
665,"Thioridazine","DB00679","Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Ticlopidine","DB00208","Ticlopidine may decrease the therapeutic effect of tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."
665,"Topotecan","DB01030","The p-glycoprotein inhibitor, Tamoxifen, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
665,"Tranylcypromine","DB00752","The CYP2D6 inhibitor, Tranylcypromine, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy."
665,"Trazodone","DB00656","Trazodone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
665,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed."
665,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed."
665,"Warfarin","DB00682","Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk."
668,"Amiloride","DB00594","Increased risk of hyperkalemia"
668,"Drospirenone","DB01395","Increased risk of hyperkalemia"
668,"Indomethacin","DB00328","Indomethacin decreases the effect of losartan"
668,"Insulin Lispro","DB00046","Concomitant therapy with angiotensin II receptor blockers may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
668,"Lithium","DB01356","Losartan increases serum levels of lithium"
668,"Potassium","DB01345","Increased risk of hyperkalemia"
668,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
668,"Rifampicin","DB01045","Rifampin decreases the effect of losartan"
668,"Spironolactone","DB00421","Increased risk of hyperkalemia"
668,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
668,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
668,"Trandolapril","DB00519","The angiotensin II receptor blocker, Losartan, may increase the adverse effects of Trandolapril. "
668,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
668,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed."
668,"Triamterene","DB00384","Increased risk of hyperkalemia"
669,"Abiraterone","DB05812","Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. "
669,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
669,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
669,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
669,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated."
669,"Asenapine","DB06216","Thioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy. "
669,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
669,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
669,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
669,"Benzylpenicillin","DB01053","Increased risk of cardiotoxicity and arrhythmias"
669,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
669,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
669,"Bupropion","DB01156","Bupropion may increase the effect and toxicity of thioridazine."
669,"Chloroquine","DB00608","Increased risk of cardiotoxicity and arrhythmias"
669,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
669,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
669,"Crizotinib","DB08865","Concurrent use with drugs that prolong QTc interval is contraindicated. "
669,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
669,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
669,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
669,"Diltiazem","DB00343","Increased risk of cardiotoxicity and arrhythmias"
669,"Diphenhydramine","DB01075","Increased risk of cardiotoxicity and arrhythmias"
669,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
669,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
669,"Donepezil","DB00843","Possible antagonism of action"
669,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
669,"Duloxetine","DB00476","Increased risk of cardiotoxicity and arrhythmias"
669,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
669,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
669,"Flecainide","DB01195","Increased risk of cardiotoxicity and arrhythmias"
669,"Fluoxetine","DB00472","Increased risk of cardiotoxicity and arrhythmias"
669,"Fluvoxamine","DB00176","Increased risk of cardiotoxicity and arrhythmias"
669,"Galantamine","DB00674","Possible antagonism of action"
669,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
669,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
669,"Guanethidine","DB01170","Thioridazine may decrease the effect of guanethidine."
669,"Halofantrine","DB01218","Increased risk of cardiotoxicity and arrhythmias"
669,"Haloperidol","DB00502","Increased risk of cardiotoxicity and arrhythmias"
669,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
669,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
669,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
669,"Lorcaserin","DB04871","Avoid combination.The combination is likely to reduce the metabolism of Thioridazine."
669,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
669,"Maprotiline","DB00934","Increased risk of cardiotoxicity and arrhythmias"
669,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
669,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
669,"Metrizamide","DB01578","Increased risk of convulsions"
669,"Mirabegron","DB08893","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
669,"Paroxetine","DB00715","Increased risk of cardiotoxicity and arrhythmias"
669,"Pentamidine","DB00738","Increased risk of cardiotoxicity and arrhythmias"
669,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
669,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
669,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
669,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
669,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
669,"Pindolol","DB00960","Increased risk of cardiotoxicity and arrhythmias"
669,"Procainamide","DB01035","Increased risk of cardiotoxicity and arrhythmias"
669,"Propafenone","DB01182","Increased risk of cardiotoxicity and arrhythmias."
669,"Propranolol","DB00571","Increased risk of cardiotoxicity and arrhythmias"
669,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
669,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
669,"Quinine","DB00468","Increased risk of cardiotoxicity and arrhythmias"
669,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
669,"Rivastigmine","DB00989","Possible antagonism of action"
669,"Sertindole","DB06144","Increased risk of cardiotoxicity and arrhythmias"
669,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
669,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
669,"Spiramycin","DB06145","Increased risk of cardiotoxicity and arrhythmias"
669,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
669,"Tacrolimus","DB00864","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
669,"Tamoxifen","DB00675","Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
669,"Tamsulosin","DB00706","Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed."
669,"Telithromycin","DB00976","Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided."
669,"Terbinafine","DB00857","Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated."
669,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
669,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
669,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
669,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism of thioridazine. Concomitant therapy is contraindicated."
669,"Toremifene","DB00539","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
669,"Tramadol","DB00193","Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production. "
669,"Tranylcypromine","DB00752","Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated. "
669,"Trimethobenzamide","DB00662","Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
669,"Trimipramine","DB00726","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
669,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
669,"Trospium","DB00209","Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
669,"Vilazodone","DB06684","Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.  Avoid combination."
669,"Voriconazole","DB00582","Additive QTc prolongation may occur. Concomitant use is contraindicated. "
669,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
669,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
669,"Zuclopenthixol","DB01624","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated."
670,"Diltiazem","DB00343","Increased effect/toxicity of moricizine"
670,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
670,"Telithromycin","DB00976","Telithromycin may reduce clearance of Moricizine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Moricizine if Telithromycin is initiated, discontinued or dose changed."
670,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moricizine if voriconazole is initiated, discontinued or dose changed."
671,"Colistimethate","DB01111","Amphotericin B may enhance the nephrotoxic effect of Colistimethate. Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely. "
671,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
671,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with Amphotericin B. Use caution during concomitant therapy. "
671,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
672,"Acetaminophen","DB00316","Acetaminophen increases the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if acetaminophen is initiated, discontinued or dose changed. "
672,"Acetylsalicylic acid","DB00945","The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin."
672,"Allopurinol","DB00437","Allopurinol may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin times and therapeutic effects of warfarin if allopurinol is initiated, discontinued or dose changed."
672,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the anticoagulant effect of warfarin by increasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if aminoglutethimide is initiated, discontinued or dose changed."
672,"Aminosalicylic Acid","DB00233","The antiplatelet effects of aminosalicylic acid may increase the bleed risk associated with warfarin. "
672,"Amiodarone","DB01118","Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed."
672,"Amobarbital","DB01351","Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed. "
672,"Amprenavir","DB00701","Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration."
672,"Aprepitant","DB00673","Aprepitant may decrease the anticoagulant effect of warfarin by decreasing its serum concentration."
672,"Atazanavir","DB01072","The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin."
672,"Avanafil","DB06237","Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.\
"
672,"Azathioprine","DB00993","Azathioprine may decrease the anticoagulant effect of warfarin."
672,"Azithromycin","DB00207","Azithromycin may increase the anticoagulant effect of warfarin by increasing its serum concentration."
672,"Betamethasone","DB00443","The corticosteroid, betamethasone, alters the anticoagulant effect of warfarin."
672,"Bezafibrate","DB01393","Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed. "
672,"Bosentan","DB00559","Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism."
672,"Butabarbital","DB00237","Butabarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butabarbital is initiated, discontinued or dose changed. "
672,"Butalbital","DB00241","Butalbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if butalbital is initiated, discontinued or dose changed. "
672,"Capecitabine","DB01101","Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect."
672,"Carbamazepine","DB00564","Carbamazepine may decrease the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if carbamazepine is initiated, discontinued or dose changed."
672,"Cefotetan","DB01330","The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin."
672,"Cefoxitin","DB01331","The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin."
672,"Ceftriaxone","DB01212","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin."
672,"Celecoxib","DB00482","Celecoxib may increase the anticoagulant effect of warfarin."
672,"Cholestyramine","DB01432","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption."
672,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if cimetidine is initiated, discontinued or dose changed."
672,"Ciprofloxacin","DB00537","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of warfarin."
672,"Cisapride","DB00604","Cisapride may increase the anticoagulant effect of warfarin."
672,"Citalopram","DB00215","The SSRI, citalopram, increases the effect of anticoagulant, warfarin."
672,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin."
672,"Clofibrate","DB00636","The fibrate increases the anticoagulant effect"
672,"Clopidogrel","DB00758","Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. "
672,"Colestipol","DB00375","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of warfarin by decreasing its absorption."
672,"Cyclophosphamide","DB00531","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of warfarin."
672,"Danazol","DB01406","Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed."
672,"Delavirdine","DB00705","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed. "
672,"Demeclocycline","DB00618","The tetracycline, demeclocycline, may increase the anticoagulant effect of warfarin."
672,"Desogestrel","DB00304","Desogestrol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if desogestrol is initiated, discontinued or dose changed. "
672,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin."
672,"Dextropropoxyphene","DB00647","Propoxyphene may increase the anticoagulant effect of warfarin."
672,"Dextrothyroxine","DB00509","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of warfarin."
672,"Diclofenac","DB00586","The antiplatelet effects of oral diclofenac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Dicloxacillin","DB00485","Dicloxacillin may decrease the anticoagulant effect of warfarin."
672,"Diflunisal","DB00861","The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Disulfiram","DB00822","Disulfiram may increase the anticoagulant effect of warfarin."
672,"Doxycycline","DB00254","The tetracycline, doxycycline, may increase the anticoagulant effect of warfarin."
672,"Dronedarone","DB04855","Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold "
672,"Drospirenone","DB01395","Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed."
672,"Drotrecogin alfa","DB00055","Increased risk of bleeding."
672,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the anticoagulant effect of warfarin."
672,"Ethchlorvynol","DB00189","Ethchlorvynol may decrease the anticoagulant effect of warfarin."
672,"Ethinyl Estradiol","DB00977","Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed."
672,"Ethynodiol","DB00823","Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose "
672,"Etodolac","DB00749","The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Etonogestrel","DB00294","Etonogestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if etonogestrel is initiated, discontinued or dose changed."
672,"Etoricoxib","DB01628","Etoricoxib may increase the anticoagulant effect of warfarin."
672,"Ezetimibe","DB00973","If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored."
672,"F","DB06223","decreases the effect of cortisone by metabolism alteration. "
672,"Fenofibrate","DB01039","Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed."
672,"Fenoprofen","DB00573","The antiplatelet effects of fenoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Floxuridine","DB00322","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if floxuridine is initiated, discontinued or dose changed."
672,"Fluconazole","DB00196","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluconazole is initiated, discontinued or dose changed."
672,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin."
672,"Fluorouracil","DB00544","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if fluorouracil is initiated, discontinued or dose changed."
672,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases the effect of anticoagulant, warfarin."
672,"Fluoxymesterone","DB01185","Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed."
672,"Flurbiprofen","DB00712","Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed."
672,"Fluvastatin","DB01095","Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed."
672,"Fluvoxamine","DB00176","Fluvoxamine may increase the anticoagulant effect of warfarin by increasing its serum concentration."
672,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin."
672,"Fosphenytoin","DB01320","Increased hydantoin levels and risk of bleeding"
672,"Gadofosveset trisodium","DB06705","In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter \
the anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR)."
672,"Gefitinib","DB00317","Gefitinib may increase the anticoagulant effect of warfarin."
672,"Gemcitabine","DB00441","Gemcitabine may increase the anticoagulant effect of warfarin."
672,"Gemfibrozil","DB01241","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed."
672,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
672,"Ginseng","DB01404","Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided."
672,"Glucagon recombinant","DB00040","Monitor therapy due to enhanced anticoagulant effects."
672,"Glucosamine","DB01296","Possible interaction and enhanced antiplatelet activity of warfarin"
672,"Glutethimide","DB01437","Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed."
672,"Griseofulvin","DB00400","Griseofulvin may decrease the anticoagulant effect of warfarin."
672,"Homoharringtonine","DB04865","Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
672,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin."
672,"Ibuprofen","DB01050","Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed."
672,"Imatinib","DB00619","Imatinib may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if imatinib is initiated, discontinued or dose changed."
672,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the anticoagulant effect of warfarin."
672,"Indomethacin","DB00328","Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of indomethacin may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if indomethacin is initiated, discontinued or dose changed."
672,"Isoniazid","DB00951","Isoniazid may increase the anticoagulant effect of warfarin."
672,"Itraconazole","DB01167","Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism."
672,"Ketoconazole","DB01026","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed."
672,"Ketoprofen","DB01009","The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Ketorolac","DB00465","The antiplatelet effects of ketorolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Leflunomide","DB01097","Leflunomide may increase the anticoagulant effect of warfarin."
672,"Levamisole","DB00848","Levamisole may increase the anticoagulant effect of warfarin."
672,"Levofloxacin","DB01137","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin."
672,"Levonorgestrel","DB00367","Levonorgestrel may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if levonorgestrel is initiated, discontinued or dose changed."
672,"Levothyroxine","DB00451","Levothyroxine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if levothyroxine is initiated, discontinued or dose changed."
672,"Liothyronine","DB00279","Liothyronine may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liothyronine is initiated, discontinued or dose changed."
672,"Liotrix","DB01583","Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed."
672,"Lomitapide","DB08827","Warfarin plasma concentrations may increase by lomitapide by 30%..\
INR levels may increase by 22%. Regular INR monitoring is required. "
672,"Lovastatin","DB00227","Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed ."
672,"Lumiracoxib","DB01283","Lumiracoxib may increase the anticoagulant effect of warfarin."
672,"Meclofenamic acid","DB00939","The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. "
672,"Medroxyprogesterone Acetate","DB00603","Medroxyprogesterone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if medroxyprogesterone is initiated, discontinued or dose changed."
672,"Mefenamic acid","DB00784","Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed."
672,"Mefloquine","DB00358","Mefloquine may increase the anticoagulant effect of warfarin."
672,"Meloxicam","DB00814","The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Mercaptopurine","DB01033","Mercaptopurine may decrease the anticoagulant effect of warfarin."
672,"Mestranol","DB01357","Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed."
672,"Methimazole","DB00763","Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed."
672,"Methohexital","DB00474","Methohexital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if methohexital is initiated, discontinued or dose changed. "
672,"Metronidazole","DB00916","Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed."
672,"Miconazole","DB01110","Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed."
672,"Minocycline","DB01017","The tetracycline, minocycline, may increase the anticoagulant effect of warfarin."
672,"Mirabegron","DB08893","Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely. "
672,"Mitotane","DB00648","Mitotane may decrease the anticoagulant effect of warfarin."
672,"Moxifloxacin","DB00218","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of warfarin."
672,"Nabumetone","DB00461","The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Nafcillin","DB00607","Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed. "
672,"Nalidixic Acid","DB00779","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin."
672,"Nandrolone decanoate","DB08804","Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed."
672,"Nandrolone phenpropionate","DB00984","Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed."
672,"Naproxen","DB00788","The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of warfarin."
672,"Nevirapine","DB00238","Nevirapine may decrease the anticoagulant effect of warfarin by increasing metabolism of R-warfarin via CYP3A4."
672,"Nicardipine","DB00622","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nicardipine is initiated, discontinued or dose changed."
672,"Norethindrone","DB00717","Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed."
672,"Norfloxacin","DB01059","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin."
672,"Norgestimate","DB00957","Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed."
672,"Ofloxacin","DB01165","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin."
672,"Orlistat","DB01083","Orlistat may increase the anticoagulant effect of warfarin."
672,"Oxandrolone","DB00621","Oxandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxandrolone is initiated, discontinued or dose changed."
672,"Oxaprozin","DB00991","The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"oxymetholone","DB06412","Oxymetholone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if oxymetholone is initiated, discontinued or dose changed."
672,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin."
672,"Paroxetine","DB00715","The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin."
672,"Pentobarbital","DB00312","Pentobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if pentobarbital is initiated, discontinued or dose changed. "
672,"Pentoxifylline","DB00806","Pentoxifylline may increase the anticoagulant effect of warfarin."
672,"Phenobarbital","DB01174","Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed."
672,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin."
672,"Phenytoin","DB00252","Warfarin may increase the serum concentration of phenytoin possibly by competing for CYP2C9 metabolism. Phenytoin may increase the anticoagulant effect of warfarin. Monitor phenytoin levels, prothrombin time, and therapeutic and adverse effects of both agents during concomitant therapy."
672,"Phylloquinone","DB01022","Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased. "
672,"Piroxicam","DB00554","Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of piroxicam may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if piroxicam is initiated, discontinued or dose changed."
672,"Prasugrel","DB06209","Coadministration with warfarin may increase the risk of bleeding. "
672,"Prednisolone","DB00860","The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin."
672,"Prednisone","DB00635","The corticosteroid, prednisone, alters the anticoagulant effect of warfarin."
672,"Primidone","DB00794","The barbiturate, primidone, decreases the anticoagulant effect of warfarin."
672,"Propafenone","DB01182","Propafenone may increase the anticoagulant effect of warfarin."
672,"Propylthiouracil","DB00550","Propylthiouracil may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if propylthiouracil is initiated, discontinued or dose changed."
672,"Quinidine","DB00908","Quinidine may increase the anticoagulant effect of warfarin."
672,"Quinine","DB00468","Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of S-warfarin by decreasing its metabolism via CYP2C9."
672,"Ranitidine","DB00863","Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)"
672,"Rifabutin","DB00615","Rifabutin may decrease the anticoagulant effect of warfarin by increasing its metabolism."
672,"Rifampicin","DB01045","Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism."
672,"S-Adenosylmethionine","DB00118","Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided."
672,"Salicylate-sodium","DB01398","The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin."
672,"Secobarbital","DB00418","Secobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if secobarbital is initiated, discontinued or dose changed. "
672,"Sitaxentan","DB06268","Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed."
672,"St. John's Wort","DB01323","St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed. "
672,"Sucralfate","DB00364","Sucralfate may reduce the absorption of warfarin. Warfarin should be administered at least 2 hours before or 6 hours after sucralfate administration. Monitor for changes in prothrombin time if sucralfate is initiated, discontinued or dose changed. "
672,"Sulfadiazine","DB00359","Sulfadiazine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfadiazine is initiated, discontinued or dose changed."
672,"Sulfamethoxazole","DB01015","Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed. "
672,"Sulfinpyrazone","DB01138","Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding. "
672,"Sulfisoxazole","DB00263","Sulfisoxazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if sulfisoxazole is initiated, discontinued or dose changed."
672,"Sulindac","DB00605","The antiplatelet effects of sulindac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Tamoxifen","DB00675","Tamoxifen, a CYP2C9 inhibitor, may increase the serum concentration of warfarin by decreasing its metabolism. Concomitant therapy is contraindicated due to significant increase in bleed risk."
672,"Telithromycin","DB00976","Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy. "
672,"Tenoxicam","DB00469","The NSAID, tenoxicam, may increase the anticoagulant effect of warfarin."
672,"Testolactone","DB00894","Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed."
672,"Testosterone","DB00624","Testosterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testosterone is initiated, discontinued or dose changed."
672,"Testosterone Propionate","DB01420","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed."
672,"Tetracycline","DB00759","Tetracycline may increase the anticoagulant effect of warfarin."
672,"Thiopental","DB00599","Thiopental may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if thiopental is initiated, discontinued or dose changed."
672,"Tiaprofenic acid","DB01600","The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"Ticlopidine","DB00208","Increased bleeding risk. Monitor INR."
672,"Tigecycline","DB00560","Tigecycline may increase the serum concentration of warfarin."
672,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed."
672,"Tolmetin","DB00500","The antiplatelet effects of tolmetin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
672,"transdermal testosterone gel","DB05275","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed."
672,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Warfarin. Monitor for increased bleeding during concomitant thearpy. "
672,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, alters the anticoagulant effect of warfarin."
672,"Triflusal","DB08814","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
672,"Trimetrexate","DB01157","The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use."
672,"Trisalicylate-choline","DB01401","The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin."
672,"Vemurafenib","DB08881","Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely. "
672,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of warfarin and vilazodone."
673,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Aprepitant","DB00673","Aprepitant may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
673,"BXT-51072","DB05631","BXT-51072 weakly inhibits midazolam clearance. "
673,"Carbamazepine","DB00564","Carbamazepine may decrease the effect of the benzodiazepine, midazolam."
673,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, midazolam."
673,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, midazolam."
673,"Clobazam","DB00349","Clobazam decrease the Cmax and AUC of midazolam by approximately 25% of both and increases the Cmax and AUC of its metabolite. Dose adjustment is not necessary. "
673,"Clozapine","DB00363","Increased risk of toxicity"
673,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
673,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
673,"Dabrafenib","DB08912","Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively. "
673,"Delavirdine","DB00705","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Diltiazem","DB00343","The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Docetaxel","DB01248","Midazolam may increase the serum levels and toxicity of docetaxel."
673,"Efavirenz","DB00625","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of the benzodiazepine, midazolam."
673,"Ethotoin","DB00754","Ethotoin may increase the metabolism of midazolam via CYP3A4."
673,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, midazolam."
673,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of midazolam via CYP3A4."
673,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, midazolam."
673,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, midazolam."
673,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam."
673,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, midazolam."
673,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, midazolam."
673,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of midazolam via CYP3A4."
673,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, midazolam."
673,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, midazolam."
673,"Phenytoin","DB00252","Phenytoin may increase the metabolism of midazolam via CYP3A4."
673,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
673,"Rifampicin","DB01045","Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed."
673,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam."
673,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam."
673,"St. John's Wort","DB01323","St. John's Wort may decrease the effect of the benzodiazepine, midazolam."
673,"Telaprevir","DB05521","Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively. "
673,"Telithromycin","DB00976","Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam."
673,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated."
673,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Midazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
673,"Vemurafenib","DB08881","Vemurafenib decreases the AUC (CYP3A4 substrate) by 39%. "
673,"Verapamil","DB00661","Verapamil may increase the serum concentration of Midazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Midazolam."
673,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased."
674,"Acetazolamide","DB00819","Increased risk of nephrotoxicity"
674,"Amphotericin B","DB00681","Increased risk of nephrotoxicity"
674,"Atracurium","DB00732","The agent increases the effect of the muscle relaxant"
674,"Benazepril","DB00542","Increased risk of nephrotoxicity"
674,"Bumetanide","DB00887","Increased ototoxicity"
674,"Candesartan","DB00796","Increased risk of nephrotoxicity"
674,"Captopril","DB01197","Increased risk of nephrotoxicity"
674,"Cefamandole","DB01326","Increased risk of nephrotoxicity"
674,"Cefapirin","DB01139","Increased risk of nephrotoxicity"
674,"Cefazolin","DB01327","Increased risk of nephrotoxicity"
674,"Cefonicid","DB01328","Increased risk of nephrotoxicity"
674,"Cefoperazone","DB01329","Increased risk of nephrotoxicity"
674,"Ceforanide","DB00923","Increased risk of nephrotoxicity"
674,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
674,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
674,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
674,"Cefradine","DB01333","Increased risk of nephrotoxicity"
674,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
674,"Ceftizoxime","DB01332","Increased risk of nephrotoxicity"
674,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
674,"Cefuroxime","DB01112","Increased risk of nephrotoxicity"
674,"Cephalothin Group","DB03450","Increased risk of nephrotoxicity"
674,"Cisplatin","DB00515","Increased risk of nephrotoxicity"
674,"Colistimethate","DB01111","Increased risk of nephrotoxicity"
674,"Cyclosporine","DB00091","Increased risk of nephrotoxicity"
674,"Didanosine","DB00900","Increased risk of nephrotoxicity"
674,"Doxacurium chloride","DB01135","The agent increases the effect of the muscle relaxant"
674,"Enalapril","DB00584","Increased risk of nephrotoxicity"
674,"Ethacrynic acid","DB00903","Increased ototoxicity"
674,"Fosinopril","DB00492","Increased risk of nephrotoxicity"
674,"Furosemide","DB00695","Increased ototoxicity"
674,"Heparin","DB01109","Increased risk of nephrotoxicity"
674,"Irbesartan","DB01029","Increased risk of nephrotoxicity"
674,"Lamivudine","DB00709","Increased risk of nephrotoxicity"
674,"Lisinopril","DB00722","Increased risk of nephrotoxicity"
674,"Lithium","DB01356","Increased risk of nephrotoxicity"
674,"Losartan","DB00678","Increased risk of nephrotoxicity"
674,"Metocurine","DB01336","The agent increases the effect of the muscle relaxant"
674,"Mivacurium","DB01226","The agent increases the effect of the muscle relaxant"
674,"Olmesartan","DB00275","Increased risk of nephrotoxicity"
674,"Pancuronium","DB01337","The agent increases the effect of the muscle relaxant"
674,"Perindopril","DB00790","Increased risk of nephrotoxicity"
674,"Phenytoin","DB00252","Increased risk of nephrotoxicity"
674,"Pipecuronium","DB01338","The agent increases the effect of the muscle relaxant"
674,"Quinapril","DB00881","Increased risk of nephrotoxicity"
674,"Ramipril","DB00178","Increased risk of nephrotoxicity"
674,"Rocuronium","DB00728","The agent increases the effect of the muscle relaxant"
674,"Spironolactone","DB00421","Increased risk of nephrotoxicity"
674,"Succinylcholine","DB00202","The agent increases the effect of the muscle relaxant"
674,"Sulfamethoxazole","DB01015","Increased risk of nephrotoxicity"
674,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Tobramycin. Use caution during concomitant therapy."
674,"Telmisartan","DB00966","Increased risk of nephrotoxicity"
674,"Thalidomide","DB01041","Thalidomide increases the renal toxicity of the aminoglycoside"
674,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Tobramycin. Ticarcillin may inactivate Tobramycin in vitro and the two agents should not be administered simultaneously through the same IV line."
674,"Topiramate","DB00273","Increased risk of nephrotoxicity"
674,"Torasemide","DB00214","Increased ototoxicity"
674,"Trimethoprim","DB00440","Increased risk of nephrotoxicity"
674,"Tubocurarine","DB01199","The agent increases the effect of the muscle relaxant"
674,"Valsartan","DB00177","Increased risk of nephrotoxicity"
674,"Vancomycin","DB00512","Increased risk of nephrotoxicity"
674,"Vecuronium","DB01339","The agent increases the effect of the muscle relaxant"
675,"Aluminium","DB01370","Aluminum may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the aluminum containing agent to minimize the interaction. "
675,"Calcium","DB01373","Formation of non-absorbable complexes"
675,"Calcium Acetate","DB00258","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containining agent to minimize the interaction. "
675,"Calcium Chloride","DB01164","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction. "
675,"Calcium Gluceptate","DB00326","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction.  "
675,"Didanosine","DB00900","Didanosine may decrease the absorption of orally administered Trovafloxacin. The Didanosine formulation contains magnesium and aluminum ions that intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Didanosine dose to minimize the interaction. This interaction is not observed with enteric coated Didanosine. "
675,"Iron","DB01592","Iron may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the iron containing agent to minimize the interaction. "
675,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
675,"Magnesium","DB01378","Formation of non-absorbable complexes"
675,"Magnesium oxide","DB01377","Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction. "
675,"Magnesium Sulfate","DB00653","Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction. "
675,"Morphine","DB00295","Morphine may reduce serum levels of Trovafloxacin decreasing the efficacy of the antibiotic. IV doses of morphine should be administered at least 2 hours after a dose of Trovafloxacin given in a fasting state or 4 hours after if given in a fed state."
675,"Quinapril","DB00881","Quinapril may decrease the absorption of orally administered Trovafloxacin. The Quinapril formulation contains magnesium ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Quinapril dose to minimize the interaction. "
675,"Sevelamer","DB00658","Sevelamer may decrease the absorption of orally administered Trovafloxacin. The Sevelamer formulation contains iron that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sevelamer dose to minimize the interaction. "
675,"Sucralfate","DB00364","Sucralfate may decrease the absorption of orally administered Trovafloxacin. The Sucralfate formulation contains aluminum ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Sucralfate dose to minimize the interaction. "
675,"Zinc","DB01593","Zinc may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the zinc containing agent to minimize the interaction. "
676,"Eptifibatide","DB00063","Pentosan can potentiate adverse effects of antiplatelet agents and thus increase bleeding risk. Combination must be used with caution."
677,"Acenocoumarol","DB01418","The corticosteroid, fludrocortisone, alters the anticoagulant effect, acenocoumarol."
677,"Acetylsalicylic acid","DB00945","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid."
677,"Ambenonium","DB01122","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, ambenonium."
677,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Anisindione","DB01125","The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione."
677,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Bismuth Subsalicylate","DB01294","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate."
677,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Dicoumarol","DB00266","The corticosteroid, fludrocortisone, alters the anticoagulant effect of dicumarol."
677,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Edrophonium","DB01010","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium."
677,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Magnesium salicylate","DB01397","The corticosteroid, fludrocortisone, may decrease the effect of magnesium salicylate. "
677,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Midodrine","DB00211","Increased arterial pressure"
677,"Neostigmine","DB01400","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine."
677,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Pyridostigmine","DB00545","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine."
677,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Salicylate-sodium","DB01398","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salicylate-sodium."
677,"Salsalate","DB01399","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate."
677,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Tacrine","DB00382","Tacrine and Fludrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
677,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, fludrocortisone."
677,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
677,"Trisalicylate-choline","DB01401","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, trisalicylate-choline."
677,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
677,"Warfarin","DB00682","The corticosteroid, fludrocortisone, alters the anticoagulant effect of warfarin."
678,"Belatacept","DB06681","Belatacept increases the Cmax and AUC of mycophenolate mofetil. "
678,"Calcium","DB01373","Formation of non-absorbable complexes"
678,"Iron","DB01592","Oral iron decreases the absorption of mycophenolate-mofetil"
678,"Iron Dextran","DB00893","Oral iron decreases the absorption of mycophenolate-mofetil"
678,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided."
678,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
678,"Tacrolimus","DB00864","Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range."
678,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
678,"Valganciclovir","DB01610","The excretion rates of Valganciclovir and/or Mycophenolate mofetil may decrease. Monitor for increased serum concentrations and toxicity of both agents."
679,"Probenecid","DB01032","Probenecid may increase the serum level of cephaloglycin."
680,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam."
680,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, flurazepam."
680,"Clozapine","DB00363","Increased risk of toxicity"
680,"Ethotoin","DB00754","Ethotoin may increase the metabolism of flurazepam via CYP3A4."
680,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, flurazepam."
680,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam."
680,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of flurazepam via CYP3A4."
680,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, flurazepam."
680,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, flurazepam."
680,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, flurazepam."
680,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, flurazepam."
680,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of flurazepam via CYP3A4."
680,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, flurazepam."
680,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, flurazepam."
680,"Phenytoin","DB00252","Phenytoin may increase the metabolism of flurazepam via CYP3A4."
680,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam."
680,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam."
680,"Telithromycin","DB00976","Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed."
680,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased. "
680,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Flurazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
680,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased."
681,"Amiloride","DB00594","Increased risk of hyperkalemia"
681,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
681,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
681,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
681,"Potassium","DB01345","Increased risk of hyperkalemia"
681,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
681,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
681,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
681,"Triamterene","DB00384","Increased risk of hyperkalemia"
682,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Phentolamine. Monitor for hypotension during concomitant therapy."
682,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phentolamine, may result in additive antihypertensive effects. Combination therapy is not recommended."
682,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
682,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phentolamine, may occur. Monitor for hypotension during concomitant therapy. "
684,"Trastuzumab","DB00072","Trastuzumab may increase the cardiotoxicity of Daunorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
685,"Aliskiren","DB09026","Monitor therapy due to potential decreased serum concentration of furosemide."
685,"Amikacin","DB00479","Increased ototoxicity"
685,"Cisplatin","DB00515","Increased ototoxicity"
685,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as furosemide.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
685,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
685,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
685,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
685,"Ethotoin","DB00754","The hydantoin decreases the effect of furosemide"
685,"Fosphenytoin","DB01320","The hydantoin decreases the effect of furosemide"
685,"Gentamicin","DB00798","Increased ototoxicity"
685,"Ginseng","DB01404","Ginseng decreases the therapeutic effect"
685,"Ibuprofen","DB01050","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide."
685,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
685,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide."
685,"Kanamycin","DB01172","Increased ototoxicity"
685,"Mephenytoin","DB00532","The hydantoin decreases the effect of furosemide"
685,"Netilmicin","DB00955","Increased ototoxicity"
685,"Phenytoin","DB00252","The hydantoin decreases the effect of furosemide"
685,"Streptomycin","DB01082","Increased ototoxicity"
685,"Sulindac","DB00605","The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, furosemide."
685,"Tobramycin","DB00684","Increased ototoxicity"
685,"Trandolapril","DB00519","The loop diuretic, Furosemide, may increase the hypotensive effect of Trandolapril. Furosemide may also increase the nephrotoxicity of Trandolapril. "
685,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
686,"Acebutolol","DB01193","Ischemia with risk of gangrene"
686,"Almotriptan","DB00918","Possible severe and prolonged vasoconstriction"
686,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of ergotamine."
686,"Amyl Nitrite","DB01612","Possible antagonism of action"
686,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of ergotamine."
686,"Atenolol","DB00335","Ischemia with risk of gangrene"
686,"Betaxolol","DB00195","Ischemia with risk of gangrene"
686,"Bevantolol","DB01295","Ischemia with risk of gangrene"
686,"Bisoprolol","DB00612","Ischemia with risk of gangrene"
686,"Carteolol","DB00521","Ischemia with risk of gangrene"
686,"Carvedilol","DB01136","Ischemia with risk of gangrene"
686,"Clarithromycin","DB01211","Risk of ergotism and severe ischemia with this association"
686,"Delavirdine","DB00705","The antiretroviral agent may increase the ergot derivative toxicity"
686,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
686,"Efavirenz","DB00625","The antiretroviral agent may increase the ergot derivative toxicity"
686,"Eletriptan","DB00216","Possible severe and prolonged vasoconstriction"
686,"Erythrityl Tetranitrate","DB01613","Possible antagonism of action"
686,"Erythromycin","DB00199","Possible ergotism and severe ischemia with this combination"
686,"Esmolol","DB00187","Ischemia with risk of gangrene"
686,"Fluconazole","DB00196","Possible ergotism and severe ischemia with this combination"
686,"Fluoxetine","DB00472","Possible ergotism and severe ischemia with this combination"
686,"Fluvoxamine","DB00176","Possible ergotism and severe ischemia with this combination"
686,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of ergot derivative"
686,"Frovatriptan","DB00998","Possible severe and prolonged vasoconstriction"
686,"Indinavir","DB00224","Indinavir may increase the serum concentration of ergotamine. Concomitant therapy is contraindicated."
686,"Isosorbide Dinitrate","DB00883","Possible antagonism of action"
686,"Isosorbide Mononitrate","DB01020","Possible antagonism of action"
686,"Itraconazole","DB01167","Possible ergotism and severe ischemia with this combination"
686,"Josamycin","DB01321","Possible ergotism and severe ischemia with this combination"
686,"Ketoconazole","DB01026","Possible ergotism and severe ischemia with this combination."
686,"Labetalol","DB00598","Ischemia with risk of gangrene"
686,"Lorcaserin","DB04871","Avoid all combinations with any ergot derivative such as ergotamine. The combination can increase the risk of developing serotonin syndrome and/or valvular heart disease."
686,"Metoprolol","DB00264","Ischemia with risk of gangrene"
686,"Nadolol","DB01203","Ischemia with risk of gangrene"
686,"Naratriptan","DB00952","Possible severe and prolonged vasoconstriction."
686,"Nefazodone","DB01149","Possible ergotism and severe ischemia with this combination"
686,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of ergot derivative"
686,"Nitroglycerin","DB00727","Possible antagonism of action"
686,"Oxprenolol","DB01580","Ischemia with risk of gangrene"
686,"Penbutolol","DB01359","Ischemia with risk of gangrene"
686,"Pentaerythritol Tetranitrate","DB06154","Possible antagonism of action"
686,"Pindolol","DB00960","Ischemia with risk of gangrene"
686,"Posaconazole","DB01263","Contraindicated co-administration"
686,"Practolol","DB01297","Ischemia with risk of gangrene"
686,"Propranolol","DB00571","Ischemia with risk of gangrene"
686,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine."
686,"Rizatriptan","DB00953","Possible severe and prolonged vasoconstriction"
686,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine."
686,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
686,"Sotalol","DB00489","Ischemia with risk of gangrene"
686,"Sumatriptan","DB00669","Possible severe and prolonged vasoconstriction"
686,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
686,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated."
686,"Timolol","DB00373","Ischemia with risk of gangrene"
686,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated."
686,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
686,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
686,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
686,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
686,"Troleandomycin","DB01361","Possible ergotism and severe ischemia with this combination"
686,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
686,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated."
686,"Zileuton","DB00744","Possible ergotism and severe ischemia with this combination"
686,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
687,"Amiodarone","DB01118","Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. "
687,"Amlodipine","DB00381","Amlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Benazepril","DB00542","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Captopril","DB01197","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Cilazapril","DB01340","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Cimetidine","DB00501","Cimetidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Ciprofloxacin","DB00537","Ciprofloxacin inhibits the metabolism and clearance of Tizanidine. Concomitant therapy is contraindicated."
687,"Diclofenac","DB00586","Diclofenac may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Donepezil","DB00843","Possible antagonism of action"
687,"Enalapril","DB00584","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Ethanol","DB00898","Ethanol increases the adverse effects of Tizanidine. The CNS depressant effects of these agents are additive."
687,"Ethinyl Estradiol","DB00977","Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed."
687,"Fluoxetine","DB00472","Fluoxetine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Fluvoxamine","DB00176","Fluvoxamine inhibits the metabolism and clearance of tizanidine. Concomitant therapy is contraindicated."
687,"Fosinopril","DB00492","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Galantamine","DB00674","Possible antagonism of action"
687,"Gemfibrozil","DB01241","Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Ketoconazole","DB01026","Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Lidocaine","DB00281","Lidocaine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Lisinopril","DB00722","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Mestranol","DB01357","Oral contraceptives decrease the clearance of Tizanidine."
687,"Methoxsalen","DB00553","Methoxsalen may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Mexiletine","DB00379","Mexilitene may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Miconazole","DB01110","Miconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Moexipril","DB00691","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Moxifloxacin","DB00218","Moxifloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Nifedipine","DB01115","Nifedipine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Norethindrone","DB00717","The contraceptive increases the effect of tizanidine"
687,"Norfloxacin","DB01059","Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Ofloxacin","DB01165","Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Perindopril","DB00790","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Primaquine","DB01087","Primaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Propafenone","DB01182","Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Propofol","DB00818","Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Quinapril","DB00881","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
687,"Ramipril","DB00178","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Rivastigmine","DB00989","Possible antagonism of action"
687,"Spirapril","DB01348","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed."
687,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Trandolapril","DB00519","Tizanidine increases the risk of hypotension with the ACE inhibitor"
687,"Tranylcypromine","DB00752","Tranylcypromine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
687,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
687,"Trimipramine","DB00726","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Tizandine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Tizandine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
687,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Tizanidine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
690,"Amiloride","DB00594","Increased risk of hyperkalemia. Monitor serum potassium levels during concomitant threapy."
690,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4."
690,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect and toxicity of eplerenone."
690,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. The combination of eplerenone with any strong CYP3A4 inhibitor is contraindicated.\
"
690,"Erythromycin","DB00199","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
690,"Fluconazole","DB00196","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
690,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of eplerenone."
690,"Ketoconazole","DB01026","Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone."
690,"Lithium","DB01356","Eplerenone increases serum levels of lithium"
690,"Nefazodone","DB01149","Nefazodone increases the effect and toxicity of eplerenone"
690,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect and toxicity of eplerenone."
690,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
690,"Potassium","DB01345","This association presents an increased risk of hyperkalemia"
690,"Ritonavir","DB00503","This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone."
690,"Saquinavir","DB01232","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
690,"Spironolactone","DB00421","This association presents an increased risk of hyperkalemia"
690,"Telithromycin","DB00976","Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed."
690,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels. "
690,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
690,"Triamterene","DB00384","This association presents an increased risk of hyperkalemia"
690,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone."
690,"Verapamil","DB00661","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
690,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated. "
691,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Amprenavir. The antiviral response should be closely monitored."
691,"Acenocoumarol","DB01418","Amprenavir may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
691,"Alprazolam","DB00404","Amprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam."
691,"Aluminium","DB01370","The antiacid decreases the absorption of amprenavir"
691,"Amiodarone","DB01118","The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone."
691,"Anisindione","DB01125","Amprenavir may increase the anticoagulant effect of anisindione by increasing its serum concentration."
691,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
691,"Atorvastatin","DB01076","Amprenavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
691,"Bepridil","DB01244","Amprenavir may increase the effect and toxicity of bepridil."
691,"Bismuth Subsalicylate","DB01294","The antiacid decreases the absorption of amprenavir"
691,"Calcium","DB01373","The antiacid decreases the absorption of amprenavir"
691,"Cisapride","DB00604","Amprenavir may increase the effect and toxicity of cisapride."
691,"Clorazepate","DB00628","Amprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."
691,"Cyclosporine","DB00091","The protease inhibitor, amprenavir, may increase the effect of cyclosporine."
691,"Delavirdine","DB00705","Decreased levels of delavirdine with increased levels of amprenavir"
691,"Diazepam","DB00829","Amprenavir may increase the effect and toxicity of the benzodiazepine, diazepam."
691,"Dicoumarol","DB00266","Amprenavir may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
691,"Dihydroergotamine","DB00320","Amprenavir may increase the serum concentration of dihydroergotamine. Concomitant therapy is contraindicated."
691,"Dihydroxyaluminium","DB01375","The antiacid decreases the absorption of amprenavir"
691,"Disulfiram","DB00822","Increased irsk of side effects (oral solution)"
691,"Ergotamine","DB00696","Amprenavir may increase the effect and toxicity of ergotamine."
691,"Ethinyl Estradiol","DB00977","Ritonavir could decrease the contraceptive efficacy"
691,"Fentanyl","DB00813","The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl."
691,"Flurazepam","DB00690","Amprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam."
691,"Fusidic Acid","DB02703","The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid."
691,"Lovastatin","DB00227","Amprenavir may increase the serum concentration of the lovastatin. Concomitant therapy is contraindicated."
691,"Magnesium","DB01378","The antiacid decreases the absorption of amprenavir"
691,"Magnesium oxide","DB01377","The antiacid decreases the absorption of amprenavir"
691,"Mestranol","DB01357","Ritonavir could decrease the contraceptive efficacy"
691,"Methadone","DB00333","The protease inhibitor, amprenavir, may decrease the effect of methadone."
691,"Metronidazole","DB00916","Increased risk of side effects (oral solution)"
691,"Midazolam","DB00683","Amprenavir may increase the effect and toxicity of the benzodiazepine, midazolam."
691,"Pimozide","DB01100","Amprenavir may increase the effect and toxicity of pimozide."
691,"Ranolazine","DB00243","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentratin of ranolazine by inhibiting its metabolism. Concomitant therapy is contraindicated."
691,"Rifabutin","DB00615","Amprenavir may increase the effect and toxicity of rifabutin."
691,"Rifampicin","DB01045","In presence of rifampin anticipate decrease of amprenavir efficiency"
691,"Sildenafil","DB00203","The protease inhibitor, amprenavir, may increase the effect and toxicity of sildenafil."
691,"Simvastatin","DB00641","Amprenavir may increase the effect and toxicity of simvastatin. Concomitant therapy is contraindicated."
691,"St. John's Wort","DB01323","St. John's Wort decreases the effect of indinavir"
691,"Tacrolimus","DB00864","The protease inhibitor, Amprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Amprenavir therapy is initiated, discontinued or altered."
691,"Tadalafil","DB00820","Amprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
691,"Tamoxifen","DB00675","Amprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
691,"Tamsulosin","DB00706","Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amprenavir is initiated, discontinued, or dose changed."
691,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Amprenavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
691,"Temsirolimus","DB06287","Amprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
691,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Amprenavir is initiated, discontinued or dose changed."
691,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
691,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Amprenavir is initiated, discontinued or dose changed."
691,"Tolterodine","DB01036","Amprenavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity. "
691,"Tramadol","DB00193","Amprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
691,"Trazodone","DB00656","The protease inhibitor, Amprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amprenavir is initiated, discontinued or dose changed. "
691,"Triazolam","DB00897","Amprenavir may increase the effect and toxicity of the benzodiazepine, triazolam."
691,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Amprenavir is initiated, discontinued or dose changed. "
691,"Vardenafil","DB00862","Amprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
691,"Venlafaxine","DB00285","Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Amprenavir is initiated, discontinued, or dose changed."
691,"Verapamil","DB00661","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Amprenavir is initiated, discontinued or dose changed. "
691,"Vinblastine","DB00570","Amprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Amprenavir is initiated, discontinued or dose changed. "
691,"Vincristine","DB00541","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Amprenavir is initiated, discontinued or dose changed.\
"
691,"Vinorelbine","DB00361","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Amprenavir is initiated, discontinued or dose changed."
691,"Vitamin E","DB00163","Increased serum levels of vitamin E"
691,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amprenavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by amprenavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
691,"Warfarin","DB00682","Amprenavir may increase the anticoagulant effect of warfarin by increasing its serum concentration."
691,"Zolpidem","DB00425","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if amprenavir is initiated, discontinued or dose changed. "
691,"Zonisamide","DB00909","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed."
691,"Zopiclone","DB01198","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if amprenavir is initiated, discontinued or dose changed."
693,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
693,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
693,"Brinzolamide","DB01194","As both brinzolamide and methazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
693,"Magnesium salicylate","DB01397","The salicylate, magnesium salicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
693,"Memantine","DB01043","Possible increased levels of memantine"
693,"Salicylate-sodium","DB01398","The salicylate, salicylate-sodium, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
693,"Salsalate","DB01399","The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
693,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
693,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
695,"Alprazolam","DB00404","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, alprazolam."
695,"Aluminium","DB01370","The antiacid decreases the effect of delavirdine"
695,"Amprenavir","DB00701","Decreased levels of delavirdine with increased levels of amprenavir"
695,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
695,"Atorvastatin","DB01076","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if delavirdine is initiated, discontinued or dose changed."
695,"Bromazepam","DB01558","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if delavirdine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
695,"Calcium","DB01373","The antiacid decreases the effect of delavirdine"
695,"Carbamazepine","DB00564","The anticonvulsant, carbamazepine, decreases the effect of delavirdine."
695,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
695,"Cisapride","DB00604","Delavirdine, a strong CYP3A4 inhibitor, may increase the metabolism of cisapride. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cisapride if delavirdine is initiated, discontinued or dose changed."
695,"Dantrolene","DB01219","Delavirdine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if delavirdine is initiated, discontinued or dose changed. "
695,"Dihydroergotamine","DB00320","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed."
695,"Ergonovine","DB01253","The antiretroviral agent may increase the ergot derivative toxicity"
695,"Ergotamine","DB00696","The antiretroviral agent may increase the ergot derivative toxicity"
695,"Etravirine","DB06414","Etravirine, when used concomitantly with Delaviridine, may experience an increase in serum concentration.  \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination. "
695,"Fosamprenavir","DB01319","Decreased levels of delavirdine with increased levels of amprenavir"
695,"Fosphenytoin","DB01320","The anticonvulsant, fosphenytoin, decreases the effect of delavirdine."
695,"Indinavir","DB00224","Delavirdine may increase the effect of indinavir."
695,"Lovastatin","DB00227","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if delavirdine is initiated, discontinued or dose changed."
695,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
695,"Magnesium","DB01378","Magnesium antacids may decrease the absorption of delavirdine."
695,"Magnesium oxide","DB01377","The antiacid decreases the effect of delavirdine"
695,"Methylergometrine","DB00353","The antiretroviral agent may increase the ergot derivative toxicity"
695,"Methylphenobarbital","DB00849","The anticonvulsant, methylphenobarbital, decreases the effect of delavirdine."
695,"Methysergide","DB00247","The antiretroviral agent may increase the ergot derivative toxicity"
695,"Midazolam","DB00683","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, midazolam."
695,"Phenobarbital","DB01174","The anticonvulsant, phenobarbital, decreases the effect of delavirdine."
695,"Phenytoin","DB00252","The anticonvulsant, phenytoin, decreases the effect of delavirdine."
695,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
695,"Rifabutin","DB00615","Rifabutin decreases the effect of delavirdine"
695,"Rifampicin","DB01045","Rifampin decreases the effect of delavirdine"
695,"Rilpivirine","DB08864","Concentration of rilpivirine increases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's. "
695,"Ritonavir","DB00503","Increases the effect of ritonavir"
695,"Saquinavir","DB01232","Increases the effect of saquinavir and hepatic toxicity"
695,"Simvastatin","DB00641","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if delavirdine is initiated, discontinued or dose changed."
695,"St. John's Wort","DB01323","St. John's Wort decreases the antiretroviral effect"
695,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Delavirdine is initiated, discontinued or dose changed."
695,"Tadalafil","DB00820","Delavirdine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
695,"Tamoxifen","DB00675","Delavirdine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
695,"Tamsulosin","DB00706","Delavirdine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Delavirdine is initiated, discontinued, or dose changed."
695,"Telithromycin","DB00976","Delavirdine may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
695,"Temsirolimus","DB06287","Delavirdine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
695,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Delavirdine is initiated, discontinued or dose changed."
695,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
695,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Delavirdine is initiated, discontinued or dose changed."
695,"Tipranavir","DB00932","Concomitant use may result in increased Tipranavir and decreased Delavirdine concentrations. Monitor for altered therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed. "
695,"Tolbutamide","DB01124","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed. "
695,"Tolterodine","DB01036","Delavirdine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
695,"Torasemide","DB00214","Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Delavirdine is initiated, discontinued or dose changed. "
695,"Tramadol","DB00193","Delavirdine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Delavirdine may decrease the effect of Tramadol by decreasing active metabolite production. "
695,"Trazodone","DB00656","The CYP3A4 inhibitor, Delavirdine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Delavirdine is initiated, discontinued or dose changed. "
695,"Triazolam","DB00897","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, triazolam."
695,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Delavirdine is initiated, discontinued or dose changed."
695,"Trimipramine","DB00726","The strong CYP3A4/CYP2D6 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Delavirdine is initiated, discontinued or dose changed. "
695,"Vardenafil","DB00862","Delavirdine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
695,"Venlafaxine","DB00285","Delaviridine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Delavirdine is initiated, discontinued, or dose changed."
695,"Verapamil","DB00661","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Delavirdine is initiated, discontinued or dose changed. "
695,"Vinblastine","DB00570","Delavirdine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Delavirdine is initiated, discontinued or dose changed."
695,"Vincristine","DB00541","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Delavirdine is initiated, discontinued or dose changed."
695,"Vinorelbine","DB00361","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Delavirdine is initiated, discontinued or dose changed."
695,"Voriconazole","DB00582","Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if delavirdine is initiated, discontinued or dose changed.	"
695,"Warfarin","DB00682","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if delavirdine is initiated, discontinued or dose changed. "
695,"Zafirlukast","DB00549","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if delavirdine is initiated, discontinued or dose changed."
695,"Zolpidem","DB00425","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if delavirdine is initiated, discontinued or dose changed. "
695,"Zonisamide","DB00909","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if delavirdine is initiated, discontinued or dose changed."
695,"Zopiclone","DB01198","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if delavirdine is initiated, discontinued or dose changed."
695,"Zuclopenthixol","DB01624","Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed. "
696,"Alfuzosin","DB00346","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Alfuzosin, may result in additive antihypertensive effects. Combination therapy is not recommended. "
696,"Amiodarone","DB01118","Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed."
696,"Amprenavir","DB00701","Amprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amprenavir is initiated, discontinued, or dose changed."
696,"Aprepitant","DB00673","Aprepitant, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Aprepitant is initiated, discontinued, or dose changed."
696,"Atazanavir","DB01072","Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed."
696,"Caffeine","DB00201","Caffeine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Caffeine is initiated, discontinued, or dose changed."
696,"Chloroquine","DB00608","Chloroquine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chloroquine is initiated, discontinued, or dose changed."
696,"Chlorpromazine","DB00477","Chlorpromazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Chlorpromazine is initiated, discontinued, or dose changed."
696,"Cimetidine","DB00501","Cimetidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cimetidine is initiated, discontinued, or dose changed."
696,"Cinacalcet","DB01012","Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cinacalcet is initiated, discontinued, or dose changed."
696,"Clarithromycin","DB01211","Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clarithromycin is initiated, discontinued, or dose changed."
696,"Clomipramine","DB01242","Clomipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clomipramine is initiated, discontinued, or dose changed."
696,"Clotrimazole","DB00257","Clotrimazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clotrimazole is initiated, discontinued, or dose changed."
696,"Clozapine","DB00363","Clozapine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clozapine is initiated, discontinued, or dose changed."
696,"Cocaine","DB00907","Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cocaine is initiated, discontinued, or dose changed."
696,"Conivaptan","DB00872","Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Conivaptan is initiated, discontinued, or dose changed."
696,"Cyclosporine","DB00091","Cyclosporine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cyclosporine is initiated, discontinued, or dose changed."
696,"Dapiprazole","DB00298","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Dapiprazole, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Darifenacin","DB00496","Darifenacin, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darifenacin is initiated, discontinued, or dose changed."
696,"Darunavir","DB01264","Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darunavir is initiated, discontinued, or dose changed."
696,"Delavirdine","DB00705","Delavirdine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Delavirdine is initiated, discontinued, or dose changed."
696,"Desipramine","DB01151","Desipramine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Desipramine is initiated, discontinued, or dose changed."
696,"Diltiazem","DB00343","Diltiazem, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diltiazem is initiated, discontinued, or dose changed."
696,"Diphenhydramine","DB01075","Diphenhydramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diphenhydramine is initiated, discontinued, or dose changed."
696,"Doxazosin","DB00590","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Doxycycline","DB00254","Doxycycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Doxycycline is initiated, discontinued, or dose changed."
696,"Duloxetine","DB00476","Duloxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Duloxetine is initiated, discontinued, or dose changed."
696,"Efavirenz","DB00625","Efavirenz, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Efavirenz is initiated, discontinued, or dose changed."
696,"Erythromycin","DB00199","Erythromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Erythromycin is initiated, discontinued, or dose changed."
696,"Etravirine","DB06414","Etravirine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Etravirine is initiated, discontinued, or dose changed."
696,"Fluconazole","DB00196","Fluconzole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluconazole is initiated, discontinued, or dose changed."
696,"Fluoxetine","DB00472","Fluoxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fluoxetine is initiated, discontinued, or dose changed."
696,"Fosamprenavir","DB01319","Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fosamprenavir is initiated, discontinued, or dose changed."
696,"Haloperidol","DB00502","Haloperidol, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Haloperidol is initiated, discontinued, or dose changed."
696,"Imatinib","DB00619","Imatinib, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imatinib is initiated, discontinued, or dose changed."
696,"Imipramine","DB00458","Imipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Imipramine is initiated, discontinued, or dose changed."
696,"Indinavir","DB00224","Indinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Indinavir is initiated, discontinued, or dose changed."
696,"Isoniazid","DB00951","Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed."
696,"Itraconazole","DB01167","Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed."
696,"Ketoconazole","DB01026","Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed."
696,"Lapatinib","DB01259","Lapatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lapatinib is initiated, discontinued, or dose changed."
696,"Lidocaine","DB00281","Lidocaine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lidocaine is initiated, discontinued, or dose changed."
696,"Lopinavir","DB01601","Lopinavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lopinavir is initiated, discontinued, or dose changed."
696,"Methadone","DB00333","Methadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed."
696,"Methimazole","DB00763","Methimazole, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methimazole is initiated, discontinued, or dose changed."
696,"Metronidazole","DB00916","Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed."
696,"Miconazole","DB01110","Miconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Miconazole is initiated, discontinued, or dose changed."
696,"Nefazodone","DB01149","Nefazodone, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nefazodone is initiated, discontinued, or dose changed."
696,"Nelfinavir","DB00220","Nelfinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nelfinavir is initiated, discontinued, or dose changed."
696,"Nicardipine","DB00622","Nicardipine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nicardipine is initiated, discontinued, or dose changed."
696,"Nilotinib","DB04868","Nilotinib, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nilotinib is initiated, discontinued, or dose changed."
696,"Norfloxacin","DB01059","Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed."
696,"Paroxetine","DB00715","Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed."
696,"Pergolide","DB01186","Pergolide, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pergolide is initiated, discontinued, or dose changed."
696,"Phenoxybenzamine","DB00925","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phenoxybenzamine, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Phentolamine","DB00692","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phentolamine, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Pioglitazone","DB01132","Pioglitazone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pioglitazone is initiated, discontinued, or dose changed."
696,"Posaconazole","DB01263","Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Posaconazole is initiated, discontinued, or dose changed."
696,"Prazosin","DB00457","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Prazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Pyrimethamine","DB00205","Pyrimethamine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pyrimethamine is initiated, discontinued, or dose changed."
696,"Quinidine","DB00908","Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed."
696,"Quinine","DB00468","Quinine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinine is initiated, discontinued, or dose changed."
696,"Ranolazine","DB00243","Ranolazine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ranolazine is initiated, discontinued, or dose changed."
696,"Ritonavir","DB00503","Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed."
696,"Saquinavir","DB01232","Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed."
696,"Sertraline","DB01104","Sertraline, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sertraline is initiated, discontinued, or dose changed."
696,"Silodosin","DB06207","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended."
696,"Sitaxentan","DB06268","Sitaxsentan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sitaxsentan is initiated, discontinued, or dose changed."
696,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Tamsulosin. Monitor for hypotension during concomitant therapy."
696,"Telithromycin","DB00976","Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed."
696,"Terazosin","DB01162","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
696,"Terbinafine","DB00857","Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Terbinafine is initiated, discontinued, or dose changed."
696,"Tetracycline","DB00759","Tetracycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tetracycline is initiated, discontinued, or dose changed."
696,"Thioridazine","DB00679","Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed."
696,"Ticlopidine","DB00208","Ticlopidine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ticlopidine is initiated, discontinued, or dose changed."
696,"Tranylcypromine","DB00752","Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tranylcypromine is initiated, discontinued, or dose changed."
696,"Trazodone","DB00656","Trazodone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Trazodone is initiated, discontinued, or dose changed."
696,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Tamsulosin, may occur. Monitor for hypotension during concomitant therapy. "
696,"Verapamil","DB00661","Verapamil, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Verapamil is initiated, discontinued, or dose changed."
696,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed."
698,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
698,"Cimetidine","DB00501","Increases the effect of the narcotic"
698,"Telithromycin","DB00976","Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed."
698,"Tranylcypromine","DB00752","Possible increased risk of serotonin syndrome. "
698,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Sufentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
698,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed."
699,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
699,"Valganciclovir","DB01610","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
699,"Zalcitabine","DB00943","Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended."
700,"Aluminium","DB01370","Formation of non absorbable complexes"
700,"Calcium","DB01373","Formation of non-absorbable complexes"
700,"Calcium Acetate","DB00258","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as ibandronate. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate. "
700,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate."
700,"Iron","DB01592","Formation of non absorbable complexes"
700,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
700,"Magnesium","DB01378","Formation of non-absorbable complexes"
700,"Magnesium oxide","DB01377","Formation of non absorbable complexes"
700,"Sucralfate","DB00364","Formation of non absorbable complexes"
702,"Acenocoumarol","DB01418","The NSAID, flurbiprofen, may increase the anticoagulant effect of acenocoumarol."
702,"Alendronate","DB00630","Increased risk of gastric toxicity"
702,"Anisindione","DB01125","The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione."
702,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
702,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
702,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
702,"Dicoumarol","DB00266","The NSAID, flurbiprofen, may increase the anticoagulant effect of dicumarol."
702,"Difluprednate","DB06781","NSAIDs may slow healing. "
702,"Eltrombopag","DB06210","Increases levels of Flurbiprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
702,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
702,"Methotrexate","DB00563","The NSAID, flurbiprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
702,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
702,"Tamoxifen","DB00675","Flurbiprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Flurbiprofen is initiated, discontinued or dose changed."
702,"Telmisartan","DB00966","Concomitant use of Telmisartan and Flurbiprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
702,"Timolol","DB00373","The NSAID, Flurbiprofen, may antagonize the antihypertensive effect of Timolol."
702,"Tolbutamide","DB01124","Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed. "
702,"Torasemide","DB00214","Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Flurbiprofen is initiated, discontinued or dose changed. "
702,"Trandolapril","DB00519","The NSAID, Flurbiprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Flurbiprofen is initiated, discontinued or dose changed.  "
702,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Flurbiprofen. Monitor for increased bleeding during concomitant thearpy. "
702,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Flurbiprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Flurbiprofen is initiated, discontinued or dose changed."
702,"Voriconazole","DB00582","Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed.	"
702,"Warfarin","DB00682","Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of flurbiprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if flurbiprofen is initiated, discontinued or dose changed."
703,"Demeclocycline","DB00618","Possible antagonism of action"
703,"Doxycycline","DB00254","Possible antagonism of action"
703,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
703,"Minocycline","DB01017","Possible antagonism of action"
703,"Tetracycline","DB00759","Possible antagonism of action"
704,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
704,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, apomorphine."
704,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
704,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, apomorphine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
704,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
704,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Thiothixene may also antagonize the effects of the anti-Parkinsonian agent, Apomorphine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses changed. "
704,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
704,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
704,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
704,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
704,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Antagonism may also occur between zuclopenthixol, a dopamine D2 receptor antagonist, and apomorphine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
705,"Acenocoumarol","DB01418","The SSRI, paroxetine, increases the effect of the anticoagulant, acenocoumarol."
705,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
705,"Amphetamine","DB00182","Risk of serotoninergic syndrome"
705,"Anisindione","DB01125","The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione."
705,"Asenapine","DB06216","Paroxetine is a substrate of CYP2D6 and concomitant therapy with asenapine (CYP2D6 inhibitor) increases concentrations of paroxetine 2-fold. May require dosing adjustments. "
705,"Atomoxetine","DB00289","The CYP2D6 inhibitor, paroxetine, may increase the effect and toxicity of atomoxetine."
705,"Benzphetamine","DB00865","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
705,"Carvedilol","DB01136","The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, carvedilol."
705,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
705,"Dexfenfluramine","DB01191","Risk of serotoninergic syndrome"
705,"Dextroamphetamine","DB01576","Risk of serotoninergic syndrome"
705,"Dextromethorphan","DB00514","Combination associated with possible serotoninergic syndrome"
705,"Dicoumarol","DB00266","The SSRI, paroxetine, increases the effect of anticoagulant, dicumarol.\
"
705,"Diethylpropion","DB00937","Risk of serotoninergic syndrome"
705,"Dihydrocodeine","DB01551","Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy."
705,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
705,"Fenfluramine","DB00574","Risk of serotoninergic syndrome"
705,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
705,"Galantamine","DB00674","Paroxetine increases the effect and toxicity of galantamine"
705,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
705,"Iloperidone","DB04946","Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% "
705,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
705,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
705,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
705,"Mazindol","DB00579","Risk of serotoninergic syndrome"
705,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
705,"Methamphetamine","DB01577","Risk of serotoninergic syndrome"
705,"Metoprolol","DB00264","The SSRI increases the effect of the beta-blocker"
705,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
705,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
705,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
705,"Phendimetrazine","DB01579","Risk of serotoninergic syndrome"
705,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
705,"Phentermine","DB00191","Risk of serotoninergic syndrome"
705,"Phenylpropanolamine","DB00397","Risk of serotoninergic syndrome"
705,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias."
705,"Propafenone","DB01182","Paroxetine may increase the effect and toxicity of propafenone."
705,"Propranolol","DB00571","The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, propranolol."
705,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
705,"Risperidone","DB00734","The SSRI, paroxetine, increases the effect and toxicity of risperidone."
705,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
705,"Selegiline","DB01037","Possible severe adverse reaction with this combination"
705,"Sibutramine","DB01105","Risk of serotoninergic syndrome"
705,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, paroxetine."
705,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
705,"Tamoxifen","DB00675","Paroxetine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
705,"Tamsulosin","DB00706","Paroxetine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Paroxetine is initiated, discontinued, or dose changed."
705,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Paroxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Paroxetine if Terbinafine is initiated, discontinued or dose changed."
705,"Tetrabenazine","DB04844","Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced "
705,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
705,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
705,"Tipranavir","DB00932","Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment."
705,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
705,"Tolterodine","DB01036","Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
705,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizures. Paroxetine may decrease the effect of Tramadol by decreasing active metabolite production."
705,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
705,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
705,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Paroxetine. Monitor for increased bleeding during concomitant thearpy. "
705,"Trimipramine","DB00726","The SSRI, Paroxetine, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Paroxetine is initiated, discontinued or dose changed. "
705,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Paroxetine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
705,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
705,"Warfarin","DB00682","The SSRI, paroxetine, increases the effect of the anticoagulant, warfarin."
705,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
705,"Zuclopenthixol","DB01624","Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed. "
707,"Acitretin","DB00459","Acitretine may cause a loss of contraceptive effect"
707,"Amobarbital","DB01351","This product may cause a slight decrease of contraceptive effect"
707,"Aprobarbital","DB01352","This product may cause a slight decrease of contraceptive effect"
707,"Artemether","DB06697","Artemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
707,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norethindrone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
707,"Bosentan","DB00559","Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
707,"Butabarbital","DB00237","This product may cause a slight decrease of contraceptive effect"
707,"Butalbital","DB00241","This product may cause a slight decrease of contraceptive effect"
707,"Butethal","DB01353","This product may cause a slight decrease of contraceptive effect"
707,"Carbamazepine","DB00564","This product may cause a slight decrease of contraceptive effect"
707,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
707,"Ethotoin","DB00754","This product may cause a slight decrease of contraceptive effect"
707,"Fosphenytoin","DB01320","This product may cause a slight decrease of contraceptive effect"
707,"Griseofulvin","DB00400","This product may cause a slight decrease of contraceptive effect"
707,"Heptabarbital","DB01354","This product may cause a slight decrease of contraceptive effect"
707,"Hexobarbital","DB01355","This product may cause a slight decrease of contraceptive effect"
707,"Lamotrigine","DB00555","The oral contraceptive decreases the effect of lamotrigine"
707,"Mephenytoin","DB00532","This product may cause a slight decrease of contraceptive effect"
707,"Methohexital","DB00474","This product may cause a slight decrease of contraceptive effect"
707,"Methylphenobarbital","DB00849","This product may cause a slight decrease of contraceptive effect"
707,"Pentobarbital","DB00312","This product may cause a slight decrease of contraceptive effect"
707,"Phenobarbital","DB01174","This product may cause a slight decrease of contraceptive effect"
707,"Phenytoin","DB00252","This product may cause a slight decrease of contraceptive effect"
707,"Pioglitazone","DB01132","Possible loss of contraceptive effect"
707,"Primidone","DB00794","This product may cause a slight decrease of contraceptive effect"
707,"Rifabutin","DB00615","Rifabutin may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."
707,"Rifampicin","DB01045","This product may cause a slight decrease of contraceptive effect"
707,"Rifapentine","DB01201","This product may cause a slight decrease of contraceptive effect"
707,"Rufinamide","DB06201","Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification "
707,"Secobarbital","DB00418","This product may cause a slight decrease of contraceptive effect"
707,"St. John's Wort","DB01323","St. John's Wort could reduce the contraceptive effect"
707,"Talbutal","DB00306","This product may cause a slight decrease of contraceptive effect"
707,"Thiopental","DB00599","Thiopental may decrease the effect of Norethindrone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
707,"Tizanidine","DB00697","The contraceptive increases the effect of tizanidine"
707,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy. "
707,"Troglitazone","DB00197","Possible loss of contraceptive effect"
707,"Warfarin","DB00682","Norethindrone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norethindrone is initiated, discontinued or dose changed."
708,"Valganciclovir","DB01610","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
709,"Donepezil","DB00843","Possible antagonism of action"
709,"Galantamine","DB00674","Possible antagonism of action"
709,"Rivastigmine","DB00989","Possible antagonism of action"
710,"Aluminium","DB01370","Formation of non-absorbable complexes"
710,"Calcium","DB01373","Formation of non-absorbable complexes"
710,"Calcium Acetate","DB00258","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as clodronate. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
710,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
710,"Dihydroxyaluminium","DB01375","Formation of non-absorbable complexes"
710,"Estramustine","DB01196","Clodronate may increase the levels of estramustine."
710,"Iron","DB01592","Formation of non-absorbable complexes"
710,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
710,"Magnesium","DB01378","Formation of non-absorbable complexes"
710,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
710,"Sucralfate","DB00364","Formation of non-absorbable complexes"
712,"Amiloride","DB00594","Increased risk of hyperkalemia"
712,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
712,"Drospirenone","DB01395","Increased risk of hyperkalemia"
712,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
712,"Potassium","DB01345","Increased risk of hyperkalemia"
712,"Spironolactone","DB00421","Increased risk of hyperkalemia"
712,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
712,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
712,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
712,"Triamterene","DB00384","Increased risk of hyperkalemia"
713,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of methoxamine."
713,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of methoxamine."
713,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine."
713,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine."
713,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine."
713,"Guanethidine","DB01170","Methoxamine may decrease the effect of guanethidine."
713,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of methoxamine."
713,"Isocarboxazid","DB01247","Increased arterial pressure"
713,"Linezolid","DB00601","Possible increase of arterial pressure"
713,"Methyldopa","DB00968","Increased arterial pressure"
713,"Midodrine","DB00211","Increased arterial pressure"
713,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of methoxamine."
713,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of methoxamine."
713,"Phenelzine","DB00780","Increased arterial pressure"
713,"Rasagiline","DB01367","Increased arterial pressure"
713,"Reserpine","DB00206","Increased arterial pressure"
713,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided. "
713,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
715,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
715,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Homatropine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
715,"Trimethobenzamide","DB00662","Trimethobenzamide and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
715,"Triprolidine","DB00427","Triprolidine and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
715,"Trospium","DB00209","Trospium and Homatropine Methylbromide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
716,"Abarelix","DB00106","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Almotriptan","DB00918","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Amiodarone","DB01118","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Amitriptyline","DB00321","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Amobarbital","DB01351","The barbiturate, Amobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Amobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Amoxapine","DB00543","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Amprenavir","DB00701","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Amprenavir is initiated, discontinued or dose changed. "
716,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
716,"Atazanavir","DB01072","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed."
716,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Buspirone","DB00490","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Butabarbital","DB00237","The barbiturate, Butabarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butabarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Butalbital","DB00241","The barbiturate, Butalbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Butalbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Cabergoline","DB00248","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Chlorpromazine","DB00477","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Chlorpromazine, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Caution should be used during concomitant therapy. "
716,"Cimetidine","DB00501","Cimetidine may increase the effect of tricyclic antidepressant, trimipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if cimetidine is initiated, discontinued or dose changed."
716,"Cinacalcet","DB01012","The strong CYP2D6 inhibitor, Cinacalcet, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Cinacalcet is initiated, discontinued or dose changed. "
716,"Cisapride","DB00604","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Citalopram","DB00215","The SSRI, Citalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Citalopram is initiated, discontinued or dose changed. "
716,"Clarithromycin","DB01211","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Clarithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution. "
716,"Clomipramine","DB01242","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Clonidine","DB00575","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Clonidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Clonidine should be withdrawn very gradually to reduce the risk of hypertensive crisis."
716,"Cocaine","DB00907","The strong CYP2D6 inhibitor, Cocaine, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. "
716,"Darunavir","DB01264","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Darunavir is initiated, discontinued or dose changed. "
716,"Dasatinib","DB01254","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Delavirdine","DB00705","The strong CYP3A4/CYP2D6 inhibitor, Delavirdine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Delavirdine is initiated, discontinued or dose changed. "
716,"Desipramine","DB01151","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
716,"Dexmedetomidine","DB00633","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Dexmedetomidine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Dexmedetomidine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
716,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Disopyramide","DB00280","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Dofetilide","DB00204","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Dolasetron","DB00757","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Domperidone","DB01184","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Donepezil","DB00843","Possible antagonism of action"
716,"Doxepin","DB01142","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Droperidol","DB00450","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Duloxetine","DB00476","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Epinephrine","DB00668","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
716,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Erythromycin","DB00199","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Escitalopram","DB01175","The SSRI, Escitalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Escitalopram is initiated, discontinued or dose changed. "
716,"Fenoterol","DB01288","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of fenoterol."
716,"Flecainide","DB01195","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Fluconazole","DB00196","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Fluconazole, a strong CYP2C19 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Concomitant therapy should be used with caution."
716,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, trimipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used cautiously."
716,"Flupentixol","DB00875","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Fluvoxamine","DB00176","The strong CYP2C19 inhibitor, fluvoxamine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Additive modulation of serotonin activity may also increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome and changes in therapeutic and adverse effects of trimipramine if fluvoxamine is initiated, discontinued or dose changed."
716,"Fosamprenavir","DB01319","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Fosamprenavir is initiated, discontinued or dose changed. "
716,"Foscarnet","DB00529","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Furazolidone","DB00614","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
716,"Galantamine","DB00674","Possible antagonism of action"
716,"Gatifloxacin","DB01044","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Gemfibrozil","DB01241","The strong CYP2C19 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Gemfibrozil is initiated, discontinued or dose changed. "
716,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
716,"Guanabenz","DB00629","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanabenz. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanabenz should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
716,"Guanethidine","DB01170","The tricyclic antidepressant, trimipramine, decreases the effect of guanethidine."
716,"Guanfacine","DB01018","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanfacine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanfacine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
716,"Halofantrine","DB01218","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Haloperidol","DB00502","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Ibutilide","DB00308","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Imatinib","DB00619","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Imatinib is initiated, discontinued or dose changed. "
716,"Imipramine","DB00458","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Indapamide","DB00808","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Indinavir","DB00224","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Indinavir is initiated, discontinued or dose changed. "
716,"Isocarboxazid","DB01247","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
716,"Isoniazid","DB00951","The strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed. "
716,"Isradipine","DB00270","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Itraconazole","DB01167","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed. "
716,"Ketoconazole","DB01026","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed. "
716,"Lapatinib","DB01259","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Levofloxacin","DB01137","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Linezolid","DB00601","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
716,"Lithium","DB01356","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Lopinavir","DB01601","The strong CYP3A4/CYP2D6 inhibitor, Lopinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Lopinavir is initiated, discontinued or dose changed. "
716,"Loxapine","DB00408","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
716,"Maprotiline","DB00934","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Mefloquine","DB00358","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Mephentermine","DB01365","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
716,"Mesoridazine","DB00933","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Methadone","DB00333","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Methohexital","DB00474","The barbiturate, Methohexital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Methohexital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Methoxamine","DB00723","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
716,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Miconazole","DB01110","The strong CYP3A4/2D6/2C19 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/2D6/2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Miconazole is initiated, discontinued or dose changed. "
716,"Midodrine","DB00211","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Midodrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
716,"Mirtazapine","DB00370","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Moclobemide","DB01171","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
716,"Modafinil","DB00745","The strong CYP2C19 inhibitor, Modafinil, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Modafinil is initiated, discontinued or dose changed. "
716,"Moxifloxacin","DB00218","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Nefazodone","DB01149","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed. "
716,"Nelfinavir","DB00220","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nelfinavir is initiated, discontinued or dose changed. "
716,"Nicardipine","DB00622","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nicardipine is initiated, discontinued or dose changed. "
716,"Nilotinib","DB04868","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
716,"Norepinephrine","DB00368","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Norepinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
716,"Norfloxacin","DB01059","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Nortriptyline","DB00540","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
716,"Octreotide","DB00104","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Omeprazole","DB00338","The strong CYP2C19 inhibitor, Omeprazole, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Omeprazole is initiated, discontinued or dose changed. "
716,"Orciprenaline","DB00816","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of orciprenaline."
716,"Paroxetine","DB00715","The SSRI, Paroxetine, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Paroxetine is initiated, discontinued or dose changed. "
716,"Pentamidine","DB00738","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Pentobarbital","DB00312","The barbiturate, Pentobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Pentobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Perflutren","DB00556","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Pergolide","DB01186","Increased risk of serotonin syndrome. Pergolide, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Monitor for symptoms of serotonin syndrome and changes in Trimipramine therapeutic and adverse effects if Pergolide is initiated, discontinued or dose changed."
716,"Pethidine","DB00454","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Phenelzine","DB00780","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
716,"Phenobarbital","DB01174","The barbiturate, Phenobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Phenobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Phenylephrine","DB00388","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
716,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of phenylpropanolamine."
716,"Pimozide","DB01100","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Posaconazole","DB01263","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Posaconazole is initiated, discontinued or dose changed. "
716,"Pramlintide","DB01278","The anticholinergic effects of Trimipramine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
716,"Probucol","DB01599","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Procainamide","DB01035","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Procarbazine","DB01168","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
716,"Promethazine","DB01069","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Propafenone","DB01182","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Protriptyline","DB00344","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Pseudoephedrine","DB00852","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of pseudoephedrine."
716,"Quetiapine","DB01224","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Quinidine","DB00908","Additive QTc-prolonging effects may occur, increasing the risk of serious cardiac arrhythmias. Quinidine, a CYP2D6/CYP3A4 inhibitor, may also inhibit the metabolism of Trimipramine, a CYP2D6/CYP3A4 substrate. Monitor for signs of cardiac arrhythmias and for changes in Trimipramine efficacy and toxicity if Quinidine is initiated, discontinued or dose changed."
716,"Ranolazine","DB00243","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
716,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifabutin is initiated, discontinued or dose changed."
716,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed."
716,"Risperidone","DB00734","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Ritonavir","DB00503","The strong CYP3A4/CYP2D6 inhibitor, Ritonavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ritonavir is initiated, discontinued or dose changed. "
716,"Rizatriptan","DB00953","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Saquinavir","DB01232","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Saquinavir is initiated, discontinued or dose changed. "
716,"Secobarbital","DB00418","The barbiturate, Secobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Secobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Selegiline","DB01037","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
716,"Sertraline","DB01104","The SSRI, Sertraline, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Sertraline is initiated, discontinued or dose changed. "
716,"Sibutramine","DB01105","Increased risk of serotonin syndrome. Concomitant therapy is contraindicated."
716,"Sitaxentan","DB06268","The strong CYP2C19 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Sitaxsentan is initiated, discontinued or dose changed. "
716,"Sotalol","DB00489","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Sparfloxacin","DB01208","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"St. John's Wort","DB01323","St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed. "
716,"Sumatriptan","DB00669","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
716,"Sunitinib","DB01268","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
716,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
716,"Telithromycin","DB00976","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Telithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution."
716,"Terbinafine","DB00857","Terbinafine may decrease the metabolism and clearance of Trimipramine. Consider alternate therapy or monitor for changes in Trimipramine efficacy and toxicity if Terbinafine is initiated, discontinued or dose changed. Alteration in Trimipramine dose may be required."
716,"Terbutaline","DB00871","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of terbutaline."
716,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
716,"Tetrabenazine","DB04844","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
716,"Thiopental","DB00599","The barbiturate, Thiopental, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Thiopental is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
716,"Thioridazine","DB00679","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
716,"Thiothixene","DB01623","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
716,"Ticlopidine","DB00208","The strong CYP2C19 inhibitor, ticlopidine, may decrease the metabolism and clearance of trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of trimipramine if ticlopidine is initiated, discontinued or dose changed."
716,"Tizanidine","DB00697","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Tizandine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Tizandine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
716,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
716,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizures."
716,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
716,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
716,"Trimethobenzamide","DB00662","Trimethobenzamide and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
716,"Triprolidine","DB00427","Triprolidine and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
716,"Trospium","DB00209","Trospium and Trimipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
716,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
716,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trimipramine by decreasing its metabolism. Additive QTc prolongation may also occur. Monitor for changes in the therapeutic and adverse effects of trimipramine if voriconazole is initiated, discontinued or dose changed."
716,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
716,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
716,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
716,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
717,"Alteplase","DB00009","IV nitroglycerin may decrease the effect of alteplase."
717,"Avanafil","DB06237","Additive vasodilation. Concomitant therapy is contraindicated. "
717,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects."
717,"Dihydroergotamine","DB00320","Possible antagonism of action"
717,"Ergonovine","DB01253","Possible antagonism of action"
717,"Ergotamine","DB00696","Possible antagonism of action"
717,"Methylergometrine","DB00353","Possible antagonism of action"
717,"Methysergide","DB00247","Possible antagonism of action"
717,"Sildenafil","DB00203","Possible significant hypotension with this combination"
717,"Tadalafil","DB00820","The vasodilatory effects of Nitroglycerin may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
717,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
717,"Udenafil","DB06267","The vasodilatory effects of Nitroglycerin may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
717,"Vardenafil","DB00862","The vasodilatory effects of Nitroglycerin may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
718,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
718,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
718,"Colistimethate","DB01111","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
718,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
718,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
718,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
718,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
718,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
720,"Acenocoumarol","DB01418","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed."
720,"Alosetron","DB00969","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed."
720,"Aminophylline","DB01223","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed."
720,"Betaxolol","DB00195","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed"
720,"Caffeine","DB00201","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Caffeine by decreasing Caffeine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Caffeine if Thiabendazole is initiated, discontinued or dose changed."
720,"Clomipramine","DB01242","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed."
720,"Clozapine","DB00363","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clozapine by decreasing Clozapine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clozapine if Thiabendazole is initiated, discontinued or dose changed."
720,"Cyclobenzaprine","DB00924","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed."
720,"Dacarbazine","DB00851","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed."
720,"Doxepin","DB01142","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed."
720,"Duloxetine","DB00476","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Duloxetine by decreasing Duloxetine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Duloxetine if Thiabendazole is initiated, discontinued or dose changed."
720,"Flutamide","DB00499","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Flutamide by decreasing Flutamide metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Flutamide if Thiabendazole is initiated, discontinued or dose changed."
720,"Fluvoxamine","DB00176","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Fluvoxamine by decreasing Fluvoxamine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Fluvoxamine if Thiabendazole is initiated, discontinued or dose changed."
720,"Guanabenz","DB00629","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Guanabenz by decreasing Guanabenz metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Guanabenz if Thiabendazole is initiated, discontinued or dose changed."
720,"Oxtriphylline","DB01303","Thiabendazole increases the effect and toxicity of theophylline"
720,"Ramelteon","DB00980","Thiabendazole increases levels/toxicity of ramelteon"
720,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Thiabendazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Thiabendazole is initiated, discontinued or if the dose is changed."
720,"Theophylline","DB00277","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Theophylline by decreasing Theophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Theophylline if Thiabendazole is initiated, discontinued or dose changed."
720,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed."
720,"Tizanidine","DB00697","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Tizanidine by decreasing Tizanidine metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Tizanidine if Thiabendazole is initiated, discontinued or dose changed."
720,"Trifluoperazine","DB00831","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed."
721,"Glucosamine","DB01296","Possible hyperglycemia"
721,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of nateglinide. Monitor for changes in fasting and postprandial blood sugars."
721,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nateglenide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nateglenide if Telithromycin is initiated, discontinued or dose changed."
721,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
721,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nateglinide if voriconazole is initiated, discontinued or dose changed."
722,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
722,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
722,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
722,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
722,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
722,"Colistimethate","DB01111","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
722,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
722,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
722,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
722,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
722,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
722,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
722,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
722,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
722,"Quinidine","DB00908","The quinine derivative increases the effect of the muscle relaxant"
722,"Quinine","DB00468","The quinine derivative increases the effect of the muscle relaxant"
722,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
722,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
724,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
724,"Carbamazepine","DB00564","Decreases the effect of risperidone"
724,"Donepezil","DB00843","Possible antagonism of action"
724,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases the effect and toxicity of risperidone."
724,"Galantamine","DB00674","Possible antagonism of action"
724,"Indinavir","DB00224","Increased risk of extrapyramidal symptoms"
724,"Itraconazole","DB01167","Increases the level of risperidone"
724,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
724,"Paliperidone","DB01267","Paliperidone is the active metabolite of risperidone, 9-OH-risperidone. Concomitant therapy may increase the adverse effects of paliperidone due to additive paliperidone exposure. Consider alternate therapy. "
724,"Paroxetine","DB00715","The SSRI, paroxetine, increases the effect and toxicity of risperidone."
724,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Risperidone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
724,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
724,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Risperidone. Consider alternate therapy or monitor for therapeutic/adverse effects of Risperidone if Terbinafine is initiated, discontinued or dose changed."
724,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
724,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
724,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
724,"Trimethobenzamide","DB00662","Trimethobenzamide and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
724,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
724,"Triprolidine","DB00427","Triprolidine and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
724,"Trospium","DB00209","Trospium and Risperidone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
724,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
724,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
724,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
724,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
726,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
726,"Cefditoren","DB01066","Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
726,"Clopidogrel","DB00758","Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. "
726,"Enoxacin","DB00467","Esomeprazole may decrease the absorption of enoxacin."
726,"Indinavir","DB00224","Omeprazole decreases the absorption of indinavir"
726,"Itraconazole","DB01167","The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole."
726,"Ketoconazole","DB01026","The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole."
726,"Rilpivirine","DB08864","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
726,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response."
727,"Donepezil","DB00843","Possible antagonism of action"
727,"Galantamine","DB00674","Possible antagonism of action"
727,"Rivastigmine","DB00989","Possible antagonism of action"
727,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Meclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
727,"Trimethobenzamide","DB00662","Trimethobenzamide and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
727,"Triprolidine","DB00427","Triprolidine and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
727,"Trospium","DB00209","Trospium and Meclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
728,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
728,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
728,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
728,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
728,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
728,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
728,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
728,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
728,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Pentamidine. Consider alternate therapy or monitor for adverse/toxic effects of Pentamidine if Ticlopidine is initiated, discontinued or dose changed."
728,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
728,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
728,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
728,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
728,"Zalcitabine","DB00943","Additive risk of pancreatitis. Concomitant therapy should be avoided. "
728,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
728,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
729,"Demeclocycline","DB00618","Possible antagonism of action"
729,"Doxycycline","DB00254","Possible antagonism of action"
729,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
729,"Minocycline","DB01017","Possible antagonism of action"
729,"Tetracycline","DB00759","Possible antagonism of action"
731,"Acenocoumarol","DB01418","The corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol."
731,"Acetylsalicylic acid","DB00945","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid."
731,"Ambenonium","DB01122","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium."
731,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Anisindione","DB01125","The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione."
731,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Bismuth Subsalicylate","DB01294","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate."
731,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Cholestyramine","DB01432","Cholestyramine may decrease the effect of hydrocortisone."
731,"Colestipol","DB00375","Cholestyramine decreases the effect of hydrocortisone"
731,"Dicoumarol","DB00266","The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol."
731,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Edrophonium","DB01010","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium."
731,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
731,"Linagliptin","DB08882","CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. "
731,"Magnesium salicylate","DB01397","The corticosteroid, hydrocortisone, may decrease the effect of magnesium salicylate. "
731,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Midodrine","DB00211","Increased arterial pressure"
731,"Neostigmine","DB01400","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine."
731,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Pyridostigmine","DB00545","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine."
731,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Salicylate-sodium","DB01398","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium."
731,"Salsalate","DB01399","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate."
731,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Tacrine","DB00382","Tacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
731,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone."
731,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
731,"Trisalicylate-choline","DB01401","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline."
731,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
731,"Warfarin","DB00682","The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin."
732,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
734,"Aminophylline","DB01223","Zileuton increases the effect and toxicity of theophylline"
734,"Bendamustine","DB06769","CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. "
734,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
734,"Eltrombopag","DB06210","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
734,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
734,"Oxtriphylline","DB01303","Zileuton increases the effect and toxicity of theophylline"
734,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
734,"Ramelteon","DB00980","Zileuton increases levels/toxicity of ramelteon"
734,"Theophylline","DB00277","Zileuton may increase the therapeutic and adverse effects of theophylline by increasing its serum concentration. Monitor for changes in the therapeutic and adverse effects of theophylline if zileuton is initiated, discontinued or dose changed. Dose alterations should be considered."
735,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as modafinil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
735,"Clozapine","DB00363","Modafinil increases the effect and toxicity of clozapine"
735,"Cyclosporine","DB00091","Modafinil decreases the effect of cyclosporine"
735,"Ethinyl Estradiol","DB00977","Modafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil."
735,"Mestranol","DB01357","Modafinil decreases the effect of the contraceptive"
735,"Roflumilast","DB01656","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
735,"Telithromycin","DB00976","Telithromycin may reduce clearance of Modafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Modafinil if Telithromycin is initiated, discontinued or dose changed."
735,"Triazolam","DB00897","Modafinil decreases the effect of triazolam"
735,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, Modafinil, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Modafinil is initiated, discontinued or dose changed. "
735,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of modafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of modafinil if voriconazole is initiated, discontinued or dose changed."
736,"Vitamin C","DB00126","Vitamin C may increase the adverse effects of deferoxamine. Transient deterioration of left ventricular function has been observed during concomitant therapy. Use caution during concomitant therapy. "
737,"Cinitapride","DB08810","Anticholinergic agents like scopolamine may reduce the action of cinitapride. "
737,"Donepezil","DB00843","Possible antagonism of action"
737,"Galantamine","DB00674","Possible antagonism of action"
737,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
737,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Scopolamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
737,"Trimethobenzamide","DB00662","Trimethobenzamide and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
737,"Triprolidine","DB00427","Triprolidine and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
737,"Trospium","DB00209","Trospium and Scopolamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
738,"Benzylpenicilloyl Polylysine","DB00895","Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects. "
738,"Donepezil","DB00843","Possible antagonism of action"
738,"Galantamine","DB00674","Possible antagonism of action"
738,"Pramlintide","DB01278","Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur."
738,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Carbinoxamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
738,"Trimethobenzamide","DB00662","Trimethobenzamide and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
738,"Triprolidine","DB00427","Triprolidine and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
738,"Trospium","DB00209","Trospium and Carbinoxamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
739,"Acenocoumarol","DB01418","The NSAID, etodolac, may increase the anticoagulant effect or acenocoumarol."
739,"Alendronate","DB00630","Increased risk of gastric toxicity"
739,"Anisindione","DB01125","The NSAID, etodolac, may increase the anticoagulant effect of anisindione."
739,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
739,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
739,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
739,"Dicoumarol","DB00266","The NSAID, etodolac, may increase the anticoagulant effect of dicumarol."
739,"Eltrombopag","DB06210","Increases levels of Etodolac via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
739,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
739,"Methotrexate","DB00563","The NSAID, etodolac, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
739,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
739,"Timolol","DB00373","The NSAID, Etodolac, may antagonize the antihypertensive effect of Timolol."
739,"Trandolapril","DB00519","The NSAID, Etodolac, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Etodolac is initiated, discontinued or dose changed.  "
739,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Etodolac. Monitor for increased bleeding during concomitant thearpy. "
739,"Warfarin","DB00682","The antiplatelet effects of etodolac may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
742,"Alfentanil","DB00802","Possible increased risk of serotonin syndrome. "
742,"Almotriptan","DB00918","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Almotriptan. Risk of serotonin syndrome and Almotriptan toxicity. Concomitant therapy should be avoided."
742,"Amitriptyline","DB00321","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Amoxapine","DB00543","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Apraclonidine","DB00964","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Apraclonidine. Concomitant therapy is contraindicated."
742,"Atomoxetine","DB00289","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Atomoxetine. These agents should not be administered within 14 days of each other."
742,"Benzphetamine","DB00865","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Benzphetamine. Concomitant therapy should be avoided."
742,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like tranylcypromine. "
742,"Brimonidine","DB00484","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Brimonidine. Concomitant therapy is contraindicated."
742,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like tranylcypromine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
742,"Bupropion","DB01156","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Bupropion. These agents should not be administered within 14 days of each other."
742,"Buspirone","DB00490","Buspirone may increase the adverse effects of Tranylcypromine. Elevation of blood pressure may occur. Concomitant therapy also may increase the risk of serotonin syndrome. Concomitant therapy should be avoided."
742,"Cabergoline","DB00248","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Citalopram","DB00215","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Clomipramine","DB01242","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Cyclobenzaprine","DB00924","Increased risk of serotonin syndrome. Concomitant use should be avoided. These agents should not be administered within 14 days of each other. "
742,"Desipramine","DB01151","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
742,"Dexfenfluramine","DB01191","Possible hypertensive crisis"
742,"Dexmedetomidine","DB00633","Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Dexmedetomidine. "
742,"Dextroamphetamine","DB01576","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Dextroamphetamine. Concomitant therapy should be avoided."
742,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Concomitant use should be avoided."
742,"Dextropropoxyphene","DB00647","Increased risk of serotonin syndrome. Concomitant use should be avoided. "
742,"Diethylpropion","DB00937","Possible hypertensive crisis"
742,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Donepezil","DB00843","Possible antagonism of action"
742,"Doxepin","DB01142","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Duloxetine","DB00476","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Entacapone","DB00494","Additive inhibition of endogenous catecholamine metabolism may increase the therapeutic/adverse effects of both agents. Concomitant therapy should be avoided."
742,"Ephedrine","DB01364","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Ephedrine. Concomitant therapy should be avoided. "
742,"Epinephrine","DB00668","Increased arterial pressure"
742,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Escitalopram","DB01175","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Fenfluramine","DB00574","Possible hypertensive crisis"
742,"Fenoterol","DB01288","Increased arterial pressure"
742,"Fentanyl","DB00813","Possible increased risk of serotonin syndrome. "
742,"Fluoxetine","DB00472","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Fluvoxamine","DB00176","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Furazolidone","DB00614","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Galantamine","DB00674","Possible antagonism of action"
742,"Guanethidine","DB01170","Tranylcypromine may decrease the effect of guanethidine."
742,"Ifosfamide","DB01181","Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Ifosmadine. "
742,"Imipramine","DB00458","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Isocarboxazid","DB01247","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"L-DOPA","DB01235","Levodopa may increase the adverse effects of Tranylcypromine. Risk of severe hypertension. Concomitant therapy should be avoided or monitored closely for adverse effects of Tranylcypromine. "
742,"Linezolid","DB00601","The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Linezolid. These agents should not be administered within 14 days of each other. "
742,"Lisdexamfetamine","DB01255","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Lisdexamfetamine. Concomitant therapy should be avoided."
742,"Lithium","DB01356","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Maprotiline","DB00934","Maprotiline may increase the adverse effects of the MAO inhibitor, Tranylcypromine. These agents should not be administered within 14 days of each other. "
742,"Mazindol","DB00579","Possible hypertensive crisis"
742,"Mephentermine","DB01365","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Concomitant therapy should be avoided. "
742,"Methamphetamine","DB01577","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Methamphetamine. Concomitant therapy should be avoided."
742,"Methotrimeprazine","DB01403","Possible severe adverse reaction with this combination"
742,"Methoxamine","DB00723","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Methoxamine. Concomitant therapy should be avoided. "
742,"Methyldopa","DB00968","The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated."
742,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Methylphenidate","DB00422","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Methylphenidate. Concomitant therapy is contraindicated."
742,"Midodrine","DB00211","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Midodrine. Concomitant therapy should be avoided."
742,"Milnacipran","DB04896","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Mirtazapine","DB00370","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Mirtazapine. These agents should not be administered within 14 days of each other."
742,"Moclobemide","DB01171","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."
742,"Nefazodone","DB01149","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."
742,"Nortriptyline","DB00540","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Orciprenaline","DB00816","Increased arterial pressure"
742,"Oxymetazoline","DB00935","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Oxymetazoline. Concomitant therapy should be avoided. "
742,"Paroxetine","DB00715","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Pergolide","DB01186","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Pethidine","DB00454","Increased risk of serotonin syndrome. Concomitant use should be avoided."
742,"Phendimetrazine","DB01579","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Phendimetrazine. Concomitant therapy should be avoided."
742,"Phenelzine","DB00780","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Phentermine","DB00191","The MAO inhibitor, tranylcypromine, may increase the vasopressor effect of the amphetamine, phentermine. Concomitant therapy should be avoided."
742,"Phenylephrine","DB00388","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Phenylephrine. Concomitant therapy should be avoided."
742,"Phenylpropanolamine","DB00397","Increased arterial pressure"
742,"Pramlintide","DB01278","The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
742,"Procarbazine","DB01168","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Promethazine","DB01069","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Protriptyline","DB00344","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Pseudoephedrine","DB00852","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Pseudoephedrine. Concomitant therapy should be avoided."
742,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Remifentanil","DB00899","Possible increased risk of serotonin syndrome. "
742,"Reserpine","DB00206","Addition of Reserpine to Tranylcypromine therapy may induce paradoxical Reserpine effects, including peripheral hypertension and central exciation. Close monitoring for adverse effects is required. Addition of Tranylcypromine to Reserpine therapy may be less of a concern. "
742,"Rizatriptan","DB00953","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant therapy should be avoided. "
742,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Selegiline","DB01037","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Sertraline","DB01104","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Sibutramine","DB01105","Increased risk of serotonin syndrome. Avoid concomitant therapy."
742,"St. John's Wort","DB01323","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Sufentanil","DB00708","Possible increased risk of serotonin syndrome. "
742,"Sumatriptan","DB00669","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Sumatriptan. Risk of serotonin syndrome and Sumatriptan toxicity. Concomitant therapy should be avoided. "
742,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tranylcypromine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Tranylcypromine, a CYP1A2 inhibitor. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. "
742,"Tamoxifen","DB00675","The CYP2D6 inhibitor, Tranylcypromine, may decrease the efficacy of Tamoxifen by reducing active metabolite production. Consider alternate therapy."
742,"Tamsulosin","DB00706","Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tranylcypromine is initiated, discontinued, or dose changed."
742,"Terbutaline","DB00871","Increased arterial pressure"
742,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Tranylcypromine. Concomitant therapy is contraindicated."
742,"Thioridazine","DB00679","Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated. "
742,"Tizanidine","DB00697","Tranylcypromine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
742,"Tolcapone","DB00323","Tolcapone and Tranylcypromine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
742,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, tranylcypromine. Tranylcypromine may decrease the effect of tramadol by decreasing active metabolite production."
742,"Trazodone","DB00656","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
742,"Trimethobenzamide","DB00662","Trimethobenzamide and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
742,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
742,"Triprolidine","DB00427","Concomitant therapy with triprolidine and tranylcypromine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."
742,"Trospium","DB00209","Trospium and Tranylcypromine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
742,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
742,"Vilazodone","DB06684","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome."
742,"Zolmitriptan","DB00315","The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated."
743,"Labetalol","DB00598","Monitor arterial pressure closely"
744,"Alprazolam","DB00404","Ethotoin may increase the metabolism of alprazolam via CYP3A4."
744,"Aminophylline","DB01223","Decreased effect of both products"
744,"Amiodarone","DB01118","Increases the effect of hydantoin"
744,"Aprepitant","DB00673","The CYP3A4 inducer, ethotoin, may decrease the effect of aprepitant."
744,"Betamethasone","DB00443","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, betamethasone."
744,"Capecitabine","DB01101","Capecitabine increases the effect of hydantoin"
744,"Chloramphenicol","DB00446","Increases phenytoin, modifies chloramphenicol"
744,"Chlordiazepoxide","DB00475","Ethotoin may increase the metabolism of chlordiazepoxide via CYP3A4."
744,"Chlorphenamine","DB01114","The antihistamine increases the effect of hydantoin"
744,"Cimetidine","DB00501","Increases the effect of hydantoin"
744,"Ciprofloxacin","DB00537","Decreases the hydantoin effect"
744,"Clomifene","DB00882","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene."
744,"Clorazepate","DB00628","Ethotoin may increase the metabolism of clorazepate via CYP3A4."
744,"Clozapine","DB00363","Hydantoin decreases the effect of clozapine"
744,"Conjugated Estrogens","DB00286","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, conjugated estrogens."
744,"Cyclosporine","DB00091","The hydantoin decreases the effect of cyclosporine"
744,"Dexamethasone","DB01234","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone."
744,"Diazepam","DB00829","Ethotoin may increase the metabolism of diazepam via CYP3A4."
744,"Diethylstilbestrol","DB00255","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, diethylstilbestrol."
744,"Disopyramide","DB00280","The hydantoin decreases the effect of disopyramide"
744,"Disulfiram","DB00822","Increases the effect of phenytoin"
744,"Doxycycline","DB00254","The anticonvulsant, ethotoin, decreases the effect of doxycycline."
744,"Estradiol","DB00783","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, estradiol."
744,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
744,"Felbamate","DB00949","Increased phenytoin levels and decreased felbamate levels"
744,"Felodipine","DB01023","The hydantoin decreases the effect of felodipine"
744,"Fluconazole","DB00196","Increases the effect of hydantoin"
744,"Fludrocortisone","DB00687","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, fludrocortisone."
744,"Fluorouracil","DB00544","Fluorouracil increases the effect of hydantoin"
744,"Fluoxetine","DB00472","Fluoxetine increases the effect of phenytoin"
744,"Flurazepam","DB00690","Ethotoin may increase the metabolism of flurazepam via CYP3A4."
744,"Fluvoxamine","DB00176","Increases the effect of hydantoin"
744,"Folic Acid","DB00158","Folic acid decreases the levels of hydantoin"
744,"Furosemide","DB00695","The hydantoin decreases the effect of furosemide"
744,"Gabapentin","DB00996","Increases the effect of hydantoin"
744,"Gefitinib","DB00317","The CYP3A4 inducer, ethotoin, may decrease the serum concentration and therapeutic effects of gefitinib."
744,"Hydrocortisone","DB00741","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone."
744,"Imatinib","DB00619","The hydantoin decreases the levels of imatinib"
744,"Isoniazid","DB00951","Isoniazid increases the effect of phenytoin in 20% of patients"
744,"Itraconazole","DB01167","Phenytoin decreases the effect of itraconazole"
744,"Lamotrigine","DB00555","Phenytoin may reduce levels of lamotrigine"
744,"Levonorgestrel","DB00367","Phenytoin decreases the contraceptive effect"
744,"Mebendazole","DB00643","The hydantoin decreases the efficiency of mebendazole"
744,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, medroxyprogesterone."
744,"Megestrol acetate","DB00351","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, megestrol."
744,"Methadone","DB00333","The hydantoin decreases the effect of methadone"
744,"Methotrexate","DB00563","The antineoplasic agent decreases the effect of hydantoin"
744,"Methoxsalen","DB00553","The hydantoin decreases the effect of psoralene"
744,"Mexiletine","DB00379","The hydantoin decreases the effect of mexiletine"
744,"Midazolam","DB00683","Ethotoin may increase the metabolism of midazolam via CYP3A4."
744,"Mirtazapine","DB00370","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
744,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
744,"Omeprazole","DB00338","Omeprazole increases the effect of hydantoin"
744,"Oxcarbazepine","DB00776","Oxcarbazepine increases the effect of hydantoin"
744,"Oxtriphylline","DB01303","Decreased effect of both products"
744,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin."
744,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin."
744,"Prednisolone","DB00860","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone."
744,"Prednisone","DB00635","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone."
744,"Quetiapine","DB01224","Phenytoin decreases the effect of quetiapine"
744,"Rifampicin","DB01045","Rifampin decreases the effect of the hydantoin"
744,"Theophylline","DB00277","Decreased effect of both products"
744,"Ticlopidine","DB00208","Ticlopidine increases the effect of hydantoin"
744,"Triamcinolone","DB00620","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, triamcinolone."
744,"Triazolam","DB00897","Ethotoin may increase the metabolism of triazolam via CYP3A4."
744,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Ethotoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
745,"Atazanavir","DB01072","The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed. "
745,"Carbamazepine","DB00564","The strong CYP2C8 inducer, Carbamazepine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Carbamazepine is initiated, discontinued or dose changed. "
745,"Celecoxib","DB00482","The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed."
745,"Demeclocycline","DB00618","Demeclocycline may increase the adverse effects of oral Tretinoin. Increased risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Desogestrel","DB00304","Oral Tretinoin may decrease the effect of oral contraceptive, Desogestrel. An alternate form of contraception should be used during concomitant therapy. "
745,"Doxycycline","DB00254","Doxycycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Drospirenone","DB01395","Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy. "
745,"Eltrombopag","DB06210","The moderate CYP2C8 inhibitor, Eltrombopag, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Eltrombopag is initiated, discontinued or dose changed."
745,"Ethinyl Estradiol","DB00977","Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy. "
745,"Ethynodiol","DB00823","Oral Tretinoin may decrease the effect of oral contraceptive, Ethynodiol Diacetate. An alternate form of contraception should be used during concomitant therapy. "
745,"Etonogestrel","DB00294","Oral Tretinoin may decrease the effect of oral contraceptive, Etonogestrel. An alternate form of contraception should be used during concomitant therapy. "
745,"Felodipine","DB01023","The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed."
745,"Fosphenytoin","DB01320","The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed. "
745,"Gemfibrozil","DB01241","The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Gemfibrozil is initiated, discontinued to dose changed. "
745,"Irbesartan","DB01029","The moderate CYP2C8 inhibitor, Irbesartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Irbesartan is initiated, discontinued to dose changed."
745,"Lapatinib","DB01259","The moderate CYP2C8 inhibitor, Lapatinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Lapatinib is initiated, discontinued to dose changed."
745,"Levonorgestrel","DB00367","Oral Tretinoin may decrease the effect of oral contraceptive, Levonorgestrel. An alternate form of contraception should be used during concomitant therapy. "
745,"Losartan","DB00678","The moderate CYP2C8 inhibitor, Losartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Losartan is initiated, discontinued to dose changed."
745,"Mestranol","DB01357","Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy. "
745,"Minocycline","DB01017","Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Natalizumab","DB00108","Oral tretinoin may increase the adverse/toxic effects of Natalizumab. Concurrent therapy should be avoided."
745,"Nilotinib","DB04868","The moderate CYP2C8 inhibitor, Nilotinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Nilotinib is initiated, discontinued to dose changed."
745,"Norethindrone","DB00717","Oral Tretinoin may decrease the effect of oral contraceptive, Norethindrone. An alternate form of contraception should be used during concomitant therapy. "
745,"Norgestimate","DB00957","Oral Tretinoin may decrease the effect of oral contraceptive, Norgestimate. An alternate form of contraception should be used during concomitant therapy. "
745,"Oxytetracycline","DB00595","Oxytetracycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Phenobarbital","DB01174","The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed. "
745,"Phenytoin","DB00252","The strong CYP2C8 inducer, Phenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenytoin is initiated, discontinued or dose changed. "
745,"Pioglitazone","DB01132","The moderate CYP2C8 inhibitor, Pioglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Pioglitazone is initiated, discontinued to dose changed."
745,"Primidone","DB00794","The strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed. "
745,"Quinine","DB00468","The moderate CYP2C8 inhibitor, Quinine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Quinine is initiated, discontinued to dose changed."
745,"Rabeprazole","DB01129","The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed."
745,"Rifampicin","DB01045","The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed. "
745,"Rifapentine","DB01201","The strong CYP2C8 inducer, Rifapentine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifapentine is initiated, discontinued or dose changed. "
745,"Ritonavir","DB00503","The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed. "
745,"Rosiglitazone","DB00412","The moderate CYP2C8 inhibitor, Rosiglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rosiglitazone is initiated, discontinued to dose changed."
745,"Secobarbital","DB00418","The strong CYP2C8 inducer, Secobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Secobarbital is initiated, discontinued or dose changed. "
745,"Sorafenib","DB00398","The strong CYP2C8 inhibitor, Sorafenib, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Sorafenib is initiated, discontinued to dose changed. "
745,"Tamoxifen","DB00675","The moderate CYP2C8 inhibitor, Tamoxifen, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Tamoxifen is initiated, discontinued to dose changed."
745,"Tetracycline","DB00759","Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Tigecycline","DB00560","Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
745,"Trastuzumab","DB00072","Increased risk of leukopenia and anemia due to synergistic effects. Monitor for signs and symptoms of adverse events during concomitant therapy."
745,"Trimethoprim","DB00440","The moderate CYP2C8 inhibitor, Trimethoprim, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Trimethoprim is initiated, discontinued to dose changed."
745,"Vitamin A","DB00162","Tretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking systemic tretinoin."
747,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
747,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
747,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
747,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
747,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
747,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
747,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
747,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
747,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
748,"Bortezomib","DB00188","Moderate CYP2C19 Inhibitors like bortezomib may decrease serum concentrations of the active metabolite(s) of Clopidogrel. Avoid concurrent use of moderate CYP2C19 inhibitors with clopidogrel whenever possible. If such a combination must be used, monitor closely for evidence of reduced clinical response to clopidogrel. "
748,"Drotrecogin alfa","DB00055","Antiplatelet agents such as clopidogrel may enhance the adverse/toxic effect of Drotrecogin Alfa. Bleeding may occur. Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents."
748,"Esomeprazole","DB00736","Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. "
748,"Etravirine","DB06414","Clopidogrel, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in the serum concentrations of it's active metabolites. \
\
Caution and close monitoring for decreased efficacy of clopidogrel is recommended. "
748,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
748,"Lansoprazole","DB00448","Lansoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent lansoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with lansoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. "
748,"Omeprazole","DB00338","Omeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Clopidogrel prescribing information recommends avoiding concurrent use with omeprazole, due to the possibility that combined use may result in decreased clopidogrel effectiveness. "
748,"Pantoprazole","DB00213","Pantoprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent pantoprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with pantoprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."
748,"Rabeprazole","DB01129","Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."
748,"Rivaroxaban","DB06228","Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding. "
748,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Clopidogrel. Monitor for increased bleeding during concomitant thearpy. "
748,"Warfarin","DB00682","Increased bleed risk may occur as a result of additive anticoagulant effects. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. "
749,"Acenocoumarol","DB01418","Tetracycline may increase the anticoagulant effect of acenocoumarol."
749,"Acitretin","DB00459","Increased risk of intracranial hypertension"
749,"Aluminium","DB01370","Formation of non-absorbable complexes"
749,"Amoxicillin","DB01060","Possible antagonism of action"
749,"Ampicillin","DB00415","Possible antagonism of action"
749,"Anisindione","DB01125","Tetracycline may increase the anticoagulant effect of anisindione."
749,"Atovaquone","DB01117","Tetracycline may decrease the effect of atovaquone."
749,"Attapulgite","DB01574","Formation of non-absorbable complexes"
749,"Azlocillin","DB01061","Possible antagonism of action"
749,"Aztreonam","DB00355","Possible antagonism of action"
749,"Bacampicillin","DB01602","Possible antagonism of action"
749,"Benzylpenicillin","DB01053","Possible antagonism of action"
749,"Bexarotene","DB00307","Tetracycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
749,"Bismuth Subsalicylate","DB01294","Formation of non-absorbable complexes"
749,"Calcium","DB01373","Formation of non-absorbable complexes"
749,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
749,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
749,"Carbenicillin","DB00578","Possible antagonism of action"
749,"Clavulanate","DB00766","Possible antagonism of action"
749,"Cloxacillin","DB01147","Possible antagonism of action"
749,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
749,"Cyclacillin","DB01000","Possible antagonism of action"
749,"Dicloxacillin","DB00485","Possible antagonism of action"
749,"Dicoumarol","DB00266","Tetracycline may increase the anticoagulant effect of dicumarol."
749,"Dihydroxyaluminium","DB01375","Formation of non-absorbable complexes"
749,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
749,"Etretinate","DB00926","Increased risk of intracranial hypertension"
749,"Flucloxacillin","DB00301","Possible antagonism of action"
749,"Hetacillin","DB00739","Possible antagonism of action"
749,"Iron","DB01592","Formation of non-absorbable complexes"
749,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
749,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
749,"Magnesium","DB01378","Formation of non-absorbable complexes"
749,"Magnesium salicylate","DB01397","Formation of non-absorbable complexes"
749,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
749,"Methicillin Acyl-Serine","DB02443","Possible antagonism of action"
749,"Methotrexate","DB00563","Tetracycline may increase methotrexate toxicity."
749,"Methoxyflurane","DB01028","Tetracycline may increase the renal toxicity of methoxyflurane."
749,"Mezlocillin","DB00948","Possible antagonism of action"
749,"Nafcillin","DB00607","Possible antagonism of action"
749,"Oxacillin","DB00713","Possible antagonism of action"
749,"Penicillin V","DB00417","Possible antagonism of action"
749,"Piperacillin","DB00319","Possible antagonism of action"
749,"Pivampicillin","DB01604","Possible antagonism of action"
749,"Pivmecillinam","DB01605","Possible antagonism of action"
749,"Quinapril","DB00881","Quinapril may decrease the absorption of tetracycline."
749,"Tamsulosin","DB00706","Tetracycline, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Tetracycline is initiated, discontinued, or dose changed."
749,"Tazobactam","DB01606","Possible antagonism of action"
749,"Ticarcillin","DB01607","Tetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Tetracycline."
749,"Tolterodine","DB01036","Tetracycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
749,"Tramadol","DB00193","Tetracycline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
749,"Trazodone","DB00656","The CYP3A4 inhibitor, Tetracycline, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tetracycline is initiated, discontinued or dose changed."
749,"Tretinoin","DB00755","Demeclocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
749,"Trisalicylate-choline","DB01401","Formation of non-absorbable complexes"
749,"Warfarin","DB00682","Tetracycline may increase the anticoagulant effect of warfarin."
749,"Zinc","DB01593","Formation of non-absorbable complexes"
751,"Clidinium","DB00771","Anticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives."
751,"Telmisartan","DB00966","Potassium Chloride may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use. "
751,"Tiotropium","DB01409","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Tiotropium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
751,"Tolterodine","DB01036","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
751,"Trandolapril","DB00519","The potassium salt may increase the hyperkalemic effect of Trandolapril."
751,"Trihexyphenidyl","DB00376","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trihexyphenidyl, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations. "
751,"Trimethobenzamide","DB00662","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
751,"Trospium","DB00209","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trospium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
752,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, irinotecan."
752,"Atazanavir","DB01072","Increases levels/effect of irinotecan"
752,"Bevacizumab","DB00112","Monitor therapy due to increased adverse effects of irinotecan."
752,"Fosphenytoin","DB01320","The hydantoin decreases the effect of irinotecan"
752,"Ketoconazole","DB01026","Ketoconazole increases the effect and toxicity of irinotecan"
752,"Pazopanib","DB06589","Irinotecan is an uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) substrate and serum concentrations may increase if administered concurrently with pazopanib, an UGT1A1 inhibitor. "
752,"Phenytoin","DB00252","The hydantoin decreases the effect of irinotecan"
752,"Regorafenib","DB08896","Regorafenib may increase levels of irinotecan, a UGT1A1 substrate. "
752,"Telithromycin","DB00976","Telithromycin may reduce clearance of Irinotecan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Irinotecan if Telithromycin is initiated, discontinued or dose changed."
752,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Irinotecan, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Irinotecan if Thiotepa is initiated, discontinued or dose changed. "
752,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
752,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of irinotecan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of irinotecan if voriconazole is initiated, discontinued or dose changed."
753,"Acenocoumarol","DB01418","The antithyroid agent, methimazole, may decrease the anticoagulant effect of acenocoumarol."
753,"Anisindione","DB01125","The antithyroid agent, methimazole, may decrease the anticoagulant effect of anisindione."
753,"Dicoumarol","DB00266","The antithyroid agent, methimazole, may decrease the anticoagulant effect of dicumarol."
753,"Digoxin","DB00390","The antithyroid agent increases the effect of digoxin"
753,"Tamoxifen","DB00675","Methimazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
753,"Tamsulosin","DB00706","Methimazole, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methimazole is initiated, discontinued, or dose changed."
753,"Warfarin","DB00682","Methimazole may decrease the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if methimazole is initiated, discontinued or dose changed."
755,"Dihydrocodeine","DB01551","Concurrent use may enhance the sedative effect of Metyrosine.  It is recommended to monitor therapy. "
756,"Demeclocycline","DB00618","Possible antagonism of action"
756,"Doxycycline","DB00254","Possible antagonism of action"
756,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
756,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
756,"Methacycline","DB00931","Possible antagonism of action"
756,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
756,"Minocycline","DB01017","Possible antagonism of action"
756,"Oxytetracycline","DB00595","Possible antagonism of action"
756,"Rolitetracycline","DB01301","Possible antagonism of action"
756,"Tetracycline","DB00759","Possible antagonism of action"
761,"Donepezil","DB00843","Possible antagonism of action"
761,"Galantamine","DB00674","Possible antagonism of action"
761,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
761,"Potassium Chloride","DB00761","Anticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives."
761,"Pramlintide","DB01278","Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur."
761,"Secretin","DB00021","Anticholinergic agents such as secretin may diminish the stimulatory effect of secretin. Avoid using drugs with substantial anticholinergic effects in patients receiving secretin whenever possible. If such agents must be used in combination, monitor response to secretin closely."
761,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clidinium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
761,"Trimethobenzamide","DB00662","Trimethobenzamide and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
761,"Triprolidine","DB00427","Triprolidine and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
761,"Trospium","DB00209","Trospium and Clidinium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
763,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, etoposide."
763,"Cyclosporine","DB00091","Cyclosporine may increase the therapeutic and adverse effects of etoposide."
763,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
763,"Telithromycin","DB00976","Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed."
763,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
763,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed."
764,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
764,"Lithium","DB01356","The thiazide diuretic, hydroflumethiazide, may increase serum levels of lithium."
764,"Trandolapril","DB00519","The thiazide diuretic, Hydroflumethiazide, may increase the hypotensive effect of Trandolapril. Hydroflumethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
764,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
765,"Abciximab","DB00054","Additive effects. Concomitant use is contraindicated."
765,"Eptifibatide","DB00063","Additive effects. Concomitant use is contraindicated."
765,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
765,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Tirofiban. Monitor for increased bleeding during concomitant thearpy. "
766,"Cyclosporine","DB00091","Oxcarbazepine decreases the effect of cyclosporine"
766,"Ethinyl Estradiol","DB00977","Oxcarbazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied upon during concomitant therapy with oxcarbazepine."
766,"Ethotoin","DB00754","Oxcarbazepine increases the effect of hydantoin"
766,"Felodipine","DB01023","Oxcarbazepine decreases the levels of felodipine"
766,"Fosphenytoin","DB01320","Oxcarbazepine increases the effect of hydantoin"
766,"Mephenytoin","DB00532","Oxcarbazepine increases the effect of hydantoin"
766,"Mestranol","DB01357","Oxcarbazepine decreases the effect of the contraceptive"
766,"Phenytoin","DB00252","Oxcarbazepine increases the effect of hydantoin"
766,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
766,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
766,"Telithromycin","DB00976","Oxcarbazepine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
766,"Temsirolimus","DB06287","Oxcarbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."
766,"Tramadol","DB00193","Oxcarbazepine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
766,"Trazodone","DB00656","The CYP3A4 inducer, Oxcarbazepine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Oxcarbazepine is initiated, discontinued or dose changed."
766,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
767,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
767,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
767,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
767,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
767,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
767,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
767,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
767,"Guanethidine","DB01170","Propiomazine may decrease the effect of guanethidine."
767,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
767,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
767,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
767,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
767,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
768,"Cyclosporine","DB00091","The macrolide, roxithromycin, may increase the effect of cyclosporine."
769,"Acenocoumarol","DB01418","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of acenocoumarol."
769,"Anisindione","DB01125","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione."
769,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as nalidixic acid. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
769,"Dicoumarol","DB00266","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of dicumarol."
769,"Warfarin","DB00682","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of warfarin."
770,"Almotriptan","DB00918","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated."
770,"Altretamine","DB00488","Risk of severe hypotension"
770,"Amitriptyline","DB00321","Possibility of severe adverse effects"
770,"Amoxapine","DB00543","Possibility of severe adverse effects"
770,"Amphetamine","DB00182","Possible hypertensive crisis"
770,"Atomoxetine","DB00289","Possible severe adverse reaction with this combination"
770,"Benzphetamine","DB00865","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
770,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like phenelzine. "
770,"Brimonidine","DB00484","MAO Inhibitors like phenelzine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
770,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like phenelzine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
770,"Bupropion","DB01156","Possible severe adverse reaction with this combination"
770,"Buspirone","DB00490","Possible blood pressure elevation"
770,"Citalopram","DB00215","Possible severe adverse reaction with this combination"
770,"Clomipramine","DB01242","Possibility of severe adverse effects"
770,"Desipramine","DB01151","Possibility of severe adverse effects"
770,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
770,"Dexfenfluramine","DB01191","Possible hypertensive crisis"
770,"Dextroamphetamine","DB01576","Possible hypertensive crisis"
770,"Dextromethorphan","DB00514","Possible severe adverse reaction"
770,"Diethylpropion","DB00937","Possible hypertensive crisis"
770,"Dobutamine","DB00841","Increased arterial pressure"
770,"Donepezil","DB00843","Possible antagonism of action"
770,"Dopamine","DB00988","Increased arterial pressure"
770,"Doxepin","DB01142","Possibility of severe adverse effects"
770,"Duloxetine","DB00476","Possible severe adverse reaction with this combination"
770,"Entacapone","DB00494","Possible hypertensive crisis with this combination"
770,"Ephedra","DB01363","Increased arterial pressure"
770,"Ephedrine","DB01364","Increased arterial pressure"
770,"Epinephrine","DB00668","Increased arterial pressure"
770,"Escitalopram","DB01175","Possible severe adverse reaction with this combination"
770,"Fenfluramine","DB00574","Possible hypertensive crisis"
770,"Fenoterol","DB01288","Increased arterial pressure"
770,"Fluoxetine","DB00472","Possible severe adverse reaction with this combination"
770,"Fluvoxamine","DB00176","Possible severe adverse reaction with this combination"
770,"Galantamine","DB00674","Possible antagonism of action"
770,"Guanethidine","DB01170","Phenelzine may decrease the effect of guanethidine."
770,"Imipramine","DB00458","Possibility of severe adverse effects"
770,"Isoprenaline","DB01064","Increased arterial pressure"
770,"L-DOPA","DB01235","Possible hypertensive crisis"
770,"Mazindol","DB00579","Possible hypertensive crisis"
770,"Mephentermine","DB01365","Increased arterial pressure"
770,"Metaraminol","DB00610","Increased arterial pressure"
770,"Methamphetamine","DB01577","Possible hypertensive crisis"
770,"Methotrimeprazine","DB01403","Possible severe adverse reaction with this combination"
770,"Methoxamine","DB00723","Increased arterial pressure"
770,"Methylphenidate","DB00422","Possible hypertensive crisis with this combination"
770,"Midodrine","DB00211","Possible hypertensive crisis with this combination"
770,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated. "
770,"Mirtazapine","DB00370","Possible severe adverse reaction with this combination"
770,"Naratriptan","DB00952","The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome."
770,"Nefazodone","DB01149","Possible severe adverse reaction with this combination"
770,"Norepinephrine","DB00368","Increased arterial pressure"
770,"Nortriptyline","DB00540","Possibility of severe adverse effects"
770,"Orciprenaline","DB00816","Increased arterial pressure"
770,"Paroxetine","DB00715","Possible severe adverse reaction with this combination"
770,"Pethidine","DB00454","Potentially fatal adverse effects"
770,"Phendimetrazine","DB01579","Possible hypertensive crisis"
770,"Phentermine","DB00191","Possible hypertensive crisis"
770,"Phenylephrine","DB00388","Increased arterial pressure"
770,"Phenylpropanolamine","DB00397","Increased arterial pressure"
770,"Pirbuterol","DB01291","Increased arterial pressure"
770,"Procaterol","DB01366","Increased arterial pressure"
770,"Protriptyline","DB00344","Possibility of severe adverse effects"
770,"Pseudoephedrine","DB00852","Increased arterial pressure"
770,"Rivastigmine","DB00989","Possible antagonism of action"
770,"Rizatriptan","DB00953","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
770,"Salbutamol","DB01001","Increased arterial pressure"
770,"Sertraline","DB01104","Possible severe adverse reaction with this combination"
770,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
770,"Sumatriptan","DB00669","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."
770,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenelzine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
770,"Terbutaline","DB00871","Increased arterial pressure"
770,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Phenelzine. Concomitant therapy is contraindicated."
770,"Tolcapone","DB00323","Tolcapone and Phenelzine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
770,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, phenelzine."
770,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
770,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
770,"Trimethobenzamide","DB00662","Trimethobenzamide and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
770,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
770,"Triprolidine","DB00427","Triprolidine and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
770,"Trospium","DB00209","Trospium and Phenelzine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
770,"Tryptophanyl-5'amp","DB01831","Possible severe adverse reaction with this combination"
770,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
770,"Vilazodone","DB06684","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome."
770,"Zolmitriptan","DB00315","The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated."
771,"Vecuronium","DB01339","Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. "
772,"Donepezil","DB00843","Possible antagonism of action"
772,"Galantamine","DB00674","Possible antagonism of action"
772,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
772,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Propantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
772,"Trimethobenzamide","DB00662","Trimethobenzamide and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
772,"Triprolidine","DB00427","Triprolidine and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
772,"Trospium","DB00209","Trospium and Propantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
773,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, estradiol."
773,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, estradiol."
773,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, estradiol."
773,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, estradiol."
773,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, estradiol."
773,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, estradiol."
773,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estradiol."
773,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estradiol."
773,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, estradiol."
773,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, estradiol."
773,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, estradiol."
773,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, estradiol."
773,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, estradiol."
773,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, estradiol."
773,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estradiol."
773,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estradiol."
773,"Prednisolone","DB00860","The estrogenic agent, estradiol, may increase the effect of the corticosteroid, prednisolone."
773,"Prednisone","DB00635","The estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone."
773,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, estradiol."
773,"Raloxifene","DB00481","Association not recommended"
773,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, estradiol."
773,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, estradiol."
773,"Tipranavir","DB00932","Estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estradiol. Use an alternate form of contraception or monitor for estrogen deficiency if Estradiol is used for hormone replacement therapy. "
773,"Ursodeoxycholic acid","DB01586","Estrogens decreases the effect of ursodiol"
774,"Acenocoumarol","DB01418","The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol."
774,"Alendronate","DB00630","Increased risk of gastric toxicity"
774,"Anisindione","DB01125","The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione."
774,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
774,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
774,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
774,"Dicoumarol","DB00266","The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol."
774,"Eltrombopag","DB06210","Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
774,"Lithium","DB01356","The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
774,"Methotrexate","DB00563","The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
774,"Tamoxifen","DB00675","Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed."
774,"Tolbutamide","DB01124","Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed. "
774,"Torasemide","DB00214","Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed. "
774,"Trandolapril","DB00519","The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.  "
774,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy. "
774,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed."
774,"Voriconazole","DB00582","Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed."
774,"Warfarin","DB00682","Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed."
777,"Aminophylline","DB01223","Acyclovir increases the effect and toxicity of theophylline"
777,"Dyphylline","DB00651","Acyclovir increases the effect and toxicity of dyphylline."
777,"Oxtriphylline","DB01303","Aciclovir may increase the effect and toxicity of oxtriphylline."
777,"Theophylline","DB00277","Acyclovir may increase the effect and toxicity of theophylline."
778,"Acenocoumarol","DB01418","The NSAID, naproxen, may increase the anticoagulant effect of acenocoumarol."
778,"Alendronate","DB00630","Increased risk of gastric toxicity"
778,"Anisindione","DB01125","The NSAID, naproxen, may increase the anticoagulant effect of anisindione."
778,"Apixaban","DB06605","Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy. "
778,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
778,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
778,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
778,"Dicoumarol","DB00266","The NSAID, naproxen, may increase the anticoagulant effect of dicumarol."
778,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
778,"Lithium","DB01356","The NSAID, naproxen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
778,"Methotrexate","DB00563","The NSAID, naproxen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
778,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
778,"Tapentadol","DB06204","Increases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required."
778,"Telmisartan","DB00966","Concomitant use of Telmisartan and Naproxen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
778,"Timolol","DB00373","The NSAID, Naproxen, may antagonize the antihypertensive effect of Timolol."
778,"Trandolapril","DB00519","The NSAID, Naproxen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Naproxen is initiated, discontinued or dose changed.  "
778,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Naproxen. Monitor for increased bleeding during concomitant thearpy. "
778,"Triflusal","DB08814","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of naproxen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
778,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of NSAIDs with vilazodone."
778,"Warfarin","DB00682","The antiplatelet effects of naproxen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
780,"Amiloride","DB00594","Increased risk of hyperkalemia"
780,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
780,"Drospirenone","DB01395","Increased risk of hyperkalemia"
780,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
780,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
780,"Potassium","DB01345","Increased risk of hyperkalemia"
780,"Spironolactone","DB00421","Increased risk of hyperkalemia"
780,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
780,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
780,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
780,"Triamterene","DB00384","Increased risk of hyperkalemia"
782,"Donepezil","DB00843","Possible antagonism of action"
782,"Galantamine","DB00674","Possible antagonism of action"
784,"Acenocoumarol","DB01418","The barbiturate, primidone, decreases the anticoagulant effect of acenocoumarol."
784,"Aminophylline","DB01223","The barbiturate, primidone, decreases the effect of aminophylline."
784,"Anisindione","DB01125","The barbiturate, primidone, decreases the anticoagulant effect of anisindione."
784,"Asenapine","DB06216","Primidone is a CYP1A2 inducer and may increase metabolism of asenapine. "
784,"Bendamustine","DB06769","CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. "
784,"Betamethasone","DB00443","The barbiturate, primidone, may decrease the effect of the corticosteroid, betamethasone."
784,"Chlorotrianisene","DB00269","The enzyme inducer, primidone, decreases the effect of the hormone agent, chlorotrianisene."
784,"Clomifene","DB00882","The enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene."
784,"Conjugated Estrogens","DB00286","The enzyme inducer, primidone, decreases the effect of the hormone agent, conjugated estrogens."
784,"Cortisone acetate","DB01380","The barbiturate, primidone, may decrease the effect of the corticosteroid, cortisone acetate."
784,"Cyclosporine","DB00091","The barbiturate, primidone, increases the effect of cyclosporine."
784,"Dexamethasone","DB01234","The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone."
784,"Dicoumarol","DB00266","The barbiturate, primidone, decreases the anticoagulant effect, dicumarol."
784,"Diethylstilbestrol","DB00255","The enzyme inducer, primidone, may decrease the effect of the hormone agent, diethylstilbestrol."
784,"Doxycycline","DB00254","The anticonvulsant, primidone, decreases the effect of doxycycline."
784,"Dyphylline","DB00651","The barbiturate, primidone, decreases the effect of dyphylline."
784,"Estradiol","DB00783","The enzyme inducer, primidone, decreases the effect of the hormone agent, estradiol."
784,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
784,"Estriol","DB04573","The enzyme inducer, primidone, decreases the effect of the hormone agent, estriol."
784,"Estrone","DB00655","The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone."
784,"Estropipate","DB04574","The enzyme inducer, primidone, decreases the effect of the hormone agent, estropipate."
784,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
784,"Etravirine","DB06414","Etravirine, when used concomitantly with Primidone (primarily metabolized to phenobarbital), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. \
"
784,"Felbamate","DB00949","Felbamate may increase the effect and toxicity of primidone."
784,"Felodipine","DB01023","The barbiturate, primidone, decreases the effect of felodipine."
784,"Fludrocortisone","DB00687","The barbiturate, primidone, may decrease the effect of the corticosteroid, fludrocortisone."
784,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, primidone."
784,"Gefitinib","DB00317","The CYP3A4 inducer, primidone, may decrease the serum concentration and therapeutic effects of gefitinib."
784,"Griseofulvin","DB00400","The barbiturate, primidone, decreases the effect of griseofulvin."
784,"Hydrocortisone","DB00741","The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone."
784,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
784,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, primidone, may decrease the effect of the hormone, medroxyprogesterone."
784,"Megestrol acetate","DB00351","The enzyme inducer, primidone, may decrease the effect of the hormone, megestrol."
784,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
784,"Methadone","DB00333","The barbiturate, primidone, decreases the effect of methadone."
784,"Methoxyflurane","DB01028","The barbiturate, primidone, increases the renal toxicity of methoxyflurane."
784,"Methylprednisolone","DB00959","The barbiturate, primidone, may decrease the effect of the corticosteroid, methylprednisolone."
784,"Metoprolol","DB00264","The barbiturate decreases the effect of metabolized beta-blocker"
784,"Metronidazole","DB00916","The barbiturate, primidone, decreases the effect of metronidazole."
784,"Nifedipine","DB01115","The barbiturate, primidone, decreases the effect of the calcium channel blocker, nifedipine."
784,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
784,"Oxtriphylline","DB01303","The barbiturate, primidone, decreases the effect of oxtriphylline."
784,"Paramethasone","DB01384","The barbiturate, primidone, may decrease the effect of the corticosteroid, paramethasone."
784,"Prednisolone","DB00860","The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone."
784,"Prednisone","DB00635","The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone."
784,"Propranolol","DB00571","The barbiturate decreases the effect of metabolized beta-blocker"
784,"Quinestrol","DB04575","The enzyme inducer, primidone, decreases the effect of the hormone agent, quinestrol."
784,"Quinidine","DB00908","The anticonvulsant, primidone, decreases the effect of quinidine."
784,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
784,"Rufinamide","DB06201","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
784,"Telithromycin","DB00976","Primidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
784,"Temsirolimus","DB06287","Primidone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
784,"Theophylline","DB00277","The barbiturate, primidone, decreases the effect of theophylline."
784,"Tramadol","DB00193","Primidone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
784,"Trazodone","DB00656","The CYP3A4 inducer, Primidone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Primidone is initiated, discontinued or dose changed."
784,"Tretinoin","DB00755","The strong CYP2C8 inducer, Primidone, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Primidone is initiated, discontinued or dose changed. "
784,"Triamcinolone","DB00620","The barbiturate, primidone, may decrease the effect of the corticosteroid, triamcinolone."
784,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Primidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
784,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
784,"Verapamil","DB00661","The barbiturate, primidone, decreases the effect of the calcium channel blocker, verapamil."
784,"Voriconazole","DB00582","The barbiturate, primidone, decreases the effect of voriconazole."
784,"Warfarin","DB00682","The barbiturate, primidone, decreases the anticoagulant effect of warfarin."
785,"Azathioprine","DB00993","Sulfasalazine may increase the toxicity of thiopurine, azathioprine."
785,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
785,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
785,"Cyclosporine","DB00091","The sulfonamide decreases the effect of cyclosporine"
785,"Digoxin","DB00390","Sulfasalazine may decrease the effect of digoxin."
785,"Mercaptopurine","DB01033","Sulfasalazine may increase the toxicity of thiopurine, mercaptopurine."
785,"Tioguanine","DB00352","Sulfasalazine may increase the toxicity of thiopurine, thioguanine."
786,"Amiloride","DB00594","Increased risk of hyperkalemia"
786,"Drospirenone","DB01395","Increased risk of hyperkalemia"
786,"Lithium","DB01356","The ARB increases serum levels of lithium"
786,"Potassium","DB01345","Increased risk of hyperkalemia"
786,"Spironolactone","DB00421","Increased risk of hyperkalemia"
786,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
786,"Trandolapril","DB00519","The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril. "
786,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
786,"Triamterene","DB00384","Increased risk of hyperkalemia"
787,"Cimetidine","DB00501","Anticipated loss of efficacy of tolazoline"
787,"Ranitidine","DB00863","Anticipated loss of efficacy of tolazoline"
787,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
788,"Atracurium","DB00732","The agent increases the effect of muscle relaxant"
788,"Bumetanide","DB00887","Increased ototoxicity"
788,"Cefamandole","DB01326","Increased risk of nephrotoxicity"
788,"Cefapirin","DB01139","Increased risk of nephrotoxicity"
788,"Cefazolin","DB01327","Increased risk of nephrotoxicity"
788,"Cefonicid","DB01328","Increased risk of nephrotoxicity"
788,"Cefoperazone","DB01329","Increased risk of nephrotoxicity"
788,"Ceforanide","DB00923","Increased risk of nephrotoxicity"
788,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
788,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
788,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
788,"Cefradine","DB01333","Increased risk of nephrotoxicity"
788,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
788,"Ceftizoxime","DB01332","Increased risk of nephrotoxicity"
788,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
788,"Cefuroxime","DB01112","Increased risk of nephrotoxicity"
788,"Cephalothin Group","DB03450","Increased risk of nephrotoxicity"
788,"Cisplatin","DB00515","Increased risk of nephrotoxicity"
788,"Colistimethate","DB01111","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
788,"Doxacurium chloride","DB01135","The agent increases the effect of muscle relaxant"
788,"Ethacrynic acid","DB00903","Increased ototoxicity"
788,"Furosemide","DB00695","Increased ototoxicity"
788,"Metocurine","DB01336","The agent increases the effect of muscle relaxant"
788,"Mivacurium","DB01226","The agent increases the effect of muscle relaxant"
788,"Pancuronium","DB01337","The agent increases the effect of muscle relaxant"
788,"Pipecuronium","DB01338","The agent increases the effect of muscle relaxant"
788,"Rocuronium","DB00728","The agent increases the effect of muscle relaxant"
788,"Succinylcholine","DB00202","The agent increases the effect of muscle relaxant"
788,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy. "
788,"Thalidomide","DB01041","Thalidomide increases the renal toxicity of the aminoglycoside"
788,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line."
788,"Torasemide","DB00214","Increased ototoxicity"
788,"Tubocurarine","DB01199","The agent increases the effect of muscle relaxant"
788,"Vecuronium","DB01339","The agent increases the effect of muscle relaxant"
791,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, halazepam."
791,"Clozapine","DB00363","Increased risk of toxicity"
791,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, halazepam."
791,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, halazepam."
791,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, halazepam."
791,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, halazepam."
791,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, halazepam."
791,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, halazepam."
792,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
792,"Cimetidine","DB00501","Increases the effect of the narcotic"
792,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of alfentanil."
792,"Fluconazole","DB00196","Increases the effect and toxicity of alfentanil"
792,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of alfentanil."
792,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of alfentanil."
792,"Rifampicin","DB01045","Rifampin reduces levels and efficacy of alfentanil"
792,"Telithromycin","DB00976","Telithromycin may reduce clearance of Alfentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Alfentanil if Telithromycin is initiated, discontinued or dose changed. "
792,"Tranylcypromine","DB00752","Possible increased risk of serotonin syndrome. "
792,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Alfentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. \
"
792,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfentanil by decreasing its metabolism. Monitor for increased anesthetic and respiratory depressant effects and consider using lower alfentanil doses or alternate anesthetic. "
794,"Donepezil","DB00843","Possible antagonism of action"
794,"Galantamine","DB00674","Possible antagonism of action"
794,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
794,"Rivastigmine","DB00989","Possible antagonism of action"
794,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dicyclomine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
794,"Trimethobenzamide","DB00662","Trimethobenzamide and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
794,"Triprolidine","DB00427","Triprolidine and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
794,"Trospium","DB00209","Trospium and Dicyclomine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
796,"Acenocoumarol","DB01418","Pentoxifylline may increase the anticoagulant effect of acenocoumarol."
796,"Aliskiren","DB09026","Monitor therapy due to enhanced antihypertensive effects of aliskiren."
796,"Aminophylline","DB01223","Pentoxifylline may increase the effect and toxicity of aminophylline."
796,"Anisindione","DB01125","Pentoxifylline may increase the anticoagulant effect of anisindione."
796,"Dicoumarol","DB00266","Pentoxifylline may increase the anticoagulant effect of dicumarol."
796,"Dyphylline","DB00651","Pentoxifylline increases the effect and toxicity of theophylline"
796,"Eptifibatide","DB00063","Monitor therapy due to enhanced antiplatelet effect."
796,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
796,"Oxtriphylline","DB01303","Pentoxifylline increases the effect and toxicity of theophylline"
796,"Theophylline","DB00277","Pentoxifylline increases the effect and toxicity of theophylline"
796,"Warfarin","DB00682","Pentoxifylline may increase the anticoagulant effect of warfarin."
798,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
798,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
798,"Diazoxide","DB01119","Significant hyperglycemic effect"
798,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
798,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
798,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
798,"Lithium","DB01356","The thiazide diuretic, indapamide, may increase serum levels of lithium."
798,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
798,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
798,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
798,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
798,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
798,"Trandolapril","DB00519","The thiazide diuretic, Indapamide, may increase the hypotensive effect of Trandolapril. Indapamide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
798,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
798,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
798,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
798,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
798,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
798,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
800,"Donepezil","DB00843","Possible antagonism of action"
800,"Galantamine","DB00674","Possible antagonism of action"
800,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
800,"Rivastigmine","DB00989","Possible antagonism of action"
800,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Biperidin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
800,"Trimethobenzamide","DB00662","Trimethobenzamide and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
800,"Triprolidine","DB00427","Triprolidine and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
800,"Trospium","DB00209","Trospium and Biperiden, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
801,"Abacavir","DB01048","Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy."
801,"Zalcitabine","DB00943","Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy."
801,"Zidovudine","DB00495","Increased risk or severity of anemia. Consider alternate therapy or monitor more closely for anemia. "
802,"Acenocoumarol","DB01418","The NSAID, phenylbutazone, may increase the anticoagulant effect of acenocoumarol."
802,"Acetohexamide","DB00414","Phenylbutazone may increase the effect of acetohexamide."
802,"Anisindione","DB01125","The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione."
802,"Chlorpropamide","DB00672","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Dicoumarol","DB00266","The NSAID, phenylbutazone, may increase the anticoagulant effect of dicumarol."
802,"Ethotoin","DB00754","The NSAID, phenylbutazone, may increase the hydantoin effect of ethotoin."
802,"Fosphenytoin","DB01320","The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin."
802,"Gliclazide","DB01120","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Glipizide","DB01067","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Glisoxepide","DB01289","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Glyburide","DB01016","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Glycodiazine","DB01382","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Lithium","DB01356","The NSAID, phenylbutazone, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
802,"Mephenytoin","DB00532","The NSAID, phenylbutazone, may increase the hydantoin effect of mephenytoin."
802,"Methotrexate","DB00563","The NSAID, phenylbutazone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
802,"Phenytoin","DB00252","The NSAID, phenylbutazone, may increase the therapeutic and adverse effects of phenytoin."
802,"Tolazamide","DB00839","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Tolbutamide","DB01124","Phenylbutazone increases the effect of the hypoglycemic agent"
802,"Warfarin","DB00682","The NSAID, phenylbutazone, may increase the anticoagulant effect of warfarin."
803,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
803,"Amiodarone","DB01118","Possible bradycardia, hypotension"
803,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may increase the effect and toxicity of fentanyl."
803,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification."
803,"Cimetidine","DB00501","Cimetidine, a moderate CYP3A4 inhibitor, may decrease the metabolism of fentanyl. Closely monitor changes in the therapeutic and adverse effects of fentanyl if cimetidine is initiated, discontinued or dose changed."
803,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. "
803,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. "
803,"Eltrombopag","DB06210","Increases levels of Fentanyl via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
803,"Fluconazole","DB00196","Fluconazole may increase levels/toxicity of fentanyl."
803,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl."
803,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect and toxicity of fentanyl."
803,"Itraconazole","DB01167","Itraconazole may increase levels/toxicity of fentanyl."
803,"Ketoconazole","DB01026","Ketoconazole may increase levels/toxicity of fentanyl."
803,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect and toxicity of fentanyl."
803,"Rifampicin","DB01045","Rifampin may decrease the serum level and therapeutic effect of fentanyl."
803,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of fentanyl/alfentanyl"
803,"Rotigotine","DB05271","Pharmacodynamic synergism may increase the effects of rotigotine. Monitor therapy closely. "
803,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl."
803,"Telithromycin","DB00976","Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed."
803,"Tranylcypromine","DB00752","Possible increased risk of serotonin syndrome. "
803,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Fentanyl, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
803,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed."
804,"Acenocoumarol","DB01418","Meloxicam may increase the anticoagulant effect of acenocoumarol."
804,"Anisindione","DB01125","Meloxicam may increase the anticoagulant effect of anisindione."
804,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
804,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
804,"Dicoumarol","DB00266","Meloxicam may increase the anticoagulant effect of dicumarol."
804,"Eltrombopag","DB06210","Increases levels of Meloxicam via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
804,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
804,"Lithium","DB01356","Meloxicam increases serum levels of lithium"
804,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
804,"Telmisartan","DB00966","Concomitant use of Telmisartan and Meloxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
804,"Timolol","DB00373","The NSAID, Meloxicam, may antagonize the antihypertensive effect of Timolol."
804,"Trandolapril","DB00519","The NSAID, Meloxicam, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meloxicam is initiated, discontinued or dose changed. "
804,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meloxicam. Monitor for increased bleeding during concomitant thearpy. "
804,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of meloxicam by decreasing its metabolism via CYP2C9 and CYP3A4. Monitor for changes in the therapeutic and adverse effects of meloxicam if voriconazole is initiated, discontinued or dose changed. "
804,"Warfarin","DB00682","The antiplatelet effects of meloxicam may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
806,"Acebutolol","DB01193","Antagonism"
806,"Alseroxylon","DB00386","Increased arterial pressure"
806,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of orciprenaline."
806,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of orciprenaline."
806,"Atenolol","DB00335","Antagonism"
806,"Betaxolol","DB00195","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like orciprenaline. Therapy should be monitored."
806,"Bevantolol","DB01295","Antagonism"
806,"Bisoprolol","DB00612","Antagonism"
806,"Carteolol","DB00521","Antagonism"
806,"Carvedilol","DB01136","Antagonism"
806,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of orciprenaline."
806,"Deserpidine","DB01089","Increased arterial pressure"
806,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of orciprenaline."
806,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline."
806,"Esmolol","DB00187","Antagonism"
806,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of orciprenaline."
806,"Isocarboxazid","DB01247","Increased arterial pressure"
806,"Labetalol","DB00598","Antagonism"
806,"Linezolid","DB00601","Possible increase of arterial pressure"
806,"Methyldopa","DB00968","Increased arterial pressure"
806,"Metoprolol","DB00264","Antagonism"
806,"Midodrine","DB00211","Increased arterial pressure"
806,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of orciprenaline."
806,"Nadolol","DB01203","Antagonism"
806,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of orciprenaline."
806,"Oxprenolol","DB01580","Antagonism"
806,"Pargyline","DB01626","Increased arterial pressure"
806,"Penbutolol","DB01359","Antagonism"
806,"Phenelzine","DB00780","Increased arterial pressure"
806,"Pindolol","DB00960","Antagonism"
806,"Practolol","DB01297","Antagonism"
806,"Propranolol","DB00571","Antagonism"
806,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of orciprenaline."
806,"Rasagiline","DB01367","Increased arterial pressure"
806,"Reserpine","DB00206","Increased arterial pressure"
806,"Sotalol","DB00489","Antagonism"
806,"Timolol","DB00373","Antagonism"
806,"Tranylcypromine","DB00752","Increased arterial pressure"
806,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of orciprenaline."
808,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Propofol, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Propofol is initiated, discontinued or if the dose is changed."
808,"Tizanidine","DB00697","Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
809,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide."
809,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide."
809,"Brinzolamide","DB01194","As both brinzolamide and acetazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
809,"Cyclosporine","DB00091","Acetazolamide may increase the effect and toxicity of cyclosporine."
809,"Memantine","DB01043","Possible increased levels of memantine"
809,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
809,"Topiramate","DB00273","Additive renal carbonic anhydrase inhibition may occur increasing the risk of crystaluria and renal calculi. Increased risk of nephrolithiasis. Consider altnerate therapy. "
809,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
809,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Acetazolamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
810,"Alfuzosin","DB00346","Tadalafil may enhance the hypotensive effect of Alfusozin. Monitor for hypotension during concomitant therapy.  "
810,"Amprenavir","DB00701","Amprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Atazanavir","DB01072","Atazanavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects."
810,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
810,"Clarithromycin","DB01211","Clarithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Conivaptan","DB00872","Conivaptan may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Darunavir","DB01264","Darunavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Delavirdine","DB00705","Delavirdine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Doxazosin","DB00590","Tadalafil may enhance the hypotensive effect of Doxazosin. Monitor for hypotension during concomitant therapy."
810,"Fosamprenavir","DB01319","Fosamprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Imatinib","DB00619","Imatinib may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Indinavir","DB00224","Indinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Isoniazid","DB00951","Isoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Isosorbide Dinitrate","DB00883","The vasodilatory effects of Isosorbide dinitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
810,"Isosorbide Mononitrate","DB01020","The vasodilatory effects of Isosobide mononitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
810,"Itraconazole","DB01167","Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Ketoconazole","DB01026","Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Lopinavir","DB01601","Lopinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Miconazole","DB01110","Miconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Nefazodone","DB01149","Nefazodone may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Nelfinavir","DB00220","Nelfinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Nicardipine","DB00622","Nicardipine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Nitroglycerin","DB00727","The vasodilatory effects of Nitroglycerin may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
810,"Pentaerythritol Tetranitrate","DB06154","Possible significant hypotension with this combination"
810,"Phenoxybenzamine","DB00925","Tadalafil may enhance the hypotensive effect of Phenoxybenzamine. Monitor for hypotension during concomitant therapy."
810,"Phentolamine","DB00692","Tadalafil may enhance the hypotensive effect of Phentolamine. Monitor for hypotension during concomitant therapy."
810,"Posaconazole","DB01263","Posaconzole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Prazosin","DB00457","Tadalafil may enhance the hypotensive effect of Prazosin. Monitor for hypotension during concomitant therapy."
810,"Quinidine","DB00908","Quinidine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Rifampicin","DB01045","Rifampin may reduce Tadalafil plasma concentrations and efficacy."
810,"Ritonavir","DB00503","Ritonavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Saquinavir","DB01232","Saquinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Tamsulosin","DB00706","Tadalafil may enhance the hypotensive effect of Tamsulosin. Monitor for hypotension during concomitant therapy."
810,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
810,"Telithromycin","DB00976","Telithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Terazosin","DB01162","Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy."
810,"Tipranavir","DB00932","Tipranavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
810,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tadalafil by decreasing its metabolism. Concomitant therapy should be avoided if possible due to high risk of tadalafil toxicity."
812,"Acenocoumarol","DB01418","Disulfiram may increase the anticoagulant effect of acenocoumarol."
812,"Aminophylline","DB01223","Disulfiram may increase the effect and toxicity of aminophylline."
812,"Amprenavir","DB00701","Increased irsk of side effects (oral solution)"
812,"Anisindione","DB01125","Disulfiram may increase the anticoagulant effect of anisindione."
812,"Chlorzoxazone","DB00356","Disulfiram may increase the serum level of chlorzoxazone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorzoxazone if diltiazem is initiated, discontinued or dose changed."
812,"Cocaine","DB00907","Increases the cardiac toxicity of cocaine"
812,"Dicoumarol","DB00266","Disulfiram may increase the anticoagulant effect of dicumarol."
812,"Dyphylline","DB00651","Increases the effect and toxicity of theophylline"
812,"Ethotoin","DB00754","Increases the effect of phenytoin"
812,"Fosphenytoin","DB01320","Disulfiram may increase the effect of fosphenytoin."
812,"Isoniazid","DB00951","Increased risk of CNS adverse effects"
812,"Mephenytoin","DB00532","Increases the effect of phenytoin"
812,"Metronidazole","DB00916","Possible acute psychosis and confusion"
812,"Oxtriphylline","DB01303","Disulfiram may increase the effect and toxicity of oxtriphylline."
812,"Phenytoin","DB00252","Disulfiram may increase the therapeutic and adverse effects of phenytoin."
812,"Theophylline","DB00277","Disulfiram may increase the effect and toxicity of theophylline."
812,"Tipranavir","DB00932","Disulfiram may cause Tipranavir (Aptivus brand) toxicity by inhibiting alcohol metabolism. Aptivus capsules contain alcohol.  "
812,"Trimethadione","DB00347","Disulfiram, a strong CYP2E1 inhibitor, may decrease the metabolism and clearance of Trimethadione, a CYP2E1 substrate. Consider alternate therapy or monitor for changes in Trimethadione therapeutic and adverse effects if Disulfiram is initiated, discontinued or dose changed. "
812,"Warfarin","DB00682","Disulfiram may increase the anticoagulant effect of warfarin."
813,"Artemether","DB06697","Artemether may decrease the effectiveness of ethynodiol diacetate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
813,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of ethynodiol diacetate it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
813,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
813,"Thiopental","DB00599","Thiopental may decrease the effect of Ethynodiol diacetate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
813,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Ethynodiol Diacetate. An alternate form of contraception should be used during concomitant therapy. "
813,"Warfarin","DB00682","Ethynodiol diacetate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethynodiol diacetate is initiated, discontinued or dose "
819,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, diazepam."
819,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, diazepam."
819,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, diazepam."
819,"Clozapine","DB00363","Increased risk of toxicity"
819,"Digoxin","DB00390","The benzodiazepine, diazepam, may increase the effect of digoxin."
819,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of the benzodiazepine, diazepam."
819,"Ethotoin","DB00754","Ethotoin may increase the metabolism of diazepam via CYP3A4."
819,"Etravirine","DB06414","Diazepam (a CYP21C9 and CYP3A4 substrate), when administered concomitantly with etravirine, may experience an increase (via CYP21C9 inhibition) or a decrease(via CYP3A4 induction) in serum concentration. Overall clinical significance is unknown. It is recommended to monitor diazepam therapy. "
819,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, diazepam."
819,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, diazepam."
819,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of diazepam via CYP3A4."
819,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, diazepam."
819,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, diazepam."
819,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam."
819,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, diazepam."
819,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, diazepam."
819,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of diazepam via CYP3A4."
819,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, diazepam."
819,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, diazepam."
819,"Phenytoin","DB00252","Phenytoin may increase the metabolism of diazepam via CYP3A4."
819,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
819,"Rifampicin","DB01045","Rifampin may decrease the effect of the benzodiazepine, diazepam."
819,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, diazepam."
819,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, diazepam."
819,"St. John's Wort","DB01323","St. John's Wort may decrease the effect of the benzodiazepine, diazepam."
819,"Telithromycin","DB00976","Telithromycin may reduce clearance of Diazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diazepam if Telithromycin is initiated, discontinued or dose changed."
819,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for adverse/toxic effects of Diazepam if Ticlopidine is initiated, discontinued or dose changed."
819,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for Diazepam toxic effects if Tipranavir is initiated or dose increased. "
819,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Diazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
819,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of diazepam by decreasing its metabolism. Monitor for diazepam toxicity if voriconazole is initiated or dose increased."
820,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
820,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
820,"Guanethidine","DB01170","Phenmetrazine may decrease the effect of guanethidine."
820,"Isocarboxazid","DB01247","Possible hypertensive crisis"
820,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
820,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
820,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
820,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase pyschotic symptoms"
820,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms"
820,"Propericiazine","DB01608","Decreased anorexic effect, may increase pyschotic symptoms"
820,"Rasagiline","DB01367","Possible hypertensive crisis"
820,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
820,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
821,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
821,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
821,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
821,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
821,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
821,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
821,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
821,"Donepezil","DB00843","Possible antagonism of action"
821,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
821,"Galantamine","DB00674","Possible antagonism of action"
821,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
821,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
821,"Guanethidine","DB01170","Trifluoperazine may decrease the effect of guanethidine."
821,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
821,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
821,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
821,"Metrizamide","DB01578","Increased risk of convulsions"
821,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
821,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
821,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
821,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
821,"Rivastigmine","DB00989","Possible antagonism of action"
821,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
821,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Trifluoperazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
821,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
821,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
821,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Trifluoperazine by decreasing Trifluoperazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Trifluoperazine if Thiabendazole is initiated, discontinued or dose changed."
821,"Trimethobenzamide","DB00662","Trimethobenzamide and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
821,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Trifluoperazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
821,"Trospium","DB00209","Trospium and Trifluoperazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
823,"Probenecid","DB01032","Probenecid may increase the serum level of cefaclor."
824,"Buserelin","DB06719","Buserelin moderately contributes to Q-Tc prolongation. Combination must be avoided because mifepristone can further enhance that effect. "
824,"Dabigatran etexilate","DB06695","May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated. "
824,"Degarelix","DB06699","Enhance QTc-prolonging effect "
824,"Etravirine","DB06414","Mifepristone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
824,"Oxytocin","DB00107","Consider therapy modification because of potential enhanced effect of Q-Tc prolongation"
824,"Pasireotide","DB06663","Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs."
824,"Tofacitinib","DB08895","Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy."
825,"Donepezil","DB00843","Possible antagonism of action"
825,"Galantamine","DB00674","Possible antagonism of action"
825,"Rivastigmine","DB00989","Possible antagonism of action"
825,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Brompheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
825,"Trimethobenzamide","DB00662","Trimethobenzamide and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
825,"Triprolidine","DB00427","Triprolidine and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
825,"Trospium","DB00209","Trospium and Brompheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
828,"Aldesleukin","DB00041","Corticosteroids such as clocortolone may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
828,"Telaprevir","DB05521","Corticosteroids such as clocortolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. "
829,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
829,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide."
829,"Amifostine","DB01143","Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Tolazamide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."
829,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
829,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
829,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
829,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, tolazamide."
829,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, tolazamide."
829,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
829,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
829,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
829,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
829,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
829,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
829,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
829,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
829,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, tolazamide."
829,"Rituximab","DB00073","Additive hypotensive effects may occur. Consider withholding Tolazamide for 12 hours prior to administration of Rituximab."
829,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of Tolazamide. Dose adjustments of Tolazamide may be required."
829,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
831,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dobutamine."
831,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dobutamine."
831,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine."
831,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine."
831,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine."
831,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, dobutamine."
831,"Guanethidine","DB01170","Dobutamine may decrease the effect of guanethidine."
831,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dobutamine."
831,"Isocarboxazid","DB01247","Increased arterial pressure"
831,"Linezolid","DB00601","Possible increase of arterial pressure"
831,"Methyldopa","DB00968","Increased arterial pressure"
831,"Midodrine","DB00211","Increased arterial pressure"
831,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of dobutamine."
831,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dobutamine."
831,"Phenelzine","DB00780","Increased arterial pressure"
831,"Rasagiline","DB01367","Increased arterial pressure"
831,"Reserpine","DB00206","Increased arterial pressure"
832,"Clozapine","DB00363","Increased risk of toxicity"
832,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, oxazepam."
832,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Oxazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
833,"Acepromazine","DB01614","Possible antagonism of action"
833,"Aceprometazine","DB01615","Possible antagonism of action"
833,"Alimemazine","DB01246","Possible antagonism of action"
833,"Alverine","DB01616","Possible antagonism of action"
833,"Amantadine","DB00915","Possible antagonism of action"
833,"Amitriptyline","DB00321","Possible antagonism of action"
833,"Amoxapine","DB00543","Possible antagonism of action"
833,"Atropine","DB00572","Possible antagonism of action"
833,"Azatadine","DB00719","Possible antagonism of action"
833,"Benzatropine","DB00245","Possible antagonism of action"
833,"Biperiden","DB00810","Possible antagonism of action"
833,"Brompheniramine","DB00835","Possible antagonism of action"
833,"Carbinoxamine","DB00748","Possible antagonism of action"
833,"Chlorphenamine","DB01114","Possible antagonism of action"
833,"Chlorpromazine","DB00477","Possible antagonism of action"
833,"Chlorprothixene","DB01239","Possible antagonism of action"
833,"Cimetidine","DB00501","Possible antagonism of action"
833,"Clemastine","DB00283","Possible antagonism of action"
833,"Clidinium","DB00771","Possible antagonism of action"
833,"Clomipramine","DB01242","Possible antagonism of action"
833,"Clozapine","DB00363","Possible antagonism of action"
833,"Cyclizine","DB01176","Possible antagonism of action"
833,"Cyclobenzaprine","DB00924","Possible antagonism of action"
833,"Cyproheptadine","DB00434","Possible antagonism of action"
833,"Darifenacin","DB00496","Possible antagonism of action"
833,"Desipramine","DB01151","Possible antagonism of action"
833,"Dexbrompheniramine","DB00405","Possible antagonism of action"
833,"Dicyclomine","DB00804","Possible antagonism of action"
833,"Dimenhydrinate","DB00985","Possible antagonism of action"
833,"Diphenhydramine","DB01075","Possible antagonism of action"
833,"Diphenoxylate","DB01081","Possible antagonism of action"
833,"Diphenylpyraline","DB01146","Possible antagonism of action"
833,"Disopyramide","DB00280","Possible antagonism of action"
833,"Doxepin","DB01142","Possible antagonism of action"
833,"Doxylamine","DB00366","Possible antagonism of action"
833,"Ethopropazine","DB00392","Possible antagonism of action"
833,"Flavoxate","DB01148","Possible antagonism of action"
833,"Flupentixol","DB00875","Possible antagonism of action"
833,"Glutethimide","DB01437","Possible antagonism of action"
833,"Glycopyrrolate","DB00986","Possible antagonism of action"
833,"Hydroxyzine","DB00557","Possible antagonism of action"
833,"Hyoscyamine","DB00424","Possible antagonism of action"
833,"Imipramine","DB00458","Possible antagonism of action"
833,"Isocarboxazid","DB01247","Possible antagonism of action"
833,"Isopropamide","DB01625","Possible antagonism of action"
833,"Loxapine","DB00408","Possible antagonism of action"
833,"Maprotiline","DB00934","Possible antagonism of action"
833,"Meclizine","DB00737","Possible antagonism of action"
833,"Mesoridazine","DB00933","Possible antagonism of action"
833,"Methdilazine","DB00902","Possible antagonism of action"
833,"Methotrimeprazine","DB01403","Possible antagonism of action"
833,"Methylscopolamine bromide","DB00462","Possible antagonism of action"
833,"Mirtazapine","DB00370","Possible antagonism of action"
833,"Moclobemide","DB01171","Possible antagonism of action"
833,"Molindone","DB01618","Possible antagonism of action"
833,"Nortriptyline","DB00540","Possible antagonism of action"
833,"Olanzapine","DB00334","Possible antagonism of action"
833,"Orphenadrine","DB01173","Possible antagonism of action"
833,"Oxybutynin","DB01062","Possible antagonism of action"
833,"Perphenazine","DB00850","Possible antagonism of action"
833,"Pethidine","DB00454","Possible antagonism of action"
833,"Phenelzine","DB00780","Possible antagonism of action"
833,"Phenindamine","DB01619","Possible antagonism of action"
833,"Pimozide","DB01100","Possible antagonism of action"
833,"Pipotiazine","DB01621","Possible antagonism of action"
833,"Procainamide","DB01035","Possible antagonism of action"
833,"Prochlorperazine","DB00433","Possible antagonism of action"
833,"Procyclidine","DB00387","Possible antagonism of action"
833,"Promazine","DB00420","Possible antagonism of action"
833,"Promethazine","DB01069","Possible antagonism of action"
833,"Propantheline","DB00782","Possible antagonism of action"
833,"Propericiazine","DB01608","Possible antagonism of action"
833,"Protriptyline","DB00344","Possible antagonism of action"
833,"Quetiapine","DB01224","Possible antagonism of action"
833,"Quinidine","DB00908","Possible antagonism of action"
833,"Quinidine barbiturate","DB01346","Possible antagonism of action"
833,"Risperidone","DB00734","Possible antagonism of action"
833,"Scopolamine","DB00747","Possible antagonism of action"
833,"Sertraline","DB01104","Possible antagonism of action"
833,"Solifenacin","DB01591","Possible antagonism of action"
833,"Thioproperazine","DB01622","Possible antagonism of action"
833,"Thioridazine","DB00679","Possible antagonism of action"
833,"Thiothixene","DB01623","Possible antagonism of action"
833,"Tizanidine","DB00697","Possible antagonism of action"
833,"Tolterodine","DB01036","Possible antagonism of action"
833,"Tranylcypromine","DB00752","Possible antagonism of action"
833,"Trazodone","DB00656","Possible antagonism of action"
833,"Trifluoperazine","DB00831","Possible antagonism of action"
833,"Triflupromazine","DB00508","Possible antagonism of action"
833,"Trihexyphenidyl","DB00376","Possible antagonism of action"
833,"Trimethobenzamide","DB00662","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
833,"Trimipramine","DB00726","Possible antagonism of action"
833,"Tripelennamine","DB00792","Possible antagonism of action"
833,"Triprolidine","DB00427","Possible antagonism of action"
833,"Trospium","DB00209","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Donepezil, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
833,"Ziprasidone","DB00246","Possible antagonism of action"
833,"Zuclopenthixol","DB01624","Possible antagonism of action"
834,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
834,"Cimetidine","DB00501","Increases the effect of the narcotic"
834,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Nalbuphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
838,"Acenocoumarol","DB01418","Levamisole may increase the anticoagulant effect of acenocoumarol."
838,"Anisindione","DB01125","Levamisole may increase the anticoagulant effect of anisindione."
838,"Dicoumarol","DB00266","Levamisole may increase the anticoagulant effect of dicumarol."
838,"Warfarin","DB00682","Levamisole may increase the anticoagulant effect of warfarin."
839,"Aminophylline","DB01223","The barbiturate, methylphenobarbital, decreases the effect of aminophylline."
839,"Betamethasone","DB00443","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, betamethasone."
839,"Clomifene","DB00882","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, clomifene."
839,"Conjugated Estrogens","DB00286","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, conjugated estrogens."
839,"Cyclosporine","DB00091","The barbiturate, methylphenobarbital, increases the effect of cyclosporine."
839,"Delavirdine","DB00705","The anticonvulsant, methylphenobarbital, decreases the effect of delavirdine."
839,"Dexamethasone","DB01234","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, dexamethasone."
839,"Diethylstilbestrol","DB00255","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
839,"Doxycycline","DB00254","The anticonvulsant, methylphenobarbital, decreases the effect of doxycycline."
839,"Estradiol","DB00783","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, estradiol."
839,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
839,"Felodipine","DB01023","The barbiturate, methylphenobarbital, decreases the effect of felodipine."
839,"Fludrocortisone","DB00687","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
839,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, methylphenobarbital."
839,"Gefitinib","DB00317","The CYP3A4 inducer, methylphenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
839,"Griseofulvin","DB00400","The barbiturate, methylphenobarbital, decreases the effect of griseofulvin."
839,"Hydrocortisone","DB00741","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
839,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
839,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
839,"Megestrol acetate","DB00351","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, megestrol."
839,"Methadone","DB00333","The barbiturate, methylphenobarbital, decreases the effect of methadone."
839,"Metronidazole","DB00916","The barbiturate, methylphenobarbital, decreases the effect of metronidazole."
839,"Nifedipine","DB01115","The barbiturate, methylphenobarbital, decreases the effect of the calcium channel blocker, nifedipine."
839,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
839,"Oxtriphylline","DB01303","The barbiturate, methylphenobarbital, decreases the effect of oxtriphylline."
839,"Prednisolone","DB00860","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisolone."
839,"Prednisone","DB00635","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone."
839,"Quinidine","DB00908","The anticonvulsant, methylphenobarbital, decreases the effect of quinidine."
839,"Theophylline","DB00277","The barbiturate, methylphenobarbital, decreases the effect of theophylline."
839,"Triamcinolone","DB00620","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, triamcinolone."
839,"Verapamil","DB00661","Methylphenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Methylphenobarbital is initiated, discontinued or dose changed. "
840,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
840,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
840,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
840,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
840,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
840,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
840,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
840,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
840,"Donepezil","DB00843","Possible antagonism of action"
840,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
840,"Galantamine","DB00674","Possible antagonism of action"
840,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
840,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
840,"Guanethidine","DB01170","Perphenazine may decrease the effect of guanethidine."
840,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
840,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
840,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
840,"Metrizamide","DB01578","Increased risk of convulsions"
840,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
840,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
840,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
840,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
840,"Rivastigmine","DB00989","Possible antagonism of action"
840,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
840,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Perphenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
840,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Perphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Perphenazine if Terbinafine is initiated, discontinued or dose changed."
840,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
840,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
840,"Trimethobenzamide","DB00662","Trimethobenzamide and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
840,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Perphenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
840,"Trospium","DB00209","Trospium and Perphenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
841,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
841,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Dacarbazine by decreasing Dacarbazine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Dacarbazine if Thiabendazole is initiated, discontinued or dose changed."
841,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
842,"Alseroxylon","DB00386","Increased arterial pressure"
842,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pseudoephedrine."
842,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pseudoephedrine."
842,"Bromocriptine","DB01200","The sympathomimetic, pseudoephedrine, increases the toxicity of bromocriptine."
842,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pseudoephedrine."
842,"Deserpidine","DB01089","Increased arterial pressure"
842,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pseudoephedrine."
842,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
842,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pseudoephedrine."
842,"Guanethidine","DB01170","Pseudoephedrine may decrease the effect of guanethidine."
842,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pseudoephedrine."
842,"Iobenguane","DB06704","Sympathomimetic that increase chances of producing a false negative imaging result "
842,"Isocarboxazid","DB01247","Increased arterial pressure"
842,"Linezolid","DB00601","Possible increase of arterial pressure"
842,"Methyldopa","DB00968","Increased arterial pressure"
842,"Midodrine","DB00211","Increased arterial pressure"
842,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of pseudoephedrine."
842,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pseudoephedrine."
842,"Pargyline","DB01626","Increased arterial pressure"
842,"Phenelzine","DB00780","Increased arterial pressure"
842,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of pseudoephedrine."
842,"Rasagiline","DB01367","Increased arterial pressure"
842,"Reserpine","DB00206","Increased arterial pressure"
842,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Pseudoephedrine. Concomitant therapy should be avoided."
842,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of pseudoephedrine."
842,"Venlafaxine","DB00285","Venlafaxine may increase the tachycardic and vasopressor effects of Pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache. "
843,"Natalizumab","DB00108","The immunosuppressant, Temozolomide, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided. "
843,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
844,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
844,"Eltrombopag","DB06210","Increases levels of Levorphanol via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
844,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Levorphanol, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
846,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Chlorphenesin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
847,"Aminophylline","DB01223","Terbinafine increases the effect and toxicity of theophylline"
847,"Amitriptyline","DB00321","Terbinafine may reduce the metabolism and clearance of Amitryptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Terbinafine is initiated, discontinued or dose changed. "
847,"Amoxapine","DB00543","Terbinafine may reduce the metabolism and clearance of Amoxapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Amoxapine if Terbinafine is initiated, discontinued or dose changed."
847,"Aripiprazole","DB01238","Terbinafine may reduce the metabolism and clearance of Aripiprazole. Consider alternate therapy or monitor for therapeutic/adverse effects of Aripiprazole if Terbinafine is initiated, discontinued or dose changed."
847,"Atomoxetine","DB00289","Terbinafine, a CYP2D6 inhibitor, may reduce the metabolism and clearance of Atomoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Atomoxetine if Terbinafine is initiated, discontinued or dose changed."
847,"Caffeine","DB00201","Terbinafine may increase the plasma concentration of Caffeine."
847,"Captopril","DB01197","Terbinafine may reduce the metabolism and clearance of Captopril. Consider alternate therapy or monitor for therapeutic/adverse effects of Captopril if Terbinafine is initiated, discontinued or dose changed."
847,"Carvedilol","DB01136","Terbinafine may reduce the metabolism and clearance of Carvedilol. Consider alternate therapy or monitor for therapeutic/adverse effects of Carvedilol if Terbinafine is initiated, discontinued or dose changed."
847,"Chloroquine","DB00608","Terbinafine may reduce the metabolism and clearance of Chloroquine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chloroquine if Terbinafine is initiated, discontinued or dose changed."
847,"Chlorpromazine","DB00477","Terbinafine may reduce the metabolism and clearance of Chlorpromazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Chlorpromazine if Terbinafine is initiated, discontinued or dose changed."
847,"Clomipramine","DB01242","Terbinafine may reduce the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for therapeutic/adverse effects of Clomipramine if Terbinafine is initiated, discontinued or dose changed."
847,"Codeine","DB00318","Terbinafine may decrease the efficacy of Codeine by inhibiting active metabolite production. Consider an alternate analgesic or monitor for effectiveness of Codeine. "
847,"Cyclosporine","DB00091","Terbinafine may decrease the plasma concentration and therapeutic effect of cyclosporine."
847,"Desipramine","DB01151","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of desipramine if terbinafine is initiated, discontinued or dose changed."
847,"Dextromethorphan","DB00514","Terbinafine may reduce the metabolism and clearance of Dextromethorphan. Consider alternate therapy or monitor for therapeutic/adverse effects of Dextromethorphan if Terbinafine is initiated, discontinued or dose changed."
847,"Doxepin","DB01142","Terbinafine may reduce the metabolism and clearance of Doxepin. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Doxepin is initiated, discontinued or dose changed."
847,"Doxorubicin","DB00997","Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed."
847,"doxorubicin TransDrug","DB05331","Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed."
847,"Duloxetine","DB00476","Terbinafine may reduce the metabolism and clearance of Duloxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Duloxetine if Terbinafine is initiated, discontinued or dose changed."
847,"Dyphylline","DB00651","Terbinafine increases the effect and toxicity of theophylline"
847,"Flecainide","DB01195","Terbinafine may reduce the metabolism and clearance of Flecainide. Consider alternate therapy or monitor for therapeutic/adverse effects of Flecainide if Terbinafine is initiated, discontinued or dose changed."
847,"Fluoxetine","DB00472","Terbinafine may reduce the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluoxetine if Terbinafine is initiated, discontinued or dose changed."
847,"Fluphenazine","DB00623","Terbinafine may reduce the metabolism and clearance of Fluphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluphenazine if Terbinafine is initiated, discontinued or dose changed."
847,"Fluvoxamine","DB00176","Terbinafine may reduce the metabolism and clearance of Fluvoxamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Fluvoxamine if Terbinafine is initiated, discontinued or dose changed."
847,"Haloperidol","DB00502","Terbinafine may reduce the metabolism and clearance of Haloperidol. Consider alternate therapy or monitor for therapeutic/adverse effects of Haloperidol if Terbinafine is initiated, discontinued or dose changed."
847,"Imipramine","DB00458","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if terbinafine is initiated, discontinued or dose changed."
847,"Lidocaine","DB00281","Terbinafine may reduce the metabolism and clearance of Lidocaine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lidocaine if Terbinafine is initiated, discontinued or dose changed."
847,"Lomustine","DB01206","Terbinafine may reduce the metabolism and clearance of Lomustine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lomustine if Terbinafine is initiated, discontinued or dose changed."
847,"Maprotiline","DB00934","Terbinafine may reduce the metabolism and clearance of Maprotiline. Consider alternate therapy or monitor for therapeutic/adverse effects of Maprotiline if Terbinafine is initiated, discontinued or dose changed."
847,"Methamphetamine","DB01577","Terbinafine may reduce the metabolism and clearance of Methamphetamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Methamphetamine if Terbinafine is initiated, discontinued or dose changed."
847,"Metoprolol","DB00264","Terbinafine may reduce the metabolism and clearance of Metoprolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Metoprolol if Terbinafine is initiated, discontinued or dose changed."
847,"Mexiletine","DB00379","Terbinafine may reduce the metabolism and clearance of Mexiletine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mexiletine if Terbinafine is initiated, discontinued or dose changed."
847,"Mirtazapine","DB00370","Terbinafine may reduce the metabolism and clearance of Mirtazapine. Consider alternate therapy or monitor for therapeutic/adverse effects of Mirtazapine if Terbinafine is initiated, discontinued or dose changed."
847,"Moclobemide","DB01171","Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed."
847,"Nefazodone","DB01149","Terbinafine may reduce the metabolism and clearance of Nefazodone. Consider alternate therapy or monitor for therapeutic/adverse effects of Nefazodone if Terbinafine is initiated, discontinued or dose changed."
847,"Nortriptyline","DB00540","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if terbinafine is initiated, discontinued or dose changed."
847,"Oxtriphylline","DB01303","Terbinafine increases the effect and toxicity of theophylline"
847,"Paroxetine","DB00715","Terbinafine may reduce the metabolism and clearance of Paroxetine. Consider alternate therapy or monitor for therapeutic/adverse effects of Paroxetine if Terbinafine is initiated, discontinued or dose changed."
847,"Perphenazine","DB00850","Terbinafine may reduce the metabolism and clearance of Perphenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Perphenazine if Terbinafine is initiated, discontinued or dose changed."
847,"Pipotiazine","DB01621","Terbinafine may reduce the metabolism and clearance of Pipotiazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Pipotiazine if Terbinafine is initiated, discontinued or dose changed."
847,"Procainamide","DB01035","Terbinafine may reduce the metabolism and clearance of Procainamide. Consider alternate therapy or monitor for therapeutic/adverse effects of Procainamide if Terbinafine is initiated, discontinued or dose changed."
847,"Promethazine","DB01069","Terbinafine may reduce the metabolism and clearance of Promethazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Promethazine if Terbinafine is initiated, discontinued or dose changed."
847,"Propafenone","DB01182","Terbinafine may reduce the metabolism and clearance of Propafenone. Consider alternate therapy or monitor for therapeutic/adverse effects of Propafenone if Terbinafine is initiated, discontinued or dose changed."
847,"Propranolol","DB00571","Terbinafine may reduce the metabolism and clearance of Propranolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Propranolol if Terbinafine is initiated, discontinued or dose changed."
847,"Protriptyline","DB00344","Terbinafine may reduce the metabolism and clearance of Protriptyline. Consider alternate therapy or monitor for therapeutic/adverse effects of Protriptyline if Terbinafine is initiated, discontinued or dose changed."
847,"Rifabutin","DB00615","Rifabutin may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided."
847,"Rifampicin","DB01045","Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure."
847,"Rifapentine","DB01201","Rifapentine may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided."
847,"Risperidone","DB00734","Terbinafine may reduce the metabolism and clearance of Risperidone. Consider alternate therapy or monitor for therapeutic/adverse effects of Risperidone if Terbinafine is initiated, discontinued or dose changed."
847,"Sertraline","DB01104","Terbinafine may reduce the metabolism and clearance of Sertraline. Consider alternate therapy or monitor for therapeutic/adverse effects of Sertraline if Terbinafine is initiated, discontinued or dose changed."
847,"Tamoxifen","DB00675","Terbinafine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
847,"Tamsulosin","DB00706","Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Terbinafine is initiated, discontinued, or dose changed."
847,"Tetrabenazine","DB04844","Terbinafine may reduce the metabolism and clearance of Tetrabenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tetrabenazine if Terbinafine is initiated, discontinued or dose changed."
847,"Theophylline","DB00277","Terbinafine increases the effect and toxicity of theophylline"
847,"Thioridazine","DB00679","Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated."
847,"Timolol","DB00373","Terbinafine may reduce the metabolism and clearance of Timolol. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Timolol is initiated, discontinued or dose changed."
847,"Tolterodine","DB01036","Terbinafine may reduce the metabolism and clearance of Tolterodine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tolterodine if Terbinafine is initiated, discontinued or dose changed."
847,"Tramadol","DB00193","Terbinafine may decrease the effect of Tramadol by decreasing active metabolite production. "
847,"Trimipramine","DB00726","Terbinafine may decrease the metabolism and clearance of Trimipramine. Consider alternate therapy or monitor for changes in Trimipramine efficacy and toxicity if Terbinafine is initiated, discontinued or dose changed. Alteration in Trimipramine dose may be required."
847,"Venlafaxine","DB00285","Terbinafine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Terbinafine is initiated, discontinued, or dose changed."
847,"Zuclopenthixol","DB01624","Terbinafine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if terbinafine is initiated, discontinued or dose changed."
849,"Digoxin","DB00390","Penicillamine decreases the effect of digoxin"
849,"Iron Dextran","DB00893","The multivalent agent decreases the effect of penicillamine"
850,"Acenocoumarol","DB01418","The corticosteroid, prednisolone, alters the anticoagulant effect, acenocoumarol."
850,"Acetylsalicylic acid","DB00945","The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid."
850,"Ambenonium","DB01122","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, ambenonium."
850,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Anisindione","DB01125","The corticosteroid, prednisolone, alters the anticoagulant effect of anisindione."
850,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Bismuth Subsalicylate","DB01294","The corticosteroid, prednisolone, may decrease the effect of the salicylate, bismuth subsalicylate."
850,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisolone."
850,"Chlorotrianisene","DB00269","The estrogenic agent, chlorotrianisene, may increase the effect of the corticosteroid, prednisolone."
850,"Clomifene","DB00882","The estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone."
850,"Conjugated Estrogens","DB00286","The estrogenic agent may increase the effect of the corticosteroid, prednisolone."
850,"Dicoumarol","DB00266","The corticosteroid, prednisolone, alters the anticoagulant effect of dicumarol."
850,"Diethylstilbestrol","DB00255","The estrogenic agent, diethylstilbestrol, may increase the effect of the corticosteroid, prednisolone."
850,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone."
850,"Edrophonium","DB01010","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium."
850,"Estradiol","DB00783","The estrogenic agent, estradiol, may increase the effect of the corticosteroid, prednisolone."
850,"Estriol","DB04573","The estrogenic agent, estriol, may increase the effect of the corticosteroid, prednisolone."
850,"Estrone","DB00655","The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone."
850,"Estropipate","DB04574","The estrogenic agent, estropipate, may increase the effect of the corticosteroid, prednisolone."
850,"Ethinyl Estradiol","DB00977","The estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone."
850,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisolone."
850,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone."
850,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Itraconazole","DB01167","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone."
850,"Ketoconazole","DB01026","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone."
850,"Magnesium salicylate","DB01397","The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate."
850,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisolone."
850,"Mestranol","DB01357","The estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone."
850,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisolone."
850,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Midodrine","DB00211","Increased arterial pressure"
850,"Neostigmine","DB01400","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine."
850,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisolone."
850,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, prednisolone."
850,"Pyridostigmine","DB00545","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, pyridostigmine."
850,"Quinestrol","DB04575","The estrogenic agent, quinestrol, may increase the effect of the corticosteroid, prednisolone."
850,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone."
850,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone."
850,"Salicylate-sodium","DB01398","The corticosteroid, prednisolone, may decrease the effect of the salicylate, salicylate-sodium."
850,"Salsalate","DB01399","The corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate."
850,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisolone."
850,"Tacrine","DB00382","Tacrine and Prednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
850,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisolone."
850,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
850,"Trisalicylate-choline","DB01401","The corticosteroid, prednisolone, may decrease the effect of the salicylate, trisalicylate-choline."
850,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
850,"Warfarin","DB00682","The corticosteroid, prednisolone, alters the anticoagulant effect of warfarin."
851,"Acenocoumarol","DB01418","The NSAID, diflunisal, may increase the anticoagulant effect of acenocoumarol."
851,"Alendronate","DB00630","Increased risk of gastric toxicity"
851,"Anisindione","DB01125","The NSAID, diflunisal, may increase the anticoagulant effect of anisindione."
851,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
851,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
851,"Dicoumarol","DB00266","The NSAID, diflunisal, may increase the anticoagulant effect of dicumarol."
851,"Eltrombopag","DB06210","Eltrombopag increases levels of Diflunisal via metabolism decrease. "
851,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
851,"Indomethacin","DB00328","Concomitant therapy with the two NSAIDs, indomethacin and diflunisal, increases the risk of NSAID-related adverse effects (e.g. GI ulcers, bleeds, increased blood pressure)."
851,"Lithium","DB01356","The NSAID, diflunisal, may decrease the renal excretion of lithium. Increased risk of lithium toxicity. "
851,"Methotrexate","DB00563","The NSAID, diflunisal, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. "
851,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
851,"Probenecid","DB01032","Probenecid increases toxicity of diflunisal"
851,"Telmisartan","DB00966","Concomitant use of Telmisartan and Diflunisal may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
851,"Timolol","DB00373","The NSAID, Diflunisal, may antagonize the antihypertensive effect of Timolol."
851,"Trandolapril","DB00519","The NSAID, Diflunisal, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Diflunisal is initiated, discontinued or dose changed.  "
851,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Diflunisal. Monitor for increased bleeding during concomitant thearpy. "
851,"Warfarin","DB00682","The antiplatelet effects of diflunisal may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
852,"Alfuzosin","DB00346","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Alfuzosin, may occur. Monitor for hypotension during concomitant therapy."
852,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
852,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Doxazosin","DB00590","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Doxazosin, may occur. Monitor for hypotension during concomitant therapy."
852,"Erythromycin","DB00199","Erythromycin, a moderate CYP3A4 inhibitor, may reduce the metabolism and clearance of vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of vardenafil if erythromycin is initiated, discontinued or dose changed."
852,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Indinavir","DB00224","Indinavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
852,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Isosorbide Dinitrate","DB00883","The vasodilatory effects of Isosorbide dinitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
852,"Isosorbide Mononitrate","DB01020","The vasodilatory effects of Isosorbide mononitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
852,"Itraconazole","DB01167","Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
852,"Ketoconazole","DB01026","Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
852,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Miconazole","DB01110","Miconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Nitroglycerin","DB00727","The vasodilatory effects of Nitroglycerin may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
852,"Pentaerythritol Tetranitrate","DB06154","Possible significant hypotension with this combination"
852,"Phenoxybenzamine","DB00925","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phenoxybenzamine, may occur. Monitor for hypotension during concomitant therapy. "
852,"Phentolamine","DB00692","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phentolamine, may occur. Monitor for hypotension during concomitant therapy. "
852,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Prazosin","DB00457","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Prazosin, may occur. Monitor for hypotension during concomitant therapy. "
852,"Procainamide","DB01035","Increased risk of cardiotoxicity and arrhythmias"
852,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Ritonavir","DB00503","Ritonavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
852,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Silodosin","DB06207","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Silodosin, may occur. Monitor for hypotension during concomitant therapy. "
852,"Tamsulosin","DB00706","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Tamsulosin, may occur. Monitor for hypotension during concomitant therapy. "
852,"Telithromycin","DB00976","Telithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
852,"Terazosin","DB01162","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy."
852,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Vardenafil. Concomitant therapy is contraindicated."
852,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of vardenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of vardenafil if voriconazole is initiated, discontinued or dose changed."
853,"Acenocoumarol","DB01418","Ranitidine may increase the anticoagulant effect of acenocoumarol. (Conflicting evidence)"
853,"Anisindione","DB01125","Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)"
853,"Atazanavir","DB01072","Ranitidine may decrease the levels/effects of atazanavir."
853,"Cefditoren","DB01066","H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
853,"Dabrafenib","DB08912","H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability. "
853,"Dasatinib","DB01254","Ranitidine may decrease the serum level of dasatinib."
853,"Dicoumarol","DB00266","Ranitidine may increase the anticoagulant effect of dicumarol. (Conflicting evidence)"
853,"Itraconazole","DB01167","The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole."
853,"Ketoconazole","DB01026","The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole."
853,"Procainamide","DB01035","The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide."
853,"Rilpivirine","DB08864","Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
853,"Tolazoline","DB00797","Anticipated loss of efficacy of tolazoline"
853,"Vismodegib","DB08828","Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine."
853,"Warfarin","DB00682","Ranitidine may increase the anticoagulant effect of warfarin. (Conflicting evidence)"
854,"Abarelix","DB00106","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Abatacept","DB01281","Avoid combination due to enhanced toxic effects of immunosuppressants."
854,"ado-trastuzumab emtansine","DB05773","Avoid combination due to the increase in immunosuppressant side effects."
854,"Amikacin","DB00479","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Amikacin. Use caution during concomitant therapy. "
854,"Amiodarone","DB01118","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Amitriptyline","DB00321","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Amoxapine","DB00543","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Amphotericin B","DB00681","Additive renal impairment may occur during concomitant therapy with Amphotericin B. Use caution during concomitant therapy. "
854,"Amprenavir","DB00701","The protease inhibitor, Amprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Amprenavir therapy is initiated, discontinued or altered."
854,"Antithymocyte globulin","DB00098","Avoid combination due to increased immunosuppressive effects"
854,"Apomorphine","DB00714","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Apramycin","DB04626","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Apramycin. Use caution during concomitant therapy. "
854,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
854,"Atazanavir","DB01072","The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered."
854,"Belatacept","DB06681","Avoid combination due to enhanced immunosuppressive effect."
854,"Belimumab","DB08879","Avoid combination due to enhanced adverse effects of immunosuppressants."
854,"Bleomycin","DB00290","Tacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
854,"Boceprevir","DB08873","Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. "
854,"Brentuximab vedotin","DB08870","Avoid combination due to the potential enhancement of toxic effects of immunosuppressants."
854,"Bromocriptine","DB01200","Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered."
854,"Carbamazepine","DB00564","Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered."
854,"Carboplatin","DB00958","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
854,"Carmustine","DB00262","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carmustine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.\
"
854,"Caspofungin","DB00520","Caspofungin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Caspofungin therapy is initiated, discontinued or altered."
854,"Chlorambucil","DB00291","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants sucb as chlorambucil. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
854,"Chloramphenicol","DB00446","Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered."
854,"Chlorpromazine","DB00477","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Cimetidine","DB00501","Cimetidine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Cimetidine therapy is initiated, discontinued or altered."
854,"Cisapride","DB00604","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Cisapride may also increase the concentration of Tacrolimus in the blood. "
854,"Cisplatin","DB00515","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Cisplatin. Use caution during concomitant therapy. "
854,"Cladribine","DB00242","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as tacrolimus. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
854,"Clarithromycin","DB01211","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, Clarithromycin, may also increase the blood concentration of Tacrolimus."
854,"Clofarabine","DB00631","Tacrolimus (topical) may enhance the adverse/toxic effect of immunosuppressants such as clofarabine. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
854,"Clomipramine","DB01242","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Clotrimazole","DB00257","The antifungal, Clotrimazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Clotrimazole therapy is initiated, discontinued or altered. "
854,"Conivaptan","DB00872","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Conivaptan is initiated, discontinued or dose changed."
854,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
854,"Cyclosporine","DB00091","Additive renal impairment may occur during concomitant therapy with cyclosporine. Combination therapy should be avoided."
854,"Danazol","DB01406","Danazol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Danazol therapy is initiated, discontinued or altered."
854,"Darunavir","DB01264","The protease inhibitor, Darunavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Darunavir therapy is initiated, discontinued or altered."
854,"Dasatinib","DB01254","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Delavirdine","DB00705","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Delavirdine is initiated, discontinued or dose changed."
854,"Desipramine","DB01151","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of tacrolimus by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tacrolimus if diltiazem therapy is initiated, discontinued or dose changed."
854,"Disopyramide","DB00280","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Dofetilide","DB00204","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Dolasetron","DB00757","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Domperidone","DB01184","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Doxepin","DB01142","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Dronedarone","DB04855","Tacrolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of tacrolimus. Monitor plasma concentrations and adjust dose accordingly. "
854,"Droperidol","DB00450","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Erythromycin","DB00199","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, erythromycin, may also increase the blood concentration of tacrolimus."
854,"Etanercept","DB00005","Avoid combination due to enhanced immunosuppressive effects"
854,"Ethinyl Estradiol","DB00977","Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered."
854,"Felodipine","DB01023","Felodipine increases tacrolimus levels"
854,"Flecainide","DB01195","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Fluconazole","DB00196","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The antifungal, fluconazole, may also increase serum concentrations of tacrolimus."
854,"Fluoxetine","DB00472","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Flupentixol","DB00875","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Fosamprenavir","DB01319","The protease inhibitor, Fosamprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Fosamprenavir therapy is initiated, discontinued or altered."
854,"Foscarnet","DB00529","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Fosphenytoin","DB01320","The hydantoin decreases the effect of tacrolimus"
854,"Gatifloxacin","DB01044","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Gemtuzumab ozogamicin","DB00056","Avoid combination of adverse effects of immunosuppressants."
854,"Gentamicin","DB00798","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Gentamicin. Use caution during concomitant therapy. "
854,"Glatiramer Acetate","DB05259","Avoid combination due to enhanced adverse effects of immunosuppressants."
854,"golimumab","DB06674","Avoid combination due to the enhancement of side effects from immunosuppressants.\
\
"
854,"Halofantrine","DB01218","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Haloperidol","DB00502","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Homoharringtonine","DB04865","Avoid combination as there is potential to increase immunosuppressant adverse effects. \
"
854,"Ibritumomab","DB00078","Avoid combination due to enhanced adverse effects of immunosuppressants. "
854,"Ibutilide","DB00308","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Imatinib","DB00619","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Imatinib is initiated, discontinued or dose changed."
854,"Imipramine","DB00458","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Indapamide","DB00808","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Indinavir","DB00224","The protease inhibitor, Indinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Indinavir therapy is initiated, discontinued or altered."
854,"Infliximab","DB00065","Avoid combination because of risk of enhance adverse effects of immunosuppressants"
854,"Isoniazid","DB00951","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed."
854,"Isradipine","DB00270","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Itraconazole","DB01167","The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered."
854,"Ketoconazole","DB01026","The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered."
854,"Lapatinib","DB01259","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Levofloxacin","DB01137","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Lopinavir","DB01601","The protease inhibitor, Lopinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Lopinavir therapy is initiated, discontinued or altered."
854,"Loxapine","DB00408","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
854,"Maprotiline","DB00934","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Mefloquine","DB00358","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Mesoridazine","DB00933","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Methadone","DB00333","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Methylprednisolone","DB00959","Methylprednisone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Methylprednisone therapy is initiated, discontinued or altered."
854,"Metoclopramide","DB01233","Metoclopramide may increase the concentration of Tacrolimus in the blood. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Metoclopramide therapy is initiated, discontinued or altered."
854,"Metronidazole","DB00916","Metronidazole increases the levels/toxicity of tacrolimus"
854,"Mibefradil","DB01388","The calcium channel blocker, Mibefradil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Mibefradil therapy is initiated, discontinued or altered."
854,"Miconazole","DB01110","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Miconazole is initiated, discontinued or dose changed."
854,"Moxifloxacin","DB00218","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Mycophenolate mofetil","DB00688","Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range."
854,"Natalizumab","DB00108","Tacrolimus may increase the toxic/adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."
854,"Nefazodone","DB01149","Nefazodone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nefazodone therapy is initiated, discontinued or altered."
854,"Nelfinavir","DB00220","The protease inhibitor, Nelfinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nelfinavir therapy is initiated, discontinued or altered."
854,"Neomycin","DB00994","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy. "
854,"Netilmicin","DB00955","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Netilmicin. Use caution during concomitant therapy. "
854,"Nicardipine","DB00622","The calcium channel blocker, Nicardipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nicardipine therapy is initiated, discontinued or altered."
854,"Nifedipine","DB01115","The calcium channel blocker, Nifedipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nifedipine therapy is initiated, discontinued or altered."
854,"Nilotinib","DB04868","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
854,"Norfloxacin","DB01059","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Nortriptyline","DB00540","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Obinutuzumab","DB08935","Avoid combination due to enhanced adverse effects of immunosuppressants. "
854,"Octreotide","DB00104","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Omalizumab","DB00043","Avoid combination due to enhanced adverse toxic effects."
854,"Omeprazole","DB00338","Omeprazole may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Omeprazole therapy is initiated, discontinued or altered."
854,"Paclitaxel","DB01229","Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants."
854,"Pegaspargase","DB00059","Tacrolimus enhances adverse effects of pegaspargase therefore the combination should be avoided."
854,"Pentamidine","DB00738","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Perflutren","DB00556","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Phenobarbital","DB01174","Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered."
854,"Phenytoin","DB00252","Phenytoin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenytoin therapy is initiated, discontinued or altered."
854,"Pimozide","DB01100","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Posaconazole","DB01263","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Posaconazole is initiated, discontinued or dose changed."
854,"Probucol","DB01599","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Procainamide","DB01035","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Propafenone","DB01182","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Protriptyline","DB00344","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Quetiapine","DB01224","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Quinidine","DB00908","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Quinidine, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance. "
854,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
854,"Ranolazine","DB00243","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Rifabutin","DB00615","Carbamazepine may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Carbamazepine therapy is initiated, discontinued or altered."
854,"Rifampicin","DB01045","Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered."
854,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
854,"Risperidone","DB00734","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Ritonavir","DB00503","The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered."
854,"Saquinavir","DB01232","The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered."
854,"Silodosin","DB06207","The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended. "
854,"Sirolimus","DB00877","Sirolimus may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Sirolimus therapy is initiated, discontinued or altered."
854,"Sotalol","DB00489","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Sparfloxacin","DB01208","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"St. John's Wort","DB01323","St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered."
854,"Streptomycin","DB01082","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Streptomycin. Use caution during concomitant therapy. "
854,"Sunitinib","DB01268","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. "
854,"Telithromycin","DB00976","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance."
854,"Temsirolimus","DB06287","Temsirolimus may decrease the blood concentration of Tacrolimus. Concomitant therapy may increase the adverse/toxic effects of both agents. Concomitant therapy should be avoided. "
854,"Teriflunomide","DB08880","Avoid combination due to the increased toxic effects of immunosuppressants.\
"
854,"Tetrabenazine","DB04844","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
854,"Thioridazine","DB00679","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
854,"Thiothixene","DB01623","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy."
854,"Tobramycin","DB00684","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Tobramycin. Use caution during concomitant therapy."
854,"Tofacitinib","DB08895","Avoid combination due to the potential increase in immunosuppressant associated adverse effects.\
"
854,"Topotecan","DB01030","The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
854,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
854,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
854,"Trimipramine","DB00726","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
854,"Troleandomycin","DB01361","The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered."
854,"Verapamil","DB00661","The calcium channel blocker, Verapamil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Verapamil therapy is initiated, discontinued or altered."
854,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed."
854,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
854,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
854,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
855,"Chlorpromazine","DB00477","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Fluoxetine","DB00472","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
855,"Fluphenazine","DB00623","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Fluvoxamine","DB00176","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
855,"Guanethidine","DB01170","Benzphetamine may decrease the effect of guanethidine."
855,"Isocarboxazid","DB01247","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
855,"Mesoridazine","DB00933","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Methotrimeprazine","DB01403","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Paroxetine","DB00715","Amphetamines may enhance the adverse/toxic effect of Serotonin Modulators. The risk of serotonin syndrome may be increased. Monitor patients closely for signs and symptoms of serotonin syndrome (e.g., agitation, tremor, tachycardia, etc.) when using amphetamines and serotonin modulators in combination."
855,"Perphenazine","DB00850","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Phenelzine","DB00780","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
855,"Prochlorperazine","DB00433","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Promethazine","DB01069","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Propericiazine","DB01608","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Rasagiline","DB01367","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
855,"Sodium bicarbonate","DB01390","Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered."
855,"Telithromycin","DB00976","Telithromycin may reduce clearance of Benzphetamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Benzphetamine if Telithromycin is initiated, discontinued or dose changed."
855,"Thioridazine","DB00679","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
855,"Trandolapril","DB00519","Benzphetamine may reduce the efficacy of Trandolapril. "
855,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Benzphetamine. Concomitant therapy should be avoided."
855,"Trifluoperazine","DB00831","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
855,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Benzphetamine."
855,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of benzphetamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of benzphetamine if voriconazole is initiated, discontinued or dose changed."
859,"Brinzolamide","DB01194","As both brinzolamide and dorzolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
861,"Acebutolol","DB01193","Antagonism"
861,"Alseroxylon","DB00386","Increased arterial pressure"
861,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of terbutaline."
861,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of terbutaline."
861,"Atenolol","DB00335","Antagonism"
861,"Betaxolol","DB00195","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like terbutaline. Therapy should be monitored."
861,"Bevantolol","DB01295","Antagonism"
861,"Bisoprolol","DB00612","Antagonism"
861,"Carteolol","DB00521","Antagonism"
861,"Carvedilol","DB01136","Antagonism"
861,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of terbutaline."
861,"Deserpidine","DB01089","Increased arterial pressure"
861,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of terbutaline."
861,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of terbutaline."
861,"Esmolol","DB00187","Antagonism"
861,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of terbutaline."
861,"Isocarboxazid","DB01247","Increased arterial pressure"
861,"Labetalol","DB00598","Antagonism"
861,"Linezolid","DB00601","Possible increase of arterial pressure"
861,"Methyldopa","DB00968","Increased arterial pressure"
861,"Metoprolol","DB00264","Antagonism"
861,"Midodrine","DB00211","Increased arterial pressure"
861,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of terbutaline."
861,"Nadolol","DB01203","Antagonism"
861,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of terbutaline."
861,"Oxprenolol","DB01580","Antagonism"
861,"Pargyline","DB01626","Increased arterial pressure"
861,"Penbutolol","DB01359","Antagonism"
861,"Phenelzine","DB00780","Increased arterial pressure"
861,"Pindolol","DB00960","Antagonism"
861,"Practolol","DB01297","Antagonism"
861,"Propranolol","DB00571","Antagonism"
861,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of terbutaline."
861,"Rasagiline","DB01367","Increased arterial pressure"
861,"Reserpine","DB00206","Increased arterial pressure"
861,"Sotalol","DB00489","Antagonism"
861,"Timolol","DB00373","Antagonism"
861,"Tranylcypromine","DB00752","Increased arterial pressure"
861,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of terbutaline."
862,"Alfuzosin","DB00346","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin. Concomitant use of alfuzosin with a strong CYP3A4 inhibitor is a listed contraindication according to alfuzosin prescribing information. "
862,"Almotriptan","DB00918","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Use an initial almotriptan dose of 6.25mg when using almotriptan with a strong CYP3A4 inhibitor, and do not exceed 12.5mg of almotriptan in any 24-hour period. Avoid concurrent use of almotriptan with a strong CYP3A4 inhibitor in patients with impaired hepatic or renal function."
862,"Artemether","DB06697","Conivaptan, a strong CYP3A inhibitor, may increase the toxicity of artemether by inhibiting its metabolism. Consider alternate therapy or allow at least 7 days to elapse between conivaptan and artemether therapy. "
862,"Bexarotene","DB00307","Conivaptan may increase the serum concentration of CYP3A4 substrates such as bexarotene. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. Consider therapy modification."
862,"Bezafibrate","DB01393","Conivaptan may increase the serum concentration of CYP3A4 substrates like bezafibrates. Consider therapy modification. Conivaptan may increase the serum concentration of CYP3A4 substrates."
862,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
862,"Bromazepam","DB01558","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if conivaptan is initiated, discontinued or dose changed. Dosage adjustments may be required. "
862,"Budesonide","DB01222","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. "
862,"Bupivacaine","DB00297","Conivaptan may increase the serum concentration of CYP3A4 Substrates such as bupivacaine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
862,"Buprenorphine","DB00921","Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
862,"Caffeine","DB00201","Conivaptan may increase the serum concentration of CYP3A4 substrates such as caffeine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
862,"Cevimeline","DB00185","Conivaptan may increase the serum concentration of CYP3A4 substrates such as cevimeline. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
862,"Colchicine","DB01394","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor. "
862,"Dantrolene","DB01219","Conivaptan may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if conivaptan is initiated, discontinued or dose changed. "
862,"Dronedarone","DB04855","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. Concurrent use of strong CYP3A4 inhibitors with dronedarone is contraindicated according to dronedarone prescribing information. "
862,"Eplerenone","DB00700","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone. The combination of eplerenone with any strong CYP3A4 inhibitor is contraindicated.\
"
862,"Everolimus","DB01590","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. Everolimus prescribing information recommends avoiding concurrent use with strong CYP3A4 inhbitors. "
862,"Fentanyl","DB00813","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fentanyl. Concurrent use of fentanyl with any CYP3A4 inhibitor may result in increased fentanyl concentrations and could increase or prolong adverse effects, including potentially fatal respiratory depression. Patients receiving fentanyl and any CYP3A4 inhibitor should be closely monitored for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate. "
862,"Fesoterodine","DB06702","CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Avoid fesoterodine doses greater than 4mg daily in patients who are also receiving strong CYP3A4 inhibitors. "
862,"Fluconazole","DB00196","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
862,"Fluticasone Propionate","DB00588","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended. "
862,"Halofantrine","DB01218","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended. "
862,"Iloperidone","DB04946","CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor. "
862,"Itraconazole","DB01167","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
862,"Ixabepilone","DB04845","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg)."
862,"Ketoconazole","DB01026","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
862,"Lurasidone","DB08815","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. Avoid use of lurasidone in patients receiving strong CYP3A4 inhibitors. "
862,"Maraviroc","DB04835","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations. "
862,"Methylprednisolone","DB00959","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Methylprednisolone. Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for increased steroid related adverse effects. "
862,"Nilotinib","DB04868","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. Nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong inhibitors of CYP3A4. "
862,"Nisoldipine","DB00401","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine. Avoid concurrent use of nisoldipine with strong inhibitors of CYP3A4, as the combination may lead to substantial increases in nisoldipine concentrations. "
862,"Paclitaxel","DB01229","Avoid combination because it will likely increase the serum concentration of CYP3A4 substrates. "
862,"Pazopanib","DB06589","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib dose to 400 mg. Further dose reductions may also be required. "
862,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
862,"Posaconazole","DB01263","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
862,"Ranolazine","DB00243","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine. The manufacturer contraindicates the use of ranolazine and strong CYP3A4 inhibitors (such as the azole antifungals).1 Monitor for increased effects/toxicity of ranolazine during concomitant use. "
862,"Rivaroxaban","DB06228","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. Consider avoiding use of rivaroxaban with any strong CYP3A4 inhibitors as many such agents are inhibitors of both CYP3A4 and P-glycoprotein. Use of rivaroxaban concomitantly with drugs that are strong inhibitors of both CYP3A4 and P-glycoprotein is specifically contraindicated. "
862,"Romidepsin","DB06176","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Romidepsin. Avoid concurrent use of strong CYP3A4 inhibitors with romidepsin when possible. "
862,"Salmeterol","DB00938","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Concurrent use of salmeterol with strong inhibitors of CYP3A4 is not recommended according to salmeterol prescribing information. "
862,"Saxagliptin","DB06335","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor. "
862,"Sildenafil","DB00203","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Sildenafil. When sildenanfil is used for treatment of pulmonary arterial hypertension, concurrent use with strong CYP3A4 inhibitors is not recommended. When sildenafil is used for treatment of erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking a strong CYP3A4 inhibitor. Due to the particularly strong effects of ritonavir, sildenafil (for erectile dysfunction) doses greater than 25 mg per 48 hours are not recommended. Of note, the interaction between CYP3A4 inhibitors and sildenafil is predicted to be greater with orally administered than with injected sildenafil. "
862,"Silodosin","DB06207","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Silodosin. Use of silodosin concomitantly with a strong CYP3A4 inhibitor is contraindicated. "
862,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Conivaptan is initiated, discontinued or dose changed."
862,"Tadalafil","DB00820","Conivaptan may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
862,"Tamoxifen","DB00675","Conivaptan may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
862,"Tamsulosin","DB00706","Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Conivaptan is initiated, discontinued, or dose changed."
862,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
862,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Conivaptan and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
862,"Temsirolimus","DB06287","Conivaptan may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
862,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Conivaptan is initiated, discontinued or dose changed."
862,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Conivaptan is initiated, discontinued or dose changed."
862,"Ticagrelor","DB08816","CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors. "
862,"Tolterodine","DB01036","Conivaptan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
862,"Tolvaptan","DB06212","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. "
862,"Toremifene","DB00539","CYP3A4 Inhibitors (Strong) such as conivaptan may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene. Concurrent use of toremifene with strong CYP3A4 inhibitors should be avoided. "
862,"Tramadol","DB00193","Conivaptan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
862,"Trazodone","DB00656","The CYP3A4 inhibitor, Conivaptan, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Conivaptan is initiated, discontinued or dose changed. "
862,"Vardenafil","DB00862","Conivaptan, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
862,"Venlafaxine","DB00285","Conivaptan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Conivaptan is initiated, discontinued, or dose changed."
862,"Verapamil","DB00661","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Conivaptan is initiated, discontinued or dose changed. "
862,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Vilazodone. Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
862,"Vinblastine","DB00570","Conivaptan, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Conivaptan is initiated, discontinued or dose changed."
862,"Vincristine","DB00541","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Conivaptan is initiated, discontinued or dose changed."
862,"Vinorelbine","DB00361","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Conivaptan is initiated, discontinued or dose changed."
862,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of conivaptan by inhibiting its metabolism. Concomitant therapy is contraindicated. "
862,"Zolpidem","DB00425","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if conivaptan is initiated, discontinued or dose changed. "
862,"Zonisamide","DB00909","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if conivaptan is initiated, discontinued or dose changed."
862,"Zopiclone","DB01198","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if conivaptan is initiated, discontinued or dose changed."
865,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
865,"Donepezil","DB00843","Possible antagonism of action"
865,"Galantamine","DB00674","Possible antagonism of action"
865,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
865,"Rivastigmine","DB00989","Possible antagonism of action"
865,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Flupenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
865,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
865,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
865,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
865,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
865,"Trimethobenzamide","DB00662","Trimethobenzamide and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
865,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
865,"Triprolidine","DB00427","Triprolidine and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
865,"Trospium","DB00209","Trospium and Flupenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
865,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
865,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
865,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
865,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
866,"Amiloride","DB00594","Increased risk of hyperkalemia"
866,"Drospirenone","DB01395","Increased risk of hyperkalemia"
866,"Lithium","DB01356","The ARB increases serum levels of lithium"
866,"Potassium","DB01345","Increased risk of hyperkalemia"
866,"Spironolactone","DB00421","Increased risk of hyperkalemia"
866,"Trandolapril","DB00519","The angiotensin II receptor blocker, Eprosartan, may increase the adverse effects of Trandolapril. "
866,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
866,"Triamterene","DB00384","Increased risk of hyperkalemia"
867,"Atazanavir","DB01072","Increases the effect and toxicity of immunosuppressant"
867,"Boceprevir","DB08873","Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. "
867,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the serum concentration of sirolimus."
867,"Cyclosporine","DB00091","Increases the effect and toxicity of sirolimus"
867,"Diltiazem","DB00343","Increases the effect and toxicity of sirolimus"
867,"Dronedarone","DB04855","Sirolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of sirolimus. Monitor plasma concentrations and adjust dose accordingly. "
867,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the serum concentration of sirolimus."
867,"Fosphenytoin","DB01320","The hydantoin decreases sirolimus levels"
867,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of sirolimus."
867,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of sirolimus."
867,"Phenytoin","DB00252","The hydantoin decreases sirolimus levels"
867,"Rifabutin","DB00615","The rifamycin decreases the effect of sirolimus"
867,"Rifampicin","DB01045","The rifamycin decreases the effect of sirolimus"
867,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
867,"Tacrolimus","DB00864","Sirolimus may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Sirolimus therapy is initiated, discontinued or altered."
867,"Telithromycin","DB00976","Telithromycin may reduce clearance of Sirolimus. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sirolimus if Telithromycin is initiated, discontinued or dose changed."
867,"Tipranavir","DB00932","Tipranavir may affect the efficacy/toxicity of Sirolimus. "
867,"Trandolapril","DB00519","Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema."
867,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
867,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of sirolimus likely by inhibition of CYP3A4-mediated metabolism or p-glyprotein transport of sirolimus. Consider alternate therapy or reduce the dose of sirolimus and monitor serum levels during concomitant therapy. "
869,"Valganciclovir","DB01610","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Emtricitabine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
870,"Amifostine","DB01143","Antihypertensives may enhance the hypotensive effect of amifostine. When amifostine is used at doses recommended for chemotherapy, antihypertensive medications should be withheld for 24 hours prior to amifostine administration to avoid excessive hypotension during or immediately after infusion. If antihypertensive therapy can not be withheld, then that patient should not receive amifostine. Caution is recommended when using amifostine at the lower doses recommended for radiotherapy, but routine interruption of antihypertensive therapy is not recommended in these patients. "
870,"Cholestyramine","DB01432","Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. "
870,"Colestipol","DB00375","Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. "
870,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
870,"Dofetilide","DB00204","Thiazide diuretics such as chlorothiazide may enhance the QTc-prolonging effect of dofetilide. Thiazide diuretics may increase the serum concentration of dofetilide. The concomitant use of hydrochlorothiazide and dofetilide is contraindicated by the manufacturer of dofetilide. Monitor for increased risk of QTc-prolongation and associated ventricular arrythmias during concomitant use of dofetilide and thiazide diuretics."
870,"Lithium","DB01356","The thiazide diuretic, chlorothiazide, may increase serum levels of lithium."
870,"Rituximab","DB00073","Antihypertensives such as chlorothiazide may enhance the hypotensive effect of Rituximab. Consider temporarily withholding antihypertensive medications for 12 hours prior to rituximab infusion to avoid excessive hypotension during or immediately after infusion."
870,"Topiramate","DB00273","Thiazide diuretics such as chlorothiazide may enhance the hypokalemic effect of topiramate. Thiazide diuretics may increase the serum concentration of topiramate. Monitor for increased topiramate concentrations/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary. "
870,"Trandolapril","DB00519","The thiazide diuretic, Chlorothiazide, may increase the hypotensive effect of Trandolapril. Chlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
870,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
871,"Amiloride","DB00594","Increased risk of hyperkalemia"
871,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
871,"Drospirenone","DB01395","Increased risk of hyperkalemia"
871,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
871,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
871,"Potassium","DB01345","Increased risk of hyperkalemia"
871,"Spironolactone","DB00421","Increased risk of hyperkalemia"
871,"Tetracycline","DB00759","Quinapril may decrease the absorption of tetracycline."
871,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
871,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
871,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
871,"Triamterene","DB00384","Increased risk of hyperkalemia"
871,"Trovafloxacin","DB00685","Quinapril may decrease the absorption of orally administered Trovafloxacin. The Quinapril formulation contains magnesium ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Quinapril dose to minimize the interaction. "
872,"Amobarbital","DB01351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, clomifene."
872,"Aprobarbital","DB01352","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, clomifene."
872,"Butabarbital","DB00237","The enzyme inducer, butabarbital, decreases the effect of the hormone agent, clomifene."
872,"Butalbital","DB00241","The enzyme inducer, butalbital, decreases the effect of the hormone agent, clomifene."
872,"Butethal","DB01353","The enzyme inducer, butethal, decreases the effect of the hormone agent, clomifene."
872,"Ethotoin","DB00754","The enzyme inducer, ethotoin, decreases the effect of the hormone agent, clomifene."
872,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene."
872,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, clomifene."
872,"Heptabarbital","DB01354","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, clomifene."
872,"Hexobarbital","DB01355","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, clomifene."
872,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, decreases the effect of the hormone agent, clomifene."
872,"Methohexital","DB00474","The enzyme inducer, methohexital, decreases the effect of the hormone agent, clomifene."
872,"Methylphenobarbital","DB00849","The enzyme inducer, methylphenobarbital, decreases the effect of the hormone agent, clomifene."
872,"Pentobarbital","DB00312","The enzyme inducer, pentobarbital, decreases the effect of the hormone agent, clomifene."
872,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene."
872,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, clomifene."
872,"Prednisolone","DB00860","The estrogenic agent, clomifene, may increase the effect of the corticosteroid, prednisolone."
872,"Prednisone","DB00635","The estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone."
872,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, clomifene."
872,"Raloxifene","DB00481","Association not recommended"
872,"Secobarbital","DB00418","The enzyme inducer, secobarbital, decreases the effect of the hormone agent, clomifene."
872,"Talbutal","DB00306","The enzyme inducer, talbutal, decreases the effect of the hormone agent, clomifene."
872,"Ursodeoxycholic acid","DB01586","Estrogens decreases the effect of ursodiol"
873,"Avanafil","DB06237","Additive vasodilation. Concomitant therapy is contraindicated. "
873,"Dihydroergotamine","DB00320","Possible antagonism of action"
873,"Ergonovine","DB01253","Possible antagonism of action"
873,"Ergotamine","DB00696","Possible antagonism of action"
873,"Methylergometrine","DB00353","Possible antagonism of action"
873,"Methysergide","DB00247","Possible antagonism of action"
873,"Sildenafil","DB00203","Possible significant hypotension with this combination"
873,"Tadalafil","DB00820","The vasodilatory effects of Isosorbide dinitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
873,"Telithromycin","DB00976","Telithromycin may reduce clearance of Isosorbide Dinitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Dinitrate if Telithromycin is initiated, discontinued or dose changed."
873,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
873,"Udenafil","DB06267","The vasodilatory effects of Isosobide dinitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
873,"Vardenafil","DB00862","The vasodilatory effects of Isosorbide dinitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
873,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide dinitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide dinitrate if voriconazole is initiated, discontinued or dose changed."
874,"Calcium","DB01373","Formation of non-absorbable complexes"
874,"Calcium Acetate","DB00258","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as risedronate. Avoid administration of oral calcium supplements within or 30 minutes after risedronate. "
874,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. "
874,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
874,"Magnesium","DB01378","Formation of non-absorbable complexes"
877,"Amikacin","DB00479","Increased ototoxicity"
877,"Cisplatin","DB00515","Increased ototoxicity"
877,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as bumetanide. Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
877,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
877,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
877,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
877,"Gentamicin","DB00798","Increased ototoxicity"
877,"Ginseng","DB01404","Ginseng may decrease the therapeutic effect of diuretic, bumetanide."
877,"Ibuprofen","DB01050","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
877,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
877,"Kanamycin","DB01172","Increased ototoxicity"
877,"Netilmicin","DB00955","Increased ototoxicity"
877,"Streptomycin","DB01082","Increased ototoxicity"
877,"Sulindac","DB00605","The NSAID, sulindac, decreases the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
877,"Tobramycin","DB00684","Increased ototoxicity"
877,"Trandolapril","DB00519","The loop diuretic, Bumetanide, may increase the hypotensive effect of Trandolapril. Bumetanide may also increase the nephrotoxicity of Trandolapril. "
877,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
878,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
878,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
881,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
881,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
883,"Alendronate","DB00630","Formation of non-absorbable complexes"
883,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
883,"Clodronate","DB00720","Formation of non-absorbable complexes"
883,"Deferiprone","DB08826","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
883,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
883,"Doxycycline","DB00254","Formation of non-absorbable complexes"
883,"Eltrombopag","DB06210","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
883,"Enoxacin","DB00467","Formation of non-absorbable complexes"
883,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
883,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
883,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
883,"Grepafloxacin","DB00365","Formation of non-absorbable complexes"
883,"Ibandronate","DB00710","Formation of non-absorbable complexes"
883,"L-DOPA","DB01235","Iron decreases the absorption of dopa derivatives"
883,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
883,"Levothyroxine","DB00451","Iron decreases the absorption of levothyroxine"
883,"Lomefloxacin","DB00978","Formation of non-absorbable complexes"
883,"Methacycline","DB00931","Formation of non-absorbable complexes"
883,"Methyldopa","DB00968","Iron decreases the absorption of dopa derivatives"
883,"Minocycline","DB01017","Formation of non-absorbable complexes"
883,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
883,"Mycophenolate mofetil","DB00688","Oral iron decreases the absorption of mycophenolate-mofetil"
883,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
883,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
883,"Oxytetracycline","DB00595","Formation of non-absorbable complexes"
883,"Pefloxacin","DB00487","Formation of non-absorbable complexes"
883,"Penicillamine","DB00859","The multivalent agent decreases the effect of penicillamine"
883,"Risedronate","DB00884","Formation of non-absorbable complexes"
883,"Temafloxacin","DB01405","Formation of non-absorbable complexes"
883,"Tetracycline","DB00759","Formation of non-absorbable complexes"
883,"Trovafloxacin","DB00685","Formation of non-absorbable complexes"
884,"Acenocoumarol","DB01418","The androgen, Testolactone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testolactone is initiated, discontinued or dose changed. "
884,"Cyclosporine","DB00091","The androgen, Testolactone, may increase the hepatotoxicity of Cyclosporine. Testolatone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity. "
884,"Warfarin","DB00682","Testolactone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if testolactone is initiated, discontinued or dose changed."
885,"Carbinoxamine","DB00748","Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects. "
887,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Aprepitant","DB00673","Aprepitant may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of triazolam if cimetidine is initiated, discontinued or dose changed."
887,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, triazolam."
887,"Clozapine","DB00363","Increased risk of toxicity"
887,"Delavirdine","DB00705","The antiviral agent, delavirdine, may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Diltiazem","DB00343","The calcium channel blocker, diltiazem, may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Efavirenz","DB00625","The antiviral agent, efavirenz, may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of the benzodiazepine, triazolam."
887,"Ethotoin","DB00754","Ethotoin may increase the metabolism of triazolam via CYP3A4."
887,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, triazolam."
887,"Fosamprenavir","DB01319","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of triazolam via CYP3A4."
887,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, triazolam."
887,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, triazolam."
887,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam."
887,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, triazolam."
887,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, triazolam."
887,"Mephenytoin","DB00532","Mephenytoin may increase the metabolism of triazolam via CYP3A4."
887,"Modafinil","DB00745","Modafinil decreases the effect of triazolam"
887,"Nefazodone","DB01149","Nefazodone increases the effect of triazolam"
887,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, triazolam."
887,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, triazolam."
887,"Phenytoin","DB00252","Phenytoin may increase the metabolism of triazolam via CYP3A4."
887,"Rifampicin","DB01045","Rifampin may decrease the effect of the benzodiazepine, triazolam."
887,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, triazolam."
887,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, triazolam."
887,"St. John's Wort","DB01323","St. John's Wort may decrease the effect of the benzodiazepine, triazolam."
887,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
887,"Telithromycin","DB00976","Telithromycin may increase the effect and toxicity of the benzodiazepine, triazolam."
887,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Triazolam. Concomitant therapy is contraindicated."
887,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Triazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
887,"Verapamil","DB00661","Verapamil may increase the serum concentration of Triazolam by decreasing its metabolism. Avoid concomitant therapy if possible or consider a dose reduction in the initial dose of Triazolam."
887,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for triazolam toxicity if voriconazole is initiated or dose increased."
888,"Abacavir","DB01048","Abacavir is partly metabolized through the alcohol dehydrogenase enzyme system. Alcohol increases the area under the curve (about 41%) of Abacavir. Interaction does not appear to be clinically significant. "
888,"gabapentin enacarbil","DB08872","Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression."
888,"Mipomersen","DB05528","The combination of these drugs will likely enhance mipomersen related hepatotoxicity. Therefore patients using both these drugs, should limit their alcohol to a daily maximum of 1 drink (or equivalent). "
888,"Perampanel","DB08883","Avoid combination due to the enhanced central nervous system depression, and likely worse behavioral and psychiatric adverse reactions.\
\
"
888,"Tizanidine","DB00697","Ethanol increases the adverse effects of Tizanidine. The CNS depressant effects of these agents are additive."
888,"Triprolidine","DB00427","Triprolidine may enhance the CNS depressant effects of Ethanol."
889,"Tranylcypromine","DB00752","Possible increased risk of serotonin syndrome. "
889,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Remifentanil, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
890,"Ganciclovir","DB01004","The antiviral agent, ganciclovir, may increase the effect and toxicity of didanosine."
890,"Tenofovir","DB00300","Tenofovir may decrease the therapeutic effects and increase the adverse effects of Didanosine. Monitor for changes in virologic response and Didanosine toxicity during concomitant therapy."
890,"Tipranavir","DB00932","Tipranavir may decrease the concentration of Didanosine."
890,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
890,"Trovafloxacin","DB00685","Didanosine may decrease the absorption of orally administered Trovafloxacin. The Didanosine formulation contains magnesium and aluminum ions that intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Didanosine dose to minimize the interaction. This interaction is not observed with enteric coated Didanosine. "
890,"Valganciclovir","DB01610","The adverse/toxic effects of Didanosine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided."
890,"Voriconazole","DB00582","Didanosine may interfere with the absorption of orally administered voriconazole. Enteric coated didanosine does not exert this effect. Didanosine buffered formulations should be administered at least 2 hours from oral voriconazole administration. "
890,"Zalcitabine","DB00943","Additive toxicities (peripheral neuropathy)"
891,"Entacapone","DB00494","Entacapone may increase the effect and toxicity of bitolterol. "
892,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
892,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
892,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
892,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
892,"Donepezil","DB00843","Possible antagonism of action"
892,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
892,"Galantamine","DB00674","Possible antagonism of action"
892,"Guanethidine","DB01170","Methdilazine may decrease the effect of guanethidine."
892,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
892,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
892,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
892,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
893,"Amikacin","DB00479","Increased ototoxicity"
893,"Cisplatin","DB00515","Increased ototoxicity"
893,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as ethacrynic acid.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
893,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
893,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
893,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
893,"Gentamicin","DB00798","Increased ototoxicity"
893,"Ginseng","DB01404","Ginseng may decrease the therapeutic effect of diuretic, ethacrynic acid."
893,"Ibuprofen","DB01050","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid."
893,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
893,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid."
893,"Kanamycin","DB01172","Increased ototoxicity"
893,"Netilmicin","DB00955","Increased ototoxicity"
893,"Streptomycin","DB01082","Increased ototoxicity"
893,"Sulindac","DB00605","The NSAID, sulindac, may decrease the diuretic and antihypertensive effects of the loop diuretic, ethacryninc acid."
893,"Tobramycin","DB00684","Increased ototoxicity"
893,"Trandolapril","DB00519","The loop diuretic, Ethacrynic acid, may increase the hypotensive effect of Trandolapril. Ethacrynic acid may also increase the nephrotoxicity of Trandolapril.  "
893,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
894,"Asenapine","DB06216","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
894,"Crizotinib","DB08865","Concurrent use with crizotinib may decrease QTc interval. Consider alternative therapy. "
894,"Ezogabine","DB04953","Concurrent use of ezogabine and ondansetron can increase QTc interval. Consider alternate therapy. "
894,"Indacaterol","DB05039","Both indacaterol and ondansetron prolong the QT interval. Consider alternate therapy. "
894,"Pazopanib","DB06589","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
894,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
895,"Latanoprost","DB00654","The concomitant use of bimatoprost and latanoprost may result in increased intraocular pressure. Consider avoiding this combination of therapy. Monitor for paradoxical increases in intraocular pressure during concomitant use. "
896,"Amprenavir","DB00701","The strong CYP3A4 inhibitor, Amprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Amprenavir is initiated, discontinued or dose changed."
896,"Atazanavir","DB01072","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Atazanavir is initiated, discontinued or dose changed."
896,"Clarithromycin","DB01211","The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Clarithromycin is initiated, discontinued or dose changed."
896,"Conivaptan","DB00872","The strong CYP3A4 inhibitor, Conivaptan, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Conivaptan is initiated, discontinued or dose changed."
896,"Darunavir","DB01264","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Darunavir is initiated, discontinued or dose changed."
896,"Delavirdine","DB00705","The strong CYP3A4 inhibitor, Delavirdine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Delavirdine is initiated, discontinued or dose changed."
896,"Fosamprenavir","DB01319","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Fosamprenavir is initiated, discontinued or dose changed."
896,"Imatinib","DB00619","The strong CYP3A4 inhibitor, Imatinib, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Imatinib is initiated, discontinued or dose changed."
896,"Indinavir","DB00224","The strong CYP3A4 inhibitor, Indinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Indinavir is initiated, discontinued or dose changed."
896,"Isoniazid","DB00951","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed."
896,"Itraconazole","DB01167","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed."
896,"Ketoconazole","DB01026","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed."
896,"Lopinavir","DB01601","The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Lopinavir is initiated, discontinued or dose changed."
896,"Mefloquine","DB00358","Mefloquine increases the risk of seizure and is contraindicated in persons with a history of convulsions. Possible reduction in the therapeutic effect of Tiagabine when used for other indications may also occur. "
896,"Miconazole","DB01110","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Miconazole is initiated, discontinued or dose changed."
896,"Nefazodone","DB01149","The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nefazodone is initiated, discontinued or dose changed."
896,"Nelfinavir","DB00220","The strong CYP3A4 inhibitor, Nelfinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nelfinavir is initiated, discontinued or dose changed."
896,"Nicardipine","DB00622","The strong CYP3A4 inhibitor, Nicardipine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nicardipine is initiated, discontinued or dose changed."
896,"Posaconazole","DB01263","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Posaconazole is initiated, discontinued or dose changed."
896,"Quinidine","DB00908","The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Quinidine is initiated, discontinued or dose changed."
896,"Ritonavir","DB00503","The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ritonavir is initiated, discontinued or dose changed."
896,"Saquinavir","DB01232","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Saquinavir is initiated, discontinued or dose changed."
896,"Telithromycin","DB00976","The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Telithromycin is initiated, discontinued or dose changed."
896,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Tiagabine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
896,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tiagabine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tiagabine if voriconazole is initiated, discontinued or dose changed."
897,"Atomoxetine","DB00289","CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of atomoxetine. Initiate atomoxetine at a reduced dose (patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor. The dose should only be increased to usual doses if symptoms fail to improve after 4 weeks. Patients established on atomoxetine therapy may require dosage reductions and should be monitored for increased levels/adverse effects with initiation/dose increase of a strong CYP2D6 inhibitor."
897,"Disulfiram","DB00822","Increases the cardiac toxicity of cocaine"
897,"Iloperidone","DB04946","CYP2D6 Inhibitors (Strong) such as cocaine may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor. "
897,"Iobenguane","DB06704","Sympathomimetic that increase chances of producing a false negative imaging result "
897,"Tamoxifen","DB00675","Cocaine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
897,"Tamsulosin","DB00706","Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cocaine is initiated, discontinued, or dose changed."
897,"Telithromycin","DB00976","Telithromycin may reduce clearance of Cocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cocaine if Telithromycin is initiated, discontinued or dose changed."
897,"Tetrabenazine","DB04844","CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor."
897,"Tolterodine","DB01036","Cocaine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
897,"Tramadol","DB00193","Cocaine may decrease the effect of Tramadol by decreasing active metabolite production. "
897,"Trimipramine","DB00726","The strong CYP2D6 inhibitor, Cocaine, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. "
897,"Venlafaxine","DB00285","Cocaine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cocaine is initiated, discontinued, or dose changed."
897,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cocaine if voriconazole is initiated, discontinued or dose changed."
897,"Zuclopenthixol","DB01624","Cocaine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cocaine is initiated, discontinued or dose changed. "
898,"Acenocoumarol","DB01418","Quinidine may increase the anticoagulant effect of acenocoumarol."
898,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
898,"Amiloride","DB00594","Amiloride may decrease the therapeutic effect of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if amiloride if initiated, discontinued or dose changed."
898,"Amiodarone","DB01118","Amiodarone may increase the effect of quinidine."
898,"Amitriptyline","DB00321","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Amobarbital","DB01351","The anticonvulsant, amobarbital, decreases the effect of quinidine."
898,"Anisindione","DB01125","Quinidine may increase the anticoagulant effect of anisindione."
898,"Aprobarbital","DB01352","The anticonvulsant, aprobarbital, decreases the effect of quinidine."
898,"Aripiprazole","DB01238","Quinidine increases the effect and toxicity of aripiprazole"
898,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
898,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias."
898,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
898,"Atracurium","DB00732","The quinine derivative increases the effect of the muscle relaxant"
898,"Bromazepam","DB01558","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if quinidine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
898,"Butabarbital","DB00237","The anticonvulsant, butabarbital, decreases the effect of quinidine."
898,"Butalbital","DB00241","The anticonvulsant, butalbital, decreases the effect of quinidine."
898,"Butethal","DB01353","The anticonvulsant, butethal, decreases the effect of quinidine."
898,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if cimetidine is initiated, discontinued or dose changed."
898,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
898,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
898,"Clomipramine","DB01242","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Codeine","DB00318","Quinidine decreases the analgesic effect of codeine"
898,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
898,"Dabigatran etexilate","DB06695","Quinidine may increase the serum concentration of dabigatran etexilate, resulting in increased bleeding. Consider modification of therapy."
898,"Dantrolene","DB01219","Quinidine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if quinidine is initiated, discontinued or dose changed. "
898,"Desipramine","DB01151","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Dextromethorphan","DB00514","Quinidine increases the toxicity of dextromethorphan"
898,"Dicoumarol","DB00266","Quinidine may increase the anticoagulant effect of dicumarol."
898,"Digitoxin","DB01396","Quinine/quinidine increases the effect of digoxin"
898,"Digoxin","DB00390","Quinine/quinidine increases the effect of digoxin"
898,"Dihydrocodeine","DB01551","Use of quinidine may reduce dihydrocodeine's analgesic effect.  "
898,"Dihydroquinidine barbiturate","DB01341","The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine."
898,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of quinidine. Monitor for changes in the therapeutic and adverse effects of quinidine if diltiazem is initiated, discontinued or dose changed."
898,"Donepezil","DB00843","Possible antagonism of action"
898,"Doxepin","DB01142","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
898,"Etravirine","DB06414","Quinidine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor quinidine therapy."
898,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
898,"Fosphenytoin","DB01320","The anticonvulsant, fosphenytoin, decreases the effect of quinidine."
898,"Galantamine","DB00674","Possible antagonism of action"
898,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
898,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
898,"Heptabarbital","DB01354","The anticonvulsant, heptabarbital, decreases the effect of quinidine."
898,"Hexobarbital","DB01355","The anticonvulsant, hexobarbital, decreases the effect of quinidine."
898,"Imipramine","DB00458","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of quinidine."
898,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of quinidine."
898,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
898,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
898,"Magnesium","DB01378","Magnesium antacids may decrease the absorption of quindine."
898,"Magnesium salicylate","DB01397","The antacid increases the effect of quinidine"
898,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
898,"Methohexital","DB00474","The anticonvulsant, methohexital, decreases the effect of quinidine."
898,"Methylphenobarbital","DB00849","The anticonvulsant, methylphenobarbital, decreases the effect of quinidine."
898,"Metocurine","DB01336","The quinine derivative increases the effect of the muscle relaxant"
898,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
898,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of quinidine"
898,"Nifedipine","DB01115","Decreased quinidine effect, increased nifedipine effect"
898,"Nortriptyline","DB00540","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Ofloxacin","DB01165","Increased risk of cardiotoxicity and arrhythmias"
898,"Pancuronium","DB01337","The quinine derivative increases the effect of the muscle relaxant"
898,"Pentobarbital","DB00312","The anticonvulsant, pentobarbital, decreases the effect of quinidine."
898,"Phenobarbital","DB01174","The anticonvulsant, phenobarbital, decreases the effect of quinidine."
898,"Phenytoin","DB00252","The anticonvulsant, phenytoin, decreases the effect of quinidine."
898,"Posaconazole","DB01263","Contraindicated co-administration"
898,"Primidone","DB00794","The anticonvulsant, primidone, decreases the effect of quinidine."
898,"Procainamide","DB01035","Quinidine increases the effect of procainamide"
898,"Propafenone","DB01182","Quinidine increases the effect of propafenone"
898,"Protriptyline","DB00344","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
898,"Quinidine barbiturate","DB01346","The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine."
898,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
898,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
898,"Rifampicin","DB01045","Rifampin decreases the effect of quinidine"
898,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of quinidine"
898,"Rivastigmine","DB00989","Possible antagonism of action"
898,"Secobarbital","DB00418","The anticonvulsant, secobarbital, decreases the effect of quinidine."
898,"Sodium bicarbonate","DB01390","The antacid increases the effect of quinidine"
898,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
898,"Succinylcholine","DB00202","The quinine derivative increases the effect of the muscle relaxant"
898,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Quinidine, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance. "
898,"Tadalafil","DB00820","Quinidine may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
898,"Talbutal","DB00306","The anticonvulsant, talbutal, decreases the effect of quinidine."
898,"Tamoxifen","DB00675","Quinidine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
898,"Tamsulosin","DB00706","Quinidine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Quinidine is initiated, discontinued, or dose changed."
898,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
898,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Quinidine and/or Telithromycin. Consider alternate therapy or monitor for changes in the the therapeutic/adverse effects of both agents during concomitant therapy."
898,"Temsirolimus","DB06287","Quinidine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
898,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Quinidine is initiated, discontinued or dose changed."
898,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
898,"Tetrabenazine","DB04844","Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. "
898,"Thiopental","DB00599","Thiopental may increase the metabolism and clearance of Quinidine. Monitor for decreased therapeutic effect of Quinidine if Thiopental is initiated."
898,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
898,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Quinidine, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Quinidine is initiated, discontinued or dose changed."
898,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated."
898,"Tolterodine","DB01036","Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
898,"Topotecan","DB01030","The p-glycoprotein inhibitor, Quinidine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
898,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
898,"Tramadol","DB00193","Quinidine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Quinidine may decrease the effect of Tramadol by decreasing active metabolite production. "
898,"Trazodone","DB00656","The CYP3A4 inhibitor, Quinidine, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Quinidine is initiated, discontinued or dose changed. "
898,"Trimipramine","DB00726","Additive QTc-prolonging effects may occur, increasing the risk of serious cardiac arrhythmias. Quinidine, a CYP2D6/CYP3A4 inhibitor, may also inhibit the metabolism of Trimipramine, a CYP2D6/CYP3A4 substrate. Monitor for signs of cardiac arrhythmias and for changes in Trimipramine efficacy and toxicity if Quinidine is initiated, discontinued or dose changed."
898,"Vardenafil","DB00862","Quinidine, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
898,"Vecuronium","DB01339","The quinine derivative increases the effect of the muscle relaxant"
898,"Venlafaxine","DB00285","Quinidine, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Quinidine is initiated, discontinued, or dose changed."
898,"Verapamil","DB00661","Concurrent therapy may result in increased serum levels of both agents. Both agents are CYP3A4 inhibitors and substrates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of the agent if the other is initiated, discontinued or dose changed."
898,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
898,"Vinblastine","DB00570","Quinidine, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Quinidine is initiated, discontinued or dose changed."
898,"Vincristine","DB00541","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Quinidine is initiated, discontinued or dose changed."
898,"Vinorelbine","DB00361","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Quinidine is initiated, discontinued or dose changed."
898,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed."
898,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
898,"Warfarin","DB00682","Quinidine may increase the anticoagulant effect of warfarin."
898,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
898,"Zolpidem","DB00425","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if quinidine is initiated, discontinued or dose changed. "
898,"Zonisamide","DB00909","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed."
898,"Zopiclone","DB01198","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if quinidine is initiated, discontinued or dose changed."
898,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed."
899,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed."
899,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed."
899,"Brinzolamide","DB01194","As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
899,"Clarithromycin","DB01211","Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed."
899,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if conivaptan is initiated, discontinued or dose changed."
899,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed."
899,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if delavirdine is initiated, discontinued or dose changed."
899,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed."
899,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if imatinib is initiated, discontinued or dose changed."
899,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if indinavir is initiated, discontinued or dose changed."
899,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed."
899,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed."
899,"Ketoconazole","DB01026","Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed."
899,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed."
899,"Mefloquine","DB00358","Mefloquine may decrease the serum concentration and therapeutic effect of zonisamide. Concomitant therapy is contraindicated in patients with history of convulsions. "
899,"Methotrimeprazine","DB01403","Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression."
899,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed."
899,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nelfinavir is initiated, discontinued or dose changed."
899,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nicardipine is initiated, discontinued or dose changed."
899,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed."
899,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if quinidine is initiated, discontinued or dose changed."
899,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed."
899,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed."
899,"Telithromycin","DB00976","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed."
899,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Zonisamide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
899,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed."
900,"Cholecalciferol","DB00169","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
900,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
902,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
902,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
902,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
902,"Bevantolol","DB01295","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
902,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
902,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
902,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
902,"Clarithromycin","DB01211","Clarithromycin may increase the effect of repaglinide."
902,"Cyclosporine","DB00091","Cyclosporine may increase the therapeutic and adverse effects of repaglinide."
902,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of repaglinide."
902,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
902,"Fluvastatin","DB01095","Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely. "
902,"Gemfibrozil","DB01241","Gemfibrozil may increase the effect and toxicity of repaglinide."
902,"Glucosamine","DB01296","Possible hyperglycemia"
902,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect of repaglinide."
902,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
902,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
902,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
902,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
902,"Penbutolol","DB01359","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
902,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
902,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
902,"Pravastatin","DB00175","Substrates of organic anion transporters may increase levels of repaglinide. Monitor concomitant therapy closely. "
902,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
902,"Rifampicin","DB01045","Rifampin decreases the effect of repaglinide"
902,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
902,"Telithromycin","DB00976","Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed."
902,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
902,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of repaglinide if voriconazole is initiated, discontinued or dose changed."
905,"Donepezil","DB00843","Possible antagonism of action"
905,"Galantamine","DB00674","Possible antagonism of action"
905,"Memantine","DB01043","Increased risk of CNS adverse effects with this association"
905,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, amantadine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
905,"Rivastigmine","DB00989","Possible antagonism of action"
905,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Amantadine. Consider alternate therapy or monitor for decreased effects of both agents. "
905,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder. "
905,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. "
906,"Acenocoumarol","DB01418","Metronidazole may increase the anticoagulant effect of acenocoumarol."
906,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of metronidazole."
906,"Amprenavir","DB00701","Increased risk of side effects (oral solution)"
906,"Anisindione","DB01125","Metronidazole may increase the anticoagulant effect of anisindione."
906,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of metronidazole."
906,"Busulfan","DB01008","Metronidazole increases the effect/toxicity of busulfan"
906,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of metronidazole."
906,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of metronidazole."
906,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of metronidazole."
906,"Carbamazepine","DB00564","Metronidazole increases the effect of carbamazepine"
906,"Dicoumarol","DB00266","Metronidazole may increase the anticoagulant effect of dicumarol."
906,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole."
906,"Disulfiram","DB00822","Possible acute psychosis and confusion"
906,"Fluorouracil","DB00544","Risk of 5-FU toxicity when associated with metronidazole"
906,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of metronidazole."
906,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of metronidazole."
906,"Lithium","DB01356","Metronidazole increases the effect and toxicity of lithium"
906,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of metronidazole."
906,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of metronidazole."
906,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of metronidazole."
906,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of metronidazole."
906,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of metronidazole."
906,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of metronidazole."
906,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of metronidazole."
906,"Tacrolimus","DB00864","Metronidazole increases the levels/toxicity of tacrolimus"
906,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of metronidazole."
906,"Tamsulosin","DB00706","Metronidazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Metronidazole is initiated, discontinued, or dose changed."
906,"Tolterodine","DB01036","Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
906,"Tramadol","DB00193","Metronidazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
906,"Trazodone","DB00656","The CYP3A4 inhibitor, Metronidazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Metronidazole is initiated, discontinued or dose changed."
906,"Warfarin","DB00682","Metronidazole may increase the serum concentration of warfarin by decreasing its metabolism. Consider alternate therapy or a dose reduction in warfarin. Monitor for changes in prothrombin time and therapeutic and adverse effects of warfarin if metronidazole is initiated, discontinued or dose changed."
907,"Carbetocin","DB01282","Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use. "
907,"Oxytocin","DB00107","Therapy modification should be considered because of enhanced oxytocic effects"
908,"Citalopram","DB00215","Increased risk of CNS adverse effects"
908,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan. Use an initial almotriptan dose of 6.25mg when using almotriptan with a strong CYP3A4 inhibitor, and do not exceed 12.5mg of almotriptan in any 24-hour period. Avoid concurrent use of almotriptan with a strong CYP3A4 inhibitor in patients with impaired hepatic or renal function."
908,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
908,"Dihydroergotamine","DB00320","Possible severe and prolonged vasoconstriction"
908,"Ergonovine","DB01253","Possible severe and prolonged vasoconstriction"
908,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction"
908,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
908,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
908,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
908,"Isocarboxazid","DB01247","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated."
908,"Itraconazole","DB01167","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
908,"Ketoconazole","DB01026","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
908,"Methylergometrine","DB00353","Possible severe and prolonged vasoconstriction"
908,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
908,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
908,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
908,"Phenelzine","DB00780","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated."
908,"Sertraline","DB01104","Increased risk of CNS adverse effects"
908,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
908,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
908,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Almotriptan. Risk of serotonin syndrome and Almotriptan toxicity. Concomitant therapy should be avoided."
908,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
908,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
908,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
908,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function. "
908,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
910,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Ketotifen, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
910,"Trimethobenzamide","DB00662","Trimethobenzamide and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
910,"Triprolidine","DB00427","Triprolidine and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
910,"Trospium","DB00209","Trospium and Ketotifen, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
911,"Alvimopan","DB06274","Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification."
911,"Atazanavir","DB01072","Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects. "
911,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 Substrates like buprenorphine. Upon completion/discontinuation of conivaptan, allow at least 7 days before initiating therapy with drugs that are CYP3A4 substrates. "
911,"Droperidol","DB00450","Droperidol may enhance the CNS depressant effect of CNS Depressants like buprenorphine. Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. "
911,"Etravirine","DB06414","Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal).  "
911,"Isocarboxazid","DB01247","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Linezolid","DB00601","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like linezolid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Moclobemide","DB01171","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Phenelzine","DB00780","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like phenelzine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Procarbazine","DB01168","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Rasagiline","DB01367","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Selegiline","DB01037","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Telithromycin","DB00976","Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed."
911,"Tranylcypromine","DB00752","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like tranylcypromine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
911,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Buprenorphine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
911,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed."
913,"Amikacin","DB00479","Increased risk of nephrotoxicity"
913,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
913,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
913,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
914,"Donepezil","DB00843","Possible antagonism of action"
914,"Galantamine","DB00674","Possible antagonism of action"
914,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
914,"Rasagiline","DB01367","Increased risk of toxicity with this association"
914,"Rivastigmine","DB00989","Possible antagonism of action"
914,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclobenzaprine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
914,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Cyclobenzaprine by decreasing Cyclobenzaprine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Cyclobenzaprine if Thiabendazole is initiated, discontinued or dose changed."
914,"Tramadol","DB00193","Increases risk of seizure. "
914,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant use should be avoided. These agents should not be administered within 14 days of each other. "
914,"Triprolidine","DB00427","Triprolidine and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
914,"Trospium","DB00209","Trospium and Cyclobenzaprine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
915,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Phenoxybenzamine. Monitor for hypotension during concomitant therapy."
915,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Phenoxybenzamine, may result in additive antihypertensive effects. Combination therapy is not recommended."
915,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
915,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Phenoxybenzamine, may occur. Monitor for hypotension during concomitant therapy. "
916,"Demeclocycline","DB00618","Increased risk of intracranial hypertension"
916,"Doxycycline","DB00254","Increased risk of intracranial hypertension"
916,"Methacycline","DB00931","Increased risk of intracranial hypertension"
916,"Methotrexate","DB00563","Acitretin/etretinate increases the effect and toxicity of methotrexate"
916,"Minocycline","DB01017","Increased risk of intracranial hypertension"
916,"Oxytetracycline","DB00595","Increased risk of intracranial hypertension"
916,"Rolitetracycline","DB01301","Increased risk of intracranial hypertension"
916,"Tetracycline","DB00759","Increased risk of intracranial hypertension"
917,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
917,"Cefditoren","DB01066","H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
917,"Enoxacin","DB00467","Famotidine may decrease the absorption of enoxacin."
917,"Itraconazole","DB01167","The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole."
917,"Ketoconazole","DB01026","The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole."
917,"Rilpivirine","DB08864","Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
918,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
919,"Carbetocin","DB01282","Misoprostol may enhance the therapeutic effect of Carbetocin. Avoid the concomitant use of carbetocin and misoprostol. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use. "
919,"Oxytocin","DB00107","Avoid combination. Manufacturer advises not to administer concomitantly due to enhanced adverse effects of oxytocin, especially when given within 4 hours of oxytocin initiation. "
920,"Alfacalcidol","DB01436","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Amiodarone","DB01118","Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted. "
920,"Bumetanide","DB00887","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as bumetanide. Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Calcitriol","DB00136","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Celecoxib","DB00482","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Chenodeoxycholic acid","DB06777","Bile Acid Sequestrants may decrease the serum concentration of Chenodiol. Consider administration of chenodiol 5 hours or more after bile acid sequestrants to reduce chenodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants. "
920,"Cholecalciferol","DB00169","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Demeclocycline","DB00618","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
920,"Desogestrel","DB00304","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Diclofenac","DB00586","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Diflunisal","DB00861","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Doxercalciferol","DB06410","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Doxycycline","DB00254","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
920,"Drospirenone","DB01395","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Ergocalciferol","DB00153","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Ethacrynic acid","DB00903","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as ethacrynic acid.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Ethinyl Estradiol","DB00977","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."
920,"Ethynodiol","DB00823","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Etodolac","DB00749","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Etonogestrel","DB00294","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Fenoprofen","DB00573","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Flurbiprofen","DB00712","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Furosemide","DB00695","Bile acid sequestrants such as colesevelam may decrease the absorption of loop diuretics such as furosemide.  Monitor for decreased serum concentrations/therapeutic effects of loop diuretics if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Glyburide","DB01016","Colesevelam may decrease the serum concentration of Glyburide. Glyburide should be administered at least 4 hours before colesevelam to minimize the risk of an interaction.\
"
920,"Ibuprofen","DB01050","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Indomethacin","DB00328","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Ketoprofen","DB01009","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Ketorolac","DB00465","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Leflunomide","DB01097","Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide. Unless using cholestyramine (or another bile acid sequestrant) together with leflunomide to intentionally enhance the removal/elimination of leflunomide, consider using an alternative to the bile acid sequestrants whenever possible. Separating the administration of these agents is unlikely to be an effective means of avoiding the interaction."
920,"Levonorgestrel","DB00367","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Meclofenamic acid","DB00939","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Medroxyprogesterone Acetate","DB00603","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Mefenamic acid","DB00784","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Meloxicam","DB00814","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Mestranol","DB01357","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."
920,"Minocycline","DB01017","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
920,"Nabumetone","DB00461","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Naproxen","DB00788","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Niacin","DB00627","Bile Acid Sequestrants may decrease the absorption of Niacin. It may be prudent to separate the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for reduced efficacy of these agents. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
920,"Norelgestromin","DB06713","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Norethindrone","DB00717","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Norgestimate","DB00957","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
920,"Oxaprozin","DB00991","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Paricalcitol","DB00910","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
920,"Phenytoin","DB00252","Colesevelam may decrease the serum concentration of Phenytoin. Phenytoin should be administered at least 4 hours prior to colesevelam. "
920,"Pioglitazone","DB01132","Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents. "
920,"Piroxicam","DB00554","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Pravastatin","DB00175","Bile Acid Sequestrants may decrease the serum concentration of Pravastatin. Administer pravastatin at least 1 hour before or 4 hours after administration of bile-acid resins (eg, cholestyramine, colestipol, colesevelam) to minimize the risk for any significant interaction. "
920,"Raloxifene","DB00481","Bile Acid Sequestrants may decrease the absorption of Raloxifene. It would seem prudent to separate the doses of raloxifene and bile acid sequestrants by at least 2 hours. The manufacturer of raloxifene recommends against coadministration of these agents.1 The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
920,"Rosiglitazone","DB00412","Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents. "
920,"Sulindac","DB00605","The bile acid sequestrant, colesevelam, may decrease the absorption of the NSAID, sulindac. Sulindac should be administered at least 1 hour before or 4 hours after colesevelam. Monitor for changes in the therapeutic and adverse effects of sulindac if colesevelam is initiated, discontinued or dose changed. "
920,"Tetracycline","DB00759","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
920,"Tiaprofenic acid","DB01600","The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect."
920,"Tolmetin","DB00500","Colesevelam may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
920,"Torasemide","DB00214","Colesevelam may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Colesevelam is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
920,"Trichlormethiazide","DB01021","The bile acid sequestrant, Colesevelam, may inhibit the absorption of Trichlormethiazide."
920,"Ursodeoxycholic acid","DB01586","Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants. "
921,"Acitretin","DB00459","Increased risk of intracranial hypertension"
921,"Amoxicillin","DB01060","Possible antagonism of action"
921,"Ampicillin","DB00415","Possible antagonism of action"
921,"Benzylpenicillin","DB01053","Possible antagonism of action"
921,"Calcium","DB01373","Formation of non-absorbable complexes"
921,"Carbenicillin","DB00578","Possible antagonism of action"
921,"Clavulanate","DB00766","Possible antagonism of action"
921,"Cloxacillin","DB01147","Possible antagonism of action"
921,"Dicloxacillin","DB00485","Possible antagonism of action"
921,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
921,"Etretinate","DB00926","Increased risk of intracranial hypertension"
921,"Flucloxacillin","DB00301","Possible antagonism of action"
921,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
921,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
921,"Magnesium","DB01378","Formation of non-absorbable complexes"
921,"Penicillin V","DB00417","Possible antagonism of action"
921,"Piperacillin","DB00319","Possible antagonism of action"
921,"Pivampicillin","DB01604","Possible antagonism of action"
921,"Pivmecillinam","DB01605","Possible antagonism of action"
922,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Tipranavir. The antiviral response should be closely monitored."
922,"Alprazolam","DB00404","Tipranavir may decrease the metabolism and clearance of Alprazolam. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. "
922,"Amiodarone","DB01118","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated."
922,"Amlodipine","DB00381","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Amlopidine. Monitor for changes in Amlopidine therapeutic and toxic effects if Tipranavir is initiated, discontinued or dose changed. "
922,"Astemizole","DB00637","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Astemizole. Concomitant therapy is contraindicated."
922,"Atazanavir","DB01072","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy. "
922,"Atorvastatin","DB01076","Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided."
922,"Bepridil","DB01244","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated."
922,"Bromazepam","DB01558","Tipranavir may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if tipranavir is initiated, discontinued or dose changed."
922,"Bromocriptine","DB01200","Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided."
922,"Budesonide","DB01222","Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration. "
922,"Carbamazepine","DB00564","Concomitant use may result in decreased Tipranavir and increased Carbamazepine concentrations. "
922,"Chlordiazepoxide","DB00475","Tipranavir may decrease the metabolism and clearance of Chlordiazepoxide. Consider alternate therapy or monitor for Alprazolam toxic effects if Tipranavir is initiated or dose increased. "
922,"Cisapride","DB00604","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Cisapride. Concomitant therapy is contraindicated."
922,"Clarithromycin","DB01211","The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment."
922,"Clobazam","DB00349","Tipranavir may decrease the metabolism and clearance of Clobazam. Consider alternate therapy or monitor for Clobazam toxic effects if Tipranavir is initiated or dose increased. "
922,"Clonazepam","DB01068","Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased. "
922,"Clorazepate","DB00628","Tipranavir may decrease the metabolism and clearance of Clorazepate. Consider alternate therapy or monitor for Clorazepate toxic effects if Tipranavir is initiated or dose increased. "
922,"Conjugated Estrogens","DB00286","Conjugated estrogens may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Conjugated estrogens. Monitor for estrogen deficiency during concomitant therapy. "
922,"Cyclosporine","DB00091","Tipranavir may affect the efficacy/toxicity of Cyclosporine. "
922,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
922,"Delavirdine","DB00705","Concomitant use may result in increased Tipranavir and decreased Delavirdine concentrations. Monitor for altered therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed. "
922,"Desipramine","DB01151","Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required. "
922,"Diazepam","DB00829","Tipranavir may decrease the metabolism and clearance of Diazepam. Consider alternate therapy or monitor for Diazepam toxic effects if Tipranavir is initiated or dose increased. "
922,"Didanosine","DB00900","Tipranavir may decrease the concentration of Didanosine."
922,"Diethylstilbestrol","DB00255","Diethylstilbestrol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Diethylstilbestrol. Monitor estrogen levels during concomitant therapy. "
922,"Dihydroergotamine","DB00320","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Dihydroergotamine. Concomitant therapy is contraindicated."
922,"Diltiazem","DB00343","Tipranavir, co-administered with Ritonavir, may alter the concentration of Diltiazem. Monitor for efficacy and adverse/toxic effects of Diltiazem. "
922,"Disulfiram","DB00822","Disulfiram may cause Tipranavir (Aptivus brand) toxicity by inhibiting alcohol metabolism. Aptivus capsules contain alcohol.  "
922,"Efavirenz","DB00625","Efavirenz may alter the serum concentration Tipranavir. Monitor for changes in Tipranavir therapeutic and adverse effects if Efavirenz is initiated, discontinued or dose changed. "
922,"Eptifibatide","DB00063","Monitor therapy due to increased antiplatelet effect."
922,"Ergoloid mesylate","DB01049","Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided."
922,"Ergonovine","DB01253","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated."
922,"Ergotamine","DB00696","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergotamine. Concomitant therapy is contraindicated."
922,"Esomeprazole","DB00736","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Esomeprazole. Consider alternate therapy or increase the dose of Esomeprazole based on the therapeutic response."
922,"Estazolam","DB01215","Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased. "
922,"Estradiol","DB00783","Estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estradiol. Use an alternate form of contraception or monitor for estrogen deficiency if Estradiol is used for hormone replacement therapy. "
922,"Estrone","DB00655","Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy. "
922,"Ethinyl Estradiol","DB00977","Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy. "
922,"Etravirine","DB06414","Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided."
922,"Felodipine","DB01023","Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine."
922,"Flecainide","DB01195","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated."
922,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of Tipranavir. Dose adjustments are not required."
922,"Fluoxetine","DB00472","Tipranavir increases the concentration of Fluoxetine. The Fluoxetine dose may require an adjustment."
922,"Flurazepam","DB00690","Tipranavir may decrease the metabolism and clearance of Flurazepam. Consider alternate therapy or monitor for Flurazepam toxic effects if Tipranavir is initiated or dose increased. "
922,"Fluticasone Propionate","DB00588","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Fluticasone propionate. Concomitant therapy should be avoided if possible."
922,"Fosamprenavir","DB01319","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy. "
922,"Fusidic Acid","DB02703","Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents. "
922,"Isradipine","DB00270","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Isradipine. Monitor for changes in Isradipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. "
922,"Itraconazole","DB01167","Tipranavir may increase the serum concentration of Itraconazole."
922,"Ketoconazole","DB01026","Tipranavir may increase the serum concentration of Ketoconazole. "
922,"Lopinavir","DB01601","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy. "
922,"Lovastatin","DB00227","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated."
922,"Mestranol","DB01357","Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy. "
922,"Methadone","DB00333","Tipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal. "
922,"Methylergometrine","DB00353","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Methylergonovine. Concomitant therapy is contraindicated."
922,"Midazolam","DB00683","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Midazolam. Concomitant therapy is contraindicated."
922,"Nevirapine","DB00238","Nevirapine, a CYP3A4 inducer, may decrease the serum concentration of Tipranavir, a CYP3A4 substrate. Monitor for changesin Tipranavir effect if Nevirapine is initiated, discontinued or dose changed. "
922,"Nicardipine","DB00622","Tipranavir, co-administered with Ritonavir, may alter the concentration of Nicardipine. Monitor for efficacy and adverse/toxic effects of Nicardipine."
922,"Nifedipine","DB01115","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. "
922,"Nimodipine","DB00393","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nimodipine. Monitor for changes in Nimodipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."
922,"Nisoldipine","DB00401","Tipranavir, co-administered with Ritonavir, may alter the concentration of Nisoldipine. Monitor for efficacy and adverse/toxic effects of Nisoldipine."
922,"Nitrendipine","DB01054","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."
922,"Omeprazole","DB00338","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Omeprazole. Consider alternate therapy or increase the dose of Omeprazole based on the therapeutic response. "
922,"Paroxetine","DB00715","Tipranavir increases the concentration of Paroxetine. The Paroxetine dose may require an adjustment."
922,"Pergolide","DB01186","Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided."
922,"Pethidine","DB00454","Tipranavir may increase the adverse/toxic effects of Meperidine. Consider alternate therapy or monitor for Meperidine toxicity during concomitant use. "
922,"Phenobarbital","DB01174","Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."
922,"Phenytoin","DB00252","Phenytoin decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."
922,"Pimozide","DB01100","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated."
922,"Posaconazole","DB01263","Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir."
922,"Pravastatin","DB00175","Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy."
922,"Prazepam","DB01588","Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased. "
922,"Propafenone","DB01182","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated."
922,"Quazepam","DB01589","Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased. "
922,"Quinidine","DB00908","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Quinidine. Concomitant therapy is contraindicated."
922,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
922,"Rifabutin","DB00615","Tipranavir increases the concentration of Rifabutin. Adjust Rifabutin dose and monitor for adverse/toxic effects. "
922,"Rifampicin","DB01045","Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended. "
922,"Rifapentine","DB01201","Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations. "
922,"Rosuvastatin","DB01098","Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy. "
922,"Saquinavir","DB01232","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy. "
922,"Sertraline","DB01104","Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment."
922,"Sildenafil","DB00203","Tipranavir, co-administered with Ritonavir, may increase the concentration of Sildenafil. Alternate therapy should be considered."
922,"Simvastatin","DB00641","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Simvastatin. Concomitant therapy is contraindicated."
922,"Sirolimus","DB00877","Tipranavir may affect the efficacy/toxicity of Sirolimus. "
922,"Sodium bicarbonate","DB01390","Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir. "
922,"St. John's Wort","DB01323","St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided."
922,"Tacrolimus","DB00864","Tipranavir may decrease the metabolism and clearance of Tacrolimus. Dose adjustments may be required. Monitor for Tacrolimus efficacy and toxicity during concomitant therapy."
922,"Tadalafil","DB00820","Tipranavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
922,"Temsirolimus","DB06287","Tipranavir may affect the efficacy/toxicity of Temsirolimus."
922,"Terfenadine","DB00342","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Terfenadine. Concomitant therapy is contraindicated."
922,"Theophylline","DB00277","Tipranavir, co-administered with Ritonavir, may decrease the concentration of Theophylline. "
922,"Trazodone","DB00656","The protease inhibitor, Tipranavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Tipranavir is initiated, discontinued or dose changed."
922,"Triazolam","DB00897","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Triazolam. Concomitant therapy is contraindicated."
922,"Valproic Acid","DB00313","Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy."
922,"Vardenafil","DB00862","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Vardenafil. Concomitant therapy is contraindicated."
922,"Verapamil","DB00661","Tipranavir, co-administered with Ritonavir, may alter the concentration of Verapamil. Monitor for efficacy and adverse/toxic effects of Verapamil."
922,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of tipranavir by decreasing its metabolism. Tipranavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
922,"Zidovudine","DB00495","Tipranavir decreases the concentration of Zidovudine. "
923,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
923,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
923,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
923,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
923,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
923,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
923,"Benzylpenicillin","DB01053","Increased risk of cardiotoxicity and arrhythmias"
923,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
923,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
923,"Chloroquine","DB00608","Increased risk of cardiotoxicity and arrhythmias"
923,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
923,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
923,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
923,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
923,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
923,"Diltiazem","DB00343","Increased risk of cardiotoxicity and arrhythmias"
923,"Diphenhydramine","DB01075","Increased risk of cardiotoxicity and arrhythmias"
923,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
923,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
923,"Donepezil","DB00843","Possible antagonism of action"
923,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
923,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
923,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
923,"Flecainide","DB01195","Increased risk of cardiotoxicity and arrhythmias"
923,"Fluoxetine","DB00472","Increased risk of cardiotoxicity and arrhythmias"
923,"Fluvoxamine","DB00176","Increased risk of cardiotoxicity and arrhythmias"
923,"Galantamine","DB00674","Possible antagonism of action"
923,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
923,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
923,"Guanethidine","DB01170","Mesoridazine may decrease the effect of guanethidine."
923,"Halofantrine","DB01218","Increased risk of cardiotoxicity and arrhythmias"
923,"Haloperidol","DB00502","Increased risk of cardiotoxicity and arrhythmias"
923,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
923,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
923,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
923,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
923,"Maprotiline","DB00934","Increased risk of cardiotoxicity and arrhythmias"
923,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
923,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
923,"Metrizamide","DB01578","Increased risk of cardiotoxicity and arrhythmias"
923,"Paroxetine","DB00715","Increased risk of cardiotoxicity and arrhythmias"
923,"Pentamidine","DB00738","Increased risk of cardiotoxicity and arrhythmias"
923,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
923,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
923,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
923,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
923,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
923,"Pindolol","DB00960","Increased risk of cardiotoxicity and arrhythmias"
923,"Procainamide","DB01035","Increased risk of cardiotoxicity and arrhythmias"
923,"Propafenone","DB01182","Increased risk of cardiotoxicity and arrhythmias."
923,"Propranolol","DB00571","Increased risk of cardiotoxicity and arrhythmias"
923,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
923,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
923,"Quinine","DB00468","Increased risk of cardiotoxicity and arrhythmias"
923,"Rivastigmine","DB00989","Possible antagonism of action"
923,"Sertindole","DB06144","Increased risk of cardiotoxicity and arrhythmias"
923,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
923,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
923,"Spiramycin","DB06145","Increased risk of cardiotoxicity and arrhythmias"
923,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Mesoridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
923,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
923,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
923,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
923,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
923,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
923,"Trimethobenzamide","DB00662","Trimethobenzamide and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
923,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
923,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Mesoridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
923,"Trospium","DB00209","Trospium and Mesoridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
923,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
923,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
923,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
923,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
924,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
924,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
924,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
924,"Donepezil","DB00843","Possible antagonism of action"
924,"Galantamine","DB00674","Possible antagonism of action"
924,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
924,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
924,"Propranolol","DB00571","Propranolol increases the serum levels of cisapride"
924,"Rivastigmine","DB00989","Possible antagonism of action"
924,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Maprotiline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
924,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
924,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Maprotiline. Consider alternate therapy or monitor for therapeutic/adverse effects of Maprotiline if Terbinafine is initiated, discontinued or dose changed."
924,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
924,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
924,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
924,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
924,"Tranylcypromine","DB00752","Maprotiline may increase the adverse effects of the MAO inhibitor, Tranylcypromine. These agents should not be administered within 14 days of each other. "
924,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
924,"Trimethobenzamide","DB00662","Trimethobenzamide and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
924,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
924,"Triprolidine","DB00427","Triprolidine and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
924,"Trospium","DB00209","Trospium and Maprotiline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
924,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
924,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
924,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
924,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
924,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
924,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
925,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Oxymetazoline. Concomitant therapy should be avoided. "
927,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
927,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
927,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms"
927,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
927,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
927,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
927,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
927,"Guanethidine","DB01170","Diethylpropion may decrease the effect of guanethidine."
927,"Isocarboxazid","DB01247","Possible hypertensive crisis"
927,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
927,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
927,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
927,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
927,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
927,"Phenelzine","DB00780","Possible hypertensive crisis"
927,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
927,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
927,"Promethazine","DB01069","Decreased anorexic effect, may increase psychotic symptoms."
927,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
927,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
927,"Rasagiline","DB01367","Possible hypertensive crisis"
927,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
927,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
927,"Tranylcypromine","DB00752","Possible hypertensive crisis"
927,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
927,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
927,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
928,"Acebutolol","DB01193","Antagonism"
928,"Atenolol","DB00335","Antagonism"
928,"Bisoprolol","DB00612","Antagonism"
928,"Carvedilol","DB01136","Antagonism"
928,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol. Concurrent use of salmeterol with strong inhibitors of CYP3A4 is not recommended according to salmeterol prescribing information. "
928,"Esmolol","DB00187","Antagonism"
928,"Indacaterol","DB05039","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
928,"Labetalol","DB00598","Antagonism"
928,"Metoprolol","DB00264","Antagonism"
928,"Nadolol","DB01203","Antagonism"
928,"Oxprenolol","DB01580","Antagonism"
928,"Pindolol","DB00960","Antagonism"
928,"Propranolol","DB00571","Antagonism"
928,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
928,"Telithromycin","DB00976","Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated."
928,"Timolol","DB00373","Antagonism"
928,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor may increase the serum concentration of salmeterol by decreasing its metabolism. Consider alternate therapy. "
929,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
929,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
929,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
929,"Eltrombopag","DB06210","Increases levels of Meclofenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
929,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
929,"Methotrexate","DB00563","The NSAID, meclofenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
929,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
929,"Telmisartan","DB00966","Concomitant use of Telmisartan and Meclofenamic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
929,"Timolol","DB00373","The NSAID, Meclofenamate, may antagonize the antihypertensive effect of Timolol."
929,"Trandolapril","DB00519","The NSAID, Meclofenamate, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Meclofenamate is initiated, discontinued or dose changed. "
929,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Meclofenamate. Monitor for increased bleeding during concomitant thearpy. "
929,"Warfarin","DB00682","The antiplatelet effects of meclofenamic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. "
930,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
930,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Methantheline, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
930,"Trimethobenzamide","DB00662","Trimethobenzamide and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
930,"Triprolidine","DB00427","Triprolidine and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
930,"Trospium","DB00209","Trospium and Methantheline, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
933,"Didanosine","DB00900","Additive toxicities (peripheral neuropathy)"
933,"Lamivudine","DB00709","Lamivudine may reduce the efficacy of zalcitabine. Combination therapy is not recommended."
933,"Pentamidine","DB00738","Additive risk of pancreatitis. Concomitant therapy should be avoided. "
933,"Ribavirin","DB00811","Ribavirin may increase the hepatotoxicity of zalcitabine. May cause lactic acidosis. MOnitor for lactic acidosis during concomitant therapy."
934,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Demcarium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
935,"Acenocoumarol","DB01418","Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol."
935,"Acetazolamide","DB00819","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide."
935,"Acetohexamide","DB00414","Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide."
935,"Anisindione","DB01125","Acetylsalicylic acid increases effect of the anticoagulant, anisindione."
935,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
935,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Chlorpropamide","DB00672","Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide."
935,"Cortisone acetate","DB01380","The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Diclofenamide","DB01144","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide."
935,"Dicoumarol","DB00266","Acetylsalicylic acid increases effect of the anticoagulant, dicumarol."
935,"Eltrombopag","DB06210","Decreases metabolism, will increase effect/level of eltrombopag."
935,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
935,"Gliclazide","DB01120","Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide."
935,"Glipizide","DB01067","Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide."
935,"Glisoxepide","DB01289","Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide."
935,"Glyburide","DB01016","Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide."
935,"Glycodiazine","DB01382","Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine."
935,"Griseofulvin","DB00400","Griseofulvin may decrease the efficacy of acetylsalicylic acid. "
935,"Heparin","DB01109","Increased risk of bleeding. "
935,"Homoharringtonine","DB04865","Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
935,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Ibuprofen","DB01050","Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended."
935,"Ketoprofen","DB01009","Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended. "
935,"Ketorolac","DB00465","Acetylsalicylic acid may increase the adverse GI effects ketorolac."
935,"Methazolamide","DB00703","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
935,"Methotrexate","DB00563","Acetylsalicylic acid increases the effect and toxicity of methotrexate."
935,"Methylprednisolone","DB00959","The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Paramethasone","DB01384","The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Probenecid","DB01032","Acetylsalicylic acid decreases the uricosuric effect of probenecid."
935,"Sulindac","DB00605","Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. "
935,"Telmisartan","DB00966","Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
935,"Tiaprofenic acid","DB01600","Increased risk of gastrointestinal bleeding. "
935,"Ticlopidine","DB00208","Increased effect of ticlopidine"
935,"Tolazamide","DB00839","Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide."
935,"Tolbutamide","DB01124","Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide."
935,"Tolmetin","DB00500","Additive adverse effects increase the risk of gastrointestinal bleeding. Possible decrease in the cardioprotective effect of acetylsalicylic acid. Monitor for increased bleeding risk during concomitant therapy. "
935,"Trandolapril","DB00519","Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed. "
935,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy. "
935,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid."
935,"Valproic Acid","DB00313","Acetylsalicylic acid increases the effect of valproic acid."
935,"Warfarin","DB00682","The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin."
938,"Demeclocycline","DB00618","Possible antagonism of action"
938,"Doxycycline","DB00254","Possible antagonism of action"
938,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
938,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
938,"Minocycline","DB01017","Possible antagonism of action"
938,"Tetracycline","DB00759","Possible antagonism of action"
939,"Carbamazepine","DB00564","Decreased effect of both products"
939,"Ethotoin","DB00754","Increased phenytoin levels and decreased felbamate levels"
939,"Fosphenytoin","DB01320","Increased phenytoin levels and decreased felbamate levels"
939,"Mephenytoin","DB00532","Increased phenytoin levels and decreased felbamate levels"
939,"Phenobarbital","DB01174","Felbamate increases the effect and toxicity of phenobarbital/primidone"
939,"Phenytoin","DB00252","Increased phenytoin levels and decreased felbamate levels"
939,"Primidone","DB00794","Felbamate may increase the effect and toxicity of primidone."
939,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
939,"Telithromycin","DB00976","Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed."
939,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Felbamate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
939,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
939,"Valproic Acid","DB00313","Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed. "
939,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed."
940,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
940,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Fexofenadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
940,"Trimethobenzamide","DB00662","Trimethobenzamide and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
940,"Triprolidine","DB00427","Triprolidine and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
940,"Trospium","DB00209","Trospium and Fexofenadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
941,"Acenocoumarol","DB01418","Isoniazid may increase the anticoagulant effect of acenocoumarol."
941,"Acetaminophen","DB00316","Risk of hepatotoxicity"
941,"Aminophylline","DB01223","Isoniazid may increase the effect and toxicity of oxtriphylline."
941,"Anisindione","DB01125","Isoniazid may increase the anticoagulant effect of anisindione."
941,"Bromazepam","DB01558","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required. "
941,"Carbamazepine","DB00564","Carbamazepine effect is increased as is isoniazid toxicity"
941,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
941,"Dantrolene","DB01219","Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed. "
941,"Dicoumarol","DB00266","Isoniazid may increase the anticoagulant effect of dicumarol."
941,"Disulfiram","DB00822","Increased risk of CNS adverse effects"
941,"Dyphylline","DB00651","Increases the effect and toxicity of theophylline"
941,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
941,"Ethotoin","DB00754","Isoniazid increases the effect of phenytoin in 20% of patients"
941,"Fosphenytoin","DB01320","Isoniazid may increase the effect of phenytoin in 20% of patients."
941,"Ketoconazole","DB01026","Isoniazid decreases the effect of ketoconazole"
941,"Mephenytoin","DB00532","Isoniazid increases the effect of phenytoin in 20% of patients"
941,"Oxtriphylline","DB01303","Isoniazid may increase the effect and toxicity of oxtriphylline."
941,"Pethidine","DB00454","Possible episodes of hypotension"
941,"Phenytoin","DB00252","Isoniazid increases the effect of phenytoin in 20% of patients"
941,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed."
941,"Tadalafil","DB00820","Isoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
941,"Tamoxifen","DB00675","Isoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed."
941,"Tamsulosin","DB00706","Isoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed."
941,"Telithromycin","DB00976","Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
941,"Temsirolimus","DB06287","Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
941,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed."
941,"Theophylline","DB00277","Isoniazid may increase the therapeutic and adverse effects of theophylline."
941,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed."
941,"Tolterodine","DB01036","Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
941,"Tramadol","DB00193","Isoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production. "
941,"Trazodone","DB00656","The CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed. "
941,"Trimipramine","DB00726","The strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed. "
941,"Vardenafil","DB00862","Isoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
941,"Venlafaxine","DB00285","Isoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed."
941,"Verapamil","DB00661","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed. "
941,"Vinblastine","DB00570","Isoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed."
941,"Vincristine","DB00541","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed."
941,"Vinorelbine","DB00361","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed."
941,"Warfarin","DB00682","Isoniazid may increase the anticoagulant effect of warfarin."
941,"Zolpidem","DB00425","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed. "
941,"Zonisamide","DB00909","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed."
941,"Zopiclone","DB01198","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed."
942,"Citalopram","DB00215","Increased risk of CNS adverse effects"
942,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
942,"Dihydroergotamine","DB00320","Naratriptan, a serotonin 5-HT1D receptor agonists, may increase the vasoconstricting effect of dihydroergotamine. Concomitant use of these two agents within 24 hours is contraindicated."
942,"Ergonovine","DB01253","Possible severe and prolonged vasocontriction"
942,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction."
942,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
942,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
942,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
942,"Isocarboxazid","DB01247","The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome."
942,"Methylergometrine","DB00353","Possible severe and prolonged vasocontriction"
942,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction."
942,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
942,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
942,"Phenelzine","DB00780","The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome."
942,"Sertraline","DB01104","Increased risk of CNS adverse effects"
942,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
942,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
942,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."
942,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
942,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
942,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
942,"Vilazodone","DB06684","Increased risk of serotonin syndrome"
942,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
943,"Citalopram","DB00215","Increased risk of CNS adverse effects"
943,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
943,"Dihydroergotamine","DB00320","Possible severe and prolonged vasoconstriction"
943,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction"
943,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
943,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
943,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
943,"Isocarboxazid","DB01247","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
943,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
943,"Moclobemide","DB01171","The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
943,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
943,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
943,"Phenelzine","DB00780","The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
943,"Propranolol","DB00571","Propranolol increases the effect and toxicity of rizatriptan"
943,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
943,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant therapy should be avoided. "
943,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
943,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
943,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
943,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
944,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
944,"Vinblastine","DB00570","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Dirithromycin is initiated, discontinued or dose changed."
944,"Vincristine","DB00541","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Dirithromycin is initiated, discontinued or dose changed.\
"
944,"Vinorelbine","DB00361","Dirithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Dirithromycin is initiated, discontinued or dose changed."
945,"Atracurium","DB00732","The agent increases the effect of muscle relaxant"
945,"Bumetanide","DB00887","Increased ototoxicity"
945,"Cefamandole","DB01326","Increased risk of nephrotoxicity"
945,"Cefapirin","DB01139","Increased risk of nephrotoxicity"
945,"Cefazolin","DB01327","Increased risk of nephrotoxicity"
945,"Cefonicid","DB01328","Increased risk of nephrotoxicity"
945,"Cefoperazone","DB01329","Increased risk of nephrotoxicity"
945,"Ceforanide","DB00923","Increased risk of nephrotoxicity"
945,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
945,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
945,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
945,"Cefradine","DB01333","Increased risk of nephrotoxicity"
945,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
945,"Ceftizoxime","DB01332","Increased risk of nephrotoxicity"
945,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
945,"Cefuroxime","DB01112","Increased risk of nephrotoxicity"
945,"Cephalothin Group","DB03450","Increased risk of nephrotoxicity"
945,"Cisplatin","DB00515","Increased risk of nephrotoxicity"
945,"Doxacurium chloride","DB01135","The agent increases the effect of muscle relaxant"
945,"Ethacrynic acid","DB00903","Increased ototoxicity"
945,"Furosemide","DB00695","Increased ototoxicity"
945,"Metocurine","DB01336","The agent increases the effect of muscle relaxant"
945,"Mivacurium","DB01226","The agent increases the effect of muscle relaxant"
945,"Pancuronium","DB01337","The agent increases the effect of muscle relaxant"
945,"Pipecuronium","DB01338","The agent increases the effect of muscle relaxant"
945,"Rocuronium","DB00728","The agent increases the effect of muscle relaxant"
945,"Succinylcholine","DB00202","The agent increases the effect of muscle relaxant"
945,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Netilmicin. Use caution during concomitant therapy. "
945,"Thalidomide","DB01041","Thalidomide increases the renal toxicity of the aminoglycoside"
945,"Torasemide","DB00214","Increased ototoxicity"
945,"Tubocurarine","DB01199","The agent increases the effect of muscle relaxant"
945,"Vecuronium","DB01339","The agent increases the effect of muscle relaxant"
946,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
946,"Eltrombopag","DB06210","Increases levels of Hydrocodone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
946,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Hydrocodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
947,"Artemether","DB06697","Artemether may decrease the effectiveness of norgestimate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
947,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norgestimate, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
947,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
947,"Thiopental","DB00599","Thiopental may decrease the effect of Norgestimate. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
947,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Norgestimate. An alternate form of contraception should be used during concomitant therapy. "
947,"Warfarin","DB00682","Norgestimate may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if norgestimate is initiated, discontinued or dose changed."
948,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
948,"Docetaxel","DB01248","Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent. "
948,"Fosphenytoin","DB01320","The antineoplasic agent decreases the effect of hydantoin"
948,"Leflunomide","DB01097","Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
948,"Natalizumab","DB00108","Immunosuppressants such as natalizumab may enhance the adverse/toxic effect of natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants."
948,"Paclitaxel","DB01229","Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent. "
948,"Phenytoin","DB00252","The antineoplasic agent decreases the effect of hydantoin"
948,"Pimecrolimus","DB00337","Pimecrolimus may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of pimecrolimus cream in patients receiving immunosuppressants. "
948,"Roflumilast","DB01656","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carboplatin. he Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
948,"Sorafenib","DB00398","Sorafenib may enhance the adverse/toxic effect of carboplatin. Concurrent use of sorafenib with carboplatin and placlitaxel in patients with squamous cell lung cancer is contraindicated. The use of this combination in other settings is not specifically contraindicated, but any such use should be approached with added caution."
948,"Tacrolimus","DB00864","Tacrolimus (Topical) may enhance the adverse/toxic effect of immunosuppressants such as carboplatin. Avoid use of tacrolimus ointment in patients receiving immunosuppressants. "
948,"Topotecan","DB01030","Administration of Topotecan after Carboplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
948,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
949,"Acetylsalicylic acid","DB00945","The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid."
949,"Aprepitant","DB00673","Increases the effect and toxicity of methylprednisolone"
949,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect of corticosteroid, methylprednisolone."
949,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Methylprednisolone. Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for increased steroid related adverse effects. "
949,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect of corticosteroid, methylprednisolone."
949,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone."
949,"Itraconazole","DB01167","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."
949,"Ketoconazole","DB01026","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."
949,"Midodrine","DB00211","Increased arterial pressure"
949,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone."
949,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, methylprednisolone."
949,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, methylprednisolone."
949,"Pyridostigmine","DB00545","The corticosteroid, methylprednisolone, may decrease the effect of the anticholinesterase, pyridostigmine."
949,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
949,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone."
949,"Tacrine","DB00382","Tacrine and Methylprednisolone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
949,"Tacrolimus","DB00864","Methylprednisone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Methylprednisone therapy is initiated, discontinued or altered."
949,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
949,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
950,"Acetohexamide","DB00414","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
950,"Chlorpromazine","DB00477","Increased effect of both drugs"
950,"Chlorpropamide","DB00672","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
950,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
950,"Diltiazem","DB00343","Increased risk of bradycardia"
950,"Disopyramide","DB00280","The beta-blocker, pindolol, may increase the toxicity of disopyramide."
950,"Dyphylline","DB00651","Antagonism of action and increased effect of theophylline"
950,"Epinephrine","DB00668","Hypertension, then bradycardia"
950,"Ergonovine","DB01253","Ischemia with risk of gangrene"
950,"Ergotamine","DB00696","Ischemia with risk of gangrene"
950,"Fenoterol","DB01288","Antagonism"
950,"Formoterol","DB00983","Antagonism"
950,"Gliclazide","DB01120","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Glipizide","DB01067","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Glisoxepide","DB01289","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Glyburide","DB01016","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Glycodiazine","DB01382","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
950,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
950,"Insulin Glargine","DB00047","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Isoprenaline","DB01064","Antagonism"
950,"Lidocaine","DB00281","The beta-blocker increases the effect and toxicity of lidocaine"
950,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
950,"Methyldopa","DB00968","Possible hypertensive crisis"
950,"Methysergide","DB00247","Ischemia with risk of gangrene"
950,"Orciprenaline","DB00816","Antagonism"
950,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
950,"Pipobroman","DB00236","Antagonism"
950,"Pirbuterol","DB01291","Antagonism"
950,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
950,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
950,"Procaterol","DB01366","Antagonism"
950,"Repaglinide","DB00912","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Salbutamol","DB01001","Antagonism"
950,"Salmeterol","DB00938","Antagonism"
950,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
950,"Terbutaline","DB00871","Antagonism"
950,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
950,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
950,"Tolazamide","DB00839","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Tolbutamide","DB01124","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
950,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
950,"Verapamil","DB00661","Increased effect of both drugs"
952,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of zaleplon by decreasing its metabolism. Reduce the initial dose of zaleplon to 5 mg in patients receiving cimetidine."
952,"Methotrimeprazine","DB01403","Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy. "
952,"Rifampicin","DB01045","Rifampin decreases the effect of zaleplon"
952,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Zaleplon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
953,"Difluprednate","DB06781","NSAIDs may slow healing. "
953,"Eltrombopag","DB06210","Eltrombopag increases levels of Bromfenac via metabolism decrease."
954,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha2-agonist, Apraclonidine. Concomitant therapy is contraindicated."
954,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
956,"Acetylsalicylic acid","DB00945","Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Amifostine","DB01143","Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
956,"Amiloride","DB00594","Telmisartan may increase the hyperkalemic effect of Amiloride. Monitor for increased serum potassium concentrations during concomitant therapy."
956,"Celecoxib","DB00482","Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Diclofenac","DB00586","Concomitant use of Telmisartan and Diclofenac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Diflunisal","DB00861","Concomitant use of Telmisartan and Diflunisal may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Digoxin","DB00390","Telmisartan may increase plasma Digoxin concentrations. Monitor Digoxin levels and adjust dose as required if Telmisartan is initiated, discontinued or dose changed."
956,"Drospirenone","DB01395","Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy. "
956,"Fenoprofen","DB00573","Concomitant use of Telmisartan and Fenoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Flurbiprofen","DB00712","Concomitant use of Telmisartan and Flurbiprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Indomethacin","DB00328","Concomitant use of Telmisartan and Indomethacin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Ketoprofen","DB01009","Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Ketorolac","DB00465","Concomitant use of Telmisartan and Ketorolac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Lithium","DB01356","Telmisartan may increase serum Lithium concentrations. Monitor serum Lithium levels during concomitant therapy to avoid Lithium toxicity."
956,"Lumiracoxib","DB01283","Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Meclofenamic acid","DB00939","Concomitant use of Telmisartan and Meclofenamic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Meloxicam","DB00814","Concomitant use of Telmisartan and Meloxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Nabumetone","DB00461","Concomitant use of Telmisartan and Nabumetone may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Naproxen","DB00788","Concomitant use of Telmisartan and Naproxen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Oxaprozin","DB00991","Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Piroxicam","DB00554","Concomitant use of Telmisartan and Piroxicam may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Potassium","DB01345","Potassium may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use."
956,"Potassium Chloride","DB00761","Potassium Chloride may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use. "
956,"Rituximab","DB00073","Telmisartan may increase the hypotensive effect of Rituximab. Telmisartan should be withheld prior to and throughout Rituximab administration. "
956,"Spironolactone","DB00421","Telmisartan may increase the hyperkalemic effect of Spironolactone. Monitor for increased serum potassium concentrations during concomitant therapy. "
956,"Sulindac","DB00605","Concomitant use of Telmisartan and Sulindac may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Tiaprofenic acid","DB01600","Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
956,"Tolmetin","DB00500","Concomitant use of Telmisartan and Tolmetin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
956,"Trandolapril","DB00519","The angiotensin II receptor blocker, Telmisartan, may increase the adverse effects of Trandolapril. "
956,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
956,"Triamterene","DB00384","Telmisartan may increase the hyperkalemic effect of Triamterene. Monitor for increased serum potassium concentrations during concomitant therapy."
957,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desloratadine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
957,"Triprolidine","DB00427","Triprolidine and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
957,"Trospium","DB00209","Trospium and Desloratadine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
958,"Carteolol","DB00521","Possible hypertensive crisis"
958,"Dobutamine","DB00841","Increased arterial pressure"
958,"Dopamine","DB00988","Increased arterial pressure"
958,"Entacapone","DB00494","Entacapone may increase the effect and toxicity of the sympathomimetic, methyldopa."
958,"Ephedra","DB01363","Increased arterial pressure"
958,"Ephedrine","DB01364","Increased arterial pressure"
958,"Epinephrine","DB00668","Increased arterial pressure"
958,"Fenoterol","DB01288","Increased arterial pressure"
958,"Haloperidol","DB00502","Methyldopa increases haloperidol effect or risk of psychosis"
958,"Iron","DB01592","Iron decreases the absorption of dopa derivatives"
958,"Iron Dextran","DB00893","Iron decreases the absorption of dopa derivatives"
958,"Isoprenaline","DB01064","Increased arterial pressure"
958,"L-DOPA","DB01235","Methyldopa increases the effect and toxicity of levodopa"
958,"Lithium","DB01356","Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy."
958,"Mephentermine","DB01365","Increased arterial pressure"
958,"Metaraminol","DB00610","Increased arterial pressure"
958,"Methoxamine","DB00723","Increased arterial pressure"
958,"Nadolol","DB01203","Possible hypertensive crisis"
958,"Norepinephrine","DB00368","Increased arterial pressure"
958,"Orciprenaline","DB00816","Increased arterial pressure"
958,"Oxprenolol","DB01580","Possible hypertensive crisis"
958,"Penbutolol","DB01359","Possible hypertensive crisis"
958,"Phenylephrine","DB00388","Increased arterial pressure"
958,"Phenylpropanolamine","DB00397","Increased arterial pressure"
958,"Pindolol","DB00960","Possible hypertensive crisis"
958,"Pirbuterol","DB01291","Increased arterial pressure"
958,"Procaterol","DB01366","Increased arterial pressure"
958,"Propranolol","DB00571","Possible hypertensive crisis"
958,"Pseudoephedrine","DB00852","Increased arterial pressure"
958,"Salbutamol","DB01001","Increased arterial pressure"
958,"Sotalol","DB00489","Possible hypertensive crisis"
958,"Terbutaline","DB00871","Increased arterial pressure"
958,"Timolol","DB00373","Possible hypertensive crisis"
958,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the adverse effects of Methyldopa. Concomitant therapy is contraindicated."
959,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Alosetron by decreasing Alosetron metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Alosetron if Thiabendazole is initiated, discontinued or dose changed."
960,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
961,"Eltrombopag","DB06210","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
962,"Dihydrocodeine","DB01551","Enhanced CNS depressant effects contraindicates concurrent use. "
962,"gabapentin enacarbil","DB08872","Avoid combination due to increased CNS depression."
962,"Perampanel","DB08883","Avoid combination with azelastine or other CNS depressants due to the combined increase of CNS depression.\
\
"
962,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Azelastine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
962,"Trimethobenzamide","DB00662","Trimethobenzamide and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
962,"Triprolidine","DB00427","Concomitant therapy with triprolidine and azelastine, two anticholinergics and CNS depressants, may result in additive adverse/toxic effects. Monitor for enhanced anticholinergic and CNS depressant effects during concomitant therapy."
962,"Trospium","DB00209","Trospium and Azelastine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
963,"Cholestyramine","DB01432","Cholestyramine may decrease the levels of ezetimibe."
963,"Cyclosporine","DB00091","Cyclosporine may increase the therapeutic and adverse effects of ezetimibe."
963,"Warfarin","DB00682","If ezetimibe is added to warfarin, a coumarin anticoagulant, the International Normalized Ratio (INR) should be appropriately monitored."
964,"Insulin Aspart","DB01306","Monitor therapy due to enhanced hypoglycemic effect."
965,"Adenosine","DB00640","Dipyridamole may increase the effect/toxicity of adenosine."
965,"Fludarabine","DB01073","Dipyridamole may decrease the effect of fludarabine."
965,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
965,"Regadenoson","DB06213","Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration. "
965,"Topotecan","DB01030","The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
965,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use."
966,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
966,"Acenocoumarol","DB01418","Telithromycin may increase the anticoagulant effect of acenocoumarol."
966,"Alfentanil","DB00802","Telithromycin may reduce clearance of Alfentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Alfentanil if Telithromycin is initiated, discontinued or dose changed. "
966,"Alfuzosin","DB00346","Telithromycin may reduce clearance of Alfuzosin. Consider alternate therapy."
966,"Alprazolam","DB00404","Telithromycin may increase the effect and toxicity of the benzodiazepine, alprazolam."
966,"ambrisentan","DB06403","Telithromycin may reduce clearance of Ambrisentan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ambrisentan if Telithromycin is initiated, discontinued or dose changed."
966,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Amiodarone","DB01118","Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed."
966,"Amlodipine","DB00381","Telithromycin may reduce clearance of Amlopidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amlopidine if Telithromycin is initiated, discontinued or dose changed."
966,"Amprenavir","DB00701","Co-administration may result in altered plasma concentrations of Amprenavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Anisindione","DB01125","Telithromycin may increase the anticoagulant effect of anisindione."
966,"Aprepitant","DB00673","Telithromycin may reduce clearance of Aprepitant. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aprepitant if Telithromycin is initiated, discontinued or dose changed."
966,"Aripiprazole","DB01238","Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed."
966,"armodafinil","DB06413","Telithromycin may reduce clearance of Armodafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Armodafinil if Telithromycin is initiated, discontinued or dose changed."
966,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
966,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
966,"Atazanavir","DB01072","Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Atorvastatin","DB01076","The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed."
966,"Benzphetamine","DB00865","Telithromycin may reduce clearance of Benzphetamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Benzphetamine if Telithromycin is initiated, discontinued or dose changed."
966,"Bisoprolol","DB00612","Telithromycin may reduce clearance of Bisoprolol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bisoprolol if Telithromycin is initiated, discontinued or dose changed."
966,"Bortezomib","DB00188","Telithromycin may reduce clearance of Bortezomib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bortezomib if Telithromycin is initiated, discontinued or dose changed."
966,"Bosentan","DB00559","Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy."
966,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
966,"Bromazepam","DB01558","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required."
966,"Bromocriptine","DB01200","Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed."
966,"Budesonide","DB01222","Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed."
966,"Buprenorphine","DB00921","Telithromycin may reduce clearance of Buprenorphine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buprenorphine if Telithromycin is initiated, discontinued or dose changed."
966,"Buspirone","DB00490","Telithromycin may reduce clearance of Buspirone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Buspirone if Telithromycin is initiated, discontinued or dose changed."
966,"Busulfan","DB01008","Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed."
966,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
966,"Calcitriol","DB00136","Telithromycin may reduce clearance of Calcitriol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Calcitriol if Telithromycin is initiated, discontinued or dose changed."
966,"Carbamazepine","DB00564","Co-administration may cause decreased Telithromycin and increased Carbemazepine plasma concentrations. Consider alternate therapy."
966,"Chlordiazepoxide","DB00475","Telithromycin may reduce clearance of Chlordiazepoxide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlordiazepoxide if Telithromycin is initiated, discontinued or dose changed."
966,"Chloroquine","DB00608","Telithromycin may reduce clearance of Chloroquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chloroquine if Telithromycin is initiated, discontinued or dose changed."
966,"Chlorphenamine","DB01114","Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed."
966,"Ciclesonide","DB01410","Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed."
966,"Cilostazol","DB01166","Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed."
966,"Cinacalcet","DB01012","Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed."
966,"Cisapride","DB00604","Telithromycin may reduce clearance of Cisapride. Concomitant therapy is contraindicated."
966,"Citalopram","DB00215","Telithromycin may reduce clearance of Citalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Citalopram if Telithromycin is initiated, discontinued or dose changed."
966,"Clarithromycin","DB01211","Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Clobazam","DB00349","Telithromycin may reduce clearance of Clobazam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clobazam if Telithromycin is initiated, discontinued or dose changed."
966,"Clonazepam","DB01068","Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed."
966,"Clorazepate","DB00628","Telithromycin may reduce clearance of Clorazepate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clorazepate if Telithromycin is initiated, discontinued or dose changed."
966,"Cocaine","DB00907","Telithromycin may reduce clearance of Cocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cocaine if Telithromycin is initiated, discontinued or dose changed."
966,"Colchicine","DB01394","Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed."
966,"Conivaptan","DB00872","Co-administration may result in altered plasma concentrations of Conivaptan and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Cyclosporine","DB00091","Telithromycin may reduce clearance of cyclosporine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of cyclosporine if telithromycin is initiated, discontinued or dose changed."
966,"Dantrolene","DB01219","Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed."
966,"Dapsone","DB00250","Telithromycin may reduce clearance of Dapsone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dapsone if Telithromycin is initiated, discontinued or dose changed."
966,"Darifenacin","DB00496","Telithromycin may reduce clearance of Darifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Darifenacin if Telithromycin is initiated, discontinued or dose changed."
966,"Darunavir","DB01264","Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Dasatinib","DB01254","Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed."
966,"Delavirdine","DB00705","Delavirdine may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Dexamethasone","DB01234","Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy. \
"
966,"Diazepam","DB00829","Telithromycin may reduce clearance of Diazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diazepam if Telithromycin is initiated, discontinued or dose changed."
966,"Dicoumarol","DB00266","Telithromycin may increase the anticoagulant effect of dicumarol."
966,"Digitoxin","DB01396","Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed."
966,"Digoxin","DB00390","Telithromycin may increase the plasma concentration of Digoxin. Monitor for changes in Digoxin efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed."
966,"Dihydroergotamine","DB00320","Telithromycin may reduce clearance of Dihydroergotamine. Concomitant therapy is contraindicated."
966,"Diltiazem","DB00343","Telithromycin may reduce clearance of Diltiazem. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Diltiazem if Telithromycin is initiated, discontinued or dose changed."
966,"Disopyramide","DB00280","Telithromycin may reduce clearance of Disopyramide. Concomitant therapy should be avoided."
966,"Docetaxel","DB01248","Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed."
966,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
966,"Doxepin","DB01142","Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed."
966,"Doxorubicin","DB00997","Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."
966,"doxorubicin TransDrug","DB05331","Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."
966,"Dronedarone","DB04855","Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
966,"Efavirenz","DB00625","Efavirenz may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Eletriptan","DB00216","Telithromycin may reduce clearance of Eletriptan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eletriptan if Telithromycin is initiated, discontinued or dose changed."
966,"Eplerenone","DB00700","Telithromycin may reduce clearance of Eplerenone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eplerenone if Telithromycin is initiated, discontinued or dose changed."
966,"Ergoloid mesylate","DB01049","Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed."
966,"Ergonovine","DB01253","Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed."
966,"Ergotamine","DB00696","Telithromycin may reduce clearance of Ergotamine. Concomitant therapy is contraindicated."
966,"Erlotinib","DB00530","Telithromycin may reduce clearance of Erlotinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erlotinib if Telithromycin is initiated, discontinued or dose changed."
966,"Erythromycin","DB00199","Telithromycin may reduce clearance of Erythromycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Erythromycin if Telithromycin is initiated, discontinued or dose changed."
966,"Escitalopram","DB01175","Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed."
966,"Eszopiclone","DB00402","Telithromycin may reduce clearance of Eszopiclone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Eszopiclone if Telithromycin is initiated, discontinued or dose changed."
966,"Ethosuximide","DB00593","Telithromycin may reduce clearance of Ethosuximide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ethosuximide if Telithromycin is initiated, discontinued or dose changed."
966,"Etoposide","DB00773","Telithromycin may reduce clearance of Etoposide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Etoposide if Telithromycin is initiated, discontinued or dose changed."
966,"Felbamate","DB00949","Telithromycin may reduce clearance of Felbamate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felbamate if Telithromycin is initiated, discontinued or dose changed."
966,"Felodipine","DB01023","Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed."
966,"Fentanyl","DB00813","Telithromycin may reduce clearance of Fentanyl. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fentanyl if Telithromycin is initiated, discontinued or dose changed."
966,"Flunisolide","DB00180","Telithromycin may reduce clearance of Flunisolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flunisolide if Telithromycin is initiated, discontinued or dose changed."
966,"Flurazepam","DB00690","Telithromycin may reduce clearance of Flurazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flurazepam if Telithromycin is initiated, discontinued or dose changed."
966,"Flutamide","DB00499","Telithromycin may reduce clearance of Flutamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Flutamide if Telithromycin is initiated, discontinued or dose changed."
966,"Fluticasone Propionate","DB00588","Telithromycin may reduce clearance of Fluticasone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Fluticasone if Telithromycin is initiated, discontinued or dose changed."
966,"Fosamprenavir","DB01319","Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Fosphenytoin","DB01320","Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy."
966,"Gefitinib","DB00317","Telithromycin may reduce clearance of Gefitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Gefitinib if Telithromycin is initiated, discontinued or dose changed."
966,"Halofantrine","DB01218","Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed."
966,"Haloperidol","DB00502","Telithromycin may reduce clearance of Haloperidol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Haloperidol if Telithromycin is initiated, discontinued or dose changed."
966,"Ifosfamide","DB01181","Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed."
966,"Imatinib","DB00619","Co-administration may result in altered plasma concentrations of Imatinib and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Indinavir","DB00224","Indinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Irinotecan","DB00762","Telithromycin may reduce clearance of Irinotecan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Irinotecan if Telithromycin is initiated, discontinued or dose changed."
966,"Isoniazid","DB00951","Isoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Isosorbide Dinitrate","DB00883","Telithromycin may reduce clearance of Isosorbide Dinitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Dinitrate if Telithromycin is initiated, discontinued or dose changed."
966,"Isosorbide Mononitrate","DB01020","Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed."
966,"Isradipine","DB00270","Telithromycin may reduce clearance of Isradipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isradipine if Telithromycin is initiated, discontinued or dose changed."
966,"Itraconazole","DB01167","Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
966,"Ixabepilone","DB04845","Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed."
966,"Ketamine","DB01221","Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed."
966,"Ketoconazole","DB01026","Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Lapatinib","DB01259","Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed."
966,"Lidocaine","DB00281","Telithromycin may reduce clearance of Lidocaine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lidocaine if Telithromycin is initiated, discontinued or dose changed."
966,"Lopinavir","DB01601","Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Lovastatin","DB00227","Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided."
966,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
966,"Maraviroc","DB04835","Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed."
966,"Mefloquine","DB00358","Telithromycin may reduce clearance of Mefloquine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mefloquine if Telithromycin is initiated, discontinued or dose changed."
966,"Methadone","DB00333","Telithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed."
966,"Methylergometrine","DB00353","Telithromycin may reduce clearance of Methylergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methylergonovine if Telithromycin is initiated, discontinued or dose changed."
966,"Methysergide","DB00247","Risk of ergotism and severe ischemia with this association"
966,"Metoprolol","DB00264","Telithromycin may possibly increase metoprolol effect"
966,"Miconazole","DB01110","Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Midazolam","DB00683","Telithromycin may increase the effect and toxicity of the benzodiazepine, midazolam."
966,"Mirtazapine","DB00370","Telithromycin may reduce clearance of Mirtazapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Mirtazapine if Telithromycin is initiated, discontinued or dose changed."
966,"Modafinil","DB00745","Telithromycin may reduce clearance of Modafinil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Modafinil if Telithromycin is initiated, discontinued or dose changed."
966,"Moricizine","DB00680","Telithromycin may reduce clearance of Moricizine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Moricizine if Telithromycin is initiated, discontinued or dose changed."
966,"Nafcillin","DB00607","Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Nateglinide","DB00731","Telithromycin may reduce clearance of Nateglenide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nateglenide if Telithromycin is initiated, discontinued or dose changed."
966,"Nefazodone","DB01149","Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Nelfinavir","DB00220","Nelfinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Nevirapine","DB00238","Nevirapine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Nicardipine","DB00622","Co-administration may result in altered plasma concentrations of Nicardipine and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
966,"Nifedipine","DB01115","Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed."
966,"Nilotinib","DB04868","Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided."
966,"Nimodipine","DB00393","Telithromycin may reduce clearance of Nimodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nimodipine if Telithromycin is initiated, discontinued or dose changed."
966,"Nisoldipine","DB00401","Telithromycin may reduce clearance of Nisoldipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nisoldipine if Telithromycin is initiated, discontinued or dose changed."
966,"Nitrendipine","DB01054","Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed."
966,"Oxcarbazepine","DB00776","Oxcarbazepine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Paclitaxel","DB01229","Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed."
966,"Pentobarbital","DB00312","Pentobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Pergolide","DB01186","Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed."
966,"Phencyclidine","DB03575","Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed."
966,"Phenobarbital","DB01174","Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Phenytoin","DB00252","Phenytoin may decrease the plasma concentration of Telithromycin by increasing its metabolism. Consider alternate therapy."
966,"Pimozide","DB01100","Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated."
966,"Pipotiazine","DB01621","Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed."
966,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
966,"Posaconazole","DB01263","Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Praziquantel","DB01058","Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed."
966,"Primidone","DB00794","Primidone may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Quetiapine","DB01224","Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed."
966,"Quinidine","DB00908","Co-administration may result in altered plasma concentrations of Quinidine and/or Telithromycin. Consider alternate therapy or monitor for changes in the the therapeutic/adverse effects of both agents during concomitant therapy."
966,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
966,"Quinine","DB00468","Telithromycin may reduce clearance of Quinine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quinine if Telithromycin is initiated, discontinued or dose changed."
966,"Ranolazine","DB00243","Telithromycin may reduce clearance of Ranolazine. Concomitant therapy should be avoided."
966,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
966,"Repaglinide","DB00912","Telithromycin may reduce clearance of Repaglinide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Repaglinide if Telithromycin is initiated, discontinued or dose changed."
966,"Rifabutin","DB00615","Rifabutin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Rifampicin","DB01045","Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided."
966,"Rifapentine","DB01201","Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
966,"Ritonavir","DB00503","Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Rivaroxaban","DB06228","Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated."
966,"Salmeterol","DB00938","Telithromycin may reduce clearance of Salmeterol. Concomitant therapy is contraindicated."
966,"Saquinavir","DB01232","Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
966,"Sibutramine","DB01105","Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed."
966,"Sildenafil","DB00203","Telithromycin may reduce clearance of Sildenafil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sildenafil if Telithromycin is initiated, discontinued or dose changed."
966,"Simvastatin","DB00641","Telithromycin may increase the adverse effects of simvastatin by decreasing its metabolism. Concomitant therapy should be avoided."
966,"Sirolimus","DB00877","Telithromycin may reduce clearance of Sirolimus. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sirolimus if Telithromycin is initiated, discontinued or dose changed."
966,"Solifenacin","DB01591","Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed."
966,"Sotalol","DB00489","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
966,"Spiramycin","DB06145","Telithromycin may reduce clearance of Spiramycin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Spiramycin if Telithromycin is initiated, discontinued or dose changed."
966,"Sufentanil","DB00708","Telithromycin may reduce clearance of Sufentanil. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sufentanil if Telithromycin is initiated, discontinued or dose changed."
966,"Sunitinib","DB01268","Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed."
966,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. Telithromycin, a strong CYP3A4 inhibitor, may also increase the serum concentration of Tacrolimus by inhibiting its metabolism and clearance."
966,"Tadalafil","DB00820","Telithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
966,"Tamoxifen","DB00675","Telithromycin may reduce clearance of Tamoxifen. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tamoxifen if Telithromycin is initiated, discontinued or dose changed."
966,"Tamsulosin","DB00706","Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic/adverse effects of Tamsulosin if Telithromycin is initiated, discontinued, or dose changed."
966,"Temsirolimus","DB06287","Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."
966,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Telithromycin is initiated, discontinued or dose changed."
966,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
966,"Tetrabenazine","DB04844","Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided."
966,"Theophylline","DB00277","Telithromycin may reduce clearance of Theophylline. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Theophylline if Telithromycin is initiated, discontinued or dose changed."
966,"Thioridazine","DB00679","Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided."
966,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
966,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Telithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Telithromycin is initiated, discontinued or dose changed."
966,"Tolterodine","DB01036","Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
966,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
966,"Tramadol","DB00193","Telithromycin may decrease the metabolism and clearance of tramadol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of tramadol if telithromycin is initiated, discontinued or dose changed.\
"
966,"Trazodone","DB00656","The CYP3A4 inhibitor, Telithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Telithromycin is initiated, discontinued or dose changed."
966,"Triazolam","DB00897","Telithromycin may increase the effect and toxicity of the benzodiazepine, triazolam."
966,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Telithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution."
966,"Valproic Acid","DB00313","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed. "
966,"Vardenafil","DB00862","Telithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
966,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
966,"Venlafaxine","DB00285","Telithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Telithromycin is initiated, discontinued, or dose changed."
966,"Verapamil","DB00661","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed."
966,"Vinblastine","DB00570","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinblastine if Telithromycin is initiated, discontinued or dose changed."
966,"Vincristine","DB00541","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Telithromycin is initiated, discontinued or dose changed."
966,"Vinorelbine","DB00361","Telithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Telithromycin is initiated, discontinued or dose changed."
966,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur."
966,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
966,"Warfarin","DB00682","Telithromycin may increase the anticoagulant effect of Warfarin. INR should be monitored and Warfarin dose adjusted accordingly during concomitant therapy. "
966,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
966,"Zolpidem","DB00425","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if telithromycin is initiated, discontinued or dose changed."
966,"Zonisamide","DB00909","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if telithromycin is initiated, discontinued or dose changed."
966,"Zopiclone","DB01198","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed."
966,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
967,"Acenocoumarol","DB01418","Increased thrombotic risk due to estrogen"
967,"Aminophylline","DB01223","The contraceptive increases the effect and toxicity of theophylline"
967,"Amobarbital","DB01351","This product may cause a slight decrease of contraceptive effect"
967,"Amoxicillin","DB01060","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Ampicillin","DB00415","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Amprenavir","DB00701","Ritonavir could decrease the contraceptive efficacy"
967,"Anisindione","DB01125","Increased thrombotic risk due to estrogen"
967,"Aprepitant","DB00673","Aprepitant could decrease the effect of the oral contraceptive"
967,"Aprobarbital","DB01352","This product may cause a slight decrease of contraceptive effect"
967,"Artemether","DB06697","Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy. "
967,"Azlocillin","DB01061","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Aztreonam","DB00355","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Bacampicillin","DB01602","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Bendamustine","DB06769","Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine. "
967,"Bosentan","DB00559","Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan."
967,"Butabarbital","DB00237","This product may cause a slight decrease of contraceptive effect"
967,"Butalbital","DB00241","This product may cause a slight decrease of contraceptive effect"
967,"Butethal","DB01353","This product may cause a slight decrease of contraceptive effect"
967,"Carbamazepine","DB00564","Carbamazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with carbamazepine."
967,"Clavulanate","DB00766","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Cloxacillin","DB01147","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."
967,"Cyclacillin","DB01000","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Cyclosporine","DB00091","The contraceptive increases the effect and toxicity of cyclosporine"
967,"Demeclocycline","DB00618","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Dicloxacillin","DB00485","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Dicoumarol","DB00266","Increased thrombotic risk due to estrogen"
967,"Doxycycline","DB00254","Doxycycline may decrease the contraceptive effect of ethinyl estradiol."
967,"Dyphylline","DB00651","The contraceptive increases the effect and toxicity of theophylline"
967,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
967,"Ethotoin","DB00754","This product may cause a slight decrease of contraceptive effect"
967,"Etoricoxib","DB01628","Etoricoxib may increase the levels of ethinyl estradiol."
967,"Flucloxacillin","DB00301","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Fosphenytoin","DB01320","This product may cause a slight decrease of contraceptive effect"
967,"Griseofulvin","DB00400","This product may cause a slight decrease of contraceptive effect"
967,"Heptabarbital","DB01354","This product may cause a slight decrease of contraceptive effect"
967,"Hetacillin","DB00739","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Hexobarbital","DB01355","This product may cause a slight decrease of contraceptive effect"
967,"Ketoconazole","DB01026","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Lamotrigine","DB00555","The oral contraceptive decreases the effect of lamotrigine"
967,"Mephenytoin","DB00532","This product may cause a slight decrease of contraceptive effect"
967,"Methacycline","DB00931","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Methohexital","DB00474","This product may cause a slight decrease of contraceptive effect"
967,"Methylphenobarbital","DB00849","This product may cause a slight decrease of contraceptive effect"
967,"Meticillin","DB01603","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Mezlocillin","DB00948","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Minocycline","DB01017","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Modafinil","DB00745","Modafinil may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on during concomitant therapy with modafinil."
967,"Nafcillin","DB00607","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Nelfinavir","DB00220","Ritonavir could decrease the contraceptive efficacy"
967,"Oxacillin","DB00713","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Oxcarbazepine","DB00776","Oxcarbazepine may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied upon during concomitant therapy with oxcarbazepine."
967,"Oxtriphylline","DB01303","The contraceptive increases the effect and toxicity of theophylline"
967,"Oxytetracycline","DB00595","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Pentobarbital","DB00312","This product may cause a slight decrease of contraceptive effect"
967,"Phenobarbital","DB01174","This product may cause a slight decrease of contraceptive effect"
967,"Phenytoin","DB00252","This product may cause a slight decrease of contraceptive effect"
967,"Piperacillin","DB00319","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Pivampicillin","DB01604","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Prednisolone","DB00860","The estrogenic agent, ethinyl estradiol, may increase the effect of the corticosteroid, prednisolone."
967,"Prednisone","DB00635","The estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone."
967,"Primidone","DB00794","This product may cause a slight decrease of contraceptive effect"
967,"Raloxifene","DB00481","Association not recommended"
967,"Rifabutin","DB00615","Rifabutin may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be solely relied on alone during concomitant therapy with rifabutin."
967,"Rifampicin","DB01045","This product may cause a slight decrease of contraceptive effect"
967,"Rifapentine","DB01201","This product may cause a slight decrease of contraceptive effect"
967,"Ritonavir","DB00503","Ritonavir could decrease the contraceptive efficacy"
967,"Rolitetracycline","DB01301","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Rufinamide","DB06201","Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification "
967,"Secobarbital","DB00418","This product may cause a slight decrease of contraceptive effect"
967,"St. John's Wort","DB01323","St. John's Wort could reduce the contraceptive effect"
967,"Tacrolimus","DB00864","Ethinyl estradiol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ethinyl estradiol therapy is initiated, discontinued or altered."
967,"Talbutal","DB00306","This product may cause a slight decrease of contraceptive effect"
967,"Tazobactam","DB01606","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Tetracycline","DB00759","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Theophylline","DB00277","The contraceptive increases the effect and toxicity of theophylline"
967,"Thiopental","DB00599","Thiopental may decrease the effect of Ethinyl estradiol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
967,"Ticarcillin","DB01607","This anti-infectious agent could decrease the effect of the oral contraceptive"
967,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, decreases Ethinyl estradiol concentrations. Ethinyl estradiol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Use an alternate form of contraception or monitor for estrogen deficiency if Ethinyl estradiol is used for hormone replacement therapy. "
967,"Tizanidine","DB00697","Ethinyl estradiol may increase the serum concentration of tizanidine. Monitor for changes in the therapeutic and adverse effects of tizanidine if ethinyl estradiol is initiated, discontinued or dose changed."
967,"Topiramate","DB00273","Topiramate may decrease the effect of the oral contraceptive, Ethinyl estradiol. An alternate form of contraception should be used during concomitant therapy."
967,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of the oral contraceptive, Ethinyl Estradiol. An alternate form of contraception should be used during concomitant therapy. "
967,"Troglitazone","DB00197","Possible loss of contracepitve effect"
967,"Ursodeoxycholic acid","DB01586","Estrogens decreases the effect of ursodiol"
967,"Warfarin","DB00682","Ethinyl estradiol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if ethinyl estradiol is initiated, discontinued or dose changed."
968,"Calcium","DB01373","Formation of non-absorbable complexes"
968,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as lomefloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
968,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
968,"Magnesium","DB01378","Formation of non-absorbable complexes"
969,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclopentolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
969,"Triprolidine","DB00427","Triprolidine and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
969,"Trospium","DB00209","Trospium and Cyclopentolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
970,"Atazanavir","DB01072","Atazanavir increases levels/toxicity of ramelteon"
970,"Ciprofloxacin","DB00537","Ciprofloxacin increases levels/toxicity of ramelteon"
970,"Enoxacin","DB00467","Enoxacin increases levels/toxicity of ramelteon"
970,"Fluconazole","DB00196","Fluconazole may increase the serum levels and toxcity of ramelteon."
970,"Fluvoxamine","DB00176","Fluvoxamine may increase the serum level and toxicity of ramelteon."
970,"Ketoconazole","DB01026","Ketoconazole may increase the serum levels and toxicity of ramelteon."
970,"Mexiletine","DB00379","Mexiletine increases levels/toxicity of ramelteon"
970,"Rifampicin","DB01045","Rifampin reduces the levels/effect of ramelteon"
970,"Tacrine","DB00382","Tacrine increases levels/toxicity of ramelteon"
970,"Thiabendazole","DB00730","Thiabendazole increases levels/toxicity of ramelteon"
970,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Ramelteon, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
970,"Zileuton","DB00744","Zileuton increases levels/toxicity of ramelteon"
972,"Carbamazepine","DB00564","Isotretinoine decreases the effect of carbamazepine"
972,"Demeclocycline","DB00618","Increased risk of intracranial hypertension"
972,"Doxycycline","DB00254","Increased risk of intracranial hypertension"
972,"Methacycline","DB00931","Increased risk of intracranial hypertension"
972,"Minocycline","DB01017","Increased risk of intracranial hypertension"
972,"Oxytetracycline","DB00595","Increased risk of intracranial hypertension"
972,"Rolitetracycline","DB01301","Increased risk of intracranial hypertension"
972,"Tetracycline","DB00759","Increased risk of intracranial hypertension"
972,"Vitamin A","DB00162","Isotretinoin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking isotretinoin."
973,"Acebutolol","DB01193","Antagonism"
973,"Atenolol","DB00335","Antagonism"
973,"Betaxolol","DB00195","Beta-Blockers (Beta1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like formoterol. Therapy should be monitored."
973,"Bevantolol","DB01295","Antagonism"
973,"Bisoprolol","DB00612","Antagonism"
973,"Carteolol","DB00521","Antagonism"
973,"Carvedilol","DB01136","Antagonism"
973,"Esmolol","DB00187","Antagonism"
973,"Indacaterol","DB05039","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
973,"Labetalol","DB00598","Antagonism"
973,"Metoprolol","DB00264","Antagonism"
973,"Nadolol","DB01203","Antagonism"
973,"Oxprenolol","DB01580","Antagonism"
973,"Penbutolol","DB01359","Antagonism"
973,"Pindolol","DB00960","Antagonism"
973,"Practolol","DB01297","Antagonism"
973,"Propranolol","DB00571","Antagonism"
973,"Sotalol","DB00489","Antagonism"
973,"Timolol","DB00373","Antagonism"
974,"Warfarin","DB00682","Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed."
975,"Donepezil","DB00843","Possible antagonism of action"
975,"Galantamine","DB00674","Possible antagonism of action"
975,"Rivastigmine","DB00989","Possible antagonism of action"
975,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Dimenhydrinate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
975,"Trimethobenzamide","DB00662","Trimethobenzamide and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
975,"Triprolidine","DB00427","Triprolidine and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
975,"Trospium","DB00209","Trospium and Dimenhydrinate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
976,"Donepezil","DB00843","Possible antagonism of action"
976,"Galantamine","DB00674","Possible antagonism of action"
976,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
976,"Rivastigmine","DB00989","Possible antagonism of action"
976,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Glycopyrrolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
976,"Trimethobenzamide","DB00662","Trimethobenzamide and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
976,"Triprolidine","DB00427","Triprolidine and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
976,"Trospium","DB00209","Trospium and Glycopyrrolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
977,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
977,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
978,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect, dopamine."
978,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of dopamine."
978,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dopamine."
978,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dopamine."
978,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine."
978,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, dopamine."
978,"Fosphenytoin","DB01320","Risk of severe hypotension"
978,"Guanethidine","DB01170","Dopamine may decrease the effect of guanethidine."
978,"Hyaluronidase","DB00070","Consider modifying therapy due to enhanced adverse effects of dopamine."
978,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of dopamine."
978,"Isocarboxazid","DB01247","Increased arterial pressure"
978,"Linezolid","DB00601","Possible increase of arterial pressure"
978,"Lurasidone","DB08815","Dopamine increases toxicity (enhanced hypotensive effects) of lurasidone. "
978,"Methyldopa","DB00968","Increased arterial pressure"
978,"Midodrine","DB00211","Increased arterial pressure"
978,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of dopamine."
978,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of dopamine."
978,"Phenelzine","DB00780","Increased arterial pressure"
978,"Phenytoin","DB00252","Risk of severe hypotension"
978,"Rasagiline","DB01367","Increased arterial pressure"
978,"Reserpine","DB00206","Increased arterial pressure"
979,"Amantadine","DB00915","Possible antagonism of action"
979,"Amitriptyline","DB00321","Possible antagonism of action"
979,"Amoxapine","DB00543","Possible antagonism of action"
979,"Azatadine","DB00719","Possible antagonism of action"
979,"Benzatropine","DB00245","Possible antagonism of action"
979,"Biperiden","DB00810","Possible antagonism of action"
979,"Brompheniramine","DB00835","Possible antagonism of action"
979,"Chlorphenamine","DB01114","Possible antagonism of action"
979,"Chlorpromazine","DB00477","Possible antagonism of action"
979,"Chlorprothixene","DB01239","Possible antagonism of action"
979,"Cimetidine","DB00501","Possible antagonism of action"
979,"Clemastine","DB00283","Possible antagonism of action"
979,"Clomipramine","DB01242","Possible antagonism of action"
979,"Clozapine","DB00363","Possible antagonism of action"
979,"Cyclizine","DB01176","Possible antagonism of action"
979,"Cyclobenzaprine","DB00924","Possible antagonism of action"
979,"Cyproheptadine","DB00434","Possible antagonism of action"
979,"Darifenacin","DB00496","Possible antagonism of action"
979,"Desipramine","DB01151","Possible antagonism of action"
979,"Dicyclomine","DB00804","Possible antagonism of action"
979,"Dimenhydrinate","DB00985","Possible antagonism of action"
979,"Diphenhydramine","DB01075","Possible antagonism of action"
979,"Disopyramide","DB00280","Possible antagonism of action"
979,"Doxepin","DB01142","Possible antagonism of action"
979,"Flavoxate","DB01148","Possible antagonism of action"
979,"Flupentixol","DB00875","Possible antagonism of action"
979,"Glutethimide","DB01437","Possible antagonism of action"
979,"Glycopyrrolate","DB00986","Possible antagonism of action"
979,"Hydroxyzine","DB00557","Possible antagonism of action"
979,"Hyoscyamine","DB00424","Possible antagonism of action"
979,"Imipramine","DB00458","Possible antagonism of action"
979,"Isocarboxazid","DB01247","Possible antagonism of action"
979,"Loxapine","DB00408","Possible antagonism of action"
979,"Maprotiline","DB00934","Possible antagonism of action"
979,"Meclizine","DB00737","Possible antagonism of action"
979,"Mesoridazine","DB00933","Possible antagonism of action"
979,"Methotrimeprazine","DB01403","Possible antagonism of action"
979,"Mirtazapine","DB00370","Possible antagonism of action"
979,"Moclobemide","DB01171","Possible antagonism of action"
979,"Nortriptyline","DB00540","Possible antagonism of action"
979,"Olanzapine","DB00334","Possible antagonism of action"
979,"Orphenadrine","DB01173","Possible antagonism of action"
979,"Oxybutynin","DB01062","Possible antagonism of action"
979,"Perphenazine","DB00850","Possible antagonism of action"
979,"Pethidine","DB00454","Possible antagonism of action"
979,"Phenelzine","DB00780","Possible antagonism of action"
979,"Pimozide","DB01100","Possible antagonism of action"
979,"Procainamide","DB01035","Possible antagonism of action"
979,"Prochlorperazine","DB00433","Possible antagonism of action"
979,"Promethazine","DB01069","Possible antagonism of action"
979,"Propericiazine","DB01608","Possible antagonism of action"
979,"Quetiapine","DB01224","Possible antagonism of action"
979,"Quinidine","DB00908","Possible antagonism of action"
979,"Thioproperazine","DB01622","Possible antagonism of action"
979,"Thioridazine","DB00679","Possible antagonism of action"
979,"Tizanidine","DB00697","Possible antagonism of action"
979,"Trazodone","DB00656","Possible antagonism of action"
979,"Trifluoperazine","DB00831","Possible antagonism of action"
979,"Trihexyphenidyl","DB00376","Possible antagonism of action"
979,"Trimethobenzamide","DB00662","The therapeutic effects of the anticholinergic, Trimethobenzamide, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
979,"Trospium","DB00209","The therapeutic effects of the anticholinergic, Trospium, and/or the acetylcholinesterase inhibitor (central), Rivastigmine, may be reduced due to antagonism. Monitor therapeutic effects of both agents."
980,"Etravirine","DB06414","Exemestane, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dosage of exemestane and to closely monitor therapy for efficacy and toxicity. "
981,"Acenocoumarol","DB01418","The NSAID, oxaprozin, may increase the anticoagulant effect of acenocoumarol."
981,"Alendronate","DB00630","Increased risk of gastric toxicity"
981,"Anisindione","DB01125","The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione."
981,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
981,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
981,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
981,"Dicoumarol","DB00266","The NSAID, oxaprozin, may increase the anticoagulant effect of dicumarol."
981,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
981,"Methotrexate","DB00563","The NSAID, oxaprozin, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
981,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
981,"Telmisartan","DB00966","Concomitant use of Telmisartan and Oxaprozin may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
981,"Timolol","DB00373","The NSAID, Oxaprozin, may antagonize the antihypertensive effect of Timolol."
981,"Trandolapril","DB00519","The NSAID, Oxaprozin, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Oxaprozin is initiated, discontinued or dose changed. "
981,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Oxaprozin. Monitor for increased bleeding during concomitant thearpy. "
981,"Warfarin","DB00682","The antiplatelet effects of oxaprozin may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
983,"Acenocoumarol","DB01418","Azathioprine may decrease the anticoagulant effect of acenocoumarol."
983,"Allopurinol","DB00437","Allopurinol may increase the effect of thiopurine, azathioprine."
983,"Aminosalicylic Acid","DB00233","Aminosalicylic acid may increase the toxicity of thiopurine, azathioprine."
983,"Anisindione","DB01125","Azathioprine may decrease the anticoagulant effect of anisindione."
983,"Atracurium","DB00732","The agent decreases the effect of the muscle relaxant"
983,"Canakinumab","DB06168","results in increased immunosuppressive effects; increases the risk of infection. "
983,"Dicoumarol","DB00266","Azathioprine may decrease the anticoagulant effect of dicumarol."
983,"Doxacurium chloride","DB01135","The agent decreases the effect of the muscle relaxant"
983,"Febuxostat","DB04854","Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes."
983,"Mesalazine","DB00244","Mesalazine may increase the toxicity of thiopurine, azathioprine."
983,"Metocurine","DB01336","The agent decreases the effect of the muscle relaxant"
983,"Mivacurium","DB01226","The agent decreases the effect of the muscle relaxant"
983,"Olsalazine","DB01250","Olsalazine may increase the toxicity of thiopurine, azathioprine."
983,"Pancuronium","DB01337","The agent decreases the effect of the muscle relaxant"
983,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
983,"Sulfasalazine","DB00795","Sulfasalazine may increase the toxicity of thiopurine, azathioprine."
983,"Trandolapril","DB00519","Trandolapril may increase the risk of neutropenia. Monitor for increased toxic effects of Azathioprine if Trandolapril is initiated or dose increased. "
983,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
983,"Tubocurarine","DB01199","The agent decreases the effect of the muscle relaxant"
983,"Vecuronium","DB01339","The agent decreases the effect of the muscle relaxant"
983,"Warfarin","DB00682","Azathioprine may decrease the anticoagulant effect of warfarin."
984,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
984,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
984,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
984,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
984,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
984,"Colistimethate","DB01111","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
984,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Neomycin. Use caution during concomitant therapy. "
984,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line."
986,"Ethotoin","DB00754","Increases the effect of hydantoin"
986,"Fosphenytoin","DB01320","Gabapentin may increase the effect of fosphenytoin."
986,"Mephenytoin","DB00532","Increases the effect of hydantoin"
986,"Phenytoin","DB00252","Gabapentin may increase the therapeutic and adverse effects of phenytoin."
986,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Gabapentin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
987,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
987,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
987,"Telithromycin","DB00976","Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."
987,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed."
987,"Trastuzumab","DB00072","Trastuzumab may increase the cardiotoxicity of Doxorubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
987,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed."
987,"Zidovudine","DB00495","Additive myelosuppression may occur. Doxorubicin may decrease the efficacy of zidovudine. Concomitant therapy should be avoided. "
988,"Citalopram","DB00215","Increased risk of CNS adverse effects"
988,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
988,"Dihydroergotamine","DB00320","Possible severe and prolonged vasoconstriction"
988,"Ergonovine","DB01253","Possible severe and prolonged vasoconstriction"
988,"Ergotamine","DB00696","Possible severe and prolonged vasoconstriction"
988,"Escitalopram","DB01175","Increased risk of CNS adverse effects"
988,"Fluoxetine","DB00472","Increased risk of CNS adverse effects"
988,"Fluvoxamine","DB00176","Increased risk of CNS adverse effects"
988,"Methylergometrine","DB00353","Possible severe and prolonged vasoconstriction"
988,"Methysergide","DB00247","Possible severe and prolonged vasoconstriction"
988,"Nefazodone","DB01149","Increased risk of CNS adverse effects"
988,"Paroxetine","DB00715","Increased risk of CNS adverse effects"
988,"Sertraline","DB01104","Increased risk of CNS adverse effects"
988,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
988,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
988,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
988,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
988,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
988,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
988,"Zolmitriptan","DB00315","Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated."
989,"Deslanoside","DB01078","Possible electrolyte variations and arrhythmias"
989,"Diazoxide","DB01119","Significant hyperglycemic effect"
989,"Digitoxin","DB01396","Possible electrolyte variations and arrhythmias"
989,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
989,"Dihydrocodeine","DB01551","Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. \
It is recommended to monitor therapy."
989,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
989,"Indacaterol","DB05039","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
989,"Insulin Lispro","DB00046","Concomitant therapy with diuretics may reduce the blood-glucose-lowering effect of insulin lispro. "
989,"Lithium","DB01356","The thiazide diuretic, hydrochlorothiazide, may increase serum levels of lithium."
989,"Tenoxicam","DB00469","Tenoxicam may antagonize the blood pressure lowering effect of Hydrochlorothiazide. Monitor for changes in the therapeutic effect of Hydrochlorothiazide if Tenoxicam is initiated, discontinued or dose changed. "
989,"Trandolapril","DB00519","The thiazide diuretic, Hydrochlorothiazide, may increase the hypotensive effect of Trandolapril. Hydrochlorothiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
989,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
990,"Demeclocycline","DB00618","Possible antagonism of action"
990,"Doxycycline","DB00254","Possible antagonism of action"
990,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
990,"Minocycline","DB01017","Possible antagonism of action"
990,"Tetracycline","DB00759","Possible antagonism of action"
991,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of salbutamol."
991,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of salbutamol."
991,"Atenolol","DB00335","Antagonism"
991,"Bisoprolol","DB00612","Antagonism"
991,"Carvedilol","DB01136","Antagonism"
991,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of salbutamol."
991,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of salbutamol."
991,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of salbutamol."
991,"Esmolol","DB00187","Antagonism"
991,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of salbutamol."
991,"Isocarboxazid","DB01247","Increased arterial pressure"
991,"Labetalol","DB00598","Antagonism"
991,"Linezolid","DB00601","Possible increase of arterial pressure"
991,"Methyldopa","DB00968","Increased arterial pressure"
991,"Metoprolol","DB00264","Antagonism"
991,"Midodrine","DB00211","Increased arterial pressure"
991,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of salbutamol."
991,"Nadolol","DB01203","Antagonism"
991,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of salbutamol."
991,"Oxprenolol","DB01580","Antagonism"
991,"Phenelzine","DB00780","Increased arterial pressure"
991,"Pindolol","DB00960","Antagonism"
991,"Propranolol","DB00571","Antagonism"
991,"Rasagiline","DB01367","Increased arterial pressure"
991,"Reserpine","DB00206","Increased arterial pressure"
991,"Timolol","DB00373","Antagonism"
994,"Abacavir","DB01048","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Ganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is required."
994,"Didanosine","DB00900","The antiviral agent, ganciclovir, may increase the effect and toxicity of didanosine."
994,"Probenecid","DB01032","Probenecid increases the effect and toxicity of ganciclovir/valganciclovir"
994,"Zidovudine","DB00495","Increased risk of hematologic toxicity. Concomitant therapy should be avoided."
995,"Belimumab","DB08879"," Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
995,"Bendamustine","DB06769","May increase risk of myelosuppression. "
995,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
998,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. "
998,"Itraconazole","DB01167","Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to those that did not receive it. Concomitant therapy may lead to toxic plasma levels of busulfan. "
998,"Metronidazole","DB00916","Metronidazole increases the effect/toxicity of busulfan"
998,"Telithromycin","DB00976","Telithromycin may reduce clearance of Busulfan. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Busulfan if Telithromycin is initiated, discontinued or dose changed."
998,"Tioguanine","DB00352","Busulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy. "
998,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
998,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed."
999,"Acenocoumarol","DB01418","The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol."
999,"Acetylsalicylic acid","DB00945","Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended. "
999,"Anisindione","DB01125","The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione."
999,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
999,"Citalopram","DB00215","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
999,"Cyclosporine","DB00091","The NSAID, ketoprofen, may increase the serum concentration of cyclosporine. Ketoprofen may also increase the nephrotoxicity of cyclosporine."
999,"Dicoumarol","DB00266","The NSAID, ketoprofen, may increase the anticoagulant effect of dicumarol."
999,"Drotrecogin alfa","DB00055","The antiplatelet effect of ketoprofen may increase the bleed risk associated with drotrecogin alfa. Consider spacing use of the two agents by at least 7 days. Increase monitoring for signs and symptoms of bleeding during concomitant therapy. "
999,"Eltrombopag","DB06210","Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
999,"Escitalopram","DB01175","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Fluoxetine","DB00472","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Fluvoxamine","DB00176","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Ginkgo biloba","DB01381","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
999,"Ginseng","DB01404","Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
999,"Ketorolac","DB00465","Concomitant use of ketoprofen and ketorolac, two NSAIDs, is contraindicated due to the risk of additive or synergistic NSAID toxicities (e.g. GI bleeding, ulceration, renal dysfunction, etc).  "
999,"Lithium","DB01356","The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed. "
999,"Methotrexate","DB00563","The NSAID, ketoprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
999,"Paroxetine","DB00715","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Pemetrexed","DB00642","The NSAID, ketoprofen, may increase increase the serum concentration of pemetrexed by decreasing its renal clearance. Patients with mild to moderate renal insufficiency (CrCl 45-79 ml/min) should avoid use of ketoprofen within 2 days of a pemetrexed dose. Patients with better renal function do not appear to be at risk. Monitor for toxicity in all patients during concomitant therapy. "
999,"S-Adenosylmethionine","DB00118","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
999,"Sertraline","DB01104","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
999,"Telmisartan","DB00966","Concomitant use of Telmisartan and Ketoprofen may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
999,"Timolol","DB00373","The NSAID, Ketoprofen, may antagonize the antihypertensive effect of Timolol."
999,"Trandolapril","DB00519","The NSAID, Ketoprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ketoprofen is initiated, discontinued or dose changed.  "
999,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ketoprofen. Monitor for increased bleeding during concomitant thearpy. "
999,"Warfarin","DB00682","The antiplatelet effects of ketoprofen may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
1000,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium."
1000,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Edrophonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
1000,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, edrophonium."
1001,"Cyproheptadine","DB00434","This combination renders test invalid"
1001,"Fosphenytoin","DB01320","The combination renders the test invalid"
1001,"Phenytoin","DB00252","The combination renders the test invalid"
1002,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the serum concentration and toxicity of cinacalcet."
1002,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of cinacalcet."
1002,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of cinacalcet."
1002,"Tamoxifen","DB00675","Cinacalcet may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
1002,"Tamsulosin","DB00706","Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Cinacalcet is initiated, discontinued, or dose changed."
1002,"Telithromycin","DB00976","Telithromycin may reduce clearance of Cinacalcet. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cinacalcet if Telithromycin is initiated, discontinued or dose changed."
1002,"Tolterodine","DB01036","Cinacalcet may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1002,"Tramadol","DB00193","Cinacalcet may decrease the effect of Tramadol by decreasing active metabolite production. "
1002,"Trimipramine","DB00726","The strong CYP2D6 inhibitor, Cinacalcet, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Cinacalcet is initiated, discontinued or dose changed. "
1002,"Venlafaxine","DB00285","Cinacalcet, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Cinacalcet is initiated, discontinued, or dose changed."
1002,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cinacalcet by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cinacalcet if voriconazole is initiated, discontinued or dose changed."
1002,"Zuclopenthixol","DB01624","Cinacalcet, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cinacalcet is initiated, discontinued or dose changed. "
1003,"Aldesleukin","DB00041","Corticosteroids such as clobetasol may diminish the antineoplastic effect of aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
1003,"Telaprevir","DB05521","Corticosteroids such as clobetasol may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. "
1005,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
1005,"Cyclosporine","DB00091","The sulfonamide decreases the effect of cyclosporine"
1005,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
1005,"Pralatrexate","DB06813","Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects. "
1005,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1005,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1005,"Warfarin","DB00682","Sulfamethoxazole may increase the anticoagulant effect of warfarin by decreasing its metabolism. Consider alternate therapy or monitor for changes in prothrombin time if sulfamethoxazole is initiated, discontinued or dose changed. "
1006,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1006,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide."
1006,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1006,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
1006,"Bevantolol","DB01295","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1006,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, glibenclamide."
1006,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1006,"Bosentan","DB00559","Increased risk of hepatic toxicity"
1006,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
1006,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1006,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, glibenclamide."
1006,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, glibenclamide."
1006,"Colesevelam","DB00930","Colesevelam may decrease the serum concentration of Glyburide. Glyburide should be administered at least 4 hours before colesevelam to minimize the risk of an interaction.\
"
1006,"Cyclosporine","DB00091","The sulfonylurea, glibenclamide, may increase the effect of cyclosporine."
1006,"Diazoxide","DB01119","Antagonism. "
1006,"Dicoumarol","DB00266","Dicumarol may increase the effect of sulfonylurea, glibenclamide."
1006,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1006,"Glucosamine","DB01296","Possible hyperglycemia"
1006,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1006,"Magnesium salicylate","DB01397","The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, glibenclamide."
1006,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1006,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1006,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1006,"Penbutolol","DB01359","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1006,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1006,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1006,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1006,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1006,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, glibenclamide."
1006,"Salicylate-sodium","DB01398","The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, glibenclamide."
1006,"Salsalate","DB01399","The salicylate, salsalate, increases the effect of the sulfonylurea, glibenclamide."
1006,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of glibenclamide. Monitor for changes in fasting and postprandial blood sugars."
1006,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
1006,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1006,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, glibenclamide."
1007,"Acenocoumarol","DB01418","The tetracycline, minocycline, may increase the anticoagulant effect of acenocoumarol."
1007,"Acitretin","DB00459","Increased risk of intracranial hypertension."
1007,"Aluminium","DB01370","Formation of non-absorbable complexes"
1007,"Amoxicillin","DB01060","Possible antagonism of action"
1007,"Ampicillin","DB00415","Possible antagonism of action"
1007,"Anisindione","DB01125","The tetracycline, minocycline, may increase the anticoagulant effect of anisindione."
1007,"Attapulgite","DB01574","Formation of non-absorbable complexes"
1007,"Azlocillin","DB01061","Possible antagonism of action"
1007,"Aztreonam","DB00355","Possible antagonism of action"
1007,"Bacampicillin","DB01602","Possible antagonism of action"
1007,"Benzylpenicillin","DB01053","Possible antagonism of action"
1007,"Bexarotene","DB00307","Tetracycline derivatives like minocycline may enhance the adverse/toxic effect of Retinoic Acid Derivatives. Due to the risk of developing pseudotumor cerebri (also known as intracranial hypertension), avoid this combination of drugs if possible. If used concomitantly, monitor for evidence of this interaction (eg, dizziness, diplopia, headache).  "
1007,"Bismuth Subsalicylate","DB01294","Formation of non-absorbable complexes"
1007,"Calcium","DB01373","Formation of non-absorbable complexes"
1007,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1007,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1007,"Carbenicillin","DB00578","Possible antagonism of action"
1007,"Clavulanate","DB00766","Possible antagonism of action"
1007,"Cloxacillin","DB01147","Possible antagonism of action"
1007,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the absorption of Tetracycline Derivatives. Monitor for decreased therapeutic effects of tetracycline derivatives if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. The manufacturer of colesevelam suggests that drugs should be administered at least 1 hour before or 4 hours after colesevelam."
1007,"Cyclacillin","DB01000","Possible antagonism of action"
1007,"Dicloxacillin","DB00485","Possible antagonism of action"
1007,"Dicoumarol","DB00266","The tetracycline, minocycline, may increase the anticoagulant effect of dicumarol."
1007,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1007,"Etretinate","DB00926","Increased risk of intracranial hypertension"
1007,"Flucloxacillin","DB00301","Possible antagonism of action"
1007,"Hetacillin","DB00739","Possible antagonism of action"
1007,"Iron","DB01592","Formation of non-absorbable complexes"
1007,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1007,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
1007,"Magnesium","DB01378","Formation of non-absorbable complexes"
1007,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1007,"Magnesium salicylate","DB01397","Formation of non-absorbable complexes"
1007,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1007,"Methicillin Acyl-Serine","DB02443","Possible antagonism of action"
1007,"Methoxyflurane","DB01028","The tetracycline, minocycline, may increase the renal toxicity of methoxyflurane."
1007,"Mezlocillin","DB00948","Possible antagonism of action"
1007,"Nafcillin","DB00607","Possible antagonism of action"
1007,"Oxacillin","DB00713","Possible antagonism of action"
1007,"Penicillin V","DB00417","Possible antagonism of action"
1007,"Piperacillin","DB00319","Possible antagonism of action"
1007,"Pivampicillin","DB01604","Possible antagonism of action"
1007,"Pivmecillinam","DB01605","Possible antagonism of action"
1007,"Tazobactam","DB01606","Possible antagonism of action"
1007,"Ticarcillin","DB01607","Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline."
1007,"Tretinoin","DB00755","Minocycline may increase the adverse effects of oral Tretinoin. Increase risk of pseudotumour cerebri. Concurrent therapy should be avoided."
1007,"Trisalicylate-choline","DB01401","Formation of non-absorbable complexes"
1007,"Warfarin","DB00682","The tetracycline, minocycline, may increase the anticoagulant effect of warfarin."
1007,"Zinc","DB01593","Formation of non-absorbable complexes"
1008,"Etravirine","DB06414","Guanfacine, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase guanfacine dosage up to 8mg/day, as tolerated, and to monitor gefitinib therapy. "
1008,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1008,"Trimipramine","DB00726","Trimipramine may reduce the antihypertensive effect of the alpha2-agonist, Guanfacine. Trimipramine may also increase the rebound hypertensive effect of Clonidine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Clonidine if Trimipramine is initiated, discontinued or dose changed. Guanfacine should be withdrawn very gradually to reduce the risk of hypertensive crisis. "
1009,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the cholinergic effects of Bethanecol, a cholinergic agonist. Monitor for increased cholinergic effects."
1010,"Avanafil","DB06237","Additive vasodilation. Concomitant therapy is contraindicated. "
1010,"Dihydroergotamine","DB00320","Possible antagonism of action"
1010,"Ergonovine","DB01253","Possible antagonism of action"
1010,"Ergotamine","DB00696","Possible antagonism of action"
1010,"Methylergometrine","DB00353","Possible antagonism of action"
1010,"Methysergide","DB00247","Possible antagonism of action"
1010,"Sildenafil","DB00203","Possible significant hypotension with this combination"
1010,"Tadalafil","DB00820","The vasodilatory effects of Isosobide mononitrate may be increased by Tadalafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
1010,"Telithromycin","DB00976","Telithromycin may reduce clearance of Isosorbide Mononitrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Isosorbide Mononitrate if Telithromycin is initiated, discontinued or dose changed."
1010,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1010,"Udenafil","DB06267","The vasodilatory effects of Isosobide mononitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
1010,"Vardenafil","DB00862","The vasodilatory effects of Isosorbide mononitrate may be increased by Vardenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
1010,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isosorbide mononitrate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of isosorbide mononitrate if voriconazole is initiated, discontinued or dose changed."
1011,"Amifostine","DB01143","Trichlormethiazide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trichlomethiazide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1011,"Cholestyramine","DB01432","The bile acid sequestrant, Cholestyramine resin, may inhibit the absorption of Trichlormethiazide."
1011,"Colesevelam","DB00930","The bile acid sequestrant, Colesevelam, may inhibit the absorption of Trichlormethiazide."
1011,"Colestipol","DB00375","The bile acid sequestrant, Colestipol, may inhibit the absorption of Trichlormethiazide."
1011,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
1011,"Dofetilide","DB00204","Trichlormethiazide may increase Dofetilide serum concentrations and increase the QTc-prolonging effect of Dofetilide. Increased risk of ventricular arrhythmias. "
1011,"Lithium","DB01356","Trichlormethiazide may increase the serum concentration of Lithium by decreasing Lithium excretion. Monitor for changes in the therapeutic/adverse effects of Lithium if Trichlorthiazide is initiated, discontinued or dose changed."
1011,"Rituximab","DB00073","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Trichlormethiazide for 12 hours prior to administration of Rituximab."
1011,"Trandolapril","DB00519","The thiazide diuretic, Trichlormethiazide, may increase the hypotensive effect of Trandolapril. Trichlormethiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
1011,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1012,"Warfarin","DB00682","Phytonadione (vitamin K) may antagonize the anticoagulant effects of warfarin. Monitor for changes in prothrombin time if phytonadione intake (either via supplements or vitamin K-rich foods) is increased or decreased. "
1013,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of felodipine."
1013,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of felodipine."
1013,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of felodipine."
1013,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of felodipine."
1013,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of felodipine."
1013,"Carbamazepine","DB00564","Carbamazepine may increase the metabolism of felodipine. Monitor for changes in the therapeutic and adverse effects of felodipine if carbamazepine is initiated, discontinued or dose changed."
1013,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine."
1013,"Erythromycin","DB00199","Erythromycin increases the effect of felodipine"
1013,"Ethotoin","DB00754","The hydantoin decreases the effect of felodipine"
1013,"Fosphenytoin","DB01320","The hydantoin decreases the effect of felodipine"
1013,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of felodipine."
1013,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of felodipine."
1013,"Itraconazole","DB01167","Itraconazole may increase the therapeutic and adverse effects of felodipine."
1013,"Josamycin","DB01321","Erythromycin increases the effect of felodipine"
1013,"Mephenytoin","DB00532","The hydantoin decreases the effect of felodipine"
1013,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of felodipine."
1013,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of felodipine."
1013,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of felodipine"
1013,"Oxcarbazepine","DB00776","Oxcarbazepine decreases the levels of felodipine"
1013,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of felodipine."
1013,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of felodipine."
1013,"Phenytoin","DB00252","The hydantoin decreases the effect of felodipine"
1013,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of felodipine."
1013,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of felodipine."
1013,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1013,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of felodipine."
1013,"Tacrolimus","DB00864","Felodipine increases tacrolimus levels"
1013,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of felodipine."
1013,"Telithromycin","DB00976","Telithromycin may reduce clearance of Felodipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Felodipine if Telithromycin is initiated, discontinued or dose changed."
1013,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Felodipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Felodipine if Thiopental is initiated, discontinued or dose changed."
1013,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may alter the concentration of Felopidine. Monitor for efficacy and adverse/toxic effects of Felopidine."
1013,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1013,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Felopidine, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Felopidine is initiated, discontinued to dose changed."
1013,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed."
1014,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1014,"Valganciclovir","DB01610","The excretion rates of Valganciclovir and/or Mycophenolic acid may decrease. Monitor for increased serum concentrations and toxicity of both agents."
1016,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1016,"Acenocoumarol","DB01418","Ketoconazole may increase the anticoagulant effect of acenocoumarol."
1016,"Alfentanil","DB00802","Ketoconazole may increase the effect and toxicity of alfentanil."
1016,"Alfuzosin","DB00346","The antifungal increases the effect of alfuzosin"
1016,"Aliskiren","DB09026","Monitor therapy due to increased serum concentration of aliskiren."
1016,"Almotriptan","DB00918","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
1016,"Alprazolam","DB00404","Ketoconazole may increase the effect of the benzodiazepine, alprazolam."
1016,"Aluminium","DB01370","Aluminum-containing antacids may decrease the effect of ketoconazole."
1016,"Amitriptyline","DB00321","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed."
1016,"Anisindione","DB01125","Ketoconazole may increase the anticoagulant effect of anisindione."
1016,"Apixaban","DB06605","Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration."
1016,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
1016,"Aripiprazole","DB01238","Ketoconazole may increase the effect of aripiprazole."
1016,"Artemether","DB06697","Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects."
1016,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1016,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
1016,"Avanafil","DB06237","Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax. "
1016,"Bedaquiline","DB08903","Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely. "
1016,"Bosentan","DB00559","Ketoconazole may increase the effect and toxicity of bosentan."
1016,"Bosutinib","DB06616","Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely. "
1016,"Bromazepam","DB01558","Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed."
1016,"Budesonide","DB01222","Ketoconazole may increase levels/effect of budesonide."
1016,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1016,"Calcium","DB01373","Calcium-containing antacids may decrease the absorption of ketoconazole."
1016,"Carbamazepine","DB00564","Ketoconazole may increase the effect of carbamazepine."
1016,"Cerivastatin","DB00439","Increased risk of myopathy/rhabdomyolysis"
1016,"Chlordiazepoxide","DB00475","Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
1016,"Ciclesonide","DB01410","Increased effects/toxicity of ciclesonide"
1016,"Cilostazol","DB01166","Ketoconazole may increase the effect of cilostazol."
1016,"Cimetidine","DB00501","The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole."
1016,"Cinacalcet","DB01012","Ketoconazole may increase the effect and toxicity of cinacalcet."
1016,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1016,"Clobazam","DB00349","Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary. "
1016,"Clonazepam","DB01068","Ketoconazole may increase the effect of the benzodiazepine, clonazepam."
1016,"Clorazepate","DB00628","Ketoconazole may increase the effect of the benzodiazepine, clorazepate."
1016,"Conivaptan","DB00872","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
1016,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
1016,"Cyclosporine","DB00091","Ketoconazole may increase the effect of cyclosporine."
1016,"Dabigatran etexilate","DB06695","Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects. "
1016,"Dabrafenib","DB08912","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
1016,"Dantrolene","DB01219","Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed. "
1016,"Darifenacin","DB00496","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1016,"Diazepam","DB00829","Ketoconazole may increase the effect of the benzodiazepine, diazepam."
1016,"Dicoumarol","DB00266","Ketoconazole may increase the anticoagulant effect of dicumarol."
1016,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
1016,"Docetaxel","DB01248","Ketoconazole may increase the serum levels and toxicity of docetaxel."
1016,"Dofetilide","DB00204","This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide"
1016,"Dronedarone","DB04855","Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
1016,"Eletriptan","DB00216","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
1016,"Eplerenone","DB00700","Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone."
1016,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination."
1016,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1016,"Esomeprazole","DB00736","The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole."
1016,"Estazolam","DB01215","Ketoconazole may increase the effect of the benzodiazepine, estazolam."
1016,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1016,"Etravirine","DB06414","Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.\
\
Ketoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.\
\
It is recommended to monitor etravirine therapy for toxicity. "
1016,"Everolimus","DB01590","Ketoconazole may increase everolimus levels/toxicity."
1016,"Famotidine","DB00927","The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole."
1016,"Fentanyl","DB00813","Ketoconazole may increase levels/toxicity of fentanyl."
1016,"Fesoterodine","DB06702","Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine. "
1016,"Fingolimod","DB08868","Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater."
1016,"Flurazepam","DB00690","Ketoconazole may increase the effect of the benzodiazepine, flurazepam."
1016,"Fluticasone furoate","DB08906","Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely. "
1016,"Galantamine","DB00674","Ketoconazole increases the effect and toxicity of galantamine"
1016,"Gefitinib","DB00317","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
1016,"Glimepiride","DB00222","Ketoconazole increases the effect of rosiglitazone"
1016,"Halazepam","DB00801","Ketoconazole may increase the effect of the benzodiazepine, halazepam."
1016,"Haloperidol","DB00502","Ketoconazole may increase the effect and toxicity of haloperidol."
1016,"Iloperidone","DB04946","Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% "
1016,"Imatinib","DB00619","Ketoconazole may increase the levels of imatinib."
1016,"Imipramine","DB00458","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed."
1016,"Indacaterol","DB05039","Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy. "
1016,"Indinavir","DB00224","Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed."
1016,"Irinotecan","DB00762","Ketoconazole increases the effect and toxicity of irinotecan"
1016,"Isoniazid","DB00951","Isoniazid decreases the effect of ketoconazole"
1016,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
1016,"Lansoprazole","DB00448","The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole."
1016,"Levomilnacipran","DB08918","Strong CYP3A4 inhibitors may increase exposure levomilnacipran. "
1016,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
1016,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1016,"Magnesium oxide","DB01377","The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption. "
1016,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1016,"Methylprednisolone","DB00959","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."
1016,"Midazolam","DB00683","Ketoconazole may increase the effect of the benzodiazepine, midazolam."
1016,"Mirabegron","DB08893","Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely. "
1016,"Nevirapine","DB00238","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed."
1016,"Nizatidine","DB00585","The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole."
1016,"Nortriptyline","DB00540","Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed."
1016,"Omeprazole","DB00338","The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole."
1016,"Ospemifene","DB04938","Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions. "
1016,"Pantoprazole","DB00213","The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole."
1016,"Pazopanib","DB06589","Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects. "
1016,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
1016,"Pioglitazone","DB01132","Ketoconazole increases the effect of pioglitazone"
1016,"Pomalidomide","DB08910","Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided. "
1016,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1016,"Prasugrel","DB06209","Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation. "
1016,"Prednisolone","DB00860","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone."
1016,"Prednisone","DB00635","The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone."
1016,"Quazepam","DB01589","Ketoconazole may increase the effect of the benzodiazepine, quazepam."
1016,"Quetiapine","DB01224","Ketoconazole may increase the therapeutic and adverse effects of quetiapine."
1016,"Quinidine","DB00908","Ketoconazole may increase the effect and toxicity of quinidine."
1016,"Quinidine barbiturate","DB01346","Ketoconazole may increase the effect and toxicity of quinidine barbiturate."
1016,"Rabeprazole","DB01129","The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole."
1016,"Ramelteon","DB00980","Ketoconazole may increase the serum levels and toxicity of ramelteon."
1016,"Ranitidine","DB00863","The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole."
1016,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
1016,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
1016,"Rifampicin","DB01045","Rifampin may decrease the effect of ketoconazole."
1016,"Ritonavir","DB00503","Ketoconazole may increase the effect and toxicity of ritonavir."
1016,"Rivaroxaban","DB06228","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
1016,"Roflumilast","DB01656","Increases roflumilast levels. "
1016,"Rosiglitazone","DB00412","Ketoconazole increases the effect of rosiglitazone"
1016,"Ruxolitinib","DB08877","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
1016,"Saquinavir","DB01232","Ketoconazole may increase the effect and toxicity of saquinavir."
1016,"Saxagliptin","DB06335","Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day. "
1016,"Sibutramine","DB01105","Ketoconazole increases the levels and toxicity of sibutramine"
1016,"Sildenafil","DB00203","Ketoconazole may increase the effect and toxicity of sildenafil."
1016,"Silodosin","DB06207","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects "
1016,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
1016,"Sirolimus","DB00877","Ketoconazole may increase the effect and toxicity of sirolimus."
1016,"Solifenacin","DB01591","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1016,"Sucralfate","DB00364","Sucralfate may decrease the absorption of ketoconazole."
1016,"Sunitinib","DB01268","Possible increase in sunitinib levels"
1016,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed."
1016,"Tacrolimus","DB00864","The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered."
1016,"Tadalafil","DB00820","Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1016,"Tamoxifen","DB00675","Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed."
1016,"Tamsulosin","DB00706","Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed."
1016,"Telaprevir","DB05521","Strong CYP3A4 inhibitors increase exposure of telaprevir. "
1016,"Telithromycin","DB00976","Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1016,"Temsirolimus","DB06287","Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1016,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed."
1016,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1016,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. "
1016,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed."
1016,"Tipranavir","DB00932","Tipranavir may increase the serum concentration of Ketoconazole. "
1016,"Tizanidine","DB00697","Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1016,"Tolbutamide","DB01124","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed."
1016,"Tolterodine","DB01036","Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1016,"Tolvaptan","DB06212","Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%. "
1016,"Topotecan","DB01030","The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1016,"Torasemide","DB00214","Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed. "
1016,"Tramadol","DB00193","Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production. "
1016,"Trazodone","DB00656","The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed."
1016,"Triazolam","DB00897","Ketoconazole may increase the effect of the benzodiazepine, triazolam."
1016,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed."
1016,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed. "
1016,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy. "
1016,"Valdecoxib","DB00580","Ketoconazole may increase the effect and toxicity of valdecoxib."
1016,"Vardenafil","DB00862","Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
1016,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1016,"Venlafaxine","DB00285","Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed."
1016,"Verapamil","DB00661","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed."
1016,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
1016,"Vinblastine","DB00570","Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed."
1016,"Vincristine","DB00541","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed."
1016,"Vinorelbine","DB00361","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed."
1016,"Voriconazole","DB00582","Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.	"
1016,"Warfarin","DB00682","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed."
1016,"Zafirlukast","DB00549","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed."
1016,"Ziprasidone","DB00246","Ketoconazole increases the effect and toxicity of ziprasidone"
1016,"Zolpidem","DB00425","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed. "
1016,"Zonisamide","DB00909","Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed."
1016,"Zopiclone","DB01198","Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed."
1017,"Demeclocycline","DB00618","The tetracycline, demeclocycline, may increase the renal toxicity of methoxyflurane."
1017,"Minocycline","DB01017","The tetracycline, minocycline, may increase the renal toxicity of methoxyflurane."
1017,"Phenobarbital","DB01174","The barbiturate, phenobarbital, increases the renal toxicity of methoxyflurane."
1017,"Primidone","DB00794","The barbiturate, primidone, increases the renal toxicity of methoxyflurane."
1017,"Tetracycline","DB00759","Tetracycline may increase the renal toxicity of methoxyflurane."
1018,"Amiloride","DB00594","Increased risk of hyperkalemia"
1018,"Drospirenone","DB01395","Increased risk of hyperkalemia"
1018,"Lithium","DB01356","The ARB increases serum levels of lithium"
1018,"Potassium","DB01345","Increased risk of hyperkalemia"
1018,"Spironolactone","DB00421","Increased risk of hyperkalemia"
1018,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1018,"Trandolapril","DB00519","The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril. "
1018,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1018,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Irbesartan, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Irbesartan is initiated, discontinued to dose changed."
1018,"Triamterene","DB00384","Increased risk of hyperkalemia"
1019,"Amiodarone","DB01118","The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Atorvastatin","DB01076","The p-glycoprotein inhibitor, Atorvastatin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Carboplatin","DB00958","Administration of Topotecan after Carboplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
1019,"Carvedilol","DB01136","The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Cisplatin","DB00515","Administration of Topotecan after Cisplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
1019,"Clarithromycin","DB01211","The p-glycoprotein inhibitor, Clarithromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Cyclosporine","DB00091","The p-glycoprotein inhibitor, Cyclosporine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Darunavir","DB01264","The p-glycoprotein inhibitor, Darunavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Dipyridamole","DB00975","The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Erythromycin","DB00199","The p-glycoprotein inhibitor, Erythromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Filgrastim","DB00099","Filgrastim may increase the adverse effects of Topotecan. Increased risk of prolonged neutropenia. Filgrastim should be administered at least 24 hours following Topotecan therapy. Monitor for signs and symptoms of neutropenia. "
1019,"Gefitinib","DB00317","The BCRP/ABCG2 inhibitor, Gefitnib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Gefitinib is initiated, discontinued or dose changed. "
1019,"Imatinib","DB00619","The BCRP/ABCG2 inhibitor, Imatinib, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Imatinib is initiated, discontinued or dose changed. "
1019,"Itraconazole","DB01167","The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Ketoconazole","DB01026","The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Lapatinib","DB01259","The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Lopinavir","DB01601","The p-glycoprotein inhibitor, Lopinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Mefloquine","DB00358","The p-glycoprotein inhibitor, Mefloquine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Natalizumab","DB00108","The immunosuppressant, Topotecan, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
1019,"Nelfinavir","DB00220","The p-glycoprotein inhibitor, Nelfinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Nicardipine","DB00622","The p-glycoprotein inhibitor, Nicardipine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Nilotinib","DB04868","The p-glycoprotein inhibitor, Nilotinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Oxaliplatin","DB00526","Administration of Topotecan after Oxaliplatin therapy may increase the risk of hematologic toxicity, such as neutropenia and/or thrombocytopenia. A dose adjustment may be required or the sequence of administration reversed. "
1019,"Pantoprazole","DB00213","The BCRP/ABCG2 inhibitor, Pantaprazole, may increase the bioavailability and serum concentration of oral Topotecan. Monitor for change in the therapeutic and adverse effects of Topotecan if Pantaprazole is initiated, discontinued or dose changed. "
1019,"Progesterone","DB00396","The p-glycoprotein inhibitor, Progesterone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Propranolol","DB00571","The p-glycoprotein inhibitor, Propranolol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Quinidine","DB00908","The p-glycoprotein inhibitor, Quinidine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Ranolazine","DB00243","The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Reserpine","DB00206","The p-glycoprotein inhibitor, Reserpine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Ritonavir","DB00503","The p-glycoprotein inhibitor, Ritonavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Saquinavir","DB01232","The p-glycoprotein inhibitor, Saquinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Sunitinib","DB01268","The p-glycoprotein inhibitor, Sunitinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1019,"Tacrolimus","DB00864","The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
1019,"Tamoxifen","DB00675","The p-glycoprotein inhibitor, Tamoxifen, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
1019,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1019,"Verapamil","DB00661","The p-glycoprotein inhibitor, Verapamil, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided."
1021,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid decreases the uricosuric effect of probenecid."
1021,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, decreases the uricosuric effect of probenecid."
1021,"Cefaclor","DB00833","Probenecid may increase the serum level of cefaclor."
1021,"Cefadroxil","DB01140","Probenecid may increase the serum level of cefadroxil."
1021,"Cefamandole","DB01326","Probenecid may increase the serum level of cefamandole."
1021,"Cefazolin","DB01327","Probenecid may increase the serum level of cefazolin."
1021,"Cefepime","DB01413","Probenecid may increase the serum level of cefepime."
1021,"Cefixime","DB00671","Probenecid may increase the serum level of cefixime."
1021,"Cefmetazole","DB00274","Probenecid may increase the serum level of cefmatzole."
1021,"Cefonicid","DB01328","Probenecid may increase the serum level of cefonicib."
1021,"Cefotaxime","DB00493","Probenecid may increase the serum level of cefotaxime."
1021,"Cefotetan","DB01330","Probenecid may increase the serum level of cefotetan."
1021,"Cefoxitin","DB01331","Probenecid may increase the serum level of cefoxitin."
1021,"Cefprozil","DB01150","Probenecid may increase the serum level of cefprozil."
1021,"Cefradine","DB01333","Probenecid may increase the serum level of cefradine."
1021,"Ceftizoxime","DB01332","Probenecid may increase the serum level of ceftizoxime."
1021,"Cefuroxime","DB01112","Probenecid may increase the serum level of cefuroxime."
1021,"Cephalexin","DB00567","Probenecid may increase the serum level of cephalexin."
1021,"Cephaloglycin","DB00689","Probenecid may increase the serum level of cephaloglycin."
1021,"Cephalothin Group","DB03450","Probenecid may increase the serum level of cephalothin."
1021,"Diflunisal","DB00861","Probenecid increases toxicity of diflunisal"
1021,"Ganciclovir","DB01004","Probenecid increases the effect and toxicity of ganciclovir/valganciclovir"
1021,"Glycerol Phenylbutyrate","DB08909","Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN and PAA."
1021,"Indomethacin","DB00328","Probenecid increases the effect/toxicity of indomethacin"
1021,"Ketorolac","DB00465","Probenecid increases toxicity of ketorolac"
1021,"Loracarbef","DB00447","Probenecid may increase the serum level of loracarbef."
1021,"Magnesium salicylate","DB01397","The salicylate, magnesium salicylate, decreases the uricosuric effect of probenecid."
1021,"Methotrexate","DB00563","Probenecid increases the effect and toxicity of methotrexate"
1021,"Moxalactam Derivative","DB02588","Probenecid may increase the serum level of the moxalactam derivative."
1021,"Pralatrexate","DB06813","Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects. "
1021,"Salicylate-sodium","DB01398","The salicylate, salicylate-sodium, decreases the uricosuric effect of probenecid."
1021,"Salsalate","DB01399","The salicylate, salsalate, decreases the uricosuric effect of probenecid."
1021,"Silodosin","DB06207","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
1021,"Tapentadol","DB06204","Increases the AUC of tapentadol by 57%. These changes are not considered clinically relevant and no change in dose is required."
1021,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, decreases the uricosuric effect of probenecid."
1021,"Valganciclovir","DB01610","Probenecid may decrease excretion of Valganciclovir. Monitor for increased serum concentration and toxicity of Valganciclovir."
1021,"Zidovudine","DB00495","Rash, malaise, myalgia"
1022,"Acenocoumarol","DB01418","Mercaptopurine may decrease the anticoagulant effect of acenocoumarol."
1022,"Allopurinol","DB00437","Allopurinol may increase the effect of thiopurine, mercaptopurine."
1022,"Aminosalicylic Acid","DB00233","Aminosalicylic acid may increase the toxicity of thiopurine, mercaptopurine."
1022,"Anisindione","DB01125","Mercaptopurine may decrease the anticoagulant effect of anisindione."
1022,"Atracurium","DB00732","The agent dereases the effect of the muscle relaxant"
1022,"Dicoumarol","DB00266","Mercaptopurine may decrease the anticoagulant effect of dicumarol."
1022,"Doxacurium chloride","DB01135","The agent dereases the effect of the muscle relaxant"
1022,"Febuxostat","DB04854","Coadministration of febuxostat with xanthine oxidase substrate drugs (azathioprine, mercaptopurine or theophylline) could increase plasma concentrations of these drugs, since these drugs are metabolized by xanthine oxidase, resulting in severe toxicity; hence their concomitant use is contraindicated. Since febuxostat does not inhibit or induce cytochrome P450 enzymes it lacks significant drug interactions with other drugs metabolized of these enzymes."
1022,"Mesalazine","DB00244","Mesalazine may increase the toxicity of thiopurine, mercaptopurine."
1022,"Metocurine","DB01336","The agent dereases the effect of the muscle relaxant"
1022,"Mivacurium","DB01226","The agent dereases the effect of the muscle relaxant"
1022,"Olsalazine","DB01250","Olsalazine may increase the toxicity of thiopurine, mercaptopurine."
1022,"Pancuronium","DB01337","The agent dereases the effect of the muscle relaxant"
1022,"Sulfasalazine","DB00795","Sulfasalazine may increase the toxicity of thiopurine, mercaptopurine."
1022,"Tioguanine","DB00352","Complete cross resistance may occur. "
1022,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1022,"Tubocurarine","DB01199","The agent dereases the effect of the muscle relaxant"
1022,"Vecuronium","DB01339","The agent dereases the effect of the muscle relaxant"
1022,"Warfarin","DB00682","Mercaptopurine may decrease the anticoagulant effect of warfarin."
1024,"Amiodarone","DB01118","Amiodarone may increase serum levels and toxicity of procainamide."
1024,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1024,"Cimetidine","DB00501","The histamine H2-receptor antagonist, cimetidine, may increase the effect of procainamide."
1024,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect of procainamide."
1024,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1024,"Dihydroquinidine barbiturate","DB01341","Quinidine increases the effect of procainamide"
1024,"Donepezil","DB00843","Possible antagonism of action"
1024,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
1024,"Galantamine","DB00674","Possible antagonism of action"
1024,"Levofloxacin","DB01137","Levofloxacin may increase the effect of procainamide."
1024,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1024,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1024,"Ofloxacin","DB01165","Ofloxacin may increase the effect of procainamide."
1024,"Quinidine","DB00908","Quinidine increases the effect of procainamide"
1024,"Quinidine barbiturate","DB01346","Quinidine increases the effect of procainamide"
1024,"Ranitidine","DB00863","The histamine H2-receptor antagonist, ranitidine, may increase the effect of procainamide."
1024,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
1024,"Rivastigmine","DB00989","Possible antagonism of action"
1024,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1024,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1024,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Procainamide. Consider alternate therapy or monitor for therapeutic/adverse effects of Procainamide if Terbinafine is initiated, discontinued or dose changed."
1024,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1024,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1024,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1024,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1024,"Trimethoprim","DB00440","Trimethoprim may reduce the clearance of Procainamide. Alternative treatments should be considered. If Trimethoprim is initiated or the dose is increased, monitor for increased toxicity of Procainamide (e.g. QTc intervals, EKG, serum drug concentrations). If Trimethoprim is discontinued or the dose decreased, monitor for reduced effects of Procainamide."
1024,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1024,"Vardenafil","DB00862","Increased risk of cardiotoxicity and arrhythmias"
1024,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1024,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1024,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1024,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1025,"Amiodarone","DB01118","Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Amprenavir","DB00701","Amprenavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity. "
1025,"Aprepitant","DB00673","Aprepitant may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Atazanavir","DB01072","Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity."
1025,"Caffeine","DB00201","Caffeine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Chlorpromazine","DB00477","Chlorpromazine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Cimetidine","DB00501","Cimetidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Cinacalcet","DB01012","Cinacalcet may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Clarithromycin","DB01211","Clarithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Clotrimazole","DB00257","Clotrimazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Cocaine","DB00907","Cocaine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Conivaptan","DB00872","Conivaptan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Cyclosporine","DB00091","Cyclosporine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Darunavir","DB01264","Darunavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Delavirdine","DB00705","Delavirdine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Desipramine","DB01151","Desipramine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Diltiazem","DB00343","Diltiazem may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Donepezil","DB00843","Possible antagonism of action"
1025,"Doxycycline","DB00254","Doxycycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Efavirenz","DB00625","Efavirenz may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Etravirine","DB06414","Etravirene may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Fluconazole","DB00196","Fluconazole may decrease the metabolism and clearance of tolterodine. Adjust tolterodine dose and monitor for efficacy and toxicity."
1025,"Fluoxetine","DB00472","Fluoxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Fosamprenavir","DB01319","Fosamprenavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Galantamine","DB00674","Possible antagonism of action"
1025,"Haloperidol","DB00502","Haloperidol may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Imatinib","DB00619","Imatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Indinavir","DB00224","Indinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.\
"
1025,"Isoniazid","DB00951","Isoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Itraconazole","DB01167","Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Ketoconazole","DB01026","Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Lapatinib","DB01259","Lapatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Lidocaine","DB00281","Lidocaine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Lopinavir","DB01601","Lopinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Metronidazole","DB00916","Metronidazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Miconazole","DB01110","Miconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Nefazodone","DB01149","Nefazodone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Nelfinavir","DB00220","Nelfinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Nicardipine","DB00622","Nicardipine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.\
"
1025,"Norfloxacin","DB01059","Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Paroxetine","DB00715","Paroxetine may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Pergolide","DB01186","Peroglide may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1025,"Posaconazole","DB01263","Posaconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Potassium Chloride","DB00761","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
1025,"Pramlintide","DB01278","Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy. "
1025,"Quinidine","DB00908","Quinidine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Ranolazine","DB00243","Ranolazine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Ritonavir","DB00503","Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Saquinavir","DB01232","Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Secretin","DB00021","The stimulatory effect of Secretin may be reduced by anticholinergics such as Tolterodine. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
1025,"Sertraline","DB01104","Sertraline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Sitaxentan","DB06268","Sitaxsentan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tolterodine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1025,"Telithromycin","DB00976","Telithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Tolterodine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tolterodine if Terbinafine is initiated, discontinued or dose changed."
1025,"Tetracycline","DB00759","Tetracycline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Trimethobenzamide","DB00662","Trimethobenzamide and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1025,"Triprolidine","DB00427","Triprolidine and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1025,"Trospium","DB00209","Trospium and Tolterodine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1025,"Verapamil","DB00661","Verapamil may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1025,"Vinblastine","DB00570","Vinblastine, a CYP3A4 inhibitor, may increase the serum concentration of Tolterodine by decreasing its metabolism. Poor CYP2D6 metabolizers metabolize Tolterodine via CYP3A4. A dose adjustment of Tolterodine may be required. Monitor for changes in the therapeutic/adverse effects of Tolterodine if Vinblastine is initiated, discontinued or dose changed. "
1025,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed."
1026,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like selegiline. "
1026,"Brimonidine","DB00484","MAO Inhibitors like selegiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
1026,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like selegiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
1026,"Citalopram","DB00215","Possible severe adverse reaction with this combination"
1026,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1026,"Dextromethorphan","DB00514","Combination associated with possible serotoninergic syndrome"
1026,"Escitalopram","DB01175","Possible severe adverse reaction with this combination"
1026,"Fluoxetine","DB00472","Possible severe adverse reaction with this combination"
1026,"Fluvoxamine","DB00176","Possible severe adverse reaction with this combination"
1026,"Moclobemide","DB01171","Decrease in selectivity"
1026,"Paroxetine","DB00715","Possible severe adverse reaction with this combination"
1026,"Pethidine","DB00454","Potentially fatal adverse effects"
1026,"Tapentadol","DB06204","Increases the toxicity of tapentadol by unknown mechanism. Discontinue selegiline at least 14 days prior to tapentadol administration. "
1026,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Selegiline. Concomitant therapy is contraindicated."
1026,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed. "
1026,"Tolcapone","DB00323","Tolcapone and Selegiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
1026,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Selegiline."
1026,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1026,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1026,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
1026,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
1026,"Vilazodone","DB06684","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
1026,"Zolmitriptan","DB00315","The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated. "
1028,"Acenocoumarol","DB01418","Fenofibrate may increase the anticoagulant effect of acenocoumarol."
1028,"Anisindione","DB01125","Fenofibrate may increase the anticoagulant effect of anisindione."
1028,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
1028,"Cerivastatin","DB00439","Increased risk of myopathy/rhabdomyolysis"
1028,"Dicoumarol","DB00266","Fenofibrate may increase the anticoagulant effect of dicumarol."
1028,"Fluvastatin","DB01095","Increased risk of myopathy/rhabdomyolysis"
1028,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
1028,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
1028,"Pitavastatin","DB08860","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
1028,"Pravastatin","DB00175","Increased risk of myopathy/rhabdomyolysis"
1028,"Rosuvastatin","DB01098","May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy."
1028,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
1028,"Ursodeoxycholic acid","DB01586","The fibric acid derivative decreases the effect of ursodiol"
1028,"Warfarin","DB00682","Fenofibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if fenofibrate is initiated, discontinued or dose changed."
1030,"Abatacept","DB01281","Thalidomide may increase the adverse effects of Abatacept. Increased risk of serious infection. Concomitant therapy should be avoided. "
1030,"Amikacin","DB00479","Thalidomide increases the renal toxicity of the aminoglycoside"
1030,"Anakinra","DB00026","Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided. "
1030,"Dexamethasone","DB01234","Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects. "
1030,"Gentamicin","DB00798","Thalidomide increases the renal toxicity of the aminoglycoside"
1030,"Natalizumab","DB00108","Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection."
1030,"Netilmicin","DB00955","Thalidomide increases the renal toxicity of the aminoglycoside"
1030,"Rilonacept","DB06372","Thalidomide may increase the adverse effects of Rilonacept. Increased risk of serious infection. Concomitant therapy should be avoided. "
1030,"Tobramycin","DB00684","Thalidomide increases the renal toxicity of the aminoglycoside"
1030,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1030,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Thalidomide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1031,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
1031,"Cyclosporine","DB00091","Melphalan increases toxicity of cyclosporine"
1031,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1032,"Acetazolamide","DB00819","Possible increased levels of memantine"
1032,"Amantadine","DB00915","Increased risk of CNS adverse effects with this association"
1032,"Diclofenamide","DB01144","Possible increased levels of memantine"
1032,"Ketamine","DB01221","Increased risk of CNS adverse effects with this association"
1032,"Methazolamide","DB00703","Possible increased levels of memantine"
1032,"Sodium bicarbonate","DB01390","Possible increased levels of memantine"
1033,"Aluminium","DB01370","Formation of non-absorbable complexes"
1033,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
1033,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
1033,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
1033,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
1033,"Digoxin","DB00390","Gatifloxacin increases the effect of digoxin"
1033,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
1033,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
1033,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
1033,"Iron","DB01592","Formation of non-absorbable complexes"
1033,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1033,"Magnesium","DB01378","Formation of non-absorbable complexes"
1033,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1033,"Magnesium salicylate","DB01397","Formation of non-absorbable complexes"
1033,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1033,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
1033,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
1033,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
1033,"Promazine","DB00420","Increased risk of cardiotoxicity and arrhythmias"
1033,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
1033,"Propiomazine","DB00777","Increased risk of cardiotoxicity and arrhythmias"
1033,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
1033,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
1033,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1033,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
1033,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1033,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1033,"Thiethylperazine","DB00372","Increased risk of cardiotoxicity and arrhythmias"
1033,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1033,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1033,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1033,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
1033,"Triflupromazine","DB00508","Increased risk of cardiotoxicity and arrhythmias"
1033,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
1033,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1033,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1033,"Zinc","DB01593","Formation of non-absorbable complexes"
1033,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1034,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
1034,"Acenocoumarol","DB01418","Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
1034,"Acetohexamide","DB00414","Rifampin may decrease the effect of sulfonylurea, acetohexamide."
1034,"Alfentanil","DB00802","Rifampin reduces levels and efficacy of alfentanil"
1034,"Aminophylline","DB01223","Rifampin decreases the effect of theophylline"
1034,"Amiodarone","DB01118","Rifampin decreases the effect of amiodarone"
1034,"Amitriptyline","DB00321","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amitriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if rifampin is initiated, discontinued or dose changed."
1034,"Amoxapine","DB00543","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, amoxapine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if rifampin is initiated, discontinued or dose changed."
1034,"Amprenavir","DB00701","In presence of rifampin anticipate decrease of amprenavir efficiency"
1034,"Anisindione","DB01125","Rifampin may decrease the anticoagulant effect of anisindione."
1034,"Aprepitant","DB00673","The CYP3A4 inducer, rifampin, may decrease the effect of aprepitant."
1034,"Artemether","DB06697","Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. John's wort is contraindicated with Coartem Tablets."
1034,"Atazanavir","DB01072","Rifampin reduces levels and efficacy of atazanavir"
1034,"Atorvastatin","DB01076","Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed."
1034,"Atovaquone","DB01117","Rifampin may decrease the effect of atovaquone."
1034,"Bedaquiline","DB08903","Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided. "
1034,"Bendamustine","DB06769","CYP1A2 metabolism may result in increased levels of active metabolites, decreases levels of bendamustine. "
1034,"Betamethasone","DB00443","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, betamethasone."
1034,"Bisoprolol","DB00612","Rifampin may decrease the serum concentration of bisprolol by increasing its metabolism."
1034,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
1034,"Bosutinib","DB06616","Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely. "
1034,"Bromazepam","DB01558","Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed. "
1034,"Bupropion","DB01156","Rifampin reduces bupropion levels"
1034,"Buspirone","DB00490","Rifampin decreases the effect of buspirone"
1034,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
1034,"Canagliflozin","DB08907","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
1034,"Caspofungin","DB00520","Decreased levels/effects of caspofungin"
1034,"Celecoxib","DB00482","Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed."
1034,"Cerivastatin","DB00439","Rifampin may decrease the effect of cerivastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of cerivastatin if rifampin is initiated, discontinued or dose changed."
1034,"Chloramphenicol","DB00446","Rifampin decreases the effect of chloramphenicol"
1034,"Chlorpropamide","DB00672","Rifampin may decrease the effect of sulfonylurea, chlorpropamide."
1034,"Clarithromycin","DB01211","The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin."
1034,"Clomipramine","DB01242","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed."
1034,"Clozapine","DB00363","Rifampin decreases the effect of clozapine"
1034,"Cortisone acetate","DB01380","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate."
1034,"Crizotinib","DB08865","Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. "
1034,"Crizotinib","DB08865","Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. "
1034,"Cyclosporine","DB00091","The rifamycin decreases the effect of cyclosporine"
1034,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
1034,"Dabrafenib","DB08912","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
1034,"Dapsone","DB00250","Decreased levels of dapsone"
1034,"Dasatinib","DB01254","Rifampin may decrease the serum level and efficacy of dasatinib."
1034,"Delavirdine","DB00705","Rifampin decreases the effect of delavirdine"
1034,"Desipramine","DB01151","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed."
1034,"Dexamethasone","DB01234","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone."
1034,"Diazepam","DB00829","Rifampin may decrease the effect of the benzodiazepine, diazepam."
1034,"Diclofenac","DB00586","Rifampin, a CYP2C9 inducer, may increase the metabolism of diclofenac."
1034,"Dicoumarol","DB00266","Rifampin may decrease the anticoagulant effect of dicumarol."
1034,"Diltiazem","DB00343","Rifampin decreases levels of diltiazem"
1034,"Disopyramide","DB00280","Rifampin decreases the effect of disopyramide"
1034,"Doxepin","DB01142","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed."
1034,"Doxycycline","DB00254","The rifamycin decreases the effect of doxycycline"
1034,"Dyphylline","DB00651","Rifampin decreases the effect of theophylline"
1034,"Enalapril","DB00584","Rifampin, a strong CYP3A4 inducer, may increase the metabolism of enalapril. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of enalapril if rifampin is initiated, discontinued or dose changed."
1034,"Erlotinib","DB00530","Decreased levels/effect of erlotinib"
1034,"Erythromycin","DB00199","The rifamycin, rifampin, may decrease the effect of the macrolide, erythromycin."
1034,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1034,"Ethotoin","DB00754","Rifampin decreases the effect of the hydantoin"
1034,"Etoricoxib","DB01628","Rifampin reduces levels and efficacy of etoricoxib"
1034,"Fentanyl","DB00813","Rifampin may decrease the serum level and therapeutic effect of fentanyl."
1034,"Fluconazole","DB00196","Rifampin may decrease the effect of fluconazole."
1034,"Fludrocortisone","DB00687","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, fludrocortisone."
1034,"Fluvastatin","DB01095","Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed."
1034,"Fosamprenavir","DB01319","Rifampin may decrease the effectiveness of fosamprenavir."
1034,"Fosphenytoin","DB01320","Rifampin may decrease the effect of fosphenytoin."
1034,"Gadoxetate","DB08884","Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal. "
1034,"Gefitinib","DB00317","Rifampin reduces levels and efficacy of gefitinib"
1034,"Gliclazide","DB01120","Rifampin may decrease the effect of sulfonylurea, gliclazide."
1034,"Glimepiride","DB00222","Rifampin may decrease the effect of sulfonylurea, glimepiride."
1034,"Glipizide","DB01067","Rifampin may decrease the effect of sulfonylurea, glipizide."
1034,"Glisoxepide","DB01289","Rifampin may decrease the effect of sulfonylurea, glisoxepide."
1034,"Glyburide","DB01016","Rifampin may decrease the effect of sulfonylurea, glibenclamide."
1034,"Glycodiazine","DB01382","Rifampin may decrease the effect of sulfonylurea, glycodiazine."
1034,"Haloperidol","DB00502","The rifamycin decreases the effect of haloperidol"
1034,"Hydrocortisone","DB00741","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone."
1034,"Imatinib","DB00619","Rifampin decreases levels of imatinib"
1034,"Imipramine","DB00458","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, imipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if rifampin is initiated, discontinued or dose changed."
1034,"Indinavir","DB00224","Rifampin decreases the effect of indinavir"
1034,"Itraconazole","DB01167","Rifampin may decrease the effect of itraconazole."
1034,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
1034,"Josamycin","DB01321","The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin."
1034,"Ketoconazole","DB01026","Rifampin may decrease the effect of ketoconazole."
1034,"Lamotrigine","DB00555","Rifampin decreases levels of lamotrigine"
1034,"Leflunomide","DB01097","Rifampin increases the effect of leflunomide"
1034,"Linagliptin","DB08882","CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. "
1034,"Losartan","DB00678","Rifampin decreases the effect of losartan"
1034,"Lovastatin","DB00227","Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed."
1034,"Mefloquine","DB00358","Rifampin lowers mefloquine levels"
1034,"Mephenytoin","DB00532","Rifampin decreases the effect of the hydantoin"
1034,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
1034,"Methadone","DB00333","The rifamycin decreases the effect of methadone"
1034,"Methylprednisolone","DB00959","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, methylprednisolone."
1034,"Metoprolol","DB00264","Rifampin may decrease the serum concentration of metoprolol by increasing its metabolism."
1034,"Mexiletine","DB00379","Rifampin decreases the effect of mexiletine"
1034,"Midazolam","DB00683","Rifampin may increase the metabolism of midazolam. Monitor for changes in the therapeutic and adverse effects of midazolam if rifampin is initiated, discontinued or dose changed."
1034,"Mirabegron","DB08893","Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely. "
1034,"Morphine","DB00295","Rifampin decreases the effect of morphine/codeine"
1034,"Mycophenolate mofetil","DB00688","Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided."
1034,"Nelfinavir","DB00220","Rifampin decreases the effect of nelfinavir"
1034,"Nifedipine","DB01115","Rifampin decreases the effect of the calcium channel blocker, nifedipine."
1034,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1034,"Nortriptyline","DB00540","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, nortriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if rifampin is initiated, discontinued or dose changed."
1034,"Ospemifene","DB04938","Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect."
1034,"Oxtriphylline","DB01303","Rifampin may decrease the effect and toxicity of oxtriphylline."
1034,"Paramethasone","DB01384","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone."
1034,"Pazopanib","DB06589","Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib. "
1034,"Phenytoin","DB00252","Rifampin may decrease the therapeutic and adverse effects of phenytoin."
1034,"Pitavastatin","DB08860","Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. "
1034,"Pitavastatin","DB08860","Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. "
1034,"Pomalidomide","DB08910","Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided. "
1034,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
1034,"Ponatinib","DB08901","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
1034,"Praziquantel","DB01058","Significant decrease in praziquantel level"
1034,"Prednisolone","DB00860","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisolone."
1034,"Prednisone","DB00635","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone."
1034,"Propafenone","DB01182","Rifampin decreases the effect of propafenone"
1034,"Propranolol","DB00571","Rifampin may decrease the serum concentration of propranolol by increasing its metabolism."
1034,"Protriptyline","DB00344","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, protriptyline, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if rifampin is initiated, discontinued or dose changed."
1034,"Quinidine","DB00908","Rifampin decreases the effect of quinidine"
1034,"Quinidine barbiturate","DB01346","Rifampin decreases the effect of quinidine"
1034,"Ramelteon","DB00980","Rifampin reduces the levels/effect of ramelteon"
1034,"Regorafenib","DB08896","Strong CYP3A4 inducers may decrease levels of regorafenib. "
1034,"Repaglinide","DB00912","Rifampin decreases the effect of repaglinide"
1034,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
1034,"Ritonavir","DB00503","Rifampin decreases the effect of ritonavir"
1034,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1034,"Rosiglitazone","DB00412","Rifampin reduces levels and efficacy of rosiglitazone"
1034,"Ruxolitinib","DB08877","Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient. "
1034,"Saquinavir","DB01232","Rifampin decreases the effect of saquinavir"
1034,"Saxagliptin","DB06335","Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases. "
1034,"Simvastatin","DB00641","Rifampin may decrease the effect of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if rifampin is initiated, discontinued or dose changed."
1034,"Sirolimus","DB00877","The rifamycin decreases the effect of sirolimus"
1034,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
1034,"Tacrolimus","DB00864","Rifampin may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Rifampin therapy is initiated, discontinued or altered."
1034,"Tadalafil","DB00820","Rifampin may reduce Tadalafil plasma concentrations and efficacy."
1034,"Tamoxifen","DB00675","The rifamycin decreases the effect of anti-estrogen"
1034,"Telaprevir","DB05521","Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated. "
1034,"Telithromycin","DB00976","Rifampin may decrease the plasma concentration of Telithromycin. Concomitant therapy should be avoided."
1034,"Temsirolimus","DB06287","Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1034,"Terbinafine","DB00857","Rifampin may increase the metabolism and clearance of Terbinafine. Co-administration may result in Terbinafine treatment failure."
1034,"Theophylline","DB00277","Rifampin decreases the effect of theophylline"
1034,"Tipranavir","DB00932","Rifampin may decrease the plasma concentration of Tipranavir. Concomitant use is not recommended. "
1034,"Tocainide","DB01056","Rifampin lowers tocainide levels/effects"
1034,"Tofacitinib","DB08895","Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity."
1034,"Tolazamide","DB00839","Rifampin may decrease the effect of sulfonylurea, tolazamide."
1034,"Tolbutamide","DB01124","Rifampin may decrease the effect of sulfonylurea, tolbutamide."
1034,"Tolvaptan","DB06212","Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
1034,"Toremifene","DB00539","The rifamycin decreases the effect of anti-estrogen"
1034,"Tramadol","DB00193","Rifampin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
1034,"Trazodone","DB00656","The CYP3A4 inducer, Rifampin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifampin is initiated, discontinued or dose changed."
1034,"Tretinoin","DB00755","The strong CYP2C8 inducer, Rifampin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifampin is initiated, discontinued or dose changed. "
1034,"Triamcinolone","DB00620","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, triamcinolone."
1034,"Triazolam","DB00897","Rifampin may decrease the effect of the benzodiazepine, triazolam."
1034,"Trimethoprim","DB00440","Rifampin decreases the effect of trimethoprim"
1034,"Trimipramine","DB00726","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, trimipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trimipramine if rifampin is initiated, discontinued or dose changed."
1034,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
1034,"Valproic Acid","DB00313","Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed. "
1034,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1034,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
1034,"Verapamil","DB00661","Rifampin, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifampin is initiated, discontinued or dose changed."
1034,"Voriconazole","DB00582","Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
1034,"Warfarin","DB00682","Rifampin may decrease the anticoagulant effect of warfarin by increasing its metabolism."
1034,"Zaleplon","DB00962","Rifampin decreases the effect of zaleplon"
1034,"Zidovudine","DB00495","Rifampin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifampin is initiated, discontinued or dose changed."
1037,"Amprenavir","DB00701","The serum concentration of Abacavir may be decreased by protease inhibitors such as Amprenavir. The antiviral response should be closely monitored."
1037,"Atazanavir","DB01072","The serum concentration of Abacavir may be decreased by protease inhibitors such as Atazanavir. The antiviral response should be closely monitored."
1037,"Darunavir","DB01264","The serum concentration of Abacavir may be decreased by protease inhibitors such as Darunavir. The antiviral response should be closely monitored."
1037,"Ethanol","DB00898","Abacavir is partly metabolized through the alcohol dehydrogenase enzyme system. Alcohol increases the area under the curve (about 41%) of Abacavir. Interaction does not appear to be clinically significant. "
1037,"Fosamprenavir","DB01319","The serum concentration of Abacavir may be decreased by protease inhibitors such as Fosamprenavir. The antiviral response should be closely monitored."
1037,"Ganciclovir","DB01004","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Ganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is required."
1037,"Indinavir","DB00224","The serum concentration of Abacavir may be decreased by protease inhibitors such as Indinavir. The antiviral response should be closely monitored."
1037,"Lopinavir","DB01601","The serum concentration of Abacavir may be decreased by protease inhibitors such as Lopinavir. The antiviral response should be closely monitored."
1037,"Nelfinavir","DB00220","The serum concentration of Abacavir may be decreased by protease inhibitors such as Nelfinavir. The antiviral response should be closely monitored."
1037,"Ribavirin","DB00811","Ribavirin may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy."
1037,"Ribavirin Monophosphate","DB01693","Ribavirin Monophosphate may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy."
1037,"Ritonavir","DB00503","The serum concentration of Abacavir may be decreased by protease inhibitors such as Ritonavir. The antiviral response should be closely monitored."
1037,"Saquinavir","DB01232","The serum concentration of Abacavir may be decreased by protease inhibitors such as Saquinavir. The antiviral response should be closely monitored."
1037,"Tipranavir","DB00932","The serum concentration of Abacavir may be decreased by protease inhibitors such as Tipranavir. The antiviral response should be closely monitored."
1037,"Valganciclovir","DB01610","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended. "
1038,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1038,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ergoloid mesylates. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergoloid mesylates if Telithromycin is initiated, discontinued or dose changed."
1038,"Tipranavir","DB00932","Tipranavir may increase the plasma concentration of Ergoloid mesylates. Concomitant therapy should be avoided."
1038,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1038,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1038,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1038,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
1038,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1038,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergoloid mesylates by decreasing their metabolism. Concomitant therapy is contraindicated. "
1038,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
1039,"Acebutolol","DB01193","Risk of inhibition of renal prostaglandins"
1039,"Acenocoumarol","DB01418","The NSAID, ibuprofen, may increase the anticoagulant effect of acenocoumarol."
1039,"Acetylsalicylic acid","DB00945","Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended."
1039,"Alendronate","DB00630","Increased risk of gastric toxicity"
1039,"Anisindione","DB01125","The NSAID, ibuprofen, may increase the anticoagulant effect of anisindione."
1039,"Atenolol","DB00335","Risk of inhibition of renal prostaglandins"
1039,"Azilsartan medoxomil","DB08822","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
1039,"Betaxolol","DB00195","Nonsteroidal Anti-Inflammatory Agents such as ibuprofen may diminish the antihypertensive effect of Beta-Blockers such as betaxolol. Monitor for increases in blood pressure if a nonsteroidal anti-inflammatory agent (NSAID) is initiated/dose increased, or decreases in blood pressure if a NSAID is discontinued/dose decreased; this is particularly important if NSAID treatment is for extended periods of time. Ophthalmic beta-blockers are likely of little concern. "
1039,"Bevantolol","DB01295","Risk of inhibition of renal prostaglandins"
1039,"Bisoprolol","DB00612","Risk of inhibition of renal prostaglandins"
1039,"Bumetanide","DB00887","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, bumetanide."
1039,"Carteolol","DB00521","Risk of inhibition of renal prostaglandins"
1039,"Carvedilol","DB01136","Risk of inhibition of renal prostaglandins"
1039,"Colesevelam","DB00930","Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-Inflammatory Agents. Monitor for decreased serum concentrations/therapeutic effects of nonsteroidal anti-inflammatory agents (NSAID) if coadministered with bile acid sequestrants. Separating the administration of doses by 2 or more hours may reduce (but not eliminate) the risk of interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam. "
1039,"Cyclosporine","DB00091","Monitor for nephrotoxicity"
1039,"Dicoumarol","DB00266","The NSAID, ibuprofen, may increase the anticoagulant effect of dicumarol."
1039,"Eltrombopag","DB06210","Increases levels of Ibuprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
1039,"Esmolol","DB00187","Risk of inhibition of renal prostaglandins"
1039,"Ethacrynic acid","DB00903","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, ethacrynic acid."
1039,"Furosemide","DB00695","The NSAID, ibuprofen, may antagonize the diuretic and antihypertensive effects of the loop diuretic, furosemide."
1039,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1039,"Homoharringtonine","DB04865","Avoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
1039,"Labetalol","DB00598","Risk of inhibition of renal prostaglandins"
1039,"Lithium","DB01356","The NSAID, ibuprofen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1039,"Methotrexate","DB00563","The NSAID, ibuprofen, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity."
1039,"Metoprolol","DB00264","Risk of inhibition of renal prostaglandins"
1039,"Nadolol","DB01203","Risk of inhibition of renal prostaglandins"
1039,"Oxprenolol","DB01580","Risk of inhibition of renal prostaglandins"
1039,"Penbutolol","DB01359","Risk of inhibition of renal prostaglandins"
1039,"Pindolol","DB00960","Risk of inhibition of renal prostaglandins"
1039,"Practolol","DB01297","Risk of inhibition of renal prostaglandins"
1039,"Pralatrexate","DB06813","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
1039,"Prasugrel","DB06209","Coadministration with NSAIDS used chronically may increase the risk of bleeding. "
1039,"Propranolol","DB00571","Risk of inhibition of renal prostaglandins"
1039,"Sotalol","DB00489","Risk of inhibition of renal prostaglandins"
1039,"Tamoxifen","DB00675","Ibuprofen may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Ibuprofen is initiated, discontinued or dose changed."
1039,"Tolbutamide","DB01124","Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed. "
1039,"Torasemide","DB00214","The NSAID, ibuprofen, may decrease the diuretic and antihypertensive effect of the loop diuretic, torasemide."
1039,"Trandolapril","DB00519","The NSAID, Ibuprofen, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Ibuprofen is initiated, discontinued or dose changed. "
1039,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Ibuprofen. Monitor for increased bleeding during concomitant thearpy. "
1039,"Triflusal","DB08814","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of ibuprofen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
1039,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Ibuprofen, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ibuprofen is initiated, discontinued or dose changed."
1039,"Vilazodone","DB06684","Increased risk of bleeding with concomitant use of non-steroidal anti-inflammatory drugs with vilazodone."
1039,"Voriconazole","DB00582","Ibuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed.	"
1039,"Warfarin","DB00682","Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of ibuprofen may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ibuprofen is initiated, discontinued or dose changed."
1041,"Demeclocycline","DB00618","Possible antagonism of action"
1041,"Doxycycline","DB00254","Possible antagonism of action"
1041,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1041,"Mestranol","DB01357","This anti-infectious agent could decreases the effect of the oral contraceptive"
1041,"Methacycline","DB00931","Possible antagonism of action"
1041,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1041,"Minocycline","DB01017","Possible antagonism of action"
1041,"Oxytetracycline","DB00595","Possible antagonism of action"
1041,"Rolitetracycline","DB01301","Possible antagonism of action"
1041,"Tetracycline","DB00759","Possible antagonism of action"
1041,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1042,"Cimetidine","DB00501","Cimetidine increases the effect of the calcium channel blocker, nitrendipine. "
1042,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nitrendipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nitrendipine if Telithromycin is initiated, discontinued or dose changed."
1042,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nitrendipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nitrendipine if Thiopental is initiated, discontinued or dose changed."
1042,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nitrendipine. Monitor for changes in Nitrendipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed."
1042,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1042,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nitrendipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nitrendipine if voriconazole is initiated, discontinued or dose changed."
1044,"Rifampicin","DB01045","Rifampin lowers tocainide levels/effects"
1044,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1045,"Succinylcholine","DB00202","Echothiophate iodide may increase the effect of succinylcholine."
1046,"Carbamazepine","DB00564","Markedly lower praziquantel levels"
1046,"Chloroquine","DB00608","Markedly lower praziquantel levels"
1046,"Etravirine","DB06414","Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
1046,"Etravirine","DB06414","Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
1046,"Phenytoin","DB00252","Markedly lower praziquantel levels"
1046,"Rifampicin","DB01045","Significant decrease in praziquantel level"
1046,"Telithromycin","DB00976","Telithromycin may reduce clearance of Praziquantel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Praziquantel if Telithromycin is initiated, discontinued or dose changed."
1046,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of praziquantel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of praziquantel if voriconazole is initiated, discontinued or dose changed."
1047,"Acenocoumarol","DB01418","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of acenocoumarol."
1047,"Aluminium","DB01370","Formation of non-absorbable complexes"
1047,"Aminophylline","DB01223","Norfloxacin may increase the effect of aminophylline."
1047,"Anisindione","DB01125","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione."
1047,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1047,"Caffeine","DB00201","Norfloxacin may increase the effect and toxicity of caffeine."
1047,"Calcium","DB01373","Formation of non-absorbable complexes"
1047,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as norfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
1047,"Clozapine","DB00363","Ciprofloxacin may increase clozapine serum levels"
1047,"Cyclosporine","DB00091","Norfloxacin may increase the effect and toxicity of cyclosporine."
1047,"Dicoumarol","DB00266","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of dicumarol."
1047,"Dyphylline","DB00651","Norfloxacin may increase the effect of dyphylline."
1047,"Foscarnet","DB00529","Increased risk of convulsions"
1047,"Iron","DB01592","Formation of non-absorbable complexes"
1047,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1047,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1047,"Magnesium","DB01378","Formation of non-absorbable complexes"
1047,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1047,"Oxtriphylline","DB01303","Norfloxacin may increase the effect of oxtriphylline."
1047,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1047,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Norfloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Norfloxacin is initiated, discontinued or if the dose is changed."
1047,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1047,"Tamsulosin","DB00706","Norfloxacin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Norfloxacin is initiated, discontinued, or dose changed."
1047,"Theophylline","DB00277","Norfloxacin may increase the effect of theophylline."
1047,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration. "
1047,"Tizanidine","DB00697","Norfloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1047,"Tolterodine","DB01036","Norfloxacin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1047,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1047,"Tramadol","DB00193","Norfloxacin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
1047,"Trazodone","DB00656","The CYP3A4 inhibitor, Norfloxacin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."
1047,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1047,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1047,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1047,"Warfarin","DB00682","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of warfarin."
1047,"Zinc","DB01593","Formation of non-absorbable complexes"
1047,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1047,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1048,"Demeclocycline","DB00618","Possible antagonism of action"
1048,"Doxycycline","DB00254","Possible antagonism of action"
1048,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1048,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1048,"Methacycline","DB00931","Possible antagonism of action"
1048,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1048,"Minocycline","DB01017","Possible antagonism of action"
1048,"Oxytetracycline","DB00595","Possible antagonism of action"
1048,"Rolitetracycline","DB01301","Possible antagonism of action"
1048,"Tetracycline","DB00759","Possible antagonism of action"
1049,"Demeclocycline","DB00618","Possible antagonism of action"
1049,"Doxycycline","DB00254","Possible antagonism of action"
1049,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1049,"Minocycline","DB01017","Possible antagonism of action"
1049,"Tetracycline","DB00759","Possible antagonism of action"
1050,"Carbamazepine","DB00564","Oxybutynin may cause carbamazepine toxicity"
1050,"Donepezil","DB00843","Possible antagonism of action"
1050,"Galantamine","DB00674","Possible antagonism of action"
1050,"Rivastigmine","DB00989","Possible antagonism of action"
1050,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Oxybutynin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1050,"Trimethobenzamide","DB00662","Trimethobenzamide and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1050,"Triprolidine","DB00427","Triprolidine and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1050,"Trospium","DB00209","Trospium and Oxybutynin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1051,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
1051,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1051,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Guanethidine","DB01170","Acetophenazine may decrease the effect of guanethidine."
1051,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
1051,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Acetophenazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1051,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1051,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
1051,"Trimethobenzamide","DB00662","Trimethobenzamide and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1051,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Acetophenazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1051,"Trospium","DB00209","Trospium and Acetophenazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1052,"Acebutolol","DB01193","Antagonism"
1052,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of isoproterenol."
1052,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of isoproterenol."
1052,"Atenolol","DB00335","Antagonism"
1052,"Bisoprolol","DB00612","Antagonism"
1052,"Carvedilol","DB01136","Antagonism"
1052,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of isoproterenol."
1052,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of isoproterenol."
1052,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of isoproterenol."
1052,"Entacapone","DB00494","Entacapone increases the effect and toxicity of the sympathomimetic, isoproterenol."
1052,"Esmolol","DB00187","Antagonism"
1052,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of isoproterenol."
1052,"Isocarboxazid","DB01247","Increased arterial pressure"
1052,"Labetalol","DB00598","Antagonism"
1052,"Linezolid","DB00601","Possible increase of arterial pressure"
1052,"Methyldopa","DB00968","Increased arterial pressure"
1052,"Metoprolol","DB00264","Antagonism"
1052,"Midodrine","DB00211","Increased arterial pressure"
1052,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of isoproterenol."
1052,"Nadolol","DB01203","Antagonism"
1052,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of isoproterenol."
1052,"Oxprenolol","DB01580","Antagonism"
1052,"Phenelzine","DB00780","Increased arterial pressure"
1052,"Pindolol","DB00960","Antagonism"
1052,"Propranolol","DB00571","Antagonism"
1052,"Rasagiline","DB01367","Increased arterial pressure"
1052,"Reserpine","DB00206","Increased arterial pressure"
1052,"Timolol","DB00373","Antagonism"
1053,"Nifedipine","DB01115","Melatonin can possibly decrease the effect of nifedipine"
1054,"Cimetidine","DB00501","H2-Antagonists such as cimetidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
1054,"Esomeprazole","DB00736","Proton pump inhibitors such as esomeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1054,"Famotidine","DB00927","H2-Antagonists such as famotidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
1054,"Lansoprazole","DB00448","Proton pump inhibitors such as lansoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1054,"Nizatidine","DB00585","H2-Antagonists such as nizatidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
1054,"Omeprazole","DB00338","Proton pump inhibitors such as omeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1054,"Pantoprazole","DB00213","Proton pump inhibitors such as pantoprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1054,"Rabeprazole","DB01129","Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1054,"Ranitidine","DB00863","H2-Antagonists such as ranitidine may decrease the serum concentration of cefditoren. Cefditoren prescribing information recommends to avoid concomitant use with H2-antagonists (eg, famotidine, ranitidine) and antacids as well. Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided."
1055,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1055,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide."
1055,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1055,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1055,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1055,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, glipizide."
1055,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, glipizide."
1055,"Cyclosporine","DB00091","The sulfonylurea, glipizide, may increase the effect of cyclosporine."
1055,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1055,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1055,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1055,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1055,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1055,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1055,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1055,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1055,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, glipizide."
1055,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of glipizide. Monitor for changes in fasting and postprandial blood sugars."
1055,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1055,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1056,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, clonazepam."
1056,"Clozapine","DB00363","Increased risk of toxicity"
1056,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, clonazepam."
1056,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, clonazepam."
1056,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, clonazepam."
1056,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, clonazepam."
1056,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, clonazepam."
1056,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, clonazepam."
1056,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, clonazepam."
1056,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clonazepam."
1056,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clonazepam."
1056,"St. John's Wort","DB01323","St. John's Wort may decrease the effect of the benzodiazepine, clonazepam."
1056,"Telithromycin","DB00976","Telithromycin may reduce clearance of Clonazepam. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Clonazepam if Telithromycin is initiated, discontinued or dose changed."
1056,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Clonazepam. Consider alternate therapy or monitor for Clonazepam toxic effects if Tipranavir is initiated or dose increased. "
1056,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Clonazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1056,"Vigabatrin","DB01080","Vigabatrin increases Cmax of clonazepam by 30% and decreases Tmax by 45% "
1056,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of clonazepam by decreasing its metabolism. Monitor for clonazepam toxicity if voriconazole is initiated or dose increased."
1057,"Amphetamine","DB00182","Decreased anorexic effect, may increase pyschotic symptoms"
1057,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
1057,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
1057,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1057,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1057,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase pyschotic symptoms."
1057,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase pyschotic symptoms"
1057,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms."
1057,"Donepezil","DB00843","Possible antagonism of action"
1057,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms."
1057,"Galantamine","DB00674","Possible antagonism of action"
1057,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1057,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1057,"Guanethidine","DB01170","Promethazine may decrease the effect of guanethidine."
1057,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1057,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms."
1057,"Methamphetamine","DB01577","Decreased anorexic effect, may increase pyschotic symptoms"
1057,"Metrizamide","DB01578","Increased risk of convulsions"
1057,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase pyschotic symptoms"
1057,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase pyschotic symptoms"
1057,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms."
1057,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms."
1057,"Rivastigmine","DB00989","Possible antagonism of action"
1057,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1057,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Promethazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1057,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Promethazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Promethazine if Terbinafine is initiated, discontinued or dose changed."
1057,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1057,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Promethazine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Promethazine if Thiotepa is initiated, discontinued or dose changed. "
1057,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1057,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1057,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1057,"Trimethobenzamide","DB00662","Trimethobenzamide and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1057,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
1057,"Triprolidine","DB00427","Triprolidine and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1057,"Trospium","DB00209","Trospium and Promethazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1057,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1057,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1060,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Atazanavir. The antiviral response should be closely monitored."
1060,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1060,"Acenocoumarol","DB01418","The protease inhibitor, atazanavir, may increase the anticoagulant effect of acenocoumarol."
1060,"Aluminium","DB01370","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias."
1060,"Amitriptyline","DB00321","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if atazanavir if initiated, discontinued or dose changed."
1060,"Amoxapine","DB00543","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if atazanavir if initiated, discontinued or dose changed."
1060,"Anisindione","DB01125","The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione."
1060,"Atorvastatin","DB01076","Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
1060,"Bepridil","DB01244","Atazanavir may increase the effect and toxicity of bepridil."
1060,"Bismuth Subsalicylate","DB01294","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Bromazepam","DB01558","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1060,"Buprenorphine","DB00921","Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir. Avoid use of buprenorphine in patients receiving atazanavir without ritonavir boosting due to possible decreases in atazanavir exposure. In patients receiving buprenorphine with atazanavir/ritonavir, monitor for increased buprenorphine effects and consider dose reductions if patients experience adverse effects. "
1060,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1060,"Calcium","DB01373","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Cimetidine","DB00501","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1060,"Clarithromycin","DB01211","Atazanavir may increase serum level of clarithromycin."
1060,"Clomipramine","DB01242","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if atazanavir is initiated, discontinued or dose changed."
1060,"Cyclosporine","DB00091","Atazanavir may increase the therapeutic and adverse effects of cyclosporine."
1060,"Dantrolene","DB01219","Atazanavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if atazanavir is initiated, discontinued or dose changed. "
1060,"Desipramine","DB01151","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if atazanavir is initiated, discontinued or dose changed."
1060,"Dicoumarol","DB00266","The protease inhibitor, atazanavir, may increase the anticoagulant effect of dicumarol."
1060,"Dihydroergotamine","DB00320","Atazanavir may increase the therapeutic and adverse effects of dihydroergotamine."
1060,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
1060,"Dihydroxyaluminium","DB01375","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Diltiazem","DB00343","Atazanavir may increase the therapeutic and adverse effects of diltiazem resulting in increased risk of AV block. Consider alternate therapy, a 50% dose reduction of diltiazem and monitor for changes in the therapeutic and adverse effects of diltiazem if atazanavir is initiated, discontinued or dose changed."
1060,"Doxepin","DB01142","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed."
1060,"Efavirenz","DB00625","Efavirenz decreases the levels/effects of atazanavir"
1060,"Eltrombopag","DB06210","Decreases metabolism, will increase effect/level of eltrombopag. UDP-glucuronosyltransferase inhibition."
1060,"Ergotamine","DB00696","Atazanavir may increase the effect and toxicity of ergotamine."
1060,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1060,"Esomeprazole","DB00736","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Etravirine","DB06414","Atazanavir, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. \
\
Etravirine, when administered concomitantly with Atazanavir, may expereince an increase in serum concentrations. \
\
Recommended to avoid use of this combination.  "
1060,"Famotidine","DB00927","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Imipramine","DB00458","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if atazanavir if initiated, discontinued or dose changed."
1060,"Indinavir","DB00224","Increased risk of hyperbilirubinemia with this association"
1060,"Irinotecan","DB00762","Increases levels/effect of irinotecan"
1060,"Lansoprazole","DB00448","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Lidocaine","DB00281","Increased risk of cardiotoxicity and arrhythmias"
1060,"Lovastatin","DB00227","Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated."
1060,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1060,"Magnesium","DB01378","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Magnesium oxide","DB01377","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Magnesium Sulfate","DB00653","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Methylergometrine","DB00353","Increases the effect and toxicity of ergot derivative"
1060,"Midazolam","DB00683","Atazanavir may increase the effect and toxicity of the benzodiazepine, midazolam."
1060,"Nevirapine","DB00238","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atazanavir by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atazanavir if nevirapine is initiated, discontinued or dose changed."
1060,"Nizatidine","DB00585","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Nortriptyline","DB00540","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if atazanavir if initiated, discontinued or dose changed."
1060,"Omeprazole","DB00338","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Pantoprazole","DB00213","This gastric pH modifier decreases the levels/effects of atazanavir"
1060,"Pimozide","DB01100","The protease inhibitor, atazanavir, may increase the effect and toxicity of pimozide."
1060,"Pitavastatin","DB08860","Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy."
1060,"Protriptyline","DB00344","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, protriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of protriptyline if atazanavir if initiated, discontinued or dose changed."
1060,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias."
1060,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
1060,"Rabeprazole","DB01129","Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir."
1060,"Ramelteon","DB00980","Atazanavir increases levels/toxicity of ramelteon"
1060,"Ranitidine","DB00863","Ranitidine may decrease the levels/effects of atazanavir."
1060,"Ranolazine","DB00243","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."
1060,"Rifabutin","DB00615","Atazanavir may increase levels/toxicity of rifabutin."
1060,"Rifampicin","DB01045","Rifampin reduces levels and efficacy of atazanavir"
1060,"Ritonavir","DB00503","Association with dose adjustment"
1060,"Sildenafil","DB00203","Increases the effect and toxicity of sildenafil"
1060,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
1060,"Sirolimus","DB00877","Increases the effect and toxicity of immunosuppressant"
1060,"Sodium bicarbonate","DB01390","This gastric pH modifier decreases the levels/effect of atazanavir"
1060,"St. John's Wort","DB01323","St. John's Wort decreases the levels/effects of atazanavir"
1060,"Sunitinib","DB01268","Possible increase in sunitinib levels"
1060,"Tacrolimus","DB00864","The protease inhibitor, Atazanavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Atazanavir therapy is initiated, discontinued or altered."
1060,"Tadalafil","DB00820","Atazanavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1060,"Tamoxifen","DB00675","Atazanavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1060,"Tamsulosin","DB00706","Atazanvir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Atazanavir is initiated, discontinued, or dose changed."
1060,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Atazanavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
1060,"Temsirolimus","DB06287","Atazanavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1060,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Atazanavir is initiated, discontinued or dose changed."
1060,"Tenofovir","DB00300","Concomitant therapy may result in decreased serum levels of Atazanavir and increased levels of Tenofovir. Concomitant therapy should only be used with the inclusion of Ritonavir."
1060,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Atazanavir is initiated, discontinued or dose changed."
1060,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Atazanavir. Consider alternate therapy. "
1060,"Tolterodine","DB01036","Atazanavir may decrease the metabolism and clearance of Tolterodine. Adjust the Tolterodine dose and monitor for efficacy and toxicity."
1060,"Tramadol","DB00193","Atazanavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1060,"Trazodone","DB00656","The protease inhibitor, Atazanavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Atazanavir is initiated, discontinued or dose changed. "
1060,"Tretinoin","DB00755","The strong CYP2C8 inhibitor, Atazanavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Atazanavir is initiated, discontinued to dose changed. "
1060,"Triazolam","DB00897","Atazanavir may increase the effect and toxicity of the benzodiazepine, triazolam."
1060,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Atazanavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Atazanavir is initiated, discontinued or dose changed."
1060,"Vardenafil","DB00862","Atazanavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1060,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1060,"Venlafaxine","DB00285","Atazanavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Atazanavir is initiated, discontinued, or dose changed."
1060,"Verapamil","DB00661","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Atazanavir is initiated, discontinued or dose changed. "
1060,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. \
"
1060,"Vinblastine","DB00570","Atazanavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Atazanavir is initiated, discontinued or dose changed."
1060,"Vincristine","DB00541","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Atazanavir is initiated, discontinued or dose changed."
1060,"Vinorelbine","DB00361","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Atazanavir is initiated, discontinued or dose changed."
1060,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
1060,"Warfarin","DB00682","The protease inhibitor, atazanavir, may increase the anticoagulant effect of warfarin."
1060,"Zolpidem","DB00425","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if atazanavir is initiated, discontinued or dose changed. "
1060,"Zonisamide","DB00909","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if atazanavir is initiated, discontinued or dose changed."
1060,"Zopiclone","DB01198","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed."
1061,"Dipyridamole","DB00975","Dipyridamole may decrease the effect of fludarabine."
1061,"Pentostatin","DB00552","Unacceptable pulmonary toxicity"
1061,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1063,"Atomoxetine","DB00289","Diphenhydramine, a moderate CYP2D6 inhibitor, may increase the therapeutic and adverse effects of atomoxetine by decreasing its metabolism."
1063,"Donepezil","DB00843","Possible antagonism of action"
1063,"Galantamine","DB00674","Possible antagonism of action"
1063,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1063,"Rivastigmine","DB00989","Possible antagonism of action"
1063,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Diphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1063,"Tamoxifen","DB00675","Diphenhydramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
1063,"Tamsulosin","DB00706","Diphenhydramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Diphenhydramine is initiated, discontinued, or dose changed."
1063,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1063,"Tramadol","DB00193","Diphenhydramine may decrease the effect of Tramadol by decreasing active metabolite production. "
1063,"Trimethobenzamide","DB00662","Trimethobenzamide and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1063,"Triprolidine","DB00427","Triprolidine and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1063,"Trospium","DB00209","Trospium and Diphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1064,"Aliskiren","DB09026","Therapy modification should be considered because atorvastatin increases aliskiren serum concentration."
1064,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
1064,"Amprenavir","DB00701","Amprenavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
1064,"Atazanavir","DB01072","Atazanavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
1064,"Bezafibrate","DB01393","Increased risk of myopathy/rhabdomyolysis"
1064,"Boceprevir","DB08873","Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored. "
1064,"Bosentan","DB00559","Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed."
1064,"Carbamazepine","DB00564","Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of atorvastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if carbamazepine is initiated, discontinued or dose changed."
1064,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the toxicity of the statin, atorvastatin."
1064,"Colchicine","DB01394","Increased risk of rhadbomyolysis with this combination."
1064,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
1064,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if delavirdine is initiated, discontinued or dose changed."
1064,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of atorvastatin. Atorvastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
1064,"Dronedarone","DB04855","Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of atorvastatin. Lower doses of atorvastatin or consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. "
1064,"Efavirenz","DB00625","Efavirenz may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if efavirenz is initiated, discontinued or dose changed."
1064,"Eltrombopag","DB06210","Eltrombopag increases levels of Atorvastatin via metabolism decrease."
1064,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the toxicity of the statin, atorvastatin."
1064,"Etravirine","DB06414","Atorvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of atorvastatin therapy. "
1064,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
1064,"Fluconazole","DB00196","Increased risk of myopathy/rhabdomyolysis"
1064,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if fosamprenavir is initiated, discontinued or dose changed."
1064,"Fusidic Acid","DB02703","Increased risk of myopathy/rhabdomyolysis"
1064,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
1064,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if imatinib is initiated, discontinued or dose changed."
1064,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
1064,"Itraconazole","DB01167","Increased risk of myopathy/rhabdomyolysis"
1064,"Josamycin","DB01321","The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin."
1064,"Ketoconazole","DB01026","Increased risk of myopathy/rhabdomyolysis"
1064,"Liraglutide","DB06655","These agents may have decreased C max and a delayed T max during coadministration."
1064,"Lomitapide","DB08827","Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4."
1064,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nefazodone is initiated, discontinued or dose changed."
1064,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nelfinavir is initiated, discontinued or dose changed."
1064,"Nevirapine","DB00238","Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nevirapine is initiated, discontinued or dose changed."
1064,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1064,"Rifabutin","DB00615","Rifabutin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifabutin is initiated, discontinued or dose changed."
1064,"Rifampicin","DB01045","Rifampin may decrease the effect of atorvastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if rifampin is initiated, discontinued or dose changed."
1064,"Ritonavir","DB00503","Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed."
1064,"Saquinavir","DB01232","Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed."
1064,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
1064,"Telithromycin","DB00976","The macrolide antibiotic, telithromycin, may increase the serum concentration of atorvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of atorvastatin if telithromycin is initiated, discontinued or dose changed."
1064,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, increases the adverse/toxic effects of Atorvastatin. Concomitant therapy should be avoided."
1064,"Topotecan","DB01030","The p-glycoprotein inhibitor, Atorvastatin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1064,"Verapamil","DB00661","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Atorvastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Atorvastatin if Verapamil is initiated, discontinued or dose changed."
1064,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed."
1065,"Aluminium","DB01370","Formation of non-absorbable complexes"
1065,"Calcium","DB01373","Formation of non-absorbable complexes"
1065,"Calcium Acetate","DB00258","Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives such as etidronic acid (etidronate). Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate. "
1065,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
1065,"Iron","DB01592","Formation of non-absorbable complexes"
1065,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1065,"Magnesium","DB01378","Formation of non-absorbable complexes"
1065,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1065,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1066,"Bendroflumethiazide","DB00436","Possible electrolyte variations and arrhythmias"
1066,"Bumetanide","DB00887","Possible electrolyte variations and arrhythmias"
1066,"Chlorthalidone","DB00310","Possible electrolyte variations and arrhythmias"
1066,"Ethacrynic acid","DB00903","Possible electrolyte variations and arrhythmias"
1066,"Furosemide","DB00695","Possible electrolyte variations and arrhythmias"
1066,"Hydrochlorothiazide","DB00999","Possible electrolyte variations and arrhythmias"
1066,"Indapamide","DB00808","Possible electrolyte variations and arrhythmias"
1066,"Metolazone","DB00524","Possible electrolyte variations and arrhythmias"
1068,"Clonazepam","DB01068","Vigabatrin increases Cmax of clonazepam by 30% and decreases Tmax by 45% "
1068,"Fosphenytoin","DB01320","Vigabatrin decreases the effect of hydantoin"
1068,"Mefloquine","DB00358","Mefloquine may decrease the serum concentration of Vigabatrin. This may increase the risk of seizure in patients receiving Vigabatrin to prevent seizures. Consider alternate therapy or monitor for changes in Vigabatrin serum concentration, therapeutic or adverse effects if Mefloquin is initiated, discontinued or dose changed. "
1068,"Methotrimeprazine","DB01403","Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy. "
1068,"Phenobarbital","DB01174","Vigabatrin reduces serum concentrations of phenobarbital by 8-16%. "
1068,"Phenytoin","DB00252","Vigabatrin reduces plasma levels of phenytoin by 16-20% which may be due to induction of CYP2C. Consider dosage adjustment. "
1068,"Sildenafil","DB00203","Increased anticonvulsant effects of vigabatrin due to pharmacodynamic synergism. Monitor for adverse effects during concomitant therapy. "
1068,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Vigabatrin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1068,"Valproic Acid","DB00313","Vigabatrin reduces serum concentrations of valproic acid by 8%. "
1069,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1069,"Donepezil","DB00843","Possible antagonism of action"
1069,"Galantamine","DB00674","Possible antagonism of action"
1070,"Bumetanide","DB00887","Increased ototoxicity"
1070,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
1070,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
1070,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
1070,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
1070,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
1070,"Colistimethate","DB01111","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1070,"Ethacrynic acid","DB00903","Increased ototoxicity"
1070,"Furosemide","DB00695","Increased ototoxicity"
1070,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Streptomycin. Use caution during concomitant therapy. "
1070,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1071,"Acenocoumarol","DB01418","Orlistat may increase the anticoagulant effect of acenocoumarol."
1071,"Anisindione","DB01125","Orlistat may increase the anticoagulant effect of anisindione."
1071,"Calcipotriol","DB02300","Orlistat may decrease the serum concentration of fat soluble vitamins like vitamin D. Hence, this applies to calcipotriol, a synthetic derivative of vitamin D. Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins. "
1071,"Cholecalciferol","DB00169","Orlistat may decrease the serum concentration of Vitamin D analogs. More specifically, orlistat may impair absorption of Vitamin D analogs such as cholecalciferol. Monitor clinical response (plasma calcium concentrations) to orally administered vitamin D analogs closely if used with orlistat. When this combination must be used, consider administering the vitamin D analog at least 2 hours before or after the administration of orlistat. "
1071,"Cyclosporine","DB00091","Orlistat decreases the effect of cyclosporine"
1071,"Dicoumarol","DB00266","Orlistat may increase the anticoagulant effect of dicumarol."
1071,"Vitamin A","DB00162","Orlistat may impair the absorption of vitamin A, a fat soluble vitamin. Oral vitamin A should be administered 2 hours prior to or post orlistat administration. "
1071,"Vitamin E","DB00163","Orlistat may impair the absorption of vitamin E, a fat soluble vitamin. Oral vitamin E should be administered 2 hours prior to or post orlistat administration.\
"
1071,"Warfarin","DB00682","Orlistat may increase the anticoagulant effect of warfarin."
1073,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Pilocarpine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity."
1075,"Artemether","DB06697","Primaquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
1075,"Lumefantrine","DB06708","Primaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
1075,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Primaquine. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Primaquine is initiated, discontinued or if the dose is changed."
1075,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Primaquine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Primaquine is initiated, discontinued or dose changed. "
1075,"Tizanidine","DB00697","Primaquine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1076,"Trandolapril","DB00519","The prostacyclin analogue, Iloprost, may increase the hypotensive effect of Trandolapril."
1077,"Epinephrine","DB00668","Increased arterial pressure"
1077,"Fenoterol","DB01288","Increased arterial pressure"
1077,"Orciprenaline","DB00816","Increased arterial pressure"
1077,"Phenylephrine","DB00388","Increased arterial pressure"
1077,"Phenylpropanolamine","DB00397","Increased arterial pressure"
1077,"Pseudoephedrine","DB00852","Increased arterial pressure"
1077,"Terbutaline","DB00871","Increased arterial pressure"
1083,"Acenocoumarol","DB01418","Fluvastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if fluvastatin is initiated, discontinued or dose changed."
1083,"Anisindione","DB01125","Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed."
1083,"Bezafibrate","DB01393","Increased risk of myopathy/rhabdomyolysis"
1083,"Cholestyramine","DB01432","Increased/decreased effect according to spacing"
1083,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
1083,"Colestipol","DB00375","Increased/decreased effect according to spacing"
1083,"Cyclosporine","DB00091","Possible myopathy and rhabdomyolysis"
1083,"Dicoumarol","DB00266","Fluvastatin may increase the anticoagulant effect of dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if fluvastatin if initiated, discontinued or dose changed."
1083,"Eltrombopag","DB06210","Increases levels of Fluvastatin via metabolism decrease. OATP transporter protein inhibition."
1083,"Etravirine","DB06414","Fluvastatin, when administered concomitantly with etravirin, may experience an increase in serum concentration. It is recommended to monitor for signs of toxicity from fluvastatin, such as myopathy and hepatic enzyme elevations."
1083,"Fenofibrate","DB01039","Increased risk of myopathy/rhabdomyolysis"
1083,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of fluvastatin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fluvastatin if fluconazole is initiated, discontinued or dose changed."
1083,"Gemfibrozil","DB01241","Increased risk of myopathy/rhabdomyolysis"
1083,"Repaglinide","DB00912","Inhibitors of CYP3A4 and P-glycoprotein may increase serum concentrations of repaglinide. Monitor concomitant therapy closely. "
1083,"Rifabutin","DB00615","Rifabutin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifabutin is initiated, discontinued or dose changed."
1083,"Rifampicin","DB01045","Rifampin may decrease the effect of fluvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of fluvastatin if rifampin is initiated, discontinued or dose changed."
1083,"Warfarin","DB00682","Fluvastatin may increase the anticoagulant effect of warfarin. Monitor for changes in the therapeutic and adverse effects of warfarin if fluvastatin is initiated, discontinued or dose changed."
1085,"Abatacept","DB01281","Therapy modification should be considered due to enhanced adverse effects of leflunomide, specifically hematologic toxicity."
1085,"Acenocoumarol","DB01418","Leflunomide may increase the anticoagulant effect of acenocoumarol."
1085,"Anisindione","DB01125","Leflunomide may increase the anticoagulant effect of anisindione."
1085,"Antithymocyte globulin","DB00098","Therapy modification may be required because the combination enhances toxic effects of leflunomide. "
1085,"Belatacept","DB06681","Consider therapy modification due to enhanced adverse effects of leflunomide, especially hematologic toxicities."
1085,"Belimumab","DB08879","Consider modifying therapy as belimumab may enhance the adverse effects of leflunomide, such as hematologic toxicities."
1085,"Bleomycin","DB00290","Immunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. "
1085,"Carboplatin","DB00958","Immunosuppressants such as carboplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
1085,"Carmustine","DB00262","Immunosuppressants such as carmustine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
1085,"Chlorambucil","DB00291","Immunosuppressants such as chlorambucil may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
1085,"Cisplatin","DB00515","Immunosuppressants such as cisplatin may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
1085,"Cladribine","DB00242","Immunosuppressants such as cladribine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
1085,"Clofarabine","DB00631","Immunosuppressants such as clofarabine may enhance the adverse/toxic effect of leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy."
1085,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease serum concentrations of the active metabolite(s) of Leflunomide. Unless using cholestyramine (or another bile acid sequestrant) together with leflunomide to intentionally enhance the removal/elimination of leflunomide, consider using an alternative to the bile acid sequestrants whenever possible. Separating the administration of these agents is unlikely to be an effective means of avoiding the interaction."
1085,"Corticotropin","DB01285","Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
1085,"Dicoumarol","DB00266","Leflunomide may increase the anticoagulant effect of dicumarol."
1085,"Eltrombopag","DB06210","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
1085,"Etanercept","DB00005","Consider modifying therapy due to enhanced adverse effects of leflunomide including hematologic toxicity."
1085,"Gemtuzumab ozogamicin","DB00056","Consider modifying therapy due to adverse effects of leflunomide including the risk of hematologic toxicity."
1085,"Glatiramer Acetate","DB05259","Consider therapy modification due to enhanced adverse effects of leflunomide including hematologic toxicity."
1085,"Ibritumomab","DB00078","May need to modify therapy to avoid adverse effects of leflunomide such as hematologic toxicity."
1085,"Infliximab","DB00065","Therapy modification should be considered in order to reduce the risk of hematologic toxicities."
1085,"Obinutuzumab","DB08935","Consider modifying therapy. Risk of hematologic toxicity of leflunomide may be increased due to enhanced adverse effects."
1085,"Omalizumab","DB00043","Consider modifying therapy due to increased adverse effects of leflunomide including hematological toxicity."
1085,"Pegaspargase","DB00059","Immunosuppressants can increase toxic effects of leflunomide such as hematologic toxicity."
1085,"Rifampicin","DB01045","Rifampin increases the effect of leflunomide"
1085,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
1085,"Teriflunomide","DB08880","Avoid combination due to increased adverse effects of teriflunomide. "
1085,"Tofacitinib","DB08895","Leflunomide may experience an increase in toxicity and adverse effects (ie. pancytopenia, agranulocytosis, thrombocytopenia). It is recommended to adjust therapy by forgoing a leflunomide loading dose, and to monitor for bone marrow suppression monthly. "
1085,"Vinblastine","DB00570","Vinblastine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinblastine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy. "
1085,"Vincristine","DB00541","Vincristine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vincristine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.\
"
1085,"Vinorelbine","DB00361","Vinorelbine may increase the adverse/toxic effects of Leflunomide. This may increase the risk of hematologic toxicities such as pancytopenia, agranulocytosis and thrombocytopenia. In patients receiving Vinorelbine, consider eliminating the loading dose of Leflunomide. Monitor for bone marrow suppression at least monthly during concomitant therapy.\
"
1085,"Warfarin","DB00682","Leflunomide may increase the anticoagulant effect of warfarin."
1086,"Colchicine","DB01394","Increased risk of rhabdomyolysis with this combination"
1086,"Cyclosporine","DB00091","Cyclosporine may increase the serum concentration of rosuvastatin. Limit rosuvastatin dosing to 5 mg/day and monitor for changes in the therapeutic and adverse effects of rosuvastatin if cyclosporine is initiated, discontinued or dose changed."
1086,"Fenofibrate","DB01039","May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy."
1086,"Gemfibrozil","DB01241","Gemfibrozil may increase the therapeutic and toxic effects of rosuvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of rosuvastatin if gemfibrozil is initiated, discontinued or dose changed."
1086,"Magnesium","DB01378","Magnesium-containing antacids may decrease the absorption of rosuvastatin."
1086,"Tipranavir","DB00932","Concomitant therapy of Rosuvastatin and Tipranavir/Ritonavir may increase Rosuvastatin and Tipranavir concentrations. Consider alternate therapy. "
1088,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of pimozide."
1088,"Aprepitant","DB00673","Increased risk of cardiotoxicity and arrhythmias"
1088,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
1088,"Atazanavir","DB01072","The protease inhibitor, atazanavir, may increase the effect and toxicity of pimozide."
1088,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
1088,"Citalopram","DB00215","The SSRI, citalopram, may increase the effect and toxicity of pimozide."
1088,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
1088,"Donepezil","DB00843","Possible antagonism of action"
1088,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
1088,"Escitalopram","DB01175","The SSRI, escitalopram, increases the effect and toxicity of pimozide."
1088,"Fluconazole","DB00196","Increased risk of cardiotoxicity and arrhythmias"
1088,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of pimozide"
1088,"Galantamine","DB00674","Possible antagonism of action"
1088,"Imatinib","DB00619","Imatinib may increase the effect and toxicity of pimozide."
1088,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect and toxicity of pimozide."
1088,"Itraconazole","DB01167","Increased risk of cardiotoxicity and arrhythmias"
1088,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
1088,"Ketoconazole","DB01026","Increased risk of cardiotoxicity and arrhythmias"
1088,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
1088,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1088,"Nefazodone","DB01149","Nefazodone may increase the effect and toxicity of pimozide."
1088,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of pimozide"
1088,"Paroxetine","DB00715","Increased risk of cardiotoxicity and arrhythmias."
1088,"Posaconazole","DB01263","Contraindicated co-administration"
1088,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect and toxicity of pimozide."
1088,"Rivastigmine","DB00989","Possible antagonism of action"
1088,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of pimozide."
1088,"Sertraline","DB01104","The SSRI, sertraline, increases the effect and toxicity of pimozide."
1088,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Pimozide, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1088,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1088,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
1088,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1088,"Telithromycin","DB00976","Telithromycin may reduce clearance of Pimozide. Concomitant therapy is contraindicated."
1088,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
1088,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1088,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1088,"Ticlopidine","DB00208","Avoid combination with pimozide and other major CYP3A4 substrates due to the potential increase of pimozide concentration.\
\
"
1088,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Pimozide. Concomitant therapy is contraindicated."
1088,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1088,"Trimethobenzamide","DB00662","Trimethobenzamide and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1088,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1088,"Triprolidine","DB00427","Triprolidine and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1088,"Troleandomycin","DB01361","Increased risk of cardiotoxicity and arrhythmias"
1088,"Trospium","DB00209","Trospium and Pimozide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1088,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pimozide by decreasing its metabolism. Increased risk of QTc prolongation and development arrhythmias. Concomitant use is contraindicated."
1088,"Vorinostat","DB02546","Additive QTc prolongation may occur. Concomitant therapy is contraindicated. "
1088,"Zileuton","DB00744","Increased risk of cardiotoxicity and arrhythmias"
1088,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1088,"Zuclopenthixol","DB01624","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated."
1089,"Acenocoumarol","DB01418","Capecitabine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
1089,"Anisindione","DB01125","Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration."
1089,"Dicoumarol","DB00266","Capecitabine may increase the anticoagulant effect of dicumarol by increasing its serum concentration."
1089,"Ethotoin","DB00754","Capecitabine increases the effect of hydantoin"
1089,"Fosphenytoin","DB01320","Capecitabine increases the effect of hydantoin"
1089,"Mephenytoin","DB00532","Capecitabine increases the effect of hydantoin"
1089,"Phenytoin","DB00252","Capecitabine increases the effect of hydantoin"
1089,"Tamoxifen","DB00675","Capecitabine may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Capecitabine is initiated, discontinued or dose changed."
1089,"Tolbutamide","DB01124","Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed. "
1089,"Torasemide","DB00214","Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Capecitabine is initiated, discontinued or dose changed. "
1089,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1089,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Capecitabine, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Capecitabine is initiated, discontinued or dose changed."
1089,"Voriconazole","DB00582","Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed. "
1089,"Warfarin","DB00682","Capecitabine may increase the serum concentration of warfarin by decreasing its metabolism. Monitor for changes in prothrombin time and therapeutic effects of warfarin if capecitabine is initiated or discontinued. Subsequent cycles of capecitabine may increase this effect."
1089,"Zafirlukast","DB00549","Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if capecitabine is initiated, discontinued or dose changed."
1091,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1092,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
1092,"Carbamazepine","DB00564","Sertraline increases the effect of carbamazepine"
1092,"Carvedilol","DB01136","The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, carvedilol."
1092,"Cilostazol","DB01166","Sertraline increases the effect of cilostazol"
1092,"Clarithromycin","DB01211","Possible serotoninergic syndrome with this combination"
1092,"Clozapine","DB00363","The antidepressant increases the effect of clozapine"
1092,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1092,"Donepezil","DB00843","Possible antagonism of action"
1092,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
1092,"Erythromycin","DB00199","Possible serotoninergic syndrome with this combination"
1092,"Fosphenytoin","DB01320","Sertraline increases the effect of hydantoin"
1092,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
1092,"Galantamine","DB00674","Possible antagonism of action"
1092,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1092,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
1092,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
1092,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
1092,"Metoprolol","DB00264","The SSRI increases the effect of the beta-blocker"
1092,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
1092,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
1092,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
1092,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
1092,"Phenytoin","DB00252","Sertraline increases the effect of hydantoin"
1092,"Pimozide","DB01100","The SSRI, sertraline, increases the effect and toxicity of pimozide."
1092,"Propafenone","DB01182","Fluoxetine increases the effect and toxicity of propafenone"
1092,"Propranolol","DB00571","The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, propranolol."
1092,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
1092,"Tamoxifen","DB00675","Sertraline may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
1092,"Tamsulosin","DB00706","Sertraline, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sertraline is initiated, discontinued, or dose changed."
1092,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Sertraline. Consider alternate therapy or monitor for therapeutic/adverse effects of Sertraline if Terbinafine is initiated, discontinued or dose changed."
1092,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1092,"Tipranavir","DB00932","Tipranavir increases the concentration of Sertraline. The Sertraline dose may require an adjustment."
1092,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
1092,"Tolterodine","DB01036","Sertraline may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1092,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. Sertraline may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Sertraline may decrease the effect of Tramadol by decreasing active metabolite production."
1092,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
1092,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1092,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Sertraline. Monitor for increased bleeding during concomitant thearpy. "
1092,"Trimipramine","DB00726","The SSRI, Sertraline, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Sertraline is initiated, discontinued or dose changed. "
1092,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Sertraline, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1092,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1092,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1093,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
1093,"Amitriptyline","DB00321","Increased risk of CNS adverse effects"
1093,"Amoxapine","DB00543","Increased risk of CNS adverse effects"
1093,"Citalopram","DB00215","Risk of serotoninergic syndrome "
1093,"Clomipramine","DB01242","Increased risk of CNS adverse effects"
1093,"Cyclosporine","DB00091","Sibutramine increases the effect and toxicity of cyclosporine"
1093,"Desipramine","DB01151","Increased risk of CNS adverse effects"
1093,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1093,"Dextromethorphan","DB00514","Combination associated with possible serotoninergic syndrome"
1093,"Dihydroergotamine","DB00320","Possible serotoninergic syndrome with this combination"
1093,"Doxepin","DB01142","Increased risk of CNS adverse effects"
1093,"Ergotamine","DB00696","Possible serotoninergic syndrome with this combination"
1093,"Erythromycin","DB00199","Erythromycin increases the effect and toxicity of sibutramine"
1093,"Escitalopram","DB01175","Risk of serotoninergic syndrome"
1093,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1093,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
1093,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
1093,"Imipramine","DB00458","Increased risk of CNS adverse effects"
1093,"Isocarboxazid","DB01247","Possible serotoninergic syndrome with this combination"
1093,"Ketoconazole","DB01026","Ketoconazole increases the levels and toxicity of sibutramine"
1093,"Lithium","DB01356","Possible serotoninergic syndrome with this combination"
1093,"Methysergide","DB00247","Possible serotoninergic syndrome"
1093,"Moclobemide","DB01171","Possible serotoninergic syndrome with this combination"
1093,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
1093,"Nefazodone","DB01149","Risk of serotoninergic syndrome"
1093,"Nortriptyline","DB00540","Increased risk of CNS adverse effects"
1093,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
1093,"Pethidine","DB00454","Possible serotoninergic syndrome"
1093,"Phenelzine","DB00780","Possible serotoninergic syndrome with this combination"
1093,"Rasagiline","DB01367","Possible serotoninergic syndrome with this combination"
1093,"Telithromycin","DB00976","Telithromycin may reduce clearance of Sibutramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sibutramine if Telithromycin is initiated, discontinued or dose changed."
1093,"Tramadol","DB00193","Sibutramine may incrase the serotonergic effect of the Tramadol. Concomitant therapy should be avoided. "
1093,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Avoid concomitant therapy."
1093,"Trazodone","DB00656","Increased risk of serotonin syndrome. Avoid concomitant therapy. "
1093,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Concomitant therapy is contraindicated."
1093,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Concurrent therapy should be avoided. "
1093,"Vilazodone","DB06684","Sibutramine may enhance the serotonergic effect of Serotonin Modulators. This may cause serotonin syndrome. Avoid combination."
1093,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sibutramine if voriconazole is initiated, discontinued or dose changed."
1093,"Zolmitriptan","DB00315","Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated. "
1097,"Acetylsalicylic acid","DB00945","Increased risk of bleeding. "
1097,"Aliskiren","DB09026","Monitor therapy due to enhanced hyperkalemic effect of aliskiren."
1097,"Aprotinin","DB06692","Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected."
1097,"corticotropin-releasing factor","DB05394","Contraindication: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. Corticorelin prescribing information describes a case in which a patient experienced a substantial fall in blood pressure and heart rate, resulting in asystole and requiring resuscitation."
1097,"Drospirenone","DB01395","Heparin can increase risk of hyperkalemia for patients on drospirenone"
1097,"Drotrecogin alfa","DB00055","The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of heparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. "
1097,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1097,"Ticlopidine","DB00208","Increased bleeding risk. Monitor aPTT."
1097,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1097,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Heparin. Monitor for increased bleeding during concomitant thearpy. "
1098,"Acenocoumarol","DB01418","Miconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism."
1098,"Anisindione","DB01125","Miconazole may increase the serum concentration of anisindione by decreasing its metabolism."
1098,"Dicoumarol","DB00266","Miconazole may increase the serum concentration of dicumarol by decreasing its metabolism."
1098,"Eltrombopag","DB06210","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
1098,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Miconazole, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Miconazole is initiated, discontinued or if the dose is changed."
1098,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Miconazole is initiated, discontinued or dose changed."
1098,"Tadalafil","DB00820","Miconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1098,"Tamoxifen","DB00675","Miconazole may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
1098,"Tamsulosin","DB00706","Miconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Miconazole is initiated, discontinued, or dose changed."
1098,"Telithromycin","DB00976","Miconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1098,"Temsirolimus","DB06287","Miconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1098,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Miconazole is initiated, discontinued or dose changed."
1098,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Miconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Miconazole is initiated, discontinued or dose changed."
1098,"Tizanidine","DB00697","Miconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1098,"Tolbutamide","DB01124","Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed. "
1098,"Tolterodine","DB01036","Miconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1098,"Torasemide","DB00214","Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Miconazole is initiated, discontinued or dose changed. "
1098,"Tramadol","DB00193","Miconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Miconazole may decrease the effect of Tramadol by decreasing active metabolite production. "
1098,"Trazodone","DB00656","The CYP3A4 inhibitor, Miconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Miconazole is initiated, discontinued or dose changed. "
1098,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Miconazole is initiated, discontinued or dose changed."
1098,"Trimipramine","DB00726","The strong CYP3A4/2D6/2C19 inhibitor, Miconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/2D6/2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Miconazole is initiated, discontinued or dose changed. "
1098,"Vardenafil","DB00862","Miconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1098,"Venlafaxine","DB00285","Miconazole, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Miconazole is initiated, discontinued, or dose changed."
1098,"Verapamil","DB00661","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Miconazole is initiated, discontinued or dose changed."
1098,"Vinblastine","DB00570","Miconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Miconazole is initiated, discontinued or dose changed."
1098,"Vincristine","DB00541","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Miconazole is initiated, discontinued or dose changed."
1098,"Vinorelbine","DB00361","Miconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Miconazole is initiated, discontinued or dose changed."
1098,"Voriconazole","DB00582","Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if miconazole is initiated, discontinued or dose changed.	"
1098,"Warfarin","DB00682","Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if miconazole is initiated, discontinued or dose changed."
1099,"Amikacin","DB00479","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1099,"Amphotericin B","DB00681","Amphotericin B may enhance the nephrotoxic effect of Colistimethate. Due to the potential for additive or synergistic nephrotoxicity between colistimethate and other nephrotoxic drugs, such as amphotericin B, this combination should be avoided whenever possible. If these agents must be used together, patients' renal function should be monitored closely. "
1099,"Atracurium","DB00732","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
1099,"Cisatracurium Besylate","DB00565","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
1099,"Gentamicin","DB00798","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1099,"Kanamycin","DB01172","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1099,"Neomycin","DB00994","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1099,"Pancuronium","DB01337","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
1099,"Rocuronium","DB00728","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
1099,"Streptomycin","DB01082","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1099,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1099,"Vancomycin","DB00512","Additive nephrotoxic effects may occur. Consider alternate therapy or monitor for renal function during concomitant therapy."
1099,"Vecuronium","DB01339","Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. "
1100,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1100,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1100,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1100,"Probenecid","DB01032","Probenecid may increase the serum level of cefuroxime."
1100,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1101,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1101,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1102,"Donepezil","DB00843","Possible antagonism of action"
1102,"Ethotoin","DB00754","The antihistamine increases the effect of hydantoin"
1102,"Fosphenytoin","DB01320","The antihistamine increases the effect of hydantoin"
1102,"Galantamine","DB00674","Possible antagonism of action"
1102,"Mephenytoin","DB00532","The antihistamine increases the effect of hydantoin"
1102,"Phenytoin","DB00252","The antihistamine increases the effect of hydantoin"
1102,"Rivastigmine","DB00989","Possible antagonism of action"
1102,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Chlorpheniramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1102,"Telithromycin","DB00976","Telithromycin may reduce clearance of Chlorpheniramine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Chlorpheniramine if Telithromycin is initiated, discontinued or dose changed."
1102,"Trimethobenzamide","DB00662","Trimethobenzamide and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1102,"Triprolidine","DB00427","Triprolidine and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1102,"Trospium","DB00209","Trospium and Chlorpheniramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1102,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chlorpheniramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorpheniramine if voriconazole is initiated, discontinued or dose changed."
1103,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of the calcium channel blocker, nifedipine. "
1103,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Cimetidine","DB00501","Cimetidine may increase the effect of the calcium channel blocker, nifedipine."
1103,"Cisapride","DB00604","Cisapride may increase the effect and toxicity of nifedipine."
1103,"Cyclosporine","DB00091","Increased risk of gingivitis"
1103,"Dihydroquinidine barbiturate","DB01341","Decreased quinidine effect, increased nifedipine effect"
1103,"Etravirine","DB06414","Nifedipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor nifedipine therapy for reduced effectiveness."
1103,"Ginseng","DB01404","Ginseng increases the effect and toxicity of nifedipine"
1103,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of the calcium channel blocker, nifedipine. "
1103,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Imatinib","DB00619","Imatinib increases the effect and toxicity of nifedipine"
1103,"Melatonin","DB01065","Melatonin can possibly decrease the effect of nifedipine"
1103,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the calcium channel blocker, nifedipine."
1103,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Quinidine","DB00908","Decreased quinidine effect, increased nifedipine effect"
1103,"Quinidine barbiturate","DB01346","Decreased quinidine effect, increased nifedipine effect"
1103,"Quinupristin","DB01369","Synercid increases the effect of ziprasidone"
1103,"Rifampicin","DB01045","Rifampin decreases the effect of the calcium channel blocker, nifedipine."
1103,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1103,"St. John's Wort","DB01323","St. John's Wort decreases the effect of nifedipine"
1103,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Nifedipine, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Nifedipine is initiated, discontinued or if the dose is changed."
1103,"Tacrolimus","DB00864","The calcium channel blocker, Nifedipine, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nifedipine therapy is initiated, discontinued or altered."
1103,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of the calcium channel blocker, nifedipine."
1103,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nifedipine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Nifedipine if Telithromycin is initiated, discontinued or dose changed."
1103,"Thiopental","DB00599","The CYP3A4 inducer, Thiopental, may increase the metabolism and clearance of Nifedipine, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Nifedipine if Thiopental is initiated, discontinued or dose changed."
1103,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of the calcium channel blocker, Nifedipine. Monitor for changes in Nifedipine therapeutic and adverse effects if Tipranavir is initiated, discontinued or dose changed. "
1103,"Tizanidine","DB00697","Nifedipine may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1103,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1103,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nifedipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nifedipine if voriconazole is initiated, discontinued or dose changed."
1105,"Rifabutin","DB00615","Rifabutin decreases the effect of atovaquone"
1105,"Rifampicin","DB01045","Rifampin may decrease the effect of atovaquone."
1105,"Tetracycline","DB00759","Tetracycline may decrease the effect of atovaquone."
1105,"Zidovudine","DB00495","Atovaquone increases the effect and toxicity of zidovudine"
1106,"Acenocoumarol","DB01418","Amiodarone may increase the anticoagulant effect of acenocoumarol."
1106,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
1106,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone."
1106,"Anisindione","DB01125","Amiodarone may increase the anticoagulant effect of anisindione."
1106,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1106,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias."
1106,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1106,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1106,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
1106,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the bioavailability of Amiodarone. Consider alternative antilipemic agent. The risk of subtherapeutic amiodarone serum concentrations when such is being used for the treatment of malignant arrhythmias can be very large. The effect (ie, reduced risk) of separating doses of these agents is unknown. Amiodarone should be administered at least 1 hour before or 4 hours after colesevelam.1 Similar dosing with other agents seems warranted. "
1106,"Cyclosporine","DB00091","Amiodarone may increase the therapeutic and adverse effects of cyclosporine."
1106,"Dabigatran etexilate","DB06695","Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy."
1106,"Dicoumarol","DB00266","Amiodarone may increase the anticoagulant effect of dicumarol."
1106,"Digoxin","DB00390","Amiodarone may increase the effect of digoxin."
1106,"Dihydroquinidine barbiturate","DB01341","Increases the effect of quinidine"
1106,"Diltiazem","DB00343","Increased risk of cardiotoxicity and arrhythmias"
1106,"Eltrombopag","DB06210","Affects hepatic enzyme CYP2C9/10 metabolism, increases effect/level of eltrombopag. "
1106,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
1106,"Ethotoin","DB00754","Increases the effect of hydantoin"
1106,"Etravirine","DB06414","Amiodarone, when used concomitantly with etravirine, may decrease in serum concentration. If possible, monitoring for decreased amiodarone levels is recommended."
1106,"Etravirine","DB06414","Amiodarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. If possible, monitoring of amiodarone levels is recommended. "
1106,"Fentanyl","DB00813","Possible bradycardia, hypotension"
1106,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
1106,"Flecainide","DB01195","Amiodarone may increase the effect and toxicity of flecainide"
1106,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone."
1106,"Fosphenytoin","DB01320","Amiodarone may increase the effect of fosphenytoin."
1106,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1106,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1106,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
1106,"Indinavir","DB00224","Indinavir increases the effect and toxicity of amiodarone"
1106,"Iohexol","DB01362","Increased risk of cardiotoxicity and arrhythmias"
1106,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1106,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1106,"Mephenytoin","DB00532","Increases the effect of hydantoin"
1106,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1106,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1106,"Nelfinavir","DB00220","Nelfinavir may increase the effect and toxicity of amiodarone."
1106,"Phenytoin","DB00252","Amiodarone may increase the therapeutic and adverse effects of phenytoin."
1106,"Procainamide","DB01035","Amiodarone may increase serum levels and toxicity of procainamide."
1106,"Quinidine","DB00908","Amiodarone may increase the effect of quinidine."
1106,"Quinidine barbiturate","DB01346","Increases the effect of qiunidine"
1106,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
1106,"Rifampicin","DB01045","Rifampin decreases the effect of amiodarone"
1106,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of amiodarone"
1106,"Roflumilast","DB01656","Increases roflumilast levels. "
1106,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone."
1106,"Simvastatin","DB00641","Increased risk of rhabdomyolysis"
1106,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1106,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1106,"Tamoxifen","DB00675","Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
1106,"Tamsulosin","DB00706","Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed."
1106,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1106,"Telithromycin","DB00976","Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed."
1106,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1106,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1106,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1106,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated."
1106,"Tizanidine","DB00697","Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. "
1106,"Tolterodine","DB01036","Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1106,"Topotecan","DB01030","The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1106,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1106,"Tramadol","DB00193","Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production. "
1106,"Trazodone","DB00656","The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed."
1106,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1106,"Vardenafil","DB00862","Increased risk of cardiotoxicity and arrhythmias"
1106,"Verapamil","DB00661","Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed. "
1106,"Voriconazole","DB00582","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed."
1106,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1106,"Warfarin","DB00682","Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed."
1106,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1106,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1107,"Aliskiren","DB09026","Monitor therapy due to enhanced hypotensive effect of aliskiren."
1107,"Bendroflumethiazide","DB00436","Significant hyperglycemic effect"
1107,"Chlorpropamide","DB00672","Antagonism. "
1107,"Chlorthalidone","DB00310","Significant hyperglycemic effect"
1107,"Fosphenytoin","DB01320","Diazoxide decreases the hydantoin effect"
1107,"Glyburide","DB01016","Antagonism. "
1107,"Hydrochlorothiazide","DB00999","Significant hyperglycemic effect"
1107,"Indapamide","DB00808","Significant hyperglycemic effect"
1107,"Phenytoin","DB00252","Diazoxide decreases the efficacy of phenytoin. "
1107,"Trandolapril","DB00519","Diazoxide may increase the hypotensive effect of Trandolapril. Monitor for changes in blood pressure."
1108,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1108,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide."
1108,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1108,"Betaxolol","DB00195","The beta-blocker, betaxolol, may decrease symptoms of hypoglycemia."
1108,"Bevantolol","DB01295","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1108,"Bismuth Subsalicylate","DB01294","The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, gliclazide."
1108,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1108,"Carteolol","DB00521","The beta-blocker, carteolol, may decrease symptoms of hypoglycemia."
1108,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1108,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, gliclazide."
1108,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, gliclazide."
1108,"Dicoumarol","DB00266","Dicumarol may increase the effect of sulfonylurea, gliclazide."
1108,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1108,"Glucosamine","DB01296","Possible hyperglycemia"
1108,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1108,"Magnesium salicylate","DB01397","The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, gliclazide."
1108,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1108,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1108,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1108,"Penbutolol","DB01359","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1108,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1108,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1108,"Practolol","DB01297","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1108,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1108,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, gliclazide."
1108,"Salicylate-sodium","DB01398","The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, gliclazide."
1108,"Salsalate","DB01399","The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide."
1108,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of gliclazide. Monitor for changes in fasting and postprandial blood sugars."
1108,"Sotalol","DB00489","The beta-blocker, sotalol, may decrease symptoms of hypoglycemia."
1108,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1108,"Trisalicylate-choline","DB01401","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, gliclazide."
1110,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium."
1110,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Ambenonium, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity. "
1110,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, ambenonium."
1112,"Acebutolol","DB01193","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1112,"Acenocoumarol","DB01418","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide."
1112,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1112,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1112,"Bosentan","DB00559","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Capecitabine","DB01101","Capecitabine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Capecitabine is initiated, discontinued or dose changed. "
1112,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1112,"Celecoxib","DB00482","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, tolbutamide."
1112,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, tolbutamide."
1112,"Dapsone","DB00250","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Dapsone. Consider alternate therapy or monitor for changes in Dapsone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Delavirdine","DB00705","Delavirdine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed. "
1112,"Digoxin","DB00390","Tolbutamide increases the effect of digoxin"
1112,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1112,"Floxuridine","DB00322","Floxuridine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Floxuridine is initiated, discontinued or dose changed. "
1112,"Fluconazole","DB00196","Fluconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Fluconazole therapeutic and adverse effects if Delavirdine is initiated, discontinued or dose changed. "
1112,"Fluorouracil","DB00544","Fluorouracil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Fluorouracil is initiated, discontinued or dose changed. "
1112,"Fluoxetine","DB00472","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fluoxetine. Consider alternate therapy or monitor for changes in Fluoxetine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Flurbiprofen","DB00712","Flurbiprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Flurbiprofen is initiated, discontinued or dose changed. "
1112,"Fosphenytoin","DB01320","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Gemfibrozil","DB01241","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed. "
1112,"Glimepiride","DB00222","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glimepiride. Consider alternate therapy or monitor for changes in Glimepiride therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Glipizide","DB01067","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Glipizide. Consider alternate therapy or monitor for changes in Glipizide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Ibuprofen","DB01050","Ibuprofen, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ibuprofen is initiated, discontinued or dose changed. "
1112,"Indomethacin","DB00328","Indomethacin, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Indomethacin is initiated, discontinued or dose changed. "
1112,"Ketamine","DB01221","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Ketoconazole","DB01026","Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed."
1112,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1112,"Losartan","DB00678","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Losartan. Consider alternate therapy or monitor for changes in Losartan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Lumiracoxib","DB01283","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Mefenamic acid","DB00784","Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed. "
1112,"Mestranol","DB01357","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1112,"Miconazole","DB01110","Miconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Miconazole is initiated, discontinued or dose changed. "
1112,"Montelukast","DB00471","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Montelukast. Consider alternate therapy or monitor for changes in Montelukast therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1112,"Nateglinide","DB00731","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Nateglinide. Consider alternate therapy or monitor for changes in Nateglinide therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Nicardipine","DB00622","Nicardipine, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Nicardipine is initiated, discontinued or dose changed. "
1112,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1112,"Paclitaxel","DB01229","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1112,"Phenytoin","DB00252","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Phenytoin. Consider alternate therapy or monitor for changes in Phenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1112,"Piroxicam","DB00554","Piroxicam, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Piroxicam is initiated, discontinued or dose changed. "
1112,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1112,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, tolbutamide."
1112,"Sitaxentan","DB06268","Sitaxsentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Sitaxsentan is initiated, discontinued or dose changed. "
1112,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of Tolbutamide. Dose adjustments of Tolbutamide may be required."
1112,"Sulfadiazine","DB00359","Tolbutamide and Sulfadiazine are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. "
1112,"Sulfamethoxazole","DB01015","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfamethoxazole. Consider alternate therapy or monitor for changes in Sulfamethoxazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Sulfinpyrazone","DB01138","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1112,"Sulfisoxazole","DB00263","Tolbutamide and Sulfisoxazole are strong CYP2C9 inhibitors and substrates. Decreased metabolism and clearance of both agents may occur during concomitant therapy. Consider alternate therpy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose(s) changed. "
1112,"Tamoxifen","DB00675","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tamoxifen. Consider alternate therapy or monitor for changes in Tamoxifen therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."
1112,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1112,"Torasemide","DB00214","Tolbutamide, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Tolbutamide is initiated, discontinued or dose changed."
1112,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Tolbutamide, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Tolbutamide is initiated, discontinued or dose changed."
1112,"Voriconazole","DB00582","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed."
1112,"Warfarin","DB00682","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if tolbutamide is initiated, discontinued or dose changed."
1112,"Zafirlukast","DB00549","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if tolbutamide is initiated, discontinued or dose changed."
1112,"Zopiclone","DB01198","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1113,"Acetaminophen","DB00316","Acetaminophen increases the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if acetaminophen is initiated, discontinued or dose changed. "
1113,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases effect of the anticoagulant, anisindione."
1113,"Allopurinol","DB00437","Allopurinol may increase the anticoagulant effect of anisindione."
1113,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the anticoagulant effect of anisindione."
1113,"Amiodarone","DB01118","Amiodarone may increase the anticoagulant effect of anisindione."
1113,"Amprenavir","DB00701","Amprenavir may increase the anticoagulant effect of anisindione by increasing its serum concentration."
1113,"Aprepitant","DB00673","Aprepitant may decrease the anticoagulant effect of anisindione by decreasing its serum concentration."
1113,"Atazanavir","DB01072","The protease inhibitor, atazanavir, may increase the anticoagulant effect of anisindione."
1113,"Azathioprine","DB00993","Azathioprine may decrease the anticoagulant effect of anisindione."
1113,"Azithromycin","DB00207","Azithromycin may increase the anticoagulant effect of anisindione by increasing its serum concentration."
1113,"Betamethasone","DB00443","The corticosteroid, betamethasone, alters the anticoagulant effect of anisindione."
1113,"Bosentan","DB00559","Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism."
1113,"Capecitabine","DB01101","Capecitabine may increase the anticoagulant effect of anisindione by increasing its serum concentration."
1113,"Carbamazepine","DB00564","Carbamazepine may decrease the anticoagulant effect of anisindione by decreasing its serum concentration."
1113,"Cefotetan","DB01330","The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione."
1113,"Cefoxitin","DB01331","The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione."
1113,"Ceftriaxone","DB01212","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione."
1113,"Celecoxib","DB00482","Celecoxib may increase the anticoagulant effect of anisindione."
1113,"Cholestyramine","DB01432","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of anisindione by decreasing its absorption."
1113,"Cimetidine","DB00501","Cimetidine may increase the anticoagulant effect of anisindione."
1113,"Ciprofloxacin","DB00537","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of anisindione."
1113,"Cisapride","DB00604","Cisapride may increase the anticoagulant effect of anisindione."
1113,"Citalopram","DB00215","The SSRI, citalopram, increases the effect of anticoagulant, anisindione."
1113,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the anticoagulant effect of anisindione."
1113,"Clofibrate","DB00636","The fibrate increases the anticoagulant effect"
1113,"Colestipol","DB00375","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of anisindione by decreasing its absorption."
1113,"Cyclophosphamide","DB00531","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of anisindione."
1113,"Danazol","DB01406","The androgen, danazol, may increase the anticoagulant effect of anisindione."
1113,"Demeclocycline","DB00618","The tetracycline, demeclocycline, may increase the anticoagulant effect of anisindione."
1113,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione."
1113,"Dextropropoxyphene","DB00647","Propoxyphene may increase the anticoagulant effect of anisindione."
1113,"Dextrothyroxine","DB00509","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of anisindione."
1113,"Diclofenac","DB00586","The NSAID, diclofenac, may increase the anticoagulant effect of anisindione."
1113,"Dicloxacillin","DB00485","Dicloxacillin may decrease the anticoagulant effect of anisindione."
1113,"Diflunisal","DB00861","The NSAID, diflunisal, may increase the anticoagulant effect of anisindione."
1113,"Disulfiram","DB00822","Disulfiram may increase the anticoagulant effect of anisindione."
1113,"Doxycycline","DB00254","The tetracycline, doxycycline, may increase the anticoagulant effect of anisindione."
1113,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the anticoagulant effect of anisindione."
1113,"Ethchlorvynol","DB00189","Ethchlorvynol may decrease the anticoagulant effect of anisindione."
1113,"Ethinyl Estradiol","DB00977","Increased thrombotic risk due to estrogen"
1113,"Etodolac","DB00749","The NSAID, etodolac, may increase the anticoagulant effect of anisindione."
1113,"Etoricoxib","DB01628","Etoricoxib may increase the anticoagulant effect of anisindione."
1113,"Fenofibrate","DB01039","Fenofibrate may increase the anticoagulant effect of anisindione."
1113,"Fenoprofen","DB00573","The NSAID, fenoprofen, may increase the anticoagulant effect of anisindione."
1113,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of anisindione by decreasing its metabolism."
1113,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, alters the anticoagulant effect of anisindione."
1113,"Fluorouracil","DB00544","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of anisindione."
1113,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases the effect of anticoagulant, anisindione."
1113,"Fluoxymesterone","DB01185","The androgen, fluoxymesterone, may increase the anticoagulant effect of anisindione."
1113,"Flurbiprofen","DB00712","The NSAID, flurbiprofen, may increase the anticoagulant effect anisindione."
1113,"Fluvastatin","DB01095","Fluvastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if fluvastatin if initiated, discontinued or dose changed."
1113,"Fluvoxamine","DB00176","Fluvoxamine may increase the anticoagulant effect of anisindione by increasing its serum concentration."
1113,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of anisindione."
1113,"Fosphenytoin","DB01320","Increased hydantoin levels and risk of bleeding"
1113,"Gefitinib","DB00317","Gefitinib may increase the anticoagulant effect of anisindione."
1113,"Gemcitabine","DB00441","Gemcitabine may increase the anticoagulant effect of anisindione."
1113,"Gemfibrozil","DB01241","Gemfibrozil may increase the anticoagulant effect of anisindione."
1113,"Glutethimide","DB01437","Glutethimide may decrease the anticoagulant effect of anisindione."
1113,"Griseofulvin","DB00400","Griseofulvin may decrease the anticoagulant effect of anisindione."
1113,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione."
1113,"Ibuprofen","DB01050","The NSAID, ibuprofen, may increase the anticoagulant effect of anisindione."
1113,"Imatinib","DB00619","Imatinib may increase the anticoagulant effect of anisindione."
1113,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the anticoagulant effect of anisindione."
1113,"Indomethacin","DB00328","The NSAID, indomethacin, may increase the anticoagulant effect of anisindione."
1113,"Isoniazid","DB00951","Isoniazid may increase the anticoagulant effect of anisindione."
1113,"Itraconazole","DB01167","Itraconazole may increase the anticoagulant effect of anisindione."
1113,"Ketoconazole","DB01026","Ketoconazole may increase the anticoagulant effect of anisindione."
1113,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase the anticoagulant effect of anisindione."
1113,"Ketorolac","DB00465","The NSAID, ketorolac, may increase the anticoagulant effect of anisindione."
1113,"Leflunomide","DB01097","Leflunomide may increase the anticoagulant effect of anisindione."
1113,"Levamisole","DB00848","Levamisole may increase the anticoagulant effect of anisindione."
1113,"Levofloxacin","DB01137","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione."
1113,"Levothyroxine","DB00451","The thyroid hormone, levothyroxine, increase the anticoagulant effect of anisindione."
1113,"Lovastatin","DB00227","Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed."
1113,"Lumiracoxib","DB01283","Lumiracoxib may increase the anticoagulant effect of anisindione."
1113,"Medroxyprogesterone Acetate","DB00603","Medroxyprogesterone may increase the anticoagulant effect of anisindione."
1113,"Mefenamic acid","DB00784","The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione."
1113,"Mefloquine","DB00358","Mefloquine may increase the anticoagulant effect of anisindione."
1113,"Meloxicam","DB00814","Meloxicam may increase the anticoagulant effect of anisindione."
1113,"Mercaptopurine","DB01033","Mercaptopurine may decrease the anticoagulant effect of anisindione."
1113,"Methimazole","DB00763","The antithyroid agent, methimazole, may decrease the anticoagulant effect of anisindione."
1113,"Metronidazole","DB00916","Metronidazole may increase the anticoagulant effect of anisindione."
1113,"Miconazole","DB01110","Miconazole may increase the serum concentration of anisindione by decreasing its metabolism."
1113,"Minocycline","DB01017","The tetracycline, minocycline, may increase the anticoagulant effect of anisindione."
1113,"Mitotane","DB00648","Mitotane may decrease the anticoagulant effect of anisindione."
1113,"Moxifloxacin","DB00218","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of anisindione."
1113,"Nabumetone","DB00461","The NSAID, nabumetone, may increase the anticoagulant effect anisindione."
1113,"Nalidixic Acid","DB00779","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of anisindione."
1113,"Naproxen","DB00788","The NSAID, naproxen, may increase the anticoagulant effect of anisindione."
1113,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of anisindione."
1113,"Nevirapine","DB00238","Nevirapine may decrease the anticoagulant effect of anisindione."
1113,"Norfloxacin","DB01059","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of anisindione."
1113,"Ofloxacin","DB01165","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione."
1113,"Orlistat","DB01083","Orlistat may increase the anticoagulant effect of anisindione."
1113,"Oxaprozin","DB00991","The NSAID, oxaprozin, may increase the anticoagulant effect of anisinodione."
1113,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione."
1113,"Paroxetine","DB00715","The SSRI, paroxetine, increases the effect of the anticoagulant, anisindione."
1113,"Pentoxifylline","DB00806","Pentoxifylline may increase the anticoagulant effect of anisindione."
1113,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione."
1113,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the anticoagulant effect of anisindione."
1113,"Phenytoin","DB00252","Increased hydantoin levels and risk of bleeding"
1113,"Piroxicam","DB00554","The NSAID, piroxicam, may increase the anticoagulant effect of anisindione."
1113,"Prednisolone","DB00860","The corticosteroid, prednisolone, alters the anticoagulant effect of anisindione."
1113,"Prednisone","DB00635","The corticosteroid, prednisone, alters the anticoagulant effect of anisindione."
1113,"Primidone","DB00794","The barbiturate, primidone, decreases the anticoagulant effect of anisindione."
1113,"Propafenone","DB01182","Propafenone may increase the anticoagulant effect of anisindione."
1113,"Propylthiouracil","DB00550","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of anisindione."
1113,"Quinidine","DB00908","Quinidine may increase the anticoagulant effect of anisindione."
1113,"Quinine","DB00468","Quinine may increase the anticoagulant effect of anisindione."
1113,"Ranitidine","DB00863","Ranitidine may increase the anticoagulant effect of anisindione. (Conflicting evidence)"
1113,"Rifabutin","DB00615","Rifabutin, may decrease the anticoagulant effect of anisindione."
1113,"Rifampicin","DB01045","Rifampin may decrease the anticoagulant effect of anisindione."
1113,"Telithromycin","DB00976","Telithromycin may increase the anticoagulant effect of anisindione."
1113,"Tenoxicam","DB00469","The NSAID, tenoxicam, may increase the anticoagulant effect of anisindione."
1113,"Testosterone","DB00624","The androgen may increase the anticoagulant effect of anisindione."
1113,"Tetracycline","DB00759","Tetracycline may increase the anticoagulant effect of anisindione."
1113,"Tigecycline","DB00560","Tigecycline may increase the anticoagulant effect of anisindione."
1113,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, alters the anticoagulant effect of anisindione."
1116,"Budesonide","DB01222","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor."
1116,"Colchicine","DB01394","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of colchicine. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function."
1116,"Eplerenone","DB00700","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of eplerenone. A lower starting dose of eplerenone (25 mg once daily) is recommended in patients with hypertension who are also taking drugs that are moderate inhibitors of CYP3A4."
1116,"Everolimus","DB01590","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of everolimus. Consider therapy modification. Recommendations regarding optimal management of this interaction vary according to specific indication and product used."
1116,"Fentanyl","DB00813","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of fentanyl. The risk of prolonged adverse effects, including potentially fatal respiratory depression is increased. Consider therapy modification."
1116,"Halofantrine","DB01218","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s). "
1116,"Lurasidone","DB08815","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor."
1116,"Ranolazine","DB00243","CYP3A4 inhibitors like ranolazine may increase the serum concentration of ranolazine. Consider therapy modification."
1116,"Tolvaptan","DB06212","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated."
1117,"Atazanavir","DB01072","Rabeprazole may decrease the serum levels and therapeutic effects of atazanavir."
1117,"Cefditoren","DB01066","Proton pump inhibitors such as rabeprazole may decrease the serum concentration of cefditoren. If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided."
1117,"Clopidogrel","DB00758","Rabeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent rabeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with rabeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."
1117,"Dasatinib","DB01254","Rabeprazole may decrease the serum level of dasatinib."
1117,"Digoxin","DB00390","Rabeprazole increases the effect of digoxin"
1117,"Enoxacin","DB00467","Rabeprazole may decrease the absorption of enoxacin."
1117,"Indinavir","DB00224","Omeprazole decreases the absorption of indinavir"
1117,"Itraconazole","DB01167","The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole."
1117,"Ketoconazole","DB01026","The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole."
1117,"Rilpivirine","DB08864","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
1117,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Rabaprazole, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rabaprazole is initiated, discontinued to dose changed."
1119,"Artemether","DB06697","Proguanil may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
1119,"Lumefantrine","DB06708","Proguanil may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
1120,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the absorption of Antidiabetic Agents (Thiazolidinedione). Separate the dosing of bile acid sequestrants and thiazolidinediones by at least 2 hours. Monitor for reduced effects of the antidiabetic agents. "
1120,"Gemfibrozil","DB01241","Gemfibrozil may increase the effect and toxicity of pioglitazone."
1120,"Glucosamine","DB01296","Possibly hyperglycemia"
1120,"Ketoconazole","DB01026","Ketoconazole increases the effect of pioglitazone"
1120,"Mestranol","DB01357","Possible loss of contraceptive effect"
1120,"Norethindrone","DB00717","Possible loss of contraceptive effect"
1120,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of pioglitazone. Monitor for changes in fasting and postprandial blood sugars."
1120,"Tamoxifen","DB00675","Pioglitazone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
1120,"Tamsulosin","DB00706","Pioglitazone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pioglitazone is initiated, discontinued, or dose changed."
1120,"Tramadol","DB00193","Pioglitazone may decrease the effect of Tramadol by decreasing active metabolite production. "
1120,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Pioglitazone, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Pioglitazone is initiated, discontinued to dose changed."
1121,"Calcium Acetate","DB00258","The divalent cation of oral Calcium Acetate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
1121,"Calcium Chloride","DB01164","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
1121,"Magnesium oxide","DB01377","The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
1121,"Magnesium Sulfate","DB00653","The divalent cation of oral Magnesium sulfate may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
1123,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1123,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1123,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1123,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
1123,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1123,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1123,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1123,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1123,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1123,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1123,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1123,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1123,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1123,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1123,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1124,"Acetohexamide","DB00414","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Chlorpropamide","DB00672","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Citalopram","DB00215","The SSRI, citalopram, may increase the bradycardic effect of the beta-blocker, carvedilol."
1124,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1124,"Cyclosporine","DB00091","Carvedilol may increase the therapeutic and adverse effects of cyclosporine."
1124,"Digoxin","DB00390","Carvedilol may increase the serum levels and effect of digoxin."
1124,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1124,"Disopyramide","DB00280","The beta-blocker, carvedilol, may increase the toxicity of disopyramide."
1124,"Epinephrine","DB00668","Hypertension, then bradycardia"
1124,"Ergonovine","DB01253","Ischemia with risk of gangrene"
1124,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1124,"Escitalopram","DB01175","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, carvedilol."
1124,"Etravirine","DB06414","Carvedilol, when used concomitantly with etravirine (a CYP2C9 inhibitor), may experience an increase in serum concentration. \
\
It is recommended to monitor for signs and symptoms of an increased response to carvedilol, such as orthostatic hypotension and bradycardia.  "
1124,"Fenoterol","DB01288","Antagonism"
1124,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the bradycardic effect of the beta-blocker, carvedilol."
1124,"Formoterol","DB00983","Antagonism"
1124,"Gliclazide","DB01120","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Glipizide","DB01067","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Glisoxepide","DB01289","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Glyburide","DB01016","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Glycodiazine","DB01382","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1124,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1124,"Insulin Aspart","DB01306","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Insulin Detemir","DB01307","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Insulin Glargine","DB00047","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Insulin Glulisine","DB01309","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Insulin Lispro","DB00046","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Isoprenaline","DB01064","Antagonism"
1124,"Lidocaine","DB00281","The beta-blocker, carvedilol, may increase the effect and toxicity of lidocaine."
1124,"Methysergide","DB00247","Ischemia with risk of gangrene"
1124,"Orciprenaline","DB00816","Antagonism"
1124,"Paroxetine","DB00715","The SSRI, paroxetine, may increase the bradycardic effect of the beta-blocker, carvedilol."
1124,"Pipobroman","DB00236","Antagonism"
1124,"Pirbuterol","DB01291","Antagonism"
1124,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1124,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1124,"Procaterol","DB01366","Antagonism"
1124,"Repaglinide","DB00912","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Salbutamol","DB01001","Antagonism"
1124,"Salmeterol","DB00938","Antagonism"
1124,"Sertraline","DB01104","The SSRI, sertraline, may increase the bradycardic effect of the beta-blocker, carvedilol."
1124,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1124,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Carvedilol. Consider alternate therapy or monitor for therapeutic/adverse effects of Carvedilol if Terbinafine is initiated, discontinued or dose changed."
1124,"Terbutaline","DB00871","Antagonism"
1124,"Tolazamide","DB00839","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Tolbutamide","DB01124","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1124,"Topotecan","DB01030","The p-glycoprotein inhibitor, Carvedilol, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1124,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1124,"Verapamil","DB00661","Increased effect of both drugs"
1125,"Acenocoumarol","DB01418","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of acenocoumarol."
1125,"Aluminium","DB01370","Formation of non-absorbable complexes"
1125,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
1125,"Anisindione","DB01125","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of anisindione."
1125,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1125,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
1125,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
1125,"Calcium","DB01373","Formation of non-absorbable complexes"
1125,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as levofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
1125,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
1125,"Dicoumarol","DB00266","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of dicumarol."
1125,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
1125,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
1125,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
1125,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
1125,"Iron","DB01592","Formation of non-absorbable complexes"
1125,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1125,"Josamycin","DB01321","Increased risk of cardiotoxicity and arrhythmias"
1125,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1125,"Magnesium","DB01378","Formation of non-absorbable complexes"
1125,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1125,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1125,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
1125,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
1125,"Procainamide","DB01035","Levofloxacin may increase the effect of procainamide."
1125,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
1125,"Promazine","DB00420","Increased risk of cardiotoxicity and arrhythmias"
1125,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
1125,"Propiomazine","DB00777","Increased risk of cardiotoxicity and arrhythmias"
1125,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
1125,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
1125,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1125,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
1125,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1125,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1125,"Thiethylperazine","DB00372","Increased risk of cardiotoxicity and arrhythmias"
1125,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1125,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1125,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1125,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
1125,"Triflupromazine","DB00508","Increased risk of cardiotoxicity and arrhythmias"
1125,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
1125,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1125,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1125,"Warfarin","DB00682","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of warfarin."
1125,"Zinc","DB01593","Formation of non-absorbable complexes"
1125,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1125,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1126,"Cyclosporine","DB00091","Sulfinpyrazone decreases the effect of cyclosporine"
1126,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Sulfinpyrazone. Consider alternate therapy or monitor for changes in Sulfinpyrazone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1126,"Warfarin","DB00682","Sulfinpyrazone may increase the anticoagulant effect of warfarin by decreasing its metabolism and protein binding. "
1127,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1127,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1127,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1127,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1128,"Probenecid","DB01032","Probenecid may increase the serum level of cefadroxil."
1130,"Altretamine","DB00488","Risk of severe hypotension"
1130,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1130,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if atazanavir if initiated, discontinued or dose changed."
1130,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1130,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as doxepin. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1130,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if carbamazepine is initiated, discontinued or dose changed."
1130,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if cimetidine is initiated, discontinued or dose changed."
1130,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1130,"Clonidine","DB00575","The tricyclic antidepressant, doxepin, decreases the effect of clonidine."
1130,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1130,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin."
1130,"Dobutamine","DB00841","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dobutamine."
1130,"Donepezil","DB00843","Possible antagonism of action"
1130,"Dopamine","DB00988","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of dopamine."
1130,"Ephedra","DB01363","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedra."
1130,"Ephedrine","DB01364","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedrine."
1130,"Epinephrine","DB00668","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of epinephrine."
1130,"Fenoterol","DB01288","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of fenoterol."
1130,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluoxetine is initiated, discontinued or dose changed."
1130,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of doxepin if fluvoxamine is initiated, discontinued or dose changed."
1130,"Galantamine","DB00674","Possible antagonism of action"
1130,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1130,"Guanethidine","DB01170","The tricyclic antidepressant, doxepin, decreases the effect of guanethidine."
1130,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
1130,"Isoprenaline","DB01064","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of isoproterenol."
1130,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1130,"Mephentermine","DB01365","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine."
1130,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1130,"Metaraminol","DB00610","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of metaraminol."
1130,"Methoxamine","DB00723","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of methoxamine."
1130,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
1130,"Norepinephrine","DB00368","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of norepinephrine."
1130,"Orciprenaline","DB00816","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of orciprenaline."
1130,"Phenelzine","DB00780","Possibility of severe adverse effects"
1130,"Phenylephrine","DB00388","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylephrine."
1130,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of phenylpropanolamine."
1130,"Pirbuterol","DB01291","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pirbuterol."
1130,"Procaterol","DB01366","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of procaterol."
1130,"Pseudoephedrine","DB00852","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pseudoephedrine."
1130,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
1130,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin."
1130,"Rasagiline","DB01367","Possibility of severe adverse effects"
1130,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifabutin is initiated, discontinued or dose changed."
1130,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, doxepin, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if rifampin is initiated, discontinued or dose changed."
1130,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed."
1130,"Rivastigmine","DB00989","Possible antagonism of action"
1130,"Salbutamol","DB01001","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of salbutamol."
1130,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
1130,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1130,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Doxepin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1130,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1130,"Telithromycin","DB00976","Telithromycin may reduce clearance of Doxepin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxepin if Telithromycin is initiated, discontinued or dose changed."
1130,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Doxepin. Consider alternate therapy or monitor for therapeutic/adverse effects of Amytriptyline if Doxepin is initiated, discontinued or dose changed."
1130,"Terbutaline","DB00871","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of terbutaline."
1130,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1130,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Doxepin by decreasing Doxepin metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Doxepin if Thiabendazole is initiated, discontinued or dose changed."
1130,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1130,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1130,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1130,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. "
1130,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
1130,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1130,"Trimethobenzamide","DB00662","Trimethobenzamide and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1130,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1130,"Triprolidine","DB00427","Triprolidine and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1130,"Trospium","DB00209","Trospium and Doxepin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1130,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1130,"Voriconazole","DB00582","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed."
1130,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1130,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1130,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1130,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1131,"Aliskiren","DB09026","Amifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered."
1131,"Azilsartan medoxomil","DB08822","Azilsartan medoxomil used in combintation with amifostine may lead to hypotension."
1131,"Chlorothiazide","DB00880","Antihypertensives may enhance the hypotensive effect of amifostine. When amifostine is used at doses recommended for chemotherapy, antihypertensive medications should be withheld for 24 hours prior to amifostine administration to avoid excessive hypotension during or immediately after infusion. If antihypertensive therapy can not be withheld, then that patient should not receive amifostine. Caution is recommended when using amifostine at the lower doses recommended for radiotherapy, but routine interruption of antihypertensive therapy is not recommended in these patients. "
1131,"Telmisartan","DB00966","Telmisartan may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Telmisartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1131,"Terazosin","DB01162","Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1131,"Tolazamide","DB00839","Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Tolazamide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."
1131,"Torasemide","DB00214","Torasemide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Torasemide should be withheld for  24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1131,"Trandolapril","DB00519","Trandolapril may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trandolapril should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1131,"Trichlormethiazide","DB01021","Trichlormethiazide may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Trichlomethiazide should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1131,"Valsartan","DB00177","Additive hypotensive effects may occur. At chemotherapeutic doses of Amifostine, Valsartan should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine."
1131,"Verapamil","DB00661","Verapamil may enhance the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Verapamil should be withheld for 24 hours prior to Amifostine administration. Caution should be used at lower Amifostine doses used during radiotherapy, but routine interruption of Verapamil therapy is not recommended."
1132,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide."
1132,"Brinzolamide","DB01194","As both brinzolamide and dichlorphenamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1132,"Memantine","DB01043","Possible increased levels of memantine"
1132,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1134,"Donepezil","DB00843","Possible antagonism of action"
1134,"Galantamine","DB00674","Possible antagonism of action"
1135,"Demeclocycline","DB00618","Possible antagonism of action"
1135,"Doxycycline","DB00254","Possible antagonism of action"
1135,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1135,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1135,"Methacycline","DB00931","Possible antagonism of action"
1135,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1135,"Minocycline","DB01017","Possible antagonism of action"
1135,"Oxytetracycline","DB00595","Possible antagonism of action"
1135,"Rolitetracycline","DB01301","Possible antagonism of action"
1135,"Tetracycline","DB00759","Possible antagonism of action"
1136,"Donepezil","DB00843","Possible antagonism of action"
1136,"Galantamine","DB00674","Possible antagonism of action"
1136,"Rivastigmine","DB00989","Possible antagonism of action"
1136,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Flavoxate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1136,"Trimethobenzamide","DB00662","Trimethobenzamide and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1136,"Triprolidine","DB00427","Triprolidine and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1136,"Trospium","DB00209","Trospium and Flavoxate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1137,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1137,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
1137,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
1137,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1137,"Atorvastatin","DB01076","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if nefazodone is initiated, discontinued or dose changed."
1137,"Bromazepam","DB01558","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nefazodone is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1137,"Buspirone","DB00490","Nefazodone increases the effect of buspirone"
1137,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1137,"Carbamazepine","DB00564","Nefazodone increases the effect of carbamazepine"
1137,"Cerivastatin","DB00439","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of cerivastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if nefazodone is initiated, discontinued or dose changed."
1137,"Cilostazol","DB01166","Nefazodone increases the effect of cilostazol"
1137,"Cisapride","DB00604","Nefazodone increases serum levels of cisapride"
1137,"Cyclosporine","DB00091","The antidepressant increases the effect and toxicity of cyclosporine"
1137,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as nefazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
1137,"Dabrafenib","DB08912","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
1137,"Dantrolene","DB01219","Nefazodone may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nefazodone is initiated, discontinued or dose changed. "
1137,"Darifenacin","DB00496","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1137,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1137,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
1137,"Dronedarone","DB04855","Nefazodone is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
1137,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
1137,"Eplerenone","DB00700","Nefazodone increases the effect and toxicity of eplerenone"
1137,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
1137,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1137,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
1137,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
1137,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
1137,"Loratadine","DB00455","Increased risk of cardiotoxicity"
1137,"Lovastatin","DB00227","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if nefazodone is initiated, discontinued or dose changed."
1137,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
1137,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
1137,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
1137,"Pimozide","DB01100","Nefazodone may increase the effect and toxicity of pimozide."
1137,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1137,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
1137,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
1137,"Saxagliptin","DB06335","Nefazodone is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
1137,"Sibutramine","DB01105","Risk of serotoninergic syndrome"
1137,"Simvastatin","DB00641","Nefazodone may increase the effect and toxicity of simvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of simvastatin if nefazodone is initiated, discontinued or dose changed."
1137,"Solifenacin","DB01591","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1137,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, nefazodone."
1137,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
1137,"Sunitinib","DB01268","Possible increase in sunitinib levels"
1137,"Tacrolimus","DB00864","Nefazodone may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Nefazodone therapy is initiated, discontinued or altered."
1137,"Tadalafil","DB00820","Nefazodone may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1137,"Tamoxifen","DB00675","Nefazodone may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1137,"Tamsulosin","DB00706","Nefazodone, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nefazodone is initiated, discontinued, or dose changed."
1137,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Nefazodone and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
1137,"Temsirolimus","DB06287","Nefazodone may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1137,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Nefazodone is initiated, discontinued or dose changed."
1137,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Nefazodone. Consider alternate therapy or monitor for therapeutic/adverse effects of Nefazodone if Terbinafine is initiated, discontinued or dose changed."
1137,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1137,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Nefazodone, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Nefazodone is initiated, discontinued or dose changed."
1137,"Tolterodine","DB01036","Nefazodone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1137,"Tolvaptan","DB06212","Nefazodone is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
1137,"Tramadol","DB00193","Nefazodone may increase tramadol toxicity by decreasing tramadol metabolism and clearance. Increased risk of serotonin syndrome. Monitor for tramadol toxicity and symptoms of serotonin syndrome."
1137,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome."
1137,"Trazodone","DB00656","Increased risk of serotonin syndrome. The CYP3A4 inhibitor, Nefazodone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for symtpoms of sertonin syndrome and changes in Trazodone efficacy/toxicity if Nefazodone is initiated, discontinued or dose changed."
1137,"Triazolam","DB00897","Nefazodone increases the effect of triazolam"
1137,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Nefazodone, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Nefazodone is initiated, discontinued or dose changed. "
1137,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Nefazodone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1137,"Vardenafil","DB00862","Nefazodone, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1137,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1137,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1137,"Verapamil","DB00661","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed."
1137,"Vinblastine","DB00570","Nefazodone, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Nefazodone is initiated, discontinued or dose changed."
1137,"Vincristine","DB00541","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Nefazodone is initiated, discontinued or dose changed."
1137,"Vinorelbine","DB00361","Nafazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Nefazodone is initiated, discontinued or dose changed."
1137,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nefazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nefazodone if voriconazole is initiated, discontinued or dose changed."
1137,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
1137,"Zolpidem","DB00425","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if nefazodone is initiated, discontinued or dose changed. "
1137,"Zonisamide","DB00909","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if nefazodone is initiated, discontinued or dose changed."
1137,"Zopiclone","DB01198","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nefazodone is initiated, discontinued or dose changed."
1138,"Probenecid","DB01032","Probenecid may increase the serum level of cefprozil."
1139,"Altretamine","DB00488","Risk of severe hypotension"
1139,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1139,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if atazanavir is initiated, discontinued or dose changed."
1139,"Avanafil","DB06237","Co-administration with avanafil resulted in an approximate 5.7% increase in AUC0-inf and 5.2% decrease in Cmax of rosiglitazone."
1139,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1139,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as desipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1139,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if carbamazepine is initiated, discontinued or dose changed."
1139,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if cimetidine is initiated, discontinued or dose changed."
1139,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1139,"Clonidine","DB00575","The tricyclic antidepressant, desipramine, decreases the effect of clonidine."
1139,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1139,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine."
1139,"Dobutamine","DB00841","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dobutamine."
1139,"Donepezil","DB00843","Possible antagonism of action"
1139,"Dopamine","DB00988","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of dopamine."
1139,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
1139,"Ephedra","DB01363","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedra."
1139,"Ephedrine","DB01364","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedrine."
1139,"Epinephrine","DB00668","Trimipramine may increase the vasopressor effect of the direct-acting alpha-/beta-agonist, Epinephrine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly."
1139,"Fenoterol","DB01288","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of fenoterol."
1139,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluoxetine is initiated, discontinued or dose changed."
1139,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of desipramine if fluvoxamine is initiated, discontinued or dose changed."
1139,"Galantamine","DB00674","Possible antagonism of action"
1139,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1139,"Guanethidine","DB01170","The tricyclic antidepressant, desipramine, decreases the effect of guanethidine."
1139,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
1139,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
1139,"Isoprenaline","DB01064","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of isoproterenol."
1139,"Mephentermine","DB01365","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of mephentermine."
1139,"Metaraminol","DB00610","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of metaraminol."
1139,"Methoxamine","DB00723","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of methoxamine."
1139,"Mirabegron","DB08893","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
1139,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
1139,"Norepinephrine","DB00368","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of norepinephrine."
1139,"Orciprenaline","DB00816","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of orciprenaline."
1139,"Phenelzine","DB00780","Possibility of severe adverse effects"
1139,"Phenylephrine","DB00388","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylephrine."
1139,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of phenylpropanolamine."
1139,"Pirbuterol","DB01291","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pirbuterol."
1139,"Procaterol","DB01366","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of procaterol."
1139,"Pseudoephedrine","DB00852","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pseudoephedrine."
1139,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
1139,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine."
1139,"Rasagiline","DB01367","Possibility of severe adverse effects"
1139,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifabutin is initiated, discontinued or dose changed."
1139,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, desipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if rifampin is initiated, discontinued or dose changed."
1139,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if ritonavir if initiated, discontinued or dose changed."
1139,"Rivastigmine","DB00989","Possible antagonism of action"
1139,"Salbutamol","DB01001","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of salbutamol."
1139,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
1139,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1139,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Desipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1139,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1139,"Tamoxifen","DB00675","Desipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
1139,"Tamsulosin","DB00706","Desipramine, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Desipramine is initiated, discontinued, or dose changed."
1139,"Terbinafine","DB00857","Terbinafine may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of desipramine if terbinafine is initiated, discontinued or dose changed."
1139,"Terbutaline","DB00871","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of terbutaline."
1139,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1139,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1139,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the concentration of Desipramine. Monitor Desipramine concentration and efficacy/toxicity and adjust dose as required. "
1139,"Tolterodine","DB01036","Desipramine may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1139,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1139,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. Desipramine may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Desipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
1139,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
1139,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1139,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1139,"Triprolidine","DB00427","Triprolidine and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1139,"Trospium","DB00209","Trospium and Desipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1139,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1139,"Vilazodone","DB06684","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved. "
1139,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1139,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1139,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1139,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1139,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1143,"Aluminium","DB01370","Formation of non-absorbable complexes"
1143,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as gemifloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
1143,"Iron","DB01592","Formation of non-absorbable complexes"
1143,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1143,"Magnesium","DB01378","Formation of non-absorbable complexes"
1143,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1143,"Magnesium salicylate","DB01397","Formation of non-absorbable complexes"
1143,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1143,"Zinc","DB01593","Formation of non-absorbable complexes"
1144,"Carbamazepine","DB00564","Carbamazepine, a strong CYP2B6 inducer, may increase the metabolism of bupropion. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bupropion if carbamazepine is initiated, discontinued or dose changed."
1144,"Cyclosporine","DB00091","Bupropion may decrease the therapeutic effect of cyclosporine."
1144,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
1144,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
1144,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
1144,"Rifabutin","DB00615","Rifampin reduces bupropion levels"
1144,"Rifampicin","DB01045","Rifampin reduces bupropion levels"
1144,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of bupropion"
1144,"Thioridazine","DB00679","Bupropion may increase the effect and toxicity of thioridazine."
1144,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Bupropion, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Bupropion if Thiotepa is initiated, discontinued or dose changed. "
1144,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the central neurotoxic effects of the Bupropion. These agents should not be administered within 14 days of each other."
1144,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Bupropion, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1144,"Zuclopenthixol","DB01624","Bupropion, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if bupropion is initiated, discontinued or dose changed. "
1145,"Acenocoumarol","DB01418","The anticoagulant effect of Acenocoumarol, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use."
1145,"Digoxin","DB00390","The absorption of Digoxin, a cardiac glycoside, may be decreased by antineoplastic agents such as Trimetrexate. Liquid forms of Digoxin do not appear to be significantly affected. Monitor Digoxin tablet efficacy if Trimetrexate therapy is initiated, discontinued or if the dose is altered."
1145,"Warfarin","DB00682","The anticoagulant effect of Warfarin, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use."
1146,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1146,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
1146,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arryhthmias"
1146,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1146,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1146,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1146,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1146,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1146,"Ranolazine","DB00243","Possible additive effect on QT prolongation"
1146,"Telithromycin","DB00976","Increased risk of cardiotoxicity and arrhythmias"
1146,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1147,"Aminophylline","DB01223","Increased risk of cardiac arrhythmia"
1147,"Labetalol","DB00598","Monitor arterial pressure closely"
1147,"Oxtriphylline","DB01303","Increased risk of cardiac arrhythmia"
1147,"Theophylline","DB00277","Increased risk of cardiac arrhythmia"
1150,"Acebutolol","DB01193","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Alfuzosin","DB00346","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided."
1150,"Amifostine","DB01143","Terazosin may increase the hypotensive effect of Amifostine. At chemotherapeutic doses of Amifostine, Terazosin should be withheld for 24 hours prior to Amifostine administration. Use caution at lower doses of Amifostine. "
1150,"Atenolol","DB00335","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Betaxolol","DB00195","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Bisoprolol","DB00612","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Carteolol","DB00521","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Carvedilol","DB01136","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Celiprolol","DB04846","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Esmolol","DB00187","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Labetalol","DB00598","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Metoprolol","DB00264","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Nadolol","DB01203","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Nebivolol","DB04861","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Oxprenolol","DB01580","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Penbutolol","DB01359","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Pindolol","DB00960","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Propranolol","DB00571","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Rituximab","DB00073","Additive antihypertensive effects may occur. Increased risk of hypotension. Consider withholding Terazosin for 12 hours prior to administration of Rituximab."
1150,"Sildenafil","DB00203","Increased risk of hypotension. "
1150,"Silodosin","DB06207","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided."
1150,"Sotalol","DB00489","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Tadalafil","DB00820","Tadalafil may enhance the hypotensive effect of Terazosin. Monitor for hypotension during concomitant therapy."
1150,"Tamsulosin","DB00706","Concomitant use of alpha1-adrenergic antagonists, Tamsulosin and Terazosin, may result in additive antihypertensive effects. Combination therapy is not recommended."
1150,"Timolol","DB00373","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1150,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1150,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Terazosin, may occur. Monitor for hypotension during concomitant therapy."
1152,"Alendronate","DB00630","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. "
1152,"Calcium Acetate","DB00258","Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
1152,"Calcium carbonate","DB06724","Calcium salts may enhance the adverse/toxic effect of calcium chloride. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
1152,"Ceftriaxone","DB01212","Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. "
1152,"Clodronate","DB00720","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
1152,"Demeclocycline","DB00618","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as demeclocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1152,"Doxycycline","DB00254","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as doxycycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1152,"Eltrombopag","DB06210","Calcium salts such as calcium chloride may decrease the serum concentration of eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. "
1152,"Etidronic acid","DB01077","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
1152,"Ibandronate","DB00710","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 60 minutes after oral ibandronate."
1152,"Levothyroxine","DB00451","Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as levothyroxine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
1152,"Liothyronine","DB00279","Calcium salts such as calcium chloride may diminish the therapeutic effect of thyroid products such as liothyronine. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
1152,"Minocycline","DB01017","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as minocycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1152,"Risedronate","DB00884","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 30 minutes after alendronate/risedronate. "
1152,"Tetracycline","DB00759","Calcium salts such as calcium chloride may decrease the serum concentration of tetracycline derivatives such as tetracycline. In general, the coadministration of oral calcium salts and oral tetracycline derivatives should be avoided. Interactions may be able to be minimized by administering oral calcium preparations several hours before or after the dose of the oral tetracycline derivatives. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives. "
1152,"Tiludronate","DB01133","Calcium salts may decrease the serum concentration of bisphosphonate derivatives. Avoid administration of oral calcium supplements within 2 hours before or after tiludronate/clodronate/etidronate."
1152,"Trientine hydrochloride","DB06824","Calcium salts such as calcium chloride may decrease the serum concentration of trientine. Trientine may decrease the serum concentration of calcium Salts. The manufacturer of trientine recommends avoiding concurrent administration with mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk. "
1152,"Trovafloxacin","DB00685","Calcium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the calcium containing agent to minimize the interaction. "
1153,"Acenocoumarol","DB01418","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol."
1153,"Aluminium","DB01370","Formation of non-absorbable complexes"
1153,"Anisindione","DB01125","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of anisindione."
1153,"Calcium","DB01373","Formation of non-absorbable complexes"
1153,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as ofloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
1153,"Dicoumarol","DB00266","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of dicumarol."
1153,"Dihydroquinidine barbiturate","DB01341","Increased risk of cardiotoxicity and arrhythmias"
1153,"Foscarnet","DB00529","Increased risk of convulsions"
1153,"Iron","DB01592","Formation of non-absorbable complexes"
1153,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1153,"Magnesium","DB01378","Formation of non-absorbable complexes"
1153,"Magnesium oxide","DB01377","Formation of non-absorbable complexes"
1153,"Procainamide","DB01035","Ofloxacin may increase the effect of procainamide."
1153,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
1153,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
1153,"Sucralfate","DB00364","Formation of non-absorbable complexes"
1153,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ofloxacin. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ofloxacin is initiated, discontinued or if the dose is changed."
1153,"Thiothixene","DB01623","The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed. "
1153,"Tizanidine","DB00697","Ofloxacin may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1153,"Warfarin","DB00682","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of warfarin."
1153,"Zinc","DB01593","Formation of non-absorbable complexes"
1154,"Diltiazem","DB00343","Diltiazem, a moderate CYP3A4 inhibitor, may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cilostazol if diltiazem is initiated, discontinued or dose changed."
1154,"Erythromycin","DB00199","Erythromycin increases the effect of cilostazol"
1154,"Fluconazole","DB00196","Fluconazole may decrease the effect of cilostazol."
1154,"Fluoxetine","DB00472","Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed."
1154,"Fluvoxamine","DB00176","Fluvoxamine increases the effect of cilostazol"
1154,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1154,"Itraconazole","DB01167","Itraconazole may increase the effect of cilostazol."
1154,"Josamycin","DB01321","Erythromycin increases the effect of cilostazol"
1154,"Ketoconazole","DB01026","Ketoconazole may increase the effect of cilostazol."
1154,"Nefazodone","DB01149","Nefazodone increases the effect of cilostazol"
1154,"Omeprazole","DB00338","Omeprazole increases the effect of cilostazol"
1154,"Sertraline","DB01104","Sertraline increases the effect of cilostazol"
1154,"Telithromycin","DB00976","Telithromycin may reduce clearance of Cilostazol. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Cilostazol if Telithromycin is initiated, discontinued or dose changed."
1154,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Cilostazol. Consider alternate therapy or monitor for adverse/toxic effects of Cilostazol if Ticlopidine is initiated, discontinued or dose changed."
1154,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Cilostazol. Monitor for increased bleeding during concomitant thearpy. "
1154,"Voriconazole","DB00582","Voriconzole may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for increased therapeutic/adverse effects of cilostazol and consider reducing the dose during concomitant therapy. "
1155,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1155,"Acenocoumarol","DB01418","Itraconazole may increase the anticoagulant effect of acenocoumarol."
1155,"Alfentanil","DB00802","Itraconazole may increase the effect and toxicity of alfentanil."
1155,"Alfuzosin","DB00346","The antifungal increases the effect of alfuzosin"
1155,"Aliskiren","DB09026","Avoid combination due to increased serum concentration of aliskiren."
1155,"Almotriptan","DB00918","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
1155,"Alprazolam","DB00404","Itraconazole may increase the effect of the benzodiazepine, alprazolam."
1155,"Aluminium","DB01370","Aluminum-containing antacids may decrease the effect of itraconazole."
1155,"Anisindione","DB01125","Itraconazole may increase the anticoagulant effect of anisindione."
1155,"Apixaban","DB06605","Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration."
1155,"Aprepitant","DB00673","This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant."
1155,"Aripiprazole","DB01238","Itraconazole may increase the effect of aripiprazole."
1155,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1155,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
1155,"Bosentan","DB00559","Itraconazole may increase the effect and toxicity of bosentan."
1155,"Bromazepam","DB01558","Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed."
1155,"Budesonide","DB01222","Itraconazole may increase levels/effect of budesonide."
1155,"Busulfan","DB01008","Itraconazole reduced busulfan clearance by up to 25% in patients receiving itraconazole compared to those that did not receive it. Concomitant therapy may lead to toxic plasma levels of busulfan. "
1155,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1155,"Calcium","DB01373","Calcium-containing antacids may decrease the effect of itraconazole."
1155,"Calcium carbonate","DB06724","The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption. "
1155,"Carbamazepine","DB00564","Itraconazole may increase the effect of carbamazepine."
1155,"Celiprolol","DB04846","Itaconazole increases levels/effect of celiprolol"
1155,"Cerivastatin","DB00439","Increased risk of myopathy/rhabdomyolysis"
1155,"Chlordiazepoxide","DB00475","Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide."
1155,"Ciclesonide","DB01410","Increased effects/toxicity of ciclesonide"
1155,"Cilostazol","DB01166","Itraconazole may increase the effect of cilostazol."
1155,"Cimetidine","DB00501","The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole."
1155,"Cinacalcet","DB01012","Itraconazole may increase the effect and toxicity of cinacalcet."
1155,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1155,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole."
1155,"Clonazepam","DB01068","Itraconazole may increase the effect of the benzodiazepine, clonazepam."
1155,"Clorazepate","DB00628","Itraconazole may increase the effect of the benzodiazepine, clorazepate."
1155,"Conivaptan","DB00872","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
1155,"Cyclosporine","DB00091","Itraconazole may increase the effect of cyclosporine."
1155,"Dantrolene","DB01219","Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed. "
1155,"Darifenacin","DB00496","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1155,"Diazepam","DB00829","Itraconazole may increase the effect of the benzodiazepine, diazepam."
1155,"Dicoumarol","DB00266","Itraconazole may increase the anticoagulant effect of dicumarol."
1155,"Digoxin","DB00390","Itraconazole increases the effect of digoxin"
1155,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
1155,"Dofetilide","DB00204","This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide"
1155,"Dronedarone","DB04855","Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
1155,"Eletriptan","DB00216","This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan"
1155,"Eplerenone","DB00700","Itraconazole may increase the effect and toxicity of eplerenone."
1155,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
1155,"Erlotinib","DB00530","Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed."
1155,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of itraconazole."
1155,"Esomeprazole","DB00736","The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole."
1155,"Estazolam","DB01215","Itraconazole may increase the effect of the benzodiazepine, estazolam."
1155,"Ethotoin","DB00754","Phenytoin decreases the effect of itraconazole"
1155,"Everolimus","DB01590","Itraconazole may increase everolimus levels/toxicity."
1155,"Famotidine","DB00927","The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole."
1155,"Felodipine","DB01023","Itraconazole may increase the therapeutic and adverse effects of felodipine."
1155,"Fentanyl","DB00813","Itraconazole may increase levels/toxicity of fentanyl."
1155,"Flurazepam","DB00690","Itraconazole may increase the effect of the benzodiazepine, flurazepam."
1155,"Fosphenytoin","DB01320","Phenytoin decreases the effect of itraconazole"
1155,"Gefitinib","DB00317","Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed."
1155,"Halazepam","DB00801","Itraconazole may increase the effect of the benzodiazepine, halazepam."
1155,"Haloperidol","DB00502","Itraconazole may increase the effect and toxicity of haloperidol."
1155,"Imatinib","DB00619","Itraconazole may increase the levels of imatinib."
1155,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
1155,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect and toxicity of itraconazole."
1155,"Lansoprazole","DB00448","The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole."
1155,"Levomethadyl Acetate","DB01227","Itraconazole increases the effect/toxicity of levomethadyl"
1155,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
1155,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1155,"Magnesium oxide","DB01377","The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption. "
1155,"Mephenytoin","DB00532","Phenytoin decreases the effect of itraconazole"
1155,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1155,"Methylprednisolone","DB00959","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone."
1155,"Midazolam","DB00683","Itraconazole may increase the effect of the benzodiazepine, midazolam."
1155,"Nizatidine","DB00585","The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole."
1155,"Omeprazole","DB00338","The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole."
1155,"Pantoprazole","DB00213","The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole."
1155,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
1155,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of itraconazole."
1155,"Phenytoin","DB00252","Phenytoin decreases the effect of itraconazole"
1155,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
1155,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1155,"Prednisolone","DB00860","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone."
1155,"Prednisone","DB00635","The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone."
1155,"Quazepam","DB01589","Itraconazole may increase the effect of the benzodiazepine, quazepam."
1155,"Quinidine","DB00908","Itraconazole may increase the effect and toxicity of quinidine."
1155,"Quinidine barbiturate","DB01346","Itraconazole may increase the effect and toxicity of quinidine barbiturate."
1155,"Rabeprazole","DB01129","The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole."
1155,"Ranitidine","DB00863","The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole."
1155,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
1155,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
1155,"Rifabutin","DB00615","Rifabutin decreases the effect of itraconazole"
1155,"Rifampicin","DB01045","Rifampin may decrease the effect of itraconazole."
1155,"Risperidone","DB00734","Increases the level of risperidone"
1155,"Ritonavir","DB00503","Itraconazole may increase the effect and toxicity of ritonavir."
1155,"Rivaroxaban","DB06228","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
1155,"Ruxolitinib","DB08877","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
1155,"Sildenafil","DB00203","Itraconazole may increase the effect and toxicity of sildenafil."
1155,"Silodosin","DB06207","Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. "
1155,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
1155,"Sirolimus","DB00877","Itraconazole may increase the effect and toxicity of sirolimus."
1155,"Solifenacin","DB01591","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1155,"Sucralfate","DB00364","Sucralfate may decrease the absorption of itraconazole."
1155,"Sunitinib","DB01268","Possible increase in sunitinib levels"
1155,"Tacrolimus","DB00864","The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered."
1155,"Tadalafil","DB00820","Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1155,"Tamoxifen","DB00675","Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1155,"Tamsulosin","DB00706","Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed."
1155,"Telithromycin","DB00976","Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1155,"Temsirolimus","DB06287","Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1155,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed."
1155,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1155,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed."
1155,"Tipranavir","DB00932","Tipranavir may increase the serum concentration of Itraconazole."
1155,"Tolterodine","DB01036","Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1155,"Tolvaptan","DB06212","Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
1155,"Topotecan","DB01030","The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1155,"Tramadol","DB00193","Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1155,"Trazodone","DB00656","The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed."
1155,"Triazolam","DB00897","Itraconazole may increase the effect of the benzodiazepine, triazolam."
1155,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed. "
1155,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy. "
1155,"Vardenafil","DB00862","Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated."
1155,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1155,"Venlafaxine","DB00285","Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed."
1155,"Verapamil","DB00661","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed. "
1155,"Vinblastine","DB00570","Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed."
1155,"Vincristine","DB00541","Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed."
1155,"Vinorelbine","DB00361","Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.\
"
1155,"Warfarin","DB00682","Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism."
1155,"Zolpidem","DB00425","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed. "
1155,"Zonisamide","DB00909","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed."
1155,"Zopiclone","DB01198","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed."
1156,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like procarbazine. "
1156,"Brimonidine","DB00484","MAO Inhibitors like procarbazine may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
1156,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like procarbazine. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
1156,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1156,"Digoxin","DB00390","The antineoplasic agent decreases the effect of digoxin"
1156,"Methotrexate","DB00563","Increased nephrotoxicity with this combination"
1156,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated.  "
1156,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated."
1156,"Tolcapone","DB00323","Tolcapone and Procarbazine decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
1156,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizure induction by the MAO inhibitor, Procarbazine."
1156,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1156,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1156,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1156,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis. "
1156,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
1156,"Zolmitriptan","DB00315","The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated. "
1157,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1157,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1157,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1157,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1157,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1157,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1157,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1157,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1157,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1157,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1157,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1157,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1158,"Acetophenazine","DB01063","Acetophenazine may decrease the effect of guanethidine."
1158,"Alimemazine","DB01246","Trimeprazine may decrease the effect of guanethidine."
1158,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, decreases the effect of guanethidine."
1158,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine."
1158,"Amphetamine","DB00182","Amphetamine may decrease the effect of guanethidine."
1158,"Benzphetamine","DB00865","Benzphetamine may decrease the effect of guanethidine."
1158,"Chlorpromazine","DB00477","Chlorpromazine may decrease the effect of guanethidine."
1158,"Chlorprothixene","DB01239","Chlorprothixene may decrease the effect of guanethidine."
1158,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, decreases the effect of guanethidine."
1158,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, decreases the effect of guanethidine."
1158,"Dexfenfluramine","DB01191","Dexfenfluramine may decrease the effect of guanethidine."
1158,"Dextroamphetamine","DB01576","Dextroamphetamine may decrease the effect of guanethidine."
1158,"Diethylpropion","DB00937","Diethylpropion may decrease the effect of guanethidine."
1158,"Dobutamine","DB00841","Dobutamine may decrease the effect of guanethidine."
1158,"Dopamine","DB00988","Dopamine may decrease the effect of guanethidine."
1158,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, decreases the effect of guanethidine."
1158,"Ephedra","DB01363","Ephedra may decrease the effect of guanethidine."
1158,"Ephedrine","DB01364","Ephedrine may decrease the effect of guanethidine."
1158,"Epinephrine","DB00668","Epinephrine may decrease the effect of guanethidine."
1158,"Ethopropazine","DB00392","Ethopropazine may decrease the effect of guanethidine."
1158,"Fenfluramine","DB00574","Fenfluramine may decrease the effect of guanethidine."
1158,"Fluphenazine","DB00623","Fluphenazine may decrease the effect of guanethidine."
1158,"Haloperidol","DB00502","Haloperidol may decrease the effect of guanethidine."
1158,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine."
1158,"Isocarboxazid","DB01247","Isocarboxazid may decrease the effect of guanethidine."
1158,"Mazindol","DB00579","Mazindol may decrease the effect of guanethidine."
1158,"Mesoridazine","DB00933","Mesoridazine may decrease the effect of guanethidine."
1158,"Metaraminol","DB00610","Metaraminol may decrease the effect of guanethidine."
1158,"Methamphetamine","DB01577","Methamphetamine may decrease the effect of guanethidine."
1158,"Methdilazine","DB00902","Methdilazine may decrease the effect of guanethidine."
1158,"Methotrimeprazine","DB01403","Methotrimeprazine may decrease the effect of guanethidine."
1158,"Methoxamine","DB00723","Methoxamine may decrease the effect of guanethidine."
1158,"Methylphenidate","DB00422","Methylphenidate may decrease the effect of guanethidine."
1158,"Norepinephrine","DB00368","Norepinephrine may decrease the effect of guanethidine."
1158,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, decreases the effect of guanethidine."
1158,"Pargyline","DB01626","Pargyline may decrease the effect of guanethidine."
1158,"Perphenazine","DB00850","Perphenazine may decrease the effect of guanethidine."
1158,"Phendimetrazine","DB01579","Phendimetrazine may decrease the effect of guanethidine."
1158,"Phenelzine","DB00780","Phenelzine may decrease the effect of guanethidine."
1158,"Phenmetrazine","DB00830","Phenmetrazine may decrease the effect of guanethidine."
1158,"Phentermine","DB00191","Phentermine may decrease the effect of guanethidine."
1158,"Phenylephrine","DB00388","Phenylephrine may decrease the effect of guanethidine."
1158,"Phenylpropanolamine","DB00397","Phenylpropanolamine may decrease the effect of guanethidine."
1158,"Prochlorperazine","DB00433","Prochlorperazine may decrease the effect of guanethidine."
1158,"Promazine","DB00420","Promazine may decrease the effect of guanethidine."
1158,"Promethazine","DB01069","Promethazine may decrease the effect of guanethidine."
1158,"Propericiazine","DB01608","Propericiazine may decrease the effect of guanethidine."
1158,"Propiomazine","DB00777","Propiomazine may decrease the effect of guanethidine."
1158,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, decreases the effect of guanethidine."
1158,"Pseudoephedrine","DB00852","Pseudoephedrine may decrease the effect of guanethidine."
1158,"Thiethylperazine","DB00372","Thiethylperazine may decrease the effect of guanethidine."
1158,"Thioridazine","DB00679","Thioridazine may decrease the effect of guanethidine."
1158,"Thiothixene","DB01623","Thiothixene may decrease the effect of guanethidine."
1158,"Tranylcypromine","DB00752","Tranylcypromine may decrease the effect of guanethidine."
1158,"Trifluoperazine","DB00831","Trifluoperazine may decrease the effect of guanethidine."
1158,"Triflupromazine","DB00508","Triflupromazine may decrease the effect of guanethidine."
1158,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, decreases the effect of guanethidine."
1159,"Amitriptyline","DB00321","Possible severe adverse reaction with this combination"
1159,"Amoxapine","DB00543","Possible severe adverse reaction with this combination"
1159,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide. "
1159,"Brimonidine","DB00484","MAO Inhibitors like moclobemide may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
1159,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like moclobemide. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
1159,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of moclobemide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moclobemide if cimetidine is initiated, discontinued or dose changed."
1159,"Citalopram","DB00215","Possible serotoninergic syndrome"
1159,"Clomipramine","DB01242","Possible severe adverse reaction with this combination"
1159,"Desipramine","DB01151","Possible severe adverse reaction with this combination"
1159,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1159,"Dextromethorphan","DB00514","Increased CNS toxicity"
1159,"Dobutamine","DB00841","Moclobemide increases the sympathomimetic effect of dobutamine."
1159,"Donepezil","DB00843","Possible antagonism of action"
1159,"Dopamine","DB00988","Moclobemide increases the sympathomimetic effect of dopamine."
1159,"Doxepin","DB01142","Possible severe adverse reaction with this combination"
1159,"Ephedra","DB01363","Moclobemide increases the sympathomimetic effect of ephedra."
1159,"Ephedrine","DB01364","Moclobemide increases the sympathomimetic effect of ephedrine."
1159,"Epinephrine","DB00668","Moclobemide increases the sympathomimetic effect of epinephrine."
1159,"Fenoterol","DB01288","Moclobemide increases the sympathomimetic effect of fenoterol."
1159,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1159,"Fluvoxamine","DB00176","Increased incidence of adverse effects with this association"
1159,"Galantamine","DB00674","Possible antagonism of action"
1159,"Imipramine","DB00458","Possible severe adverse reaction with this combination"
1159,"Isoprenaline","DB01064","Moclobemide increases the sympathomimetic effect of isoproterenol."
1159,"Mephentermine","DB01365","Moclobemide increases the sympathomimetic effect of mephentermine."
1159,"Metaraminol","DB00610","Moclobemide increases the sympathomimetic effect of metaraminol."
1159,"Methoxamine","DB00723","Moclobemide increases the sympathomimetic effect of methoxamine."
1159,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated. "
1159,"Norepinephrine","DB00368","Moclobemide increases the sympathomimetic effect of norepinephrine."
1159,"Nortriptyline","DB00540","Possible severe adverse reaction with this combination"
1159,"Orciprenaline","DB00816","Moclobemide increases the sympathomimetic effect of orciprenaline."
1159,"Paroxetine","DB00715","Possible severe adverse reaction with this combination"
1159,"Pethidine","DB00454","Increased CNS toxicity (can cause death)"
1159,"Phenylephrine","DB00388","Moclobemide increases the sympathomimetic effect of phenylephrine."
1159,"Phenylpropanolamine","DB00397","Moclobemide increases the sympathomimetic effect of phenylpropanolamine."
1159,"Pirbuterol","DB01291","Moclobemide increases the sympathomimetic effect of pirbuterol."
1159,"Procaterol","DB01366","Moclobemide increases the sympathomimetic effect of procaterol."
1159,"Protriptyline","DB00344","Possible severe adverse reaction with this combination"
1159,"Pseudoephedrine","DB00852","Moclobemide increases the sympathomimetic effect of pseudoephedrine."
1159,"Rivastigmine","DB00989","Possible antagonism of action"
1159,"Rizatriptan","DB00953","The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
1159,"Salbutamol","DB01001","Moclobemide increases the sympathomimetic effect of salbutamol."
1159,"Selegiline","DB01037","Decrease in selectivity"
1159,"Sertraline","DB01104","Possible severe adverse reaction with this combination"
1159,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
1159,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Moclobemide, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1159,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for therapeutic/adverse effects of Moclobemide if Terbinafine is initiated, discontinued or dose changed."
1159,"Terbutaline","DB00871","Moclobemide increases the sympathomimetic effect of terbutaline."
1159,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated."
1159,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Moclobemide. Consider alternate therapy or monitor for adverse/toxic effects of Moclobemide if Ticlopidine is initiated, discontinued or dose changed."
1159,"Tolcapone","DB00323","Tolcapone and Moclobemide decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
1159,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, moclobemide."
1159,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1159,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1159,"Trimethobenzamide","DB00662","Trimethobenzamide and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1159,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
1159,"Triprolidine","DB00427","Triprolidine and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1159,"Trospium","DB00209","Trospium and Moclobemide, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1159,"Tryptophanyl-5'amp","DB01831","Possible severe adverse reaction with this combination"
1159,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided. "
1159,"Zolmitriptan","DB00315","The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated. "
1160,"Bumetanide","DB00887","Increased ototoxicity"
1160,"Cefotaxime","DB00493","Increased risk of nephrotoxicity"
1160,"Cefotetan","DB01330","Increased risk of nephrotoxicity"
1160,"Cefoxitin","DB01331","Increased risk of nephrotoxicity"
1160,"Ceftazidime","DB00438","Increased risk of nephrotoxicity"
1160,"Ceftriaxone","DB01212","Increased risk of nephrotoxicity"
1160,"Colistimethate","DB01111","Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate. Due to the potential for additive or synergistic toxicities (including both nephrotoxicity and neuromuscular blockade) between colistimethate and the aminoglycoside antibiotics, this combination should be avoided whenever possible. If these agents must be used together, patients' renal and neuromuscular function should be monitored closely. "
1160,"Ethacrynic acid","DB00903","Increased ototoxicity"
1160,"Furosemide","DB00695","Increased ototoxicity"
1160,"Ticarcillin","DB01607","Ticarcillin may reduce the serum concentration of Kanamycin. Ticarcillin may inactivate Kanamycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1161,"Docetaxel","DB01248","Orphenadrine may increase the serum levels and toxicity of docetaxel."
1161,"Donepezil","DB00843","Possible antagonism of action"
1161,"Galantamine","DB00674","Possible antagonism of action"
1161,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
1161,"Rivastigmine","DB00989","Possible antagonism of action"
1161,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Orphenadrine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1161,"Trimethobenzamide","DB00662","Trimethobenzamide and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1161,"Triprolidine","DB00427","Triprolidine and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1161,"Trospium","DB00209","Trospium and Orphenadrine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1162,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
1162,"Acenocoumarol","DB01418","The barbiturate, phenobarbital, decreases the anticoagulant effect of acenocoumarol."
1162,"Aminophylline","DB01223","The barbiturate, phenobarbital, decreases the effect of aminophylline."
1162,"Anisindione","DB01125","The barbiturate, phenobarbital, decreases the anticoagulant effect of anisindione."
1162,"Asenapine","DB06216","Phenobarbital is a CYP1A2 inducer and may increase metabolism of asenapine. "
1162,"Bendamustine","DB06769","Increases levels of bendamustine by decreasing metabolism. Ethinyl Estradiol is a CYP1A2 inhibitor and concurrent administration may result in elevated plasma concentrations of bendamustine. "
1162,"Betamethasone","DB00443","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, betamethasone."
1162,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
1162,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
1162,"Canagliflozin","DB08907","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
1162,"Chlorotrianisene","DB00269","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, chlorotrianisene."
1162,"Clomifene","DB00882","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, clomifene."
1162,"Conjugated Estrogens","DB00286","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, conjugated estrogens."
1162,"Cortisone acetate","DB01380","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, cortisone acetate."
1162,"Cyclosporine","DB00091","The barbiturate, phenobarbital, may decrease the therapeutic effect of cyclosporine by increasing its metabolism."
1162,"Dabrafenib","DB08912","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
1162,"Dasatinib","DB01254","Phenobarbital may decrease the serum level and efficacy of dasatinib."
1162,"Delavirdine","DB00705","The anticonvulsant, phenobarbital, decreases the effect of delavirdine."
1162,"Dexamethasone","DB01234","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1162,"Dicoumarol","DB00266","The barbiturate, phenobarbital, decreases the anticoagulant effect, dicumarol."
1162,"Diethylstilbestrol","DB00255","The enzyme inducer, phenobarbital, may decrease the therapeutic effect of diethylstilbestrol."
1162,"Disopyramide","DB00280","Phenobarbital decreases levels of disopyramide"
1162,"Doxycycline","DB00254","The anticonvulsant, phenobarbital, may decrease the therapeutic effect of doxycycline."
1162,"Dyphylline","DB00651","The barbiturate, phenobarbital, decreases the effect of dyphylline."
1162,"Estradiol","DB00783","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estradiol."
1162,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
1162,"Estriol","DB04573","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estriol."
1162,"Estrone","DB00655","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone."
1162,"Estropipate","DB04574","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estropipate."
1162,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1162,"Etravirine","DB06414","Etravirine, when used concomitantly with phenobarbital, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
1162,"Felbamate","DB00949","Felbamate increases the effect and toxicity of phenobarbital/primidone"
1162,"Felodipine","DB01023","The barbiturate, phenobarbital, decreases the effect of felodipine."
1162,"Fludrocortisone","DB00687","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
1162,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, phenobarbital."
1162,"Gefitinib","DB00317","The CYP3A4 inducer, phenobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
1162,"Griseofulvin","DB00400","The barbiturate, phenobarbital, decreases the effect of griseofulvin."
1162,"Hydrocortisone","DB00741","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
1162,"Imatinib","DB00619","Phenobarbital decreases levels of imatinib"
1162,"Itraconazole","DB01167","The barbiturate, phenobarbital, decreases the effect of itraconazole."
1162,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
1162,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1162,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, phenobarbital, may decrease the effect of the hormone, medroxyprogesterone."
1162,"Megestrol acetate","DB00351","The enzyme inducer, phenobarbital, may decrease the effect of the hormone, megestrol."
1162,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
1162,"Methadone","DB00333","The barbiturate, phenobarbital, decreases the effect of methadone."
1162,"Methoxyflurane","DB01028","The barbiturate, phenobarbital, increases the renal toxicity of methoxyflurane."
1162,"Methylprednisolone","DB00959","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, methylprednisolone."
1162,"Metoprolol","DB00264","The barbiturate decreases the effect of the metabolized beta-blocker"
1162,"Metronidazole","DB00916","The barbiturate, phenobarbital, decreases the effect of metronidazole."
1162,"Nifedipine","DB01115","The barbiturate, phenobarbital, may decrease the effect of the calcium channel blocker, nifedipine."
1162,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1162,"Oxtriphylline","DB01303","The barbiturate, phenobarbital, decreases the effect of oxtriphylline."
1162,"Paramethasone","DB01384","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, paramethasone."
1162,"Prednisolone","DB00860","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisolone."
1162,"Prednisone","DB00635","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone."
1162,"Propranolol","DB00571","The barbiturate decreases the effect of the metabolized beta-blocker"
1162,"Quinestrol","DB04575","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, quinestrol."
1162,"Quinidine","DB00908","The anticonvulsant, phenobarbital, decreases the effect of quinidine."
1162,"Regorafenib","DB08896","Strong CYP3A4 inducers may decrease levels of regorafenib. "
1162,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
1162,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1162,"Rufinamide","DB06201","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
1162,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
1162,"Tacrolimus","DB00864","Phenobarbital may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Phenobarbital therapy is initiated, discontinued or altered."
1162,"Telithromycin","DB00976","Phenobarbital may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
1162,"Temsirolimus","DB06287","Phenobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1162,"Theophylline","DB00277","The barbiturate, phenobarbital, decreases the effect of theophylline."
1162,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Phenobarbital. Consider alternate therapy or monitor for adverse/toxic effects of Phenobarbital if Ticlopidine is initiated, discontinued or dose changed."
1162,"Tipranavir","DB00932","Phenobarbial decreases the concentration of Tipranavir. Monitor for decreased Tipranavir efficacy."
1162,"Tramadol","DB00193","Phenobarbital may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
1162,"Trazodone","DB00656","The CYP3A4 inducer, Phenobarbital, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Phenobarbital is initiated, discontinued or dose changed."
1162,"Tretinoin","DB00755","The strong CYP2C8 inducer, Phenobarbital, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Phenobarbital is initiated, discontinued or dose changed. "
1162,"Triamcinolone","DB00620","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, triamcinolone."
1162,"Trimipramine","DB00726","The barbiturate, Phenobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Phenobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
1162,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Phenobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1162,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
1162,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1162,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
1162,"Verapamil","DB00661","Phenobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Phenobarbital is initiated, discontinued or dose changed."
1162,"Vigabatrin","DB01080","Vigabatrin reduces serum concentrations of phenobarbital by 8-16%. "
1162,"Voriconazole","DB00582","Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated."
1162,"Warfarin","DB00682","Phenobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if phenobarbital is initiated, discontinued or dose changed."
1163,"Almotriptan","DB00918","Increased risk of CNS adverse effects"
1163,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1163,"Carvedilol","DB01136","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, carvedilol."
1163,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1163,"Eletriptan","DB00216","Increased risk of CNS adverse effects"
1163,"Frovatriptan","DB00998","Increased risk of CNS adverse effects"
1163,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1163,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
1163,"Ketoprofen","DB01009","Concomitant therapy may result in additive antiplatelet effects and increase the risk of bleeding. Monitor for increased risk of bleeding during concomitant therapy. "
1163,"Linezolid","DB00601","Combination associated with possible serotoninergic syndrome"
1163,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1163,"Metoprolol","DB00264","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, metoprolol."
1163,"Naratriptan","DB00952","Increased risk of CNS adverse effects"
1163,"Oxycodone","DB00497","Increased risk of serotonin syndrome"
1163,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
1163,"Pimozide","DB01100","The SSRI, escitalopram, increases the effect and toxicity of pimozide."
1163,"Propranolol","DB00571","The SSRI, escitalopram, may increase the bradycardic effect of the beta-blocker, propranolol."
1163,"Rasagiline","DB01367","Possible severe adverse reaction with this combination"
1163,"Rizatriptan","DB00953","Increased risk of CNS adverse effects"
1163,"Selegiline","DB01037","Possible severe adverse reaction with this combination"
1163,"Sibutramine","DB01105","Risk of serotoninergic syndrome"
1163,"St. John's Wort","DB01323","St. John's Wort increases the effect and toxicity of the SSRI, escitalopram."
1163,"Sumatriptan","DB00669","Increased risk of CNS adverse effects"
1163,"Telaprevir","DB05521","Telaprevir decreases Cmax, Cmin, and AUC of escitalopram however the mechanism of this interaction is unknown. Concomitant therapy may call for dose adjustment. "
1163,"Telithromycin","DB00976","Telithromycin may reduce clearance of Escitalopram. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Escitalopram if Telithromycin is initiated, discontinued or dose changed."
1163,"Tiaprofenic acid","DB01600","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1163,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Escitalopram. Consider alternate therapy or monitor for adverse/toxic effects of Ambrisentan if Escitalopram is initiated, discontinued or dose changed."
1163,"Tolmetin","DB00500","Increased antiplatelet effects may enhance the risk of bleeding. Alternate therapy may be considered or monitor for inreased bleeding during concomitant therapy. "
1163,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizures."
1163,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
1163,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1163,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Escitalopram. Monitor for increased bleeding during concomitant thearpy. "
1163,"Trimipramine","DB00726","The SSRI, Escitalopram, may decrease the metabolism and clearance of Trimipramine. Increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if Escitalopram is initiated, discontinued or dose changed. "
1163,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Escitalopram, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1163,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1163,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of escitalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of escitalopram if voriconazole is initiated, discontinued or dose changed."
1163,"Ziprasidone","DB00246","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
1163,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
1163,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1164,"Donepezil","DB00843","Possible antagonism of action"
1164,"Galantamine","DB00674","Possible antagonism of action"
1164,"Rivastigmine","DB00989","Possible antagonism of action"
1164,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Cyclizine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1164,"Trimethobenzamide","DB00662","Trimethobenzamide and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1164,"Triprolidine","DB00427","Triprolidine and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1164,"Trospium","DB00209","Trospium and Cyclizine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1165,"Trastuzumab","DB00072","Trastuzumab may increase the cardiotoxicity of Idarubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1169,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, ifosfamide."
1169,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
1169,"Etravirine","DB06414","Ifosfamide, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience an increase in the serum concentrations of its active metabolites. It is recommended to monitor for toxicity of ifosfamide therapy."
1169,"Pazopanib","DB06589","Ifosfamide decreases plasma levels of pazopanib. "
1169,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ifosfamide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ifosfamide if Telithromycin is initiated, discontinued or dose changed."
1169,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Ifosfamide. Consider alternate therapy or monitor for adverse/toxic effects of Ifosfamide if Ticlopidine is initiated, discontinued or dose changed."
1169,"Tranylcypromine","DB00752","Tranylcypromine, a strong CYP2A6 inhibitor, may decrease the metabolism and clearance of Ifosmadine. "
1169,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1169,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed."
1170,"Acenocoumarol","DB01418","Propafenone may increase the anticoagulant effect of acenocoumarol."
1170,"Aminophylline","DB01223","Propafenone increases the effect of theophylline"
1170,"Anisindione","DB01125","Propafenone may increase the anticoagulant effect of anisindione."
1170,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1170,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1170,"Cyclosporine","DB00091","Propafenone increases the effect and toxicity of cyclosporine"
1170,"Dicoumarol","DB00266","Propafenone may increase the anticoagulant effect of dicumarol."
1170,"Digoxin","DB00390","Propafenone increases the effect of digoxin"
1170,"Dihydroquinidine barbiturate","DB01341","Quinidine increases the effect of propafenone"
1170,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
1170,"Dyphylline","DB00651","Propafenone increases the effect of theophylline"
1170,"Etravirine","DB06414","Propafenone, when used concomitantly with Etravirine, may experience a decrease in serum concentration. It is recommended to monitor for continued efficacy of propafenone therapy. \
"
1170,"Fluoxetine","DB00472","Additive QTc-prolongation may occur increasing the risk of serious life-threatening arrhythmias. Fluoxetine may also increase the serum concentration of propafenone. Use caution during concomitant therapy and monitor for QTc-prolongation."
1170,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1170,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias."
1170,"Metoprolol","DB00264","Propafenone may increase the effect of beta-blocker, metoprolol."
1170,"Mexiletine","DB00379","Propafenone may increase the effect and toxicity of mexilitine."
1170,"Mirabegron","DB08893","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
1170,"Oxtriphylline","DB01303","Propafenone increases the effect of theophylline"
1170,"Paroxetine","DB00715","Paroxetine may increase the effect and toxicity of propafenone."
1170,"Propranolol","DB00571","Propafenone may increase the effect of the beta-blocker, propranolol."
1170,"Quinidine","DB00908","Quinidine increases the effect of propafenone"
1170,"Quinidine barbiturate","DB01346","Quinidine increases the effect of propafenone"
1170,"Rifabutin","DB00615","Rifampin decreases the effect of propafenone"
1170,"Rifampicin","DB01045","Rifampin decreases the effect of propafenone"
1170,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of propafenone"
1170,"Sertraline","DB01104","Fluoxetine increases the effect and toxicity of propafenone"
1170,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1170,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Propafenone. Consider alternate therapy or monitor for therapeutic/adverse effects of Propafenone if Terbinafine is initiated, discontinued or dose changed."
1170,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias."
1170,"Theophylline","DB00277","Propafenone increases the effect of theophylline"
1170,"Thiopental","DB00599","Thiopental may increase the metabolism and clearance of Propafenone. Monitor for decreased therapeutic effect of Propafenone if Thiopental is initiated."
1170,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias."
1170,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1170,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Propafenone. Concomitant therapy is contraindicated."
1170,"Tizanidine","DB00697","Propafenone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1170,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1170,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1170,"Venlafaxine","DB00285","Propafenone increases the effect and toxicity of venlafaxine"
1170,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1170,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1170,"Warfarin","DB00682","Propafenone may increase the anticoagulant effect of warfarin."
1170,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1170,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1172,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1172,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1172,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1172,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1172,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1172,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1172,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1172,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1173,"Acenocoumarol","DB01418","The androgen, fluoxymesterone, may increase the anticoagulant effect of acenocoumarol."
1173,"Anisindione","DB01125","The androgen, fluoxymesterone, may increase the anticoagulant effect of anisindione."
1173,"Dicoumarol","DB00266","The androgen, fluoxymesterone, may increase the anticoagulant effect of dicumarol."
1173,"Warfarin","DB00682","Fluoxymesterone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if fluoxymesterone is initiated, discontinued or dose changed."
1174,"Tamoxifen","DB00675","Pergolide may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
1174,"Tamsulosin","DB00706","Pergolide, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Pergolide is initiated, discontinued, or dose changed."
1174,"Telithromycin","DB00976","Telithromycin may reduce clearance of Pergolide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pergolide if Telithromycin is initiated, discontinued or dose changed."
1174,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pergolide. Consider alternate therapy or monitor for decreased effects of both agents. "
1174,"Tipranavir","DB00932","Tipranavir may increase the plasma concentration of Pergolide. Concomitant therapy should be avoided."
1174,"Tolterodine","DB01036","Peroglide may decrease the metabolism and clearance of Tolterodine. Monitor for adverse/toxic effects of Tolterodine. "
1174,"Tramadol","DB00193","Pergolide may decrease the effect of Tramadol by decreasing active metabolite production. Increased risk of serotonin syndrome. Monitor for Tramadol efficacy and symptoms of serotonin syndrome."
1174,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1174,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1174,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Pergolide, a strong CYP2D6 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Monitor for symptoms of serotonin syndrome and changes in Trimipramine therapeutic and adverse effects if Pergolide is initiated, discontinued or dose changed."
1174,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1174,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of pergolide likely by decreasing its metabolism. Concomitant therapy is contraindicated."
1174,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder. "
1174,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
1174,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed."
1178,"Aluminium","DB01370","The aluminium salt decreases the absorption of lincosamides"
1178,"Atracurium","DB00732","The agent increases the effect of muscle relaxant"
1178,"Attapulgite","DB01574","The aluminium salt decreases the absorption of lincosamides"
1178,"Cyclosporine","DB00091","Clindamycin may decrease the therapeutic effect of cyclosporine."
1178,"Dihydroxyaluminium","DB01375","The aluminium salt decreases the absorption of lincosamides"
1178,"Doxacurium chloride","DB01135","The agent increases the effect of muscle relaxant"
1178,"Kaolin","DB01575","The aluminium salt decreases the absorption of lincosamides"
1178,"Metocurine","DB01336","The agent increases the effect of muscle relaxant"
1178,"Mivacurium","DB01226","The agent increases the effect of muscle relaxant"
1178,"Pancuronium","DB01337","The agent increases the effect of muscle relaxant"
1178,"Pipecuronium","DB01338","The agent increases the effect of muscle relaxant"
1178,"Rocuronium","DB00728","The agent increases the effect of muscle relaxant"
1178,"Succinylcholine","DB00202","The agent increases the effect of muscle relaxant"
1178,"Tubocurarine","DB01199","The agent increases the effect of muscle relaxant"
1178,"Vecuronium","DB01339","The agent increases the effect of muscle relaxant"
1179,"Acetophenazine","DB01063","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Alimemazine","DB01246","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Chlorpromazine","DB00477","Decreased anorexic effect, may increase psychotic symptoms."
1179,"Ethopropazine","DB00392","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1179,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
1179,"Guanethidine","DB01170","Dexfenfluramine may decrease the effect of guanethidine."
1179,"Insulin Aspart","DB01306","Fenfluramine increases the effect of insulin"
1179,"Insulin Detemir","DB01307","Fenfluramine increases the effect of insulin"
1179,"Insulin Glulisine","DB01309","Fenfluramine increases the effect of insulin"
1179,"Isocarboxazid","DB01247","Risk of hypertensive crisis."
1179,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Methdilazine","DB00902","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
1179,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Phenelzine","DB00780","Possible hypertensive crisis"
1179,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase psychotic symptoms."
1179,"Promazine","DB00420","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms."
1179,"Propericiazine","DB01608","Decreased anorexic effect, may increase psychotic symptoms."
1179,"Propiomazine","DB00777","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Rasagiline","DB01367","Possible hypertensive crisis"
1179,"Thiethylperazine","DB00372","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Tranylcypromine","DB00752","Possible hypertensive crisis"
1179,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Triflupromazine","DB00508","Decreased anorexic effect, may increase psychotic symptoms"
1179,"Venlafaxine","DB00285","Risk of serotoninergic syndrome"
1180,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1180,"Cimetidine","DB00501","Increases the effect of the narcotic"
1180,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Oxymorphone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1181,"Acetohexamide","DB00414","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Chlorpropamide","DB00672","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1181,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1181,"Disopyramide","DB00280","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Epinephrine","DB00668","Hypertension, then bradycardia"
1181,"Ergonovine","DB01253","Ischemia with risk of gangrene"
1181,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1181,"Fenoterol","DB01288","Antagonism"
1181,"Formoterol","DB00983","Antagonism"
1181,"Gliclazide","DB01120","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Glipizide","DB01067","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Glisoxepide","DB01289","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Glyburide","DB01016","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1181,"Indacaterol","DB05039","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
1181,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1181,"Insulin Aspart","DB01306","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Insulin Detemir","DB01307","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Insulin Glargine","DB00047","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Insulin Glulisine","DB01309","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Insulin Lispro","DB00046","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1181,"Isoprenaline","DB01064","Antagonism"
1181,"Lidocaine","DB00281","The beta-blocker, acebutolol, may increase the effect and toxicity of lidocaine. "
1181,"Methysergide","DB00247","Ischemia with risk of gangrene"
1181,"Orciprenaline","DB00816","Antagonism"
1181,"Pipobroman","DB00236","Antagonism"
1181,"Pirbuterol","DB01291","Antagonism"
1181,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1181,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1181,"Repaglinide","DB00912","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Salmeterol","DB00938","Antagonism"
1181,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1181,"Terbutaline","DB00871","Antagonism"
1181,"Tolazamide","DB00839","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Tolbutamide","DB01124","Acebutolol may decrease symptoms of hypoglycemia and increase the time required for the body to compensate for hypoglycemia."
1181,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1181,"Verapamil","DB00661","Increased effect of both drugs"
1182,"Acetazolamide","DB00819","As both brinzolamide and acetazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1182,"Diclofenamide","DB01144","As both brinzolamide and dichlorphenamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1182,"Dorzolamide","DB00869","As both brinzolamide and dorzolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1182,"Methazolamide","DB00703","As both brinzolamide and methazolamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1182,"Topiramate","DB00273","As both brinzolamide and topiramate are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1182,"Zonisamide","DB00909","As both brinzolamide and zonisamide are carbonic anhydrase inhibitors, there is an increased risk of adverse effects.The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Avoid concurrent use of different carbonic anhydrase inhibitors when possible."
1183,"Amiodarone","DB01118","Amiodarone may increase the effect and toxicity of flecainide"
1183,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1183,"Cimetidine","DB00501","Cimetidine, a moderate CYP2D6 inhibitor, may decrease the metabolism of flecainide."
1183,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1183,"Duloxetine","DB00476","Possible increase in the levels of this agent when used with duloxetine"
1183,"Etravirine","DB06414","Flecainide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor flecainide therapy. "
1183,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1183,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1183,"Mirabegron","DB08893","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
1183,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1183,"Ritonavir","DB00503","Ritonavir increases the toxicity of the anti-arrhythmic"
1183,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1183,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Flecainide. Consider alternate therapy or monitor for therapeutic/adverse effects of Flecainide if Terbinafine is initiated, discontinued or dose changed."
1183,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1183,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1183,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1183,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated."
1183,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1183,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1183,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1183,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1183,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1183,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1184,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk. "
1184,"Clodronate","DB00720","Clodronate may increase the levels of estramustine."
1184,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1185,"Amiloride","DB00594","Increased risk of hyperkalemia"
1185,"Aprotinin","DB06692","In study of nine patients with untreated hypertension, aprotinin infused intravenously in a dose of 2 million KIU over two hours blocked the acute hypotensive effect of 100mg of captopril."
1185,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
1185,"Drospirenone","DB01395","Increased risk of hyperkalemia"
1185,"Icatibant","DB06196","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
1185,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
1185,"Potassium","DB01345","Increased risk of hyperkalemia"
1185,"Spironolactone","DB00421","Increased risk of hyperkalemia"
1185,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Captopril. Consider alternate therapy or monitor for therapeutic/adverse effects of Captopril if Terbinafine is initiated, discontinued or dose changed."
1185,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
1185,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1185,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1185,"Triamterene","DB00384","Increased risk of hyperkalemia"
1186,"Amprenavir","DB00701","Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if amprenavir is initiated, discontinued or dose changed."
1186,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if atazanavir is initiated, discontinued or dose changed."
1186,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if clarithromycin is initiated, discontinued or dose changed."
1186,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if conivaptan is initiated, discontinued or dose changed."
1186,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if darunavir is initiated, discontinued or dose changed."
1186,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if delavirdine is initiated, discontinued or dose changed."
1186,"Erythromycin","DB00199","The macrolide antibiotic, erythromycin, may increase the serum concentration of zopiclone. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if erythromycin is initiated, discontinued or dose changed. "
1186,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed."
1186,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if imatinib is initiated, discontinued or dose changed."
1186,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if indinavir is initiated, discontinued or dose changed."
1186,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed."
1186,"Itraconazole","DB01167","Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed."
1186,"Ketoconazole","DB01026","Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed."
1186,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if lopinavir is initiated, discontinued or dose changed."
1186,"Methotrimeprazine","DB01403","Additive CNS depressant effects. Reduce zopiclone dose by half upon initiation of methotrimeprazine. Zopiclone dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression."
1186,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nefazodone is initiated, discontinued or dose changed."
1186,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nelfinavir is initiated, discontinued or dose changed."
1186,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if nicardipine is initiated, discontinued or dose changed."
1186,"Posaconazole","DB01263","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if posaconazole is initiated, discontinued or dose changed."
1186,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if quinidine is initiated, discontinued or dose changed."
1186,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ritonavir is initiated, discontinued or dose changed."
1186,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if saquinavir is initiated, discontinued or dose changed."
1186,"Telithromycin","DB00976","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if telithromycin is initiated, discontinued or dose changed."
1186,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Zopiclone. Consider alternate therapy or monitor for changes in Zopiclone therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1186,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Zopiclone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1186,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed."
1187,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1187,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1187,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1187,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
1187,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1187,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1187,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1187,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1187,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1187,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1187,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1187,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1187,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1187,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1187,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1188,"Acetophenazine","DB01063","The phenothiazine decreases the effect of bromocriptine"
1188,"Alimemazine","DB01246","The phenothiazine decreases the effect of bromocriptine"
1188,"Chlorpromazine","DB00477","The phenothiazine decreases the effect of bromocriptine"
1188,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1188,"Erythromycin","DB00199","Erythromycin increases serum levels of bromocriptine"
1188,"Ethopropazine","DB00392","The phenothiazine decreases the effect of bromocriptine"
1188,"Fluphenazine","DB00623","The phenothiazine decreases the effect of bromocriptine"
1188,"Josamycin","DB01321","Erythromycin increases serum levels of bromocriptine"
1188,"Mesoridazine","DB00933","The phenothiazine decreases the effect of bromocriptine"
1188,"Methdilazine","DB00902","The phenothiazine decreases the effect of bromocriptine"
1188,"Methotrimeprazine","DB01403","The phenothiazine decreases the effect of bromocriptine"
1188,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, bromocriptine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1188,"Perphenazine","DB00850","The phenothiazine decreases the effect of bromocriptine"
1188,"Phenylpropanolamine","DB00397","The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine."
1188,"Prochlorperazine","DB00433","The phenothiazine decreases the effect of bromocriptine"
1188,"Promazine","DB00420","The phenothiazine decreases the effect of bromocriptine"
1188,"Promethazine","DB01069","The phenothiazine decreases the effect of bromocriptine"
1188,"Propiomazine","DB00777","The phenothiazine decreases the effect of bromocriptine"
1188,"Pseudoephedrine","DB00852","The sympathomimetic, pseudoephedrine, increases the toxicity of bromocriptine."
1188,"Tacrolimus","DB00864","Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered."
1188,"Telithromycin","DB00976","Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed."
1188,"Thiethylperazine","DB00372","The phenothiazine decreases the effect of bromocriptine"
1188,"Thioridazine","DB00679","The phenothiazine decreases the effect of bromocriptine"
1188,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Bromocriptine. Consider alternate therapy or monitor for decreased effects of both agents. "
1188,"Tipranavir","DB00932","Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided."
1188,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1188,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1188,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1188,"Trifluoperazine","DB00831","The phenothiazine decreases the effect of bromocriptine"
1188,"Triflupromazine","DB00508","The phenothiazine decreases the effect of bromocriptine"
1188,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
1188,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1188,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated. "
1188,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder. "
1188,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. \
Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy."
1188,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1189,"Abiraterone","DB05812","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
1189,"Bromazepam","DB01558","Rifapentine may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifapentine is initiated, discontinued or dose changed. "
1189,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
1189,"Erlotinib","DB00530","Decreased levels/effect of erlotinib"
1189,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
1189,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1189,"Methadone","DB00333","The rifamycin decreases the effect of methadone"
1189,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1189,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
1189,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1189,"Telithromycin","DB00976","Rifapentine may decrease the plasma concentration of Telithromycin. Consider alternate therapy. "
1189,"Temsirolimus","DB06287","Rifapentine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1189,"Terbinafine","DB00857","Rifapentine may increase the metabolism and clearance of Terbinafine. To avoid Terbinafine treatment failure, co-administration should be avoided."
1189,"Tipranavir","DB00932","Concomitant therapy may cause decreased Tipranavir and increased Rifapentine plasma concentrations. "
1189,"Tramadol","DB00193","Rifapentine may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
1189,"Trazodone","DB00656","The CYP3A4 inducer, Rifapentine, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Rifapentine is initiated, discontinued or dose changed."
1189,"Tretinoin","DB00755","The strong CYP2C8 inducer, Rifapentine, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Rifapentine is initiated, discontinued or dose changed. "
1189,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1189,"Vemurafenib","DB08881","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
1189,"Verapamil","DB00661","Rifapentine, a CYP3A4 inducer, may decrease the serum concentration of Verapamil by increasing its metabolism (particularly in the intestinal mucosa) and decreasing its absorption. Monitor for changes in the therapeutic/adverse effects of Verapamil if Rifapentine is initiated, discontinued or dose changed."
1189,"Voriconazole","DB00582","Rifapentine may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifapentin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated."
1189,"Zidovudine","DB00495","Rifapentin may decrease the serum concentration of zidovudine by increasing its metabolism. Monitor for changes in the serum concentration and therapeutic and adverse effects of zidovudine if rifapentin is initiated, discontinued or dose changed. "
1190,"Carbamazepine","DB00564","Concomitant therapy may results in additive adverse CNS effects."
1190,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Levetiracetam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1191,"Acetohexamide","DB00414","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
1191,"Chlorpropamide","DB00672","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1191,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene."
1191,"Disopyramide","DB00280","The beta-blocker, nadolol, may increase the toxicity of disopyramide."
1191,"Dyphylline","DB00651","Antagonism of action and increased effect of theophylline"
1191,"Epinephrine","DB00668","Hypertension, then bradycardia"
1191,"Ergonovine","DB01253","Ischemia with risk of gangrene"
1191,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1191,"Fenoterol","DB01288","Antagonism"
1191,"Formoterol","DB00983","Antagonism"
1191,"Gliclazide","DB01120","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Glipizide","DB01067","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Glisoxepide","DB01289","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Glyburide","DB01016","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Glycodiazine","DB01382","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1191,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1191,"Insulin Glargine","DB00047","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Isoprenaline","DB01064","Antagonism"
1191,"Lidocaine","DB00281","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Methyldopa","DB00968","Possible hypertensive crisis"
1191,"Methysergide","DB00247","Ischemia with risk of gangrene"
1191,"Orciprenaline","DB00816","Antagonism"
1191,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
1191,"Pipobroman","DB00236","Antagonism"
1191,"Pirbuterol","DB01291","Antagonism"
1191,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1191,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1191,"Procaterol","DB01366","Antagonism"
1191,"Repaglinide","DB00912","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Salbutamol","DB01001","Antagonism"
1191,"Salmeterol","DB00938","Antagonism"
1191,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1191,"Terbutaline","DB00871","Antagonism"
1191,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
1191,"Tolazamide","DB00839","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Tolbutamide","DB01124","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1191,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1191,"Verapamil","DB00661","Increased effect of both drugs"
1192,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1194,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1194,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
1194,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Lomustine. Consider alternate therapy or monitor for therapeutic/adverse effects of Lomustine if Terbinafine is initiated, discontinued or dose changed."
1194,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1196,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
1196,"Amitriptyline","DB00321","Increased risk of cardiotoxicity and arrhythmias"
1196,"Amoxapine","DB00543","Increased risk of cardiotoxicity and arrhythmias"
1196,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1196,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1196,"Bepridil","DB01244","Increased risk of cardiotoxicity and arrhythmias"
1196,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may decrease the absorption of quinolone antibiotics such as sparfloxacin. Of concern only with oral administration of both agents. Interactions can be minimized by administering oral quinolone at least 2 hours before, or 6 hours after, the dose of an oral calcium supplement. Monitor for decreased therapeutic effects of oral quinolones if administered with oral calcium supplements. "
1196,"Chlorpromazine","DB00477","Increased risk of cardiotoxicity and arrhythmias"
1196,"Clomipramine","DB01242","Increased risk of cardiotoxicity and arrhythmias"
1196,"Desipramine","DB01151","Increased risk of cardiotoxicity and arrhythmias"
1196,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
1196,"Doxepin","DB01142","Increased risk of cardiotoxicity and arrhythmias"
1196,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
1196,"Fluphenazine","DB00623","Increased risk of cardiotoxicity and arrhythmias"
1196,"Imipramine","DB00458","Increased risk of cardiotoxicity and arrhythmias"
1196,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1196,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1196,"Methotrimeprazine","DB01403","Increased risk of cardiotoxicity and arrhythmias"
1196,"Nortriptyline","DB00540","Increased risk of cardiotoxicity and arrhythmias"
1196,"Perphenazine","DB00850","Increased risk of cardiotoxicity and arrhythmias"
1196,"Prochlorperazine","DB00433","Increased risk of cardiotoxicity and arrhythmias"
1196,"Promethazine","DB01069","Increased risk of cardiotoxicity and arrhythmias"
1196,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
1196,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1196,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1196,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1196,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1196,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1196,"Trifluoperazine","DB00831","Increased risk of cardiotoxicity and arrhythmias"
1196,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1196,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1196,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1196,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1196,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1197,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1197,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Dezocine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1198,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1199,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1199,"Acenocoumarol","DB01418","The macrolide, clarithromycin, may increase the anticoagulant effect of acenocoumarol."
1199,"Alprazolam","DB00404","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, alprazolam."
1199,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
1199,"Aminophylline","DB01223","Clarithromycin may increase the effect amd toxicity of aminophylline."
1199,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
1199,"Anisindione","DB01125","The macrolide, clarithromycin, may increase the anticoagulant effect of anisindione."
1199,"Aprepitant","DB00673","The CYP3A4 inhibitor, clarithromycin, may increase the effect and toxicity of aprepitant."
1199,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1199,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1199,"Atazanavir","DB01072","Atazanavir may increase serum level of clarithromycin."
1199,"Atorvastatin","DB01076","The macrolide, clarithromycin, may increase the toxicity of the statin, atorvastatin."
1199,"Bretylium","DB01158","Increased risk of cardiotoxicity and arrhythmias"
1199,"Bromazepam","DB01558","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if clarithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1199,"Buspirone","DB00490","Clarithromycin may increase the effect and toxicity of buspirone."
1199,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1199,"Carbamazepine","DB00564","Clarithromycin may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic or adverse effects of carbamazepine if clarithromycin is initiated, discontinued or dose changed."
1199,"Cerivastatin","DB00439","The macrolide, clarithromycin, may increase the toxicity of the statin, cerivastatin."
1199,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1199,"Citalopram","DB00215","Possible serotoninergic syndrome with this combination"
1199,"Colchicine","DB01394","Severe colchicine toxicity can occur"
1199,"Cyclosporine","DB00091","The macrolide, clarithromycin, may increase the effect of cyclosporine."
1199,"Dabrafenib","DB08912","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
1199,"Dantrolene","DB01219","Clarithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if clarithromycin is initiated, discontinued or dose changed. "
1199,"Darifenacin","DB00496","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1199,"Darunavir","DB01264","Increased levels of clarithromycin"
1199,"Diazepam","DB00829","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, diazepam."
1199,"Dicoumarol","DB00266","The macrolide, clarithromycin, may increase the anticoagulant effect of dicumarol."
1199,"Digoxin","DB00390","The macrolide, clarithromycin, may increase the effect of digoxin in 10% of patients."
1199,"Dihydroergotamine","DB00320","Risk of ergotism and severe ischemia with this association"
1199,"Disopyramide","DB00280","Increased risk of cardiotoxicity and arrhythmias"
1199,"Dofetilide","DB00204","Increased risk of cardiotoxicity and arrhythmias"
1199,"Dronedarone","DB04855","Clarithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
1199,"Dyphylline","DB00651","Increases the effect and toxicity of theophylline "
1199,"Efavirenz","DB00625","Efavirenz decreases levels of clarithromycin"
1199,"Eletriptan","DB00216","The macrolide, clarithromycin, may increase the effect and toxicity of eletriptan."
1199,"Eplerenone","DB00700","The macrolide, clarithromycin, may increase the effect and toxicity of eplerenone."
1199,"Ergotamine","DB00696","Risk of ergotism and severe ischemia with this association"
1199,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1199,"Etravirine","DB06414","Clarithromycin (and other macrolide antibiotics), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to use alternative antibiotic agents if available. If concurrent therapy cannot be avoided, monitor for reduced effectiveness of clarithromycin. "
1199,"Everolimus","DB01590","The macrolide, clarithromycin, may increase the serum concentration and toxicity of everolimus."
1199,"Fluoxetine","DB00472","Possible serotoninergic syndrome with this combination"
1199,"Fosphenytoin","DB01320","Clarithromycin may increase the therapeutic and adverse effects of fosphenytoin."
1199,"Gefitinib","DB00317","This CYP3A4 inhibitor increases levels/toxicity of gefitinib"
1199,"Iloperidone","DB04946","Clarithromycin is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% "
1199,"Imatinib","DB00619","The macrolide, clarithromycin, may increase the serum concentration of imatinib."
1199,"Indinavir","DB00224","Indinavir may decrease the effectiveness of clarithromycin by decreasing the formatin of the active metabolite, 14-hydroxy-clarithromycin. Clarithromycin may increase the serum concentration of indinavir. Indinavir may increase the serum concentration of clarithromycin. Consider alternate therapy or monitor the efficacy and adverse effects of both agents more closely during concomitant therapy."
1199,"Itraconazole","DB01167","The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole."
1199,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
1199,"Lovastatin","DB00227","The macrolide, clarithromycin, may increase the toxicity of the statin, lovastatin."
1199,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1199,"Methylprednisolone","DB00959","The macrolide, clarithromycin, may increase the effect of corticosteroid, methylprednisolone."
1199,"Methysergide","DB00247","Risk of ergotism and severe ischemia with this association"
1199,"Midazolam","DB00683","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, midazolam."
1199,"Oxtriphylline","DB01303","Clarithromycin may increase the effect and toxicity of oxtriphylline."
1199,"Pazopanib","DB06589","Clarithromycin is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. "
1199,"Phenytoin","DB00252","Clarithromycin may increase the therapeutic and adverse effects of phenytoin."
1199,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
1199,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1199,"Quetiapine","DB01224","The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine."
1199,"Quinidine","DB00908","Increased risk of cardiotoxicity and arrhythmias"
1199,"Quinidine barbiturate","DB01346","Increased risk of cardiotoxicity and arrhythmias"
1199,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1199,"Ranolazine","DB00243","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum level of ranolazine. Concomitant therapy is contraindicated."
1199,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
1199,"Repaglinide","DB00912","Clarithromycin may increase the effect of repaglinide."
1199,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the macrolide, clarithromycin."
1199,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the macrolide, clarithromycin."
1199,"Saxagliptin","DB06335","Clarithromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
1199,"Sertraline","DB01104","Possible serotoninergic syndrome with this combination"
1199,"Sildenafil","DB00203","Increases the effect and toxicity of sildenafil"
1199,"Simvastatin","DB00641","The macrolide, clarithromycin, may increase the toxicity of the statin, simvastatin."
1199,"Sirolimus","DB00877","The macrolide, clarithromycin, may increase the serum concentration of sirolimus."
1199,"Solifenacin","DB01591","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1199,"Sotalol","DB00489","Increased risk of cardiotoxicity and arrhythmias"
1199,"Sunitinib","DB01268","Possible increase in sunitinib levels"
1199,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. The macrolide antibiotic, Clarithromycin, may also increase the blood concentration of Tacrolimus."
1199,"Tadalafil","DB00820","Clarithromycin may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1199,"Tamoxifen","DB00675","Clarithromycin may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1199,"Tamsulosin","DB00706","Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clarithromycin is initiated, discontinued, or dose changed."
1199,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Clarithromycin and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
1199,"Temsirolimus","DB06287","Clarithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1199,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Clarithromycin is initiated, discontinued or dose changed."
1199,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1199,"Theophylline","DB00277","Clarithromycin may increase the therapeutic and adverse effects of theophylline."
1199,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1199,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Clarithromycin, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Clarithromycin is initiated, discontinued or dose changed."
1199,"Tipranavir","DB00932","The concentrations of Tipranavir and Clarithromycin increase during concomitant therapy. Dose adjustments are required for patients with renal impairment."
1199,"Tolterodine","DB01036","Clarithromycin may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1199,"Tolvaptan","DB06212","Clarithromycin is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
1199,"Topotecan","DB01030","The p-glycoprotein inhibitor, Clarithromycin, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1199,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1199,"Tramadol","DB00193","Clarithromycin may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1199,"Trazodone","DB00656","The CYP3A4 inhibitor, Clarithromycin, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Clarithromycin is initiated, discontinued or dose changed. "
1199,"Triazolam","DB00897","The macrolide, clarithromycin, may increase the effect of the benzodiazepine, triazolam."
1199,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Clarithromycin, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution. "
1199,"Valproic Acid","DB00313","The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed. "
1199,"Vardenafil","DB00862","Clarithromycin, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1199,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1199,"Venlafaxine","DB00285","Clarithromycin, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Clarithromycin is initiated, discontinued, or dose changed."
1199,"Verapamil","DB00661","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Clarithromycin is initiated, discontinued or dose changed. "
1199,"Vilazodone","DB06684","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
1199,"Vinblastine","DB00570","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinblastine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Clarithromycin is initiated, discontinued or dose changed."
1199,"Vincristine","DB00541","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vincristine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Clarithromycin is initiated, discontinued or dose changed."
1199,"Vinorelbine","DB00361","Clarithromycin, a CYP3A4 and p-glycoprotein inhibitor, may increase the Vinorelbine serum concentration and distribution in certain cells. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Clarithromycin is initiated, discontinued or dose changed.\
"
1199,"Vismodegib","DB08828","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
1199,"Voriconazole","DB00582","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed."
1199,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1199,"Warfarin","DB00682","The macrolide, clarithromycin, may increase the anticoagulant effect of warfarin."
1199,"Zidovudine","DB00495","Clarithromycin may decrease the serum concentration of zidovudine. Increased myelosuppression in mice has been observed. Consider staggering doses during concomitant therapy and closely monitor response to zidovudine therapy."
1199,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1199,"Zolpidem","DB00425","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if clarithromycin is initiated, discontinued or dose changed. "
1199,"Zonisamide","DB00909","Clarithromcyin, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if clarithromycin is initiated, discontinued or dose changed."
1199,"Zopiclone","DB01198","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if clarithromycin is initiated, discontinued or dose changed."
1199,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1200,"Acenocoumarol","DB01418","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of acenocoumarol."
1200,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1200,"Anisindione","DB01125","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of anisindione."
1200,"Calcium Acetate","DB00258","Calcium Salts (Intravenous) may enhance the adverse/toxic effect of Ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. "
1200,"Calcium Chloride","DB01164","Calcium Salts (Intravenous) may enhance the adverse/toxic effect of ceftriaxone. Ceftriaxone binds to calcium forming an insoluble precipitate. Concurrent or sequential use (within 48 hours) of ceftriaxone with calcium-containing solutions is contraindicated in neonates (28 days of age or younger). In other patients, these solutions can be used sequentially if the infusion lines are flushed with a compatible fluid between ceftriaxone and calcium-containing solution infusion. "
1200,"Dicoumarol","DB00266","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of dicumarol."
1200,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1200,"Kanamycin","DB01172","Increased risk of nephrotoxicity"
1200,"Neomycin","DB00994","Increased risk of nephrotoxicity"
1200,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1200,"Streptomycin","DB01082","Increased risk of nephrotoxicity"
1200,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1200,"Warfarin","DB00682","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of warfarin."
1202,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1203,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, estazolam."
1203,"Clozapine","DB00363","Increased risk of toxicity"
1203,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, estazolam."
1203,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, estazolam."
1203,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, estazolam."
1203,"Kava","DB01322","Kava may increase the effect of the benzodiazepine, estazolam."
1203,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, estazolam."
1203,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, estazolam."
1203,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, estazolam."
1203,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, estazolam."
1203,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, estazolam."
1203,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Estazolam. Consider alternate therapy or monitor for Estazolam toxic effects if Tipranavir is initiated or dose increased. "
1203,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Estazolam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1203,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of estazolam by decreasing its metabolism. Monitor for estazolam toxicity if voriconazole is initiated or dose increased."
1206,"Artemether","DB06697","Halofantrine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options. "
1206,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s). "
1206,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrmazole may increase the serum concentration of halofantrine. Extreme caution, with possibly increased monitoring of cardiac status (e.g., ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).\
"
1206,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation). Concurrent use of orally inhaled fluticasone with strong CYP3A4 inhibitors is not recommended. "
1206,"Lumefantrine","DB06708","Halofantrine may increase the adverse effects of lumefantrine. Additive QTc-prolongation may occur. Combination therapy is contraindicated and therapies should not be administered within one month of each other due to the long half-life of lumefantrine. "
1206,"Mefloquine","DB00358","Increased risk of cardiac toxicity"
1206,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1206,"Posaconazole","DB01263","Contraindicated co-administration"
1206,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1206,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1206,"Telithromycin","DB00976","Telithromycin may reduce clearance of Halofantrine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Halofantrine if Telithromycin is initiated, discontinued or dose changed."
1206,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1206,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1206,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1206,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
1206,"Verapamil","DB00661","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Halofantrine by decreasing its metabolism. Extreme caution with increased cardiac status monitoring should be used during concomitant therapy. "
1206,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of halofantrine by decreasing its metabolism by CYP3A4.  Concomitant therapy should be avoided due to the concentration-dependent risk of QTc prolongation related to halofantrine. "
1206,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1206,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1206,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1207,"Atazanavir","DB01072","Atazanavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if atazanavir is initiated, discontinued or dose changed. "
1207,"Clarithromycin","DB01211","Clarithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if clarithromycin is initiated, discontinued or dose changed. "
1207,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if conivaptan is initiated, discontinued or dose changed. "
1207,"Darunavir","DB01264","Darunavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if darunavir is initiated, discontinued or dose changed. "
1207,"Delavirdine","DB00705","Delavirdine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if delavirdine is initiated, discontinued or dose changed. "
1207,"Fosamprenavir","DB01319","Fosamprenavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if fosamprenavir is initiated, discontinued or dose changed. "
1207,"Imatinib","DB00619","Imatinib may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if imatinib is initiated, discontinued or dose changed. "
1207,"Indinavir","DB00224","Indinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if indinavir is initiated, discontinued or dose changed. "
1207,"Isoniazid","DB00951","Isoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed. "
1207,"Itraconazole","DB01167","Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed. "
1207,"Ketoconazole","DB01026","Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed. "
1207,"Lopinavir","DB01601","Lopinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if lopinavir is initiated, discontinued or dose changed. "
1207,"Methotrimeprazine","DB01403","Concomitant therapy may result in additive CNS depressant effects. The dosage of dantrolene should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression."
1207,"Nefazodone","DB01149","Nefazodone may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nefazodone is initiated, discontinued or dose changed. "
1207,"Nelfinavir","DB00220","Nelfinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nelfinavir is initiated, discontinued or dose changed. "
1207,"Nicardipine","DB00622","Nicardipine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if nicardipine is initiated, discontinued or dose changed. "
1207,"Posaconazole","DB01263","Posaconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if posaconazole is initiated, discontinued or dose changed. "
1207,"Quinidine","DB00908","Quinidine may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if quinidine is initiated, discontinued or dose changed. "
1207,"Ritonavir","DB00503","Ritonavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ritonavir is initiated, discontinued or dose changed. "
1207,"Saquinavir","DB01232","Saquinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if saquinavir is initiated, discontinued or dose changed. "
1207,"Telithromycin","DB00976","Telithromycin may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if telithromycin is initiated, discontinued or dose changed."
1207,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Dantrolene, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1207,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed."
1209,"Memantine","DB01043","Increased risk of CNS adverse effects with this association"
1209,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ketamine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ketamine if Telithromycin is initiated, discontinued or dose changed."
1209,"Thiotepa","DB04572","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Ketamine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Ketamine if Thiotepa is initiated, discontinued or dose changed. "
1209,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Ketamine. Consider alternate therapy or monitor for changes in Ketamine therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1209,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed."
1210,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of budesonide. The clinical significance of this interaction is greater for oral budesonide than for orally inhaled budesonide. Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor."
1210,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a moderate CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. "
1210,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation). onsider reducing the oral budesonide dose when used together with a strong CYP3A4 inhibitor. This interaction is likely less severe with orally inhaled budesonide. Any patient receiving both budesonide and a strong CYP3A4 inhibitor should be monitored closely for signs/symptoms of corticosteroid excess. "
1210,"Itraconazole","DB01167","Itraconazole may increase levels/effect of budesonide."
1210,"Ketoconazole","DB01026","Ketoconazole may increase levels/effect of budesonide."
1210,"Telithromycin","DB00976","Telithromycin may reduce clearance of Budesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Budesonide if Telithromycin is initiated, discontinued or dose changed."
1210,"Tipranavir","DB00932","Tipranavir may increase the plasma concentration of Budesonide. Monitor for toxic Budesonide effects during concomitant administration. "
1210,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed."
1211,"Aciclovir","DB00787","Acyclovir increases the effect and toxicity of theophylline"
1211,"Adenosine","DB00640","This xanthine decreases the effect of adenosine"
1211,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of aminophylline."
1211,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of aminophylline."
1211,"Atracurium","DB00732","Theophylline decreases the effect of muscle relaxant"
1211,"Bromazepam","DB01558","Aminophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if aminophylline is initiated, discontinued or dose changed. "
1211,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of aminophylline."
1211,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of aminophylline."
1211,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of aminophylline."
1211,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of aminophylline. Aminophylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
1211,"Carteolol","DB00521","Antagonism of action and increased effect of theophylline"
1211,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of aminophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aminophylline if cimetidine is initiated, discontinued or dose changed."
1211,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect of aminophylline."
1211,"Clarithromycin","DB01211","Clarithromycin may increase the effect amd toxicity of aminophylline."
1211,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline."
1211,"Disulfiram","DB00822","Disulfiram may increase the effect and toxicity of aminophylline."
1211,"Doxacurium chloride","DB01135","Theophylline decreases the effect of muscle relaxant"
1211,"Enoxacin","DB00467","Enoxacin may increase the effect of aminophylline."
1211,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, aminophylline."
1211,"Ethinyl Estradiol","DB00977","The contraceptive increases the effect and toxicity of theophylline"
1211,"Ethotoin","DB00754","Decreased effect of both products"
1211,"Fluvoxamine","DB00176","Fluvoxamine may increase the effect and toxicity of aminophylline."
1211,"Fosphenytoin","DB01320","Decreased effect of both products"
1211,"Grepafloxacin","DB00365","Grepafloxacin may increase the effect of aminophylline."
1211,"Halothane","DB01159","Increased risk of cardiac arrhythmia"
1211,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of aminophylline."
1211,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of aminophylline."
1211,"Interferon Alfa-2a, Recombinant","DB00034","Interferon increases the effect and toxicity of theophylline"
1211,"Interferon Alfa-2b, Recombinant","DB00105","Interferon increases the effect and toxicity of theophylline"
1211,"Interferon alfa-n1","DB00011","Interferon increases the effect and toxicity of theophylline"
1211,"Isoniazid","DB00951","Isoniazid may increase the effect and toxicity of oxtriphylline."
1211,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline."
1211,"Lithium","DB01356","Theophylline decreases serum levels of lithium"
1211,"Mephenytoin","DB00532","Decreased effect of both products"
1211,"Mestranol","DB01357","The contraceptive increases the effect and toxicity of theophylline"
1211,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of aminophylline."
1211,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of aminophylline."
1211,"Metocurine","DB01336","Theophylline decreases the effect of muscle relaxant"
1211,"Mexiletine","DB00379","Mexiletine increases the effect and toxicity of theophylline"
1211,"Mivacurium","DB01226","Theophylline decreases the effect of muscle relaxant"
1211,"Nadolol","DB01203","Antagonism of action and increased effect of theophylline"
1211,"Norfloxacin","DB01059","Norfloxacin may increase the effect of aminophylline."
1211,"Pancuronium","DB01337","Theophylline decreases the effect of muscle relaxant"
1211,"Pefloxacin","DB00487","Pefloxacin may increase the effect of aminophylline."
1211,"Peginterferon alfa-2a","DB00008","Interferon increases the effect and toxicity of theophylline"
1211,"Peginterferon alfa-2b","DB00022","Interferon increases the effect and toxicity of theophylline"
1211,"Penbutolol","DB01359","Antagonism of action and increased effect of theophylline"
1211,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of aminophylline."
1211,"Pentoxifylline","DB00806","Pentoxifylline may increase the effect and toxicity of aminophylline."
1211,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of aminophylline."
1211,"Phenytoin","DB00252","Decreased effect of both products"
1211,"Pindolol","DB00960","Antagonism of action and increased effect of theophylline"
1211,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of aminophylline."
1211,"Propafenone","DB01182","Propafenone increases the effect of theophylline"
1211,"Propranolol","DB00571","Antagonism of action and increased effect of theophylline"
1211,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of aminophylline."
1211,"Regadenoson","DB06213","Reduces duration of >2-fold increase in peak flow velocity. No effect on heart rate increase."
1211,"Rifampicin","DB01045","Rifampin decreases the effect of theophylline"
1211,"Ritonavir","DB00503","Ritonavir decreases the effect of theophylline"
1211,"Rofecoxib","DB00533","Rofecoxib increases the effect and toxicity of theophylline"
1211,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of aminophylline."
1211,"Sotalol","DB00489","Antagonism of action and increased effect of theophylline"
1211,"St. John's Wort","DB01323","St. John's Wort decreases the effect of theophylline"
1211,"Tacrine","DB00382","Tacrine may reduce the elimination rate of Aminophylline. Monitor for changes in the therapeutic and toxic effects of theophylline if Tacrine is initiated, discontinued or if the dose is changed."
1211,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of aminophylline."
1211,"Temazepam","DB00231","Aminophylline may decrease the efficacy of Temazepam. Monitor for changes in the therapeutic effect of Temazepam if Aminophylline is initiated, discontinued or dose changed. "
1211,"Terbinafine","DB00857","Terbinafine increases the effect and toxicity of theophylline"
1211,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Aminophylline by decreasing Aminophylline metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Aminophylline if Thiabendazole is initiated, discontinued or dose changed."
1211,"Ticlopidine","DB00208","Ticlopidine increases the effect and toxicity of theophylline"
1211,"Timolol","DB00373","Antagonism of action and increased effect of theophylline"
1211,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect and toxicity of theophylline derivative, aminophylline."
1211,"Tubocurarine","DB01199","Theophylline decreases the effect of muscle relaxant"
1211,"Vecuronium","DB01339","Theophylline decreases the effect of muscle relaxant"
1211,"Verapamil","DB00661","Verapamil increases the effect of theophylline"
1211,"Zafirlukast","DB00549","Zafirlukast serum concentrations may be decreased by the theophylline derivative Aminophylline."
1211,"Zileuton","DB00744","Zileuton increases the effect and toxicity of theophylline"
1212,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1212,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine."
1212,"Donepezil","DB00843","Possible antagonism of action"
1212,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of quetiapine."
1212,"Ethotoin","DB00754","Phenytoin decreases the effect of quetiapine"
1212,"Etravirine","DB06414","Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required."
1212,"Fosphenytoin","DB01320","Phenytoin decreases the effect of quetiapine"
1212,"Galantamine","DB00674","Possible antagonism of action"
1212,"Ketoconazole","DB01026","Ketoconazole may increase the therapeutic and adverse effects of quetiapine."
1212,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1212,"Mephenytoin","DB00532","Phenytoin decreases the effect of quetiapine"
1212,"Phenytoin","DB00252","Phenytoin decreases the effect of quetiapine"
1212,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1212,"Rivastigmine","DB00989","Possible antagonism of action"
1212,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1212,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1212,"Telithromycin","DB00976","Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed."
1212,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
1212,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1212,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1212,"Trimethobenzamide","DB00662","Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1212,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1212,"Triprolidine","DB00427","Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1212,"Trospium","DB00209","Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1212,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed."
1212,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1212,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1212,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1213,"Apixaban","DB06605","Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy. "
1213,"Drotrecogin alfa","DB00055","Combination should be used with caution after weighing advantages and disadvantages. Low molecular weight heparins such as enoxaparin may increase the adverse effects of drotrecogin. Monitor for bleeding if used concomitantly. "
1213,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1213,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Exoxaparin. Monitor for increased bleeding during concomitant thearpy. "
1214,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1214,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1214,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1214,"Carbamazepine","DB00564","Decrease the effect of muscle relaxant"
1214,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1214,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1214,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1214,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1214,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1214,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1214,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1214,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1214,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1214,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1214,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1215,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1215,"Itraconazole","DB01167","Itraconazole increases the effect/toxicity of levomethadyl"
1215,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1216,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1217,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, paclitaxel."
1217,"Axitinib","DB06626","Avoid combination due to potential for decrease in serum concentration of axitinib."
1217,"Carboplatin","DB00958","Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as paclitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent. "
1217,"Cisplatin","DB00515","Cisplatin increases the effect and toxicity of paclitaxel"
1217,"Clozapine","DB00363","Avoid combination due to the potential enhancement of agranulocytosis by clozapine. "
1217,"Conivaptan","DB00872","Avoid combination because it will likely increase the serum concentration of CYP3A4 substrates. "
1217,"Etravirine","DB06414","Paclitaxel, when used concomitantly with NNRTIs, may experience an increase in serum concentration. It is recommended to monitor for paclitaxel toxicity."
1217,"Gemcitabine","DB00441","Paclitaxel increases the effect/toxicity of gemcitabine"
1217,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection.\
"
1217,"Pazopanib","DB06589","Pazopanib increases exposure of paclitaxel "
1217,"Pimecrolimus","DB00337","Avoid combination due to the enhancement of adverse effects of immunosuppressants. "
1217,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1217,"St. John's Wort","DB01323","Avoid combination due to potential decrease in serum concentration of paclitaxel."
1217,"Tacrolimus","DB00864","Avoid combination of topical tacrolimus due to the potential enhancement of adverse effects of immunosuppressants."
1217,"Telithromycin","DB00976","Telithromycin may reduce clearance of Paclitaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Paclitaxel if Telithromycin is initiated, discontinued or dose changed."
1217,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Paclitaxel. Consider alternate therapy or monitor for changes in Paclitaxel therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1217,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Concomitant therapy may also increase Trastuzumab serum concentration and decrease Paclitaxel serum concentrations. Monitor closely for adverse events and therapeutic response.  "
1217,"Valrubicin","DB00385","The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects."
1217,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed."
1220,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Saquinavir. The antiviral response should be closely monitored."
1220,"Abiraterone","DB05812","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
1220,"Alprazolam","DB00404","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, alprazolam."
1220,"Amiodarone","DB01118","The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone."
1220,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1220,"Asenapine","DB06216","Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
1220,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1220,"Atorvastatin","DB01076","Saquinavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if saquinavir is initiated, discontinued or dose changed."
1220,"Bromazepam","DB01558","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if saquinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1220,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
1220,"Chlordiazepoxide","DB00475","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, chlordiazepoxide."
1220,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1220,"Clonazepam","DB01068","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clonazepam."
1220,"Clorazepate","DB00628","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, clorazepate."
1220,"Cyclosporine","DB00091","The protease inhibitor, saquinavir, may increase the effect of cyclosporine."
1220,"Dantrolene","DB01219","Saquinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if saquinavir is initiated, discontinued or dose changed. "
1220,"Darunavir","DB01264","Decreased levels of darunavir"
1220,"Delavirdine","DB00705","Increases the effect of saquinavir and hepatic toxicity"
1220,"Diazepam","DB00829","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, diazepam."
1220,"Dihydroergotamine","DB00320","The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine."
1220,"Efavirenz","DB00625","Efavirenz decreases the effect of saquinavir"
1220,"Eplerenone","DB00700","This CYP3A4 inhibitor increases the effect and toxicity of eplerenone"
1220,"Ergotamine","DB00696","The protease inhibitor, saquinavir, may increase the effect and toxicity of the ergot derivative, ergotamine."
1220,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1220,"Estazolam","DB01215","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, estazolam."
1220,"Etravirine","DB06414","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
1220,"Fentanyl","DB00813","The protease inhibitor, saquinavir, may increase the effect and toxicity of fentanyl."
1220,"Flurazepam","DB00690","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, flurazepam."
1220,"Fusidic Acid","DB02703","The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid."
1220,"Indinavir","DB00224","Possible antagonism of action"
1220,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of saquinavir."
1220,"Lovastatin","DB00227","Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. "
1220,"Midazolam","DB00683","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, midazolam."
1220,"Nevirapine","DB00238","Decreases the effect of saquinavir"
1220,"Pazopanib","DB06589","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
1220,"Pimozide","DB01100","The protease inhibitor, saquinavir, may increase the effect and toxicity of pimozide."
1220,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1220,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
1220,"Rifabutin","DB00615","Rifabutin decreases the effect of saquinavir"
1220,"Rifampicin","DB01045","Rifampin decreases the effect of saquinavir"
1220,"Tacrolimus","DB00864","The protease inhibitor, Saquinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Saquinavir therapy is initiated, discontinued or altered."
1220,"Tadalafil","DB00820","Saquinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1220,"Tamoxifen","DB00675","Saquinavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1220,"Tamsulosin","DB00706","Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Saquinavir is initiated, discontinued, or dose changed."
1220,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1220,"Telithromycin","DB00976","Saquinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1220,"Temsirolimus","DB06287","Saquinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1220,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Saquinavir is initiated, discontinued or dose changed."
1220,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1220,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Saquinavir is initiated, discontinued or dose changed."
1220,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Saquinavir. Consider alternate therapy. "
1220,"Tolterodine","DB01036","Saquinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1220,"Tolvaptan","DB06212","Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
1220,"Topotecan","DB01030","The p-glycoprotein inhibitor, Saquinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1220,"Tramadol","DB00193","Saquinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1220,"Trazodone","DB00656","The protease inhibitor, Saquinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Saquinavir is initiated, discontinued or dose changed. "
1220,"Triazolam","DB00897","The protease inhibitor, saquinavir, may increase the effect of the benzodiazepine, triazolam."
1220,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Saquinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Saquinavir is initiated, discontinued or dose changed. "
1220,"Vardenafil","DB00862","Saquinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1220,"Vemurafenib","DB08881","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
1220,"Venlafaxine","DB00285","Saquinavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Saquinavir is initiated, discontinued, or dose changed."
1220,"Verapamil","DB00661","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Saquinavir is initiated, discontinued or dose changed."
1220,"Vinblastine","DB00570","Saquinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Saquinavir is initiated, discontinued or dose changed."
1220,"Vincristine","DB00541","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Saquinavir is initiated, discontinued or dose changed."
1220,"Vinorelbine","DB00361","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Saquinavir is initiated, discontinued or dose changed."
1220,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed."
1220,"Zolpidem","DB00425","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if saquinavir is initiated, discontinued or dose changed. "
1220,"Zonisamide","DB00909","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if saquinavir is initiated, discontinued or dose changed."
1220,"Zopiclone","DB01198","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if saquinavir is initiated, discontinued or dose changed."
1221,"Cyclosporine","DB00091","Metoclopramide increases serum levels of cyclosporine"
1221,"L-DOPA","DB01235","Levodopa decreases the effect of metoclopramide"
1221,"Lurasidone","DB08815","Increases toxicity and risk of extrapyramidal effects of lurasidone by antidopaminergic effects. Concomitant therapy should be avoided."
1221,"Paliperidone","DB01267","Metoclopramide may increase the risk of extrapyramidal side effects of paliperidone. Concomitant therapy should be avoided. "
1221,"Tacrolimus","DB00864","Metoclopramide may increase the concentration of Tacrolimus in the blood. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Metoclopramide therapy is initiated, discontinued or altered."
1221,"Tetrabenazine","DB04844","Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
1221,"Venlafaxine","DB00285","Possible serotoninergic syndrome with this combination"
1221,"Vilazodone","DB06684","Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. "
1221,"Zuclopenthixol","DB01624","Additive dopamine D2 receptor antagonism may cause dopaminergic imbalance in the nigrostriatal (dopamine D1 receptors) and striatopallidal (dopamine D2 receptors). Increased risk of extrapyramidal reactions and neuroleptic malignant syndrome. Concomitant therapy should be avoided. "
1222,"Acenocoumarol","DB01418","The corticosteroid, dexamethasone, alters the anticoagulant effect, acenocoumarol."
1222,"Acetylsalicylic acid","DB00945","The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
1222,"Ambenonium","DB01122","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, ambenonium."
1222,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the effect of dexamethasone."
1222,"Amobarbital","DB01351","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Anisindione","DB01125","The corticosteroid, dexamethasone, alters the anticoagulant effect of anisindione."
1222,"Aprepitant","DB00673","Aprepitant may increase the effect and toxicity of dexamethasone."
1222,"Aprobarbital","DB01352","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Asparaginase Erwinia chrysanthemi","DB08886","Monitor therapy as asparaginase erwinia chrysanthemi may increase the serum concentration of dexamethasone due to a decrease of hepatic proteins necessary for dexamethasone metabolism."
1222,"Butabarbital","DB00237","The barbiturate, butabarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Butalbital","DB00241","The barbiturate, butalbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Butethal","DB01353","The barbiturate, butethal, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Dabigatran etexilate","DB06695","P-Glycoprotein inducers such as dexamethasone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
1222,"Dicoumarol","DB00266","The corticosteroid, dexamethasone, alters the anticoagulant effect of dicumarol."
1222,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Edrophonium","DB01010","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, edrophonium."
1222,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
1222,"Ethotoin","DB00754","The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Heptabarbital","DB01354","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Hexobarbital","DB01355","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Imatinib","DB00619","Dexamethasone may decrease levels of imatinib."
1222,"Lurasidone","DB08815","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. Will decrease Cmax of lurasidone by 85%."
1222,"Magnesium salicylate","DB01397","The corticosteroid, dexamethasone, may decrease the effect of magnesium salicylate. "
1222,"Mephenytoin","DB00532","The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Methohexital","DB00474","The barbiturate, methohexital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Midodrine","DB00211","Increased arterial pressure"
1222,"Neostigmine","DB01400","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine."
1222,"Pentobarbital","DB00312","The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Pyridostigmine","DB00545","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
1222,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Rilpivirine","DB08864","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
1222,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1222,"Salsalate","DB01399","The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate."
1222,"Secobarbital","DB00418","The barbiturate, secobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Sunitinib","DB01268","Possible decrease in sunitinib levels"
1222,"Tacrine","DB00382","Tacrine and Dexamethasone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
1222,"Talbutal","DB00306","The barbiturate, talbutal, may decrease the effect of the corticosteroid, dexamethasone."
1222,"Telithromycin","DB00976","Co-administration may cause decreased Telithromycin and increased Dexamethasone plasma concentrations. Consider alternate therapy. \
"
1222,"Temsirolimus","DB06287","Dexamethasone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1222,"Thalidomide","DB01041","Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects. "
1222,"Tramadol","DB00193","Dexamethasone may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
1222,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1222,"Trazodone","DB00656","The CYP3A4 inducer, Dexamethasone, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Dexamethasone is initiated, discontinued or dose changed."
1222,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1222,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1222,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed."
1222,"Warfarin","DB00682","The corticosteroid, dexamethasone, alters the anticoagulant effect of warfarin."
1223,"Fosphenytoin","DB01320","The hydantoin decreases the effect of levodopa"
1223,"Iron Dextran","DB00893","Iron decreases the absorption of dopa derivatives"
1223,"Isocarboxazid","DB01247","Possible hypertensive crisis"
1223,"Methyldopa","DB00968","Methyldopa increases the effect and toxicity of levodopa"
1223,"Metoclopramide","DB01233","Levodopa decreases the effect of metoclopramide"
1223,"Paliperidone","DB01267","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, levodopa. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1223,"Phenelzine","DB00780","Possible hypertensive crisis"
1223,"Phenytoin","DB00252","The hydantoin decreases the effect of levodopa"
1223,"Tetrabenazine","DB04844","Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa."
1223,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Levodopa. Consider alternate therapy or monitor for decreased effects of both agents. "
1223,"Tranylcypromine","DB00752","Levodopa may increase the adverse effects of Tranylcypromine. Risk of severe hypertension. Concomitant therapy should be avoided or monitored closely for adverse effects of Tranylcypromine. "
1223,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder. "
1223,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1225,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Bromodiphenhydramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1225,"Trimethobenzamide","DB00662","Trimethobenzamide and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1225,"Triprolidine","DB00427","Triprolidine and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1225,"Trospium","DB00209","Trospium and Bromodiphenhydramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1226,"Carbamazepine","DB00564","Carbamazepine, a strong CYP3A4 inducer, may decrease the serum concentration of aripiprazole by increasing its metabolism."
1226,"Dihydroquinidine barbiturate","DB01341","Quinidine increases the effect and toxicity of aripiprazole"
1226,"Etravirine","DB06414","Ariprazole, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dose of oral aripiprazole to maintain therapeutic efficacy, and to adjust the dose of aripiprazole appropriately when the dose of etravirine is altered.  "
1226,"Itraconazole","DB01167","Itraconazole may increase the effect of aripiprazole."
1226,"Ketoconazole","DB01026","Ketoconazole may increase the effect of aripiprazole."
1226,"Quinidine","DB00908","Quinidine increases the effect and toxicity of aripiprazole"
1226,"Quinidine barbiturate","DB01346","Quinidine increases the effect and toxicity of aripiprazole"
1226,"Tacrine","DB00382","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Aripiprazole. Monitor for extrapyramidal symptoms. "
1226,"Telithromycin","DB00976","Telithromycin may reduce clearance of Aripiprazole. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Aripiprazole if Telithromycin is initiated, discontinued or dose changed."
1226,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Aripiprazole. Consider alternate therapy or monitor for therapeutic/adverse effects of Aripiprazole if Terbinafine is initiated, discontinued or dose changed."
1226,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
1226,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Aripiprazole, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1226,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aripiprazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aripiprazole if voriconazole is initiated, discontinued or dose changed."
1227,"Donepezil","DB00843","Possible antagonism of action"
1227,"Galantamine","DB00674","Possible antagonism of action"
1227,"Guanethidine","DB01170","Chlorprothixene may decrease the effect of guanethidine."
1227,"Rivastigmine","DB00989","Possible antagonism of action"
1228,"Trandolapril","DB00519","The prostacyclin analogue, Epoprostenol, may increase the hypotensive effect of Trandolapril. "
1229,"Acenocoumarol","DB01418","Gemfibrozil may increase the anticoagulant effect of acenocoumarol."
1229,"Anisindione","DB01125","Gemfibrozil may increase the anticoagulant effect of anisindione."
1229,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
1229,"Bexarotene","DB00307","Gemfibrozil may increase the serum concentration of bexarotene. This combination should be avoided."
1229,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as gemfibrozil may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
1229,"Cerivastatin","DB00439","Increased risk of myopathy/rhabdomyolysis"
1229,"Dabrafenib","DB08912","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
1229,"Dicoumarol","DB00266","Gemfibrozil may increase the anticoagulant effect of dicumarol."
1229,"Fluvastatin","DB01095","Increased risk of myopathy/rhabdomyolysis"
1229,"Glimepiride","DB00222","Gemfibrozil increases the effect and toxicity of rosiglitazone/pioglitazone"
1229,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
1229,"Pioglitazone","DB01132","Gemfibrozil may increase the effect and toxicity of pioglitazone."
1229,"Pitavastatin","DB08860","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both gemfibrozil and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
1229,"Pravastatin","DB00175","Increased risk of myopathy/rhabdomyolysis"
1229,"Repaglinide","DB00912","Gemfibrozil may increase the effect and toxicity of repaglinide."
1229,"Rosiglitazone","DB00412","Increases the effect and toxicity of rosiglitazone/pioglitazone"
1229,"Rosuvastatin","DB01098","Gemfibrozil may increase the therapeutic and toxic effects of rosuvastatin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of rosuvastatin if gemfibrozil is initiated, discontinued or dose changed."
1229,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
1229,"Tacrine","DB00382","The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Gemfibrozil, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Gemfibrozil is initiated, discontinued or if the dose is changed."
1229,"Tamoxifen","DB00675","Gemfibrozil may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Gemfibrozil  is initiated, discontinued or dose changed."
1229,"Tizanidine","DB00697","Gemfibrozil may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration."
1229,"Tolbutamide","DB01124","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Gemfibrozil is initiated, discontinued or dose changed. "
1229,"Torasemide","DB00214","Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Gemfibrozil is initiated, discontinued or dose changed. "
1229,"Tretinoin","DB00755","The strong CYP2C8 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Gemfibrozil is initiated, discontinued to dose changed. "
1229,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Gemfibrozil is initiated, discontinued or dose changed."
1229,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, Gemfibrozil, may decrease the metabolism and clearance of Trimipramine, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Gemfibrozil is initiated, discontinued or dose changed. "
1229,"Ursodeoxycholic acid","DB01586","The fibric acid derivative decreases the effect of ursodiol"
1229,"Voriconazole","DB00582","Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed.	"
1229,"Warfarin","DB00682","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if gemfibrozil is initiated, discontinued or dose changed."
1229,"Zafirlukast","DB00549","Gemfibrozil, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if gemfibrozil is initiated, discontinued or dose changed."
1230,"Altretamine","DB00488","Risk of severe hypotension"
1230,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1230,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if atazanavir is initiated, discontinued or dose changed."
1230,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of tricyclic antidepressants like clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1230,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. "
1230,"Cimetidine","DB00501","Cimetidine may increase the effect of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if cimetidine is initiated, discontinued or dose changed."
1230,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1230,"Clonidine","DB00575","The tricyclic antidepressant, clomipramine, may decrease the effect of clonidine."
1230,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1230,"Dihydroquinidine barbiturate","DB01341","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine."
1230,"Dobutamine","DB00841","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dobutamine."
1230,"Donepezil","DB00843","Possible antagonism of action"
1230,"Dopamine","DB00988","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of dopamine."
1230,"Ephedra","DB01363","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedra."
1230,"Ephedrine","DB01364","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedrine."
1230,"Epinephrine","DB00668","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of epinephrine."
1230,"Fenoterol","DB01288","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of fenoterol."
1230,"Fluoxetine","DB00472","The SSRI, fluoxetine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluoxetine is initiated, discontinued or dose changed."
1230,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, may increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Additive modulation of serotonin activity also increases the risk of serotonin syndrome. Monitor for development of serotonin syndrome during concomitant therapy. Monitor for changes in the therapeutic and adverse effects of clomipramine if fluvoxamine is initiated, discontinued or dose changed."
1230,"Galantamine","DB00674","Possible antagonism of action"
1230,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1230,"Guanethidine","DB01170","The tricyclic antidepressant, clomipramine, decreases the effect of guanethidine."
1230,"Isocarboxazid","DB01247","Possibility of severe adverse effects"
1230,"Isoprenaline","DB01064","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of isoproterenol."
1230,"Mephentermine","DB01365","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of mephentermine."
1230,"Metaraminol","DB00610","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of metaraminol."
1230,"Methoxamine","DB00723","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of methoxamine."
1230,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
1230,"Norepinephrine","DB00368","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of norepinephrine."
1230,"Orciprenaline","DB00816","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of orciprenaline."
1230,"Phenelzine","DB00780","Possibility of severe adverse effects"
1230,"Phenylephrine","DB00388","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylephrine."
1230,"Phenylpropanolamine","DB00397","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of phenylpropanolamine."
1230,"Pirbuterol","DB01291","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pirbuterol."
1230,"Procaterol","DB01366","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of procaterol."
1230,"Pseudoephedrine","DB00852","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pseudoephedrine."
1230,"Quinidine","DB00908","Additive QTc-prolonging effects may occur. Quinidine may also increase the serum concentration of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if quinidine is initiated, discontinued or dose changed. Monitor for the development of torsades de pointes during concomitant therapy."
1230,"Quinidine barbiturate","DB01346","Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine."
1230,"Rasagiline","DB01367","Possibility of severe adverse effects"
1230,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifabutin is initiated, discontinued or dose changed."
1230,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the tricyclic antidepressant, clomipramine, by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if rifampin is initiated, discontinued or dose changed."
1230,"Ritonavir","DB00503","Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if ritonavir if initiated, discontinued or dose changed."
1230,"Rivastigmine","DB00989","Possible antagonism of action"
1230,"Salbutamol","DB01001","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of salbutamol."
1230,"Sibutramine","DB01105","Increased risk of CNS adverse effects"
1230,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1230,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Clomipramine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1230,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1230,"Tamoxifen","DB00675","Clomipramine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. "
1230,"Tamsulosin","DB00706","Clomipramine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Clomipramine is initiated, discontinued, or dose changed."
1230,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for therapeutic/adverse effects of Clomipramine if Terbinafine is initiated, discontinued or dose changed."
1230,"Terbutaline","DB00871","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of terbutaline."
1230,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1230,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Clomipramine by decreasing Clomipramine metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Clomipramine if Thiabendazole is initiated, discontinued or dose changed."
1230,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1230,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Clomipramine. Consider alternate therapy or monitor for adverse/toxic effects of Clomipramine if Ticlopidine is initiated, discontinued or dose changed."
1230,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1230,"Tramadol","DB00193","Tramadol increases the risk of serotonin syndrome and seizures. Clomipramine may decrease the effect of Tramadol by decreasing active metabolite production. "
1230,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
1230,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1230,"Trimethobenzamide","DB00662","Trimethobenzamide and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1230,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. Additive QTc-prolongation may also occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1230,"Triprolidine","DB00427","Triprolidine and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1230,"Trospium","DB00209","Trospium and Clomipramine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1230,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1230,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1230,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1230,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1230,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1230,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1232,"Amprenavir","DB00701","Amprenavir may increase the effect and toxicity of bepridil."
1232,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1232,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1232,"Atazanavir","DB01072","Atazanavir may increase the effect and toxicity of bepridil."
1232,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1232,"Etravirine","DB06414","Bepridil (withdrawn from US. market), when used concomitantly with etravirine, may experience a decrease in serum concentration. If possible, it is recommended to monitor for decreased bepridil concentrations and therapeutic efficacy. "
1232,"Fosamprenavir","DB01319","Amprenavir increases the effect and toxicity of bepridil"
1232,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1232,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1232,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1232,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1232,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1232,"Ritonavir","DB00503","Ritonavir increases the effect and toxicity of bepridil"
1232,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1232,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1232,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1232,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Bepridil. Concomitant therapy is contraindicated."
1234,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
1234,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1234,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Donepezil","DB00843","Possible antagonism of action"
1234,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Galantamine","DB00674","Possible antagonism of action"
1234,"Guanethidine","DB01170","Trimeprazine may decrease the effect of guanethidine."
1234,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
1234,"Pramlintide","DB01278","The anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1234,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Trimeprazine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1234,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1234,"Trimethobenzamide","DB00662","Trimethobenzamide and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1234,"Triprolidine","DB00427","Triprolidine and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1234,"Trospium","DB00209","Trospium and Trimeprazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1235,"Almotriptan","DB00918","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, almotriptan. Concomitant therapy is contraindicated."
1235,"Altretamine","DB00488","Risk of severe hypotension"
1235,"Amitriptyline","DB00321","Possibility of severe adverse effects"
1235,"Amoxapine","DB00543","Possibility of severe adverse effects"
1235,"Amphetamine","DB00182","Possible hypertensive crisis"
1235,"Atomoxetine","DB00289","Possible severe adverse reaction with this combination"
1235,"Benzphetamine","DB00865","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
1235,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid. "
1235,"Brimonidine","DB00484","MAO Inhibitors like isocarboxazid may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
1235,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like isocarboxazid. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
1235,"Bupropion","DB01156","Possible severe adverse reaction with this combination"
1235,"Buspirone","DB00490","Possible blood pressure elevation"
1235,"Citalopram","DB00215","Possible severe adverse reaction with this combination"
1235,"Clomipramine","DB01242","Possibility of severe adverse effects"
1235,"Desipramine","DB01151","Possibility of severe adverse effects"
1235,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1235,"Dexfenfluramine","DB01191","Risk of hypertensive crisis."
1235,"Dextroamphetamine","DB01576","Possible hypertensive crisis"
1235,"Dextromethorphan","DB00514","Possible severe adverse reaction"
1235,"Diethylpropion","DB00937","Possible hypertensive crisis"
1235,"Dobutamine","DB00841","Increased arterial pressure"
1235,"Donepezil","DB00843","Possible antagonism of action"
1235,"Dopamine","DB00988","Increased arterial pressure"
1235,"Doxepin","DB01142","Possibility of severe adverse effects"
1235,"Duloxetine","DB00476","Possible severe adverse reaction with this combination"
1235,"Entacapone","DB00494","Possible hypertensive crisis with this combination"
1235,"Ephedra","DB01363","Increased arterial pressure"
1235,"Ephedrine","DB01364","Increased arterial pressure"
1235,"Epinephrine","DB00668","Increased arterial pressure"
1235,"Escitalopram","DB01175","Possible severe adverse reaction with this combination"
1235,"Fenfluramine","DB00574","Possible hypertensive crisis"
1235,"Fenoterol","DB01288","Increased arterial pressure"
1235,"Fluoxetine","DB00472","Possible severe adverse reaction with this combination"
1235,"Fluvoxamine","DB00176","Possible severe adverse reaction with this combination"
1235,"Galantamine","DB00674","Possible antagonism of action"
1235,"Guanethidine","DB01170","Isocarboxazid may decrease the effect of guanethidine."
1235,"Imipramine","DB00458","Possibility of severe adverse effects"
1235,"Isoprenaline","DB01064","Increased arterial pressure"
1235,"L-DOPA","DB01235","Possible hypertensive crisis"
1235,"L-Tryptophan","DB00150","Possible severe adverse reaction with this combination"
1235,"Mazindol","DB00579","Possible hypertensive crisis"
1235,"Mephentermine","DB01365","Increased arterial pressure"
1235,"Metaraminol","DB00610","Increased arterial pressure"
1235,"Methamphetamine","DB01577","Possible hypertensive crisis"
1235,"Methotrimeprazine","DB01403","Possible severe adverse reaction with this combination"
1235,"Methoxamine","DB00723","Increased arterial pressure"
1235,"Methylphenidate","DB00422","Possible hypertensive crisis with this combination"
1235,"Midodrine","DB00211","Possible hypertensive crisis with this combination"
1235,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated. "
1235,"Mirtazapine","DB00370","Possible severe adverse reaction with this combination"
1235,"Naratriptan","DB00952","The use of two serotonin modulators increases the risk of serotonin syndrome. Consider alternate therapy or monitor for signs and symptoms of serotonin syndrome."
1235,"Nefazodone","DB01149","Possible severe adverse reaction with this combination"
1235,"Norepinephrine","DB00368","Increased arterial pressure"
1235,"Nortriptyline","DB00540","Possibility of severe adverse effects"
1235,"Orciprenaline","DB00816","Increased arterial pressure"
1235,"Paroxetine","DB00715","Possible severe adverse reaction with this combination"
1235,"Pethidine","DB00454","Potentially fatal adverse effects"
1235,"Phendimetrazine","DB01579","Possible hypertensive crisis"
1235,"Phenmetrazine","DB00830","Possible hypertensive crisis"
1235,"Phentermine","DB00191","Possible hypertensive crisis"
1235,"Phenylephrine","DB00388","Increased arterial pressure"
1235,"Phenylpropanolamine","DB00397","Increased arterial pressure"
1235,"Pirbuterol","DB01291","Increased arterial pressure"
1235,"Procaterol","DB01366","Increased arterial pressure"
1235,"Protriptyline","DB00344","Possibility of severe adverse effects"
1235,"Pseudoephedrine","DB00852","Increased arterial pressure"
1235,"Rivastigmine","DB00989","Possible antagonism of action"
1235,"Rizatriptan","DB00953","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated."
1235,"Salbutamol","DB01001","Increased arterial pressure"
1235,"Sertraline","DB01104","Possible severe adverse reaction with this combination"
1235,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
1235,"Sumatriptan","DB00669","The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, sumatriptan. Concomitant therapy is contraindicated."
1235,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Isocarboxazid, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1235,"Terbutaline","DB00871","Increased arterial pressure"
1235,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated."
1235,"Tolcapone","DB00323","Tolcapone and Isocarboxazid decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects."
1235,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, isocarboxazid."
1235,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1235,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1235,"Trimethobenzamide","DB00662","Trimethobenzamide and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1235,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
1235,"Triprolidine","DB00427","Triprolidine and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1235,"Trospium","DB00209","Trospium and Isocarboxazid, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1235,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1235,"Vilazodone","DB06684","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
1235,"Zolmitriptan","DB00315","The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated."
1236,"Aprepitant","DB00673","Aprepitant may change levels of the chemotherapy agent, docetaxel."
1236,"Carboplatin","DB00958","Platinum derivatives such as carboplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administering the taxane derivative before the platinum derivative seems prudent. "
1236,"Cisplatin","DB00515","Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as docetaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity. Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent. "
1236,"Erythromycin","DB00199","Erythromycin may increase the serum levels and toxicity of docetaxel."
1236,"Josamycin","DB01321","Josamycin may increase the serum levels and toxicity of docetaxel."
1236,"Ketoconazole","DB01026","Ketoconazole may increase the serum levels and toxicity of docetaxel."
1236,"Midazolam","DB00683","Midazolam may increase the serum levels and toxicity of docetaxel."
1236,"Orphenadrine","DB01173","Orphenadrine may increase the serum levels and toxicity of docetaxel."
1236,"Quinupristin","DB01369","This combination presents an increased risk of toxicity."
1236,"Telithromycin","DB00976","Telithromycin may reduce clearance of Docetaxel. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Docetaxel if Telithromycin is initiated, discontinued or dose changed."
1236,"Testosterone","DB00624","Testosterone may increase the serum levels and toxicity of docetaxel."
1236,"Testosterone Propionate","DB01420","Testosterone propionate may increase the serum levels and toxicity of docetaxel."
1236,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1236,"Valrubicin","DB00385","The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects. "
1236,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed."
1238,"Azathioprine","DB00993","Olsalazine may increase the toxicity of thiopurine, azathioprine."
1238,"Mercaptopurine","DB01033","Olsalazine may increase the toxicity of thiopurine, mercaptopurine."
1238,"Tioguanine","DB00352","Olsalazine may increase the toxicity of thiopurine, thioguanine."
1241,"Acebutolol","DB01193","Ischemia with risk of gangrene"
1241,"Almotriptan","DB00918","Possible severe and prolonged vasoconstriction"
1241,"Atenolol","DB00335","Ischmeia with risk of gangrene"
1241,"Bisoprolol","DB00612","Ischemia with risk of gangrene"
1241,"Carvedilol","DB01136","Ischemia with risk of gangrene"
1241,"Delavirdine","DB00705","The antiretroviral agent may increase the ergot derivative toxicity"
1241,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1241,"Efalizumab","DB00095","The antiretroviral agent may increase the ergot derivative"
1241,"Eletriptan","DB00216","Possible severe and prolonged vasoconstriction"
1241,"Epinephrine","DB00668","Possible marked increase of arterial pressure"
1241,"Erythromycin","DB00199","Possible ergotism and severe ischemia with this combination"
1241,"Esmolol","DB00187","Ischemia with risk of gangrene"
1241,"Frovatriptan","DB00998","Possible severe and prolonged vasoconstriction"
1241,"Isosorbide Dinitrate","DB00883","Possible antagonism of action"
1241,"Isosorbide Mononitrate","DB01020","Possible antagonism of action"
1241,"Labetalol","DB00598","Ischemia with risk of gangrene"
1241,"Metoprolol","DB00264","Ischemia with risk of gangrene"
1241,"Nadolol","DB01203","Ischemia with risk of gangrene"
1241,"Naratriptan","DB00952","Possible severe and prolonged vasocontriction"
1241,"Nitroglycerin","DB00727","Possible antagonism of action"
1241,"Oxprenolol","DB01580","Ischemia with risk of gangrene"
1241,"Pentaerythritol Tetranitrate","DB06154","Possible antagonism of action"
1241,"Phenylephrine","DB00388","Possible marked increase of arterial pressure"
1241,"Pindolol","DB00960","Ischemia with risk of gangrene"
1241,"Propranolol","DB00571","Ischemia with risk of gangrene"
1241,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ergonovine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ergonivine if Telithromycin is initiated, discontinued or dose changed."
1241,"Timolol","DB00373","Ischemia with risk of gangrene"
1241,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Ergonovine. Concomitant therapy is contraindicated."
1241,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1241,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1241,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1241,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
1241,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1241,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergonovine by decreasing its metabolism. Concomitant therapy is contraindicated. "
1241,"Zolmitriptan","DB00315","Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. "
1242,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1242,"Eptifibatide","DB00063","Monitor therapy due to enhanced anticoagulant effect."
1242,"Etravirine","DB06414","Dasatinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. \
\
It is recommended to avoid this combination if possible. If concurrent therapy cannot be avoided it is recommended to increase the dose of dasitinib and monitor for efficacy and toxicity.  "
1242,"Omeprazole","DB00338","Omeprazole may decrease the serum level of dasatinib."
1242,"Pantoprazole","DB00213","Pantoprazole may decrease the serum level of dasatinib."
1242,"Phenobarbital","DB01174","Phenobarbital may decrease the serum level and efficacy of dasatinib."
1242,"Phenytoin","DB00252","Phenytoin may decrease the serum level and efficacy of dasatinib."
1242,"Rabeprazole","DB01129","Rabeprazole may decrease the serum level of dasatinib."
1242,"Ranitidine","DB00863","Ranitidine may decrease the serum level of dasatinib."
1242,"Rifampicin","DB01045","Rifampin may decrease the serum level and efficacy of dasatinib."
1242,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1242,"Telithromycin","DB00976","Telithromycin may reduce clearance of Dasatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Dasatinib if Telithromycin is initiated, discontinued or dose changed."
1242,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1242,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1242,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1242,"Voriconazole","DB00582","Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed."
1242,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1242,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1242,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1243,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1243,"Trandolapril","DB00519","Lisdexamfetamine may reduce the efficacy of Trandolapril. "
1243,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Lisdexamfetamine. Concomitant therapy should be avoided."
1243,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Lisdexamfetamine."
1246,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1246,"Etravirine","DB06414","Lapatinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination."
1246,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1246,"Pazopanib","DB06589","Lapatinib is a weak inhibitor of CYP3A4, BCRP, and p-glycoprotein and may increase exposure of pazopanib. AUC and Cmax increase by 50-60%. "
1246,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1246,"Tamsulosin","DB00706","Lapatinib, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lapatinib is initiated, discontinued, or dose changed."
1246,"Telithromycin","DB00976","Telithromycin may reduce clearance of Lapatinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Lapatinib if Telithromycin is initiated, discontinued or dose changed."
1246,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1246,"Tolterodine","DB01036","Lapatinib may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1246,"Topotecan","DB01030","The p-glycoprotein inhibitor, Lapatinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1246,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1246,"Tramadol","DB00193","Lapatinib may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
1246,"Trazodone","DB00656","The CYP3A4 inhibitor, Lapatinib, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lapatinib is initiated, discontinued or dose changed."
1246,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Lapatinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Lapatinib is initiated, discontinued to dose changed."
1246,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. "
1246,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lapatinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lapatinib if voriconazole is initiated, discontinued or dose changed."
1246,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1246,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1246,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1248,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of sitagliptin. Monitor for changes in fasting and postprandial blood sugars."
1250,"Apixaban","DB06605","Avoid combination. Otherwise, posaconazole will likely increase apixaban serum concentration."
1250,"Astemizole","DB00637","Contraindicated co-administration"
1250,"Bromazepam","DB01558","Posaconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if posaconazole is initiated, discontinued or dose changed."
1250,"Cimetidine","DB00501","Significant decrease of posaconazole levels"
1250,"Cisapride","DB00604","Contraindicated co-administration"
1250,"Conivaptan","DB00872","Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. "
1250,"Cyclosporine","DB00091","Increased level of cyclosporine"
1250,"Dantrolene","DB01219","Posaconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if posaconazole is initiated, discontinued or dose changed. "
1250,"Dihydroergotamine","DB00320","Contraindicated co-administration"
1250,"Ergotamine","DB00696","Contraindicated co-administration"
1250,"Fosphenytoin","DB01320","Modifications of drug levels for both agents"
1250,"Halofantrine","DB01218","Contraindicated co-administration"
1250,"Ivacaftor","DB08820","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
1250,"Methysergide","DB00247","Contraindicated co-administration"
1250,"Phenytoin","DB00252","Modifications of drug levels for both agents"
1250,"Pimozide","DB01100","Contraindicated co-administration"
1250,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1250,"Quinidine","DB00908","Contraindicated co-administration"
1250,"Regorafenib","DB08896","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
1250,"Rifabutin","DB00615","Modification of drug levels for both agents"
1250,"Rivaroxaban","DB06228","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
1250,"Tacrolimus","DB00864","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Posaconazole is initiated, discontinued or dose changed."
1250,"Tadalafil","DB00820","Posaconzole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1250,"Tamoxifen","DB00675","Posaconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1250,"Tamsulosin","DB00706","Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Posaconazole is initiated, discontinued, or dose changed."
1250,"Telithromycin","DB00976","Posaconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1250,"Temsirolimus","DB06287","Posaconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1250,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Posaconazole is initiated, discontinued or dose changed."
1250,"Terfenadine","DB00342","Contraindicated co-administration"
1250,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Posaconazole is initiated, discontinued or dose changed."
1250,"Tipranavir","DB00932","Tipranavir may increase the serum concentration of Posaconazole. Posaconazole may increase the serum concentration of Tipranavir."
1250,"Tolterodine","DB01036","Posaconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1250,"Tramadol","DB00193","Posaconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1250,"Trazodone","DB00656","The CYP3A4 inhibitor, Posaconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Posaconazole is initiated, discontinued or dose changed. "
1250,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Posaconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Posaconazole is initiated, discontinued or dose changed. "
1250,"Vardenafil","DB00862","Posaconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1250,"Venlafaxine","DB00285","Posaconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Posaconazole is initiated, discontinued, or dose changed."
1250,"Verapamil","DB00661","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Posaconazole is initiated, discontinued or dose changed."
1250,"Vinblastine","DB00570","Posaconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Posaconazole is initiated, discontinued or dose changed."
1250,"Vincristine","DB00541","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Posaconazole is initiated, discontinued or dose changed."
1250,"Vinorelbine","DB00361","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Posaconazole is initiated, discontinued or dose changed."
1250,"Zolpidem","DB00425","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if posaconazole is initiated, discontinued or dose changed. "
1250,"Zonisamide","DB00909","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if posaconazole is initiated, discontinued or dose changed."
1250,"Zopiclone","DB01198","Posaconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if posaconazole is initiated, discontinued or dose changed."
1251,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Darunavir. The antiviral response should be closely monitored."
1251,"Bromazepam","DB01558","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if darunavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1251,"Clarithromycin","DB01211","Increased levels of clarithromycin"
1251,"Dantrolene","DB01219","Darunavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if darunavir is initiated, discontinued or dose changed. "
1251,"Etravirine","DB06414","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
1251,"Lidocaine","DB00281","Possible increase in lidocaine levels"
1251,"Lopinavir","DB01601","Decreased levels of darunavir"
1251,"Lovastatin","DB00227","Darunavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. \
"
1251,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1251,"Saquinavir","DB01232","Decreased levels of darunavir"
1251,"Tacrolimus","DB00864","The protease inhibitor, Darunavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Darunavir therapy is initiated, discontinued or altered."
1251,"Tadalafil","DB00820","Darunavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1251,"Tamoxifen","DB00675","Darunavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1251,"Tamsulosin","DB00706","Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Darunavir is initiated, discontinued, or dose changed."
1251,"Telithromycin","DB00976","Co-administration may result in altered plasma concentrations of Darunavir and/or Telithromycin. Consider alternate therapy or monitor the therapeutic/adverse effects of both agents."
1251,"Temsirolimus","DB06287","Darunavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1251,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Darunavir is initiated, discontinued or dose changed."
1251,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Darunavir is initiated, discontinued or dose changed."
1251,"Tolterodine","DB01036","Darunavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1251,"Topotecan","DB01030","The p-glycoprotein inhibitor, Darunavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1251,"Tramadol","DB00193","Darunavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1251,"Trazodone","DB00656","The protease inhibitor, Darunavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Darunavir is initiated, discontinued or dose changed. "
1251,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Darunavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Darunavir is initiated, discontinued or dose changed. "
1251,"Vardenafil","DB00862","Darunavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1251,"Venlafaxine","DB00285","Darunavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Darunavir is initiated, discontinued, or dose changed."
1251,"Verapamil","DB00661","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Darunavir is initiated, discontinued or dose changed. "
1251,"Vinblastine","DB00570","Darunavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Darunavir is initiated, discontinued or dose changed."
1251,"Vincristine","DB00541","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Darunavir is initiated, discontinued or dose changed."
1251,"Vinorelbine","DB00361","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Darunavir is initiated, discontinued or dose changed."
1251,"Voriconazole","DB00582","Darunavir may reduce serum concentrations and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy.  "
1251,"Zolpidem","DB00425","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if darunavir is initiated, discontinued or dose changed. "
1251,"Zonisamide","DB00909","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if darunavir is initiated, discontinued or dose changed."
1251,"Zopiclone","DB01198","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if darunavir is initiated, discontinued or dose changed."
1252,"Peginterferon alfa-2a","DB00008","Co-administration of Peginterferon alpha-2a and Telbivudine may increase the risk of serious peripheral neuropathy."
1254,"Amantadine","DB00915","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, amantadine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"Apomorphine","DB00714","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, apomorphine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"Bromocriptine","DB01200","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, bromocriptine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"L-DOPA","DB01235","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, levodopa. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"Methotrimeprazine","DB01403","The CNS depressant agents, paliperidone and methotrimeprazine, may cause additive CNS depressant effects. Monitor for increased CNS depressant effects during concomitant therapy. "
1254,"Metoclopramide","DB01233","Metoclopramide may increase the risk of extrapyramidal side effects of paliperidone. Concomitant therapy should be avoided. "
1254,"Pramipexole","DB00413","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, pramipexole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"Risperidone","DB00734","Paliperidone is the active metabolite of risperidone, 9-OH-risperidone. Concomitant therapy may increase the adverse effects of paliperidone due to additive paliperidone exposure. Consider alternate therapy. "
1254,"Ropinirole","DB00268","The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, ropinirole. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. "
1254,"Tacrine","DB00382","Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Paliperidone. Monitor for extrapyramidal symptoms."
1254,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
1254,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Paliperidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1255,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1255,"Atazanavir","DB01072","Possible increase in sunitinib levels"
1255,"Bevacizumab","DB00112","Sunitinib may enhance the adverse/toxic effect of bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of sunitinib. This combination is contraindicated."
1255,"Carbamazepine","DB00564","Possible decrease in sunitinib levels"
1255,"Clarithromycin","DB01211","Possible increase in sunitinib levels"
1255,"Dexamethasone","DB01234","Possible decrease in sunitinib levels"
1255,"Indinavir","DB00224","Possible increase in sunitinib levels"
1255,"Itraconazole","DB01167","Possible increase in sunitinib levels"
1255,"Ketoconazole","DB01026","Possible increase in sunitinib levels"
1255,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1255,"Nefazodone","DB01149","Possible increase in sunitinib levels"
1255,"Nelfinavir","DB00220","Possible increase in sunitinib levels"
1255,"Phenobarbital","DB01174","Possible decrease in sunitinib levels"
1255,"Phenytoin","DB00252","Possible decrease in sunitinib levels"
1255,"Rifabutin","DB00615","Possible decrease in sunitinib levels"
1255,"Rifampicin","DB01045","Possible decrease in sunitinib levels"
1255,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1255,"Telithromycin","DB00976","Telithromycin may reduce clearance of Sunitinib. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Sunitinib if Telithromycin is initiated, discontinued or dose changed."
1255,"Temsirolimus","DB06287","Co-administration of Temsirolimus and Sunitinib may result in serious adverse drug reactions. "
1255,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1255,"Topotecan","DB01030","The p-glycoprotein inhibitor, Sunitinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1255,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1255,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1255,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1255,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed."
1255,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1255,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1255,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1262,"Metoprolol","DB00264","Increased effect of both drugs"
1262,"Propranolol","DB00571","Increased effect of both drugs"
1262,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1263,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. "
1263,"Danazol","DB01406","Monitor therapy due to reduced hypoglycemic effect of exenatide."
1263,"Pegvisomant","DB00082","Monitor therapy due to enhanced hypoglycemic effect."
1263,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of exenatide. Monitor for changes in fasting and postprandial blood sugars."
1265,"Aclidinium","DB08897","May increase the risk of inhibition of GI motility via pharmacodynamic synergism. Consider alternate therapy. "
1265,"Alimemazine","DB01246","The anticholinergic effects of Trimeprazine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Carbinoxamine","DB00748","Pramlintide may enhance the anticholinergic effect of Anticholinergics such as carbinoxamine. These effects are specific to the gastrointestinal tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced gastrointestinal motility may occur."
1265,"Clidinium","DB00771","Pramlintide may enhance the anticholinergic effect of anticholinergics such as clidinium. These effects are specific to the GI tract. Use caution during concomitant therapy with pramlintide and anticholinergics. Additive effects on reduced GI motility may occur."
1265,"Doxylamine","DB00366","May cause additive slowing of GI motility."
1265,"Insulin Lispro","DB00046","Concomitant therapy with drugs that may increase the blood-glucose-lowering effect of insulin lispro and thus the chance of hypoglycemia should be monitored closely. "
1265,"Thiothixene","DB01623","The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Tiotropium","DB01409","The anticholinergic effects of Tiotropium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Tolterodine","DB01036","Additive reduction in gut motility may occur. Consider alternate therapy or use caution during concomitant therapy. "
1265,"Tranylcypromine","DB00752","The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Trihexyphenidyl","DB00376","The anticholinergic effects of Trihexyphenidyl may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Trimethobenzamide","DB00662","The anticholinergic effects of Trimethobenzamide may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Trimipramine","DB00726","The anticholinergic effects of Trimipramine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Triprolidine","DB00427","The anticholinergic effects of Triprolidine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Trospium","DB00209","The anticholinergic effects of Trospium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1265,"Zuclopenthixol","DB01624","May cause additive reduction in GI motility. Use caution or consider alternate therapy. "
1267,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events."
1268,"Anakinra","DB00026","Avoid combination due to enhanced adverse effects of abatacept"
1268,"Belimumab","DB08879","Avoid combination due to enhanced adverse effects of belimumab."
1268,"Certolizumab pegol","DB08904","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
1268,"Denosumab","DB06643","Monitor therapy due to enhanced effects of immunosuppressants and the risk of serious infections."
1268,"Etanercept","DB00005","Avoid combination because of increased adverse effects of Abatacept."
1268,"golimumab","DB06674","Avoid combination with abatacept due to the increased chance of serious infection.\
\
"
1268,"Infliximab","DB00065","The combination shoould be avoided as there have been reports of increased risk of serious infections. "
1268,"Leflunomide","DB01097","Therapy modification should be considered due to enhanced adverse effects of leflunomide, specifically hematologic toxicity."
1268,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab and the risk of infections."
1268,"Pimecrolimus","DB00337","Avoid combination due to enhanced adverse effects of immunosuppressive agents."
1268,"Rituximab","DB00073","Avoid combination due to enhanced adverse effects of abatacept."
1268,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive action."
1268,"Sipuleucel-T","DB06688","Monitor therapy due to reduced therapeutic effect of sipuleucel-t."
1268,"Tacrolimus","DB00864","Avoid combination due to enhanced toxic effects of immunosuppressants."
1268,"Thalidomide","DB01041","Thalidomide may increase the adverse effects of Abatacept. Increased risk of serious infection. Concomitant therapy should be avoided. "
1268,"Tocilizumab","DB06273","Avoid combination due to enhanced adverse effects of abatacept."
1268,"Tofacitinib","DB08895","Avoid combination due to the potential increase in tofacitinib related adverse effects."
1268,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1269,"Dinoprostone","DB00917","Dinoprostone may enhance the therapeutic effect of carbetocin. Avoid concomitant use of carbetocin with dinoprostone. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use. "
1269,"Misoprostol","DB00929","Misoprostol may enhance the therapeutic effect of Carbetocin. Avoid the concomitant use of carbetocin and misoprostol. The oxytocic activity of carbetocin (oxytocin analogue) may be augmented by agents used to promote cervical ripening (eg, dinoprostone, misoprostol). Dinoprostone (vaginal insert) prescribing information recommends waiting at least 30 minute following its removal before initiating treatment with oxytocic agents. A similar approach might be anticipated with misoprostol use. "
1270,"Acenocoumarol","DB01418","Lumiracoxib may increase the anticoagulant effect of acenocoumarol."
1270,"Anisindione","DB01125","Lumiracoxib may increase the anticoagulant effect of anisindione."
1270,"Dicoumarol","DB00266","Lumiracoxib may increase the anticoagulant effect of dicumarol."
1270,"Lithium","DB01356","The COX-2 inhibitor increases serum levels of lithium"
1270,"Telmisartan","DB00966","Concomitant use of Telmisartan and Lumiracoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
1270,"Timolol","DB00373","The NSAID, Lumiracoxib, may antagonize the antihypertensive effect of Timolol."
1270,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Lumiracoxib. Consider alternate therapy or monitor for changes in Lumiracoxib therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1270,"Trandolapril","DB00519","The NSAID, Lumiracoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Lumiracoxib is initiated, discontinued or dose changed. "
1270,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Lumiracoxib. Monitor for increased bleeding during concomitant thearpy. "
1270,"Warfarin","DB00682","Lumiracoxib may increase the anticoagulant effect of warfarin."
1272,"Aldesleukin","DB00041","Corticosteroids may diminish the antineoplastic effect of Aldesleukin. Avoid conccurent use of corticosteroids with aldesleukin. "
1272,"Aprepitant","DB00673","Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen."
1272,"Fosaprepitant","DB06717","Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant. "
1272,"Leflunomide","DB01097","Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity. Also, patients receiving both leflunomide and another immunosuppressive medication should be monitored for bone marrow suppression at least monthly throughout the duration of concurrent therapy. "
1272,"Pyridostigmine","DB00545","The corticosteroid, corticotropin, may decrease the effect of the anticholinesterase, pyridostigmine."
1272,"Tacrine","DB00382","Tacrine and Corticotropin may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
1272,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1272,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1273,"Acebutolol","DB01193","Antagonism"
1273,"Alseroxylon","DB00386","Increased arterial pressure"
1273,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, may increase the sympathomimetic effect of fenoterol."
1273,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of fenoterol."
1273,"Atenolol","DB00335","Antagonism"
1273,"Betaxolol","DB00195","Beta-Blockers (Beta-1 Selective) like betaxolol may diminish the bronchodilatory effect of Beta2-Agonists like fenoterol.  Therapy should be monitored."
1273,"Bevantolol","DB01295","Antagonism"
1273,"Bisoprolol","DB00612","Antagonism"
1273,"Carteolol","DB00521","Antagonism"
1273,"Carvedilol","DB01136","Antagonism"
1273,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of fenoterol."
1273,"Deserpidine","DB01089","Increased arterial pressure"
1273,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of fenoterol."
1273,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of fenoterol."
1273,"Esmolol","DB00187","Antagonism"
1273,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of fenoterol."
1273,"Isocarboxazid","DB01247","Increased arterial pressure"
1273,"Labetalol","DB00598","Antagonism"
1273,"Linezolid","DB00601","Possible increase of arterial pressure"
1273,"Methyldopa","DB00968","Increased arterial pressure"
1273,"Metoprolol","DB00264","Antagonism"
1273,"Midodrine","DB00211","Increased arterial pressure"
1273,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of fenoterol."
1273,"Nadolol","DB01203","Antagonism"
1273,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of fenoterol."
1273,"Oxprenolol","DB01580","Antagonism"
1273,"Pargyline","DB01626","Increased arterial pressure"
1273,"Penbutolol","DB01359","Antagonism"
1273,"Phenelzine","DB00780","Increased arterial pressure"
1273,"Pindolol","DB00960","Antagonism"
1273,"Practolol","DB01297","Antagonism"
1273,"Propranolol","DB00571","Antagonism"
1273,"Protriptyline","DB00344","The tricyclic antidepressant, protriptyline, increases the sympathomimetic effect of fenoterol."
1273,"Rasagiline","DB01367","Increased arterial pressure"
1273,"Reserpine","DB00206","Increased arterial pressure"
1273,"Sotalol","DB00489","Antagonism"
1273,"Timolol","DB00373","Antagonism"
1273,"Tranylcypromine","DB00752","Increased arterial pressure"
1273,"Trimipramine","DB00726","The tricyclic antidepressant, trimipramine, increases the sympathomimetic effect of fenoterol."
1274,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1274,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide."
1274,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1274,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1274,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1274,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, glisoxepide."
1274,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, glisoxepide."
1274,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1274,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1274,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1274,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1274,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1274,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1274,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1274,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1274,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, glisoxepide."
1274,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1275,"Acebutolol","DB01193","Antagonism"
1275,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of pirbuterol."
1275,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of pirbuterol."
1275,"Atenolol","DB00335","Antagonism"
1275,"Bisoprolol","DB00612","Antagonism"
1275,"Carvedilol","DB01136","Antagonism"
1275,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of pirbuterol."
1275,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of pirbuterol."
1275,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of pirbuterol."
1275,"Esmolol","DB00187","Antagonism"
1275,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of pirbuterol."
1275,"Isocarboxazid","DB01247","Increased arterial pressure"
1275,"Labetalol","DB00598","Antagonism"
1275,"Linezolid","DB00601","Possible increase of arterial pressure"
1275,"Methyldopa","DB00968","Increased arterial pressure"
1275,"Metoprolol","DB00264","Antagonism"
1275,"Midodrine","DB00211","Increased arterial pressure"
1275,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of pirbuterol."
1275,"Nadolol","DB01203","Antagonism"
1275,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of pirbuterol."
1275,"Oxprenolol","DB01580","Antagonism"
1275,"Phenelzine","DB00780","Increased arterial pressure"
1275,"Pindolol","DB00960","Antagonism"
1275,"Propranolol","DB00571","Antagonism"
1275,"Rasagiline","DB01367","Increased arterial pressure"
1275,"Reserpine","DB00206","Increased arterial pressure"
1275,"Timolol","DB00373","Antagonism"
1276,"Acetazolamide","DB00819","The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide."
1276,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1276,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1276,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the salicylate, bismuth subsalicylate."
1276,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate."
1276,"Gliclazide","DB01120","The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, gliclazide."
1276,"Glyburide","DB01016","The salicylate, bismuth subsalicylate, increases the effect of the sulfonylurea, glibenclamide."
1276,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, bismuth subsalicylate."
1276,"Methazolamide","DB00703","The salicylate, bismuth subsalicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
1276,"Methotrexate","DB00563","The salicylate, bismuth subsalicylate, increases the effect and toxicity of methotrexate."
1276,"Minocycline","DB01017","Formation of non-absorbable complexes"
1276,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the salicylate, bismuth subsalicylate."
1276,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate."
1276,"Probenecid","DB01032","The salicylate, bismuth subsalicylate, decreases the uricosuric effect of probenecid."
1276,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1276,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, bismuth subsalicylate."
1277,"Chlorpropamide","DB00672","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1277,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1277,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1277,"Disopyramide","DB00280","The beta-blocker, bevantolol, may increase the toxicity of disopyramide."
1277,"Epinephrine","DB00668","Hypertension, then bradycardia"
1277,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1277,"Fenoterol","DB01288","Antagonism"
1277,"Formoterol","DB00983","Antagonism"
1277,"Gliclazide","DB01120","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1277,"Glyburide","DB01016","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1277,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1277,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1277,"Insulin Glargine","DB00047","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1277,"Methysergide","DB00247","Ischemia with risk of gangrene"
1277,"Orciprenaline","DB00816","Antagonism"
1277,"Pipobroman","DB00236","Antagonism"
1277,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1277,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1277,"Repaglinide","DB00912","The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia."
1277,"Terbutaline","DB00871","Antagonism"
1278,"Chlorpropamide","DB00672","Possible hyperglycemia"
1278,"Eptifibatide","DB00063","Monitor therapy due to enhanced antiplatelet effect."
1278,"Gliclazide","DB01120","Possible hyperglycemia"
1278,"Glimepiride","DB00222","Possible hyperglycemia"
1278,"Glyburide","DB01016","Possible hyperglycemia"
1278,"Metformin","DB00331","Possible hyperglycemia"
1278,"Miglitol","DB00491","Possible hyperglycemia"
1278,"Nateglinide","DB00731","Possible hyperglycemia"
1278,"Pioglitazone","DB01132","Possibly hyperglycemia"
1278,"Repaglinide","DB00912","Possible hyperglycemia"
1278,"Warfarin","DB00682","Possible interaction and enhanced antiplatelet activity of warfarin"
1279,"Acetohexamide","DB00414","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Chlorpropamide","DB00672","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1279,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1279,"Disopyramide","DB00280","The beta-blocker, practolol, may increase the toxicity of disopyramide."
1279,"Epinephrine","DB00668","Hypertension, then bradycardia"
1279,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1279,"Fenoterol","DB01288","Antagonism"
1279,"Formoterol","DB00983","Antagonism"
1279,"Gliclazide","DB01120","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Glyburide","DB01016","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1279,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1279,"Insulin Glargine","DB00047","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Methysergide","DB00247","Ischemia with risk of gangrene"
1279,"Orciprenaline","DB00816","Antagonism"
1279,"Oxprenolol","DB01580","Antagonism"
1279,"Pipobroman","DB00236","Antagonism"
1279,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1279,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1279,"Repaglinide","DB00912","The beta-blocker, practolol, may decrease symptoms of hypoglycemia."
1279,"Terbutaline","DB00871","Antagonism"
1280,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
1280,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
1281,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
1281,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
1282,"Acitretin","DB00459","Increased risk of intracranial hypertension"
1282,"Amoxicillin","DB01060","Possible antagonism of action"
1282,"Ampicillin","DB00415","Possible antagonism of action"
1282,"Benzylpenicillin","DB01053","Possible antagonism of action"
1282,"Carbenicillin","DB00578","Possible antagonism of action"
1282,"Clavulanate","DB00766","Possible antagonism of action"
1282,"Cloxacillin","DB01147","Possible antagonism of action"
1282,"Dicloxacillin","DB00485","Possible antagonism of action"
1282,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1282,"Etretinate","DB00926","Increased risk of intracranial hypertension"
1282,"Flucloxacillin","DB00301","Possible antagonism of action"
1282,"Isotretinoin","DB00982","Increased risk of intracranial hypertension"
1282,"Penicillin V","DB00417","Possible antagonism of action"
1282,"Piperacillin","DB00319","Possible antagonism of action"
1282,"Pivampicillin","DB01604","Possible antagonism of action"
1282,"Pivmecillinam","DB01605","Possible antagonism of action"
1283,"Aciclovir","DB00787","Aciclovir may increase the effect and toxicity of oxtriphylline."
1283,"Adenosine","DB00640","This xanthine decreases the effect of adenosine"
1283,"Amobarbital","DB01351","The barbiturate, amobarbital, decreases the effect of oxtriphylline."
1283,"Aprobarbital","DB01352","The barbiturate, aprobarbital, decreases the effect of oxtriphylline."
1283,"Atracurium","DB00732","Theophylline decreases the effect of muscle relaxant"
1283,"Butabarbital","DB00237","The barbiturate, butabarbital, decreases the effect of oxtriphylline."
1283,"Butalbital","DB00241","The barbiturate, butalbital, decreases the effect of oxtriphylline."
1283,"Butethal","DB01353","The barbiturate, butethal, decreases the effect of oxtriphylline."
1283,"Carbamazepine","DB00564","Carbamazepine may decrease the serum concentration of oxtriphylline. Oxtriphylline may decrease the serum concentration of carbamazepine. Monitor for changes in the therapeutic effect of both agents if concomitant therapy is initiated, discontinued or dose changed."
1283,"Carteolol","DB00521","Antagonism of action and increased effect of theophylline"
1283,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of oxtriphylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of oxtriphylline if cimetidine is initiated, discontinued or dose changed."
1283,"Ciprofloxacin","DB00537","Ciprofloxacin may increase the effect of oxtriphylline."
1283,"Clarithromycin","DB01211","Clarithromycin may increase the effect and toxicity of oxtriphylline."
1283,"Dihydroquinidine barbiturate","DB01341","The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline."
1283,"Disulfiram","DB00822","Disulfiram may increase the effect and toxicity of oxtriphylline."
1283,"Doxacurium chloride","DB01135","Theophylline decreases the effect of muscle relaxant"
1283,"Enoxacin","DB00467","Enoxacin may increase the effect of oxtriphylline."
1283,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
1283,"Ethinyl Estradiol","DB00977","The contraceptive increases the effect and toxicity of theophylline"
1283,"Ethotoin","DB00754","Decreased effect of both products"
1283,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic and adverse effects of oxtriphylline."
1283,"Fosphenytoin","DB01320","Decreased effect of both products"
1283,"Grepafloxacin","DB00365","Grepafloxacin may increase the effect of oxtriphylline."
1283,"Halothane","DB01159","Increased risk of cardiac arrhythmia"
1283,"Heptabarbital","DB01354","The barbiturate, heptabarbital, decreases the effect of oxtriphylline."
1283,"Hexobarbital","DB01355","The barbiturate, hexobarbital, decreases the effect of oxtriphylline."
1283,"Interferon Alfa-2a, Recombinant","DB00034","Interferon increases the effect and toxicity of theophylline"
1283,"Interferon Alfa-2b, Recombinant","DB00105","Interferon increases the effect and toxicity of theophylline"
1283,"Interferon alfa-n1","DB00011","Interferon increases the effect and toxicity of theophylline"
1283,"Isoniazid","DB00951","Isoniazid may increase the effect and toxicity of oxtriphylline."
1283,"Josamycin","DB01321","The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
1283,"Lithium","DB01356","Theophylline decreases serum levels of lithium"
1283,"Mephenytoin","DB00532","Decreased effect of both products"
1283,"Mestranol","DB01357","The contraceptive increases the effect and toxicity of theophylline"
1283,"Methohexital","DB00474","The barbiturate, methohexital, decreases the effect of oxtriphylline."
1283,"Methylphenobarbital","DB00849","The barbiturate, methylphenobarbital, decreases the effect of oxtriphylline."
1283,"Metocurine","DB01336","Theophylline decreases the effect of muscle relaxant"
1283,"Mexiletine","DB00379","Mexiletine increases the effect and toxicity of theophylline"
1283,"Mivacurium","DB01226","Theophylline decreases the effect of muscle relaxant"
1283,"Nadolol","DB01203","Antagonism of action and increased effect of theophylline"
1283,"Norfloxacin","DB01059","Norfloxacin may increase the effect of oxtriphylline."
1283,"Pancuronium","DB01337","Theophylline decreases the effect of muscle relaxant"
1283,"Pefloxacin","DB00487","Pefloxacin may increase the effect of oxtriphylline."
1283,"Peginterferon alfa-2a","DB00008","Interferon increases the effect and toxicity of theophylline"
1283,"Peginterferon alfa-2b","DB00022","Interferon increases the effect and toxicity of theophylline"
1283,"Penbutolol","DB01359","Antagonism of action and increased effect of theophylline"
1283,"Pentobarbital","DB00312","The barbiturate, pentobarbital, decreases the effect of oxtriphylline."
1283,"Pentoxifylline","DB00806","Pentoxifylline increases the effect and toxicity of theophylline"
1283,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the effect of oxtriphylline."
1283,"Phenytoin","DB00252","Decreased effect of both products"
1283,"Pindolol","DB00960","Antagonism of action and increased effect of theophylline"
1283,"Primidone","DB00794","The barbiturate, primidone, decreases the effect of oxtriphylline."
1283,"Propafenone","DB01182","Propafenone increases the effect of theophylline"
1283,"Propranolol","DB00571","Antagonism of action and increased effect of theophylline"
1283,"Quinidine barbiturate","DB01346","The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline."
1283,"Rifampicin","DB01045","Rifampin may decrease the effect and toxicity of oxtriphylline."
1283,"Ritonavir","DB00503","Ritonavir decreases the effect of theophylline"
1283,"Rofecoxib","DB00533","Rofecoxib increases the effect and toxicity of theophylline"
1283,"Secobarbital","DB00418","The barbiturate, secobarbital, decreases the effect of oxtriphylline."
1283,"Sotalol","DB00489","Antagonism of action and increased effect of theophylline"
1283,"St. John's Wort","DB01323","St. John's Wort decreases the effect of theophylline"
1283,"Tacrine","DB00382","Tacrine increases the effect and toxicity of theophylline"
1283,"Talbutal","DB00306","The barbiturate, talbutal, decreases the effect of oxtriphylline."
1283,"Terbinafine","DB00857","Terbinafine increases the effect and toxicity of theophylline"
1283,"Thiabendazole","DB00730","Thiabendazole increases the effect and toxicity of theophylline"
1283,"Ticlopidine","DB00208","Ticlopidine increases the effect and toxicity of theophylline"
1283,"Timolol","DB00373","Antagonism of action and increased effect of theophylline"
1283,"Troleandomycin","DB01361","The macrolide, troleandomycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
1283,"Tubocurarine","DB01199","Theophylline decreases the effect of muscle relaxant"
1283,"Vecuronium","DB01339","Theophylline decreases the effect of muscle relaxant"
1283,"Verapamil","DB00661","Verapamil increases the effect of theophylline"
1283,"Zileuton","DB00744","Zileuton increases the effect and toxicity of theophylline"
1284,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1284,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1284,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1284,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1284,"Clofibrate","DB00636","Increases the effect of insulin"
1284,"Danazol","DB01406","Monitor therapy due to decreased hypoglycemic effect of insulin aspart."
1284,"Dexfenfluramine","DB01191","Fenfluramine increases the effect of insulin"
1284,"Edetic Acid","DB00974","Monitor therapy due to enhanced hypoglycemic effect."
1284,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1284,"Fenfluramine","DB00574","Fenfluramine increases the effect of insulin"
1284,"Pegvisomant","DB00082","Monitor therapy due to enhanced hypoglycemic effect."
1284,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of insulin aspart. Monitor for changes in fasting and postprandial blood sugars."
1285,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1285,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1285,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1285,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1285,"Clofibrate","DB00636","Increases the effect of insulin"
1285,"Dexfenfluramine","DB01191","Fenfluramine increases the effect of insulin"
1285,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1285,"Fenfluramine","DB00574","Fenfluramine increases the effect of insulin"
1285,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of insulin detemir. Monitor for changes in fasting and postprandial blood sugars."
1286,"Acebutolol","DB01193","The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia."
1286,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1286,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1286,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1286,"Clofibrate","DB00636","Increases the effect of insulin"
1286,"Dexfenfluramine","DB01191","Fenfluramine increases the effect of insulin"
1286,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1286,"Fenfluramine","DB00574","Fenfluramine increases the effect of insulin"
1286,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars."
1287,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Fosamprenavir. The antiviral response should be closely monitored."
1287,"Acenocoumarol","DB01418","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of acenocoumarol."
1287,"Alprazolam","DB00404","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, alprazolam."
1287,"Aluminium","DB01370","The antiacid decreases the absorption of amprenavir"
1287,"Amiodarone","DB01118","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone."
1287,"Anisindione","DB01125","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of anisindione."
1287,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1287,"Atorvastatin","DB01076","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if fosamprenavir is initiated, discontinued or dose changed."
1287,"Bepridil","DB01244","Amprenavir increases the effect and toxicity of bepridil"
1287,"Bromazepam","DB01558","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1287,"Calcium","DB01373","The antiacid decreases the absorption of amprenavir"
1287,"Cisapride","DB00604","Amprenavir increases the effect and toxicity of cisapride"
1287,"Clorazepate","DB00628","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, clorazepate."
1287,"Cyclosporine","DB00091","The protease inhibitor, fosamprenavir, may increase the effect of cyclosporine."
1287,"Dantrolene","DB01219","Fosamprenavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if fosamprenavir is initiated, discontinued or dose changed. "
1287,"Delavirdine","DB00705","Decreased levels of delavirdine with increased levels of amprenavir"
1287,"Diazepam","DB00829","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, diazepam."
1287,"Dicoumarol","DB00266","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of dicumarol."
1287,"Dihydroergotamine","DB00320","Amprenavir increases the effect and toxicity of ergot derivative"
1287,"Ergotamine","DB00696","Amprenavir increases the effect and toxicity of ergot derivative"
1287,"Etravirine","DB06414","Fosamprenavir, when administered concomitantly with etravirine, may experience an increase in the serum concentration of its active metabolits. It is recommended to avoid this combination. "
1287,"Fentanyl","DB00813","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fentanyl."
1287,"Flurazepam","DB00690","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, flurazepam."
1287,"Fusidic Acid","DB02703","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid."
1287,"Lovastatin","DB00227","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Concomitant therapy is contraindicated."
1287,"Lurasidone","DB08815","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
1287,"Magnesium","DB01378","The antiacid decreases the absorption of amprenavir"
1287,"Magnesium oxide","DB01377","The antiacid decreases the absorption of amprenavir"
1287,"Methadone","DB00333","The protease inhibitor, fosamprenavir, may decrease the effect of methadone."
1287,"Midazolam","DB00683","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, midazolam."
1287,"Pimozide","DB01100","Amprenavir increases the effect and toxicity of pimozide"
1287,"Ranolazine","DB00243","Increased levels of ranolazine - risk of toxicity"
1287,"Rifabutin","DB00615","Amprenavir increases the effect and toxicity of rifabutin"
1287,"Rifampicin","DB01045","Rifampin may decrease the effectiveness of fosamprenavir."
1287,"Sildenafil","DB00203","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of sildenafil."
1287,"Simvastatin","DB00641","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if fosamprenavir is initiated, discontinued or dose changed."
1287,"St. John's Wort","DB01323","St. John's Wort decreases the effect of indinavir"
1287,"Tacrolimus","DB00864","The protease inhibitor, Fosamprenavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Fosamprenavir therapy is initiated, discontinued or altered."
1287,"Tadalafil","DB00820","Fosamprenavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1287,"Tamoxifen","DB00675","Fosmprenavir may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. "
1287,"Tamsulosin","DB00706","Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Fosamprenavir is initiated, discontinued, or dose changed."
1287,"Telithromycin","DB00976","Fosamprevavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1287,"Temsirolimus","DB06287","Fosamprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1287,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Fosamprenavir is initiated, discontinued or dose changed."
1287,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1287,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Fosamprenavir is initiated, discontinued or dose changed."
1287,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Fosamprenavir. Consider alternate therapy. "
1287,"Tolterodine","DB01036","Fosamprenavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1287,"Tramadol","DB00193","Fosamprenavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. "
1287,"Trazodone","DB00656","The protease inhibitor, Fosamprenavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosamprenavir is initiated, discontinued or dose changed. "
1287,"Triazolam","DB00897","Fosamprenavir may increase the effect and toxicity of the benzodiazepine, triazolam."
1287,"Trimipramine","DB00726","The strong CYP3A4 inhibitor, Fosamprenavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Fosamprenavir is initiated, discontinued or dose changed. "
1287,"Vardenafil","DB00862","Fosamprenavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1287,"Venlafaxine","DB00285","Fosamprenavir, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Fosamprenavir is initiated, discontinued, or dose changed."
1287,"Verapamil","DB00661","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Fosamprenavir is initiated, discontinued or dose changed. "
1287,"Vinblastine","DB00570","Fosamprenavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Fosamprenavir is initiated, discontinued or dose changed."
1287,"Vincristine","DB00541","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Fosamprenavir is initiated, discontinued or dose changed."
1287,"Vinorelbine","DB00361","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Fosamprenavir is initiated, discontinued or dose changed."
1287,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of fosamprenavir by decreasing its metabolism. Fosamprenavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. "
1287,"Warfarin","DB00682","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of warfarin."
1287,"Zolpidem","DB00425","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if fosamprenavir is initiated, discontinued or dose changed. "
1287,"Zonisamide","DB00909","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if fosamprenavir is initiated, discontinued or dose changed."
1287,"Zopiclone","DB01198","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if fosamprenavir is initiated, discontinued or dose changed."
1288,"Acenocoumarol","DB01418","Increased hydantoin levels and risk of bleeding"
1288,"Alprazolam","DB00404","Fosphenytoin may increase the metabolism of alprazolam via CYP3A4."
1288,"Aminophylline","DB01223","Decreased effect of both products"
1288,"Amiodarone","DB01118","Amiodarone may increase the effect of fosphenytoin."
1288,"Anisindione","DB01125","Increased hydantoin levels and risk of bleeding"
1288,"Aprepitant","DB00673","The CYP3A4 inducer, fosphenytoin, may decrease the effect of aprepitant."
1288,"Atracurium","DB00732","Phenytoin decreases the effect of muscle relaxant"
1288,"Betamethasone","DB00443","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, betamethasone."
1288,"Bleomycin","DB00290","The antineoplasic agent decreases the effect of hydantoin"
1288,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
1288,"Capecitabine","DB01101","Capecitabine increases the effect of hydantoin"
1288,"Carboplatin","DB00958","The antineoplasic agent decreases the effect of hydantoin"
1288,"Carmustine","DB00262","The antineoplasic agent decreases the effect of hydantoin"
1288,"Chloramphenicol","DB00446","Increases phenytoin, modifies chloramphenicol"
1288,"Chlordiazepoxide","DB00475","Fosphenytoin may increase the metabolism of chlordiazepoxide via CYP3A4."
1288,"Chlorotrianisene","DB00269","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, chlorotrianisene."
1288,"Chlorphenamine","DB01114","The antihistamine increases the effect of hydantoin"
1288,"Cimetidine","DB00501","Cimetidine may increase the serum concentration of fosphenytoin by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of fosphenytoin if cimetidine is initiated, discontinued or dose changed."
1288,"Cisplatin","DB00515","The antineoplasic agent decreases the effect of hydantoin"
1288,"Clarithromycin","DB01211","Clarithromycin may increase the therapeutic and adverse effects of fosphenytoin."
1288,"Clomifene","DB00882","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, clomifene."
1288,"Clorazepate","DB00628","Fosphenytoin may increase the metabolism of clorazepate via CYP3A4."
1288,"Clozapine","DB00363","Hydantoin decreases the effect of clozapine"
1288,"Conjugated Estrogens","DB00286","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, conjugated estrogens."
1288,"Cortisone acetate","DB01380","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, cortisone acetate."
1288,"Cyclosporine","DB00091","The hydantoin decreases the effect of cyclosporine"
1288,"Delavirdine","DB00705","The anticonvulsant, fosphenytoin, decreases the effect of delavirdine."
1288,"Dexamethasone","DB01234","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, dexamethasone."
1288,"Diazepam","DB00829","Fosphenytoin may increase the metabolism of diazepam via CYP3A4."
1288,"Diazoxide","DB01119","Diazoxide decreases the hydantoin effect"
1288,"Dicoumarol","DB00266","Increased hydantoin levels and risk of bleeding"
1288,"Diethylstilbestrol","DB00255","The enzyme inducer, fosphenytoin, may decrease the therapeutic effect of diethylstilbestrol."
1288,"Disopyramide","DB00280","The hydantoin decreases the effect of disopyramide"
1288,"Disulfiram","DB00822","Disulfiram may increase the effect of fosphenytoin."
1288,"Dopamine","DB00988","Risk of severe hypotension"
1288,"Doxacurium chloride","DB01135","Phenytoin decreases the effect of muscle relaxant"
1288,"Doxycycline","DB00254","The anticonvulsant, fosphenytoin, decreases the effect of doxycycline."
1288,"Dyphylline","DB00651","Decreased effect of both products"
1288,"Estradiol","DB00783","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estradiol."
1288,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
1288,"Estriol","DB04573","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estriol."
1288,"Estrone","DB00655","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone."
1288,"Estropipate","DB04574","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estropipate."
1288,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1288,"Etravirine","DB06414","Etravirine, when administered concomitantly with fosphenytoin, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
1288,"Felbamate","DB00949","Increased phenytoin levels and decreased felbamate levels"
1288,"Felodipine","DB01023","The hydantoin decreases the effect of felodipine"
1288,"Fluconazole","DB00196","Fluconazole may increase the effect of hydantoin."
1288,"Fludrocortisone","DB00687","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, fludrocortisone."
1288,"Fluorouracil","DB00544","Fluorouracil increases the effect of hydantoin"
1288,"Fluoxetine","DB00472","Fluoxetine increases the effect of phenytoin"
1288,"Flurazepam","DB00690","Fosphenytoin may increase the metabolism of flurazepam via CYP3A4."
1288,"Fluvoxamine","DB00176","Fluvoxamine may increase the therapeutic and adverse effects of fosphenytoin."
1288,"Folic Acid","DB00158","Folic acid decreases the levels of hydantoin"
1288,"Furosemide","DB00695","The hydantoin decreases the effect of furosemide"
1288,"Gabapentin","DB00996","Gabapentin may increase the effect of fosphenytoin."
1288,"Gefitinib","DB00317","The CYP3A4 inducer, fosphenytoin, may decrease the serum concentration and therapeutic effects of gefitinib."
1288,"Hydrocortisone","DB00741","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone."
1288,"Imatinib","DB00619","The hydantoin decreases the levels of imatinib"
1288,"Irinotecan","DB00762","The hydantoin decreases the effect of irinotecan"
1288,"Isoniazid","DB00951","Isoniazid may increase the effect of phenytoin in 20% of patients."
1288,"Itraconazole","DB01167","Phenytoin decreases the effect of itraconazole"
1288,"L-DOPA","DB01235","The hydantoin decreases the effect of levodopa"
1288,"Lamotrigine","DB00555","Phenytoin may reduce levels of lamotrigine"
1288,"Levonorgestrel","DB00367","Phenytoin decreases the contraceptive effect"
1288,"Lopinavir","DB01601","Levels of both drugs are affected"
1288,"Lurasidone","DB08815","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
1288,"Mebendazole","DB00643","The hydantoin decreases the efficiency of mebendazole"
1288,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, medroxyprogesterone."
1288,"Megestrol acetate","DB00351","The enzyme inducer, fosphenytoin, may decrease the effect of the hormone, megestrol."
1288,"Mestranol","DB01357","This product may cause a slight decrease of contraceptive effect"
1288,"Methadone","DB00333","The hydantoin decreases the effect of methadone"
1288,"Methotrexate","DB00563","The antineoplasic agent decreases the effect of hydantoin"
1288,"Methoxsalen","DB00553","The hydantoin decreases the effect of psoralene"
1288,"Methylprednisolone","DB00959","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, methylprednisolone."
1288,"Metocurine","DB01336","Phenytoin decreases the effect of muscle relaxant"
1288,"Metyrapone","DB01011","The combination renders the test invalid"
1288,"Mexiletine","DB00379","The hydantoin decreases the effect of mexiletine"
1288,"Midazolam","DB00683","Fosphenytoin may increase the metabolism of midazolam via CYP3A4."
1288,"Mirtazapine","DB00370","The hydantoins may reduce mirtazapine plasma concentrations and pharmacological effects"
1288,"Mivacurium","DB01226","Phenytoin decreases the effect of muscle relaxant"
1288,"Nisoldipine","DB00401","Phenytoin decreases the efficiency of nisoldipine"
1288,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1288,"Omeprazole","DB00338","Omeprazole increases the effect of hydantoin"
1288,"Oxcarbazepine","DB00776","Oxcarbazepine increases the effect of hydantoin"
1288,"Oxtriphylline","DB01303","Decreased effect of both products"
1288,"Oxyphenbutazone","DB03585","The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin."
1288,"Pancuronium","DB01337","Phenytoin decreases the effect of muscle relaxant"
1288,"Paramethasone","DB01384","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, paramethasone."
1288,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the hydantoin effect of fosphenytoin."
1288,"Posaconazole","DB01263","Modifications of drug levels for both agents"
1288,"Prednisolone","DB00860","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisolone."
1288,"Prednisone","DB00635","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone."
1288,"Quetiapine","DB01224","Phenytoin decreases the effect of quetiapine"
1288,"Quinestrol","DB04575","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, quinestrol."
1288,"Quinidine","DB00908","The anticonvulsant, fosphenytoin, decreases the effect of quinidine."
1288,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1288,"Rifampicin","DB01045","Rifampin may decrease the effect of fosphenytoin."
1288,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1288,"Sertraline","DB01104","Sertraline increases the effect of hydantoin"
1288,"Sirolimus","DB00877","The hydantoin decreases sirolimus levels"
1288,"Sucralfate","DB00364","Sucralfate decreases the effect of hydantoin"
1288,"Sulfadiazine","DB00359","The sulfonamide increases the effect of hydantoin"
1288,"Sulfamethizole","DB00576","The sulfonamide increases the effect of hydantoin"
1288,"Tacrolimus","DB00864","The hydantoin decreases the effect of tacrolimus"
1288,"Telithromycin","DB00976","Fosphenytoin may decrease the plasma concentration of Telithromycin. Consider alternate therapy."
1288,"Temsirolimus","DB06287","Fosphenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1288,"Theophylline","DB00277","Decreased effect of both products"
1288,"Thiotepa","DB04572","Possible increase in thiotepa levels"
1288,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for adverse/toxic effects of Fosphenytoin if Ticlopidine is initiated, discontinued or dose changed."
1288,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Fosphenytoin. Consider alternate therapy or monitor for changes in Fosphenytoin therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1288,"Topiramate","DB00273","Increased phenytoin/decreased topiramate"
1288,"Tramadol","DB00193","Fosphenytoin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. "
1288,"Trazodone","DB00656","The CYP3A4 inducer, Fosphenytoin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Fosphenytoin is initiated, discontinued or dose changed."
1288,"Tretinoin","DB00755","The strong CYP2C8 inducer, Fosphenytoin, may increase the metabolism and clearance of oral Tretinoin. Consider alternate therapy to avoid failure of Tretinoin therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Fosphenytoin is initiated, discontinued or dose changed. "
1288,"Triamcinolone","DB00620","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, triamcinolone."
1288,"Triazolam","DB00897","Fosphenytoin may increase the metabolism of triazolam via CYP3A4."
1288,"Trimethoprim","DB00440","Trimethoprim increases the effect of hydantoin"
1288,"Trioxsalen","DB04571","The hydantoin decreases the effect of psoralene"
1288,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Fosphenytoin, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1288,"Tubocurarine","DB01199","Phenytoin decreases the effect of muscle relaxant"
1288,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1288,"Vecuronium","DB01339","Phenytoin decreases the effect of muscle relaxant"
1288,"Vigabatrin","DB01080","Vigabatrin decreases the effect of hydantoin"
1288,"Vinblastine","DB00570","The antineoplasic agent decreases the effect of hydantoin"
1288,"Voriconazole","DB00582","The hydantoin decreases the effect of voriconazole"
1288,"Warfarin","DB00682","Increased hydantoin levels and risk of bleeding"
1289,"Alprazolam","DB00404","The macrolide, josamycin, may increase the effect of the benzodiazepine, alprazolam."
1289,"Aminophylline","DB01223","The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, aminophylline."
1289,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1289,"Atorvastatin","DB01076","The macrolide, josamycin, may increase the toxicity of the statin, atorvastatin."
1289,"Bromocriptine","DB01200","Erythromycin increases serum levels of bromocriptine"
1289,"Buspirone","DB00490","The macrolide, josamycin, may increase the effect and toxicity of buspirone."
1289,"Carbamazepine","DB00564","The macrolide, josamycin, may increase the effect of carbamazepine."
1289,"Cerivastatin","DB00439","The macrolide, josamycin, may increase the toxicity of the statin, cerivastatin."
1289,"Cilostazol","DB01166","Erythromycin increases the effect of cilostazol"
1289,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1289,"Citalopram","DB00215","Possible serotoninergic sydrome with this combination"
1289,"Clozapine","DB00363","Erythromycin increases the effect of clozapine"
1289,"Cyclosporine","DB00091","The macrolide, josamycin, may increase the effect of cyclosporine."
1289,"Diazepam","DB00829","The macrolide, josamycin, may increase the effect of the benzodiazepine, diazepam."
1289,"Digoxin","DB00390","The macrolide, josamycin, may increase the effect of digoxin in 10% of patients."
1289,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
1289,"Docetaxel","DB01248","Josamycin may increase the serum levels and toxicity of docetaxel."
1289,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
1289,"Felodipine","DB01023","Erythromycin increases the effect of felodipine"
1289,"Fluoxetine","DB00472","Possible serotoninergic syndrome with this combination"
1289,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1289,"Imatinib","DB00619","The macrolide, josamycin, may increase the serum concentration of imatinib."
1289,"Itraconazole","DB01167","The macrolide, josamycin, may increase the effect and toxicity of itraconazole."
1289,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1289,"Lovastatin","DB00227","The macrolide, josamycin, may increase the toxicity of the statin, lovastatin."
1289,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1289,"Methysergide","DB00247","Possible ergotism and severe ischemia with this combination"
1289,"Midazolam","DB00683","The macrolide, josamycin, may increase the effect of the benzodiazepine, midazolam."
1289,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1289,"Oxtriphylline","DB01303","The macrolide, josamycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
1289,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
1289,"Repaglinide","DB00912","The macrolide, josamycin, may increase the effect of repaglinide."
1289,"Rifabutin","DB00615","The rifamycin, rifabutin, may decrease the effect of the macrolide, josamycin."
1289,"Rifampicin","DB01045","The rifamycin, rifampin, may decrease the effect of the macrolide, josamycin."
1289,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1289,"Theophylline","DB00277","The macrolide, josamycin, may increase the effect and toxicity of theophylline."
1289,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1289,"Triazolam","DB00897","The macrolide, josamycin, may increase the effect of the benzodiazepine, triazolam."
1290,"Alprazolam","DB00404","Kava may increase the effect of the benzodiazepine, alprazolam."
1290,"Chlordiazepoxide","DB00475","Kava may increase the effect of the benzodiazepine, chlordiazepoxide."
1290,"Clobazam","DB00349","Kava may increase the effect of the benzodiazepine, clobazam."
1290,"Clonazepam","DB01068","Kava may increase the effect of the benzodiazepine, clonazepam."
1290,"Clorazepate","DB00628","Kava may increase the effect of the benzodiazepine, clorazepate."
1290,"Diazepam","DB00829","Kava may increase the effect of the benzodiazepine, diazepam."
1290,"Estazolam","DB01215","Kava may increase the effect of the benzodiazepine, estazolam."
1290,"Flurazepam","DB00690","Kava may increase the effect of the benzodiazepine, flurazepam."
1290,"Lorazepam","DB00186","Kava may increase the effect of the benzodiazepine, lorazepam."
1290,"Midazolam","DB00683","Kava may increase the effect of the benzodiazepine, midazolam."
1290,"Oxazepam","DB00842","Kava may increase the effect of the benzodiazepine, oxazepam."
1290,"Temazepam","DB00231","Kava may increase the effect of the benzodiazepine, temazepam."
1290,"Triazolam","DB00897","Kava may increase the effect of the benzodiazepine, triazolam."
1291,"Alprazolam","DB00404","St. John's Wort may decrease the effect of the benzodiazepine, alprazolam."
1291,"Aminophylline","DB01223","St. John's Wort decreases the effect of theophylline"
1291,"Amprenavir","DB00701","St. John's Wort decreases the effect of indinavir"
1291,"Atazanavir","DB01072","St. John's Wort decreases the levels/effects of atazanavir"
1291,"Axitinib","DB06626","Avoid combination due to the likely decreased levels of axitinib."
1291,"Boceprevir","DB08873","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
1291,"Cabazitaxel","DB06772","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
1291,"Cabozantinib","DB08875","Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers."
1291,"Citalopram","DB00215","St. John's Wort increases the effect and toxicity of the SSRI, citalopram."
1291,"Clonazepam","DB01068","St. John's Wort may decrease the effect of the benzodiazepine, clonazepam."
1291,"Cyclosporine","DB00091","St. John's Wort decreases the effect of cyclosporine"
1291,"Delavirdine","DB00705","St. John's Wort decreases the antiretroviral effect"
1291,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1291,"Diazepam","DB00829","St. John's Wort may decrease the effect of the benzodiazepine, diazepam."
1291,"Digoxin","DB00390","St. John's Wort decreases the effect of digoxin"
1291,"Efavirenz","DB00625","St. John's Wort decreases the antiretroviral effect"
1291,"Erlotinib","DB00530","Decreased levels/effect of erlotinib"
1291,"Escitalopram","DB01175","St. John's Wort increases the effect and toxicity of the SSRI, escitalopram."
1291,"Estradiol valerate/Dienogest","DB08866","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
1291,"Ethinyl Estradiol","DB00977","St. John's Wort could reduce the contraceptive effect"
1291,"Etravirine","DB06414","Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
1291,"Fluoxetine","DB00472","St. John's Wort increases the effect and toxicity of the SSRI, fluoxetine."
1291,"Fluvoxamine","DB00176","St. John's Wort increases the effect and toxicity of the SSRI, fluvoxamine."
1291,"Fosamprenavir","DB01319","St. John's Wort decreases the effect of indinavir"
1291,"Gefitinib","DB00317","The CYP3A4 inducer, St. John's Wort, may decrease the serum concentration and therapeutic effects of gefitinib."
1291,"Imatinib","DB00619","St. John's Wort decreases levels of imatinib"
1291,"Indinavir","DB00224","St. John's Wort decreases the effect of indinavir"
1291,"Ivacaftor","DB08820","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
1291,"Methadone","DB00333","St. John's Wort decreases levels/effect of methadone"
1291,"Midazolam","DB00683","St. John's Wort may decrease the effect of the benzodiazepine, midazolam."
1291,"Nefazodone","DB01149","St. John's Wort increases the effect and toxicity of the SSRI, nefazodone."
1291,"Nelfinavir","DB00220","St. John's Wort decreases the effect of indinavir"
1291,"Nevirapine","DB00238","St. John's Wort decreases nevirapine effect"
1291,"Nifedipine","DB01115","St. John's Wort decreases the effect of nifedipine"
1291,"Norethindrone","DB00717","St. John's Wort could reduce the contraceptive effect"
1291,"Omeprazole","DB00338","St. John's Wort decreases the levels/effects of omeprazole "
1291,"Oxtriphylline","DB01303","St. John's Wort decreases the effect of theophylline"
1291,"Paclitaxel","DB01229","Avoid combination due to potential decrease in serum concentration of paclitaxel."
1291,"Paroxetine","DB00715","St. John's Wort increases the effect and toxicity of the SSRI, paroxetine."
1291,"Perampanel","DB08883","Avoid combination due to the potential decrease in perampanel concentration. "
1291,"Rasagiline","DB01367","Increased risk of toxicity with this association"
1291,"Regorafenib","DB08896","Strong CYP3A4 inducers may decrease levels of regorafenib. "
1291,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1291,"Tacrolimus","DB00864","St. John's Wort may decrease the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if St. John's Wort therapy is initiated, discontinued or altered."
1291,"Temsirolimus","DB06287","St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
1291,"Theophylline","DB00277","St. John's Wort decreases the effect of theophylline"
1291,"Tipranavir","DB00932","St. John's Wort may decrease the concentration and efficacy of Tipranavir. Concomitant therapy should be avoided."
1291,"Tolvaptan","DB06212","St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
1291,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1291,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1291,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1291,"Triazolam","DB00897","St. John's Wort may decrease the effect of the benzodiazepine, triazolam."
1291,"Trimipramine","DB00726","St. John's Wort may decrease serum concentrations of Trimipramine. Possible increased risk of serotonin syndrome. Monitor for changes in Trimipramine efficacy and toxicity if St. John's Wort is initiated, discontinued or dose changed. "
1291,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
1291,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
1291,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1291,"Voriconazole","DB00582","St. John's Wort may decrease the serum concentration of voriconazole by increasing its elimination. Concomitant therapy is contraindicated. "
1291,"Warfarin","DB00682","St. John's Wort may decrease the serum concentration of warfarin by increasing its metabolism. Concomitant therapy should be avoided. Monitor for changes in the therapeutic and adverse effects of warfarin if St. John's Wort is initiated, discontinued or dose changed. "
1291,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1292,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
1292,"Lithium","DB01356","The thiazide diuretic, polythiazide, may increase serum levels of lithium."
1292,"Trandolapril","DB00519","The thiazide diuretic, Polythiazide, may increase the hypotensive effect of Trandolapril. Polythiazide may also increase the nephrotoxicity of Trandolapril. Monitor for postural hypotension at initiation of concomitant therapy and renal dysfunction during chronic therapy. "
1292,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1293,"Digoxin","DB00390","Possible electrolyte variations and arrhythmias"
1293,"Lithium","DB01356","The thiazide diuretic, quinethazone, may increase serum levels of lithium."
1294,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1294,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1294,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1294,"Probenecid","DB01032","Probenecid may increase the serum level of cefamandole."
1294,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1295,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1295,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1295,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1295,"Probenecid","DB01032","Probenecid may increase the serum level of cefazolin."
1295,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1296,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1296,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1296,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1296,"Probenecid","DB01032","Probenecid may increase the serum level of cefonicib."
1296,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1297,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1297,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1297,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1297,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1298,"Acenocoumarol","DB01418","The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol."
1298,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1298,"Anisindione","DB01125","The cephalosporin, cefotetan, may increase the anticoagulant effect of anisindione."
1298,"Dicoumarol","DB00266","The cephalosporin, cefotetan, may increase the anticoagulant effect of dicumarol."
1298,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1298,"Kanamycin","DB01172","Increased risk of nephrotoxicity"
1298,"Neomycin","DB00994","Increased risk of nephrotoxicity"
1298,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1298,"Probenecid","DB01032","Probenecid may increase the serum level of cefotetan."
1298,"Streptomycin","DB01082","Increased risk of nephrotoxicity"
1298,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1298,"Warfarin","DB00682","The cephalosporin, cefotetan, may increase the anticoagulant effect of warfarin."
1299,"Acenocoumarol","DB01418","The cephalosporin, cefoxitin, may increase the anticoagulant effect of acenocoumarol."
1299,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1299,"Anisindione","DB01125","The cephalosporin, cefoxitin, may increase the anticoagulant effect of anisindione."
1299,"Dicoumarol","DB00266","The cephalosporin, cefoxitin, may increase the anticoagulant effect of dicumarol."
1299,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1299,"Kanamycin","DB01172","Increased risk of nephrotoxicity"
1299,"Neomycin","DB00994","Increased risk of nephrotoxicity"
1299,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1299,"Probenecid","DB01032","Probenecid may increase the serum level of cefoxitin."
1299,"Streptomycin","DB01082","Increased risk of nephrotoxicity"
1299,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1299,"Warfarin","DB00682","The cephalosporin, cefoxitin, may increase the anticoagulant effect of warfarin."
1300,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1300,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1300,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1300,"Probenecid","DB01032","Probenecid may increase the serum level of ceftizoxime."
1300,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1301,"Amikacin","DB00479","Increased risk of nephrotoxicity"
1301,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
1301,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
1301,"Probenecid","DB01032","Probenecid may increase the serum level of cefradine."
1301,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1302,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1302,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1302,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1302,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
1302,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1302,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1302,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1302,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1302,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1302,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1302,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1302,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1302,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1302,"Quinidine","DB00908","The quinine derivative increases the effect of the muscle relaxant"
1302,"Quinine","DB00468","The quinine derivative increases the effect of the muscle relaxant"
1302,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1302,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1303,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1303,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1303,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1303,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
1303,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1303,"Colistimethate","DB01111","Colistimethate may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and polymyxin antibiotics (e.g., colistimethate, polymyxin B)."
1303,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1303,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1303,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1303,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1303,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1303,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1303,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1303,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1303,"Quinidine","DB00908","The quinine derivative increases the effect of the muscle relaxant"
1303,"Quinine","DB00468","The quinine derivative increases the effect of the muscle relaxant"
1303,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1303,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1304,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1304,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1304,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1304,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1304,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1304,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1304,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1305,"Amikacin","DB00479","The agent increases the effect of muscle relaxant"
1305,"Aminophylline","DB01223","Theophylline decreases the effect of muscle relaxant"
1305,"Azathioprine","DB00993","The agent decreases the effect of the muscle relaxant"
1305,"Betamethasone","DB00443","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Carbamazepine","DB00564","Decreases the effect of muscle relaxant"
1305,"Clindamycin","DB01190","The agent increases the effect of muscle relaxant"
1305,"Colistimethate","DB01111","Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. "
1305,"Corticotropin","DB01285","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Cortisone acetate","DB01380","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Dexamethasone","DB01234","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Fludrocortisone","DB00687","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Fosphenytoin","DB01320","Phenytoin decreases the effect of muscle relaxant"
1305,"Gentamicin","DB00798","The agent increases the effect of muscle relaxant"
1305,"Hydrocortisone","DB00741","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Lincomycin","DB01627","The agent increases the effect of muscle relaxant"
1305,"Mercaptopurine","DB01033","The agent dereases the effect of the muscle relaxant"
1305,"Methylprednisolone","DB00959","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Netilmicin","DB00955","The agent increases the effect of muscle relaxant"
1305,"Oxtriphylline","DB01303","Theophylline decreases the effect of muscle relaxant"
1305,"Phenytoin","DB00252","Phenytoin decreases the effect of the muscle relaxant"
1305,"Piperacillin","DB00319","The agent increases the effect of the muscle relaxant"
1305,"Polymyxin B Sulfate","DB00781","Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. "
1305,"Prednisolone","DB00860","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Prednisone","DB00635","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1305,"Quinidine","DB00908","The quinine derivative increases the effect of the muscle relaxant"
1305,"Quinine","DB00468","Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided."
1305,"Theophylline","DB00277","Theophylline decreases the effect of the muscle relaxant"
1305,"Tobramycin","DB00684","The agent increases the effect of the muscle relaxant"
1305,"Triamcinolone","DB00620","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1306,"Amiloride","DB00594","Increased risk of hyperkalemia"
1306,"Drospirenone","DB01395","Increased risk of hyperkalemia"
1306,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
1306,"Potassium","DB01345","Increased risk of hyperkalemia"
1306,"Spironolactone","DB00421","Increased risk of hyperkalemia"
1306,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
1306,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1306,"Triamterene","DB00384","Increased risk of hyperkalemia"
1307,"Amiloride","DB00594","Decreases the antiarrhythmic effect of quinidine"
1307,"Aminophylline","DB01223","The barbiturate, dihydroquinidine barbiturate, decreases the effect of aminophylline."
1307,"Amiodarone","DB01118","Increases the effect of quinidine"
1307,"Amitriptyline","DB00321","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, amitriptyline."
1307,"Aripiprazole","DB01238","Quinidine increases the effect and toxicity of aripiprazole"
1307,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias"
1307,"Betamethasone","DB00443","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."
1307,"Cimetidine","DB00501","Increases the effect of quinidine"
1307,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1307,"Clomipramine","DB01242","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, clomipramine."
1307,"Codeine","DB00318","Quinidine decreases the analgesic effect of codeine"
1307,"Cyclosporine","DB00091","The barbiturate, dihydroquinidine barbiturate, increases the effect of cyclosporine."
1307,"Desipramine","DB01151","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, desipramine."
1307,"Dexamethasone","DB01234","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone."
1307,"Dextromethorphan","DB00514","Quinidine increases the toxicity of dextromethorphan"
1307,"Digoxin","DB00390","Quinine/quinidine increases the effect of digoxin"
1307,"Diltiazem","DB00343","Increases the effect and toxicity of quinidine"
1307,"Doxepin","DB01142","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, doxepin."
1307,"Doxycycline","DB00254","The anticonvulsant, dihydroquinidine barbiturate, decreases the effect of doxycycline."
1307,"Felodipine","DB01023","The barbiturate, dihydroquinidine barbiturate, decreases the effect of felodipine."
1307,"Fludrocortisone","DB00687","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone."
1307,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, dihydroquinidine barbiturate."
1307,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1307,"Gefitinib","DB00317","The CYP3A4 inducer, dihydroquinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib."
1307,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1307,"Griseofulvin","DB00400","The barbiturate, dihydroquinidine barbiturate, decreases the effect of griseofulvin."
1307,"Hydrocortisone","DB00741","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone."
1307,"Imipramine","DB00458","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, imipramine."
1307,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1307,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1307,"Magnesium","DB01378","The antiacid decreases the absorption of quinidine"
1307,"Methadone","DB00333","The barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone."
1307,"Metronidazole","DB00916","The barbiturate, dihydroquinidine barbiturate, decreases the effect of metronidazole."
1307,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1307,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of quindine"
1307,"Nifedipine","DB01115","Decreased quinidine effect, increased nifedipine effect"
1307,"Nortriptyline","DB00540","Dihydroquinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline."
1307,"Ofloxacin","DB01165","Increased risk of cardiotoxicity and arrhythmias"
1307,"Oxtriphylline","DB01303","The barbiturate, dihydroquinidine barbiturate, decreases the effect of oxtriphylline."
1307,"Prednisolone","DB00860","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone."
1307,"Prednisone","DB00635","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."
1307,"Procainamide","DB01035","Quinidine increases the effect of procainamide"
1307,"Propafenone","DB01182","Quinidine increases the effect of propafenone"
1307,"Quinidine","DB00908","The anticonvulsant, dihydroquinidine. barbiturate, decreases the effect of quinidine."
1307,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1307,"Theophylline","DB00277","The barbiturate, dihydroquinidine barbiturate, decreases the effect of theophylline."
1307,"Triamcinolone","DB00620","The barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."
1308,"Amiloride","DB00594","Increased risk of hyperkalemia"
1308,"Lithium","DB01356","The ARB increases serum levels of lithium"
1308,"Potassium","DB01345","Increased risk of hyperkalemia"
1308,"Triamterene","DB00384","Increased risk of hyperkalemia"
1309,"Aluminium","DB01370","Risk of alkalosis in renal impairment"
1309,"Amiloride","DB00594","Risk of alkalosis in renal impairment"
1309,"Calcium","DB01373","Formation of non-absorbable complexes"
1309,"Eplerenone","DB00700","Risk of alkalosis in renal impairment"
1309,"Magnesium","DB01378","Risk of alkalosis in renal impairment"
1309,"Potassium","DB01345","Risk of alkalosis in renal impairment"
1309,"Spironolactone","DB00421","Risk of alkalosis in renal impairment"
1309,"Triamterene","DB00384","Antagonism of action"
1310,"Amiloride","DB00594","Increased risk of hyperkalemia"
1310,"Benazepril","DB00542","Increased risk of hyperkalemia"
1310,"Candesartan","DB00796","Increased risk of hyperkalemia"
1310,"Captopril","DB01197","Increased risk of hyperkalemia"
1310,"Cilazapril","DB01340","Increased risk of hyperkalemia"
1310,"Drospirenone","DB01395","Increased risk of hyperkalemia"
1310,"Enalapril","DB00584","Increased risk of hyperkalemia"
1310,"Eplerenone","DB00700","This association presents an increased risk of hyperkalemia"
1310,"Eprosartan","DB00876","Increased risk of hyperkalemia"
1310,"Forasartan","DB01342","Increased risk of hyperkalemia"
1310,"Fosinopril","DB00492","Increased risk of hyperkalemia"
1310,"Irbesartan","DB01029","Increased risk of hyperkalemia"
1310,"Lisinopril","DB00722","Increased risk of hyperkalemia"
1310,"Lithium","DB01356","The urine alkalizer decreases the effect of lithium"
1310,"Losartan","DB00678","Increased risk of hyperkalemia"
1310,"Moexipril","DB00691","Increased risk of hyperkalemia"
1310,"Perindopril","DB00790","Increased risk of hyperkalemia"
1310,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
1310,"Quinapril","DB00881","Increased risk of hyperkalemia"
1310,"Ramipril","DB00178","Increased risk of hyperkalemia"
1310,"Saprisartan","DB01347","Increased risk of hyperkalemia"
1310,"Spirapril","DB01348","Increased risk of hyperkalemia"
1310,"Spironolactone","DB00421","Increased risk of hyperkalemia"
1310,"Tasosartan","DB01349","Increased risk of hyperkalemia"
1310,"Telmisartan","DB00966","Potassium may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use."
1310,"Trandolapril","DB00519","Increased risk of hyperkalemia"
1310,"Triamterene","DB00384","Increased risk of hyperkalemia"
1310,"Valsartan","DB00177","Increased risk of hyperkalemia"
1311,"Amiloride","DB00594","Decreases the antiarrhythmic effect of quinidine"
1311,"Aminophylline","DB01223","The barbiturate, quinidine barbiturate, decreases the effect of aminophylline."
1311,"Amiodarone","DB01118","Increases the effect of qiunidine"
1311,"Amitriptyline","DB00321","Quinidine barbiturate increases the effect of tricyclic antidepressant, amitriptyline."
1311,"Aripiprazole","DB01238","Quinidine increases the effect and toxicity of aripiprazole"
1311,"Atazanavir","DB01072","Increased risk of cardiotoxicity and arrhythmias"
1311,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1311,"Betamethasone","DB00443","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, betamethasone."
1311,"Cimetidine","DB00501","Increases the effect of quinidine"
1311,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1311,"Clarithromycin","DB01211","Increased risk of cardiotoxicity and arrhythmias"
1311,"Clomipramine","DB01242","Quinidine barbiturate increases the effect of tricyclic antidepressant, clomipramine."
1311,"Codeine","DB00318","Quinidine decreases the analgesic effect of codeine"
1311,"Cyclosporine","DB00091","The barbiturate, quinidine barbiturate, increases the effect of cyclosporine."
1311,"Desipramine","DB01151","Quinidine barbiturate increases the effect of tricyclic antidepressant, desipramine."
1311,"Dexamethasone","DB01234","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, dexamethasone."
1311,"Dextromethorphan","DB00514","Quinidine increases the toxicity of dextromethorphan"
1311,"Digoxin","DB00390","Quinine/quinidine increases the effect of digoxin"
1311,"Diltiazem","DB00343","Increases the effect and toxicity of quinidine"
1311,"Donepezil","DB00843","Possible antagonism of action"
1311,"Doxepin","DB01142","Quinidine barbiturate increases the effect of tricyclic antidepressant, doxepin."
1311,"Doxycycline","DB00254","The anticonvulsant, quinidine barbiturate, decreases the effect of doxycycline."
1311,"Erythromycin","DB00199","Increased risk of cardiotoxicity and arrhythmias"
1311,"Felodipine","DB01023","The barbiturate, quinidine barbiturate, decreases the effect of felodipine."
1311,"Fludrocortisone","DB00687","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, fludrocortisone."
1311,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, quinidine barbiturate."
1311,"Galantamine","DB00674","Possible antagonism of action"
1311,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1311,"Gefitinib","DB00317","The CYP3A4 inducer, quinidine barbiturate, may decrease the serum concentration and therapeutic effects of gefitinib."
1311,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1311,"Griseofulvin","DB00400","The barbiturate, quinidine barbiturate, decreases the effect of griseofulvin."
1311,"Hydrocortisone","DB00741","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone."
1311,"Imipramine","DB00458","Quinidine barbiturate increases the effect of tricyclic antidepressant, imipramine."
1311,"Itraconazole","DB01167","Itraconazole may increase the effect and toxicity of quinidine barbiturate."
1311,"Ketoconazole","DB01026","Ketoconazole may increase the effect and toxicity of quinidine barbiturate."
1311,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1311,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1311,"Magnesium","DB01378","The antiacid decreases the absorption of quinidine"
1311,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1311,"Methadone","DB00333","The barbiturate, quinidine barbiturate, decreases the effect of methadone."
1311,"Metronidazole","DB00916","The barbiturate, quinidine barbiturate, decreases the effect of metronidazole."
1311,"Moxifloxacin","DB00218","Increased risk of cardiotoxicity and arrhythmias"
1311,"Nelfinavir","DB00220","Nelfinavir increases the effect and toxicity of quinidine"
1311,"Nifedipine","DB01115","Decreased quinidine effect, increased nifedipine effect"
1311,"Nortriptyline","DB00540","Quinidine barbiturate increases the effect of the tricyclic antidepressant, nortriptyline."
1311,"Ofloxacin","DB01165","Increased risk of cardiotoxicity and arrhythmias"
1311,"Oxtriphylline","DB01303","The barbiturate, quinidine barbiturate, decreases the effect of oxtriphylline."
1311,"Prednisolone","DB00860","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisolone."
1311,"Prednisone","DB00635","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone."
1311,"Procainamide","DB01035","Quinidine increases the effect of procainamide"
1311,"Propafenone","DB01182","Quinidine increases the effect of propafenone"
1311,"Quinidine","DB00908","The anticonvulsant, quinidine. barbiturate, decreases the effect of quinidine."
1311,"Quinupristin","DB01369","This combination presents an increased risk of toxicity"
1311,"Rifampicin","DB01045","Rifampin decreases the effect of quinidine"
1311,"Telithromycin","DB00976","Increased risk of cardiotoxicity and arrhythmias"
1311,"Theophylline","DB00277","The barbiturate, quinidine barbiturate, decreases the effect of theophylline."
1311,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
1311,"Triamcinolone","DB00620","The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, triamcinolone."
1312,"Amiloride","DB00594","Increased risk of hyperkalemia"
1312,"Lithium","DB01356","The ARB increases serum levels of lithium"
1312,"Potassium","DB01345","Increased risk of hyperkalemia"
1312,"Triamterene","DB00384","Increased risk of hyperkalemia"
1313,"Amiloride","DB00594","Increased risk of hyperkalemia"
1313,"Lithium","DB01356","The ACE inhibitor increases serum levels of lithium"
1313,"Potassium","DB01345","Increased risk of hyperkalemia"
1313,"Tizanidine","DB00697","Tizanidine increases the risk of hypotension with the ACE inhibitor"
1313,"Triamterene","DB00384","Increased risk of hyperkalemia"
1314,"Amiloride","DB00594","Increased risk of hyperkalemia"
1314,"Lithium","DB01356","The ARB increases serum levels of lithium"
1314,"Potassium","DB01345","Increased risk of hyperkalemia"
1314,"Triamterene","DB00384","Increased risk of hyperkalemia"
1315,"Aminophylline","DB01223","The barbiturate, amobarbital, decreases the effect of aminophylline."
1315,"Betamethasone","DB00443","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, betamethasone."
1315,"Clomifene","DB00882","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, clomifene."
1315,"Conjugated Estrogens","DB00286","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, conjugated estrogens."
1315,"Cyclosporine","DB00091","The barbiturate, amobarbital, increases the effect of cyclosporine."
1315,"Dexamethasone","DB01234","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1315,"Diethylstilbestrol","DB00255","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
1315,"Doxycycline","DB00254","The anticonvulsant, amobarbital, decreases the effect of doxycycline."
1315,"Eltrombopag","DB06210","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
1315,"Estradiol","DB00783","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, estradiol."
1315,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1315,"Felodipine","DB01023","The barbiturate, amobarbital, decreases the effect of felodipine."
1315,"Fludrocortisone","DB00687","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
1315,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, amobarbital."
1315,"Gefitinib","DB00317","The CYP3A4 inducer, amobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
1315,"Griseofulvin","DB00400","The barbiturate, amobarbital, decreases the effect of griseofulvin."
1315,"Hydrocortisone","DB00741","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
1315,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1315,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
1315,"Megestrol acetate","DB00351","The enzyme inducer, amobarbital, decreases the effect of the hormone agent, megestrol."
1315,"Methadone","DB00333","The barbiturate, amobarbital, decreases the effect of methadone."
1315,"Metronidazole","DB00916","The barbiturate, amobarbital, decreases the effect of metronidazole."
1315,"Nifedipine","DB01115","The barbiturate, amobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1315,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1315,"Oxtriphylline","DB01303","The barbiturate, amobarbital, decreases the effect of oxtriphylline."
1315,"Prednisolone","DB00860","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisolone."
1315,"Prednisone","DB00635","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone."
1315,"Quinidine","DB00908","The anticonvulsant, amobarbital, decreases the effect of quinidine."
1315,"Theophylline","DB00277","The barbiturate, amobarbital, decreases the effect of theophylline."
1315,"Triamcinolone","DB00620","The barbiturate, amobarbital, may decrease the effect of the corticosteroid, triamcinolone."
1315,"Trimipramine","DB00726","The barbiturate, Amobarbital, may increase the metabolism and clearance of Trimipramine. Monitor for changes in the therapeutics and adverse effects of Trimipramine if Amobarbital is initiated, discontinued or dose changed. Dose adjustments of Trimipramine may be required. "
1315,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Amobarbital, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1315,"Verapamil","DB00661","Amobarbital, a CYP3A4 inducer, may increase the serum concentration of Verapamil, a CYP3A4 substrate. Monitor for changes in the therapeutic/adverse effects of Verapamil if Amobarbital is initiated, discontinued or dose changed. "
1315,"Voriconazole","DB00582","Amobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated.  "
1315,"Warfarin","DB00682","Amobarbital may decrease the serum concentration of warfarin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of warfarin if amobarbital is initiated, discontinued or dose changed. "
1316,"Aminophylline","DB01223","The barbiturate, aprobarbital, decreases the effect of aminophylline."
1316,"Betamethasone","DB00443","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, betamethasone."
1316,"Clomifene","DB00882","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, clomifene."
1316,"Conjugated Estrogens","DB00286","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, conjugated estrogens."
1316,"Cyclosporine","DB00091","The barbiturate, aprobarbital, increases the effect of cyclosporine."
1316,"Dexamethasone","DB01234","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1316,"Diethylstilbestrol","DB00255","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
1316,"Doxycycline","DB00254","The anticonvulsant, aprobarbital, decreases the effect of doxycycline."
1316,"Estradiol","DB00783","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, estradiol."
1316,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1316,"Felodipine","DB01023","The barbiturate, aprobarbital, decreases the effect of felodipine."
1316,"Fludrocortisone","DB00687","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
1316,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, aprobarbital."
1316,"Gefitinib","DB00317","The CYP3A4 inducer, aprobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
1316,"Griseofulvin","DB00400","The barbiturate, aprobarbital, decreases the effect of griseofulvin."
1316,"Hydrocortisone","DB00741","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
1316,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1316,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
1316,"Megestrol acetate","DB00351","The enzyme inducer, aprobarbital, decreases the effect of the hormone agent, megestrol."
1316,"Methadone","DB00333","The barbiturate, aprobarbital, decreases the effect of methadone."
1316,"Metronidazole","DB00916","The barbiturate, aprobarbital, decreases the effect of metronidazole."
1316,"Nifedipine","DB01115","The barbiturate, aprobarbital, decreases the effect of the calcium channel blocker, nifedipine. "
1316,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1316,"Oxtriphylline","DB01303","The barbiturate, aprobarbital, decreases the effect of oxtriphylline."
1316,"Prednisolone","DB00860","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisolone."
1316,"Prednisone","DB00635","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone."
1316,"Quinidine","DB00908","The anticonvulsant, aprobarbital, decreases the effect of quinidine."
1316,"Theophylline","DB00277","The barbiturate, aprobarbital, decreases the effect of theophylline."
1316,"Triamcinolone","DB00620","The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, triamcinolone."
1317,"Aminophylline","DB01223","The barbiturate, butethal, decreases the effect of aminophylline."
1317,"Betamethasone","DB00443","The barbiturate, butethal, may decrease the effect of the corticosteroid, betamethasone."
1317,"Clomifene","DB00882","The enzyme inducer, butethal, decreases the effect of the hormone agent, clomifene."
1317,"Conjugated Estrogens","DB00286","The enzyme inducer, butethal, decreases the effect of the hormone agent, conjugated estrogens."
1317,"Cyclosporine","DB00091","The barbiturate, butethal, increases the effect of cyclosporine."
1317,"Dexamethasone","DB01234","The barbiturate, butethal, may decrease the effect of the corticosteroid, dexamethasone."
1317,"Diethylstilbestrol","DB00255","The enzyme inducer, butethal, decreases the effect of the hormone agent, diethylstilbestrol."
1317,"Doxycycline","DB00254","The anticonvulsant, butethal, decreases the effect of doxycycline."
1317,"Estradiol","DB00783","The enzyme inducer, butethal, decreases the effect of the hormone agent, estradiol."
1317,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1317,"Felodipine","DB01023","The barbiturate, butethal, decreases the effect of felodipine."
1317,"Fludrocortisone","DB00687","The barbiturate, butethal, may decrease the effect of the corticosteroid, fludrocortisone."
1317,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, butethal."
1317,"Gefitinib","DB00317","The CYP3A4 inducer, butethal, may decrease the serum concentration and therapeutic effects of gefitinib."
1317,"Griseofulvin","DB00400","The barbiturate, butethal, decreases the effect of griseofulvin."
1317,"Hydrocortisone","DB00741","The barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone."
1317,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1317,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, butethal, decreases the effect of the hormone agent, medroxyprogesterone."
1317,"Megestrol acetate","DB00351","The enzyme inducer, butethal, decreases the effect of the hormone agent, megestrol."
1317,"Methadone","DB00333","The barbiturate, butethal, decreases the effect of methadone."
1317,"Metronidazole","DB00916","The barbiturate, butethal, decreases the effect of metronidazole."
1317,"Nifedipine","DB01115","The barbiturate, butethal, decreases the effect of the calcium channel blocker, nifedipine."
1317,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1317,"Oxtriphylline","DB01303","The barbiturate, butethal, decreases the effect of oxtriphylline."
1317,"Prednisolone","DB00860","The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisolone."
1317,"Prednisone","DB00635","The barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone."
1317,"Quinidine","DB00908","The anticonvulsant, butethal, decreases the effect of quinidine."
1317,"Theophylline","DB00277","The barbiturate, butethal, decreases the effect of theophylline."
1317,"Triamcinolone","DB00620","The barbiturate, butethal, may decrease the effect of the corticosteroid, triamcinolone."
1318,"Aminophylline","DB01223","The barbiturate, heptabarbital, decreases the effect of aminophylline."
1318,"Betamethasone","DB00443","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, betamethasone."
1318,"Clomifene","DB00882","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, clomifene."
1318,"Conjugated Estrogens","DB00286","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, conjugated estrogens."
1318,"Cyclosporine","DB00091","The barbiturate, heptabarbital, increases the effect of cyclosporine."
1318,"Dexamethasone","DB01234","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, dexamethasone."
1318,"Diethylstilbestrol","DB00255","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, diethylstilbestrol."
1318,"Doxycycline","DB00254","The anticonvulsant, heptabarbital, decreases the effect of doxycycline."
1318,"Estradiol","DB00783","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, estradiol."
1318,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1318,"Felodipine","DB01023","The barbiturate, heptabarbital, decreases the effect of felodipine."
1318,"Fludrocortisone","DB00687","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, fludrocortisone."
1318,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, heptabarbital."
1318,"Gefitinib","DB00317","The CYP3A4 inducer, heptabarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
1318,"Griseofulvin","DB00400","The barbiturate, heptabarbital, decreases the effect of griseofulvin."
1318,"Hydrocortisone","DB00741","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone."
1318,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1318,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, medroxyprogesterone."
1318,"Megestrol acetate","DB00351","The enzyme inducer, heptabarbital, decreases the effect of the hormone agent, megestrol."
1318,"Methadone","DB00333","The barbiturate, heptabarbital, decreases the effect of methadone."
1318,"Metronidazole","DB00916","The barbiturate, heptabarbital, decreases the effect of metronidazole."
1318,"Nifedipine","DB01115","The barbiturate, heptabarbital, decreases the effect of the calcium channel blocker, nifedipine. "
1318,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1318,"Oxtriphylline","DB01303","The barbiturate, heptabarbital, decreases the effect of oxtriphylline."
1318,"Prednisolone","DB00860","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisolone."
1318,"Prednisone","DB00635","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone."
1318,"Quinidine","DB00908","The anticonvulsant, heptabarbital, decreases the effect of quinidine."
1318,"Theophylline","DB00277","The barbiturate, heptabarbital, decreases the effect of theophylline."
1318,"Triamcinolone","DB00620","The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, triamcinolone."
1319,"Aminophylline","DB01223","The barbiturate, hexobarbital, decreases the effect of aminophylline."
1319,"Betamethasone","DB00443","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, betamethasone."
1319,"Clomifene","DB00882","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, clomifene."
1319,"Conjugated Estrogens","DB00286","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, conjugated estrogens."
1319,"Cyclosporine","DB00091","The barbiturate, hexobarbital, increases the effect of cyclosporine."
1319,"Dexamethasone","DB01234","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, dexamethasone."
1319,"Diethylstilbestrol","DB00255","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, diethylstilbestrol."
1319,"Doxycycline","DB00254","The anticonvulsant, hexobarbital, decreases the effect of doxycycline."
1319,"Estradiol","DB00783","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, estradiol."
1319,"Ethinyl Estradiol","DB00977","This product may cause a slight decrease of contraceptive effect"
1319,"Felodipine","DB01023","The barbiturate, hexobarbital, decreases the effect of felodipine."
1319,"Fludrocortisone","DB00687","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, fludrocortisone."
1319,"Folic Acid","DB00158","Folic acid decreases the effect of anticonvulsant, hexobarbital."
1319,"Gefitinib","DB00317","The CYP3A4 inducer, hexobarbital, may decrease the serum concentration and therapeutic effects of gefitinib."
1319,"Griseofulvin","DB00400","The barbiturate, hexobarbital, decreases the effect of griseofulvin."
1319,"Hydrocortisone","DB00741","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone."
1319,"Levonorgestrel","DB00367","Phenobarbital decreases the effect of levonorgestrel"
1319,"Medroxyprogesterone Acetate","DB00603","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, medroxyprogesterone."
1319,"Megestrol acetate","DB00351","The enzyme inducer, hexobarbital, decreases the effect of the hormone agent, megestrol."
1319,"Methadone","DB00333","The barbiturate, hexobarbital, decreases the effect of methadone."
1319,"Metronidazole","DB00916","The barbiturate, hexobarbital, decreases the effect of metronidazole."
1319,"Nifedipine","DB01115","The barbiturate, hexobarbital, decreases the effect of the calcium channel blocker, nifedipine."
1319,"Norethindrone","DB00717","This product may cause a slight decrease of contraceptive effect"
1319,"Oxtriphylline","DB01303","The barbiturate, hexobarbital, decreases the effect of oxtriphylline."
1319,"Prednisolone","DB00860","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisolone."
1319,"Prednisone","DB00635","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone."
1319,"Quinidine","DB00908","The anticonvulsant, hexobarbital, decreases the effect of quinidine."
1319,"Theophylline","DB00277","The barbiturate, hexobarbital, decreases the effect of theophylline."
1319,"Triamcinolone","DB00620","The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, triamcinolone."
1320,"Aminophylline","DB01223","Theophylline decreases serum levels of lithium"
1320,"Azilsartan medoxomil","DB08822","Azilsartan medoxomil may increase lithium serum concentrations."
1320,"Benazepril","DB00542","The ACE inhibitor increases serum levels of lithium"
1320,"Bendroflumethiazide","DB00436","The thiazide diuretic, bendroflumethiazide, may increase serum levels of lithium."
1320,"Benzthiazide","DB00562","The thiazide diuretic, benzthiazide, may increase serum levels of lithium."
1320,"Caffeine","DB00201","Caffeine decreases serum levels of lithium"
1320,"Candesartan","DB00796","The ARB increases serum levels of lithium"
1320,"Captopril","DB01197","The ACE inhibitor increases serum levels of lithium"
1320,"Celecoxib","DB00482","The COX-2 inhibitor increases serum levels of lithium"
1320,"Chlorothiazide","DB00880","The thiazide diuretic, chlorothiazide, may increase serum levels of lithium."
1320,"Chlorthalidone","DB00310","The thiazide diuretic, chlorthalidone, may increase serum levels of lithium."
1320,"Cilazapril","DB01340","The ACE inhibitor increases serum levels of lithium"
1320,"Citric Acid","DB04272","The urine alkalizer decreases the effect of lithium"
1320,"Cyclothiazide","DB00606","The thiazide diuretic, cyclothiazide, may increase serum levels of lithium."
1320,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1320,"Diclofenac","DB00586","The NSAID, diclofenac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Diflunisal","DB00861","The NSAID, diflunisal, may decrease the renal excretion of lithium. Increased risk of lithium toxicity. "
1320,"Dyphylline","DB00651","Theophylline decreases serum levels of lithium"
1320,"Enalapril","DB00584","The ACE inhibitor increases serum levels of lithium"
1320,"Eplerenone","DB00700","Eplerenone increases serum levels of lithium"
1320,"Eprosartan","DB00876","The ARB increases serum levels of lithium"
1320,"Etoricoxib","DB01628","Etoricoxib increases serum levels of lithium"
1320,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases serum levels of lithium."
1320,"Fluvoxamine","DB00176","The SSRI, fluvoxamine, increases serum levels of lithium."
1320,"Forasartan","DB01342","The ARB increases serum levels of lithium"
1320,"Fosinopril","DB00492","The ACE inhibitor increases serum levels of lithium"
1320,"Haloperidol","DB00502","Possible extrapyramidal effects and neurotoxicity with this combination"
1320,"Hydrochlorothiazide","DB00999","The thiazide diuretic, hydrochlorothiazide, may increase serum levels of lithium."
1320,"Hydroflumethiazide","DB00774","The thiazide diuretic, hydroflumethiazide, may increase serum levels of lithium."
1320,"Ibuprofen","DB01050","The NSAID, ibuprofen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Indapamide","DB00808","The thiazide diuretic, indapamide, may increase serum levels of lithium."
1320,"Indomethacin","DB00328","The NSAID, indomethacin, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Iodine","DB05247","Possible hypothyroidism with this combination"
1320,"Irbesartan","DB01029","The ARB increases serum levels of lithium"
1320,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase the serum concentration of lithium by decreasing its renal clearance. Consider a dose reduction in lithium upon initiation of ketoprofen therapy. Monitor for changes in the therapeutic and adverse effects of lithium if ketoprofen is initiated, discontinued or does changed. "
1320,"Ketorolac","DB00465","The NSAID, ketorolac, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Lisinopril","DB00722","The ACE inhibitor increases serum levels of lithium"
1320,"Losartan","DB00678","Losartan increases serum levels of lithium"
1320,"Lumiracoxib","DB01283","The COX-2 inhibitor increases serum levels of lithium"
1320,"Mefenamic acid","DB00784","The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Meloxicam","DB00814","Meloxicam increases serum levels of lithium"
1320,"Methyclothiazide","DB00232","The thiazide diuretic, methyclothiazide, may increase serum levels of lithium."
1320,"Methyldopa","DB00968","Methyldopa may increase the adverse effects of lithium without affecting lithium serum levels. Monitor for signs and symptoms of lithium toxicity during concomitant therapy."
1320,"Metolazone","DB00524","The thiazide diuretic, metolazone, may increase serum levels of lithium."
1320,"Metronidazole","DB00916","Metronidazole increases the effect and toxicity of lithium"
1320,"Moexipril","DB00691","The ACE inhibitor increases serum levels of lithium"
1320,"Naproxen","DB00788","The NSAID, naproxen, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Oxtriphylline","DB01303","Theophylline decreases serum levels of lithium"
1320,"Perindopril","DB00790","The ACE inhibitor increases serum levels of lithium"
1320,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Piroxicam","DB00554","The NSAID, piroxicam, may decrease the renal excretion of lithium. Increased risk of lithium toxicity."
1320,"Polythiazide","DB01324","The thiazide diuretic, polythiazide, may increase serum levels of lithium."
1320,"Potassium","DB01345","The urine alkalizer decreases the effect of lithium"
1320,"Quinapril","DB00881","The ACE inhibitor increases serum levels of lithium"
1320,"Quinethazone","DB01325","The thiazide diuretic, quinethazone, may increase serum levels of lithium."
1320,"Ramipril","DB00178","The ACE inhibitor increases serum levels of lithium"
1320,"Rofecoxib","DB00533","The COX-2 inhibitor increases serum levels of lithium"
1320,"Salmon Calcitonin","DB00017","Monitor therapy because calcitonin may reduce the serum concentration of lithium. "
1320,"Saprisartan","DB01347","The ARB increases serum levels of lithium"
1320,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
1320,"Sodium bicarbonate","DB01390","The urine alkalizer decreases the effect of lithium"
1320,"Spirapril","DB01348","The ACE inhibitor increases serum levels of lithium"
1320,"Sumatriptan","DB00669","Possible serotoninergic syndrome with this combination"
1320,"Tasosartan","DB01349","The ARB increases serum levels of lithium"
1320,"Telmisartan","DB00966","Telmisartan may increase serum Lithium concentrations. Monitor serum Lithium levels during concomitant therapy to avoid Lithium toxicity."
1320,"Tenoxicam","DB00469","Tenoxicam may increase the serum concentration of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tenoxicam is initiated, discontinued or dose changed."
1320,"Tetrabenazine","DB04844","Inhibit biochemical and behavioural effects of tetrabenazine. Heed caution when using agents in combination. "
1320,"Theophylline","DB00277","Theophylline decreases serum levels of lithium"
1320,"Tiaprofenic acid","DB01600","Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed. "
1320,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
1320,"Tolmetin","DB00500","Tolmetin may increase the risk of Lithium toxicity by decreasing the renal elminiation of Lithium. A dose adjustment of Lithium may be required. Monitor for changes in Lithium therapeutic and adverse effects if Tolmetin is initiated, discontinued or dose changed. "
1320,"Topiramate","DB00273","Topiramate could modify lithium levels"
1320,"Trandolapril","DB00519","Trandolapril may increase the serum concentration of Lithium increasing the risk of Lithium toxicity. Monitor for changes in Lithium serum concentrations, toxicity and efficacy if Trandolapril is initiated, discontinued or dose changed."
1320,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1320,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1320,"Trichlormethiazide","DB01021","Trichlormethiazide may increase the serum concentration of Lithium by decreasing Lithium excretion. Monitor for changes in the therapeutic/adverse effects of Lithium if Trichlorthiazide is initiated, discontinued or dose changed."
1320,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. "
1320,"Valdecoxib","DB00580","The COX-2 inhibitor increases serum levels of lithium"
1320,"Valsartan","DB00177","Valsartan may increase serum lithium concentrations. Monitor serum lithium levels during concomitant therapy to avoid lithium toxicity."
1320,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1320,"Verapamil","DB00661","Signs of lithium toxicity"
1320,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
1321,"Aminophylline","DB01223","The contraceptive increases the effect and toxicity of theophylline"
1321,"Amoxicillin","DB01060","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Ampicillin","DB00415","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Amprenavir","DB00701","Ritonavir could decrease the contraceptive efficacy"
1321,"Aprepitant","DB00673","Aprepitant could decrease the effect of the oral contraceptive"
1321,"Artemether","DB06697","Artemether may decrease the effectiveness of mestranol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy. "
1321,"Benzylpenicillin","DB01053","This anti-infectious agent could decreases the effect of the oral contraceptive"
1321,"Bosentan","DB00559","Decreases the effect of contraceptive"
1321,"Carbamazepine","DB00564","This product may cause a slight decrease of contraceptive effect"
1321,"Carbenicillin","DB00578","This anti-infectious agent could decreases the effect of the oral contraceptive"
1321,"Clavulanate","DB00766","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Cloxacillin","DB01147","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Estrogens). Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. Ethinyl estradiol patches and vaginal rings may also be somewhat impacted by this interaction, though the extent and significance of such an interaction is uncertain."
1321,"Cyclosporine","DB00091","The contraceptive increases the effect and toxicity of cyclosporine"
1321,"Demeclocycline","DB00618","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Dicloxacillin","DB00485","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Doxycycline","DB00254","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Flucloxacillin","DB00301","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Fosphenytoin","DB01320","This product may cause a slight decrease of contraceptive effect"
1321,"Griseofulvin","DB00400","This product may cause a slight decrease of contraceptive effect"
1321,"Itraconazole","DB01167","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Ketoconazole","DB01026","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Lamotrigine","DB00555","The oral contraceptive decreases the effect of lamotrigine"
1321,"Minocycline","DB01017","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Modafinil","DB00745","Modafinil decreases the effect of the contraceptive"
1321,"Nelfinavir","DB00220","Ritonavir could decrease the contraceptive efficacy"
1321,"Oxcarbazepine","DB00776","Oxcarbazepine decreases the effect of the contraceptive"
1321,"Oxtriphylline","DB01303","The contraceptive increases the effect and toxicity of theophylline"
1321,"Penicillin V","DB00417","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Phenobarbital","DB01174","This product may cause a slight decrease of contraceptive effect"
1321,"Phenytoin","DB00252","This product may cause a slight decrease of contraceptive effect"
1321,"Pioglitazone","DB01132","Possible loss of contraceptive effect"
1321,"Piperacillin","DB00319","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Pivampicillin","DB01604","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Prednisolone","DB00860","The estrogenic agent, mestranol, may increase the effect of the corticosteroid, prednisolone."
1321,"Prednisone","DB00635","The estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone."
1321,"Primidone","DB00794","This product may cause a slight decrease of contraceptive effect"
1321,"Raloxifene","DB00481","Association not recommended"
1321,"Rifabutin","DB00615","This product may cause a slight decrease of the contraceptive effect"
1321,"Rifampicin","DB01045","This product may cause a slight decrease of contraceptive effect"
1321,"Tetracycline","DB00759","This anti-infectious agent could decrease the effect of the oral contraceptive"
1321,"Theophylline","DB00277","The contraceptive increases the effect and toxicity of theophylline"
1321,"Thiopental","DB00599","Thiopental may decrease the effect of Mestranol. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
1321,"Tipranavir","DB00932","Mestranol may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Mestranol. Use an alternate form of contraception or monitor for estrogen deficiency if Mestranol is used for hormone replacement therapy. "
1321,"Tizanidine","DB00697","Oral contraceptives decrease the clearance of Tizanidine."
1321,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Mestranol. Consider alternate therapy or monitor for changes in Mestranol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1321,"Topiramate","DB00273","Topiramate may decrease the effect of the oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy."
1321,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Mestranol. An alternate form of contraception should be used during concomitant therapy. "
1321,"Warfarin","DB00682","Mestranol may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if mestranol is initiated, discontinued or dose changed."
1322,"Aminophylline","DB01223","Antagonism of action and increased effect of theophylline"
1322,"Chlorpropamide","DB00672","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1322,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1322,"Digoxin","DB00390","Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia."
1322,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1322,"Disopyramide","DB00280","The beta-blocker, penbutolol,  may increase the toxicity of disopyramide."
1322,"Epinephrine","DB00668","Hypertension, then bradycardia"
1322,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1322,"Fenoterol","DB01288","Antagonism"
1322,"Formoterol","DB00983","Antagonism"
1322,"Gliclazide","DB01120","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1322,"Glyburide","DB01016","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1322,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1322,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1322,"Insulin Glargine","DB00047","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1322,"Lidocaine","DB00281","Penbutolol increases the volume of distribution of lidocaine in normal subjects. This could result in a requirement for higher loading doses of lidocaine."
1322,"Methyldopa","DB00968","Possible hypertensive crisis"
1322,"Methysergide","DB00247","Ischemia with risk of gangrene"
1322,"Orciprenaline","DB00816","Antagonism"
1322,"Oxtriphylline","DB01303","Antagonism of action and increased effect of theophylline"
1322,"Pipobroman","DB00236","Antagonism"
1322,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1322,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1322,"Repaglinide","DB00912","The beta-blocker, penbutolol, may decrease symptoms of hypoglycemia."
1322,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1322,"Terbutaline","DB00871","Antagonism"
1322,"Theophylline","DB00277","Antagonism of action and increased effect of theophylline"
1322,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1323,"Aminophylline","DB01223","The macrolide, troleandomycin, may increase the effect and toxicity of theophylline derivative, aminophylline."
1323,"Aprepitant","DB00673","This CYP3A4 inhibitor increases the effect and toxicity of aprepitant"
1323,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1323,"Carbamazepine","DB00564","The macrolide, troleandomycin, may increase the effect of carbamazepine."
1323,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1323,"Citalopram","DB00215","Possible serotoninergic syndrome with this combination"
1323,"Colchicine","DB01394","Severe colchicine toxicity can occur"
1323,"Cyclosporine","DB00091","The macrolide, troleandomycin, may increase the effect of cyclosporine."
1323,"Dihydroergotamine","DB00320","Possible ergotism and severe ischemia with this combination"
1323,"Eletriptan","DB00216","The macrolide, troleandomycin, may increase the effect and toxicity of eletriptan."
1323,"Eplerenone","DB00700","The macrolide, troleandomycin, may increase the effect and toxicity of eplerenone."
1323,"Ergotamine","DB00696","Possible ergotism and severe ischemia with this combination"
1323,"Erlotinib","DB00530","This CYP3A4 inhibitor increases levels/toxicity of erlotinib"
1323,"Fluoxetine","DB00472","Possible serotoninergic syndrome with this combination"
1323,"Methysergide","DB00247","Possible ergotism and severe ischemia with this combination"
1323,"Oxtriphylline","DB01303","The macrolide, troleandomycin, may increase the effect and toxicity of the theophylline derivative, oxtriphylline."
1323,"Pimozide","DB01100","Increased risk of cardiotoxicity and arrhythmias"
1323,"Tacrolimus","DB00864","The macrolide antibiotic, Troleandomycin, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Troleandomycin therapy is initiated, discontinued or altered."
1323,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1323,"Theophylline","DB00277","The macrolide, troleandomycin, may increase the effect and toxicity of theophylline."
1324,"Amiodarone","DB01118","Increased risk of cardiotoxicity and arrhythmias"
1325,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedra."
1325,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedra."
1325,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedra."
1325,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedra."
1325,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedra."
1325,"Guanethidine","DB01170","Ephedra may decrease the effect of guanethidine."
1325,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedra."
1325,"Isocarboxazid","DB01247","Increased arterial pressure"
1325,"Linezolid","DB00601","Possible increase of arterial pressure"
1325,"Methyldopa","DB00968","Increased arterial pressure"
1325,"Midodrine","DB00211","Increased arterial pressure"
1325,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of ephedra."
1325,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedra."
1325,"Phenelzine","DB00780","Increased arterial pressure"
1325,"Rasagiline","DB01367","Increased arterial pressure"
1325,"Reserpine","DB00206","Increased arterial pressure"
1325,"Trandolapril","DB00519","Ephedra may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy."
1326,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of ephedrine."
1326,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of ephedrine."
1326,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of ephedrine."
1326,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of ephedrine."
1326,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
1326,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of ephedrine."
1326,"Guanethidine","DB01170","Ephedrine may decrease the effect of guanethidine."
1326,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of ephedrine."
1326,"Iobenguane","DB06704","Sympathomimetic that increase chances of producing a false negative imaging result "
1326,"Isocarboxazid","DB01247","Increased arterial pressure"
1326,"Linezolid","DB00601","Possible increase of arterial pressure"
1326,"Methyldopa","DB00968","Increased arterial pressure"
1326,"Midodrine","DB00211","Increased arterial pressure"
1326,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of ephedrine."
1326,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of ephedrine."
1326,"Phenelzine","DB00780","Increased arterial pressure"
1326,"Rasagiline","DB01367","Increased arterial pressure"
1326,"Reserpine","DB00206","Increased arterial pressure"
1326,"Rotigotine","DB05271","Risk of sedation may decrease with concomitant therapy. Monitor therapy closely. "
1326,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of Ephedrine. Concomitant therapy should be avoided. "
1326,"Venlafaxine","DB00285","Venlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
1327,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of mephentermine."
1327,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of mephentermine."
1327,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of mephentermine."
1327,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of mephentermine."
1327,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of mephentermine."
1327,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of mephentermine."
1327,"Isocarboxazid","DB01247","Increased arterial pressure"
1327,"Linezolid","DB00601","Possible increase of arterial pressure"
1327,"Methyldopa","DB00968","Increased arterial pressure"
1327,"Midodrine","DB00211","Increased arterial pressure"
1327,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of mephentermine."
1327,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of mephentermine."
1327,"Phenelzine","DB00780","Increased arterial pressure"
1327,"Rasagiline","DB01367","Increased arterial pressure"
1327,"Reserpine","DB00206","Increased arterial pressure"
1327,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Concomitant therapy should be avoided. "
1327,"Trimipramine","DB00726","Trimipramine may increase the vasopressor effect of the alpha1-agonist, Mephentermine. Avoid combination if possible. Monitor sympathetic response to therapy if used concomitantly. "
1328,"Amitriptyline","DB00321","The tricyclic antidepressant, amitriptyline, increases the sympathomimetic effect of procaterol."
1328,"Amoxapine","DB00543","The tricyclic antidepressant, amoxapine, increases the sympathomimetic effect of procaterol."
1328,"Atenolol","DB00335","Antagonism"
1328,"Bisoprolol","DB00612","Antagonism"
1328,"Carvedilol","DB01136","Antagonism"
1328,"Clomipramine","DB01242","The tricyclic antidepressant, clomipramine, increases the sympathomimetic effect of procaterol."
1328,"Desipramine","DB01151","The tricyclic antidepressant, desipramine, increases the sympathomimetic effect of procaterol."
1328,"Doxepin","DB01142","The tricyclic antidepressant, doxepin, increases the sympathomimetic effect of procaterol."
1328,"Esmolol","DB00187","Antagonism"
1328,"Imipramine","DB00458","The tricyclic antidepressant, imipramine, increases the sympathomimetic effect of procaterol."
1328,"Isocarboxazid","DB01247","Increased arterial pressure"
1328,"Labetalol","DB00598","Antagonism"
1328,"Linezolid","DB00601","Possible increase of arterial pressure"
1328,"Methyldopa","DB00968","Increased arterial pressure"
1328,"Metoprolol","DB00264","Antagonism"
1328,"Midodrine","DB00211","Increased arterial pressure"
1328,"Moclobemide","DB01171","Moclobemide increases the sympathomimetic effect of procaterol."
1328,"Nadolol","DB01203","Antagonism"
1328,"Nortriptyline","DB00540","The tricyclic antidepressant, nortriptyline, increases the sympathomimetic effect of procaterol."
1328,"Phenelzine","DB00780","Increased arterial pressure"
1328,"Pindolol","DB00960","Antagonism"
1328,"Propranolol","DB00571","Antagonism"
1328,"Rasagiline","DB01367","Increased arterial pressure"
1328,"Reserpine","DB00206","Increased arterial pressure"
1328,"Timolol","DB00373","Antagonism"
1329,"Altretamine","DB00488","Risk of severe hypotension"
1329,"Amitriptyline","DB00321","Possibility of severe adverse effects"
1329,"Amoxapine","DB00543","Possibility of severe adverse effects"
1329,"Amphetamine","DB00182","Possible hypertensive crisis"
1329,"Atomoxetine","DB00289","Possible severe adverse reaction with this combination"
1329,"Benzphetamine","DB00865","MAO Inhibitors may enhance the hypertensive effect of Amphetamines. Concomitant use of amphetamines and monoamine oxidase inhibitors (MAOI) should be avoided. If used concomitantly, careful monitoring of blood pressure must occur. It may take up to 2 weeks after the discontinuation of an MAOI for the effects to dissipate enough to afford safety to the administration of interacting agents. "
1329,"Bezafibrate","DB01393","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) rasagiline. "
1329,"Brimonidine","DB00484","MAO Inhibitors like rasagiline may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic). The concomitant use of monoamine oxidase inhibitors and ophthalmic alpha2 agonists is contraindicated. "
1329,"Buprenorphine","DB00921","Buprenorphine may enhance the adverse/toxic effect of MAO Inhibitors like rasagiline. When possible, avoid use of buprenorphine in patients who have used a monoamine oxidase inhibitor within the past 14 days due to possible severe adverse effects. "
1329,"Bupropion","DB01156","Possible severe adverse reaction with this combination"
1329,"Buspirone","DB00490","Possible blood pressure elevation"
1329,"Ciprofloxacin","DB00537","Ciprofloxacin, a strong CYP1A2 inhibitor, may decrease the metabolism of rasagiline. Monitor for changes in the therapeutic and adverse effects of rasagiline if ciprofloxacin is initiated or discontinued."
1329,"Citalopram","DB00215","Possible severe adverse reaction with this combination"
1329,"Clomipramine","DB01242","Possibility of severe adverse effects"
1329,"Cyclobenzaprine","DB00924","Increased risk of toxicity with this association"
1329,"Desipramine","DB01151","Possibility of severe adverse effects"
1329,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1329,"Dexfenfluramine","DB01191","Possible hypertensive crisis"
1329,"Dextroamphetamine","DB01576","Possible hypertensive crisis"
1329,"Dextromethorphan","DB00514","Possible severe adverse reaction"
1329,"Diethylpropion","DB00937","Possible hypertensive crisis"
1329,"Dobutamine","DB00841","Increased arterial pressure"
1329,"Dopamine","DB00988","Increased arterial pressure"
1329,"Doxepin","DB01142","Possibility of severe adverse effects"
1329,"Duloxetine","DB00476","Possible severe adverse reaction with this combination"
1329,"Ephedra","DB01363","Increased arterial pressure"
1329,"Ephedrine","DB01364","Increased arterial pressure"
1329,"Epinephrine","DB00668","Increased arterial pressure"
1329,"Escitalopram","DB01175","Possible severe adverse reaction with this combination"
1329,"Fenfluramine","DB00574","Possible hypertensive crisis"
1329,"Fenoterol","DB01288","Increased arterial pressure"
1329,"Fluoxetine","DB00472","Possible severe adverse reaction with this combination"
1329,"Fluvoxamine","DB00176","Possible severe adverse reaction with this combination"
1329,"Imipramine","DB00458","Possibility of severe adverse effects"
1329,"Isoprenaline","DB01064","Increased arterial pressure"
1329,"Mazindol","DB00579","Possible hypertensive crisis"
1329,"Mephentermine","DB01365","Increased arterial pressure"
1329,"Metaraminol","DB00610","Increased arterial pressure"
1329,"Methamphetamine","DB01577","Possible hypertensive crisis"
1329,"Methoxamine","DB00723","Increased arterial pressure"
1329,"Methylphenidate","DB00422","Possible hypertensive crisis with this combination."
1329,"Midodrine","DB00211","Risk of hypertensive crisis."
1329,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated.  "
1329,"Mirtazapine","DB00370","Possible severe adverse reaction with this combination"
1329,"Nefazodone","DB01149","Possible severe adverse reaction with this combination"
1329,"Norepinephrine","DB00368","Increased arterial pressure"
1329,"Nortriptyline","DB00540","Possibility of severe adverse effects"
1329,"Orciprenaline","DB00816","Increased arterial pressure"
1329,"Paroxetine","DB00715","Possible severe adverse reaction with this combination"
1329,"Pethidine","DB00454","Increased risk of serotonin syndrome. Concomitant use should be avoided."
1329,"Phendimetrazine","DB01579","Possible hypertensive crisis"
1329,"Phenmetrazine","DB00830","Possible hypertensive crisis"
1329,"Phentermine","DB00191","Possible hypertensive crisis"
1329,"Phenylephrine","DB00388","Increased arterial pressure"
1329,"Phenylpropanolamine","DB00397","Increased arterial pressure"
1329,"Pirbuterol","DB01291","Increased arterial pressure"
1329,"Procaterol","DB01366","Increased arterial pressure"
1329,"Protriptyline","DB00344","Possibility of severe adverse effects"
1329,"Pseudoephedrine","DB00852","Increased arterial pressure"
1329,"Salbutamol","DB01001","Increased arterial pressure"
1329,"Sertraline","DB01104","Possible severe adverse reaction with this combination"
1329,"Sibutramine","DB01105","Possible serotoninergic syndrome with this combination"
1329,"St. John's Wort","DB01323","Increased risk of toxicity with this association"
1329,"Tapentadol","DB06204","Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration. "
1329,"Terbutaline","DB00871","Increased arterial pressure"
1329,"Tetrabenazine","DB04844","Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated."
1329,"Tolcapone","DB00323","Tolcapone and Rasagiline decrease the metabolism of endogenous catecholamines. Concomitant therapy may result in increased catecholamine effects. Consider alternate therapy or use cautiously and monitor for increased catecholamine effects. "
1329,"Tramadol","DB00193","Tramadol may increase the risk of serotonin syndrome and seizure induction by the MAO inhibitor, rasagiline."
1329,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. "
1329,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1329,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Avoid combination or monitor for symptoms of serotonin syndrome and/or hypertensive crisis."
1329,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
1329,"Zolmitriptan","DB00315","The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated. "
1330,"Amlodipine","DB00381","This combination presents an increased risk of toxicity"
1330,"Arsenic trioxide","DB01169","This combination presents an increased risk of toxicity"
1330,"Astemizole","DB00637","This combination presents an increased risk of toxicity"
1330,"Atorvastatin","DB01076","This combination presents an increased risk of toxicity"
1330,"Carbamazepine","DB00564","This combination presents an increased risk of toxicity"
1330,"Cerivastatin","DB00439","This combination presents an increased risk of toxicity"
1330,"Cisapride","DB00604","This combination presents an increased risk of toxicity"
1330,"Clarithromycin","DB01211","This combination presents an increased risk of toxicity"
1330,"Cyclosporine","DB00091","Synercid increases the effect of cyclosporine"
1330,"Delavirdine","DB00705","This combination presents an increased risk of toxicity"
1330,"Diazepam","DB00829","This combination presents an increased risk of toxicity"
1330,"Dihydroquinidine barbiturate","DB01341","This combination presents an increased risk of toxicity"
1330,"Diltiazem","DB00343","This combination presents an increased risk of toxicity"
1330,"Disopyramide","DB00280","This combination presents an increased risk of toxicity"
1330,"Docetaxel","DB01248","This combination presents an increased risk of toxicity."
1330,"Dofetilide","DB00204","This combination presents an increased risk of toxicity"
1330,"Droperidol","DB00450","This combination presents an increased risk of toxicity"
1330,"Erythromycin","DB00199","This combination presents an increased risk of toxicity"
1330,"Etoposide","DB00773","This combination presents an increased risk of toxicity"
1330,"Felbamate","DB00949","This combination presents an increased risk of toxicity"
1330,"Felodipine","DB01023","This combination presents an increased risk of toxicity"
1330,"Flecainide","DB01195","This combination presents an increased risk of toxicity"
1330,"Foscarnet","DB00529","This combination presents an increased risk of toxicity"
1330,"Fosphenytoin","DB01320","This combination presents an increased risk of toxicity"
1330,"Gatifloxacin","DB01044","This combination presents an increased risk of toxicity"
1330,"Grepafloxacin","DB00365","This combination presents an increased risk of toxicity"
1330,"Halofantrine","DB01218","This combination presents an increased risk of toxicity"
1330,"Indinavir","DB00224","This combination presents an increased risk of toxicity"
1330,"Isradipine","DB00270","This combination presents an increased risk of toxicity"
1330,"Lercanidipine","DB00528","This combination presents an increased risk of toxicity"
1330,"Levofloxacin","DB01137","This combination presents an increased risk of toxicity"
1330,"Levomethadyl Acetate","DB01227","This combination presents an increased risk of toxicity"
1330,"Lidocaine","DB00281","This combination presents an increased risk of toxicity"
1330,"Losartan","DB00678","This combination presents an increased risk of toxicity"
1330,"Lovastatin","DB00227","This combination presents an increased risk of toxicity"
1330,"Methylprednisolone","DB00959","This combination presents an increased risk of toxicity"
1330,"Midazolam","DB00683","This combination presents an increased risk of toxicity"
1330,"Moexipril","DB00691","This combination presents an increased risk of toxicity"
1330,"Moxifloxacin","DB00218","This combination presents an increased risk of toxicity"
1330,"Nevirapine","DB00238","This combination presents an increased risk of toxicity"
1330,"Nicardipine","DB00622","This combination presents an increased risk of toxicity"
1330,"Nifedipine","DB01115","Synercid increases the effect of ziprasidone"
1330,"Nimodipine","DB00393","This combination presents an increased risk of toxicity"
1330,"Nisoldipine","DB00401","This combination presents an increased risk of toxicity"
1330,"Octreotide","DB00104","This combination presents an increased risk of toxicity"
1330,"Paclitaxel","DB01229","This combination presents an increased risk of toxicity"
1330,"Pentamidine","DB00738","This combination presents an increased risk of toxicity"
1330,"Quetiapine","DB01224","This combination presents an increased risk of toxicity"
1330,"Quinidine","DB00908","This combination presents an increased risk of toxicity"
1330,"Quinidine barbiturate","DB01346","This combination presents an increased risk of toxicity"
1330,"Ritonavir","DB00503","This combination presents an increased risk of toxicity"
1330,"Salmeterol","DB00938","This combination presents an increased risk of toxicity"
1330,"Simvastatin","DB00641","This combination presents an increased risk of toxicity"
1330,"Tacrolimus","DB00864","This combination presents an increased risk of toxicity"
1330,"Tamoxifen","DB00675","This combination presents an increased risk of toxicity"
1330,"Teniposide","DB00444","This combination presents an increased risk of toxicity"
1330,"Terfenadine","DB00342","This combination presents an increased risk of toxicity"
1330,"Tizanidine","DB00697","This combination presents an increased risk of toxicity"
1330,"Venlafaxine","DB00285","This combination presents an increased risk of toxicity"
1330,"Verapamil","DB00661","This combination presents an increased risk of toxicity"
1330,"Vinblastine","DB00570","This combination presents an increased risk of toxicity"
1330,"Vincristine","DB00541","This combination presents an increased risk of toxicity"
1330,"Vindesine","DB00309","This combination presents an increased risk of toxicity"
1330,"Vinorelbine","DB00361","This combination presents an increased risk of toxicity"
1331,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1331,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1331,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1331,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1331,"Clindamycin","DB01190","The aluminium salt decreases the absorption of lincosamides"
1331,"Clodronate","DB00720","Formation of non-absorbable complexes"
1331,"Dapsone","DB00250","Formation of non-absorbable complexes"
1331,"Deferasirox","DB01609","Possible physicochemical interaction"
1331,"Delavirdine","DB00705","The antiacid decreases the effect of delavirdine"
1331,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1331,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1331,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
1331,"Fosamprenavir","DB01319","The antiacid decreases the absorption of amprenavir"
1331,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1331,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1331,"Grepafloxacin","DB00365","Formation of non-absorbable complexes "
1331,"Ibandronate","DB00710","Formation of non absorbable complexes"
1331,"Indinavir","DB00224","The antacid decreases the absorption of indinavir"
1331,"Itraconazole","DB01167","Aluminum-containing antacids may decrease the effect of itraconazole."
1331,"Ketoconazole","DB01026","Aluminum-containing antacids may decrease the effect of ketoconazole."
1331,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1331,"Lincomycin","DB01627","The aluminium salt decreases the absorption of lincosamides"
1331,"Minocycline","DB01017","Formation of non-absorbable complexes"
1331,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1331,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1331,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1331,"Penciclovir","DB00299","The multivalent agent decreases the effect of penicillamine"
1331,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
1331,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1331,"Trovafloxacin","DB00685","Aluminum may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the aluminum containing agent to minimize the interaction. "
1332,"Alendronate","DB00630","Formation of non-absorbable complexes"
1332,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1332,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1332,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1332,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1332,"Clodronate","DB00720","Formation of non-absorbable complexes"
1332,"Dapsone","DB00250","Formation of non-absorbable complexes"
1332,"Deferiprone","DB08826","Deferiprone serum concentrations may be decreased by calcium salts."
1332,"Delavirdine","DB00705","The antiacid decreases the effect of delavirdine"
1332,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1332,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1332,"Enoxacin","DB00467","Formation of non-absorbable complexes"
1332,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
1332,"Fosamprenavir","DB01319","The antiacid decreases the absorption of amprenavir"
1332,"Grepafloxacin","DB00365","Calcium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours."
1332,"Ibandronate","DB00710","Formation of non-absorbable complexes"
1332,"Indinavir","DB00224","Calcium may decrease the absorption of indinavir."
1332,"Itraconazole","DB01167","Calcium-containing antacids may decrease the effect of itraconazole."
1332,"Ketoconazole","DB01026","Calcium-containing antacids may decrease the absorption of ketoconazole."
1332,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1332,"Levothyroxine","DB00451","Calcium decreases absorption of levothyroxine"
1332,"Lomefloxacin","DB00978","Formation of non-absorbable complexes"
1332,"Methacycline","DB00931","Formation of non-absorbable complexes"
1332,"Minocycline","DB01017","Formation of non-absorbable complexes"
1332,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1332,"Mycophenolate mofetil","DB00688","Formation of non-absorbable complexes"
1332,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1332,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1332,"Oxytetracycline","DB00595","Formation of non-absorbable complexes"
1332,"Pefloxacin","DB00487","Formation of non-absorbable complexes"
1332,"Polystyrene sulfonate","DB01344","Formation of non-absorbable complexes"
1332,"Risedronate","DB00884","Formation of non-absorbable complexes"
1332,"Temafloxacin","DB01405","Formation of non-absorbable complexes"
1332,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1332,"Trovafloxacin","DB00685","Formation of non-absorbable complexes"
1333,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1333,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1333,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1333,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1333,"Clindamycin","DB01190","The aluminium salt decreases the absorption of lincosamides"
1333,"Clodronate","DB00720","Formation of non-absorbable complexes"
1333,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1334,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1334,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1334,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1334,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1334,"Clodronate","DB00720","Formation of non-absorbable complexes"
1334,"Dapsone","DB00250","Formation of non-absorbable complexes"
1334,"Delavirdine","DB00705","The antiacid decreases the effect of delavirdine"
1334,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1334,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1334,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
1334,"Fosamprenavir","DB01319","The antiacid decreases the absorption of amprenavir"
1334,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1334,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1334,"Grepafloxacin","DB00365","Formation of non-absorbable complexes "
1334,"Ibandronate","DB00710","Formation of non absorbable complexes"
1334,"Indinavir","DB00224","The antacid decreases the absorption of indinavir"
1334,"Itraconazole","DB01167","The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption. "
1334,"Ketoconazole","DB01026","The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption. "
1334,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1334,"Minocycline","DB01017","Formation of non-absorbable complexes"
1334,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1334,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1334,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1334,"Tiludronate","DB01133","The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. "
1334,"Trovafloxacin","DB00685","Magnesium may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the magnesium containing agent to minimize the interaction. "
1335,"Alendronate","DB00630","Formation of non-absorbable complexes"
1335,"Amprenavir","DB00701","The antiacid decreases the absorption of amprenavir"
1335,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effects of atazanavir"
1335,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1335,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1335,"Clodronate","DB00720","Formation of non-absorbable complexes"
1335,"Dapsone","DB00250","Formation of non-absorbable complexes"
1335,"Deferiprone","DB08826","Deferiprone serum concentrations may be decreased by magnesium salts."
1335,"Delavirdine","DB00705","Magnesium antacids may decrease the absorption of delavirdine."
1335,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1335,"Dihydroquinidine barbiturate","DB01341","The antiacid decreases the absorption of quinidine"
1335,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1335,"Enoxacin","DB00467","Formation of non-absorbable complexes"
1335,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
1335,"Fosamprenavir","DB01319","The antiacid decreases the absorption of amprenavir"
1335,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1335,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1335,"Grepafloxacin","DB00365","Magnesium may decrease the absorption of grepafloxacin. Doses should be spaced apart by at least 2 hours."
1335,"Ibandronate","DB00710","Formation of non-absorbable complexes"
1335,"Indinavir","DB00224","Magnesium may decrease the absorption of indinavir."
1335,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1335,"Lomefloxacin","DB00978","Formation of non-absorbable complexes"
1335,"Methacycline","DB00931","Formation of non-absorbable complexes"
1335,"Minocycline","DB01017","Formation of non-absorbable complexes"
1335,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1335,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1335,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1335,"Oxytetracycline","DB00595","Formation of non-absorbable complexes"
1335,"Pefloxacin","DB00487","Formation of non-absorbable complexes"
1335,"Polystyrene sulfonate","DB01344","Risk of alkalosis in renal impairment"
1335,"Quinidine","DB00908","Magnesium antacids may decrease the absorption of quindine."
1335,"Quinidine barbiturate","DB01346","The antiacid decreases the absorption of quinidine"
1335,"Risedronate","DB00884","Formation of non-absorbable complexes"
1335,"Rosuvastatin","DB01098","Magnesium-containing antacids may decrease the absorption of rosuvastatin."
1335,"Temafloxacin","DB01405","Formation of non-absorbable complexes"
1335,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1335,"Trovafloxacin","DB00685","Formation of non-absorbable complexes"
1336,"Acetylsalicylic acid","DB00945","The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid."
1336,"F","DB06223","decreases the effect of cortisone by metabolism alteration. "
1336,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, cortisone acetate."
1336,"Midodrine","DB00211","Increased arterial pressure"
1336,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, cortisone acetate."
1336,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, cortisone acetate."
1336,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, cortisone acetate."
1336,"Pyridostigmine","DB00545","The corticosteroid, cortisone acetate, may decrease the effect of the anticholinesterase, pyridostigmine."
1336,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, cortisone acetate."
1336,"Tacrine","DB00382","Tacrine and Cortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects."
1336,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
1336,"Vecuronium","DB01339","Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. "
1337,"Abciximab","DB00054","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Acenocoumarol","DB01418","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. "
1337,"Acetylsalicylic acid","DB00945","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Alteplase","DB00009","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Anagrelide","DB00261","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Argatroban","DB00278","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Bivalirudin","DB00006","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Cilostazol","DB01166","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Citalopram","DB00215","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Clopidogrel","DB00758","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Dabigatran etexilate","DB06695","Additive anticoagulant/antiplatelet effects of gingko may increase bleed risk for patients on dabigatran. Concomitant therapy should be avoided."
1337,"Diclofenac","DB00586","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Diflunisal","DB00861","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Dipyridamole","DB00975","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Enoxaparin","DB01225","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Eptifibatide","DB00063","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Escitalopram","DB01175","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Etodolac","DB00749","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Fenoprofen","DB00573","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Fluoxetine","DB00472","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Flurbiprofen","DB00712","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Fluvoxamine","DB00176","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Fondaparinux sodium","DB00569","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Ginseng","DB01404","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Heparin","DB01109","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Ibuprofen","DB01050","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Indomethacin","DB00328","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Ketoprofen","DB01009","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1337,"Ketorolac","DB00465","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Lepirudin","DB00001","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Meclofenamic acid","DB00939","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Meloxicam","DB00814","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Nabumetone","DB00461","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Naproxen","DB00788","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Oxaprozin","DB00991","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Paroxetine","DB00715","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Piroxicam","DB00554","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Prasugrel","DB06209","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Reteplase","DB00015","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Rivaroxaban","DB06228","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"S-Adenosylmethionine","DB00118","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Sertraline","DB01104","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Sulindac","DB00605","Ginkgo biloba may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided."
1337,"Tacrine","DB00382","Ginkgo biloba may cause additive/toxic cholinergic effects when administered with Tacrine. Monitor for cholinergic toxicity. "
1337,"Tenecteplase","DB00031","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Tiaprofenic acid","DB01600","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1337,"Ticlopidine","DB00208","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Tirofiban","DB00775","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1337,"Tolmetin","DB00500","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1337,"Trazodone","DB00656","Increased effect and toxicity of both agents"
1337,"Urokinase","DB00013","Increased risk of bleeding. "
1337,"Warfarin","DB00682","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1338,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine."
1338,"Atenolol","DB00335","The beta-blocker, atenolol, may decrease symptoms of hypoglycemia."
1338,"Bisoprolol","DB00612","The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia."
1338,"Carvedilol","DB01136","The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia."
1338,"Chloramphenicol","DB00446","Chloramphenicol may increase the effect of sulfonylurea, glycodiazine."
1338,"Clofibrate","DB00636","Clofibrate may increase the effect of sulfonylurea, glycodiazine."
1338,"Esmolol","DB00187","The beta-blocker, esmolol, may decrease symptoms of hypoglycemia."
1338,"Labetalol","DB00598","The beta-blocker, labetalol, may decrease symptoms of hypoglycemia."
1338,"Metoprolol","DB00264","The beta-blocker, metoprolol, may decrease symptoms of hypoglycemia."
1338,"Nadolol","DB01203","The beta-blocker, nadolol, may decrease symptoms of hypoglycemia."
1338,"Oxprenolol","DB01580","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1338,"Phenylbutazone","DB00812","Phenylbutazone increases the effect of the hypoglycemic agent"
1338,"Pindolol","DB00960","The beta-blocker, pindolol, may decrease symptoms of hypoglycemia."
1338,"Propranolol","DB00571","The beta-blocker, propranolol, may decrease symptoms of hypoglycemia."
1338,"Rifampicin","DB01045","Rifampin may decrease the effect of sulfonylurea, glycodiazine."
1338,"Timolol","DB00373","The beta-blocker, timolol, may decrease symptoms of hypoglycemia."
1339,"Acetylsalicylic acid","DB00945","The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid."
1339,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, paramethasone."
1339,"Midodrine","DB00211","Increased arterial pressure"
1339,"Phenobarbital","DB01174","The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, paramethasone."
1339,"Phenytoin","DB00252","The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, paramethasone."
1339,"Primidone","DB00794","The barbiturate, primidone, may decrease the effect of the corticosteroid, paramethasone."
1339,"Pyridostigmine","DB00545","The corticosteroid, paramethasone, may decrease the effect of the anticholinesterase, pyridostigmine."
1339,"Rifampicin","DB01045","The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, paramethasone."
1340,"Astemizole","DB00637","Increased risk of cardiotoxicity and arrhythmias"
1340,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1340,"Cisapride","DB00604","Mibefradil increases levels of cisapride"
1340,"Tacrolimus","DB00864","The calcium channel blocker, Mibefradil, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Mibefradil therapy is initiated, discontinued or altered."
1340,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1341,"Atazanavir","DB01072","This gastric pH modifier decreases the levels/effect of atazanavir"
1341,"Benzphetamine","DB00865","Alkalinizing agents such as sodium bicarbonate may decrease the excretion of amphetamines like benzphetamine. Increased clinical effects and/or toxicity may occur. Therapy modification should be considered."
1341,"Deferiprone","DB08826","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
1341,"Eltrombopag","DB06210","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
1341,"Lithium","DB01356","The urine alkalizer decreases the effect of lithium"
1341,"Memantine","DB01043","Possible increased levels of memantine"
1341,"Methenamine mandelate","DB06146","Urine alkalizer decreases the effect of methenamine"
1341,"Quinidine","DB00908","The antacid increases the effect of quinidine"
1341,"Ticlopidine","DB00208","Sodium bicarbonate may decrease Ticlopidine levels. Administer agents 1 to 2 hours apart. "
1341,"Tipranavir","DB00932","Sodium bicarbonate may decrease the absorption of Tipranavir. Separate administration of the agents and monitor for decreased efficacy of Tipranavir. "
1341,"Trandolapril","DB00519","Sodium bicarbonate may decrease the absorption of Trandolapril. Administration should be spaced."
1342,"Aliskiren","DB09026","Monitor therapy due to decreased antihypertensive effects of aliskiren. "
1342,"Asenapine","DB06216","Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
1342,"Atomoxetine","DB00289","The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine"
1343,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
1343,"Cerivastatin","DB00439","Increased risk of myopathy/rhabdomyolysis"
1343,"Cholestyramine","DB01432","Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.\
"
1343,"Conivaptan","DB00872","Conivaptan may increase the serum concentration of CYP3A4 substrates like bezafibrates. Consider therapy modification. Conivaptan may increase the serum concentration of CYP3A4 substrates."
1343,"Cyclosporine","DB00091","Cyclosporine may enhance the nephrotoxic effect of fibric acid derivatives like bezafibrate. Fibric acid derivatives may decrease the serum concentration of cyclosporine. Extra monitoring of renal function and cyclosporine concentrations will likely be required. Adjustment of cyclosporine dose may be necessary."
1343,"Fluvastatin","DB01095","Increased risk of myopathy/rhabdomyolysis"
1343,"Isocarboxazid","DB01247","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like isocarboxazid. "
1343,"Linezolid","DB00601","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like linezolid. "
1343,"Lovastatin","DB00227","Increased risk of myopathy/rhabdomyolysis"
1343,"Moclobemide","DB01171","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like moclobemide. "
1343,"Phenelzine","DB00780","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like phenelzine. "
1343,"Pravastatin","DB00175","Increased risk of myopathy/rhabdomyolysis"
1343,"Procarbazine","DB01168","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like procarbazine. "
1343,"Rasagiline","DB01367","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) rasagiline. "
1343,"Selegiline","DB01037","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like selegiline. "
1343,"Tranylcypromine","DB00752","MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate. Avoid concomitant use of bezafibrate with monoamine oxidase inhibitors (MAOIs) like tranylcypromine. "
1343,"Warfarin","DB00682","Bezafibrate may increase the anticoagulant effect of warfarin. Monitor prothrombin time and therapeutic and adverse effects of warfarin if bezafibrate is initiated, discontinued or dose changed. "
1344,"Atorvastatin","DB01076","Increased risk of rhadbomyolysis with this combination."
1344,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of colchicine. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function."
1344,"Cerivastatin","DB00439","Increased risk of rhabdomyolysis with this combination"
1344,"Clarithromycin","DB01211","Severe colchicine toxicity can occur"
1344,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of colchicine. Reduce colchicine dose (for gout flares: to 1.2 mg x 1 dose, with next dose no sooner than 3 days later; for Familial Mediterranean Fever: to no more than 1.2 mg/day) when using in combination with a moderate CYP3A4 inhibitor such as erythromycin or verapamil. Increase monitoring for colchicine-related toxicity when using such combinations. Use extra caution in patients with impaired renal and/or hepatic function. "
1344,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine. In patients with normal renal and hepatic function, reduce colchicine dose (for gout flares: to 0.6 mg x 1 dose, followed by 0.3 mg 1 hour later, with next dose no sooner than 3 days later; for gout flare prophylaxis: if target dose would otherwise be 0.6 mg daily, change to 0.3 mg every other day, and if target dose would otherwise be 0.6 mg twice daily, change to 0.3 mg daily; for Familial Mediterranean Fever: to no more than 0.6 mg/day) when using in combination with a strong CYP3A4 inhibitor such as clarithromycin or ritonavir. Increase monitoring for colchicine-related toxicity when using such combinations. Colchicine use is contraindicated in patients with impaired renal and/or hepatic function who are also receiving a strong CYP3A4 inhibitor. "
1344,"Cyclosporine","DB00091","Increased toxicity of both drugs"
1344,"Erythromycin","DB00199","Severe colchicine toxicity can occur"
1344,"Fluvastatin","DB01095","Increased risk of rhabdomyolysis with this combination"
1344,"Lovastatin","DB00227","Increased risk of rhabdomyolysis with this combination"
1344,"Pitavastatin","DB08860","Increased incidence of myotoxicity including rhabdomyolysis during concomitant therapy. The mechanism of this interaction is unclear, it may arise from pharmacodynamic and/or pharmacokinetic interactions. "
1344,"Pravastatin","DB00175","Increased risk of rhabdomyolysis with this combination"
1344,"Rosuvastatin","DB01098","Increased risk of rhabdomyolysis with this combination"
1344,"Simvastatin","DB00641","Increased risk of rhabdomyolysis with this combination"
1344,"Telithromycin","DB00976","Telithromycin may reduce clearance of Colchicine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Colchicine if Telithromycin is initiated, discontinued or dose changed."
1344,"Troleandomycin","DB01361","Severe colchicine toxicity can occur"
1344,"Verapamil","DB00661","Verapamil may increase the serum concentration of Colchicine. This likely occurs via Verapamil-mediated inhibition of CYP3A4 and p-glycoprotein-mediated transport. Monitor for changes in the therapeutic/adverse effects of Colchicine if Verapamil is initiated, discontinued or dose changed."
1344,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of colchicine by decreasing its metabolism. A dose reduction of colchicine is recommended along with increased monitoring for colchicine toxicity. Concomitant therapy is contraindicated in patients with renal and/or hepatic impairment. "
1345,"Artemether","DB06697","Artemether may decrease the effectiveness of drospirinone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
1345,"Benazepril","DB00542","Increased risk of hyperkalemia"
1345,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of drospirenone, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
1345,"Boceprevir","DB08873","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
1345,"Candesartan","DB00796","Increased risk of hyperkalemia"
1345,"Captopril","DB01197","Increased risk of hyperkalemia"
1345,"Cilazapril","DB01340","Increased risk of hyperkalemia"
1345,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
1345,"Enalapril","DB00584","Increased risk of hyperkalemia"
1345,"Eprosartan","DB00876","Increased risk of hyperkalemia"
1345,"Fosinopril","DB00492","Increased risk of hyperkalemia"
1345,"Heparin","DB01109","Heparin can increase risk of hyperkalemia for patients on drospirenone"
1345,"Irbesartan","DB01029","Increased risk of hyperkalemia"
1345,"Lisinopril","DB00722","Increased risk of hyperkalemia"
1345,"Losartan","DB00678","Increased risk of hyperkalemia"
1345,"Olmesartan","DB00275","Increased risk of hyperkalemia"
1345,"Perindopril","DB00790","Increased risk of hyperkalemia"
1345,"Potassium","DB01345","Increased risk of hyperkalemia"
1345,"Quinapril","DB00881","Increased risk of hyperkalemia"
1345,"Ramipril","DB00178","Increased risk of hyperkalemia"
1345,"Telmisartan","DB00966","Telmisartan may increase the hyperkalemic effect of Drospirenone. Monitor for increased serum potassium concentrations during concomitant therapy. "
1345,"Thiopental","DB00599","Thiopental may decrease the effect of Drospirenone. Contraceptive failure may occur. Alternative nonhomomonal contraception should be used during concomitant therapy. "
1345,"Trandolapril","DB00519","Increased risk of hyperkalemia. Monitor serum potassium levels. "
1345,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1345,"Tretinoin","DB00755","Oral Tretinoin may decrease the effect of oral contraceptive, Drospirenone. An alternate form of contraception should be used during concomitant therapy. "
1345,"Triamterene","DB00384","Increased risk of hyperkalemia"
1345,"Warfarin","DB00682","Drospirenone may alter the anticoagulant effect of warfarin. Concomitant therapy should be avoided. Monitor for changes in coagulation status if drospirenone is initiated, discontinued or dose changed."
1346,"Bendroflumethiazide","DB00436","Possible electrolyte variations and arrhythmias"
1346,"Bumetanide","DB00887","Possible electrolyte variations and arrhythmias"
1346,"Chlorthalidone","DB00310","Possible electrolyte variations and arrhythmias"
1346,"Ethacrynic acid","DB00903","Possible electrolyte variations and arrhythmias"
1346,"Furosemide","DB00695","Possible electrolyte variations and arrhythmias"
1346,"Hydrochlorothiazide","DB00999","Possible electrolyte variations and arrhythmias"
1346,"Indapamide","DB00808","Possible electrolyte variations and arrhythmias"
1346,"Metolazone","DB00524","Possible electrolyte variations and arrhythmias"
1346,"Quinidine","DB00908","Quinine/quinidine increases the effect of digoxin"
1346,"Quinine","DB00468","Quinine/quinidine increases the effect of digoxin"
1346,"Telithromycin","DB00976","Telithromycin may reduce clearance of Digitoxin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Digitoxin if Telithromycin is initiated, discontinued or dose changed."
1346,"Verapamil","DB00661","Verapamil may increase the serum concentration of Digitoxin by decreasing its metabolism and clearance. Monitor for changes in the therapeutic/adverse effects of Digitoxin if Verpamail is initiated, discontinued or dose changed."
1346,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of digitoxin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of digitoxin if voriconazole is initiated, discontinued or dose changed."
1347,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of magnesium salicylate. "
1347,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of magnesium salicylate. "
1347,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of magnesium salicylate. "
1347,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1347,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1347,"Gliclazide","DB01120","The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, gliclazide."
1347,"Glyburide","DB01016","The salicylate, magnesium salicylate, increases the effect of the sulfonylurea, glibenclamide."
1347,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of magnesium salicylate. "
1347,"Methazolamide","DB00703","The salicylate, magnesium salicylate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
1347,"Methotrexate","DB00563","The salicylate, magnesium salicylate, increases the effect and toxicity of methotrexate."
1347,"Minocycline","DB01017","Formation of non-absorbable complexes"
1347,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate."
1347,"Prednisone","DB00635","The corticosteroid, prednisolone, may decrease the effect of magnesium salicylate. "
1347,"Probenecid","DB01032","The salicylate, magnesium salicylate, decreases the uricosuric effect of probenecid."
1347,"Quinidine","DB00908","The antacid increases the effect of quinidine"
1347,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1347,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of magnesium salicylate."
1348,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Gliclazide","DB01120","The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, gliclazide."
1348,"Glyburide","DB01016","The salicylate, salicylate-sodium, increases the effect of the sulfonylurea, glibenclamide."
1348,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Methazolamide","DB00703","The salicylate, salicylate-sodium, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
1348,"Methotrexate","DB00563","The salicylate, salicylate-sodium, increases the effect and toxicity of methotrexate."
1348,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Probenecid","DB01032","The salicylate, salicylate-sodium, decreases the uricosuric effect of probenecid."
1348,"Sulindac","DB00605","Risk of additive toxicity (e.g. bleed risk). Salicylate-sodium may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."
1348,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salicylate-sodium."
1348,"Warfarin","DB00682","The antiplatelet effects of sodium salicylate may increase the bleed risk associated with warfarin."
1349,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the salicylate, salsalate."
1349,"Chlorpropamide","DB00672","The salicylate, salsalate, increases the effect of the sulfonylurea, chlorpropamide."
1349,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the salicylate, salsalate."
1349,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, salsalate."
1349,"Gliclazide","DB01120","The salicylate, salsalate, increases the effect of the sulfonylurea, gliclazide."
1349,"Glyburide","DB01016","The salicylate, salsalate, increases the effect of the sulfonylurea, glibenclamide."
1349,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate."
1349,"Methazolamide","DB00703","The salicylate, salsalate, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
1349,"Methotrexate","DB00563","The salicylate, salsalate, increases the effect and toxicity of methotrexate."
1349,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the salicylate, salsalate."
1349,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate."
1349,"Probenecid","DB01032","The salicylate, salsalate, decreases the uricosuric effect of probenecid."
1349,"Sulindac","DB00605","Risk of additive toxicity (e.g. bleed risk). Salsalate may decrease the serum concentration of sulindac. Consider alternate therapy or monitor for changes in the therapeutic effects of sulindac and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed."
1349,"Tiaprofenic acid","DB01600","Increased risk of gastrointestinal bleeding. "
1349,"Tolmetin","DB00500","Additive effects increase the risk of GI bleeding. Monitor for increased bleeding risk during concomitant therapy. "
1349,"Trandolapril","DB00519","The salicylate, Salsalate, may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Salsalate is initiated, discontinued or dose changed. "
1349,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the salicylate, Salsalate. Monitor for increased bleeding during concomitant thearpy. "
1349,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, salsalate."
1350,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, may decrease the effect of the anticholinesterase, neostigmine."
1350,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the anticholinesterase, neostigmine."
1350,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine."
1350,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the anticholinesterase, neostigmine."
1350,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine."
1350,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the anticholinesterase, neostigmine."
1351,"Betamethasone","DB00443","The corticosteroid, betamethasone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Chlorpropamide","DB00672","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, chlorpropamide."
1351,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Gliclazide","DB01120","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, gliclazide."
1351,"Glyburide","DB01016","The salicylate, trisalicylate-choline, increases the effect of the sulfonylurea, glibenclamide."
1351,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Methazolamide","DB00703","The salicylate, trisalicylate-choline, at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide."
1351,"Methotrexate","DB00563","The salicylate, trisalicylate-choline, increases the effect and toxicity of methotrexate."
1351,"Minocycline","DB01017","Formation of non-absorbable complexes"
1351,"Prednisolone","DB00860","The corticosteroid, prednisolone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Prednisone","DB00635","The corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Probenecid","DB01032","The salicylate, trisalicylate-choline, decreases the uricosuric effect of probenecid."
1351,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1351,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, may decrease the effect of the salicylate, trisalicylate-choline."
1351,"Warfarin","DB00682","The antiplatelet effects of trisalicylate-choline may increase the bleed risk associated with warfarin."
1352,"Amphetamine","DB00182","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1352,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
1352,"Brimonidine","DB00484","Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification. "
1352,"Bromazepam","DB01558","Concomitant therapy may result in additive CNS depressant effects. The dosage of bromazepam should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression. "
1352,"Bromocriptine","DB01200","The phenothiazine decreases the effect of bromocriptine"
1352,"Carisoprodol","DB00395","Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy. "
1352,"Cisapride","DB00604","Increased risk of cardiotoxicity and arrhythmias"
1352,"Dantrolene","DB01219","Concomitant therapy may result in additive CNS depressant effects. The dosage of dantrolene should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression."
1352,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Donepezil","DB00843","Possible antagonism of action"
1352,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Galantamine","DB00674","Possible antagonism of action"
1352,"Gatifloxacin","DB01044","Increased risk of cardiotoxicity and arrhythmias"
1352,"Grepafloxacin","DB00365","Increased risk of cardiotoxicity and arrhythmias"
1352,"Guanethidine","DB01170","Methotrimeprazine may decrease the effect of guanethidine."
1352,"Isocarboxazid","DB01247","Possible severe adverse reaction with this combination"
1352,"Levofloxacin","DB01137","Increased risk of cardiotoxicity and arrhythmias"
1352,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1352,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Methamphetamine","DB01577","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Metrizamide","DB01578","Increased risk of convulsions"
1352,"Paliperidone","DB01267","The CNS depressant agents, paliperidone and methotrimeprazine, may cause additive CNS depressant effects. Monitor for increased CNS depressant effects during concomitant therapy. "
1352,"Pargyline","DB01626","Possible severe adverse reaction with this combination"
1352,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
1352,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms"
1352,"Rivastigmine","DB00989","Possible antagonism of action"
1352,"Sparfloxacin","DB01208","Increased risk of cardiotoxicity and arrhythmias"
1352,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1352,"Tramadol","DB00193","Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required. "
1352,"Tranylcypromine","DB00752","Possible severe adverse reaction with this combination"
1352,"Vigabatrin","DB01080","Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy. "
1352,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1352,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1352,"Zaleplon","DB00962","Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy. "
1352,"Ziconotide","DB06283","Additive CNS depressant effects may occur. A dose reduction of ziconotide may be required. Monitor for increased CNS depression during concomitant therapy."
1352,"Ziprasidone","DB00246","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
1352,"Zolpidem","DB00425","Additive CNS depressant effects. Reduce zolpidem dose by half upon initiation of methotrimeprazine. Zolpidem dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression. "
1352,"Zonisamide","DB00909","Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression."
1352,"Zopiclone","DB01198","Additive CNS depressant effects. Reduce zopiclone dose by half upon initiation of methotrimeprazine. Zopiclone dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression."
1352,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed."
1353,"Bumetanide","DB00887","Ginseng may decrease the therapeutic effect of diuretic, bumetanide."
1353,"Digoxin","DB00390","Changes in digoxin serum levels"
1353,"Ethacrynic acid","DB00903","Ginseng may decrease the therapeutic effect of diuretic, ethacrynic acid."
1353,"Furosemide","DB00695","Ginseng decreases the therapeutic effect"
1353,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
1353,"Ketoprofen","DB01009","Increased risk of bleeding due to additive anticoagulant properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1353,"Nifedipine","DB01115","Ginseng increases the effect and toxicity of nifedipine"
1353,"Sulindac","DB00605","Ginseng may enhance the anticoagulant effect of sulindac. Increased risk of bleeding, bruising and altered mental status due to CNS bleeds. Concomitant therapy should be avoided. "
1353,"Tenecteplase","DB00031","Increased risk of bleeding. "
1353,"Tiaprofenic acid","DB01600","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1353,"Tolmetin","DB00500","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1353,"Trandolapril","DB00519","Ginseng may antagonize the antihypertensive effect of Trandolapril. Monitor Trandolapril efficacy."
1353,"Urokinase","DB00013","Increased risk of bleeding. "
1353,"Warfarin","DB00682","Additive anticoagulant effects increase the risk of bleeding. Concomitant therapy should be avoided."
1354,"Calcium","DB01373","Formation of non-absorbable complexes"
1354,"Iron Dextran","DB00893","Formation of non-absorbable complexes"
1354,"Magnesium","DB01378","Formation of non-absorbable complexes"
1355,"Acenocoumarol","DB01418","The androgen, danazol, may increase the anticoagulant effect of acenocoumarol."
1355,"Anisindione","DB01125","The androgen, danazol, may increase the anticoagulant effect of anisindione."
1355,"Carbamazepine","DB00564","Danazol may decrease the metabolism of carbamazepine. Monitor for changes in the therapeutic and adverse effects of carbamazepine if danazol is initiated, discontinued or dose changed."
1355,"Cyclosporine","DB00091","The androgen, danazol, may increase the effect and toxicity of cyclosporine."
1355,"Dicoumarol","DB00266","The androgen, danazol, may increase the anticoagulant effect of dicumarol."
1355,"Exenatide","DB01276","Monitor therapy due to reduced hypoglycemic effect of exenatide."
1355,"Insulin Aspart","DB01306","Monitor therapy due to decreased hypoglycemic effect of insulin aspart."
1355,"Lovastatin","DB00227","Risk of severe myopathy/rhabdomyolysis with this combination"
1355,"Tacrolimus","DB00864","Danazol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Danazol therapy is initiated, discontinued or altered."
1355,"Warfarin","DB00682","Danazol may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if danazol is initiated, discontinued or dose changed."
1357,"Indacaterol","DB05039","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
1358,"Potassium Chloride","DB00761","The ulcerative effects of solid oral dosage forms of KCl may be enhanced by Tiotropium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations."
1358,"Pramlintide","DB01278","The anticholinergic effects of Tiotropium may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1358,"Secretin","DB00021","The stimulatory effect of Secretin may be reduced by anticholinergics such as Tiotropium. Concomitant use of Secretin and drugs with substantial anticholinergic effects should be avoided. If combination therapy must be used, Secretin efficacy should be closely monitored."
1358,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Tiotropium, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1358,"Trimethobenzamide","DB00662","Trimethobenzamide and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1358,"Triprolidine","DB00427","Triprolidine and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1358,"Trospium","DB00209","Trospium and Tiotropium, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1359,"Itraconazole","DB01167","Increased effects/toxicity of ciclesonide"
1359,"Ketoconazole","DB01026","Increased effects/toxicity of ciclesonide"
1359,"Nelfinavir","DB00220","Increased effects/toxicity of ciclesonide"
1359,"Ritonavir","DB00503","Increased effects/toxicity of ciclesonide"
1359,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ciclesonide. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ciclesonide if Telithromycin is initiated, discontinued or dose changed."
1359,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ciclesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ciclesonide if voriconazole is initiated, discontinued or dose changed."
1362,"Probenecid","DB01032","Probenecid may increase the serum level of cefepime."
1366,"Acetaminophen","DB00316","Acetaminophen may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if acetaminophen is initiated, discontinued or dose changed. "
1366,"Acetylsalicylic acid","DB00945","Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol."
1366,"Allopurinol","DB00437","Allopurinol may increase the anticoagulant effect of acenocoumarol."
1366,"Aminoglutethimide","DB00357","Aminoglutethimide may decrease the anticoagulant effect of acenocoumarol."
1366,"Amiodarone","DB01118","Amiodarone may increase the anticoagulant effect of acenocoumarol."
1366,"Amprenavir","DB00701","Amprenavir may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
1366,"Aprepitant","DB00673","Aprepitant may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration."
1366,"Atazanavir","DB01072","The protease inhibitor, atazanavir, may increase the anticoagulant effect of acenocoumarol."
1366,"Azathioprine","DB00993","Azathioprine may decrease the anticoagulant effect of acenocoumarol."
1366,"Azithromycin","DB00207","Azithromycin may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
1366,"Betamethasone","DB00443","The corticosteroid, betamethasone, alters the anticoagulant effect, acenocoumarol."
1366,"Bosentan","DB00559","Bosentan may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
1366,"Butabarbital","DB00237","Barbiturates like butabarbital may increase the metabolism of Vitamin K Antagonists like acenocoumarol. onitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. "
1366,"Butalbital","DB00241","Barbiturates such as butalbital may increase the metabolism of Vitamin K Antagonists such as acenocoumarol. Monitor for decreased therapeutic effects of oral anticoagulants if a barbiturate is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if a barbiturate is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following barbiturate initiation/dosage changes. "
1366,"Capecitabine","DB01101","Capecitabine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
1366,"Carbamazepine","DB00564","Carbamazepine may decrease the anticoagulant effect of acenocoumarol by decreasing its serum concentration."
1366,"Cefotetan","DB01330","The cephalosporin, cefotetan, may increase the anticoagulant effect of acenocoumarol."
1366,"Cefoxitin","DB01331","The cephalosporin, cefoxitin, may increase the anticoagulant effect of acenocoumarol."
1366,"Ceftriaxone","DB01212","The cephalosporin, ceftriaxone, may increase the anticoagulant effect of acenocoumarol."
1366,"Celecoxib","DB00482","Celecoxib may increase the anticoagulant effect of acenocoumarol."
1366,"Cholestyramine","DB01432","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption."
1366,"Cimetidine","DB00501","Cimetidine may increase the anticoagulant effect of acenocoumarol."
1366,"Ciprofloxacin","DB00537","The quinolone antibiotic, ciprofloxacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Cisapride","DB00604","Cisapride may increase the anticoagulant effect of acenocoumarol."
1366,"Citalopram","DB00215","The SSRI, citalopram, increases the effect of anticoagulant, acenocoumarol."
1366,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the anticoagulant effect of acenocoumarol."
1366,"Clofibrate","DB00636","The fibrate increases the anticoagulant effect"
1366,"Colestipol","DB00375","The bile acid sequestrant, colestipol, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption."
1366,"Cyclophosphamide","DB00531","The antineoplastic agent, cyclophosphamide may alter the anticoagulant effect of acenocoumarol."
1366,"Danazol","DB01406","The androgen, danazol, may increase the anticoagulant effect of acenocoumarol."
1366,"Demeclocycline","DB00618","The tetracycline, demeclocycline, may increase the anticoagulant effect of acenocoumarol."
1366,"Dexamethasone","DB01234","The corticosteroid, dexamethasone, alters the anticoagulant effect, acenocoumarol."
1366,"Dextropropoxyphene","DB00647","Propoxyphene may increase the anticoagulant effect of acenocoumarol."
1366,"Dextrothyroxine","DB00509","The thyroid hormone, dextrothyroxine, increase the anticoagulant effect of acenocoumarol."
1366,"Dicloxacillin","DB00485","Dicloxacillin may decrease the anticoagulant effect of acenocoumarol."
1366,"Diflunisal","DB00861","The NSAID, diflunisal, may increase the anticoagulant effect of acenocoumarol."
1366,"Disulfiram","DB00822","Disulfiram may increase the anticoagulant effect of acenocoumarol."
1366,"Doxycycline","DB00254","The tetracycline, doxycycline, may increase the anticoagulant effect of acenocoumarol."
1366,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the anticoagulant effect of acenocoumarol."
1366,"Ethchlorvynol","DB00189","Ethchlorvynol may decrease the anticoagulant effect of acenocoumarol."
1366,"Ethinyl Estradiol","DB00977","Increased thrombotic risk due to estrogen"
1366,"Etodolac","DB00749","The NSAID, etodolac, may increase the anticoagulant effect or acenocoumarol."
1366,"Etoricoxib","DB01628","Etoricoxib may increase the anticoagulant effect of acenocoumarol."
1366,"Fenofibrate","DB01039","Fenofibrate may increase the anticoagulant effect of acenocoumarol."
1366,"Fenoprofen","DB00573","The NSAID, fenoprofen, may increase the anticoagulant effect of acenocoumarol."
1366,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism."
1366,"Fludrocortisone","DB00687","The corticosteroid, fludrocortisone, alters the anticoagulant effect, acenocoumarol."
1366,"Fluorouracil","DB00544","The antineoplasic agent, fluorouracil, may increase the anticoagulant effect of acenocoumarol."
1366,"Fluoxetine","DB00472","The SSRI, fluoxetine, increases the effect of anticoagulant, acenocoumarol."
1366,"Fluoxymesterone","DB01185","The androgen, fluoxymesterone, may increase the anticoagulant effect of acenocoumarol."
1366,"Flurbiprofen","DB00712","The NSAID, flurbiprofen, may increase the anticoagulant effect of acenocoumarol."
1366,"Fluvastatin","DB01095","Fluvastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if fluvastatin is initiated, discontinued or dose changed."
1366,"Fluvoxamine","DB00176","Fluvoxamine may increase the anticoagulant effect of acenocoumarol by increasing its serum concentration."
1366,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the anticoagulant effect of acenocoumarol."
1366,"Fosphenytoin","DB01320","Increased hydantoin levels and risk of bleeding"
1366,"Gefitinib","DB00317","Gefitinib may increase the anticoagulant effect of acenocoumarol."
1366,"Gemcitabine","DB00441","Gemcitabine may increase the anticoagulant effect of acenocoumarol."
1366,"Gemfibrozil","DB01241","Gemfibrozil may increase the anticoagulant effect of acenocoumarol."
1366,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. "
1366,"Glutethimide","DB01437","Glutethimide may decrease the anticoagulant effect of acenocoumarol."
1366,"Griseofulvin","DB00400","Griseofulvin may decrease the anticoagulant effect of acenocoumarol."
1366,"Hydrocortisone","DB00741","The corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol."
1366,"Ibuprofen","DB01050","The NSAID, ibuprofen, may increase the anticoagulant effect of acenocoumarol."
1366,"Imatinib","DB00619","Imatinib may increase the anticoagulant effect of acenocoumarol."
1366,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the anticoagulant effect of acenocoumarol."
1366,"Indomethacin","DB00328","The NSAID, indomethacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Isoniazid","DB00951","Isoniazid may increase the anticoagulant effect of acenocoumarol."
1366,"Itraconazole","DB01167","Itraconazole may increase the anticoagulant effect of acenocoumarol."
1366,"Ketoconazole","DB01026","Ketoconazole may increase the anticoagulant effect of acenocoumarol."
1366,"Ketoprofen","DB01009","The NSAID, ketoprofen, may increase the anticoagulant effect of acenocoumarol."
1366,"Ketorolac","DB00465","The NSAID, ketorolac, may increase the anticoagulant effect of acenocoumarol."
1366,"Leflunomide","DB01097","Leflunomide may increase the anticoagulant effect of acenocoumarol."
1366,"Levamisole","DB00848","Levamisole may increase the anticoagulant effect of acenocoumarol."
1366,"Levofloxacin","DB01137","The quinolone antibiotic, levofloxacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Levothyroxine","DB00451","The thyroid hormone, levothyroxine, increase the anticoagulant effect of acenocoumarol."
1366,"Lovastatin","DB00227","Lovastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if lovastatin is initiated, discontinued or dose changed."
1366,"Lumiracoxib","DB01283","Lumiracoxib may increase the anticoagulant effect of acenocoumarol."
1366,"Medroxyprogesterone Acetate","DB00603","Medroxyprogesterone may increase the anticoagulant effect of acenocoumarol."
1366,"Mefenamic acid","DB00784","The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol."
1366,"Mefloquine","DB00358","Mefloquine may increase the anticoagulant effect of acenocoumarol."
1366,"Meloxicam","DB00814","Meloxicam may increase the anticoagulant effect of acenocoumarol."
1366,"Mercaptopurine","DB01033","Mercaptopurine may decrease the anticoagulant effect of acenocoumarol."
1366,"Methimazole","DB00763","The antithyroid agent, methimazole, may decrease the anticoagulant effect of acenocoumarol."
1366,"Metronidazole","DB00916","Metronidazole may increase the anticoagulant effect of acenocoumarol."
1366,"Miconazole","DB01110","Miconazole may increase the serum concentration of acenocoumarol by decreasing its metabolism."
1366,"Minocycline","DB01017","The tetracycline, minocycline, may increase the anticoagulant effect of acenocoumarol."
1366,"Mitotane","DB00648","Mitotane may decrease the anticoagulant effect of acenocoumarol."
1366,"Moxifloxacin","DB00218","The quinolone antibiotic, moxifloxacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Nabumetone","DB00461","The NSAID, nabumetone, may increase the anticoagulant effect of acenocoumarol."
1366,"Nalidixic Acid","DB00779","The quinolone antibiotic, nalidixic acid, may increase the anticoagulant effect of acenocoumarol."
1366,"Naproxen","DB00788","The NSAID, naproxen, may increase the anticoagulant effect of acenocoumarol."
1366,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the anticoagulant effect of acenocoumarol."
1366,"Nevirapine","DB00238","Nevirapine may decrease the anticoagulant effect of acenocoumarol."
1366,"Norfloxacin","DB01059","The quinolone antibiotic, norfloxacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Ofloxacin","DB01165","The quinolone antibiotic, ofloxacin, may increase the anticoagulant effect of acenocoumarol."
1366,"Orlistat","DB01083","Orlistat may increase the anticoagulant effect of acenocoumarol."
1366,"Oxaprozin","DB00991","The NSAID, oxaprozin, may increase the anticoagulant effect of acenocoumarol."
1366,"Oxyphenbutazone","DB03585","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of acenocoumarol."
1366,"Paroxetine","DB00715","The SSRI, paroxetine, increases the effect of the anticoagulant, acenocoumarol."
1366,"Pentoxifylline","DB00806","Pentoxifylline may increase the anticoagulant effect of acenocoumarol."
1366,"Phenobarbital","DB01174","The barbiturate, phenobarbital, decreases the anticoagulant effect of acenocoumarol."
1366,"Phenylbutazone","DB00812","The NSAID, phenylbutazone, may increase the anticoagulant effect of acenocoumarol."
1366,"Phenytoin","DB00252","Increased hydantoin levels and risk of bleeding"
1366,"Piroxicam","DB00554","The NSAID, piroxicam, may increase the anticoagulant effect of acenocoumarol."
1366,"Prednisolone","DB00860","The corticosteroid, prednisolone, alters the anticoagulant effect, acenocoumarol."
1366,"Prednisone","DB00635","The corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol."
1366,"Primidone","DB00794","The barbiturate, primidone, decreases the anticoagulant effect of acenocoumarol."
1366,"Propafenone","DB01182","Propafenone may increase the anticoagulant effect of acenocoumarol."
1366,"Propylthiouracil","DB00550","The anti-thyroid agent, propylthiouracil, may decrease the anticoagulant effect of acenocoumarol."
1366,"Quinidine","DB00908","Quinidine may increase the anticoagulant effect of acenocoumarol."
1366,"Quinine","DB00468","Quinine, a moderate CYP2C9 inhibitor, may increase the serum concentration of acenocoumarol by decreasing its metabolism via CYP2C9."
1366,"Ranitidine","DB00863","Ranitidine may increase the anticoagulant effect of acenocoumarol. (Conflicting evidence)"
1366,"Rifabutin","DB00615","Rifabutin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
1366,"Rifampicin","DB01045","Rifampin may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism."
1366,"Sulindac","DB00605","The NSAID, sulindac, may increase the anticoagulant effect of acenocoumarol. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. "
1366,"Tamoxifen","DB00675","Tamoxifen may increase the serum concentration of Acenocoumarol increasing the risk of bleeding. Concomitant therapy should be avoided."
1366,"Telithromycin","DB00976","Telithromycin may increase the anticoagulant effect of acenocoumarol."
1366,"Tenoxicam","DB00469","The NSAID, tenoxicam, may increase the anticoagulant effect of acenocoumarol."
1366,"Testolactone","DB00894","The androgen, Testolactone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testolactone is initiated, discontinued or dose changed. "
1366,"Testosterone","DB00624","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed. "
1366,"Testosterone Propionate","DB01420","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed."
1366,"Tetracycline","DB00759","Tetracycline may increase the anticoagulant effect of acenocoumarol."
1366,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Acenocoumarol by decreasing Acenocoumarol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Acenocoumarol if Thiabendazole is initiated, discontinued or dose changed."
1366,"Thiopental","DB00599","Thiopental may increase the metabolism of the Vitamin K antagonist, Acenocoumarol. Acenocoumarol dose adjustment may be required."
1366,"Tiaprofenic acid","DB01600","Increased risk of bleeding. "
1366,"Tigecycline","DB00560","Tigecycline may increase the anticoagulant effect of acenocoumarol."
1366,"Tolbutamide","DB01124","Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Acenocoumarol. Consider alternate therapy or monitor for changes in Acenocoumarol therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. "
1366,"Tolmetin","DB00500","Increased risk of bleeding. Monitor for signs and symptoms of bleeding."
1366,"transdermal testosterone gel","DB05275","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed."
1366,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Acenocoumarol. Monitor for increased bleeding during concomitant thearpy. "
1366,"Triamcinolone","DB00620","The corticosteroid, triamcinolone, alters the anticoagulant effect, acenocoumarol."
1366,"Trimetrexate","DB01157","The anticoagulant effect of Acenocoumarol, a Vitamin K antagonist, may be altered by antineoplastics such as Trimetrexate. Monitor for changes in the anticoagulant effects of warfarin and other coumarin derivatives during concomitant use."
1366,"Zafirlukast","DB00549","Zafirlukast may inhibit the metabolism of the vitamin K antagonist Acenocoumarol and increase INR and risk of bleeding."
1368,"Acenocoumarol","DB01418","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed."
1368,"Cyclosporine","DB00091","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."
1368,"Docetaxel","DB01248","Testosterone propionate may increase the serum levels and toxicity of docetaxel."
1368,"Warfarin","DB00682","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed."
1380,"Acenocoumarol","DB01418","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of acenocoumarol by decreasing its absorption."
1380,"Anisindione","DB01125","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of anisindione by decreasing its absorption."
1380,"Bezafibrate","DB01393","Bile acid sequestrants like cholestyramine may decrease the absorption of fibric acid derivatives like bezafibrate. Therapy modification should be considered. If concomitant therapy is used, separate doses by at least 2 hours to minimize this interaction. Fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.\
"
1380,"Chlorothiazide","DB00880","Bile acid sequestrants may decrease the absorption of thiazide diuretics such as chlorothiazide. The diuretic response is likewise decreased. Monitor for decreased therapeutic effects of thiazide diuretics if coadministered with a bile acid sequestrant. If these agents are used concomitantly, separate doses 2 or more hours to minimize the interaction. "
1380,"Cholecalciferol","DB00169","Bile acid sequestrants such as cholestyramine may decrease the serum concentration of Vitamin D analogs such as cholecalciferol. More specifically, bile acid sequestrants may impair absorption of Vitamin D analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants. Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
1380,"Dicoumarol","DB00266","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of dicumarol by decreasing its absorption."
1380,"Digoxin","DB00390","The resin decreases the effect of digoxin"
1380,"Ezetimibe","DB00973","Cholestyramine may decrease the levels of ezetimibe."
1380,"Fluvastatin","DB01095","Increased/decreased effect according to spacing"
1380,"Hydrocortisone","DB00741","Cholestyramine may decrease the effect of hydrocortisone."
1380,"Levothyroxine","DB00451","The resin, cholestyramine, decreases the absorption of the thyroid hormone, levothyroxine."
1380,"Liothyronine","DB00279","The resin, cholestyramine, decreases the absorption of the thyroid hormones, liothyronine."
1380,"Liotrix","DB01583","The resin, cholestyramine, decreases the absorption of the thyroid hormone, liotrix."
1380,"Lomitapide","DB08827","Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours. "
1380,"Methotrexate","DB00563","Decreased levels of methotrexate"
1380,"Raloxifene","DB00481","The resin decreases the effect of raloxifene"
1380,"Spironolactone","DB00421","Increased risk of acidosis and hyperkalemia"
1380,"Sulindac","DB00605","The bile acid sequestrant, cholestyramine, may decrease the absorption of the NSAID, sulindac. Monitor for changes in the therapeutic and adverse effects of sulindac if cholestyramine is initiated, discontinued or dose changed. Administering the two agents 2 or more hours apart may reduce, but not eliminate, the risk of this interactions."
1380,"Tenoxicam","DB00469","Cholestyramine may decrease the serum concentration of Tenoxicam by increasing clearance. Monitor for changes in Tenoxicam therapeutic and adverse effects if Cholestyramine is initiated, discontinued or dose changed. "
1380,"Thyroglobulin","DB01584","The resin, cholestyramine, decreases the absorption of the thyroid hormone, thyroglobulin."
1380,"Tiaprofenic acid","DB01600","The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect."
1380,"Tolmetin","DB00500","Cholestyramine may decrease the absorption of Tolmetin. Monitor for changes in the therapeutic and adverse effects of Tolmetin if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction. "
1380,"Torasemide","DB00214","Cholestyramine may decrease the bioavailability of Torasemide by inhibiting Torasemide absorption. Monitor for changes in the therapeutic and adverse effects of Torasemide if Cholestyramine is initiated, discontinued or dose changed. Spacing administration by at least 2 hours may reduce the risk of interaction."
1380,"Trichlormethiazide","DB01021","The bile acid sequestrant, Cholestyramine resin, may inhibit the absorption of Trichlormethiazide."
1380,"Troglitazone","DB00197","Decreases the effect of troglitazone"
1380,"Ursodeoxycholic acid","DB01586","The resin decreases the effect of ursodiol"
1380,"Warfarin","DB00682","The bile acid sequestrant, cholestyramine, may decrease the anticoagulant effect of warfarin by decreasing its absorption."
1384,"Calcipotriol","DB02300","Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use."
1384,"Cholecalciferol","DB00169","Vitamin D analogs may enhance the adverse/toxic effect of other Vitamin D analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
1384,"Colesevelam","DB00930","Bile acid sequestrants such as colesevelam may decrease the serum concentration of Vitamin D Analogs. More specifically, bile acid sequestrants may impair absorption of Vitamin D Analogs. Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (e.g., cholestyramine). Monitor plasma calcium concentrations in patients receiving combined therapy with these agents. This is particularly important in patients receiving higher doses of a bile acid sequestant (i.e., 30 g/day or more of cholestyramine or equivalent) or in patients experiencing bile acid sequestrant-induced steatorrhea. Specific recommendations regarding the separation of administration of these agents are not defined; however, it would seem prudent to separate the administration of these agents by several hours to minimize the potential risk of interaction. Similar precautions do not apply to parenterally administered vitamin D analogs. "
1385,"Acenocoumarol","DB01418","Glutethimide may decrease the anticoagulant effect of acenocoumarol."
1385,"Anisindione","DB01125","Glutethimide may decrease the anticoagulant effect of anisindione."
1385,"Dicoumarol","DB00266","Glutethimide may decrease the anticoagulant effect of dicumarol."
1385,"Donepezil","DB00843","Possible antagonism of action"
1385,"Galantamine","DB00674","Possible antagonism of action"
1385,"Rivastigmine","DB00989","Possible antagonism of action"
1385,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Glutethimide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1385,"Warfarin","DB00682","Glutethimide may decrease the serum concentration of warfarin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if glutethimide is initiated, discontinued or dose changed."
1399,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1399,"Cimetidine","DB00501","Cimetidine increases the effect of the narcotic"
1429,"Tolvaptan","DB06212","Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
1429,"Ulipristal","DB08867","Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. "
1437,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1446,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1469,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
1484,"Clozapine","DB00363","Increased risk of toxicity"
1491,"Alvimopan","DB06274","Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days. "
1491,"Ammonium chloride","DB06767","May enhance excretion of dihydrocodeine. Recommended to monitor for reduced therapeutic effect. "
1491,"Amphetamine","DB00182","Amphetamines may enhance analgesic effects of dihydrocodeine. Monitor for enhanced analgesia. Dose reductions of dihydrocodeine may be appropriate. "
1491,"Azelastine","DB00972","Enhanced CNS depressant effects contraindicates concurrent use. "
1491,"Chlorpromazine","DB00477","Phenothiazines may enhance hypotensive effects of opioid analgesics. It is recommended to monitor patients for hypotension.  "
1491,"Clozapine","DB00363","CNS depressants may enhance the adverse effects and toxicity of other CNS depressants. It is recommended to monitor therapy. "
1491,"Desmopressin","DB00035","Opioids may enhance the adverse effects and toxicity of desmopressin. It is recommended to monitor therapy. "
1491,"Droperidol","DB00450","Enhanced CNS depressant effects are possible. Consider dose reduction of a CNS agent, if concurrent use is not avoidable.  "
1491,"Hydrochlorothiazide","DB00999","Dihydrocodeine may enhance the hypotensive effects of thiazide diuretics. \
It is recommended to monitor therapy."
1491,"Hydroxyzine","DB00557","May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. "
1491,"Magnesium Sulfate","DB00653","May enhance CNS depressant effects of CNS depressants. It is recommended to monitor therapy. "
1491,"Metyrosine","DB00765","Concurrent use may enhance the sedative effect of Metyrosine.  It is recommended to monitor therapy. "
1491,"Octreotide","DB00104","Concurrent use may enhance the analgesic effect of dihydrocodeine. It is recommended to monitor therapy, and reduce the dose of dihydrocodeine as appropriate.  "
1491,"Oprelvekin","DB00038","May increase the serum levels of opioid analgesics. It is recommended to monitor therapy for the signs and symptoms of respiratory depression and enhanced sedation. "
1491,"Paroxetine","DB00715","Opioid analgesics may enhance the 5HT effects of SSRIs to cause serotonin syndrome. It is recommended to monitor therapy."
1491,"Pegvisomant","DB00082","Opioids may diminish the therapeutic effect of pegvisomant. It is recommended to monitor therapy. "
1491,"Perampanel","DB08883","Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known. "
1491,"Pramipexole","DB00413","Dihydrocodeine may enhance the sedative effect of pramipexole. It is recommended to monitor therapy"
1491,"Quinidine","DB00908","Use of quinidine may reduce dihydrocodeine's analgesic effect.  "
1491,"Ropinirole","DB00268","Dihydrocodeine may enhance the sedative effect of ropinirole. It is recommended to monitor therapy"
1491,"Rotigotine","DB05271","Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy."
1491,"Succinylcholine","DB00202","May enhance the bradycardic effect of opioid analgesics. It is recommended to monitor therapy. "
1491,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Dihydrocodeine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1491,"Zolpidem","DB00425","Enhanced CNS depressant effects contraindicates concurrent use for certain brand name formulations of zolpidem. "
1498,"Aminophylline","DB01223","Aminophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if aminophylline is initiated, discontinued or dose changed. "
1498,"Atazanavir","DB01072","Atazanavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if atazanavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Cimetidine","DB00501","Co-administration with cimetidine will cause a reduction in bromazepam clearance and increases half-life. "
1498,"Clarithromycin","DB01211","Clarithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if clarithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Clozapine","DB00363","Bromazepam may increase the adverse effects of clozapine. Consider alternate therapy or a reduction in the bromazepam dose. Monitor for respiratory depression and hypotension if concomitant therapy is initiated."
1498,"Conivaptan","DB00872","Conivaptan, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if conivaptan is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Darunavir","DB01264","Darunavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if darunavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Delavirdine","DB00705","Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if delavirdine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Diltiazem","DB00343","Diltiazem may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if diltiazem is initiated, discontinued or dose changed."
1498,"Dyphylline","DB00651","Dyphylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if dyphylline is initiated, discontinued or dose changed. "
1498,"Erythromycin","DB00199","Erythromcyin may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if erythromycin is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Fluconazole","DB00196","Fluconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if fluconazole is initiated, discontinued or dose changed. "
1498,"Fosamprenavir","DB01319","Fosamprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if fosamprenavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Imatinib","DB00619","Imatinib, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if imatinib is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Indinavir","DB00224","Indinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if indinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Isoniazid","DB00951","Isoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Itraconazole","DB01167","Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed."
1498,"Ketoconazole","DB01026","Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed."
1498,"Lopinavir","DB01601","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if lopinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Methotrimeprazine","DB01403","Concomitant therapy may result in additive CNS depressant effects. The dosage of bromazepam should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression. "
1498,"Nefazodone","DB01149","Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nefazodone is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Nelfinavir","DB00220","Nelfinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nelfinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Nicardipine","DB00622","Nicardipine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if nicardipine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Posaconazole","DB01263","Posaconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if posaconazole is initiated, discontinued or dose changed."
1498,"Propranolol","DB00571","Co-administration with propranolol will cause a reduction in bromazepam clearance and increases half-life. "
1498,"Quinidine","DB00908","Quinidine, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if quinidine is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Rifabutin","DB00615","Rifabutin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifabutin is initiated, discontinued or dose changed. "
1498,"Rifampicin","DB01045","Rifampin may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifampin is initiated, discontinued or dose changed. "
1498,"Rifapentine","DB01201","Rifapentine may decrease the serum concentration of bromazepam by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if rifapentine is initiated, discontinued or dose changed. "
1498,"Ritonavir","DB00503","Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if ritonavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Saquinavir","DB01232","Saquinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if saquinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1498,"Telithromycin","DB00976","Telithromycin, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if telithromycin is initiated, discontinued or dose changed. Dosage adjustments may be required."
1498,"Theophylline","DB00277","Theophylline may decrease the therapeutic effect of bromazepam. Monitor for changes in the therapeutic effects of bromazepam if theophylline is initiated, discontinued or dose changed. "
1498,"Tipranavir","DB00932","Tipranavir may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if tipranavir is initiated, discontinued or dose changed."
1498,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Bromazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1498,"Verapamil","DB00661","Verapamil may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or a reductin in the bromazepam dose. Monitor for changes in the therapeutic and adverse effects of bromazepam if verapamil is initiated, discontinued or dose changed."
1498,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if voriconazole is initiated, discontinued or dose changed."
1503,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Chloral hydrate, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1514,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1514,"Clindamycin","DB01190","The aluminium salt decreases the absorption of lincosamides"
1514,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1514,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1514,"Lincomycin","DB01627","The aluminium salt decreases the absorption of lincosamides"
1514,"Minocycline","DB01017","Formation of non-absorbable complexes"
1514,"Penciclovir","DB00299","The multivalent agent decreases the effect of penicillamine"
1514,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1515,"Chloroquine","DB00608","The antiacid decreases the absorption of chloroquine"
1515,"Clindamycin","DB01190","The aluminium salt decreases the absorption of lincosamides"
1515,"Lincomycin","DB01627","The aluminium salt decreases the absorption of lincosamides"
1515,"Penciclovir","DB00299","The multivalent agent decreases the effect of penicillamine"
1516,"Chlorpromazine","DB00477","Decreased anorexic effect, may increases psychotic symptoms"
1516,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1516,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
1516,"Guanethidine","DB01170","Dextroamphetamine may decrease the effect of guanethidine."
1516,"Isocarboxazid","DB01247","Possible hypertensive crisis"
1516,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
1516,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Phenelzine","DB00780","Possible hypertensive crisis"
1516,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase pyschotic symptoms"
1516,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms"
1516,"Propericiazine","DB01608","Decreased anorexic effect, may increase pyschotic symptoms"
1516,"Rasagiline","DB01367","Possible hypertensive crisis"
1516,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1516,"Trandolapril","DB00519","Dextroamphetamine may reduce the efficacy of Trandolapril. "
1516,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Dextroamphetamine. Concomitant therapy should be avoided."
1516,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
1516,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Dextroamphetamine."
1517,"Chlorpromazine","DB00477","Decreased anorexic effect, may increases psychotic symptoms"
1517,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1517,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
1517,"Guanethidine","DB01170","Methamphetamine may decrease the effect of guanethidine."
1517,"Isocarboxazid","DB01247","Possible hypertensive crisis"
1517,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
1517,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Phenelzine","DB00780","Possible hypertensive crisis"
1517,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase pyschotic symptoms"
1517,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms"
1517,"Propericiazine","DB01608","Decreased anorexic effect, may increase pyschotic symptoms"
1517,"Rasagiline","DB01367","Possible hypertensive crisis"
1517,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Methamphetamine. Consider alternate therapy or monitor for therapeutic/adverse effects of Methamphetamine if Terbinafine is initiated, discontinued or dose changed."
1517,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1517,"Trandolapril","DB00519","Methamphetamine may reduce the efficacy of Trandolapril. "
1517,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Methamphetamine. Concomitant therapy should be avoided."
1517,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
1517,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Methamphetamine."
1518,"Chlorpromazine","DB00477","Increased risk of convulsions"
1518,"Fluphenazine","DB00623","Increased risk of convulsions"
1518,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
1518,"Methotrimeprazine","DB01403","Increased risk of convulsions"
1518,"Perphenazine","DB00850","Increased risk of convulsions"
1518,"Prochlorperazine","DB00433","Increased risk of convulsions"
1518,"Promethazine","DB01069","Increased risk of convulsions"
1518,"Propericiazine","DB01608","Increased risk of convulsions"
1518,"Thioridazine","DB00679","Increased risk of convulsions"
1518,"Trifluoperazine","DB00831","Increased risk of convulsions"
1519,"Chlorpromazine","DB00477","Decreased anorexic effect, may increases psychotic symptoms"
1519,"Fluoxetine","DB00472","Risk of serotoninergic syndrome"
1519,"Fluphenazine","DB00623","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Fluvoxamine","DB00176","Risk of serotoninergic syndrome"
1519,"Guanethidine","DB01170","Phendimetrazine may decrease the effect of guanethidine."
1519,"Isocarboxazid","DB01247","Possible hypertensive crisis"
1519,"Mesoridazine","DB00933","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Methotrimeprazine","DB01403","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Paroxetine","DB00715","Risk of serotoninergic syndrome"
1519,"Perphenazine","DB00850","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Phenelzine","DB00780","Possible hypertensive crisis"
1519,"Prochlorperazine","DB00433","Decreased anorexic effect, may increase pyschotic symptoms"
1519,"Promethazine","DB01069","Decreased anorexic effect, may increase pyschotic symptoms"
1519,"Propericiazine","DB01608","Decreased anorexic effect, may increase pyschotic symptoms"
1519,"Rasagiline","DB01367","Possible hypertensive crisis"
1519,"Thioridazine","DB00679","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
1519,"Trandolapril","DB00519","Phendimetrazine may reduce the efficacy of Trandolapril. "
1519,"Tranylcypromine","DB00752","The MAO inhibitor, Tranylcypromine, may increase the vasopressor effect of the amphetamine, Phendimetrazine. Concomitant therapy should be avoided."
1519,"Trifluoperazine","DB00831","Decreased anorexic effect, may increase psychotic symptoms"
1519,"Triprolidine","DB00427","Triprolidine may reduce the sedative effect of the antihistamine, Phendimetrazine."
1520,"Acetohexamide","DB00414","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Chlorpropamide","DB00672","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Clonidine","DB00575","Increased hypertension when clonidine stopped"
1520,"Dihydroergotamine","DB00320","Ischemia with risk of gangrene"
1520,"Disopyramide","DB00280","The beta-blocker, oxprenolol, may increase the toxicity of disopyramide."
1520,"Epinephrine","DB00668","Hypertension, then bradycardia"
1520,"Ergonovine","DB01253","Ischemia with risk of gangrene"
1520,"Ergotamine","DB00696","Ischemia with risk of gangrene"
1520,"Fenoterol","DB01288","Antagonism"
1520,"Formoterol","DB00983","Antagonism"
1520,"Gliclazide","DB01120","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Glipizide","DB01067","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Glisoxepide","DB01289","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Glyburide","DB01016","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Glycodiazine","DB01382","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Ibuprofen","DB01050","Risk of inhibition of renal prostaglandins"
1520,"Indomethacin","DB00328","Risk of inhibition of renal prostaglandins"
1520,"Insulin Glargine","DB00047","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Isoprenaline","DB01064","Antagonism"
1520,"Lidocaine","DB00281","The beta-blocker increases the effect and toxicity of lidocaine"
1520,"Methyldopa","DB00968","Possible hypertensive crisis"
1520,"Methysergide","DB00247","Ischemia with risk of gangrene"
1520,"Orciprenaline","DB00816","Antagonism"
1520,"Pipobroman","DB00236","Antagonism"
1520,"Pirbuterol","DB01291","Antagonism"
1520,"Piroxicam","DB00554","Risk of inhibition of renal prostaglandins"
1520,"Practolol","DB01297","Antagonism"
1520,"Prazosin","DB00457","Risk of hypotension at the beginning of therapy"
1520,"Repaglinide","DB00912","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Salbutamol","DB01001","Antagonism"
1520,"Salmeterol","DB00938","Antagonism"
1520,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
1520,"Terbutaline","DB00871","Antagonism"
1520,"Tolazamide","DB00839","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Tolbutamide","DB01124","The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia."
1520,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1520,"Verapamil","DB00661","Increased effect of both drugs"
1521,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
1521,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
1522,"Chlorpropamide","DB00672","Sulfonamide/sulfonylurea: possible hypoglycemia"
1522,"Cyclosporine","DB00091","The sulfonamide decreases the effect of cyclosporine"
1522,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
1523,"Calcium Acetate","DB00258","Calcium salts such as calcium acetate may diminish the therapeutic effect of thyroid products such as liotrix. Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased, or increased effects if an oral calcium supplement is discontinued/dose decreased. "
1523,"Cholestyramine","DB01432","The resin, cholestyramine, decreases the absorption of the thyroid hormone, liotrix."
1523,"Colestipol","DB00375","The resin, colestipol, decreases the absorption of the thyroid hormone, liotrix."
1523,"Digoxin","DB00390","The thyroid hormone, liotrix, decreases the effect of digoxin."
1523,"Warfarin","DB00682","Liotrix may contribute to the anticoagulant effect of warfarin by increasing the metabolism of vitamin K-dependent clotting factors. Monitor for changes in prothrombin time and anticoagulant effects if liotrix is initiated, discontinued or dose changed."
1524,"Cholestyramine","DB01432","The resin, cholestyramine, decreases the absorption of the thyroid hormone, thyroglobulin."
1524,"Colestipol","DB00375","The resin, colestipol, decreases the absorption of the thyroid hormone, thyroglobulin."
1524,"Digoxin","DB00390","The thyroid hormone, thyroglobulin, decreases the effect of digoxin."
1525,"Cholestyramine","DB01432","The resin decreases the effect of ursodiol"
1525,"Clofibrate","DB00636","The fibric acid derivative decreases the effect of ursodiol"
1525,"Clomifene","DB00882","Estrogens decreases the effect of ursodiol"
1525,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Ursodiol. Consider administration of ursodiol 5 hours or more after bile acid sequestrants to minimize ursodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of ursodiol in patients receiving bile acid sequestrants. "
1525,"Colestipol","DB00375","The resin decreases the effect of ursodiol"
1525,"Conjugated Estrogens","DB00286","Estrogens decreases the effect of ursodiol"
1525,"Cyclosporine","DB00091","Ursodiol increases the levels of cyclosporine"
1525,"Diethylstilbestrol","DB00255","Estrogens decreases the effect of ursodiol"
1525,"Estradiol","DB00783","Estrogens decreases the effect of ursodiol"
1525,"Ethinyl Estradiol","DB00977","Estrogens decreases the effect of ursodiol"
1525,"Fenofibrate","DB01039","The fibric acid derivative decreases the effect of ursodiol"
1525,"Gemfibrozil","DB01241","The fibric acid derivative decreases the effect of ursodiol"
1526,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, ketazolam."
1526,"Clozapine","DB00363","Increased risk of toxicity"
1526,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, ketazolam."
1527,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, prazepam."
1527,"Clozapine","DB00363","Increased risk of toxicity"
1527,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, prazepam."
1527,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, prazepam."
1527,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, prazepam."
1527,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Prazepam. Consider alternate therapy or monitor for Prazepam toxic effects if Tipranavir is initiated or dose increased. "
1527,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Prazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1527,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of prazepam by decreasing its metabolism. Monitor for prazepam toxicity if voriconazole is initiated or dose increased."
1528,"Cimetidine","DB00501","Cimetidine may increase the effect of the benzodiazepine, quazepam."
1528,"Clozapine","DB00363","Increased risk of toxicity"
1528,"Fluconazole","DB00196","Fluconazole may increase the effect of the benzodiazepine, quazepam."
1528,"Indinavir","DB00224","The protease inhibitor, indinavir, may increase the effect of the benzodiazepine, quazepam."
1528,"Itraconazole","DB01167","Itraconazole may increase the effect of the benzodiazepine, quazepam."
1528,"Ketoconazole","DB01026","Ketoconazole may increase the effect of the benzodiazepine, quazepam."
1528,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect of the benzodiazepine, quazepam."
1528,"Omeprazole","DB00338","Omeprazole may increase the effect of the benzodiazepine, quazepam."
1528,"Tipranavir","DB00932","Tipranavir may decrease the metabolism and clearance of Quazepam. Consider alternate therapy or monitor for Quazepam toxic effects if Tipranavir is initiated or dose increased. "
1528,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Quazepam, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
1529,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of everolimus. Consider therapy modification. Recommendations regarding optimal management of this interaction vary according to specific indication and product used."
1529,"Clarithromycin","DB01211","The macrolide, clarithromycin, may increase the serum concentration and toxicity of everolimus."
1529,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate)such as clotrimazole may increase the serum concentration of everolimus. The prescribing information for the Afinitor branded everolimus product lists indication-specific recommendations for managing this interaction. "
1529,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus. Everolimus prescribing information recommends avoiding concurrent use with strong CYP3A4 inhbitors. "
1529,"Erythromycin","DB00199","The macrolide, erythromycin, may increase the serum concentration and toxicity of everolimus."
1529,"Etravirine","DB06414","Everolimus, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. If concurrent therapy cannot be avoided, a gradual dosage increase of everolimus is recommended."
1529,"Fluconazole","DB00196","Fluconazole may increase everolimus levels/toxicity."
1529,"Itraconazole","DB01167","Itraconazole may increase everolimus levels/toxicity."
1529,"Ketoconazole","DB01026","Ketoconazole may increase everolimus levels/toxicity."
1529,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
1529,"Verapamil","DB00661","Concomitant administration may increase the serum concentrations of both agents. Concurrent use should be avoided. "
1529,"Voriconazole","DB00582","Voriconzole, a strong CYP3A4 inhibitor, may increase the serum concentration of everolimus by decreasing its metabolism. Concurrent therapy should be avoided. "
1530,"Clarithromycin","DB01211","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1530,"Donepezil","DB00843","Possible antagonism of action"
1530,"Galantamine","DB00674","Possible antagonism of action"
1530,"Itraconazole","DB01167","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1530,"Ketoconazole","DB01026","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1530,"Nefazodone","DB01149","This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism"
1530,"Nelfinavir","DB00220","This potent CYP3A4 inhibitor slows darifenacin / solifenacin metabolism"
1530,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Solifenacin, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1530,"Telithromycin","DB00976","Telithromycin may reduce clearance of Solifenacin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Solifenacin if Telithromycin is initiated, discontinued or dose changed."
1530,"Trimethobenzamide","DB00662","Trimethobenzamide and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1530,"Triprolidine","DB00427","Triprolidine and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1530,"Trospium","DB00209","Trospium and Solifenacin, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1530,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of solifenacin if voriconazole is initiated, discontinued or dose changed."
1531,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1531,"Clodronate","DB00720","Formation of non-absorbable complexes"
1531,"Deferiprone","DB08826","Deferiprone serum concentrations may be decreased by iron salts except for ferric gluconate, ferumoxytol, iron dextran complex, and iron sucrose."
1531,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1531,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1531,"Etidronic acid","DB01077","Formation of non-absorbable complexes"
1531,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1531,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1531,"Grepafloxacin","DB00365","Formation of non-absorbable complexes "
1531,"Ibandronate","DB00710","Formation of non absorbable complexes"
1531,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1531,"Levothyroxine","DB00451","Iron decreases absorption of levothyroxine"
1531,"Methyldopa","DB00968","Iron decreases the absorption of dopa derivatives"
1531,"Minocycline","DB01017","Formation of non-absorbable complexes"
1531,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1531,"Mycophenolate mofetil","DB00688","Oral iron decreases the absorption of mycophenolate-mofetil"
1531,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1531,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1531,"Pancrelipase","DB00085","If pancrelipase and iron salts are used in combination then monitor therapy. Pancrelipase may decrease the absorption of iron salts except for ferumoxytol, iron dextran complex, and iron sucrose."
1531,"Penciclovir","DB00299","The multivalent agent decreases the effect of penicillamine"
1531,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1531,"Trovafloxacin","DB00685","Iron may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the iron containing agent to minimize the interaction. "
1532,"Ciprofloxacin","DB00537","Formation of non-absorbable complexes"
1532,"Deferiprone","DB08826","Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride."
1532,"Demeclocycline","DB00618","Formation of non-absorbable complexes"
1532,"Doxycycline","DB00254","Formation of non-absorbable complexes"
1532,"Gatifloxacin","DB01044","Formation of non-absorbable complexes"
1532,"Gemifloxacin","DB01155","Formation of non-absorbable complexes"
1532,"Grepafloxacin","DB00365","Formation of non-absorbable complexes "
1532,"Levofloxacin","DB01137","Formation of non-absorbable complexes"
1532,"Minocycline","DB01017","Formation of non-absorbable complexes"
1532,"Moxifloxacin","DB00218","Formation of non-absorbable complexes"
1532,"Norfloxacin","DB01059","Formation of non-absorbable complexes"
1532,"Ofloxacin","DB01165","Formation of non-absorbable complexes"
1532,"Tetracycline","DB00759","Formation of non-absorbable complexes"
1532,"Trovafloxacin","DB00685","Zinc may decrease the absorption of orally administered Trovafloxacin. Administer Trovafloxacin 2 hours before or 6 hours after a dose of the zinc containing agent to minimize the interaction. "
1533,"Clozapine","DB00363","Increased risk of toxicity"
1534,"Clozapine","DB00363","Increased risk of toxicity"
1535,"Cyclosporine","DB00091","Imipenem increases the effect and toxicity of cyclosporine"
1535,"Valganciclovir","DB01610","Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"
1536,"Cyclosporine","DB00091","Imipenem increases the effect and toxicity of cyclosporine"
1536,"Valganciclovir","DB01610","Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"
1537,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1537,"Cyclosporine","DB00091","Probucol decreases the effect of cyclosporine"
1537,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1537,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1537,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1537,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1537,"Trimipramine","DB00726","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1537,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1537,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1537,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
1537,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1538,"Acenocoumarol","DB01418","Increased risk of bleeding. "
1538,"Acetylsalicylic acid","DB00945","Increased risk of gastrointestinal bleeding. "
1538,"Aminosalicylic Acid","DB00233","Increased risk of gastrointestinal bleeding. "
1538,"Cholestyramine","DB01432","The bile acid sequestrant, Cholestyramine resin, may reduce Tiaprofenic acid absorption and therapeutic effect."
1538,"Citalopram","DB00215","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Colesevelam","DB00930","The bile acid sequestrant, Colesevelam, may reduce Tiaprofenic acid absorption and therapeutic effect."
1538,"Colestipol","DB00375","The bile acid sequestrant, Colestipol, may reduce Tiaprofenic acid absorption and therapeutic effect."
1538,"Cyclosporine","DB00091","Tiaprofenic acid may increase the nephrotoxicity and/or the serum concentration of cyclosporine. Consider altnerate therapy or monitor for increased cyclosporine concentrations and nephrotoxicity during concomitant therapy."
1538,"Escitalopram","DB01175","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Fluoxetine","DB00472","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Fluvoxamine","DB00176","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Ginkgo biloba","DB01381","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1538,"Ginseng","DB01404","Increased risk of bleeding due to additive antiplatelet properties of the two agents. Concomitant therapy should be avoided or monitored carefully for bleeding, bruising and altered mental status, which may be caused by CNS bleeds."
1538,"Ketorolac","DB00465","Concomitant therapy is contraindicated due to the risk of synergistic NSAID toxicity."
1538,"Lithium","DB01356","Tiaprofenic acid may increase the therapeutic/adverse effects of Lithium by increasing Lithium serum concentrations. Monitor for changes in the therapeutic/adverse effects of Lithium if Tiaprofenic acid is initiated, discontinued or dose changed. "
1538,"Methotrexate","DB00563","Tiaprofenic acid may decrease renal excretion of methotrexate. Consider alternate therapy or monitor for methotrexate toxicity."
1538,"Paroxetine","DB00715","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Pemetrexed","DB00642","Tiaprofenic acid may decrease Pemetrexed excretion. Tiaprofenic acid should not be used around the time when Pemetrexed is administered. "
1538,"Salsalate","DB01399","Increased risk of gastrointestinal bleeding. "
1538,"Sertraline","DB01104","Additive antiplatelet effects increase the risk of bleeding. Consider alternate therapy or monitor for increased bleeding. "
1538,"Telmisartan","DB00966","Concomitant use of Telmisartan and Tiaprofenic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. "
1538,"Timolol","DB00373","The NSAID, Tiaprofenic acid, may antagonize the antihypertensive effect of Timolol."
1538,"Trandolapril","DB00519","The NSAID, Tiaprofenic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Tiaprofenic acid is initiated, discontinued or dose changed.  "
1538,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Tiaprofenic acid. Monitor for increased bleeding during concomitant thearpy. "
1538,"Warfarin","DB00682","The antiplatelet effects of tiaprofenic acid may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy."
1539,"Abacavir","DB01048","The serum concentration of Abacavir may be decreased by protease inhibitors such as Lopinavir. The antiviral response should be closely monitored."
1539,"Bromazepam","DB01558","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if lopinavir is initiated, discontinued or dose changed. Dosage adjustments may be required. "
1539,"Dantrolene","DB01219","Lopinavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if lopinavir is initiated, discontinued or dose changed. "
1539,"Darunavir","DB01264","Decreased levels of darunavir"
1539,"Etravirine","DB06414","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
1539,"Fosphenytoin","DB01320","Levels of both drugs are affected"
1539,"Phenytoin","DB00252","Levels of both drugs are affected"
1539,"Pitavastatin","DB08860","Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."
1539,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
1539,"Roflumilast","DB01656","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1539,"Tacrolimus","DB00864","The protease inhibitor, Lopinavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Lopinavir therapy is initiated, discontinued or altered."
1539,"Tadalafil","DB00820","Lopinavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity."
1539,"Tamoxifen","DB00675","Lopinavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided."
1539,"Tamsulosin","DB00706","Lopinavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Lopinavir is initiated, discontinued, or dose changed."
1539,"Telithromycin","DB00976","Lopinavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects."
1539,"Temsirolimus","DB06287","Lopinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
1539,"Teniposide","DB00444","The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Lopinavir is initiated, discontinued or dose changed."
1539,"Tiagabine","DB00906","The strong CYP3A4 inhibitor, Lopinavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Lopinavir is initiated, discontinued or dose changed."
1539,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the plasma concentration of Lopinavir. Consider alternate therapy. "
1539,"Tolterodine","DB01036","Lopinavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
1539,"Topotecan","DB01030","The p-glycoprotein inhibitor, Lopinavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
1539,"Tramadol","DB00193","Lopinavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Lopinavir may decrease the effect of Tramadol by decreasing active metabolite production. "
1539,"Trazodone","DB00656","The protease inhibitor, Lopinavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Lopinavir is initiated, discontinued or dose changed. "
1539,"Trimipramine","DB00726","The strong CYP3A4/CYP2D6 inhibitor, Lopinavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Lopinavir is initiated, discontinued or dose changed. "
1539,"Vardenafil","DB00862","Lopinavir, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil."
1539,"Venlafaxine","DB00285","Lopinavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Lopinavir is initiated, discontinued, or dose changed."
1539,"Verapamil","DB00661","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Lopinavir is initiated, discontinued or dose changed."
1539,"Vinblastine","DB00570","Lopinavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Lopinavir is initiated, discontinued or dose changed."
1539,"Vincristine","DB00541","Lopinavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Lopinavir is initiated, discontinued or dose changed."
1539,"Vinorelbine","DB00361","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Lopinavir is initiated, discontinued or dose changed."
1539,"Voriconazole","DB00582","Lopinavir may reduce serum concentration and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy."
1539,"Zolpidem","DB00425","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if lopinavir is initiated, discontinued or dose changed. "
1539,"Zonisamide","DB00909","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if lopinavir is initiated, discontinued or dose changed."
1539,"Zopiclone","DB01198","Lopinavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if lopinavir is initiated, discontinued or dose changed."
1539,"Zuclopenthixol","DB01624","Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed. "
1540,"Demeclocycline","DB00618","Possible antagonism of action"
1540,"Doxycycline","DB00254","Possible antagonism of action"
1540,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1540,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1540,"Minocycline","DB01017","Possible antagonism of action"
1540,"Tetracycline","DB00759","Possible antagonism of action"
1541,"Demeclocycline","DB00618","Possible antagonism of action"
1541,"Doxycycline","DB00254","Possible antagonism of action"
1541,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1542,"Demeclocycline","DB00618","Possible antagonism of action"
1542,"Doxycycline","DB00254","Possible antagonism of action"
1542,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1542,"Mestranol","DB01357","This anti-infectious agent could decrease the effect of the oral contraceptive"
1542,"Methacycline","DB00931","Possible antagonism of action"
1542,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1542,"Minocycline","DB01017","Possible antagonism of action"
1542,"Oxytetracycline","DB00595","Possible antagonism of action"
1542,"Rolitetracycline","DB01301","Possible antagonism of action"
1542,"Tetracycline","DB00759","Possible antagonism of action"
1543,"Demeclocycline","DB00618","Possible antagonism of action"
1543,"Doxycycline","DB00254","Possible antagonism of action"
1543,"Methacycline","DB00931","Possible antagonism of action"
1543,"Minocycline","DB01017","Possible antagonism of action"
1543,"Oxytetracycline","DB00595","Possible antagonism of action"
1543,"Rolitetracycline","DB01301","Possible antagonism of action"
1543,"Tetracycline","DB00759","Possible antagonism of action"
1544,"Demeclocycline","DB00618","Possible antagonism of action"
1544,"Doxycycline","DB00254","Possible antagonism of action"
1544,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1544,"Minocycline","DB01017","Possible antagonism of action"
1544,"Tetracycline","DB00759","Possible antagonism of action"
1545,"Amikacin","DB00479","Ticarcillin may reduce the serum concentration of Amikacin. Ticarcillin may inactivate Amikacin in vitro and the two agents should not be administered simultaneously through the same IV line. "
1545,"Demeclocycline","DB00618","Demeclocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Demeclocycline."
1545,"Doxycycline","DB00254","Doxycycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Doxycycline."
1545,"Ethinyl Estradiol","DB00977","This anti-infectious agent could decrease the effect of the oral contraceptive"
1545,"Fusidic Acid","DB02703","Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid."
1545,"Gentamicin","DB00798","Ticarcillin may reduce the serum concentration of Gentamicin. Ticarcillin may inactivate Gentamicin in vitro and the two agents should not be administered simultaneously through the same IV line."
1545,"Kanamycin","DB01172","Ticarcillin may reduce the serum concentration of Kanamycin. Ticarcillin may inactivate Kanamycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1545,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
1545,"Minocycline","DB01017","Minocycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Minocycline."
1545,"Neomycin","DB00994","Ticarcillin may reduce the serum concentration of Neomycin. Ticarcillin may inactivate Neomycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1545,"Oxytetracycline","DB00595","Oxytetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Oxytetracycline."
1545,"Streptomycin","DB01082","Ticarcillin may reduce the serum concentration of Streptomycin. Ticarcillin may inactivate Streptomycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1545,"Tetracycline","DB00759","Tetracycline may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Tetracycline."
1545,"Tobramycin","DB00684","Ticarcillin may reduce the serum concentration of Tobramycin. Ticarcillin may inactivate Tobramycin in vitro and the two agents should not be administered simultaneously through the same IV line."
1546,"Amphetamine","DB00182","Decreased anorexic effect, may increase pyschotic symptoms"
1546,"Benzphetamine","DB00865","Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. "
1546,"Dexfenfluramine","DB01191","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Dextroamphetamine","DB01576","Decreased anorexic effect, may increase pyschotic symptoms"
1546,"Diethylpropion","DB00937","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Donepezil","DB00843","Possible antagonism of action"
1546,"Fenfluramine","DB00574","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Galantamine","DB00674","Possible antagonism of action"
1546,"Guanethidine","DB01170","Propericiazine may decrease the effect of guanethidine."
1546,"Mazindol","DB00579","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Methamphetamine","DB01577","Decreased anorexic effect, may increase pyschotic symptoms"
1546,"Metrizamide","DB01578","Increased risk of convulsions"
1546,"Phendimetrazine","DB01579","Decreased anorexic effect, may increase pyschotic symptoms"
1546,"Phenmetrazine","DB00830","Decreased anorexic effect, may increase pyschotic symptoms"
1546,"Phentermine","DB00191","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Phenylpropanolamine","DB00397","Decreased anorexic effect, may increase psychotic symptoms."
1546,"Rivastigmine","DB00989","Possible antagonism of action"
1546,"Terfenadine","DB00342","Increased risk of cardiotoxicity and arrhythmias"
1547,"Aluminium","DB01370","Possible physicochemical interaction"
1547,"Bivalirudin","DB00006","Anticoagulants increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity."
1547,"Etravirine","DB06414","Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy. "
1547,"Tofacitinib","DB08895","Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy. \
"
1548,"Abacavir","DB01048","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Abacavir, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended. "
1548,"Adefovir Dipivoxil","DB00718","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Adefovir Dipivoxil, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
1548,"Cilastatin","DB01597","Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"
1548,"Didanosine","DB00900","The adverse/toxic effects of Didanosine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided."
1548,"Emtricitabine","DB00879","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Emtricitabine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
1548,"Imipenem","DB01598","Generalized convulsions have been reported in patients taking Ganciclovir and Imipenem-cilastatin. Concomitant therapy should be avoided. (Note: Valganciclovir is converted to Ganciclovir in vivo)"
1548,"Lamivudine","DB00709","The adverse/toxic effects of reverse transcriptase inhibitors (nucleoside), such as Lamivudine, may be enhanced by Valganciclovir. There is a risk of hematologic toxicity. Diligent monitoring during concomitant therapy is recommended."
1548,"Mycophenolate mofetil","DB00688","The excretion rates of Valganciclovir and/or Mycophenolate mofetil may decrease. Monitor for increased serum concentrations and toxicity of both agents."
1548,"Mycophenolic acid","DB01024","The excretion rates of Valganciclovir and/or Mycophenolic acid may decrease. Monitor for increased serum concentrations and toxicity of both agents."
1548,"Probenecid","DB01032","Probenecid may decrease excretion of Valganciclovir. Monitor for increased serum concentration and toxicity of Valganciclovir."
1548,"Tenofovir","DB00300","The excretion rates of Valganciclovir and/or Tenofovir may decrease as both drugs are eliminated by active tubular secretion. Monitor for increased serum concentrations and toxicity of both agents."
1548,"Zidovudine","DB00495","The adverse/toxic effects of Zidovudine, a reverse transcriptase inhibitor (nucleoside), may be enhanced by Valganciclovir. There is a significant risk of hematologic toxicity. Concomitant therapy should be avoided."
1549,"Artemether","DB06697","Hydroxychloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
1549,"Digoxin","DB00390","Hydroxychloroquine increases the effect of digoxin"
1549,"Lumefantrine","DB06708","Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
1549,"Methotrexate","DB00563","Hydroxychloroquine increases the effect and toxicity of methotrexate"
1549,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
1550,"Dihydroergotamine","DB00320","Possible antagonism of action"
1550,"Ergotamine","DB00696","Possible antagonism of action"
1550,"Methysergide","DB00247","Possible antagonism of action"
1550,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
1551,"Dihydroergotamine","DB00320","Possible antagonism of action"
1551,"Ergotamine","DB00696","Possible antagonism of action"
1551,"Methysergide","DB00247","Possible antagonism of action"
1552,"Donepezil","DB00843","Possible antagonism of action"
1552,"Galantamine","DB00674","Possible antagonism of action"
1553,"Donepezil","DB00843","Possible antagonism of action"
1553,"Galantamine","DB00674","Possible antagonism of action"
1554,"Donepezil","DB00843","Possible antagonism of action"
1554,"Galantamine","DB00674","Possible antagonism of action"
1555,"Donepezil","DB00843","Possible antagonism of action"
1555,"Galantamine","DB00674","Possible antagonism of action"
1555,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Molindone, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1555,"Tetrabenazine","DB04844","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
1555,"Trimethobenzamide","DB00662","Trimethobenzamide and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1555,"Triprolidine","DB00427","Triprolidine and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1555,"Trospium","DB00209","Trospium and Molindone, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1556,"Donepezil","DB00843","Possible antagonism of action"
1556,"Galantamine","DB00674","Possible antagonism of action"
1556,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Phenindamine, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
1556,"Trimethobenzamide","DB00662","Trimethobenzamide and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1556,"Triprolidine","DB00427","Triprolidine and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1556,"Trospium","DB00209","Trospium and Phenindamine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1558,"Donepezil","DB00843","Possible antagonism of action"
1558,"Galantamine","DB00674","Possible antagonism of action"
1558,"Telithromycin","DB00976","Telithromycin may reduce clearance of Pipotiazine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Pipotiazine if Telithromycin is initiated, discontinued or dose changed."
1558,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Pipotiazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Pipotiazine if Terbinafine is initiated, discontinued or dose changed."
1558,"Triprolidine","DB00427","The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Pipotiazine. Monitor for symptoms of ventricular arrhythmias."
1558,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pipotiazine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of pipotiazine if voriconazole is initiated, discontinued or dose changed."
1559,"Donepezil","DB00843","Possible antagonism of action"
1559,"Galantamine","DB00674","Possible antagonism of action"
1559,"Rivastigmine","DB00989","Possible antagonism of action"
1560,"Abarelix","DB00106","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Amantadine","DB00915","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Amantadine. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Amiodarone","DB01118","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Amitriptyline","DB00321","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Amoxapine","DB00543","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Apomorphine","DB00714","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Thiothixene may also antagonize the effects of the anti-Parkinsonian agent, Apomorphine. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or doses changed. "
1560,"Arsenic trioxide","DB01169","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1560,"Bromocriptine","DB01200","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Bromocriptine. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Chlorpromazine","DB00477","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Ciprofloxacin","DB00537","The strong CYP1A2 inhibitor, Ciprofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ciprofloxacin is initiated, discontinued or dose changed. "
1560,"Cisapride","DB00604","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Clarithromycin","DB01211","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Clomipramine","DB01242","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Dasatinib","DB01254","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Desipramine","DB01151","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Disopyramide","DB00280","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Dofetilide","DB00204","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Dolasetron","DB00757","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Domperidone","DB01184","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Donepezil","DB00843","Possible antagonism of action"
1560,"Doxepin","DB01142","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Droperidol","DB00450","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Erythromycin","DB00199","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Flecainide","DB01195","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Fluconazole","DB00196","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Fluoxetine","DB00472","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Flupentixol","DB00875","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Fluvoxamine","DB00176","The strong CYP1A2 inhibitor, Fluvoxamine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Fluvoxamine is initiated, discontinued or dose changed. "
1560,"Foscarnet","DB00529","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Galantamine","DB00674","Possible antagonism of action"
1560,"Gatifloxacin","DB01044","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Guanethidine","DB01170","Thiothixene may decrease the effect of guanethidine."
1560,"Halofantrine","DB01218","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Haloperidol","DB00502","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Ibutilide","DB00308","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Imipramine","DB00458","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Indapamide","DB00808","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Isradipine","DB00270","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Ketoconazole","DB01026","The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. "
1560,"L-DOPA","DB01235","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Levodopa. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Lapatinib","DB01259","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Levofloxacin","DB01137","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Lidocaine","DB00281","The strong CYP1A2 inhibitor, Lidocaine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Lidocaine is initiated, discontinued or dose changed. "
1560,"Loxapine","DB00408","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
1560,"Maprotiline","DB00934","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Mefloquine","DB00358","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Mesoridazine","DB00933","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Methadone","DB00333","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Methoxsalen","DB00553","The strong CYP1A2 inhibitor, Methoxsalen, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Methoxsalen is initiated, discontinued or dose changed. "
1560,"Mexiletine","DB00379","The strong CYP1A2 inhibitor, Mexiletine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Mexiletine is initiated, discontinued or dose changed. "
1560,"Moxifloxacin","DB00218","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Nilotinib","DB04868","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
1560,"Norfloxacin","DB01059","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. The strong CYP1A2 inhibitor, Norfloxacin, may also decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Nortriptyline","DB00540","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Octreotide","DB00104","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Ofloxacin","DB01165","The strong CYP1A2 inhibitor, Ofloxacin, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ofloxacin is initiated, discontinued or dose changed. "
1560,"Pentamidine","DB00738","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Perflutren","DB00556","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Pergolide","DB01186","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pergolide. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Pimozide","DB01100","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Pramipexole","DB00413","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Pramipexole. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Pramlintide","DB01278","The anticholinergic effects of Tranylcypromine may be enhanced by Pramlintide. Additive effects of reduced GI motility may occur. Pramlintide slows gastic emptying and should not be used with drugs that alter GI motility (e.g. anticholinergics). Consider alternative treatments or use caution during concomitant therapy."
1560,"Primaquine","DB01087","The strong CYP1A2 inhibitor, Primaquine, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Primaquine is initiated, discontinued or dose changed. "
1560,"Probucol","DB01599","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Procainamide","DB01035","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Propafenone","DB01182","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Protriptyline","DB00344","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Quetiapine","DB01224","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Quinine","DB00468","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
1560,"Ranolazine","DB00243","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Risperidone","DB00734","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Ropinirole","DB00268","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Ropinirole. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Rotigotine","DB05271","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Rotigotine. Consider alternate therapy or monitor for decreased effects of both agents. "
1560,"Sotalol","DB00489","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Sparfloxacin","DB01208","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Sunitinib","DB01268","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thiothixene, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1560,"Tacrolimus","DB00864","Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution."
1560,"Telithromycin","DB00976","May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. "
1560,"Tetrabenazine","DB04844","Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."
1560,"Thiabendazole","DB00730","The strong CYP1A2 inhibitor, Thiobendazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Thiobendazole is initiated, discontinued or dose changed."
1560,"Thioridazine","DB00679","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
1560,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1560,"Trimethobenzamide","DB00662","Trimethobenzamide and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1560,"Trimipramine","DB00726","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1560,"Triprolidine","DB00427","Triprolidine and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1560,"Trospium","DB00209","Trospium and Thiothixene, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1560,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1560,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1560,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1560,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Abarelix","DB00106","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Amantadine","DB00915","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and amantadine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. "
1561,"Amiodarone","DB01118","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Amitriptyline","DB00321","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Amoxapine","DB00543","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Apomorphine","DB00714","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Antagonism may also occur between zuclopenthixol, a dopamine D2 receptor antagonist, and apomorphine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Arsenic trioxide","DB01169","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Asenapine","DB06216","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Azithromycin","DB00207","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Bromocriptine","DB01200","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Bupropion","DB01156","Bupropion, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if bupropion is initiated, discontinued or dose changed. "
1561,"Chlorpromazine","DB00477","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Chlorpromazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if chlorpromazine is initiated, discontinued or dose changed. "
1561,"Cinacalcet","DB01012","Cinacalcet, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cinacalcet is initiated, discontinued or dose changed. "
1561,"Cisapride","DB00604","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Citalopram","DB00215","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Clarithromycin","DB01211","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Clomipramine","DB01242","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Cocaine","DB00907","Cocaine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if cocaine is initiated, discontinued or dose changed. "
1561,"Dasatinib","DB01254","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Delavirdine","DB00705","Delavirdine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if delavirdine is initiated, discontinued or dose changed. "
1561,"Desipramine","DB01151","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Disopyramide","DB00280","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Dofetilide","DB00204","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Dolasetron","DB00757","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Domperidone","DB01184","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Donepezil","DB00843","Possible antagonism of action"
1561,"Doxepin","DB01142","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Dronedarone","DB04855","Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated.  "
1561,"Droperidol","DB00450","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Erythromycin","DB00199","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Escitalopram","DB01175","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Etravirine","DB06414","Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy."
1561,"Flecainide","DB01195","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Fluconazole","DB00196","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Fluoxetine","DB00472","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Fluoxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if fluoxetine is initiated, discontinued or dose changed. "
1561,"Flupentixol","DB00875","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Foscarnet","DB00529","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Galantamine","DB00674","Possible antagonism of action"
1561,"Halofantrine","DB01218","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Haloperidol","DB00502","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Ibutilide","DB00308","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Iloperidone","DB04946","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Imipramine","DB00458","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Indapamide","DB00808","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Isradipine","DB00270","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"L-DOPA","DB01235","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and levodopa, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Lapatinib","DB01259","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Levofloxacin","DB01137","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Lopinavir","DB01601","Lopinavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if lopinavir is initiated, discontinued or dose changed. "
1561,"Loxapine","DB00408","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
1561,"Maprotiline","DB00934","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Mefloquine","DB00358","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Mesoridazine","DB00933","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Methadone","DB00333","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Methotrimeprazine","DB01403","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed."
1561,"Metoclopramide","DB01233","Additive dopamine D2 receptor antagonism may cause dopaminergic imbalance in the nigrostriatal (dopamine D1 receptors) and striatopallidal (dopamine D2 receptors). Increased risk of extrapyramidal reactions and neuroleptic malignant syndrome. Concomitant therapy should be avoided. "
1561,"Moxifloxacin","DB00218","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Nilotinib","DB04868","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided. "
1561,"Norfloxacin","DB01059","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Nortriptyline","DB00540","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Octreotide","DB00104","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Paroxetine","DB00715","Paroxetine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if paroxetine is initiated, discontinued or dose changed. "
1561,"Pazopanib","DB06589","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Pentamidine","DB00738","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Perflutren","DB00556","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Pergolide","DB01186","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pergolide, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed. Pergolide, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if pergolide is initiated, discontinued or dose changed."
1561,"Pimozide","DB01100","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated."
1561,"Pramipexole","DB00413","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and pramipexole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Pramlintide","DB01278","May cause additive reduction in GI motility. Use caution or consider alternate therapy. "
1561,"Probucol","DB01599","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Procainamide","DB01035","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Propafenone","DB01182","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Protriptyline","DB00344","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Quetiapine","DB01224","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Quinidine","DB00908","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Quinidine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if quinidine is initiated, discontinued or dose changed."
1561,"Quinine","DB00468","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided."
1561,"Ranolazine","DB00243","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Risperidone","DB00734","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Ritonavir","DB00503","Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed. "
1561,"Romidepsin","DB06176","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Ropinirole","DB00268","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and ropinirole, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Rotigotine","DB05271","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
1561,"Sotalol","DB00489","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Sparfloxacin","DB01208","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Sunitinib","DB01268","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Zuclopenthixol, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents."
1561,"Tacrolimus","DB00864","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Telavancin","DB06402","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Telithromycin","DB00976","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Terbinafine","DB00857","Terbinafine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if terbinafine is initiated, discontinued or dose changed."
1561,"Tetrabenazine","DB04844","Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."
1561,"Thioridazine","DB00679","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated."
1561,"Thiothixene","DB01623","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
1561,"Trimethobenzamide","DB00662","Trimethobenzamide and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1561,"Trimipramine","DB00726","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Triprolidine","DB00427","Triprolidine and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects."
1561,"Trospium","DB00209","Trospium and Zuclopenthixol, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
1561,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
1561,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
1562,"Donepezil","DB00843","Possible antagonism of action"
1562,"Galantamine","DB00674","Possible antagonism of action"
1562,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
1563,"Epinephrine","DB00668","Increased arterial pressure"
1563,"Fenoterol","DB01288","Increased arterial pressure"
1563,"Guanethidine","DB01170","Pargyline may decrease the effect of guanethidine."
1563,"Methotrimeprazine","DB01403","Possible severe adverse reaction with this combination"
1563,"Milnacipran","DB04896","Increase serotonin levels. Combination therapy is contraindicated. "
1563,"Orciprenaline","DB00816","Increased arterial pressure"
1563,"Phenylephrine","DB00388","Increased arterial pressure"
1563,"Phenylpropanolamine","DB00397","Increased arterial pressure"
1563,"Pseudoephedrine","DB00852","Increased arterial pressure"
1563,"Terbutaline","DB00871","Increased arterial pressure"
1564,"Aluminium","DB01370","The aluminium salt decreases the absorption of lincosamides"
1564,"Atracurium","DB00732","The agent increases the effect of muscle relaxant"
1564,"Attapulgite","DB01574","The aluminium salt decreases the absorption of lincosamides"
1564,"Doxacurium chloride","DB01135","The agent increases the effect of muscle relaxant"
1564,"Erythromycin","DB00199","Possible antagonism of action with this combination."
1564,"Kaolin","DB01575","The aluminium salt decreases the absorption of lincosamides"
1564,"Metocurine","DB01336","The agent increases the effect of muscle relaxant"
1564,"Mivacurium","DB01226","The agent increases the effect of muscle relaxant"
1564,"Pancuronium","DB01337","The agent increases the effect of muscle relaxant"
1564,"Pipecuronium","DB01338","The agent increases the effect of muscle relaxant"
1564,"Rocuronium","DB00728","The agent increases the effect of muscle relaxant"
1564,"Succinylcholine","DB00202","The agent increases the effect of muscle relaxant"
1564,"Tubocurarine","DB01199","The agent increases the effect of muscle relaxant"
1564,"Vecuronium","DB01339","The agent increases the effect of muscle relaxant"
1565,"Acenocoumarol","DB01418","Etoricoxib may increase the anticoagulant effect of acenocoumarol."
1565,"Anisindione","DB01125","Etoricoxib may increase the anticoagulant effect of anisindione."
1565,"Dicoumarol","DB00266","Etoricoxib may increase the anticoagulant effect of dicumarol."
1565,"Ethinyl Estradiol","DB00977","Etoricoxib may increase the levels of ethinyl estradiol."
1565,"Lithium","DB01356","Etoricoxib increases serum levels of lithium"
1565,"Rifampicin","DB01045","Rifampin reduces levels and efficacy of etoricoxib"
1565,"Warfarin","DB00682","Etoricoxib may increase the anticoagulant effect of warfarin."
1592,"Abatacept","DB01281","Consider therapy modification due to enhanced immunosuppressive action."
1592,"Amiodarone","DB01118","Increases roflumilast levels. "
1592,"Antithymocyte globulin","DB00098","Therapy may need to be modified due to enhanced immunosuppressive effects."
1592,"armodafinil","DB06413","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1592,"Belatacept","DB06681","Consider modifying therapy due to enhanced immunosuppressive effect."
1592,"Belimumab","DB08879","Consider therapy modification due to enhanced immunosuppressive effect. "
1592,"Bleomycin","DB00290","Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning."
1592,"Bosentan","DB00559","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Carbamazepine","DB00564","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1592,"Carboplatin","DB00958","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carboplatin. he Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
1592,"Carmustine","DB00262","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as carmustine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
1592,"Chlorambucil","DB00291","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as chlorambucil. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
1592,"Cimetidine","DB00501","Increases roflumilast levels. "
1592,"Cisplatin","DB00515","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cisplatin. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible."
1592,"Cladribine","DB00242","Roflumilast may enhance the immunosuppressive effect of immunosuppressants such as cladribine. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
1592,"Clofarabine","DB00631","Roflumilast may enhance the immunosuppressive effect of Immunosuppressants. The Canadian roflumilast product monograph recommends avoiding concurrent use of roflumilast with any immunosuppressant medications due to the antiinflammatory/immune altering effects of roflumilast and the lack of relevant clinical experience with such use. Of note, this recommendation to avoid concurrent use does not apply to either inhaled corticosteroids (which have much more limited systemic immune-suppressing actions) or short-term systemic corticosteroid use. U.S. prescribing information does not contain this warning; but it appears prudent to avoid this combination when possible. "
1592,"Dexamethasone","DB01234","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Efavirenz","DB00625","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Erythromycin","DB00199","Increases roflumilast levels. "
1592,"Etanercept","DB00005","Due to enhanced immunosuppressive effects, therapy modification should be considered."
1592,"Etravirine","DB06414","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Etravirine","DB06414","Roflumilast, when used concomitantly with etravirine, may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy."
1592,"Fluvoxamine","DB00176","Increases roflumilast levels. "
1592,"Fosphenytoin","DB01320","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Gemtuzumab ozogamicin","DB00056","Consider therapy modification due to enhanced immunosuppressive effect."
1592,"Glatiramer Acetate","DB05259","Consider therapy modification due to enhanced immunosuppressive effects."
1592,"Ibritumomab","DB00078","Consider modifying therapy due to enhanced immunosuppressive effect."
1592,"Infliximab","DB00065","Roflumilast enhances the adverse effects of immune suppressants thus a therapy modification should be considered."
1592,"Ketoconazole","DB01026","Increases roflumilast levels. "
1592,"Lopinavir","DB01601","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1592,"Modafinil","DB00745","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1592,"Nafcillin","DB00607","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Nevirapine","DB00238","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Obinutuzumab","DB08935","Consider therapy modification due to enhanced immunosuppressive effect."
1592,"Omalizumab","DB00043","Consider therapy modification due to enhanced immunosuppressive effects."
1592,"Omeprazole","DB00338","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1592,"Oxcarbazepine","DB00776","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Pegaspargase","DB00059","Consider therapy modification because pegaspargase enhances the immunosuppressive effect of roflumilast."
1592,"Pentobarbital","DB00312","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Phenobarbital","DB01174","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1592,"Primidone","DB00794","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1592,"Rifabutin","DB00615","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Rifampicin","DB01045","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. Also decreases the level or effect of roflumilast by affecting CYP1A2 metabolism. "
1592,"Rifapentine","DB01201","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Ritonavir","DB00503","Affects CYP1A2 metabolism; decreases level or effect of roflumilast. "
1592,"St. John's Wort","DB01323","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
1592,"Tofacitinib","DB08895","Roflumilast, when used in combination with tofacitinib, may increase the immunosuppressive effect of tofaciitinib and other immunosuppressive agents.   It is recommended to modify therapy. "
1592,"Zafirlukast","DB00549","Increases roflumilast levels. "
1628,"Abacavir","DB01048","Ribavirin Monophosphate may increase the hepatotoxicity of reverse transcriptase inhibitors (nucleoside) such as Abacavir. Lactic acidosis may occur. Consider modifying therapy."
1761,"Moclobemide","DB01171","Possible severe adverse reaction with this combination"
1761,"Phenelzine","DB00780","Possible severe adverse reaction with this combination"
2207,"Alfacalcidol","DB01436","Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use."
2207,"Aluminum hydroxide","DB06723","Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
2207,"Cholecalciferol","DB00169","Vitamin D Analogs may enhance the adverse/toxic effect of other Vitamin D Analogs. Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). hough not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. "
2207,"Orlistat","DB01083","Orlistat may decrease the serum concentration of fat soluble vitamins like vitamin D. Hence, this applies to calcipotriol, a synthetic derivative of vitamin D. Administer oral fat soluble vitamins at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins. "
2207,"Sucralfate","DB00364","Vitamin D Analogs may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration. Avoid chronic and/or excessive use of aluminum and aluminum-containing products (such as sucralfate) in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
2345,"Methotrexate","DB00563","The penicillin increases the effect and toxicity of methotrexate"
2345,"Minocycline","DB01017","Possible antagonism of action"
2345,"Tetracycline","DB00759","Possible antagonism of action"
2443,"Abarelix","DB00106","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Amiodarone","DB01118","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Amitriptyline","DB00321","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Amoxapine","DB00543","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Apomorphine","DB00714","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Arsenic trioxide","DB01169","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
2443,"Asenapine","DB06216","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Azithromycin","DB00207","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Chlorpromazine","DB00477","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Cisapride","DB00604","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Clarithromycin","DB01211","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Clomipramine","DB01242","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Dasatinib","DB01254","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Desipramine","DB01151","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Disopyramide","DB00280","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Dofetilide","DB00204","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Dolasetron","DB00757","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Domperidone","DB01184","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Doxepin","DB01142","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Dronedarone","DB04855","Additive QTc prolongation may occur. Concomitant therapy is contraindicated. "
2443,"Droperidol","DB00450","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Erythromycin","DB00199","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Flecainide","DB01195","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Fluconazole","DB00196","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Fluoxetine","DB00472","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Flupentixol","DB00875","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Foscarnet","DB00529","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Gatifloxacin","DB01044","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Halofantrine","DB01218","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Haloperidol","DB00502","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Ibutilide","DB00308","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Imipramine","DB00458","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Indapamide","DB00808","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Isradipine","DB00270","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Lapatinib","DB01259","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Levofloxacin","DB01137","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Loxapine","DB00408","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
2443,"Maprotiline","DB00934","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Mefloquine","DB00358","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Mesoridazine","DB00933","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Methadone","DB00333","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Methotrimeprazine","DB01403","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Moxifloxacin","DB00218","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Nilotinib","DB04868","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
2443,"Norfloxacin","DB01059","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Nortriptyline","DB00540","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Octreotide","DB00104","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Pentamidine","DB00738","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Perflutren","DB00556","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Pimozide","DB01100","Additive QTc prolongation may occur. Concomitant therapy is contraindicated. "
2443,"Probucol","DB01599","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Procainamide","DB01035","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Propafenone","DB01182","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Protriptyline","DB00344","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Quetiapine","DB01224","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Quinidine","DB00908","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Quinine","DB00468","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
2443,"Ranolazine","DB00243","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Risperidone","DB00734","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Sotalol","DB00489","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Sparfloxacin","DB01208","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Sunitinib","DB01268","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Tacrolimus","DB00864","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Telithromycin","DB00976","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Tetrabenazine","DB04844","Additive QTc prolongation may occur. Concomitant therapy should be avoided."
2443,"Thioridazine","DB00679","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Thiothixene","DB01623","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Toremifene","DB00539","Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration."
2443,"Trimipramine","DB00726","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2443,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
2443,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
2482,"Probenecid","DB01032","Probenecid may increase the serum level of the moxalactam derivative."
2592,"Amprenavir","DB00701","The protease inhibitor, amprenavir, may increase the effect and toxicity of fusidic acid."
2592,"Atorvastatin","DB01076","Increased risk of myopathy/rhabdomyolysis"
2592,"Fosamprenavir","DB01319","The protease inhibitor, fosamprenavir, may increase the effect and toxicity of fusidic acid."
2592,"Indinavir","DB00224","Indinavir may increase the effect and toxicity of fusidic acid."
2592,"Nelfinavir","DB00220","The protease inhibitor, nelfinavir, may increase the effect and toxicity of fusidic acid."
2592,"Penicillin V","DB00417","Fusidic acid may diminish the therapeutic effect of penicillins. To management this interaction, penicillin should be administered 2 hours before fusidic acid."
2592,"Ritonavir","DB00503","The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid."
2592,"Saquinavir","DB01232","The protease inhibitor, saquinavir, may increase the effect and toxicity of fusidic acid."
2592,"Simvastatin","DB00641","Increased risk of myopathy/rhabdomyolysis"
2592,"Ticarcillin","DB01607","Fusidic acid may reduce the effect of Ticarcillin by inhibiting bacterial growth. Ticarcillin exerts its effects on actively growing bacteria. To achieve synergism, Ticarcillin should be administered at least 2 hours prior to using Fusidic acid."
2592,"Tipranavir","DB00932","Concomitant therapy of Tipranavir with Fusidic acid may result in increased serum concentrations of both agents. Consider alternate therapy or monitor for increased serum concentrations and toxocity of both agents. "
2997,"Tacrine","DB00382","The acetylcholinesterase inhibitor, Tacrine, may increase the adverse/toxic effects of Acetylcholine, a cholinergic agonist. Monitor for increased cholinergic effects and toxicity. "
3093,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
3306,"Gentamicin","DB00798","Increased risk of nephrotoxicity"
3306,"Netilmicin","DB00955","Increased risk of nephrotoxicity"
3306,"Probenecid","DB01032","Probenecid may increase the serum level of cephalothin."
3306,"Tobramycin","DB00684","Increased risk of nephrotoxicity"
3424,"Telithromycin","DB00976","Telithromycin may reduce clearance of Phencyclidine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Phencyclidine if Telithromycin is initiated, discontinued or dose changed."
3424,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of phencyclidine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of phencyclidine if voriconazole is initiated, discontinued or dose changed."
3433,"Acenocoumarol","DB01418","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of acenocoumarol."
3433,"Alendronate","DB00630","Increased risk of gastric toxicity"
3433,"Anisindione","DB01125","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of anisindione."
3433,"Dicoumarol","DB00266","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of dicumarol."
3433,"Ethotoin","DB00754","The NSAID, oxyphenbutazone, may increase the hydantoin effect of ethotoin."
3433,"Fosphenytoin","DB01320","The NSAID, oxphenbutazone, may increase the hydantoin effect of fosphenytoin."
3433,"Mephenytoin","DB00532","The NSAID, oxyphenbutazone, may increase the hydantoin effect of mephenytoin."
3433,"Phenytoin","DB00252","The NSAID, oxphenbutazone, may increase the therapeutic and adverse effects of phenytoin."
3433,"Warfarin","DB00682","The NSAID, oxyphenbutazone, may increase the anticoagulant effect of warfarin."
3741,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
4048,"Etravirine","DB06414","Etravirine, when used concomitantly with rifamycin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
4099,"Azilsartan medoxomil","DB08822","Increases serum potassium. "
4099,"Eltrombopag","DB06210","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
4099,"Lithium","DB01356","The urine alkalizer decreases the effect of lithium"
4381,"Fosphenytoin","DB01320","The hydantoin decreases the effect of psoralene"
4381,"Phenytoin","DB00252","The hydantoin decreases the effect of psoralene"
4382,"Bendamustine","DB06769","Increases toxicity through pharmacodynamic synergism. Additive myelosuppression."
4382,"Bupropion","DB01156","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Bupropion, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Bupropion if Thiotepa is initiated, discontinued or dose changed. "
4382,"Cyclophosphamide","DB00531","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Cyclophosphamide, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Cyclophosphamide if Thiotepa is initiated, discontinued or dose changed. "
4382,"Fosphenytoin","DB01320","Possible increase in thiotepa levels"
4382,"Irinotecan","DB00762","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Irinotecan, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Irinotecan if Thiotepa is initiated, discontinued or dose changed. "
4382,"Ketamine","DB01221","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Ketamine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Ketamine if Thiotepa is initiated, discontinued or dose changed. "
4382,"Natalizumab","DB00108","The immunosuppressant, Thiotepa, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided."
4382,"Phenytoin","DB00252","Possible increase in thiotepa levels"
4382,"Promethazine","DB01069","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Promethazine, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Promethazine if Thiotepa is initiated, discontinued or dose changed. "
4382,"Selegiline","DB01037","Thiotepa, a strong CYP2B6 inhibitor, may decrease the metabolism and clearance of Selegiline, a CYP2B6 substrate. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Selegiline if Thiotepa is initiated, discontinued or dose changed. "
4382,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
4383,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estriol."
4383,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estriol."
4383,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estriol."
4383,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estriol."
4383,"Prednisolone","DB00860","The estrogenic agent, estriol, may increase the effect of the corticosteroid, prednisolone."
4383,"Prednisone","DB00635","The estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone."
4383,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, estriol."
4383,"Raloxifene","DB00481","Association not recommended"
4384,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estropipate."
4384,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estropipate."
4384,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estropipate."
4384,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estropipate."
4384,"Prednisolone","DB00860","The estrogenic agent, estropipate, may increase the effect of the corticosteroid, prednisolone."
4384,"Prednisone","DB00635","The estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone."
4384,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, estropipate."
4384,"Raloxifene","DB00481","Association not recommended"
4385,"Fosphenytoin","DB01320","The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, quinestrol."
4385,"Griseofulvin","DB00400","The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, quinestrol."
4385,"Phenobarbital","DB01174","The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, quinestrol."
4385,"Phenytoin","DB00252","The enzyme inducer, phenytoin, decreases the effect of the hormone agent, quinestrol."
4385,"Prednisolone","DB00860","The estrogenic agent, quinestrol, may increase the effect of the corticosteroid, prednisolone."
4385,"Prednisone","DB00635","The estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone."
4385,"Primidone","DB00794","The enzyme inducer, primidone, decreases the effect of the hormone agent, quinestrol."
4432,"Tacrolimus","DB00864","Additive renal impairment may occur during concomitant therapy with aminoglycosides such as Apramycin. Use caution during concomitant therapy. "
4637,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects."
4637,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  When used with a strong CYP3A4 inhibitor, the adult dose of maraviroc should be decreased to 150 mg twice daily. Maraviroc is contraindicated in patients with severe renal impairment (creatinine clearance less than 30 mL/min) receiving a strong CYP3A4 inhibitor. Maraviroc may be administered at a dose of 300 mg twice daily with concomitant tipranavir/ritonavir but not with other ritonavir combinations. "
4637,"Etravirine","DB06414","Maraviroc, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
4637,"Telithromycin","DB00976","Telithromycin may reduce clearance of Maraviroc. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Maraviroc if Telithromycin is initiated, discontinued or dose changed."
4637,"Topiramate","DB00273","Topiramate, a CYP3A4 inducer, may decrease the serum concentration of Maraviroc by increasing Maraviroc metabolism and clearance. A dose adjustment of Maraviroc may be required. Monitor for changes in Maraviroc therapeutic and adverse effects if Topiramate is initiated, discontinued or dose changed. "
4637,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of maraviroc by decreasing its metabolism. A dose reduction in maraviroc is warranted. Monitor for changes in the therapeutic and adverse effects of maraviroc if voriconazole is initiated, discontinued or dose changed."
4640,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
4643,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Flunarizine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
4645,"Haloperidol","DB00502","The anticholinergic increases the risk of psychosis and tardive dyskinesia"
4645,"Tacrine","DB00382","The therapeutic effects of the central acetylcholinesterase inhibitor, Tacrine, and/or the anticholinergic, Mepenzolate, may be reduced due to antagonism. The interaction may be beneficial when the anticholinergic action is a side effect. Monitor for decreased efficacy of both agents."
4645,"Trimethobenzamide","DB00662","Trimethobenzamide and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
4645,"Triprolidine","DB00427","Triprolidine and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects."
4645,"Trospium","DB00209","Trospium and Mepenzolate, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects."
4646,"Acetophenazine","DB01063","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Aripiprazole","DB01238","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
4646,"Chlorpromazine","DB00477","May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Clozapine","DB00363","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Cocaine","DB00907","CYP2D6 Inhibitors (Strong) such as cocaine may increase the serum concentration of tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. Patients receiving a strong inhibitor of CYP2D6 together with tetrabenazine should not exceed 50mg of tetrabenazine. Also, patients already taking tetrabenazine prior to starting a strong CYP2D6 inhibitor should have their tetrabenazine dose reduced by 50% upon initiation of the strong CYP2D6 inhibitor."
4646,"Droperidol","DB00450","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Fluoxetine","DB00472","Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. "
4646,"Flupentixol","DB00875","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Fluphenazine","DB00623","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Furazolidone","DB00614","Tetrabenazine may increase the adverse/toxic effects of Furazolidine. Concomitant therapy is contraindicated."
4646,"Haloperidol","DB00502","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. May cause dopamine deficiency. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Isocarboxazid","DB01247","Tetrabenazine may increase the adverse/toxic effects of Isocarboxazid. Concomitant therapy is contraindicated."
4646,"L-DOPA","DB01235","Tetrabenazine may cause Parkinsonian symptoms and neutralize the effect of Levodopa."
4646,"Linezolid","DB00601","Tetrabenazine may increase the adverse/toxic effects of Linezolid. Concomitant therapy is contraindicated."
4646,"Lithium","DB01356","Inhibit biochemical and behavioural effects of tetrabenazine. Heed caution when using agents in combination. "
4646,"Loxapine","DB00408","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
4646,"Mesoridazine","DB00933","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Metoclopramide","DB01233","Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Moclobemide","DB01171","Tetrabenazine may increase the adverse/toxic effects of Moclobemide. Concomitant therapy is contraindicated."
4646,"Molindone","DB01618","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Olanzapine","DB00334","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Paliperidone","DB01267","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects. Similar pharmacologic properties thus combination therapy will worsen the severity of sedative, parkinsonian, and extrapyramidal adverse effects. "
4646,"Paroxetine","DB00715","Paroxetine is a strong CYP2D6 inhibitor thus increasing half life of dihydrotetrabenazine moieties. Dose of tetrabenazine should be reduced "
4646,"Perphenazine","DB00850","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Phenelzine","DB00780","Tetrabenazine may increase the adverse/toxic effects of Phenelzine. Concomitant therapy is contraindicated."
4646,"Pimozide","DB01100","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Procarbazine","DB01168","Tetrabenazine may increase the adverse/toxic effects of Procarbazine. Concomitant therapy is contraindicated."
4646,"Prochlorperazine","DB00433","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Quetiapine","DB01224","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Quinidine","DB00908","Strong CYP2D6 inhibitors may increase exposure of the metabolites of tetrabenazine. Consider a reduction of dose. "
4646,"Rasagiline","DB01367","Tetrabenazine may increase the adverse/toxic effects of Rasagiline. Concomitant therapy is contraindicated."
4646,"Reserpine","DB00206","Reserpine may increase the adverse/toxic effects of tetrabenazine as they have similar pharmacologic properties. Concomitant therapy is contraindicated."
4646,"Risperidone","DB00734","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Selegiline","DB01037","Tetrabenazine may increase the adverse/toxic effects of Selegiline. Concomitant therapy is contraindicated."
4646,"Tacrolimus","DB00864","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
4646,"Telithromycin","DB00976","Telithromycin may increase the QTc-prolonging effect of Tetrabenazine. Concomitant therapy should be avoided."
4646,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Tetrabenazine. Consider alternate therapy or monitor for therapeutic/adverse effects of Tetrabenazine if Terbinafine is initiated, discontinued or dose changed."
4646,"Thioridazine","DB00679","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Thiothixene","DB01623","Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."
4646,"Toremifene","DB00539","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
4646,"Tranylcypromine","DB00752","Tetrabenazine may increase the adverse/toxic effects of Tranylcypromine. Concomitant therapy is contraindicated."
4646,"Trifluoperazine","DB00831","May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects."
4646,"Trimipramine","DB00726","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
4646,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Tetrabenazine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
4646,"Voriconazole","DB00582","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
4646,"Vorinostat","DB02546","Additive QTc prolongation may occur. Concomitant therapy should be avoided."
4646,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided."
4646,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. QTc prolongation can lead to Torsade de Pointes (TdP). Concomitant therapy should be avoided."
4647,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg)."
4647,"Telithromycin","DB00976","Telithromycin may reduce clearance of Ixabepilone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Ixabepilone if Telithromycin is initiated, discontinued or dose changed."
4647,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ixabepilone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ixabepilone if voriconazole is initiated, discontinued or dose changed."
4655,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated."
4655,"Atorvastatin","DB01076","Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of atorvastatin. Lower doses of atorvastatin or consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. "
4655,"Clarithromycin","DB01211","Clarithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone. Concurrent use of strong CYP3A4 inhibitors with dronedarone is contraindicated according to dronedarone prescribing information. "
4655,"Crizotinib","DB08865","Concurrent use with drugs that prolong QTc interval is contraindicated. "
4655,"Cyclosporine","DB00091","Cyclosporine is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Dabigatran etexilate","DB06695","Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of dabigatran 1.1-1.9-fold. "
4655,"Digoxin","DB00390","Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of digoxin 2.5-fold. "
4655,"Diltiazem","DB00343","Diltiazem is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker. "
4655,"Etravirine","DB06414","Dronedarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. "
4655,"Fingolimod","DB08868","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
4655,"Itraconazole","DB01167","Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Ketoconazole","DB01026","Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
4655,"Metoprolol","DB00264","Metoprolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase metoprolol exposure 1.6-fold. Lower dose of metoprolol. "
4655,"Nefazodone","DB01149","Nefazodone is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Propranolol","DB00571","Propranolol is a CYP2D6 substrate and because dronedarone inhibits this enzyme, will increase propranolol exposure 1.3-fold. Lower dose of metoprolol. "
4655,"Ritonavir","DB00503","Ritonavir is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Simvastatin","DB00641","Dronedarone is a CYP2D6 inhibitor thus increasing serum concentrations of simvastatin 4-fold. Lower doses of simvastatin and doses should not exceed 20 mg to avoid statin-induced toxicities like myopathy. Consider rosuvastatin as cholesterol lowering therapy as there is no significant interaction between rosuvastatin and dronedarone. "
4655,"Sirolimus","DB00877","Sirolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of sirolimus. Monitor plasma concentrations and adjust dose accordingly. "
4655,"Tacrolimus","DB00864","Tacrolimus is a CYP3A substrate with a narrow therapeutic index thus concomitant therapy with dronedarone will increase plasma levels of tacrolimus. Monitor plasma concentrations and adjust dose accordingly. "
4655,"Telithromycin","DB00976","Telithromycin is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Verapamil","DB00661","Verapamil is a moderate CYP3A4 inhibitor and will increase dronedarone levels 1.4-1.7 fold. Decrease doses of non-dihyropyridinic calcium-channel blocker. "
4655,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated. "
4655,"Voriconazole","DB00582","Voriconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. "
4655,"Vorinostat","DB02546","Additive QTc prolongation may occur. Concomitant therapy is contraindicated. "
4655,"Warfarin","DB00682","Dronedarone is a moderate inhibitor of CYP3A4 which is responsible for warfarin metabolism. Increases serum concentration of S-isomer warfarin by 1.2 fold "
4655,"Ziprasidone","DB00246","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
4655,"Zuclopenthixol","DB01624","Additive or synergistic QTc-prolonging effects may occur. Concomitant therapy is contraindicated.  "
4661,"Terazosin","DB01162","Increased risk of hypotension. Initiate concomitant therapy cautiously."
4661,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
4665,"Acetylsalicylic acid","DB00945","Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
4665,"Ibuprofen","DB01050","Avoid combination with ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
4665,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection.\
"
4665,"Pimecrolimus","DB00337","Avoid combination as there is potential to increase immunosuppressant adverse effects. \
"
4665,"Tacrolimus","DB00864","Avoid combination as there is potential to increase immunosuppressant adverse effects. \
"
4665,"Tofacitinib","DB08895","Avoid combination with tofacitinib and other potent immunosuppressants as there is potential to increase the immunosuppressant effects. Other less potent immunosuppressants such as methotrexate, at antirheumatic doses, and other non-disease modifying antirheumatic drugs (non-DMARDs) can be combined.  \
"
4665,"Warfarin","DB00682","Avoid combination with warfarin and other anticoagulants due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. "
4668,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
4668,"Bendamustine","DB06769","P-glycoprotein (MDR-1) efflux transporter increases bendamustine levels. "
4668,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib. Nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong inhibitors of CYP3A4. "
4668,"Etravirine","DB06414","Nilotinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
4668,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
4668,"Tacrolimus","DB00864","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
4668,"Tamoxifen","DB00675","Nilotinib may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy."
4668,"Tamsulosin","DB00706","Nilotinib, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Nilotinib is initiated, discontinued, or dose changed."
4668,"Telithromycin","DB00976","Telithromycin may reduce clearance of Nilotinib. Concomitant therapy should be avoided."
4668,"Thiothixene","DB01623","May cause additive QTc-prolonging effects. Concomitant therapy should be avoided."
4668,"Topotecan","DB01030","The p-glycoprotein inhibitor, Nilotinib, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. "
4668,"Toremifene","DB00539","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
4668,"Tramadol","DB00193","Nilotinib may decrease the effect of Tramadol by decreasing active metabolite production. "
4668,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
4668,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Nilotinib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Nilotinib is initiated, discontinued to dose changed."
4668,"Trimipramine","DB00726","May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated."
4668,"Voriconazole","DB00582","Voriconazole may increase the serum concentration of nilotinib by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Concomitant therapy should be avoided. "
4668,"Vorinostat","DB02546","Additive QTc prolongation may occur. Concomitant therapy should be avoided. "
4668,"Ziprasidone","DB00246","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
4668,"Zuclopenthixol","DB01624","Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy should be avoided. "
4671,"Ergotamine","DB00696","Avoid all combinations with any ergot derivative such as ergotamine. The combination can increase the risk of developing serotonin syndrome and/or valvular heart disease."
4671,"Thioridazine","DB00679","Avoid combination.The combination is likely to reduce the metabolism of Thioridazine."
4696,"Clonidine","DB00575","Because Savella inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine's anti-hypertensive effect."
4696,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
4696,"Digoxin","DB00390","Use of Savella concomitantly with digoxin may be associated with potentiation of adverse hemodynamic effects. Co-administration of Savella and intravenous digoxin should be avoided. "
4696,"Furazolidone","DB00614","Increase serotonin levels. Combination therapy is contraindicated. "
4696,"Iobenguane","DB06704","Milnacipran decreases the effects of Iobenguane thus increases the risk of producing a false-negative result. May discontinue milnacipran for at least 5 half-live. "
4696,"Isocarboxazid","DB01247","Increase serotonin levels. Combination therapy is contraindicated. "
4696,"Moclobemide","DB01171","Increase serotonin levels. Combination therapy is contraindicated. "
4696,"Pargyline","DB01626","Increase serotonin levels. Combination therapy is contraindicated. "
4696,"Phenelzine","DB00780","Increase serotonin levels. Combination therapy is contraindicated. "
4696,"Procarbazine","DB01168","Increase serotonin levels. Combination therapy is contraindicated.  "
4696,"Rasagiline","DB01367","Increase serotonin levels. Combination therapy is contraindicated.  "
4696,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Concomitant therapy should be avoided. A significant washout period, dependent on the half-lives of the agents, should be employed between therapies."
4696,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
4696,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
4699,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
4718,"Treprostinil","DB00374","Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. "
4734,"Estradiol valerate/Dienogest","DB08866","Pharmacodynamic synergist; contraindicated. "
4734,"Fluconazole","DB00196","Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with ospemifene. Fluconazole increases the systemic exposure of ospemifene by 2.7-fold. Administration of fluconazole with ospemifene may increase the risk of adverse events. "
4734,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions. "
4734,"Omeprazole","DB00338","Moderate CYP2C19 inhibitors may increase levels of ospemifene. Monitor concomitant therapy closely. "
4734,"Rifampicin","DB01045","Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of ospemifene by 58%. Therefore, co-administration of ospemifene with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of ospemifene, which may decrease the clinical effect."
4740,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
4740,"Clarithromycin","DB01211","Clarithromycin is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% "
4740,"Cocaine","DB00907","CYP2D6 Inhibitors (Strong) such as cocaine may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor. "
4740,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor. "
4740,"Fluoxetine","DB00472","Fluoxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% "
4740,"Ketoconazole","DB01026","Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% "
4740,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
4740,"Paroxetine","DB00715","Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% "
4740,"Ziprasidone","DB00246","Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. "
4740,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
4747,"Carbamazepine","DB00564","Ezogabine increases the clearance of carbamazepine (30%). The mechanism of this interaction is unknown. "
4747,"Lamotrigine","DB00555","In healthy adults, the AUCs of lamotrigine and ezogabine were both increased. The clinical significance of this is still unknown. Multiple doses of ezogabine also increase the clearance and decrease the terminal half-life of lamotrigine. "
4747,"Ondansetron","DB00904","Concurrent use of ezogabine and ondansetron can increase QTc interval. Consider alternate therapy. "
4747,"Phenytoin","DB00252","Ezogabine increases the clearance of phenytoin (30%). The mechanism of this interaction is unknown. "
4825,"Acebutolol","DB01193","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
4825,"Amiodarone","DB01118","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Amitriptyline","DB00321","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Asenapine","DB06216","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Atenolol","DB00335","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
4825,"Bambuterol","DB01408","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
4825,"Betamethasone","DB00443","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Bisoprolol","DB00612","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
4825,"Chlorthalidone","DB00310","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Cyclobenzaprine","DB00924","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Desipramine","DB01151","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Erythromycin","DB00199","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
4825,"Ethacrynic acid","DB00903","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Formoterol","DB00983","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
4825,"Furosemide","DB00695","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Haloperidol","DB00502","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
4825,"Hydrochlorothiazide","DB00999","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Hydrocortisone","DB00741","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy. "
4825,"Ondansetron","DB00904","Both indacaterol and ondansetron prolong the QT interval. Consider alternate therapy. "
4825,"Prednisone","DB00635","Concomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia. "
4825,"Propranolol","DB00571","Beta-adrenergic antagonists, especially those that are not cardioselective, may interfere with the effect of indacaterol when administered concurrently. Beta-blockers may exacerbate bronchospasms in patients with COPD. "
4825,"Ritonavir","DB00503","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
4825,"Salmeterol","DB00938","Concomitant use with other inhaled, long acting beta2-adrenergic drugs may result in an overdose. Adverse cardiovascular effects and fatalities have been associated with excessive use of inhaled sympathomimetic drugs. "
4825,"Verapamil","DB00661","Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. "
5024,"Lamotrigine","DB00555","Methsuximide decreases the effect of lamotrigine"
5024,"Ticlopidine","DB00208","Ticlopidine may decrease the metabolism and clearance of Methsuximide. Consider alternate therapy or monitor for adverse/toxic effects of Methsuximide if Ticlopidine is initiated, discontinued or dose changed."
5024,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Methsuximide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
5036,"Denosumab","DB06643","Monitor therapy due to enhanced immunosuppressive effects and the risk of infections. "
5036,"Leflunomide","DB01097","Consider therapy modification due to enhanced adverse effects of leflunomide including hematologic toxicity."
5036,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab including the risk of infections."
5036,"Pimecrolimus","DB00337","Avoid combination due to enhanced immunosuppressive effects."
5036,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5036,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive effects."
5036,"Sipuleucel-T","DB06688","Monitor therapy due to decreased therapeutic effect of sipuleucel-T.\
"
5036,"Tacrolimus","DB00864","Avoid combination due to enhanced adverse effects of immunosuppressants."
5036,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
5036,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effects of immunosuppressants."
5037,"Vancomycin","DB00512","Additive nephrotoxic effects may occur. Avoid concomitant therapy. "
5045,"Clobazam","DB00349","Concomitant therapy may potentiate adverse CNS effects such as increased sedation or respiratory depression. Monitor therapy closely. "
5045,"Dihydrocodeine","DB01551","Dihydrocodeine may enhance the sedative effect of rotigotine. It is recommended to monitor therapy."
5045,"Enflurane","DB00228","Risk of sedation may increase with concomitant therapy. Monitor therapy closely. "
5045,"Ephedrine","DB01364","Risk of sedation may decrease with concomitant therapy. Monitor therapy closely. "
5045,"Fentanyl","DB00813","Pharmacodynamic synergism may increase the effects of rotigotine. Monitor therapy closely. "
5045,"Loxapine","DB00408","Pharmacodynamic antagonism may decrease the effects of rotigotine. Consider alternate therapy. "
5045,"Thiothixene","DB01623","Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Rotigotine. Consider alternate therapy or monitor for decreased effects of both agents. "
5045,"Triprolidine","DB00427","The CNS depressants, Triprolidine and Rotigotine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. "
5045,"Ziprasidone","DB00246","The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder."
5045,"Zuclopenthixol","DB01624","Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and rotigotine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed."
5047,"Acenocoumarol","DB01418","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Acenocoumarol. Monitor for changes in the therapeutic effect of Acenocoumarol if Testosterone is initiated, discontinued or dose changed."
5047,"Cyclosporine","DB00091","The androgen, Testosterone, may increase the hepatotoxicity of Cyclosporine. Testosterone may also elevate serum concentrations of Cyclosporine. Consider alternate therapy or monitor for signs of renal and hepatic toxicity."
5047,"Warfarin","DB00682","The androgen, Testosterone, may incrase the anticoagulant effect of the Vitamin K antagonist, Warfarin. Monitor for changes in the therapeutic effect of Warfarin if Testosterone is initiated, discontinued or dose changed."
5063,"Bosentan","DB00559","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. "
5063,"Carbamazepine","DB00564","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. "
5063,"Dexamethasone","DB01234","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Efavirenz","DB00625","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Etravirine","DB06414","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Fosphenytoin","DB01320","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Nafcillin","DB00607","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Nevirapine","DB00238","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Pentobarbital","DB00312","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Phenobarbital","DB01174","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Phenytoin","DB00252","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Primidone","DB00794","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Rifabutin","DB00615","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Rifampicin","DB01045","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"Rifapentine","DB01201","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5063,"St. John's Wort","DB01323","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5099,"Telithromycin","DB00976","Telithromycin may reduce clearance of Doxorubicin. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Doxorubicin if Telithromycin is initiated, discontinued or dose changed."
5099,"Terbinafine","DB00857","Terbinafine may reduce the metabolism and clearance of Doxorubicin. Consider alternate therapy or monitor for therapeutic/adverse effects of Doxorubicin if Terbinafine is initiated, discontinued or dose changed."
5157,"Heparin","DB01109","Contraindication: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination. Corticorelin prescribing information describes a case in which a patient experienced a substantial fall in blood pressure and heart rate, resulting in asystole and requiring resuscitation."
5271,"Alfuzosin","DB00346","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Alprazolam","DB00404","Telaprevir inhibits systemic metabolism of alprazolam and dose adjustment may be necessary. "
5271,"Amlodipine","DB00381","Telaprevir inhibits the metabolism of amlodipine and concomitant therapy is contraindicated. "
5271,"Atorvastatin","DB01076","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Cisapride","DB00604","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Clobetasol propionate","DB01013","Corticosteroids such as clobetasol may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. "
5271,"Clocortolone","DB00838","Corticosteroids such as clocortolone may decrease the serum concentration of telaprevir. Telaprevir may increase the serum concentration of Corticosteroids. Concurrent use of telaprevir and systemic corticosteroids is not recommended. When possible, consider alternatives, and if such a combination is necessary, use extra caution, monitoring patients for excessive systemic steroid effects as well as for diminished telaprevir effects. "
5271,"Conivaptan","DB00872","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Cyclosporine","DB00091","Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. "
5271,"Digoxin","DB00390","Telaprevir is a substrate of p-glycoprotein and thus increases the AUC and Cmax of digoxin. This indicates an increased absorption of digoxin. Lowest dose of digoxin should be used first and levels be closely monitored. \
"
5271,"Dihydroergotamine","DB00320","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Efavirenz","DB00625","Inducers of CYP3A enzymes will decrease telaprevir levels. "
5271,"Ergotamine","DB00696","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Escitalopram","DB01175","Telaprevir decreases Cmax, Cmin, and AUC of escitalopram however the mechanism of this interaction is unknown. Concomitant therapy may call for dose adjustment. "
5271,"Etravirine","DB06414","Telaprevir, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor telaprevir therapy closely."
5271,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors increase exposure of telaprevir. "
5271,"Lomitapide","DB08827","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Lovastatin","DB00227","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Methadone","DB00333","Telaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients. "
5271,"Midazolam","DB00683","Telaprevir increases AUC and Cmax of oral midazolam by approximately 9-fold and 3-fold respectively. "
5271,"Nelfinavir","DB00220","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Pimozide","DB01100","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
5271,"Raltegravir","DB06817","Telaprevir increases the exposure of raltegravir by up to 31%  but this interaction is considered as not clinically relevant. "
5271,"Rifampicin","DB01045","Strong CYP3A4 inducers will decrease levels of telaprevir. Concomitant therapy is contraindicated. "
5271,"Ritonavir","DB00503","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Simvastatin","DB00641","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Tacrolimus","DB00864","Telaprevir increases levels by affecting CYP3A4 metabolism. Must monitor levels closely with concomitant therapy. "
5271,"Tadalafil","DB00820","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5271,"Triazolam","DB00897","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
5272,"Ethanol","DB00898","The combination of these drugs will likely enhance mipomersen related hepatotoxicity. Therefore patients using both these drugs, should limit their alcohol to a daily maximum of 1 drink (or equivalent). "
5338,"Belimumab","DB08879","Avoid combination due to the increased risk of belimumab associated side effects.\
\
\
"
5338,"Clozapine","DB00363","Avoid combination due to the increased potential for agranulocytosis. "
5338,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection."
5338,"Phenytoin","DB00252","Avoid combination with phenytoin and other strong CYP3A4 inducers due to the likely increase in metabolism of ado-trastuzumab emtansine to its active component, DM1."
5338,"Pimecrolimus","DB00337","Avoid combination due to the increase in immunosuppressant side effects.\
\
"
5338,"Tacrolimus","DB00864","Avoid combination due to the increase in immunosuppressant side effects."
5338,"Tofacitinib","DB08895","Avoid combination with tofacitinib and other potent immunosuppressants due to the likely enhancement of immunosuppression."
5373,"Atazanavir","DB01072","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Bosutinib","DB06616","Abiraterone increases levels by P-glycoprotein (MDR1) efflux transporter. Consider alternate therapy. "
5373,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Dextromethorphan","DB00514","Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. "
5373,"Indinavir","DB00224","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Nefazodone","DB01149","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Nelfinavir","DB00220","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Phenobarbital","DB01174","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Rifabutin","DB00615","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Rifapentine","DB01201","Strong CYP3A4 inducers may decrease levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Saquinavir","DB01232","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Telithromycin","DB00976","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5373,"Thioridazine","DB00679","Abiraterone increases levels by affecting CYP2D6 metabolism. Interaction is significant so monitor closely. "
5373,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. "
5513,"Mesoridazine","DB00933","Increased risk of cardiotoxicity and arrhythmias"
5513,"Thioridazine","DB00679","Increased risk of cardiotoxicity and arrhythmias"
5514,"Methenamine mandelate","DB06146","Possible crystallization of urates with this combination"
5514,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
5517,"Methotrexate","DB00563","The sulfamide increases the toxicity of methotrexate"
5520,"Adalimumab","DB00051","Increases immunosuppressive effects and risk of infection. "
5520,"Alefacept","DB00092","Increases immunosuppressive effects and risk of infection. "
5520,"Anakinra","DB00026","results in increased immunosuppressive effects; increases the risk of infection. "
5520,"Antithymocyte globulin","DB00098","results in increased immunosuppressive effects; increases the risk of infection. "
5520,"Azathioprine","DB00993","results in increased immunosuppressive effects; increases the risk of infection. "
5520,"Basiliximab","DB00074","results in increased immunosuppressive effects; increases the risk of infection. "
5520,"Etanercept","DB00005","Combination should be avoided because Etanercept increase the toxic effects of canakinumab including neutropenia. "
5520,"golimumab","DB06674","Avoid combination with canakinumab due to the increased chance of neutropenia and/or serious infection."
5520,"Infliximab","DB00065","Avoid combination due to increased risk of infection as anti-TNF agents enhance adverse effects of Canakinumab."
5520,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection.\
\
"
5520,"Pimecrolimus","DB00337","Avoid combination due the potential increase in immunosuppressant adverse effects.\
"
5520,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5520,"Tofacitinib","DB08895","Avoid combination with tofacitinib and other potent immunosuppressants due to potential enhancement of immunosuppressant effects."
5521,"Vemurafenib","DB08881","Consider therapy modification due to enhanced hepatotoxicity of vemurafenib"
5523,"Benazepril","DB00542","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Captopril","DB01197","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Enalapril","DB00584","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Fosinopril","DB00492","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Moexipril","DB00691","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Perindopril","DB00790","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Quinapril","DB00881","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Ramipril","DB00178","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5523,"Trandolapril","DB00519","Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. "
5524,"Carbamazepine","DB00564","Decrease concentration of rufinamide thus monitor therapy "
5524,"Ethinyl Estradiol","DB00977","Rufinamide decreases plasma concentrations of ethinyl estradiol, thus consider therapy modification "
5524,"Norethindrone","DB00717","Rufinamide decreases plasma concentrations of norethindrone, thus consider therapy modification "
5524,"Phenobarbital","DB01174","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
5524,"Phenytoin","DB00252","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
5524,"Primidone","DB00794","Increases clearance of rufinamide thus decreasing plasma concentration of rufinamide."
5524,"Valproic Acid","DB00313","Valproic acid may increase the therapeutic/toxic effects of Rufinamide. Consider alternate therapy or monitor for changes in Rufinamide serum concentrations, therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. Decreases clearance of rufinamide and is a selective inhibitor of human carboxylesterase thus increasing serum concentrations. "
5526,"Alvimopan","DB06274","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5526,"Desvenlafaxine","DB06700","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5526,"Naproxen","DB00788","Increases the AUC of tapentadol by 17%. These changes are not considered clinically relevant and no change in dose is required."
5526,"Probenecid","DB01032","Increases the AUC of tapentadol by 57%. These changes are not considered clinically relevant and no change in dose is required."
5526,"Rasagiline","DB01367","Increases the toxicity of tapentadol by unknown mechanism. Discontinue rasagiline at least 14 days prior to tapentadol administration. "
5526,"Selegiline","DB01037","Increases the toxicity of tapentadol by unknown mechanism. Discontinue selegiline at least 14 days prior to tapentadol administration. "
5526,"Zolmitriptan","DB00315","Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. "
5527,"Chloramphenicol","DB00446","Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. "
5527,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Silodosin. Use of silodosin concomitantly with a strong CYP3A4 inhibitor is contraindicated. "
5527,"Diltiazem","DB00343","Moderate inhibitors of CYP3A4 may increase levels of silodosin. Monitor concomitant therapy closely. "
5527,"Erythromycin","DB00199","Erythromycin is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects"
5527,"Fluconazole","DB00196","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
5527,"Indinavir","DB00224","Indinavir is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated. "
5527,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. "
5527,"Ketoconazole","DB01026","Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects "
5527,"Probenecid","DB01032","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
5527,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. "
5527,"Tacrolimus","DB00864","The p-glycoprotein inhibitor, Tacrolimus, may increase the bioavailability of Silodosin. Increased Silodosin exposure may result in Silodosin toxicity. Concurrent use if not recommended. "
5527,"Tamsulosin","DB00706","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy is not recommended."
5527,"Terazosin","DB01162","Additive antihypertensive effects may occur. Increase risk of orthostatic hypotension and syncope. Concomitant therapy should be avoided."
5527,"Valproic Acid","DB00313","Strong UGT2B7 inhibitors may increase levels of silodosin. Monitor concomitant therapy closely. "
5527,"Vardenafil","DB00862","Additive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Silodosin, may occur. Monitor for hypotension during concomitant therapy. "
5527,"Verapamil","DB00661","Verapamil is a moderate inhibitor of CYP3A4 and inhibits P-glycoprotein thus increasing the potential for adverse effects"
5527,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism. Concomitant therapy is contraindicated. "
5528,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
5528,"Ibuprofen","DB01050","Coadministration with NSAIDS used chronically may increase the risk of bleeding. "
5528,"Ketoconazole","DB01026","Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation. "
5528,"Lansoprazole","DB00448","Lansoprazole is a CYP2C19 substrate which decreases AUC and Cmax of prasugrel. Despite these decreases, there was no significant reduction of inhibition of platelet aggregation. "
5528,"Ritonavir","DB00503","Ritonavir is a inhibitor of CYP3A4, thus blocking the bioactivation of prasugrel. As a result, a reduction in prasugrel efficiency may be observed in patients.  "
5528,"Warfarin","DB00682","Coadministration with warfarin may increase the risk of bleeding. "
5529,"Acetaminophen","DB00316","Eltrombopag increases acetaminophen levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Acetylsalicylic acid","DB00945","Decreases metabolism, will increase effect/level of eltrombopag."
5529,"Aluminum hydroxide","DB06723","Decreases levels of eltrombopag by GI absorption inhibition. "
5529,"Amiodarone","DB01118","Affects hepatic enzyme CYP2C9/10 metabolism, increases effect/level of eltrombopag. "
5529,"Amobarbital","DB01351","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
5529,"Atazanavir","DB01072","Decreases metabolism, will increase effect/level of eltrombopag. UDP-glucuronosyltransferase inhibition."
5529,"Atorvastatin","DB01076","Eltrombopag increases levels of Atorvastatin via metabolism decrease."
5529,"Bromfenac","DB00963","Eltrombopag increases levels of Bromfenac via metabolism decrease."
5529,"Butabarbital","DB00237","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
5529,"Butalbital","DB00241","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
5529,"Calcium Acetate","DB00258","Calcium Salts such as calcium acetate may decrease the serum concentration of Eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. "
5529,"Calcium carbonate","DB06724","Decreases levels of eltrombopag by GI absorption inhibition. "
5529,"Calcium Chloride","DB01164","Calcium salts such as calcium chloride may decrease the serum concentration of eltrombopag. Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours. "
5529,"Carbamazepine","DB00564","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
5529,"Celecoxib","DB00482","Eltrombopag increases levels of Celecoxib via metabolism decrease."
5529,"Cimetidine","DB00501","Affects hepatic CYP1A2 metabolism, will decrease effect/level of eltrombopag.\
Affects hepatic CYP2C9/10 metabolism, will decrease effect/level of eltrombopag."
5529,"Ciprofloxacin","DB00537","Affects hepatic CYP1A2 metabolism, will increase effect/level of eltrombopag."
5529,"Citric Acid","DB04272","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Diclofenac","DB00586","Eltrombopag increases levels of Diclofenac via metabolism decrease. UDP-glucuronosyltransferase inhibition."
5529,"Diflunisal","DB00861","Eltrombopag increases levels of Diflunisal via metabolism decrease. "
5529,"Diltiazem","DB00343","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
5529,"Efavirenz","DB00625","Affects hepatic enzyme CYP2C9/10 metabolism and may increase the level of eltrombopag. "
5529,"Enoxacin","DB00467","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
5529,"Erythromycin","DB00199","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
5529,"Ethinyl Estradiol","DB00977","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
5529,"Etodolac","DB00749","Increases levels of Etodolac via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
5529,"Fenoprofen","DB00573","Increases levels of Fenoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
5529,"Fentanyl","DB00813","Increases levels of Fentanyl via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
5529,"Flurbiprofen","DB00712","Increases levels of Flurbiprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition. "
5529,"Fluvastatin","DB01095","Increases levels of Fluvastatin via metabolism decrease. OATP transporter protein inhibition."
5529,"Fluvoxamine","DB00176","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
5529,"Fluvoxamine","DB00176","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
5529,"Grepafloxacin","DB00365","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
5529,"Hydrocodone","DB00956","Increases levels of Hydrocodone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Hydromorphone","DB00327","Increases levels of Hydromorphone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Ibuprofen","DB01050","Increases levels of Ibuprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Indomethacin","DB00328","Increases levels of Indomethacin via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Iron Dextran","DB00893","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Iron sucrose","DB06790","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Isoniazid","DB00951","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
5529,"Ketoprofen","DB01009","Increases levels of Ketoprofen via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Ketorolac","DB00465","Increases levels of Ketorolac via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Leflunomide","DB01097","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
5529,"Levorphanol","DB00854","Increases levels of Levorphanol via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Magnesium Sulfate","DB00653","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Meclofenamic acid","DB00939","Increases levels of Meclofenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Mefenamic acid","DB00784","Increases levels of Mefenamic acid via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Meloxicam","DB00814","Increases levels of Meloxicam via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Methadone","DB00333","Increases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Methotrexate","DB00563","Increases levels of Methotrexate via metabolism decrease. OATP transporter protein inhibition."
5529,"Mexiletine","DB00379","Affects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect."
5529,"Miconazole","DB01110","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
5529,"Morphine","DB00295","Eltrombopag increases Morphine levels via decreasing metabolism. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Pethidine","DB00454","Increases levels of Meperidine via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance. "
5529,"Selenium Sulfide","DB00971","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Sodium bicarbonate","DB01390","Levels of eltrombopag are decreased due to GI inhibition. Separate administration by at least 4 hours. "
5529,"Tretinoin","DB00755","The moderate CYP2C8 inhibitor, Eltrombopag, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Eltrombopag is initiated, discontinued or dose changed."
5529,"Valproic Acid","DB00313","Affects hepatic CYP2C9/10 metabolism, will increase effect/level of eltrombopag."
5529,"Valsartan","DB00177","Eltrombopag may increase the therapeutic and/or toxic effects of Valsartan. Increased Valsartan serum concentrations may be caused by inhibition of hepatic uptake and decreased metabolism. Consider dose modification, alternate therapy or monitor for changes in the therapeutic and toxic effects of Valsartan if Eltrombopag is initiated, discontinued or dose changed.  "
5529,"Zileuton","DB00744","Affects hepatic enzyme CYP1A2 metabolism and may increase the level of eltrombopag. "
5530,"Barbital","DB01483","Barbital is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of tolvaptan. This combination is contraindicated."
5530,"Carbamazepine","DB00564","Carbamazepine is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Clarithromycin","DB01211","Clarithromycin is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
5530,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) may increase the serum concentration of tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. "
5530,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Tolvaptan. Coadministration of a strong CYP3A4 inhibitor with tolvaptan is contraindicated. "
5530,"Digoxin","DB00390","Tolvaptan increases serum digoxin concentrations due to competitive inhibition of P-glycoprotein in the liver, intestine, and kidney. P-glycoprotein facilitates digoxin efflux thus inhibition of this protein will increase incidence of adverse effects. "
5530,"Diltiazem","DB00343","Diltiazem is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
5530,"Erythromycin","DB00199","Erythromycin is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
5530,"Etravirine","DB06414","Tolvaptan may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5530,"Fluconazole","DB00196","Fluconazole is a moderate inhibitor of CYP3A4 and will considerably increase tolvaptan serum concentrations"
5530,"Itraconazole","DB01167","Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
5530,"Ketoconazole","DB01026","Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%. "
5530,"Nefazodone","DB01149","Nefazodone is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
5530,"Phenytoin","DB00252","Phenytoin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Rifabutin","DB00615","Rifabutin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Rifampicin","DB01045","Rifampin is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Ritonavir","DB00503","Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
5530,"Saquinavir","DB01232","Saquinavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. "
5530,"St. John's Wort","DB01323","St. John's Wort is a CYP3A4 inducer and will decrease serum concentrations of tolvaptan and ultimately, its clinical effects. "
5530,"Verapamil","DB00661","Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan. Concomitant therapy is contraindicated. "
5530,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Tolvaptan by decreasing its metabolism. Concomitant therapy is contraindicated. "
5531,"Aminophylline","DB01223","Reduces duration of >2-fold increase in peak flow velocity. No effect on heart rate increase."
5531,"Caffeine","DB00201","Caffeine may diminish the vasodilatory effect of Regadenoson. Regadenoson prescribing information recommends avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior the the administration of regadenoson. The impact of low doses of caffeine-containing products such as coffee, tea, and colas is unclear. "
5531,"Dipyridamole","DB00975","Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration. "
5531,"Theophylline","DB00277","Non-specific adenosine receptor antagonist may interfere with the vasodilation activity of regadenoson. Avoid methylxanthines for at least 12 hours before administration of regadenoson. "
5532,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5532,"Carbamazepine","DB00564","Carbamazepine is a CYP1A2 inducer that decreases asenapine's exposure by 20%. "
5532,"Fluvoxamine","DB00176","Fluvoxamine is a CYP1A2 inhibitor that increases exposure of asenapine by 30%. "
5532,"Indacaterol","DB05039","Concomitant therapy with monoamine oxidase inhibitors, tricyclic antidepressants, or other drugs that prolong the QTc interval should be monitored closely. These drugs may potentiate the effect of adrenergic agonist on the cardiovascular system. "
5532,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5532,"Ondansetron","DB00904","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5532,"Paroxetine","DB00715","Paroxetine is a substrate of CYP2D6 and concomitant therapy with asenapine (CYP2D6 inhibitor) increases concentrations of paroxetine 2-fold. May require dosing adjustments. "
5532,"Phenobarbital","DB01174","Phenobarbital is a CYP1A2 inducer and may increase metabolism of asenapine. "
5532,"Phenytoin","DB00252","Phenytoin is a CYP1A2 inducer and may increase metabolism of asenapine. "
5532,"Primidone","DB00794","Primidone is a CYP1A2 inducer and may increase metabolism of asenapine. "
5532,"Saquinavir","DB01232","Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
5532,"Sildenafil","DB00203","Increased incidence of adverse effects (hypotension) due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
5532,"Thioridazine","DB00679","Thioridazine is a CYP2D6 substrate in which concomitant therapy with asenapine will increase serum levels of thioridazine. Consider alternative therapy. "
5532,"Toremifene","DB00539","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5532,"Valproic Acid","DB00313","Valproate completely inhibits the glucuronidation of asenapine but does not effect its exposure. Dose adjustment is not necessary with concomitant therapy. "
5532,"Voriconazole","DB00582","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
5532,"Vorinostat","DB02546","Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
5532,"Yohimbine","DB01392","Increased incidence of adverse effects due to pharmacodynamic synergism. Concomitant therapy should be avoided. "
5532,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
5532,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
5533,"Valproic Acid","DB00313","Valproic acid toxicity may occur at any time during the treatment course and should be considered in patients with acute changes in mentation, especially if there has been a recent change in antiepileptic therapy.\
"
5534,"Apixaban","DB06605","Avoid combination. Otherwise, excessive anticoagulation will likely occur."
5534,"Bivalirudin","DB00006","Anticoagulants may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. "
5534,"Clopidogrel","DB00758","Antiplatelet agents such as clopidogrel may enhance the anticoagulant effect of rivaroxaban. Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding. Canadian rivaroxaban labeling recommends avoiding concurrent use with any antiplatelet agent, while the U.S. rivaroxaban labeling recommends caution and increased monitoring if used with any other antiplatelet agent. Any combined use should only be undertaken with increased monitoring for evidence of bleeding. "
5534,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban. Consider avoiding use of rivaroxaban with any strong CYP3A4 inhibitors as many such agents are inhibitors of both CYP3A4 and P-glycoprotein. Use of rivaroxaban concomitantly with drugs that are strong inhibitors of both CYP3A4 and P-glycoprotein is specifically contraindicated. "
5534,"Dabigatran etexilate","DB06695","Using additional anticoagulants such as dabigatran can increase the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. "
5534,"Eptifibatide","DB00063","Consider modifying therapy due to enhanced anticoagulant effect."
5534,"Etravirine","DB06414","Rivaroxaban may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy."
5534,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided."
5534,"Itraconazole","DB01167","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
5534,"Ketoconazole","DB01026","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
5534,"Posaconazole","DB01263","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated."
5534,"Ritonavir","DB00503","Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 like ritonavir and P-glycoproteins are contraindicated."
5534,"Tamoxifen","DB00675","Tamoxifen may increase serum concentrations of Rivaroxaban increasing the risk of bleeding. Concomitant therapy should be avoided."
5534,"Telithromycin","DB00976","Telithromycin may reduce clearance of Rivaroxaban. Concomitant therapy is contraindicated."
5534,"Treprostinil","DB00374","The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the anticoagulant, Rivaroxaban. Monitor for increased bleeding during concomitant thearpy. "
5534,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of rivaroxaban by decreasing its metabolism. Increased bleed risks may occur. Consider alternate therapy. "
5535,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects. "
5535,"Desipramine","DB01151","Co-administration with avanafil resulted in an approximate 5.7% increase in AUC0-inf and 5.2% decrease in Cmax of rosiglitazone."
5535,"Erythromycin","DB00199","Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.\
"
5535,"Isosorbide Dinitrate","DB00883","Additive vasodilation. Concomitant therapy is contraindicated. "
5535,"Isosorbide Mononitrate","DB01020","Additive vasodilation. Concomitant therapy is contraindicated. "
5535,"Ketoconazole","DB01026","Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax. "
5535,"Nitroglycerin","DB00727","Additive vasodilation. Concomitant therapy is contraindicated. "
5535,"Omeprazole","DB00338","Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole. "
5535,"Ritonavir","DB00503","Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil. "
5535,"Rosiglitazone","DB00412","Co-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone. "
5535,"Warfarin","DB00682","Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.\
"
5538,"Isosorbide Dinitrate","DB00883","The vasodilatory effects of Isosobide dinitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
5538,"Isosorbide Mononitrate","DB01020","The vasodilatory effects of Isosobide mononitrate may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
5538,"Nitroglycerin","DB00727","The vasodilatory effects of Nitroglycerin may be increased by Udenafil. Severe hypotension may occur. Concomitant therapy is contraindicated."
5539,"Carisoprodol","DB00395","Strong CYP2C19 inhibitors such as sitaxentan may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased."
5539,"Tamoxifen","DB00675","Sitaxsentan may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Sitaxsentan is initiated, discontinued or dose changed."
5539,"Tamsulosin","DB00706","Sitaxsentan, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Sitaxsentan is initiated, discontinued, or dose changed."
5539,"Tofacitinib","DB08895","Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily. "
5539,"Tolbutamide","DB01124","Sitaxsentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Sitaxsentan is initiated, discontinued or dose changed. "
5539,"Tolterodine","DB01036","Sitaxsentan may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
5539,"Torasemide","DB00214","Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Sitaxsentan is initiated, discontinued or dose changed. "
5539,"Tramadol","DB00193","Sitaxsentan may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance."
5539,"Trazodone","DB00656","The CYP3A4 inhibitor, Sitaxsenten, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Norfloxacin is initiated, discontinued or dose changed."
5539,"Trimethoprim","DB00440","The strong CYP2C9 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Sitaxsentan is initiated, discontinued or dose changed."
5539,"Trimipramine","DB00726","The strong CYP2C19 inhibitor, Sitaxsentan, may decrease the metabolism and clearance of Trimipramine, a CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Sitaxsentan is initiated, discontinued or dose changed. "
5539,"Voriconazole","DB00582","Sitaxsentan, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sitaxsentan is initiated, discontinued or dose changed."
5539,"Warfarin","DB00682","Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Warfarin doses should be decreased by 80% upon initiated of concomitant therapy. Monitor for changes in the therapeutic and adverse effects of warfarin if sitaxentan is initiated, discontinued or dose changed."
5539,"Zafirlukast","DB00549","Sitaxentan, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if sitaxentan is initiated, discontinued or dose changed."
5541,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of abatacept."
5541,"Dextromethorphan","DB00514","Dextromethorphan is a CYP2D6 and CYP3A4 substrate. Exposure of dextromethorphan decreases following administration of tocilizumab."
5541,"Etanercept","DB00005","Avoid combination due to enhanced immunosuppressive effects."
5541,"golimumab","DB06674","Avoid combination due to the enhanced immunosuppression by TNF blockers.\
"
5541,"Infliximab","DB00065","Avoid combination because enhanced immunosuppression by anti-TNF agents."
5541,"Omeprazole","DB00338","Omeprazole is a CYP2C19 and CYP3A4 substrate. Exposure of omeprazole decreases following administration of tocilizumab.. "
5541,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5541,"Simvastatin","DB00641","Simvastatin is a CYP3A4 and OATP1B1 substrate. Exposure of simvastatin decreases following administration of tocilizumab. "
5541,"Tofacitinib","DB08895","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
"
5542,"Alfentanil","DB00802","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Amiodarone","DB01118","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Atorvastatin","DB01076","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Buprenorphine","DB00921","Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification."
5542,"Butorphanol","DB00611","Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan. "
5542,"Clarithromycin","DB01211","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Clotrimazole","DB00257","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Codeine","DB00318","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Dextromoramide","DB01529","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Dextropropoxyphene","DB00647","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Dezocine","DB01209","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Difenoxin","DB01501","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Dihydrocodeine","DB01551","Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days. "
5542,"Diphenoxylate","DB01081","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Dipipanone","DB01491","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Fentanyl","DB00813","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Heroin","DB01452","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Hydrocodone","DB00956","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Hydromorphone","DB00327","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Ivacaftor","DB08820","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Levomethadyl Acetate","DB01227","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Levorphanol","DB00854","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Methadone","DB00333","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Morphine","DB00295","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Nalbuphine","DB00844","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Oxycodone","DB00497","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Oxymorphone","DB01192","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Papaverine","DB01113","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Pentazocine","DB00652","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Pethidine","DB00454","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Quinidine","DB00908","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
5542,"Sufentanil","DB00708","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Tapentadol","DB06204","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5542,"Tramadol","DB00193","Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. "
5544,"Aminoglutethimide","DB00357","Aminoglutethimide may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."
5544,"Amprenavir","DB00701","Amprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Atazanavir","DB01072","Atazanavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Bosentan","DB00559","Bosentan may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Carbamazepine","DB00564","Carbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Clarithromycin","DB01211","Clarithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Conivaptan","DB00872","Conivaptan may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Darunavir","DB01264","Darunavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Delavirdine","DB00705","Delavirdine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Dexamethasone","DB01234","Dexamethasone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Efavirenz","DB00625","Efavirenz may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Fluorouracil","DB00544","Co-administration of Temsirolimus and Fluorouracil may result in serious adverse drug reactions. "
5544,"Fosamprenavir","DB01319","Fosamprenavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Fosphenytoin","DB01320","Fosphenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Gemcitabine","DB00441","Co-administration of Temsirolimus and Gemcitabine may result in serious adverse drug reactions. "
5544,"Imatinib","DB00619","Imatinib may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Indinavir","DB00224","Indinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Isoniazid","DB00951","Isoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Itraconazole","DB01167","Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Ketoconazole","DB01026","Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Lopinavir","DB01601","Lopinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Miconazole","DB01110","Miconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Nafcillin","DB00607","Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Natalizumab","DB00108","Temsirolimus may increase the toxicity of Natalizumab. Concomitant therapy should be avoided."
5544,"Nefazodone","DB01149","Nefazodone may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Nelfinavir","DB00220","Nelfinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Nevirapine","DB00238","Nevirapine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Nicardipine","DB00622","Nicardipine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Oxcarbazepine","DB00776","Oxcarbamazepine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided."
5544,"Pentobarbital","DB00312","Pentobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Phenobarbital","DB01174","Phenobarbital may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Phenytoin","DB00252","Phenytoin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Posaconazole","DB01263","Posaconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Primidone","DB00794","Primidone may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Quinidine","DB00908","Quinidine may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Rifabutin","DB00615","Rifabutin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Rifampicin","DB01045","Rifampin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Rifapentine","DB01201","Rifapentine may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5544,"Ritonavir","DB00503","Ritonavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"Saquinavir","DB01232","Saquinavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. "
5544,"St. John's Wort","DB01323","St. John's Wort may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	"
5544,"Sunitinib","DB01268","Co-administration of Temsirolimus and Sunitinib may result in serious adverse drug reactions. "
5544,"Tacrolimus","DB00864","Temsirolimus may decrease the blood concentration of Tacrolimus. Concomitant therapy may increase the adverse/toxic effects of both agents. Concomitant therapy should be avoided. "
5544,"Telithromycin","DB00976","Telithromycin may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided."
5544,"Tipranavir","DB00932","Tipranavir may affect the efficacy/toxicity of Temsirolimus."
5544,"Trandolapril","DB00519","Increased risk of angioedema. Monitor for signs and symptoms of facial and systemic edema and/or erythema."
5544,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
5544,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of temsirolimus and its active metabolite, sirolimus, by decreasing their metabolism. Concomitant therapy should be avoided."
5548,"Clarithromycin","DB01211","Clarithromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin. Limit saxagliptin dose to 2.5 mg/day and monitor for increased saxagliptin levels/effects (e.g., hypoglycemia) with concomitant administration of a strong CYP3A4 inhibitor (e.g., ketoconazole). Monitor for decreased saxagliptin levels/effects with discontinuation of concomitant CYP3A4 inhibitor. "
5548,"Diltiazem","DB00343","Diltiazem is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 109%. Exposure of the active metabolite decreased by 34%. However, these changes in pharmacokinetics are not clinical significant. "
5548,"Erythromycin","DB00199","Erythromycin is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Indinavir","DB00224","Indinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Ketoconazole","DB01026","Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Nefazodone","DB01149","Nefazodone is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Nelfinavir","DB00220","Nelfinavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Rifampicin","DB01045","Rifampin is a strong inducer of CYP3A4 which decreases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also increases. "
5548,"Ritonavir","DB00503","Ritonavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. "
5548,"Simvastatin","DB00641","Simvastatin is a moderate inhibitor of CYP3A4 and increases AUC of saxagliptin by 12%. Exposure of the active metabolite decreased by 2%. However, these changes in pharmacokinetics are not clinical significant. "
5548,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of saxagliptin. Monitor for changes in fasting and postprandial blood sugars."
5548,"Voriconazole","DB00582","Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of saxagliptin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of saxagliptin if voriconazole is initiated, discontinued or dose changed."
5550,"Adalimumab","DB00051","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Alefacept","DB00092","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Anakinra","DB00026","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Antithymocyte globulin","DB00098","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Azathioprine","DB00993","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Basiliximab","DB00074","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Belatacept","DB06681","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5550,"Belatacept","DB06681","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5550,"Belatacept","DB06681","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5550,"Canakinumab","DB06168","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Cyclosporine","DB00091","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Daclizumab","DB00111","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Denileukin diftitox","DB00004","decreases effects of toxoids by pharmacodynamic antagonism. "
5550,"Denosumab","DB06643","Use caution with patients on concomitant immunosuppressants or those with compromised immune systems; increased risk of serious infection. "
5550,"Efalizumab","DB00095","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Etanercept","DB00005","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Everolimus","DB01590","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Glatiramer Acetate","DB05259","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"golimumab","DB06674","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"golimumab","DB06674","Avoid combination due to the enhancement of rilonacept associated side effects.\
"
5550,"Hydroxychloroquine","DB01611","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Infliximab","DB00065","Anti-TNF alfa agents enhance adverse effects of rilonacept thus combination should be avoided."
5550,"Leflunomide","DB01097","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Methotrexate","DB00563","Rilonacept and methotrexate both increase immunosuppressive effects; combination may increase risk of myelosuppression. "
5550,"Muromonab","DB00075","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Mycophenolate mofetil","DB00688","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Sipuleucel-T","DB06688","decreases effectiveness of APC8015 by pharmacodynamic antagonism. "
5550,"Sirolimus","DB00877","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Tacrolimus","DB00864","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Temsirolimus","DB06287","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Thalidomide","DB01041","Thalidomide may increase the adverse effects of Rilonacept. Increased risk of serious infection. Concomitant therapy should be avoided. "
5550,"Tocilizumab","DB06273","results in increased immunosuppressive effects; increases the risk of infection. "
5550,"Trastuzumab","DB00072","Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. "
5551,"Amiodarone","DB01118","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Astemizole","DB00637","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Bepridil","DB01244","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Cisapride","DB00604","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5551,"Disopyramide","DB00280","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Ibutilide","DB00308","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Indapamide","DB00808","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Ondansetron","DB00904","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Pentamidine","DB00738","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Pimozide","DB01100","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Procainamide","DB01035","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Quinidine","DB00908","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Saquinavir","DB01232","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Sotalol","DB00489","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Terfenadine","DB00342","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5551,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
5551,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
5552,"Amiodarone","DB01118","Amiodarone, when used concomitantly with etravirine, may decrease in serum concentration. If possible, monitoring for decreased amiodarone levels is recommended."
5552,"Amiodarone","DB01118","Amiodarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. If possible, monitoring of amiodarone levels is recommended. "
5552,"Apixaban","DB06605","Apixaban, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. Concomitant use should be avoided. "
5552,"Aripiprazole","DB01238","Ariprazole, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dose of oral aripiprazole to maintain therapeutic efficacy, and to adjust the dose of aripiprazole appropriately when the dose of etravirine is altered.  "
5552,"Artemether","DB06697","Artemether, when administered concomitantly with etravirine, may experience a decrease in serum concentrations of active metabolites such as dihydroartemisinin; however, artemether may increase in serum concentration. \
\
Etravirine, when used with artemether, may increase in serum concentration.  \
\
Caution and monitoring of therapeuric efficacy of artemether is recommended. "
5552,"Atazanavir","DB01072","Atazanavir, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. \
\
Etravirine, when administered concomitantly with Atazanavir, may expereince an increase in serum concentrations. \
\
Recommended to avoid use of this combination.  "
5552,"Atorvastatin","DB01076","Atorvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of atorvastatin therapy. "
5552,"Axitinib","DB06626","Axitinib, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. Recommended to avoid use of this combination. "
5552,"Bepridil","DB01244","Bepridil (withdrawn from US. market), when used concomitantly with etravirine, may experience a decrease in serum concentration. If possible, it is recommended to monitor for decreased bepridil concentrations and therapeutic efficacy. "
5552,"Boceprevir","DB08873","The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown. "
5552,"Bortezomib","DB00188","Bortezombib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5552,"Bosutinib","DB06616","Bosutinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5552,"Brentuximab vedotin","DB08870","Brentuximab, when used concomitantly with etravirine, may experience a decrease in serum concentrations. The levels of an active metabolite of brentuximab, monomethyl auristatin E, may decrease. It is recommended to monitor efficacy of brentuximab therapy. "
5552,"Buprenorphine","DB00921","Buprenorphine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for a decrease in buprenorphine levels (ie. reduced analgesia, and signs of opioid withdrawal).  "
5552,"Cabozantinib","DB08875","Cabozantinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by 40mg (without exceeding 180mg/day).  "
5552,"Carbamazepine","DB00564","Carbamazepine, when used concomitantly with certain NNRTIs (ie. efavirenz), may experience a decrease in serum concentration. \
\
Etravirine, and other NNRTIs, when used concomitantly with carbamazepine, may experience an increase in serum concentration. \
\
It is recommended to avoid this combination. "
5552,"Carvedilol","DB01136","Carvedilol, when used concomitantly with etravirine (a CYP2C9 inhibitor), may experience an increase in serum concentration. \
\
It is recommended to monitor for signs and symptoms of an increased response to carvedilol, such as orthostatic hypotension and bradycardia.  "
5552,"Citalopram","DB00215","Citalopram, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience an increase in serum concentration. \
\
It is recommended to maintain the dose of citalopram below 20mg/day, and to monitor for toxicity. The symptoms which often accompany citalopram overdose are dizziness, sweating, nausea, vomiting, tremor, somnolence,sinus tachycardia,amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, acute renal failure, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and torsade de pointes). "
5552,"Clarithromycin","DB01211","Clarithromycin (and other macrolide antibiotics), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to use alternative antibiotic agents if available. If concurrent therapy cannot be avoided, monitor for reduced effectiveness of clarithromycin. "
5552,"Clopidogrel","DB00758","Clopidogrel, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in the serum concentrations of it's active metabolites. \
\
Caution and close monitoring for decreased efficacy of clopidogrel is recommended. "
5552,"Crizotinib","DB08865","Crizotinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5552,"Darunavir","DB01264","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
5552,"Dasatinib","DB01254","Dasatinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. \
\
It is recommended to avoid this combination if possible. If concurrent therapy cannot be avoided it is recommended to increase the dose of dasitinib and monitor for efficacy and toxicity.  "
5552,"Deferasirox","DB01609","Etravirine, when administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy. "
5552,"Delavirdine","DB00705","Etravirine, when used concomitantly with Delaviridine, may experience an increase in serum concentration.  \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination. "
5552,"Diazepam","DB00829","Diazepam (a CYP21C9 and CYP3A4 substrate), when administered concomitantly with etravirine, may experience an increase (via CYP21C9 inhibition) or a decrease(via CYP3A4 induction) in serum concentration. Overall clinical significance is unknown. It is recommended to monitor diazepam therapy. "
5552,"Digoxin","DB00390","Digoxin, when administered concomitantly with etravirine, may experience an increase in serum concentration. It is recommended to monitor serum levels of digoxin and titrate dosage to achieve desired therapeutic range. Pre-emptive dose adjustments are not required."
5552,"Disopyramide","DB00280","Disopyramide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor for disopyramide therapy. "
5552,"Dronedarone","DB04855","Dronedarone, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5552,"Efavirenz","DB00625","Etravirine, when used concomitantly with Efavirenz, may experience a  significant decrease in plasma levels and a loss of efficacy. \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy. It is recommended to avoid this combination. "
5552,"Everolimus","DB01590","Everolimus, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. If concurrent therapy cannot be avoided, a gradual dosage increase of everolimus is recommended."
5552,"Exemestane","DB00990","Exemestane, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase the dosage of exemestane and to closely monitor therapy for efficacy and toxicity. "
5552,"Flecainide","DB01195","Flecainide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor flecainide therapy. "
5552,"Fluvastatin","DB01095","Fluvastatin, when administered concomitantly with etravirin, may experience an increase in serum concentration. It is recommended to monitor for signs of toxicity from fluvastatin, such as myopathy and hepatic enzyme elevations."
5552,"Fosamprenavir","DB01319","Fosamprenavir, when administered concomitantly with etravirine, may experience an increase in the serum concentration of its active metabolits. It is recommended to avoid this combination. "
5552,"Fosphenytoin","DB01320","Etravirine, when administered concomitantly with fosphenytoin, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5552,"Gefitinib","DB00317","Gefitinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase gefitinib dosage, if clinically appropriate, and to monitor for gefitinib therapy for efficacy and toxicity. "
5552,"Guanfacine","DB01018","Guanfacine, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase guanfacine dosage up to 8mg/day, as tolerated, and to monitor gefitinib therapy. "
5552,"Ifosfamide","DB01181","Ifosfamide, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience an increase in the serum concentrations of its active metabolites. It is recommended to monitor for toxicity of ifosfamide therapy."
5552,"Imatinib","DB00619","Imatinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by a minimum of 50%, and to monitor therapy.  "
5552,"Ivacaftor","DB08820","Ivacaftor, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination."
5552,"Ketoconazole","DB01026","Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.\
\
Ketoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.\
\
It is recommended to monitor etravirine therapy for toxicity. "
5552,"Lapatinib","DB01259","Lapatinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination."
5552,"Lidocaine","DB00281","Lidocaine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor lidocaine therapy."
5552,"Linagliptin","DB08882","Linagliptin, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy if possible, and to monitor linagliptin therapy if concurrent use cannot be avoided."
5552,"Lopinavir","DB01601","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
5552,"Lovastatin","DB00227","Lovastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of lovastatin therapy. "
5552,"Lurasidone","DB08815","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
5552,"Lurasidone","DB08815","Lurasidone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Maraviroc","DB04835","Maraviroc, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Methadone","DB00333","Methadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal."
5552,"Mexiletine","DB00379","Mexiletine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor mexiletine therapy for reduced effectiveness."
5552,"Mifepristone","DB00834","Mifepristone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Nevirapine","DB00238","Nevirapine may cause a significant decrease in plasma levels of etravirine and a loss of efficacy. \
Combination of two NNRTIs has not been demonstrated to be of benefit to HIV therapy."
5552,"Nifedipine","DB01115","Nifedipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor nifedipine therapy for reduced effectiveness."
5552,"Nilotinib","DB04868","Nilotinib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Nisoldipine","DB00401","Nisoldipine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Paclitaxel","DB01229","Paclitaxel, when used concomitantly with NNRTIs, may experience an increase in serum concentration. It is recommended to monitor for paclitaxel toxicity."
5552,"Pazopanib","DB06589","Pazopanib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Peginterferon alfa-2a","DB00008","Etravirine (a CYP2C9 substrate), when used concomitantly with peginterferon alfa-2a, may experience a decrease in serum concentration. It is recommended to monitor effectiveness of etravirine therapy."
5552,"Perampanel","DB08883","Perampanel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Phenobarbital","DB01174","Etravirine, when used concomitantly with phenobarbital, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Phenytoin","DB00252","Etravirine, when used concomitantly with phenytoin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Praziquantel","DB01058","Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Praziquantel","DB01058","Praziquantel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Primidone","DB00794","Etravirine, when used concomitantly with Primidone (primarily metabolized to phenobarbital), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. \
"
5552,"Propafenone","DB01182","Propafenone, when used concomitantly with Etravirine, may experience a decrease in serum concentration. It is recommended to monitor for continued efficacy of propafenone therapy. \
"
5552,"Quetiapine","DB01224","Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required."
5552,"Quinidine","DB00908","Quinidine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor quinidine therapy."
5552,"Rifabutin","DB00615","Etravirine may experience a decrease in serum concentration. It is recommended to monitor etravirine therapy for efficacy. The combination of rifabutin and etravirine therapy is contraindicated if a protease inhibitor which is ritonavir boosted is also being used.  "
5552,"Rifamycin Cgp 4832","DB04220","Etravirine, when used concomitantly with rifamycin, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Rilpivirine","DB08864","Rilpivirine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. Use of rilpivirine and other NNRTIs is containdicated. "
5552,"Rivaroxaban","DB06228","Rivaroxaban may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy."
5552,"Roflumilast","DB01656","Affects CYP3A4 metabolism, decreases level or effect of roflumilast. "
5552,"Roflumilast","DB01656","Roflumilast, when used concomitantly with etravirine, may experience a decrease in serum concentration. U.S prescribing information recommends avoiding concurrent therapy."
5552,"Romidepsin","DB06176","Romidepsin, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Saquinavir","DB01232","Etravirine, when used concomitantly with protease inhibitors, may experience a decrease in serum concentration. \
\
Protease inhibitors, when used concomitantly with etravirine, may experience an increase in serum concentration. \
\
Ritonavir boosting of etravirine therapy is a requirement to concurrent therapy. In addition, it is recommended to monitor serum concentrations of the antiretrovirals, as well as to monitor antiretroviral therapy for efficacy.  "
5552,"Sildenafil","DB00203","Sildenafil (and other phosphodiesterase 5 inhibitors), when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor the efficacy of sildenafil therapy."
5552,"Simvastatin","DB00641","Simvastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of simvastatin therapy."
5552,"Sorafenib","DB00398","Sorafebib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"St. John's Wort","DB01323","Etravirine may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Tamsulosin","DB00706","Etravirine, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Etravirine is initiated, discontinued, or dose changed."
5552,"Telaprevir","DB05521","Telaprevir, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor telaprevir therapy closely."
5552,"Ticagrelor","DB08816","Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Tipranavir","DB00932","Tipranavir, co-administered with Ritonavir, may decrease the effect of Etravirene by decreasing Etravirene serum concentration. Concomitant therapy should be avoided."
5552,"Tolterodine","DB01036","Etravirene may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity."
5552,"Tolvaptan","DB06212","Tolvaptan may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Toremifene","DB00539","Toremifene, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Tramadol","DB00193","Tramadol,when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration and efficacy due to increased tramadol metabolism and clearance."
5552,"Trazodone","DB00656","The CYP3A4 inducer, Etravirene, may decrease Trazodone efficacy/toxicity by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Etravirine is initiated, discontinued or dose changed."
5552,"Vandetanib","DB05294","Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  "
5552,"Vincristine","DB00541","Vincristine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5552,"Voriconazole","DB00582","Etravirine, when used concomitantly with variconazole, may experience an increase in serum concentration due to decreased metabolism of etravirine. \
\
Voriconazole, when used concomitantly with etravirine (a CYP2C19 inhibitor), may experience a decrease in serum concentration. \
\
Monitor for changes in efficacy and toxicity of both agents if concomitant therapy is initiated, modified or discontinued. "
5552,"Zuclopenthixol","DB01624","Zuclopenthixol (especially oral dosage form) may experience a decrease in serum concentration when used concomitantly with etravirine. It is recommended to monitor zuclopenthixol therapy for efficacy."
5556,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5556,"Carbamazepine","DB00564","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Cimetidine","DB00501","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Clarithromycin","DB01211","Clarithromycin is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. "
5556,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib dose to 400 mg. Further dose reductions may also be required. "
5556,"Erythromycin","DB00199","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Etravirine","DB06414","Pazopanib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
5556,"Ifosfamide","DB01181","Ifosfamide decreases plasma levels of pazopanib. "
5556,"Irinotecan","DB00762","Irinotecan is an uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) substrate and serum concentrations may increase if administered concurrently with pazopanib, an UGT1A1 inhibitor. "
5556,"Itraconazole","DB01167","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Ivacaftor","DB08820","Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy. "
5556,"Ketoconazole","DB01026","Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects. "
5556,"Lapatinib","DB01259","Lapatinib is a weak inhibitor of CYP3A4, BCRP, and p-glycoprotein and may increase exposure of pazopanib. AUC and Cmax increase by 50-60%. "
5556,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5556,"Nefazodone","DB01149","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Ondansetron","DB00904","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
5556,"Paclitaxel","DB01229","Pazopanib increases exposure of paclitaxel "
5556,"Rifabutin","DB00615","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Rifampicin","DB01045","Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib. "
5556,"Ritonavir","DB00503","Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. "
5556,"Saquinavir","DB01232","Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. "
5556,"Simvastatin","DB00641","Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects. "
5556,"Toremifene","DB00539","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
5556,"Ziprasidone","DB00246","Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated."
5556,"Zuclopenthixol","DB01624","Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP)."
5559,"Dabigatran etexilate","DB06695","Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects. "
5559,"Enoxaparin","DB01225","Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy. "
5559,"Eptifibatide","DB00063","Monitor therapy due to potential risk of bleeding. "
5559,"Etravirine","DB06414","Apixaban, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. Concomitant use should be avoided. "
5559,"Itraconazole","DB01167","Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration."
5559,"Ketoconazole","DB01026","Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration."
5559,"Naproxen","DB00788","Due to pharmacodynamic interaction, a 50-60% increase in anti-Factor Xa activity may be observed with concomitant therapy. "
5559,"Posaconazole","DB01263","Avoid combination. Otherwise, posaconazole will likely increase apixaban serum concentration."
5559,"Ritonavir","DB00503","Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration."
5559,"Rivaroxaban","DB06228","Avoid combination. Otherwise, excessive anticoagulation will likely occur."
5559,"Voriconazole","DB00582","Avoid combination. Otherwise, voriconazole will likely increase apixaban serum concentration."
5561,"Abiraterone","DB05812","Abiraterone increases levels by P-glycoprotein (MDR1) efflux transporter. Consider alternate therapy. "
5561,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
5561,"Digoxin","DB00390","Bosutinib is a substrate and inhibitor of p-glycoprotein (p-gp) and may increase levels of other p-gp substrates. "
5561,"Etravirine","DB06414","Bosutinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination. "
5561,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely. "
5561,"Lansoprazole","DB00448","Concomitant lansoprazole (PPI) decreased bosutinib Cmax by 46% and AUC by 26% compared to bosutinib alone. Consider using short-acting antacids or H2 blockers instead of PPIs to avoid a reduction in bosutinib exposure. Separate antacid or H2 blocker dosing and BOSULIF dosing by more than 2 hours. "
5561,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of bosutinib. Monitor concomitant therapy closely. "
5563,"Clobazam","DB00349","Clobazam decreases levels by affecting CYP3A4 metabolism. Consider alternate therapy. "
5563,"Etravirine","DB06414","Axitinib, when administered concomitantly with etravirine, may experience a decrease in serum concentrations. Recommended to avoid use of this combination. "
5563,"Paclitaxel","DB01229","Avoid combination due to potential for decrease in serum concentration of axitinib."
5563,"Perampanel","DB08883","Avoid combination with axitinib or other major CYP3A4 drug susbtrates due to the potential decrease in the drug's  concentration by perampanel induction of CYP3A4.\
 "
5563,"Phenytoin","DB00252","Avoid combination with phenytoin and other strong, moderate, or weak CYP3A4 inducers due to the likely decreased levels of axitinib.\
\
\
"
5563,"St. John's Wort","DB01323","Avoid combination due to the likely decreased levels of axitinib."
5565,"Abatacept","DB01281","Monitor therapy due to enhanced effects of immunosuppressants and the risk of serious infections."
5565,"Antithymocyte globulin","DB00098","Monitor therapy because of the enhanced immunosuppressive effect and increased risk of infections."
5565,"Belatacept","DB06681","Montinor therapy due to enhanced adverse effects of immunosuppressants and the risk of infections."
5565,"Belimumab","DB08879","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
5565,"Etanercept","DB00005","Monitor therapy as there may be an enhanced immunosuppressive effect."
5565,"Gemtuzumab ozogamicin","DB00056","Monitor therapy due to enhanced adverse effects of immunosuppressants including the risk of infections. "
5565,"Glatiramer Acetate","DB05259","Monitor therapy due to enhanced immunosuppressive effects and the risk of infections. "
5565,"Ibritumomab","DB00078","Monitor therapy for enhanced immunosuppressive effects and increased risk of infections."
5565,"Infliximab","DB00065","Therapy should be monitored when combination is initiated as there may be an increase in serious infections. "
5565,"Obinutuzumab","DB08935","Monitor therapy due to increased risk of infections due to adverse effects of immunosuppressants."
5565,"Omalizumab","DB00043","Monitor therapy due to increased risk of infections consequent to increased adverse effects of immunosuppressants."
5565,"Pegaspargase","DB00059","Monitor therapy due to increased immunosuppressive effect and risk of infections."
5565,"Pralatrexate","DB06813","Increased immunosuppresive effects and risk of infection. Monitor for adverse effects . "
5565,"Rilonacept","DB06372","Use caution with patients on concomitant immunosuppressants or those with compromised immune systems; increased risk of serious infection. "
5565,"Tofacitinib","DB08895","Denosumab, when used in combination with tofacitinib, may increase tofaciitinib toxicity and worsen side effects. It may specifically increase the risk of serious infection. It is recommended to monitor therapy. "
5566,"Acetaminophen","DB00316","These agents may have decreased C max and a delayed T max during coadministration."
5566,"Atorvastatin","DB01076","These agents may have decreased C max and a delayed T max during coadministration."
5566,"Azilsartan medoxomil","DB08822","Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. "
5566,"Digoxin","DB00390","These agents may have decreased C max and a delayed T max during coadministration."
5566,"Griseofulvin","DB00400","Cmax may be increased.\
"
5566,"Insulin Regular","DB00030","Coadministration may increase the risk of hypoglycemia. A lower dose of the antidiabetic agent may be needed.\
"
5566,"Somatropin recombinant","DB00052","Somatropin may antagonize the hypoglycemic effect of liraglutide. Monitor for changes in fasting and postprandial blood sugars."
5567,"Mifepristone","DB00834","Avoid combination with mifepristone and other moderate to high risk QTc prolonging agents. The combinaton may enhance the QTc-prolonging effect of these drugs."
5568,"Abatacept","DB01281","Avoid combination with abatacept due to the increased chance of serious infection.\
\
"
5568,"Anakinra","DB00026","Avoid combination with anakinra due to the increased chance of serious infection.\
"
5568,"Belimumab","DB08879","Avoid combination with belimumab due to the increased chance of belimumab associated side effects.\
\
"
5568,"Canakinumab","DB06168","Avoid combination with canakinumab due to the increased chance of neutropenia and/or serious infection."
5568,"Certolizumab pegol","DB08904","Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol."
5568,"Infliximab","DB00065","Avoid combination with infliximab due to the potential increased immunosuppression of infliximab.\
\
"
5568,"Natalizumab","DB00108","Avoid combination due to the increased chance of infection.\
\
"
5568,"Pimecrolimus","DB00337","Avoid combination due to enhancement of side effects from immunosuppressants.\
"
5568,"Rilonacept","DB06372","results in increased immunosuppressive effects; increases the risk of infection. "
5568,"Rilonacept","DB06372","Avoid combination due to the enhancement of rilonacept associated side effects.\
"
5568,"Tacrolimus","DB00864","Avoid combination due to the enhancement of side effects from immunosuppressants.\
\
"
5568,"Tocilizumab","DB06273","Avoid combination due to the enhanced immunosuppression by TNF blockers.\
"
5568,"Tofacitinib","DB08895","Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy."
5569,"Belimumab","DB08879","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
5569,"Denosumab","DB06643","Montinor therapy due to enhanced adverse effects of immunosuppressants and the risk of infections."
5569,"Leflunomide","DB01097","Consider therapy modification due to enhanced adverse effects of leflunomide, especially hematologic toxicities."
5569,"Mycophenolate mofetil","DB00688","Belatacept increases the Cmax and AUC of mycophenolate mofetil. "
5569,"Natalizumab","DB00108","Avoid infection due to enhanced adverse effects of natalizumab and the risk of infections. "
5569,"Pimecrolimus","DB00337","Avoid combination due to enhanced effects of immunosuppressants."
5569,"Pralatrexate","DB06813","Increased immunosuppresive effects and risk of infection. Monitor for adverse effects . "
5569,"Rilonacept","DB06372","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5569,"Rilonacept","DB06372","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5569,"Rilonacept","DB06372","Belatacept decreases immunosuppressive effects while rilonacept increases immunosuppressive effects. Potential risk of infection although the effect of interaction is not known; use caution and monitor closely if using both. "
5569,"Roflumilast","DB01656","Consider modifying therapy due to enhanced immunosuppressive effect."
5569,"Sipuleucel-T","DB06688","Monitor therapy due to to potential decrease in therapeutic effect of sipuleucel-t."
5569,"Tacrolimus","DB00864","Avoid combination due to enhanced immunosuppressive effect."
5569,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
5569,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect of immunosuppressants. "
5570,"Amitriptyline","DB00321","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved."
5570,"Atazanavir","DB01072","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. \
"
5570,"Carbamazepine","DB00564","Carbamazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors (SSRI). Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Carbamazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes."
5570,"Celecoxib","DB00482","Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). To minimize the risk of bleeding associated with this combination, consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent, such as a proton pump inhibitor for the time that combined selective serotonin reuptake inhibitor (SSRIs) and nonsteroidal anti-inflammatory drugs (NSAIDs) is necessary. "
5570,"Cimetidine","DB00501","Cimetidine may decrease the metabolism of Selective Serotonin Reuptake Inhibitors. Consider using an alternative H2-antagonist to avoid the risk of selective serotonin reuptake inhibitor (SSRI) toxicity. Monitor for increased therapeutic or toxic effects of SSRI if cimetidine is initiated/dose increased, or decreased effects if cimetidine is discontinued/dose decreased. "
5570,"Clarithromycin","DB01211","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
5570,"Clozapine","DB00363","Selective Serotonin Reuptake Inhibitors may decrease the metabolism of clozapine. If concurrent use of these agents is employed, monitor for increased toxic effects of clozapine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased effects if a SSRI is discontinued/dose decreased."
5570,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may increase the serum concentration of Vilazodone. Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
5570,"Desipramine","DB01151","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved. "
5570,"Dextromethorphan","DB00514","Consideration should be given to avoiding the concomitant use of dextromethorphan and selective serotonin reuptake inhibitors (SSRI). Monitor for toxic effects of dextromethorphan (eg, CNS, Cardiovascular) if an SSRI is initiated or the dose is increased. SSRIs, other than fluoxetine and paroxetine, may be safer alternatives due to lesser CYP2D6 inhibition; however, the mechanism for the interaction is not fully understood, and caution is still advised. "
5570,"Diclofenac","DB00586","Increased risk of bleeding with concomitant use of NSAIDs with vilazodone."
5570,"Drotrecogin alfa","DB00055","Increase monitoring for signs/symptoms of bleeding during concomitant therapy. If possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents. "
5570,"Ibuprofen","DB01050","Increased risk of bleeding with concomitant use of non-steroidal anti-inflammatory drugs with vilazodone."
5570,"Isocarboxazid","DB01247","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
5570,"Ketoconazole","DB01026","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
5570,"Ketorolac","DB00465","Increased risk of bleeding with concomitant use of vilazodone and ketorolac"
5570,"L-Tryptophan","DB00150","Due to risks of enhanced serotonin activity and/or adverse reactions (e.g., serotonin syndrome), concomitant use of selective serotonin reuptake inhibitors (SSRIs) and tryptophan is not recommended. Avoid combination."
5570,"Linezolid","DB00601","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
5570,"Metoclopramide","DB01233","Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome. "
5570,"Mexiletine","DB00379","Monitor for increased serum concentrations/toxic effects of mexiletine if a selective serotonin reuptake inhibitor (SSRI) is initiated/dose increased, or decreased concentrations/effects if an SSRI is discontinued/dose decreased. "
5570,"Naproxen","DB00788","Increased risk of bleeding with concomitant use of NSAIDs with vilazodone."
5570,"Naratriptan","DB00952","Increased risk of serotonin syndrome"
5570,"Nortriptyline","DB00540","Monitor for toxic effects of tricyclic antidepressants if a selective serotonin reuptake inhibitor (SSRI) is initiated or the dose is increased. The influence of the SSRI may take several days or weeks to be fully realized or resolved. "
5570,"Phenelzine","DB00780","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome."
5570,"Piroxicam","DB00554","Increased risk of bleeding with concomitant use of NSAIDs and vilazodone"
5570,"Quinidine","DB00908","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
5570,"Selegiline","DB01037","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Avoid combination."
5570,"Sibutramine","DB01105","Sibutramine may enhance the serotonergic effect of Serotonin Modulators. This may cause serotonin syndrome. Avoid combination."
5570,"Sumatriptan","DB00669","Increased risk of serotonin syndrome"
5570,"Thioridazine","DB00679","Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes.  Avoid combination."
5570,"Tranylcypromine","DB00752","MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome."
5570,"Voriconazole","DB00582","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. "
5570,"Warfarin","DB00682","Increased risk of bleeding with concomitant use of warfarin and vilazodone."
5573,"Captopril","DB01197","In study of nine patients with untreated hypertension, aprotinin infused intravenously in a dose of 2 million KIU over two hours blocked the acute hypotensive effect of 100mg of captopril."
5573,"Heparin","DB01109","Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected."
5573,"Tenecteplase","DB00031","Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase. "
5573,"Urokinase","DB00013","Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase."
5576,"Amiodarone","DB01118","Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy."
5576,"Apixaban","DB06605","Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects. "
5576,"Carbamazepine","DB00564","P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Dexamethasone","DB01234","P-Glycoprotein inducers such as dexamethasone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Doxorubicin","DB00997","P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Dronedarone","DB04855","Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of dabigatran 1.1-1.9-fold. "
5576,"Eptifibatide","DB00063","Monitor therapy due to increased bleeding."
5576,"Ginkgo biloba","DB01381","Additive anticoagulant/antiplatelet effects of gingko may increase bleed risk for patients on dabigatran. Concomitant therapy should be avoided."
5576,"Ketoconazole","DB01026","Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects. "
5576,"Lomitapide","DB08827","Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.  "
5576,"Mifepristone","DB00834","May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated. "
5576,"Nefazodone","DB01149","P-Glycoprotein inducers such as nefazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Pantoprazole","DB00213","Proton pump inhibitors may decrease the bioavailability of dabigatran by 28% and increase inter-patient pharmacokinetic variability, especially in females. However, dose adjustment is not required. "
5576,"Prazosin","DB00457","P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Quinidine","DB00908","Quinidine may increase the serum concentration of dabigatran etexilate, resulting in increased bleeding. Consider modification of therapy."
5576,"Rifampicin","DB01045","P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Rivaroxaban","DB06228","Using additional anticoagulants such as dabigatran can increase the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. "
5576,"Tipranavir","DB00932","P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Trazodone","DB00656","P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5576,"Verapamil","DB00661","Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered."
5576,"Vinblastine","DB00570","P-Glycoprotein inducers such as vinblastine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided."
5578,"Amiodarone","DB01118","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5578,"Amitriptyline","DB00321","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5578,"Amoxapine","DB00543","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5578,"Apomorphine","DB00714","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Asenapine","DB06216","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Azithromycin","DB00207","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Bepridil","DB01244","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Chloroquine","DB00608","Chloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options. "
5578,"Chlorpromazine","DB00477","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Cisapride","DB00604","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Citalopram","DB00215","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Clarithromycin","DB01211","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Clomipramine","DB01242","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Conivaptan","DB00872","Conivaptan, a strong CYP3A inhibitor, may increase the toxicity of artemether by inhibiting its metabolism. Consider alternate therapy or allow at least 7 days to elapse between conivaptan and artemether therapy. "
5578,"Dasatinib","DB01254","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Degarelix","DB06699","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Desipramine","DB01151","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Desogestrel","DB00304","Artemether may decrease the effectiveness of desogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Disopyramide","DB00280","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Dofetilide","DB00204","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Dolasetron","DB00757","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Domperidone","DB01184","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Doxepin","DB01142","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Dronedarone","DB04855","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated."
5578,"Droperidol","DB00450","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Drospirenone","DB01395","Artemether may decrease the effectiveness of drospirinone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Erythromycin","DB00199","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Escitalopram","DB01175","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Ethinyl Estradiol","DB00977","Artemether may decrease the effectiveness of ethinyl estradiol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy. "
5578,"Ethynodiol","DB00823","Artemether may decrease the effectiveness of ethynodiol diacetate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Etonogestrel","DB00294","Artemether may decrease the effectiveness of etonogestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Etravirine","DB06414","Artemether, when administered concomitantly with etravirine, may experience a decrease in serum concentrations of active metabolites such as dihydroartemisinin; however, artemether may increase in serum concentration. \
\
Etravirine, when used with artemether, may increase in serum concentration.  \
\
Caution and monitoring of therapeuric efficacy of artemether is recommended. "
5578,"Flecainide","DB01195","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Fluconazole","DB00196","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Fluoxetine","DB00472","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Flupentixol","DB00875","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Foscarnet","DB00529","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Gadobutrol","DB06703","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5578,"Gadofosveset trisodium","DB06705","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Halofantrine","DB01218","Halofantrine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options. "
5578,"Haloperidol","DB00502","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Hydroxychloroquine","DB01611","Hydroxychloroquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Ibutilide","DB00308","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Iloperidone","DB04946","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Imipramine","DB00458","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Indapamide","DB00808","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Isradipine","DB00270","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Ketoconazole","DB01026","Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects."
5578,"Lapatinib","DB01259","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Levofloxacin","DB01137","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Levonorgestrel","DB00367","Artemether may decrease the effectiveness of levonorgestrel by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Loxapine","DB00408","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Maprotiline","DB00934","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Medroxyprogesterone Acetate","DB00603","Artemether may decrease the effectiveness of medroxyprogesterone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Mefloquine","DB00358","Mefloquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Mesoridazine","DB00933","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Mestranol","DB01357","Artemether may decrease the effectiveness of mestranol by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy. "
5578,"Methadone","DB00333","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Methotrimeprazine","DB01403","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Moxifloxacin","DB00218","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Nilotinib","DB04868","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5578,"Norelgestromin","DB06713","Artemether may decrease the effectiveness of norelgestromin by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Norethindrone","DB00717","Artemether may decrease the effectiveness of norethindrone by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Norfloxacin","DB01059","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Norgestimate","DB00957","Artemether may decrease the effectiveness of norgestimate by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5578,"Nortriptyline","DB00540","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Octreotide","DB00104","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Pazopanib","DB06589","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Pentamidine","DB00738","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Perflutren","DB00556","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Pimozide","DB01100","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
5578,"Primaquine","DB01087","Primaquine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Probucol","DB01599","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Procainamide","DB01035","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Proguanil","DB01131","Proguanil may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Propafenone","DB01182","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Protriptyline","DB00344","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Pyrimethamine","DB00205","Pyrimethamine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Quetiapine","DB01224","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Quinidine","DB00908","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Quinine","DB00468","Quinine may increase the adverse effects of artemether. Combination therapy is contraindicated unless there are no other treatment options."
5578,"Ranolazine","DB00243","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Rifampicin","DB01045","Oral administration of rifampin, a strong CYP3A4 inducer, with Coartem Tablets resulted in significant decreases in exposure to artemether, dihydroartemisinin (DHA, metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively, when compared to exposure values after Coartem Tablets alone. Concomitant use of strong inducers of CYP3A4 such as rifampin, carbamazepine, phenytoin and St. John's wort is contraindicated with Coartem Tablets."
5578,"Risperidone","DB00734","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Romidepsin","DB06176","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Saquinavir","DB01232","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Sotalol","DB00489","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Sparfloxacin","DB01208","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Sunitinib","DB01268","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Tacrolimus","DB00864","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Telithromycin","DB00976","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Tetrabenazine","DB04844","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Thioridazine","DB00679","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated."
5578,"Thiothixene","DB01623","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Toremifene","DB00539","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Trimipramine","DB00726","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Voriconazole","DB00582","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Vorinostat","DB02546","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5578,"Ziprasidone","DB00246","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5580,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5580,"Mifepristone","DB00834","Enhance QTc-prolonging effect "
5581,"Almotriptan","DB00918","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Amitriptyline","DB00321","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Amoxapine","DB00543","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Bromocriptine","DB01200","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Buspirone","DB00490","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Citalopram","DB00215","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Clomipramine","DB01242","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Desipramine","DB01151","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Dextromethorphan","DB00514","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Dihydroergotamine","DB00320","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Dipivefrin","DB00449","Desvenlafaxine may increase the tachycardic and vasopressor effects of dipivefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Doxepin","DB01142","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Duloxetine","DB00476","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Eletriptan","DB00216","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Ephedrine","DB01364","Desvenlafaxine may increase the tachycardic and vasopressor effects of ephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Epinephrine","DB00668","Desvenlafaxine may increase the tachycardic and vasopressor effects of epinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Ergoloid mesylate","DB01049","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Ergonovine","DB01253","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Ergotamine","DB00696","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Escitalopram","DB01175","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Fluoxetine","DB00472","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Fluvoxamine","DB00176","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Frovatriptan","DB00998","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Imipramine","DB00458","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Isocarboxazid","DB01247","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Isometheptene","DB06706","Desvenlafaxine may increase the tachycardic and vasopressor effects of isometheptene. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"L-Tryptophan","DB00150","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Levonordefrin","DB06707","Desvenlafaxine may increase the tachycardic and vasopressor effects of levonordefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Linezolid","DB00601","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Lithium","DB01356","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Maprotiline","DB00934","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Methylergometrine","DB00353","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Milnacipran","DB04896","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Mirtazapine","DB00370","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Moclobemide","DB01171","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Naratriptan","DB00952","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Nefazodone","DB01149","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Norepinephrine","DB00368","Desvenlafaxine may increase the tachycardic and vasopressor effects of norepinephrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Nortriptyline","DB00540","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Paroxetine","DB00715","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Pethidine","DB00454","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Phenelzine","DB00780","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Procarbazine","DB01168","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Promethazine","DB01069","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Protriptyline","DB00344","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Pseudoephedrine","DB00852","Desvenlafaxine may increase the tachycardic and vasopressor effects of pseudoephedrine. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5581,"Rasagiline","DB01367","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Rizatriptan","DB00953","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"S-Adenosylmethionine","DB00118","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Selegiline","DB01037","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Sertraline","DB01104","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Sibutramine","DB01105","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"St. John's Wort","DB01323","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Sumatriptan","DB00669","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Tapentadol","DB06204","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Tramadol","DB00193","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Tranylcypromine","DB00752","Increased risk of serotonin syndrome. Ensure adequate washout period between therapies to avoid toxicity. Concurrent therapy should be avoided."
5581,"Trazodone","DB00656","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Trimipramine","DB00726","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Venlafaxine","DB00285","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5581,"Zolmitriptan","DB00315","Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome."
5583,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. Avoid fesoterodine doses greater than 4mg daily in patients who are also receiving strong CYP3A4 inhibitors. "
5583,"Fluconazole","DB00196","Fluconazole is a moderate CYP3A4 inhibitor thus reducing clearance. Monitor for adverse effects when using concomitant therapy with fesoterodine. "
5583,"Ketoconazole","DB01026","Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine. "
5584,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5584,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Consider alternate therapy or monitor closely for QTc-prolongation. "
5585,"Amitriptyline","DB00321","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function"
5585,"Cocaine","DB00907","Sympathomimetic that increase chances of producing a false negative imaging result "
5585,"Ephedrine","DB01364","Sympathomimetic that increase chances of producing a false negative imaging result "
5585,"Imipramine","DB00458","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it inhibits noradrenaline transporter function"
5585,"Labetalol","DB00598","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores"
5585,"Milnacipran","DB04896","Milnacipran decreases the effects of Iobenguane thus increases the risk of producing a false-negative result. May discontinue milnacipran for at least 5 half-live. "
5585,"Phenylephrine","DB00388","Sympathomimetic that increase chances of producing a false negative imaging result "
5585,"Phenylpropanolamine","DB00397","Sympathomimetic that increase chances of producing a false negative imaging result "
5585,"Pseudoephedrine","DB00852","Sympathomimetic that increase chances of producing a false negative imaging result "
5585,"Reserpine","DB00206","May diminish the therapeutic effect and increase chances of producing a false negative imaging result of Iobenguane as it depletes or inhibit reuptake of noradrenaline stores"
5586,"Artemether","DB06697","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5586,"Lumefantrine","DB06708","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5586,"Warfarin","DB00682","In a clinical trial of 10 patients receiving a stable dose of warfarin, a single dose of ABLAVAR (0.05 mmol/kg) did not alter \
the anticoagulant activity of warfarin as measured by the International Normalized Ratio (INR)."
5587,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of isometheptene. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5588,"Desvenlafaxine","DB06700","Desvenlafaxine may increase the tachycardic and vasopressor effects of levonordefrin. Consider alternate therapy or monitor for increased sympathomimetic effects, such as increased blood pressure, chest pain and headache."
5589,"Amiodarone","DB01118","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Amitriptyline","DB00321","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Amoxapine","DB00543","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Apomorphine","DB00714","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Arsenic trioxide","DB01169","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Asenapine","DB06216","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Azithromycin","DB00207","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Bepridil","DB01244","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Chloroquine","DB00608","Chloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Chlorpromazine","DB00477","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Cisapride","DB00604","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Citalopram","DB00215","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Dapsone","DB00250","Concomitant therapy may increase the risk of adverse hemolytic reactions. Monitor patients closely for symptoms of hemolytic reactions during concomitant therapy. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, methoglobulin reductase deficiency or hemoglobin M are at higher risk of experiencing hemolytic reactions. "
5589,"Doxepin","DB01142","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Dronedarone","DB04855","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
5589,"Droperidol","DB00450","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Erythromycin","DB00199","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Escitalopram","DB01175","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Flecainide","DB01195","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Fluconazole","DB00196","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Fluoxetine","DB00472","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Flupentixol","DB00875","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Foscarnet","DB00529","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Gadobutrol","DB06703","Additive QTc-prolongation may occur. Consider alternate therapy or monitor closely for QTc-prolongation. "
5589,"Gadofosveset trisodium","DB06705","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Halofantrine","DB01218","Halofantrine may increase the adverse effects of lumefantrine. Additive QTc-prolongation may occur. Combination therapy is contraindicated and therapies should not be administered within one month of each other due to the long half-life of lumefantrine. "
5589,"Haloperidol","DB00502","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Hydroxychloroquine","DB01611","Hydroxychloroquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Ibutilide","DB00308","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Iloperidone","DB04946","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Imipramine","DB00458","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Indapamide","DB00808","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Isradipine","DB00270","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Lapatinib","DB01259","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Levofloxacin","DB01137","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Loxapine","DB00408","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Maprotiline","DB00934","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Mefloquine","DB00358","Mefloquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Mesoridazine","DB00933","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Methadone","DB00333","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Methotrimeprazine","DB01403","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Moxifloxacin","DB00218","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Nilotinib","DB04868","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Norfloxacin","DB01059","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Nortriptyline","DB00540","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Octreotide","DB00104","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Pazopanib","DB06589","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Pentamidine","DB00738","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Perflutren","DB00556","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Pimozide","DB01100","Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. "
5589,"Primaquine","DB01087","Primaquine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Probucol","DB01599","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Procainamide","DB01035","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Proguanil","DB01131","Proguanil may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Propafenone","DB01182","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Protriptyline","DB00344","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Pyrimethamine","DB00205","Pyrimethamine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Quetiapine","DB01224","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Quinidine","DB00908","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Quinine","DB00468","Quinine may increase the adverse effects of lumefantrine. Combination therapy is contraindicated unless there are no other treatment options. "
5589,"Ranolazine","DB00243","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Risperidone","DB00734","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Romidepsin","DB06176","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Sotalol","DB00489","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Sparfloxacin","DB01208","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Sunitinib","DB01268","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Tacrolimus","DB00864","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Tamoxifen","DB00675","Lumefantrine, a moderate CYP2D6 inhibitor, may decrease the formation of highly potent tamoxifen metabolites. Concomitant therapy may decrease the effectiveness of tamoxifen. Consider alternate therapy."
5589,"Telavancin","DB06402","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Telithromycin","DB00976","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Tetrabenazine","DB04844","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Thioridazine","DB00679","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Thiothixene","DB01623","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Toremifene","DB00539","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Trimipramine","DB00726","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Voriconazole","DB00582","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Vorinostat","DB02546","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Ziprasidone","DB00246","Additive QTc-prolongation may occur. Concomitant therapy should be avoided. "
5589,"Zuclopenthixol","DB01624","Additive QTc-prolongation may occur. Concomitant therapy should be avoided."
5590,"Betaxolol","DB00195","Beta-Blockers like betaxolol may worsen brochoconstriction and decrease the effectiveness of agents used to treat the resulting bronchoconstriction. Use of betaxolol and methacholine concomitantly is contraindicated."
5594,"Artemether","DB06697","Artemether may decrease the effectiveness of norelgestromin by increasing its metabolism via CYP3A4. Consider an alternate non-hormonal means of contraception during artemether therapy."
5594,"Bexarotene","DB00307","Bexarotene may decrease the serum concentration of Contraceptives (Progestins). Since bexarotene is teratogenic and can lower serum concentrations of norelgestromin, it is advised that women of childbearing potential use two forms of contraception (including at least one non-hormonal form)."
5594,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Contraceptives (Progestins). Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant. Consider alternatives in order to avoid this combination when possible, due to the risk for impaired contraceptive effectiveness. "
5598,"Corticotropin","DB01285","Fosaprepitant may increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect. The manufacturer of fosaprepitant states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone.1 Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. Monitor for increased effects of systemic corticosteroids when coadmininistered with fosaprepitant or aprepitant. "
5600,"Capromab","DB00089","Avoid combination because luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide."
5600,"Mifepristone","DB00834","Buserelin moderately contributes to Q-Tc prolongation. Combination must be avoided because mifepristone can further enhance that effect. "
5602,"Calcipotriol","DB02300","Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
5602,"Cholecalciferol","DB00169","Vitamin D analogs such as cholecalciferol may increase the serum concentration of aluminum hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations. Avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking vitamin D analogs. Any patients consuming such a combination should be monitored closely for aluminum status and signs/symptoms of aluminum-related toxicities. "
5602,"Deferiprone","DB08826","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
5602,"Eltrombopag","DB06210","Decreases levels of eltrombopag by GI absorption inhibition. "
5603,"Calcium Acetate","DB00258","Calcium salts may enhance the adverse/toxic effect of calcium acetate. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
5603,"Calcium Chloride","DB01164","Calcium salts may enhance the adverse/toxic effect of calcium chloride. Concurrent use of other calcium salts with calcium acetate should be avoided when possible. This combination is particularly dangerous in patients with other risk factors for hypercalcemia, such as those with end-stage renal disease. "
5603,"Eltrombopag","DB06210","Decreases levels of eltrombopag by GI absorption inhibition. "
5603,"Itraconazole","DB01167","The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption. "
5630,"Atazanavir","DB01072","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Carbamazepine","DB00564","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Cisplatin","DB00515","Platinum derivatives such as cisplatin may enhance the myelosuppressive effect of taxane derivatives such as cabazitaxel. Administer taxane derivative before platinum derivative when given as sequential infusions to limit toxicity.Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane derivative before the platinum derivative seems prudent. "
5630,"Clarithromycin","DB01211","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Indinavir","DB00224","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Itraconazole","DB01167","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Ketoconazole","DB01026","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Nefazodone","DB01149","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Nelfinavir","DB00220","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Phenobarbital","DB01174","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Phenytoin","DB00252","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Rifabutin","DB00615","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Rifampicin","DB01045","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Rifapentine","DB01201","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Ritonavir","DB00503","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Saquinavir","DB01232","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"St. John's Wort","DB01323","Concomitant therapy with a strong CYP3A inducer may decrease concentrations of cabazitaxel. Avoid concomitant therapy. "
5630,"Telithromycin","DB00976","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5630,"Voriconazole","DB00582","Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy."
5632,"Colesevelam","DB00930","Bile Acid Sequestrants may decrease the serum concentration of Chenodiol. Consider administration of chenodiol 5 hours or more after bile acid sequestrants to reduce chenodiol adsorption in the gastrointestinal tract. Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants. "
5633,"Drotrecogin alfa","DB00055","Low molecular weight heparin (LMWH) such as dalteparin may enhance the adverse/toxic effect of drotrecogin alfa. Bleeding may occur. "
5634,"Bromfenac","DB00963","NSAIDs may slow healing. "
5634,"Diclofenac","DB00586","NSAIDs may slow healing. "
5634,"Flurbiprofen","DB00712","NSAIDs may slow healing. "
5634,"Ketorolac","DB00465","NSAIDs may slow healing. "
5634,"Nepafenac","DB06802","NSAIDs may slow healing. "
5638,"Difluprednate","DB06781","NSAIDs may slow healing. "
5644,"Belatacept","DB06681","Increased immunosuppresive effects and risk of infection. Monitor for adverse effects . "
5644,"Celecoxib","DB00482","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Denosumab","DB06643","Increased immunosuppresive effects and risk of infection. Monitor for adverse effects . "
5644,"Diclofenac","DB00586","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Diflunisal","DB00861","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Etodolac","DB00749","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Fenoprofen","DB00573","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Flurbiprofen","DB00712","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Ibuprofen","DB01050","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Indomethacin","DB00328","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Meclofenamic acid","DB00939","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Meloxicam","DB00814","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Nabumetone","DB00461","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Naproxen","DB00788","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Oxaprozin","DB00991","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Palifermin","DB00039","Increases the toxicity of pralatrexate. Avoid concomitant therapy or do not use palifermin within 24 hours after administration of pralatrexate. "
5644,"Piroxicam","DB00554","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Probenecid","DB01032","Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects. "
5644,"Sulfamethoxazole","DB01015","Decreases renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects. "
5644,"Sulindac","DB00605","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5644,"Tolmetin","DB00500","NSAIDs increase the risk of toxicity due to impairment of renal clearance of pralatrexate thus increasing exposure. Monitor for adverse effects or adjust dose of pralatrexate. "
5645,"Telaprevir","DB05521","Telaprevir increases the exposure of raltegravir by up to 31%  but this interaction is considered as not clinically relevant. "
5646,"Drotrecogin alfa","DB00055","Low molecular weight heparins (LMWHs) such as tinzaparin may enhance the adverse/toxic effects of drotrecogin alfa. Bleeding may occur. The potential benefits of drotrecogin alfa should be weighed against the increased risk of bleeding in patients on therapeutic doses of LMWHs."
7574,"Warfarin","DB00682","Nandrolone may increase the serum concentration and anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if nandrolone is initiated, discontinued or dose changed."
7580,"Atropine","DB00572","Anticholinergic agents like atropine may reduce the action of cinitapride."
7580,"Digoxin","DB00390","Cinitapride can alter the absorption of digoxin as it simulates gastric emptying."
7580,"Digoxin Immune Fab (Ovine)","DB00076","Cinitapride can alter the absorption of digoxin as it simulates gastric emptying."
7580,"Methylscopolamine bromide","DB00462","Anticholinergic agents like methylscopolamine may reduce the action of cinitapride. "
7580,"Scopolamine","DB00747","Anticholinergic agents like scopolamine may reduce the action of cinitapride. "
7582,"Drotrecogin alfa","DB00055","The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin. "
7583,"Ibuprofen","DB01050","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of ibuprofen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
7583,"Naproxen","DB00788","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of naproxen to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
7583,"Piroxicam","DB00554","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of glisentide to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
7583,"Warfarin","DB00682","The metabolite of triflusal, 2-hydroxy-4-trifluoro-methyl-benzoic acid (HTB), impairs the serum protein binding of warfarin to the same extent as acetylsalisylic acid. Thus, the free fraction of glisentide may be increased. A dosage reduction may be required if used in combination. "
7584,"Atazanavir","DB01072","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Bicalutamide","DB01128","CYP3A4 Inhibitors like bicalutamide may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor."
7584,"Bosentan","DB00559","Concomitant therapy with a CYP3A4 substrate and inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Carbamazepine","DB00564","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Chloramphenicol","DB00446","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Clarithromycin","DB01211","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Clotrimazole","DB00257","CYP3A4 Inhibitors (Moderate) such as clotrimazole may increase the serum concentration of lurasidone. Limit adult lurasidone dose to 40 mg/day in patients receiving a moderate CYP3A4 inhibitor. "
7584,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone. Avoid use of lurasidone in patients receiving strong CYP3A4 inhibitors. "
7584,"Darunavir","DB01264","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Delavirdine","DB00705","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Dexamethasone","DB01234","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. Will decrease Cmax of lurasidone by 85%."
7584,"Dopamine","DB00988","Dopamine increases toxicity (enhanced hypotensive effects) of lurasidone. "
7584,"Epinephrine","DB00668","Epinephrine increases toxicity (enhance hypotensive effects) of lurasidone by pharmacodynamic synergism. "
7584,"Etravirine","DB06414","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Etravirine","DB06414","Lurasidone, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
7584,"Fosamprenavir","DB01319","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Fosphenytoin","DB01320","Concomitant therapy with a CYP3A4 inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Imatinib","DB00619","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Indinavir","DB00224","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Itraconazole","DB01167","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Ketoconazole","DB01026","Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. "
7584,"Metoclopramide","DB01233","Increases toxicity and risk of extrapyramidal effects of lurasidone by antidopaminergic effects. Concomitant therapy should be avoided."
7584,"Nafcillin","DB00607","Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated. "
7585,"Conivaptan","DB00872","CYP3A4 Inhibitors (Strong) such as conivaptan may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor. Avoid use of ticagrelor in combination with strong CYP3A4 inhibitors. "
7585,"Etravirine","DB06414","Etravirine, when used concomitantly with ritonavir boosted ticagrelor, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
7585,"Lomitapide","DB08827","Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated. "
7585,"Lovastatin","DB00227","Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects. "
7585,"Simvastatin","DB00641","Patients receiving more than 40 mg per day of simvastatin may be at increased risk of statin-related adverse effects. "
7588,"Alvimopan","DB06274","Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. "
7588,"Bendamustine","DB06769","Increases levels of bendamustine by P-glycoprotein (MDR-1) efflux transporter. "
7588,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Erythromycin","DB00199","Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. "
7588,"Etravirine","DB06414","Ivacaftor, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination."
7588,"Fluconazole","DB00196","Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. "
7588,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Pazopanib","DB06589","Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy. "
7588,"Phenobarbital","DB01174","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Posaconazole","DB01263","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Rifabutin","DB00615","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"St. John's Wort","DB01323","Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Telithromycin","DB00976","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7588,"Tofacitinib","DB08895","Ivacaftor, when used in combination with tofacitinib, may increase tofaciitinib concentrations, It is recommended to monitor therapy for signs of toxicity or worsened side effects. "
7588,"Vismodegib","DB08828","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy. "
7588,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. "
7589,"Acetylsalicylic acid","DB00945","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Amifostine","DB01143","Azilsartan medoxomil used in combintation with amifostine may lead to hypotension."
7589,"Avanafil","DB06237","Pharmacodynamic synergist- increases effects. "
7589,"Benazepril","DB00542","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Captopril","DB01197","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Celecoxib","DB00482","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Citric Acid","DB04272","Increases serum potassium. "
7589,"Diclofenac","DB00586","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Diflunisal","DB00861","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Enalapril","DB00584","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Etodolac","DB00749","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Exenatide","DB01276","Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. "
7589,"Fenoprofen","DB00573","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Flurbiprofen","DB00712","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Fosinopril","DB00492","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Ibuprofen","DB01050","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Indomethacin","DB00328","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Ketoprofen","DB01009","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Ketorolac","DB00465","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Liraglutide","DB06655","Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. "
7589,"Lisinopril","DB00722","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Lithium","DB01356","Azilsartan medoxomil may increase lithium serum concentrations."
7589,"Maraviroc","DB04835","Pharmacodynamic synergist- increases effects."
7589,"Meclofenamic acid","DB00939","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Mefenamic acid","DB00784","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Meloxicam","DB00814","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Moexipril","DB00691","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Nabumetone","DB00461","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Naproxen","DB00788","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Nitroglycerin","DB00727","Pharmacodynamic synergist- increases effects."
7589,"Oxaprozin","DB00991","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Perindopril","DB00790","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Piroxicam","DB00554","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Quinapril","DB00881","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Ramipril","DB00178","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7589,"Rituximab","DB00073","Azilsartan medoxomil used in combination with rituximab may lead to hypotension."
7589,"Sulfasalazine","DB00795","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Sulindac","DB00605","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Tadalafil","DB00820","Pharmacodynamic synergist- increases effects."
7589,"Tolmetin","DB00500","Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. "
7589,"Trandolapril","DB00519","Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  "
7592,"Aluminum hydroxide","DB06723","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
7592,"Calcium","DB01373","Deferiprone serum concentrations may be decreased by calcium salts."
7592,"Iron","DB01592","Deferiprone serum concentrations may be decreased by iron salts except for ferric gluconate, ferumoxytol, iron dextran complex, and iron sucrose."
7592,"Iron Dextran","DB00893","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
7592,"Iron sucrose","DB06790","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
7592,"Magnesium","DB01378","Deferiprone serum concentrations may be decreased by magnesium salts."
7592,"Sodium bicarbonate","DB01390","Deferiprone may decrease gastrointestinal absorption by chelating to other ions. Interaction is significant so monitor closely. "
7592,"Zinc","DB01593","Deferiprone serum concentrations may be decreased by zinc salts except for zinc chloride."
7593,"Atorvastatin","DB01076","Atorvastatin, and other weak CYP3A4 inhibitors (such as amiodarone, amlodipine, alprazolam, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginko, goldenseal, isoniazide, lapatinib, nilotinib, oral contraceptives, pazopanib, ranitidine, ranolazine, tipranavir/ritonavir, ticagrelor, zileuton) increase lomitapide levels by 2-fold. Thus lomipatide should be dosed at a maximum of 30mg daily when used concomitantly with weak inhibitors of CYP3A4."
7593,"Boceprevir","DB08873","Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated. "
7593,"Cholestyramine","DB01432","Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours. "
7593,"Ciprofloxacin","DB00537","The effect of coadminstration of lomipatide with ciproflaxacin, and other moderate CYP3A4 inhibitors (such as aprepitant, amprenavir, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) is unknown. However, as coadministration is likely to increase serum concentrations of lomipatide, concomitant use is contraindicated.  "
7593,"Colestipol","DB00375","Bile acid sequestrants also used for treating high cholesterol may interfere with the absorption of oral medications, thus separate administration by 4 hours. "
7593,"Crizotinib","DB08865","Strong CYP3A4 inhibitors may increase levels of crizotinib. Concomitant therapy is contraindicated. "
7593,"Dabigatran etexilate","DB06695","Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.  "
7593,"Lovastatin","DB00227","Lovastatin plasma concentrations may increase by lomitapide."
7593,"Simvastatin","DB00641","Simvastatin plasma concentrations are doubled by lomitapide. To prevent dose related adverse effects such as myopathy and rhabdomyolysis it is recommended to reduce the dose of simvastatin by 50%. See FDA label for additional dosage instructions. \
"
7593,"Telaprevir","DB05521","Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7593,"Ticagrelor","DB08816","Ticagrelor increases levels of lomitapide by affecting CYP3A4 enzyme metabolism. Concomitant therapy is contraindicated. "
7593,"Warfarin","DB00682","Warfarin plasma concentrations may increase by lomitapide by 30%..\
INR levels may increase by 22%. Regular INR monitoring is required. "
7594,"Azithromycin","DB00207","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
7594,"Clarithromycin","DB01211","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
7594,"Erythromycin","DB00199","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. "
7594,"Ivacaftor","DB08820","P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy. "
7594,"Omeprazole","DB00338","Vismodegib serum concentrations may be decreased by proton pump inhibitors such as omeprazole."
7594,"Ranitidine","DB00863","Vismodegib serum concentrations may be decreased by histamine 2 receptor antagonists such as ranitidine."
7607,"Atazanavir","DB01072","Increases serum concentration of pitavastatin and the potential for adverse drug reactions. Avoid concomitant drug therapy."
7607,"Colchicine","DB01394","Increased incidence of myotoxicity including rhabdomyolysis during concomitant therapy. The mechanism of this interaction is unclear, it may arise from pharmacodynamic and/or pharmacokinetic interactions. "
7607,"Cyclosporine","DB00091","Cyclosporine decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."
7607,"Erythromycin","DB00199","Erythromycin decreases metabolism of pitavastatin. Do not exceed 1 mg per day of pitavastatin or use alternative therapy. "
7607,"Fenofibrate","DB01039","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both fenofibrate and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
7607,"Gemfibrozil","DB01241","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both gemfibrozil and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
7607,"Lopinavir","DB01601","Lopinavir decreases metabolism of pitavastatin thus increasing serum concentration. Avoid concomitant drug therapy."
7607,"Niacin","DB00627","Increased incidence of adverse drug reactions (ie. rhabdomyolysis) of both niacin and pitavastatin via pharmacodynamic synergism. Use alternative therapy. "
7607,"Rifampicin","DB01045","Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. "
7607,"Rifampicin","DB01045","Rifampin significantly increased pitavastatin exposure. In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded. "
7608,"Carbamazepine","DB00564","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Delavirdine","DB00705","Concentration of rilpivirine increases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's. "
7608,"Dexamethasone","DB01234","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Efavirenz","DB00625","Concentration of rilpivirine decreases by affecting CYP3A4 metabolism. Concomitant use is contraindicated. Rilpivirine should not be used with other NNRTI's. "
7608,"Esomeprazole","DB00736","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Etravirine","DB06414","Rilpivirine, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy. Use of rilpivirine and other NNRTIs is containdicated. "
7608,"Famotidine","DB00927","Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Lansoprazole","DB00448","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Methadone","DB00333","Dose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone. "
7608,"Omeprazole","DB00338","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Oxcarbazepine","DB00776","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Pantoprazole","DB00213","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Phenobarbital","DB01174","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Phenytoin","DB00252","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Rabeprazole","DB01129","Proton-pump inhibitors increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Ranitidine","DB00863","Histamine-2 receptor antagonists increase gastric pH which causes a decrease in the exposure of rilpivirine thus reducing efficacy. "
7608,"Rifabutin","DB00615","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Rifampicin","DB01045","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7608,"Rifapentine","DB01201","Strong inducers of CYP3A4 decrease the exposure of rilpivirine thus decreasing efficacy. "
7609,"Bosutinib","DB06616","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
7609,"Cisapride","DB00604","Concurrent use with drugs that prolong QTc interval is contraindicated. "
7609,"Disopyramide","DB00280","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
7609,"Dronedarone","DB04855","Concurrent use with drugs that prolong QTc interval is contraindicated. "
7609,"Etravirine","DB06414","Crizotinib, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination. "
7609,"Fluticasone Propionate","DB00588","Concurrent use with crizotinib may prolong QTc interval. Consider alternative therapy. "
7609,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
7609,"Lomitapide","DB08827","Strong CYP3A4 inhibitors may increase levels of crizotinib. Concomitant therapy is contraindicated. "
7609,"Midazolam","DB00683","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
7609,"Midazolam","DB00683","Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. "
7609,"Ondansetron","DB00904","Concurrent use with crizotinib may decrease QTc interval. Consider alternative therapy. "
7609,"Quinidine","DB00908","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
7609,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. "
7609,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of crizotinib. Monitor concomitant therapy closely. "
7609,"Tacrolimus","DB00864","Strong CYP3A4 inhibitors may increase levels of crizotinib. Consider alternative therapy. "
7609,"Thioridazine","DB00679","Concurrent use with drugs that prolong QTc interval is contraindicated. "
7610,"Bosentan","DB00559","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Carbamazepine","DB00564","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Dexamethasone","DB01234","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Efavirenz","DB00625","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Fosphenytoin","DB01320","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Nafcillin","DB00607","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Nevirapine","DB00238","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Ospemifene","DB04938","Pharmacodynamic synergist; contraindicated. "
7610,"Pentobarbital","DB00312","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Phenobarbital","DB01174","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Phenytoin","DB00252","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Primidone","DB00794","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Rifabutin","DB00615","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"Rifapentine","DB01201","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7610,"St. John's Wort","DB01323","Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  "
7611,"Amiodarone","DB01118","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
7611,"Belimumab","DB08879","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
7611,"Disopyramide","DB00280","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
7611,"Dofetilide","DB00204","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
7611,"Dronedarone","DB04855","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
7611,"Ibutilide","DB00308","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes. "
7611,"Ketoconazole","DB01026","Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater."
7611,"Procainamide","DB01035","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
7611,"Quinidine","DB00908","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
7611,"Sotalol","DB00489","Pharmacodynamic synergist. Contraindicated. Increased risk of bradycardia, AV block, and torsade de pointes."
7613,"Bleomycin","DB00290","Pulmonary toxicity of bleomycin may be increased. Avoid combination."
7613,"Etravirine","DB06414","Brentuximab, when used concomitantly with etravirine, may experience a decrease in serum concentrations. The levels of an active metabolite of brentuximab, monomethyl auristatin E, may decrease. It is recommended to monitor efficacy of brentuximab therapy. "
7613,"Natalizumab","DB00108","Avoid combination due to the increased risk of concurrent infection."
7613,"Pimecrolimus","DB00337","Avoid combination due to the potential enhancement of toxic effects of immunosuppressants"
7613,"Tacrolimus","DB00864","Avoid combination due to the potential enhancement of toxic effects of immunosuppressants."
7615,"Azelastine","DB00972","Avoid combination due to increased CNS depression."
7615,"Ethanol","DB00898","Avoid combination due to ethanol induced increased absorption of gabapentin enacarbil and increased CNS depression."
7616,"Alfuzosin","DB00346","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Atorvastatin","DB01076","Boceprevir increases the exposure of atorvastatin. Concomitant therapy should be closely monitored. "
7616,"Carbamazepine","DB00564","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Cisapride","DB00604","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Conivaptan","DB00872","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Dihydroergotamine","DB00320","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Drospirenone","DB01395","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Etravirine","DB06414","The exposure of etravirine decreases whereas boceprevir's exposure increased. Therapeutic implications of this observation is unknown. "
7616,"Fosphenytoin","DB01320","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Lomitapide","DB08827","Boceprevir increases levels of lomipatide by 27 folds by inhibiting CYP3A4 metabolism. Concomitant therapy of Boceprevir and strong CYP3A4 inhibitors (such as clarithromycin, conivaptan, indinavir, intraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, variconazole) with lomipatide is contraindicated. "
7616,"Midazolam","DB00683","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Phenobarbital","DB01174","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Phenytoin","DB00252","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Pimozide","DB01100","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7616,"Ponatinib","DB08901","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7616,"Pravastatin","DB00175","Boceprevir increases pravastatin AUC by 60% with boceprevir. Concomitant therapy should be closely monitored. "
7616,"Rifampicin","DB01045","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Sirolimus","DB00877","Boceprevir increases levels of sirolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. "
7616,"St. John's Wort","DB01323","Strong CYP3A4 inducers will decrease levels of boceprevir. Concomitant therapy is contraindicated. "
7616,"Tacrolimus","DB00864","Boceprevir increases levels of tacrolimus by affecting CYP3A4 metabolism. Concomitant therapy requires close monitoring. "
7616,"Tadalafil","DB00820","Boceprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. "
7617,"Cyclosporine","DB00091","Cyclosporin is an inhibitor of p-glycoprotein and concomitant therapy will result in a increase in Cmax and AUC of fidaxomicin and its metabolite. "
7618,"Etravirine","DB06414","Cabozantinib, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to avoid this combination if alternative are available. If concurrent use is not avoidable, it is recommended to increase the dosage of cabozantinib by 40mg (without exceeding 180mg/day).  "
7618,"St. John's Wort","DB01323","Avoid combination. May decrease concentration of cabozantinib. Also avoid all other strong CYP3A4 inducers."
7620,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
7620,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
7620,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of ruxolitinib. Closely monitor patient. "
7620,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. "
7622,"Abatacept","DB01281","Avoid combination due to enhanced adverse effects of belimumab."
7622,"ado-trastuzumab emtansine","DB05773","Avoid combination due to the increased risk of belimumab associated side effects.\
\
\
"
7622,"Belatacept","DB06681","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
7622,"Bevacizumab","DB00112","Avoid combination due to enhanced adverse effects of bevacizumab"
7622,"Cyclophosphamide","DB00531","Avoid combination due to enhanced toxic effects of cyclophosphamide."
7622,"Denosumab","DB06643","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
7622,"Etanercept","DB00005","Avoid combination because of enhanced adverse effects of belimumab."
7622,"Etanercept","DB00005","Avoid combination due to enhanced toxic effects of belimumab."
7622,"Fingolimod","DB08868","Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
7622,"Gemtuzumab ozogamicin","DB00056","Avoid combination due to enhanced adverse effects of belimumab."
7622,"golimumab","DB06674","Avoid combination with belimumab due to the increased chance of belimumab associated side effects.\
\
"
7622,"Hydroxyurea","DB01005"," Belimumab increases the immunosupressive effect. Interaction is significant so monitor closely. "
7622,"Ibritumomab","DB00078","Avoid combination due to enhanced adverse effects of belimumab."
7622,"Leflunomide","DB01097","Consider modifying therapy as belimumab may enhance the adverse effects of leflunomide, such as hematologic toxicities."
7622,"Natalizumab","DB00108","Avoid combination due to enhance adverse effects of natalizumab such as the risk of concurrent infections. "
7622,"Obinutuzumab","DB08935","Avoid combination due to enhanced toxic effects of monoclonal antibody."
7622,"Omalizumab","DB00043","Avoid combination due to enhanced toxic effects of monoclonal antibodies."
7622,"Pimecrolimus","DB00337","Avoid combination due to enhanced toxic effects of immunosuppressants."
7622,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive effect. "
7622,"Sipuleucel-T","DB06688","Monitor therapy due to decreased therapeutic effect of sipuleucel-t."
7622,"Tacrolimus","DB00864","Avoid combination due to enhanced adverse effects of immunosuppressants."
7622,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7623,"Leflunomide","DB01097","Avoid combination due to increased adverse effects of teriflunomide. "
7623,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection.\
\
"
7623,"Pimecrolimus","DB00337","Avoid combination due to the increased toxic effects of immunosuppressants. "
7623,"Tacrolimus","DB00864","Avoid combination due to the increased toxic effects of immunosuppressants.\
"
7624,"Atazanavir","DB01072","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Caffeine","DB00201","Vemurafenib increases the AUC of caffeine (CYP1A2 substrate) 2.6-fold. "
7624,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Dextromethorphan","DB00514","Vemurafenib increases the AUC (CYP2D6 substrate) by 47% . "
7624,"Indinavir","DB00224","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Ipilimumab","DB06186","Consider therapy modification due to enhanced hepatotoxicity of vemurafenib"
7624,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Midazolam","DB00683","Vemurafenib decreases the AUC (CYP3A4 substrate) by 39%. "
7624,"Nefazodone","DB01149","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Nelfinavir","DB00220","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Phenobarbital","DB01174","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Rifabutin","DB00615","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Rifapentine","DB01201","Strong CYP3A4 inducers may decrease levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Saquinavir","DB01232","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Telithromycin","DB00976","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. "
7624,"Warfarin","DB00682","Vemurafenib increases the AUC of S-warfarin (CYP2C9 substrate). Monitor concomitant therapy closely. "
7625,"Carbamazepine","DB00564","CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. "
7625,"Etravirine","DB06414","Linagliptin, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy if possible, and to monitor linagliptin therapy if concurrent use cannot be avoided."
7625,"Hydrocortisone","DB00741","CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. "
7625,"Prednisone","DB00635","CYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely. "
7625,"Rifampicin","DB01045","CYP3A4 and p-glycoprotein inducers may decreases levels of linagliptin. Monitor concomitant therapy closely. "
7625,"Ritonavir","DB00503","CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely. "
7626,"Axitinib","DB06626","Avoid combination with axitinib or other major CYP3A4 drug susbtrates due to the potential decrease in the drug's  concentration by perampanel induction of CYP3A4.\
 "
7626,"Azelastine","DB00972","Avoid combination with azelastine or other CNS depressants due to the combined increase of CNS depression.\
\
"
7626,"Dihydrocodeine","DB01551","Enhanced CNS depressant effects. Consider therapy modification, and avoid performing complex and high risk activities like driving until side effects are known. "
7626,"Ethanol","DB00898","Avoid combination due to the enhanced central nervous system depression, and likely worse behavioral and psychiatric adverse reactions.\
\
"
7626,"Etravirine","DB06414","Perampanel, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy."
7626,"Phenytoin","DB00252","Avoid combination with phenytoin or other strong CYP3A4 inducers due to the likely decrease of perampanel concentration. If the combination must be used, an increase in perampanel dose is necessary.\
 "
7626,"St. John's Wort","DB01323","Avoid combination due to the potential decrease in perampanel concentration. "
7627,"Rifampicin","DB01045","Substrates of OATP1B1 and OATP1B3 may limit uptake of gadoxetate disodium into heptatocytes. This may alter the intensity of the signal. "
7628,"Clozapine","DB00363","Avoid combination with systemic aflibercept due to enhanced adverse effects of clozapine, including the risk of agranulocytosis"
7629,"Dexamethasone","DB01234","Monitor therapy as asparaginase erwinia chrysanthemi may increase the serum concentration of dexamethasone due to a decrease of hepatic proteins necessary for dexamethasone metabolism."
7636,"Desipramine","DB01151","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
7636,"Digoxin","DB00390","Mirabegron increased Cmax and AUC of digoxin. Initiate therapy with digoxin at lowest possible dose. Monitor concomitant therapy closely. "
7636,"Flecainide","DB01195","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
7636,"Ketoconazole","DB01026","Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely. "
7636,"Metoprolol","DB00264","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
7636,"Propafenone","DB01182","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
7636,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of mirabegron. Monitor concomitant therapy closely. "
7636,"Thioridazine","DB00679","Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. "
7636,"Warfarin","DB00682","Mirabegron increased Cmax and AUC of S- and R-warfarin. Monitor concomitant therapy closely. "
7638,"Abatacept","DB01281","Avoid combination due to the potential increase in tofacitinib related adverse effects."
7638,"Adalimumab","DB00051","Adalimumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
7638,"ado-trastuzumab emtansine","DB05773","Avoid combination with tofacitinib and other potent immunosuppressants due to the likely enhancement of immunosuppression."
7638,"Anakinra","DB00026","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
"
7638,"Antithymocyte globulin","DB00098","Avoid combination due to enhanced immunosuppressive effects."
7638,"Belatacept","DB06681","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"Belimumab","DB08879","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"Canakinumab","DB06168","Avoid combination with tofacitinib and other potent immunosuppressants due to potential enhancement of immunosuppressant effects."
7638,"Certolizumab pegol","DB08904","Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
7638,"Clozapine","DB00363","Avoid combination due to the increased risk of clozapine induced agranulocytosis. \
"
7638,"Cyclosporine","DB00091","Cyclosporin (and other strong immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression and infection. It is recommended to avoid concurrent therapy. "
7638,"Deferasirox","DB01609","Tofacitinib (and other CYP3A4 substrates), when used in combination with deferasirox, may experience a decrease in concentration. It is recommended to monitor therapy. \
"
7638,"Denosumab","DB06643","Denosumab, when used in combination with tofacitinib, may increase tofaciitinib toxicity and worsen side effects. It may specifically increase the risk of serious infection. It is recommended to monitor therapy. "
7638,"Etanercept","DB00005","Etanercept increases the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
7638,"Fluconazole","DB00196","Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily. "
7638,"Gemtuzumab ozogamicin","DB00056","Avoid combination due to enhancement of immunosuppressants."
7638,"Glatiramer Acetate","DB05259","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"golimumab","DB06674","Golimumab, and other anti-TNF immunosuppressants, when used in combination with tofacitinib, may increase the serum concentration of tofacitinib, and increase tofacitinib associated side effects and immunosuppresion. It is recommended to avoid concurrent therapy."
7638,"Homoharringtonine","DB04865","Avoid combination with tofacitinib and other potent immunosuppressants as there is potential to increase the immunosuppressant effects. Other less potent immunosuppressants such as methotrexate, at antirheumatic doses, and other non-disease modifying antirheumatic drugs (non-DMARDs) can be combined.  \
"
7638,"Ibritumomab","DB00078","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"Infliximab","DB00065","Avoid combination with infliximab and other anti-TNF drugs due to the potential enhancement of tofacitinib related adverse effects.\
"
7638,"Ivacaftor","DB08820","Ivacaftor, when used in combination with tofacitinib, may increase tofaciitinib concentrations, It is recommended to monitor therapy for signs of toxicity or worsened side effects. "
7638,"Leflunomide","DB01097","Leflunomide may experience an increase in toxicity and adverse effects (ie. pancytopenia, agranulocytosis, thrombocytopenia). It is recommended to adjust therapy by forgoing a leflunomide loading dose, and to monitor for bone marrow suppression monthly. "
7638,"Mifepristone","DB00834","Mifepristone, when used in combination with tofacitinib, may increase tofacitinib concentrations. It is recommended to adjust therapy by using a minimized dose of tofacitinib, and monitoring for increased tofacitinib concentrations and signs of toxicity, during and 2 weeks after discontinuation of mifepristone therapy."
7638,"Natalizumab","DB00108","Avoid combination due to the increased risk of infection.\
\
"
7638,"Obinutuzumab","DB08935","Avoid combination due to enhanced immunosuppressive effect."
7638,"Omalizumab","DB00043","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"Pegaspargase","DB00059","Avoid combination due to enhanced immunosuppressive effect of tofacitinib."
7638,"Phenytoin","DB00252","Avoid combination with phenytoin and other strong CYP3A4 inducers due to the potential decrease in tofacitinib serum levels.\
\
"
7638,"Pimecrolimus","DB00337","Avoid combination due to the potential increase in immunosuppressant associated adverse effects.\
\
"
7638,"Rifampicin","DB01045","Rifampin (and other potent CYP3A4 inducers), when used in combination with tofacitinib, may decrease tofacitinib toxicity."
7638,"Rituximab","DB00073","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
\
"
7638,"Roflumilast","DB01656","Roflumilast, when used in combination with tofacitinib, may increase the immunosuppressive effect of tofaciitinib and other immunosuppressive agents.   It is recommended to modify therapy. "
7638,"Sitaxentan","DB06268","Sitaxentan (moderate CYP3A4 inhibitors, strong CYP2C19 inhbitors), when used in combination with tofacitinib, may increase tofaciitinib serum concentration toxicity and adverse effects. It is recommended to adjust therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5 mg daily. "
7638,"Tacrolimus","DB00864","Avoid combination due to the potential increase in immunosuppressant associated adverse effects.\
"
7638,"Tocilizumab","DB06273","Avoid combination due to the potential increase in tofacitinib related adverse effects.\
"
7638,"Trastuzumab","DB00072","Trastuzumab, when used in combination with tofacitinib, may increase tofacitinib adverse effects, ie. neutropenic effects. It is recommended to monitor therapy. "
7639,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of regorafenib. "
7639,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7639,"Irinotecan","DB00762","Regorafenib may increase levels of irinotecan, a UGT1A1 substrate. "
7639,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7639,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7639,"Phenobarbital","DB01174","Strong CYP3A4 inducers may decrease levels of regorafenib. "
7639,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of regorafenib. "
7639,"Posaconazole","DB01263","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7639,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of regorafenib. "
7639,"St. John's Wort","DB01323","Strong CYP3A4 inducers may decrease levels of regorafenib. "
7639,"Telithromycin","DB00976","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7639,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of regorafenib. "
7640,"Pramlintide","DB01278","May increase the risk of inhibition of GI motility via pharmacodynamic synergism. Consider alternate therapy. "
7641,"Leucovorin","DB00650","Do not administer leucovorin within 2 hours of glucarpidase due to the fact that leucovorin is degraded by glucarpidase."
7644,"Boceprevir","DB08873","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Conivaptan","DB00872","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Indinavir","DB00224","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Itraconazole","DB01167","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Lopinavir","DB01601","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Nefazodone","DB01149","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Nelfinavir","DB00220","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Posaconazole","DB01263","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Saquinavir","DB01232","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Telaprevir","DB05521","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Telithromycin","DB00976","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7644,"Voriconazole","DB00582","Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. "
7646,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely. "
7646,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease exposure of bedaquiline. Co-administration should be avoided. "
7647,"Abatacept","DB01281","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
7647,"Anakinra","DB00026","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
7647,"Etanercept","DB00005","Avoid combination as certolizumab pegol toxic effects would be enhanced."
7647,"golimumab","DB06674","Avoid combination due to the potential increased immunosuppression of Certolizumab Pegol."
7647,"Infliximab","DB00065","Avoid combination because anti-TNF agents increase adverse effects of certolizumab pegol"
7647,"Natalizumab","DB00108","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
7647,"Rituximab","DB00073","Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. "
7647,"Tofacitinib","DB08895","Certolizumab (and other anti-TNF immunosuppressants), when used in combination with tofacitinib, may increase the risk of added immunosuppression. It is recommended to avoid concurrent therapy."
7649,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely. "
7649,"Ritonavir","DB00503","Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy. "
7650,"Aliskiren","DB09026","Monitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects."
7650,"Digoxin","DB00390","When coadministered with 300 mg canagliflozin, the AUC and mean peak drug concentration of digoxin increased. Monitor concomitant therapy closely. "
7650,"Phenobarbital","DB01174","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
7650,"Phenytoin","DB00252","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
7650,"Rifampicin","DB01045","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
7650,"Ritonavir","DB00503","Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. "
7652,"Haloperidol","DB00502","Haloperidol may induce hyperammonemia. Monitor ammonia levels closely when use of haloperidol is necessary in UCD patients."
7652,"Prednisone","DB00635","Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly."
7652,"Probenecid","DB01032","Probenecid may inhibit the renal excretion of metabolites of glycerol phenylbutyrate including PAGN and PAA."
7652,"Valproic Acid","DB00313","Valproic acid may induce hyperammonemia. Monitor ammonia levels closely when use of valproic acid is necessary in UCD patients."
7653,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided. "
7653,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of pomalidomide. Concomitant therapy should be avoided. "
7655,"Carbamazepine","DB00564","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
7655,"Clarithromycin","DB01211","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
7655,"Gemfibrozil","DB01241","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
7655,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
7655,"Midazolam","DB00683","Dabrafenib decreased the maximum concentration (Cmax) and area under the curve (AUC) of midazolam (a substrate of CYP3A4) by 61% and 74%, respectively. "
7655,"Nefazodone","DB01149","Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. "
7655,"Pantoprazole","DB00213","Proton pump inhibitors may alter the solubility of dabrafenib and reduce its bioavailability. "
7655,"Phenobarbital","DB01174","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
7655,"Phenytoin","DB00252","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
7655,"Ranitidine","DB00863","H2-receptor antagonists may alter the solubility of dabrafenib and reduce its bioavailability. "
7655,"Rifampicin","DB01045","Strong CYP3A4 inducers may decrease levels of dabrafenib. Consider alternate therapy. "
7661,"Ketoconazole","DB01026","Strong CYP3A4 inhibitors may increase exposure levomilnacipran. "
7673,"Aliskiren","DB09026","Obinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion. "
7673,"Belimumab","DB08879","Avoid combination due to enhanced toxic effects of monoclonal antibody."
7673,"Clozapine","DB00363","Risk of agranulocytosis may be increased due to enhanced adverse effects of clozapine by myelosuppressive agents. It is recommanded that combination may be avoided."
7673,"Denosumab","DB06643","Monitor therapy due to increased risk of infections due to adverse effects of immunosuppressants."
7673,"Eptifibatide","DB00063","Monitor therapy due to increased risk of bleeding events."
7673,"Leflunomide","DB01097","Consider modifying therapy. Risk of hematologic toxicity of leflunomide may be increased due to enhanced adverse effects."
7673,"Natalizumab","DB00108","Avoid combination due to enhanced adverse effects of natalizumab. "
7673,"Pimecrolimus","DB00337","Avoid combination due to enhanced immunosuppressive effects.\
"
7673,"Roflumilast","DB01656","Consider therapy modification due to enhanced immunosuppressive effect."
7673,"Sipuleucel-T","DB06688","Monitor therapy due to diminished therapeutic effect of sipuleucel-t."
7673,"Tacrolimus","DB00864","Avoid combination due to enhanced adverse effects of immunosuppressants. "
7673,"Tofacitinib","DB08895","Avoid combination due to enhanced immunosuppressive effect."
7673,"Trastuzumab","DB00072","Monitor therapy due to enhanced neutropenic effect of immunosuppressants\
"
7757,"Alfuzosin","DB00346","Monitor therapy due to enhanced hypotensive effect of aliskiren."
7757,"Amifostine","DB01143","Amifostine hypotensive effect can be exacerbated with administration of antihypertensives. If amifostine is administered, no antihypertensives should be administered within 24 hours. If the antihypertensives can't be withheld, amifostine should not be administered."
7757,"Atorvastatin","DB01076","Therapy modification should be considered because atorvastatin increases aliskiren serum concentration."
7757,"Brimonidine","DB00484","Monitor therapy because of enhanced hypotensive effect."
7757,"Canagliflozin","DB08907","Monitor therapy because canagliflozin may enhance aliskiren antihypertensive and hyperkalemic effects."
7757,"Cyclosporine","DB00091","Avoid combination because cyclosporine increases aliskiren serum concentration."
7757,"Diazoxide","DB01119","Monitor therapy due to enhanced hypotensive effect of aliskiren."
7757,"Duloxetine","DB00476","Monitor therapy due to enhanced orthostatic hypotensive effect of duloxetine."
7757,"Furosemide","DB00695","Monitor therapy due to potential decreased serum concentration of furosemide."
7757,"Heparin","DB01109","Monitor therapy due to enhanced hyperkalemic effect of aliskiren."
7757,"Itraconazole","DB01167","Avoid combination due to increased serum concentration of aliskiren."
7757,"Ketoconazole","DB01026","Monitor therapy due to increased serum concentration of aliskiren."
7757,"Methylphenidate","DB00422","Monitor therapy due to reduced antihypertensive effect of aliskiren."
7757,"Obinutuzumab","DB08935","Obinutuzumab antihypertensive effect may be enhanced. Administration of antihypertensives should be withheld 12 hours before infusion of obinutuzumab and 1 hour after the end of infusion. "
7757,"Pentoxifylline","DB00806","Monitor therapy due to enhanced antihypertensive effects of aliskiren."
7757,"Rituximab","DB00073","Consider therapy modification due to enhanced hypotensive effect of rituximab."
7757,"Verapamil","DB00661","Monitor therapy due to increased concentration of aliskiren. "
7757,"Yohimbine","DB01392","Monitor therapy due to decreased antihypertensive effects of aliskiren. "
